1395192
D001971_D009203 CID bromocriptine_8/NN (r_dobj) receiving_7/VBG (r_acl) patient_6/NN (r_pobj) in_3/IN (r_prep) infarction_2/NN
D001971_D009203 CID Bromocriptine_0/NNP (r_nsubjpass) implicated_3/VBN (l_prep) in_4/IN (l_pobj) reports_8/NNS (l_prep) of_9/IN (l_pobj) infarction_11/NN
7949506
D003000_D054537 CID clonidine_10/NN (l_acl) resulting_13/VBG (l_prep) in_14/IN (l_pobj) block_19/NN
D003000_D054537 CID clonidine_8/NN (r_pobj) of_7/IN (r_prep) dose_6/NN (r_pobj) of_3/IN (r_prep) addition_2/NN (r_pobj) After_0/IN (r_prep) developed_16/VBD (l_dobj) block_19/NN
D003000_D054537 CID clonidine_4/NN (r_nmod) mg_6/NNP (r_compound) bid_7/NN (l_ccomp) developed_9/VBD (l_dobj) block_12/NN
D003000_D007022 CID clonidine_10/NN (l_acl) resulting_13/VBG (l_prep) in_14/IN (l_pobj) block_19/NN (l_conj) hypotension_25/NN
D003000_D007022 CID clonidine_8/NN (r_pobj) of_7/IN (r_prep) dose_6/NN (r_pobj) of_3/IN (r_prep) addition_2/NN (r_pobj) After_0/IN (r_prep) developed_16/VBD (l_dobj) block_19/NN (l_conj) hypotension_22/NN
D014700_D054537 CID verapamil_12/NN (r_conj) clonidine_10/NN (l_acl) resulting_13/VBG (l_prep) in_14/IN (l_pobj) block_19/NN
D014700_D007022 CID verapamil_12/NN (r_conj) clonidine_10/NN (l_acl) resulting_13/VBG (l_prep) in_14/IN (l_pobj) block_19/NN (l_conj) hypotension_25/NN
D014700_D006929 NONE verapamil_10/NN (r_pobj) with_9/IN (r_prep) treated_8/VBN (l_nsubjpass) woman_4/NN (l_prep) with_5/IN (l_pobj) hyperaldosteronism_6/NNP
D013148_D006929 NONE spironolactone_16/NNP (r_nmod) d_20/NN (r_conj) treated_8/VBN (l_nsubjpass) woman_4/NN (l_prep) with_5/IN (l_pobj) hyperaldosteronism_6/NNP
7967231
C059447_D020195 NONE S-312_0/JJ (r_dep) ,_1/, (r_dep) S-312-d_2/NN (r_amod) antagonists_13/NNS (r_nsubj) showed_15/VBD (l_dobj) effects_17/NNS (l_prep) on_18/IN (l_pobj) convulsions_22/NNS
C059447_D020195 NONE S-312-d_2/NN (r_amod) antagonists_13/NNS (r_nsubj) showed_15/VBD (l_dobj) effects_17/NNS (l_prep) on_18/IN (l_pobj) convulsions_22/NNS
-1_D020195 NONE S-312-l_6/NNP (r_conj) S-312-d_2/NN (r_amod) antagonists_13/NNS (r_nsubj) showed_15/VBD (l_dobj) effects_17/NNS (l_prep) on_18/IN (l_pobj) convulsions_22/NNS
D002118_D020195 NONE calcium_11/NN (r_compound) channel_12/NN (r_compound) antagonists_13/NNS (r_nsubj) showed_15/VBD (l_dobj) effects_17/NNS (l_prep) on_18/IN (l_pobj) convulsions_22/NNS
D005444_D020195 NONE flunarizine_57/NNP (r_pobj) of_56/IN (r_prep) that_55/DT (r_nsubj) was_58/VBD (r_advcl) were_31/VBD (r_conj) showed_15/VBD (l_dobj) effects_17/NNS (l_prep) on_18/IN (l_pobj) convulsions_22/NNS
C059447_D012640 NONE S-312-d_5/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (r_nsubjpass) observed_10/VBN (l_prep) against_11/IN (l_pobj) convulsions_14/NNS
C059447_D012640 NONE S-312-d_5/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (r_nsubjpass) observed_10/VBN (r_advcl) observed_36/VBN (l_prep) in_37/IN (l_pobj) convulsions_38/NNS
D010433_D012640 CID pentylenetetrazole_17/NNP (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) convulsions_14/NNS
D010433_D012640 CID pentylenetetrazole_17/NNP (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) convulsions_14/NNS (r_pobj) against_11/IN (r_prep) observed_10/VBN (r_advcl) observed_36/VBN (l_prep) in_37/IN (l_pobj) convulsions_38/NNS
D001534_D012640 CID bemegride_25/NNP (r_conj) mg/kg_20/CD (r_appos) pentylenetetrazole_17/NNP (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) convulsions_14/NNS
D001534_D012640 CID bemegride_25/NNP (r_conj) mg/kg_20/CD (r_appos) pentylenetetrazole_17/NNP (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) convulsions_14/NNS (r_pobj) against_11/IN (r_prep) observed_10/VBN (r_advcl) observed_36/VBN (l_prep) in_37/IN (l_pobj) convulsions_38/NNS
D016202_D012640 NONE aspartate_47/NN (r_pobj) by_40/IN (r_agent) induced_39/VBN (r_acl) convulsions_38/NNS (r_pobj) in_37/IN (r_prep) observed_36/VBN (l_advcl) observed_10/VBN (l_prep) against_11/IN (l_pobj) convulsions_14/NNS
D016202_D012640 NONE aspartate_47/NN (r_pobj) by_40/IN (r_agent) induced_39/VBN (r_acl) convulsions_38/NNS
D010852_D012640 CID picrotoxin_49/NNP (r_conj) aspartate_47/NN (r_pobj) by_40/IN (r_agent) induced_39/VBN (r_acl) convulsions_38/NNS (r_pobj) in_37/IN (r_prep) observed_36/VBN (l_advcl) observed_10/VBN (l_prep) against_11/IN (l_pobj) convulsions_14/NNS
D010852_D012640 CID picrotoxin_49/NNP (r_conj) aspartate_47/NN (r_pobj) by_40/IN (r_agent) induced_39/VBN (r_acl) convulsions_38/NNS
C059447_D004827 NONE S-312-d_0/NN (r_nsubj) be_2/VB (l_prep) in_4/IN (l_pobj) therapy_6/NN (l_prep) of_7/IN (l_pobj) types_9/NNS (l_prep) of_10/IN (l_pobj) epilepsy_12/NN
20927253
D019386_D010146 CID alendronate_6/NNP (r_pobj) of_5/IN (r_prep) administration_4/NN (r_pobj) after_3/IN (r_prep) Diffuse_0/VB (l_dobj) pain_2/NN
D019386_D010146 CID alendronate_20/NNP (r_pobj) of_19/IN (r_prep) administration_18/NN (r_pobj) after_15/IN (r_prep) admitted_4/VBN (l_prep) with_11/IN (l_pobj) pain_14/NN
D004164_D010024 NONE bisphosphonates_13/NNP (r_nsubjpass) used_16/VBN (r_conj) caused_2/VBN (l_nsubjpass) Osteoporosis_0/NN
D004164_D010024 NONE bisphosphonate_11/NN (r_npadvmod) related_13/VBN (r_amod) pain_14/NN (r_nsubjpass) considered_18/VBN (r_conj) report_7/VB (l_nsubj) patients_3/NNS (l_prep) with_4/IN (l_pobj) osteoporosis_5/NN
D004164_D010024 NONE bisphosphonate_11/NN (r_npadvmod) related_13/VBN (r_amod) pain_14/NN (r_nsubjpass) considered_18/VBN (l_prep) before_19/IN (l_pcomp) ascribing_20/VBG (l_prep) to_23/IN (l_pobj) osteoporosis_24/NN
D019386_D010024 NONE Alendronate_0/NNP (r_nsubj) is_5/VBZ (l_acomp) effective_6/JJ (l_prep) for_7/IN (l_pobj) treatment_10/NN (l_prep) of_13/IN (l_pobj) osteoporosis_14/NN
-1_D010024 NONE biphosphonate_3/NN (r_appos) Alendronate_0/NNP (r_nsubj) is_5/VBZ (l_acomp) effective_6/JJ (l_prep) for_7/IN (l_pobj) treatment_10/NN (l_prep) of_13/IN (l_pobj) osteoporosis_14/NN
D004164_D010146 NONE bisphosphonate_11/NN (r_npadvmod) related_13/VBN (r_amod) pain_14/NN (r_nsubjpass) considered_18/VBN (r_conj) report_7/VB (l_dobj) pain_8/NN
D004164_D010146 NONE bisphosphonate_11/NN (r_npadvmod) related_13/VBN (r_amod) pain_14/NN
19681452
D003042_D002543 NONE cocaine_8/NN (r_nmod) intoxication_11/NN (r_pobj) after_7/IN (r_prep) infarction_2/NN (l_prep) of_3/IN (l_pobj) pallidus_6/NNP
D003042_D020520 NONE cocaine_8/NN (r_nmod) intoxication_11/NN (r_pobj) after_7/IN (r_prep) infarction_2/NN (l_prep) of_3/IN (l_pobj) pallidus_6/NNP
D003042_D020520 NONE cocaine_8/NN (r_pobj) of_7/IN (r_prep) use_6/NN (r_pobj) after_4/IN (r_prep) infarcts_3/NNS
D000431_D002543 NONE alcohol_10/NN (r_conj) cocaine_8/NN (r_nmod) intoxication_11/NN (r_pobj) after_7/IN (r_prep) infarction_2/NN (l_prep) of_3/IN (l_pobj) pallidus_6/NNP
D000431_D020520 NONE alcohol_10/NN (r_conj) cocaine_8/NN (r_nmod) intoxication_11/NN (r_pobj) after_7/IN (r_prep) infarction_2/NN (l_prep) of_3/IN (l_pobj) pallidus_6/NNP
D003042_D002544 NONE Cocaine_0/NN (r_nsubj) is_1/VBZ (l_attr) factor_4/NN (l_prep) for_5/IN (l_pobj) stroke_10/NN
D003042_D020521 NONE Cocaine_0/NN (r_nsubj) is_1/VBZ (l_attr) factor_4/NN (l_prep) for_5/IN (l_pobj) stroke_10/NN
D000431_D002545 NONE alcohol_19/NN (r_pobj) after_17/IN (r_prep) present_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) man_9/NN (l_prep) with_10/IN (l_pobj) ischemia_12/NN (l_prep) of_13/IN (l_pobj) pallidus_16/NNP
D003042_D002545 CID cocaine_22/NN (r_compound) use_23/NN (r_conj) alcohol_19/NN (r_pobj) after_17/IN (r_prep) present_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) man_9/NN (l_prep) with_10/IN (l_pobj) ischemia_12/NN (l_prep) of_13/IN (l_pobj) pallidus_16/NNP
D003932_D020520 CID heroin_11/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (l_nsubjpass) infarctions_5/NNS
D003932_D020520 CID heroin_12/NN (r_compound) use_13/NN (r_pobj) without_10/IN (r_prep) infarcts_3/NNS
D003042_D001145 NONE cocaine_12/NN (r_pobj) to_11/IN (r_prep) related_10/VBN (l_nsubj) arrhythmia_6/NN
D003042_D012131 NONE cocaine_12/NN (r_pobj) to_11/IN (r_prep) related_10/VBN (l_nsubj) arrhythmia_6/NN (l_conj) dysfunction_9/NN
D003042_-1 NONE cocaine_12/NN (r_pobj) to_11/IN (r_prep) related_10/VBN (r_pobj) In_0/IN (r_prep) were_16/VBD (l_attr) causes_20/NNS (l_prep) of_21/IN (l_pobj) hypoperfusion_23/NN
D000431_D001145 NONE ethanol_14/NN (r_compound) use_15/NN (r_conj) cocaine_12/NN (r_pobj) to_11/IN (r_prep) related_10/VBN (l_nsubj) arrhythmia_6/NN
D000431_D012131 NONE ethanol_14/NN (r_compound) use_15/NN (r_conj) cocaine_12/NN (r_pobj) to_11/IN (r_prep) related_10/VBN (l_nsubj) arrhythmia_6/NN (l_conj) dysfunction_9/NN
D000431_-1 NONE ethanol_14/NN (r_compound) use_15/NN (r_conj) cocaine_12/NN (r_pobj) to_11/IN (r_prep) related_10/VBN (r_pobj) In_0/IN (r_prep) were_16/VBD (l_attr) causes_20/NNS (l_prep) of_21/IN (l_pobj) hypoperfusion_23/NN
3083835
D010406_D000707 CID Penicillin_0/NN (r_compound) anaphylaxis_1/NN
D010406_D000707 CID penicillin_4/NN (r_compound) anaphylaxis_5/NN
D010406_D000707 CID penicillin_4/NN (r_compound) anaphylaxis_5/NN (r_pobj) of_2/IN (r_prep) case_1/NN (r_nsubjpass) described_7/VBN (l_conj) reviewed_27/VBN (l_nsubjpass) terminology_11/NN (l_conj) occurrence_13/NN (l_conj) manifestations_16/NNS (l_conj) pathogenesis_18/NN (l_prep) of_24/IN (l_pobj) anaphylaxis_25/NN
D010406_D000707 CID penicillin_7/NN (r_compound) anaphylaxis_8/NN
816141
D002512_D000743 CID Cephalothin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) anemia_5/NN
D002512_D000743 CID cephalothin_13/JJ (r_compound) therapy_14/NN (r_dobj) receiving_12/VBG (r_advcl) developed_5/VBD (l_dobj) anemia_10/NN
D002512_D007674 NONE cephalothin_13/JJ (r_compound) therapy_14/NN (r_dobj) receiving_12/VBG (r_advcl) developed_5/VBD (l_nsubj) patient_1/NN (l_prep) with_2/IN (l_pobj) disease_4/NN
19549709
C107135_D002289 NONE everolimus_2/NN (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_prep) with_8/IN (l_pobj) NSCLC_10/NNP
C107135_D002289 NONE RAD001_4/NNP (r_appos) everolimus_2/NN (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_prep) with_8/IN (l_pobj) NSCLC_10/NNP
C107135_D002289 NONE RAD001_0/NNP (r_nsubj) shown_16/VBN (l_dobj) phase_17/NN (l_relcl) efficacy_19/NN (l_prep) in_20/IN (l_pobj) NSCLC_21/NNP
C107135_D002289 NONE RAD001_0/NNP (r_nmod) day_4/NN (r_nsubj) was_5/VBD (l_advcl) showing_9/VBG (l_dobj) activity_12/NN (l_prep) in_13/IN (l_pobj) NSCLC_15/NNP
C107135_D002289 NONE RAD001_2/NNP (r_pobj) of_1/IN (r_prep) Evaluation_0/NN (l_conj) therapy_5/NN (l_prep) for_6/IN (l_pobj) NSCLC_8/NNP
D020123_D002289 NONE rapamycin_10/NN (r_pobj) of_9/IN (r_prep) target_8/NN (r_pobj) of_5/IN (r_prep) inhibitor_4/NN (r_appos) RAD001_0/NNP (r_nsubj) shown_16/VBN (l_dobj) phase_17/NN (l_relcl) efficacy_19/NN (l_prep) in_20/IN (l_pobj) NSCLC_21/NNP
D010984_D002289 NONE platinum_16/NN (r_appos) regimens_13/NNS (r_pobj) with_7/IN (r_prep) patients_5/NNS (l_nmod) IIIb_1/NNS (l_conj) NSCLC_4/NNP
D014443_D064420 NONE tyrosine_1/NN (r_compound) inhibitors_3/NNS (r_nsubj) received_9/VBD (l_prep) until_15/IN (l_pobj) progression_16/NN (l_conj) toxicity_19/NN
C107135_D064420 NONE RAD001_10/NNP (r_dobj) received_9/VBD (l_prep) until_15/IN (l_pobj) progression_16/NN (l_conj) toxicity_19/NN
8135424
D005442_D012640 CID Flumazenil_0/NNP (r_nsubj) induces_1/VBZ (l_dobj) seizures_2/NNS
D005442_D012640 CID flumazenil_5/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) unmask_7/VB (l_dobj) seizures_8/NNS
D005442_D012640 CID Flumazenil_0/NNP (r_nsubj) unmask_2/VB (l_dobj) seizures_3/NNS
D003042_D012640 CID cocaine_7/NN (r_compound) diazepam_9/NN (r_compound) intoxications_10/NNS (r_pobj) in_5/IN (r_prep) seizures_2/NNS
D003042_D012640 CID cocaine_11/NN (r_compound) benzodiazepine_13/NN (r_compound) intoxication_14/NN (r_pobj) in_9/IN (r_prep) seizures_8/NNS
D003042_D012640 CID cocaine_15/NN (r_compound) diazepam_17/NN (r_compound) intoxications_18/NNS (r_pobj) of_13/IN (r_prep) model_12/NN (r_pobj) in_10/IN (r_prep) increase_5/VB (r_conj) unmask_2/VB (l_dobj) seizures_3/NNS
D003975_D012640 CID diazepam_9/NN (r_compound) intoxications_10/NNS (r_pobj) in_5/IN (r_prep) seizures_2/NNS
D003975_D012640 CID diazepam_17/NN (r_compound) intoxications_18/NNS (r_pobj) of_13/IN (r_prep) model_12/NN (r_pobj) in_10/IN (r_prep) increase_5/VB (r_conj) unmask_2/VB (l_dobj) seizures_3/NNS
D001569_D012640 NONE benzodiazepine_3/JJ (r_compound) antagonist_4/NN (r_compound) flumazenil_5/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) unmask_7/VB (l_dobj) seizures_8/NNS
D001569_D012640 NONE benzodiazepine_13/NN (r_compound) intoxication_14/NN (r_pobj) in_9/IN (r_prep) seizures_8/NNS
8748050
D000639_D001927 CID amitriptyline_2/NN (r_compound) therapy_3/NN (r_pobj) during_1/IN (r_prep) Encephalopathy_0/NNS
D000639_D001927 CID amitriptyline_12/NN (r_compound) therapy_13/NN (r_pobj) of_11/IN (r_prep) course_10/NN (r_pobj) in_8/IN (r_prep) developed_7/VBN (r_acl) encephalopathy_6/NN
D000639_D009459 NONE amitriptyline_2/NN (r_compound) therapy_3/NN (r_pobj) during_1/IN (r_prep) Encephalopathy_0/NNS (r_nsubj) are_5/VBP (l_nsubj) syndrome_8/NN
D000639_D020230 NONE amitriptyline_2/NN (r_compound) therapy_3/NN (r_pobj) during_1/IN (r_prep) Encephalopathy_0/NNS (r_nsubj) are_5/VBP (l_nsubj) syndrome_8/NN (l_conj) disorders_13/NNS (l_compound) spectrum_12/NN (l_compound) syndrome_11/NN
D000639_D003866 NONE amitriptyline_12/NN (r_compound) therapy_13/NN (r_pobj) of_11/IN (r_prep) course_10/NN (r_pobj) in_8/IN (r_prep) developed_7/VBN (r_acl) encephalopathy_6/NN (r_pobj) of_5/IN (r_prep) case_4/NN (r_dobj) describes_2/VBZ (l_prep) during_15/IN (l_pobj) remission_17/NN (l_prep) of_18/IN (l_pobj) depression_20/NN
2239937
D002119_D006934 CID carbonate_8/NN (r_compound) therapy_9/NN (r_pobj) on_6/IN (r_prep) patients_5/NNS (r_pobj) in_3/IN (r_prep) Etiology_0/NN (l_prep) of_1/IN (l_pobj) hypercalcemia_2/NN
D002119_D006934 CID carbonate_15/NN (r_pobj) to_13/IN (r_prep) switching_12/VBG (r_pcomp) after_11/IN (r_prep) became_9/VBD (l_attr) hypercalcemic_10/JJ
D010710_D006934 NONE phosphate_19/NN (r_compound) binder_20/NN (r_pobj) as_16/IN (r_prep) switching_12/VBG (r_pcomp) after_11/IN (r_prep) became_9/VBD (l_attr) hypercalcemic_10/JJ
D002118_D006934 NONE calcium_17/NN (r_compound) reabsorption_18/NN (r_nmod) rate_22/NN (r_pobj) of_15/IN (r_prep) parameters_14/NNS (r_nsubjpass) compared_28/VBN (l_prep) In_0/IN (l_pobj) order_1/NN (l_acl) identify_3/VB (l_dobj) factors_5/NNS (l_acl) associated_6/VBN (l_prep) with_7/IN (l_pobj) development_9/NN (l_prep) of_10/IN (l_pobj) hypercalcemia_11/NN
D002118_D006934 NONE calcium_8/NN (r_compound) values_9/NNS (r_pobj) with_6/IN (r_prep) episodes_5/NNS (l_compound) hypercalcemic_4/JJ
D002118_D006934 NONE calcium_8/NN (r_compound) values_9/NNS (r_pobj) with_6/IN (r_prep) episodes_5/NNS (r_dobj) experiencing_3/VBG (r_pcomp) to_2/IN (r_prep) addition_1/NN (r_pobj) In_0/IN (r_prep) exhibited_31/VBD (l_nsubj) patients_26/NNS (l_prep) in_27/IN (l_pobj) group_30/NN (l_compound) hypercalcemic_29/NNP
D002118_D006934 NONE calcium_38/NN (r_compound) concentration_39/NN (r_pobj) in_35/IN (r_prep) increase_34/NN (r_dobj) exhibited_31/VBD (l_prep) In_0/IN (l_pobj) addition_1/NN (l_prep) to_2/IN (l_pcomp) experiencing_3/VBG (l_dobj) episodes_5/NNS (l_compound) hypercalcemic_4/JJ
D002118_D006934 NONE calcium_38/NN (r_compound) concentration_39/NN (r_pobj) in_35/IN (r_prep) increase_34/NN (r_dobj) exhibited_31/VBD (l_nsubj) patients_26/NNS (l_prep) in_27/IN (l_pobj) group_30/NN (l_compound) hypercalcemic_29/NNP
D002118_D007674 NONE calcium_17/NN (r_compound) reabsorption_18/NN (r_nmod) rate_22/NN (r_pobj) of_15/IN (r_prep) parameters_14/NNS (r_nsubjpass) compared_28/VBN (l_prep) with_29/IN (l_pobj) results_30/NNS (l_prep) in_31/IN (l_pobj) patients_34/NNS (l_appos) length_41/NN (l_conj) etiology_48/NN (l_prep) of_49/IN (l_pobj) disease_51/NN
18399341
D004837_D007022 NONE epinephrine_24/NN (r_compound) infusion_25/NN (r_dobj) required_23/VBD (l_advcl) treat_27/VB (l_dobj) hypotension_28/NN
8392553
C056595_D006331 NONE clentiazem_3/NNS (l_prep) against_4/IN (l_pobj) injury_9/NN
C056595_D006331 NONE clentiazem_3/NNP (r_nsubj) attenuated_4/VBD (l_dobj) injury_9/NN
D004837_D006331 NONE epinephrine_5/NN (r_npadvmod) induced_7/VBN (r_amod) injury_9/NN
D004837_D006331 NONE epinephrine_5/NN (r_npadvmod) induced_7/VBN (r_amod) injury_9/NN
C056595_D009202 NONE clentiazem_5/NNP (l_appos) antagonist_10/NN (l_prep) on_12/IN (l_pobj) cardiomyopathy_16/NN
C106746_D009202 NONE 1,5-benzothiazepine_8/CD (r_nummod) calcium_9/NN (r_compound) antagonist_10/NN (l_prep) on_12/IN (l_pobj) cardiomyopathy_16/NN
D002118_D009202 NONE calcium_9/NN (r_compound) antagonist_10/NN (l_prep) on_12/IN (l_pobj) cardiomyopathy_16/NN
D004837_D009202 CID epinephrine_13/NN (r_npadvmod) induced_15/VBN (r_amod) cardiomyopathy_16/NN
D004837_D007511 NONE epinephrine_3/NN (r_compound) infusion_4/NN (r_pobj) With_0/IN (r_prep) died_10/VBD (l_conj) observed_26/VBN (l_nsubjpass) lesions_18/NNS
D004837_D007511 NONE epinephrine_4/NN (r_npadvmod) induced_6/VBN (r_amod) death_7/NN (r_dobj) prevented_3/VBD (l_conj) attenuated_15/VBD (l_dobj) lesions_19/NNS
D004837_D005355 NONE epinephrine_3/NN (r_compound) infusion_4/NN (r_pobj) With_0/IN (r_prep) died_10/VBD (l_conj) observed_26/VBN (l_nsubjpass) lesions_18/NNS (l_conj) fibrosis_20/NN
D004837_D005355 NONE epinephrine_4/NN (r_npadvmod) induced_6/VBN (r_amod) death_7/NN (r_dobj) prevented_3/VBD (l_conj) attenuated_15/VBD (l_dobj) lesions_19/NNS (l_conj) fibrosis_21/NN
C056595_D007511 NONE clentiazem_2/NNS (r_pobj) with_1/IN (r_prep) Treatment_0/NN (r_nsubj) prevented_3/VBD (l_conj) attenuated_15/VBD (l_dobj) lesions_19/NNS
C056595_D005355 NONE clentiazem_2/NNS (r_pobj) with_1/IN (r_prep) Treatment_0/NN (r_nsubj) prevented_3/VBD (l_conj) attenuated_15/VBD (l_dobj) lesions_19/NNS (l_conj) fibrosis_21/NN
4631913
D014750_D011552 CID sulfate_3/NN (l_prep) on_4/IN (l_pobj) infections_6/NNS
D014750_D007970 CID sulfate_11/NN (r_pobj) of_9/IN (r_prep) mg_8/NNS (r_pobj) of_4/IN (r_prep) inoculation_3/NN (r_conj) Intravenous_0/JJ (r_nsubjpass) followed_13/VBN (l_agent) by_14/IN (l_pobj) leukopenia_15/NN
D014750_D007239 NONE sulfate_21/NN (r_dative) given_19/VBN (r_prep) inoculation_1/NN (r_nsubj) resulted_25/VBN (l_prep) in_26/IN (l_pobj) infection_28/NN
6305660
1359137
D014150_D006966 CID Neuroleptic_0/NNP (r_npadvmod) associated_2/VBN (r_amod) hyperprolactinemia_3/NN
D014150_D006966 CID medications_14/NNS (r_pobj) with_11/IN (r_prep) associated_10/VBN (r_acl) outpatients_3/NNS (l_prep) with_4/IN (l_pobj) hyperprolactinemia_5/NNP
D014150_D006966 CID neuroleptic_12/NN (r_amod) associated_14/VBN (r_amod) hyperprolactinemia_15/NNP
D014150_D000568 CID medications_14/NNS (r_pobj) with_11/IN (r_prep) associated_10/VBN (r_acl) outpatients_3/NNS (l_prep) with_4/IN (l_pobj) hyperprolactinemia_5/NNP (l_conj) oligomenorrhea_9/NNP (l_nmod) amenorrhea_7/NNP
D014150_D000568 CID neuroleptic_12/NN (r_amod) associated_14/VBN (r_amod) hyperprolactinemia_15/NNP (l_conj) galactorrhea_19/NNP (l_nmod) amenorrhea_17/NNP
D014150_D009839 CID medications_14/NNS (r_pobj) with_11/IN (r_prep) associated_10/VBN (r_acl) outpatients_3/NNS (l_prep) with_4/IN (l_pobj) hyperprolactinemia_5/NNP (l_conj) oligomenorrhea_9/NNP
D001971_D006966 NONE bromocriptine_18/NNP (r_pobj) with_17/IN (r_prep) treated_16/VBN (l_nsubjpass) outpatients_3/NNS (l_prep) with_4/IN (l_pobj) hyperprolactinemia_5/NNP
D001971_D006966 NONE bromocriptine_3/NNP (r_nsubjpass) evaluated_7/VBN (l_prep) as_8/IN (l_pobj) therapy_10/NN (l_prep) for_11/IN (l_pobj) hyperprolactinemia_15/NNP
D001971_D000568 NONE bromocriptine_18/NNP (r_pobj) with_17/IN (r_prep) treated_16/VBN (l_nsubjpass) outpatients_3/NNS (l_prep) with_4/IN (l_pobj) hyperprolactinemia_5/NNP (l_conj) oligomenorrhea_9/NNP (l_nmod) amenorrhea_7/NNP
D001971_D000568 NONE bromocriptine_3/NNP (r_nsubjpass) evaluated_7/VBN (l_prep) as_8/IN (l_pobj) therapy_10/NN (l_prep) for_11/IN (l_pobj) hyperprolactinemia_15/NNP (l_conj) galactorrhea_19/NNP (l_nmod) amenorrhea_17/NNP
D001971_D009839 NONE bromocriptine_18/NNP (r_pobj) with_17/IN (r_prep) treated_16/VBN (l_nsubjpass) outpatients_3/NNS (l_prep) with_4/IN (l_pobj) hyperprolactinemia_5/NNP (l_conj) oligomenorrhea_9/NNP
D001971_D011618 CID bromocriptine_11/NN (r_dobj) taking_10/VBG (r_advcl) worsened_6/VBN (l_dobj) symptoms_8/NNS
D001971_D005687 NONE bromocriptine_3/NNP (r_nsubjpass) evaluated_7/VBN (l_prep) as_8/IN (l_pobj) therapy_10/NN (l_prep) for_11/IN (l_pobj) hyperprolactinemia_15/NNP (l_conj) galactorrhea_19/NNP
D014150_D005687 NONE neuroleptic_12/NN (r_amod) associated_14/VBN (r_amod) hyperprolactinemia_15/NNP (l_conj) galactorrhea_19/NNP
24614773
D014635_D010291 NONE valproate_25/NN (r_advmod) started_23/VBN (r_conj) had_7/VBD (l_dobj) number_9/NN (l_prep) of_10/IN (l_pobj) admissions_11/NNS (l_prep) with_12/IN (l_pobj) hemiparesis_15/NN
D014635_D020325 NONE valproate_25/NN (r_advmod) started_23/VBN (l_prep) for_26/IN (l_pobj) migraine_29/NN
D016202_D001927 NONE aspartate_20/NN (r_nsubj) were_26/VBD (r_conj) showed_5/VBD (l_dobj) changes_6/NNS (l_amod) consistent_7/JJ (l_prep) with_8/IN (l_pobj) encephalopathy_9/NN
D016202_D001927 NONE NMDA_22/NNP (r_appos) aspartate_20/NN (r_nsubj) were_26/VBD (r_conj) showed_5/VBD (l_dobj) changes_6/NNS (l_amod) consistent_7/JJ (l_prep) with_8/IN (l_pobj) encephalopathy_9/NN
D016202_D001927 NONE NMDA_9/NNP (r_compound) encephalitis_13/NN (r_conj) encephalopathy_7/NN
D014635_D001927 NONE valproate_4/NN (r_advmod) induced_6/VBN (r_amod) encephalopathy_7/NN
D014635_D004660 NONE valproate_4/NN (r_advmod) induced_6/VBN (r_amod) encephalopathy_7/NN (l_conj) encephalitis_13/NN
D016202_D004660 NONE NMDA_9/NNP (r_compound) encephalitis_13/NN
15282950
D010936_D009202 NONE chebula_4/NNP (l_prep) against_5/IN (l_pobj) injury_8/NN
D010936_D009202 NONE fruits_8/NNS (r_pobj) of_5/IN (r_prep) extract_4/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) examined_16/VBN (l_conj) induced_25/VBD (l_dobj) damage_27/NN
D007545_D009202 CID isoproterenol_11/NN (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) injury_8/NN
D007545_D009202 CID isoproterenol_18/NNP (r_pobj) in_17/IN (r_prep) examined_16/VBN (l_conj) induced_25/VBD (l_dobj) damage_27/NN
16911931
D019259_D006509 NONE lamivudine_7/NNP (r_pobj) with_6/IN (r_prep) combined_5/VBN (r_acl) globulin_4/NN (l_compound) B_2/NNP
D019259_D006509 NONE lamivudine_7/NNP (r_pobj) with_6/IN (r_prep) combined_5/VBN (l_prep) in_8/IN (l_pobj) prevention_9/NN (l_prep) of_10/IN (l_pobj) recurrence_13/NN (l_compound) B_12/NNP
D019259_D006509 NONE lamivudine_9/NN (r_conj) HBIg_6/NNS (r_appos) globulin_4/NN (l_nmod) B_2/NNP
D019259_D006509 NONE lamivudine_9/NN (r_conj) HBIg_6/NNS (r_appos) globulin_4/NN (l_prep) in_10/IN (l_pobj) prophylaxis_11/NN (l_prep) of_12/IN (l_pobj) recurrence_14/NN (l_prep) of_15/IN (l_pobj) B_17/NN
D006514_D006509 NONE HBsAg_27/NNP (r_nmod) patients_29/NNS (r_pobj) of_26/IN (r_prep) survival_25/NN (r_dobj) improved_23/VBN (l_nsubj) globulin_4/NN (l_nmod) B_2/NNP
D006514_D006509 NONE HBsAg_27/NNP (r_nmod) patients_29/NNS (r_pobj) of_26/IN (r_prep) survival_25/NN (r_dobj) improved_23/VBN (l_nsubj) globulin_4/NN (l_prep) in_10/IN (l_pobj) prophylaxis_11/NN (l_prep) of_12/IN (l_pobj) recurrence_14/NN (l_prep) of_15/IN (l_pobj) B_17/NN
19531695
D005424_D003693 CID flecainide_6/JJ (r_compound) concentrations_8/NNS (r_pobj) with_4/IN (r_prep) patient_3/NN (r_pobj) in_1/IN (r_prep) Delirium_0/NNP
D005424_D003693 CID flecainide_5/NN (r_npadvmod) induced_7/VBN (r_amod) delirium_8/NN
D005424_D003693 CID Flecainide_0/NNP (r_nsubj) cause_11/VB (l_dobj) delirium_12/NN
D005424_D003693 CID flecainide_17/NNP (l_appos) substrate_21/NN (l_conj) paroxetine_24/NNP (l_appos) inhibitor_28/NN (l_conj) reports_35/NNS (l_prep) of_36/IN (l_pobj) delirium_40/NN
D005424_D003693 CID flecainide_37/NN (r_npadvmod) induced_39/VBN (r_amod) delirium_40/NN
D005424_D003693 CID flecainide_7/NNP (r_nsubj) was_8/VBD (l_attr) cause_11/NN (l_prep) of_12/IN (l_pobj) delirium_16/NN
D005424_D003693 CID flecainide_31/NNP (r_pobj) between_30/IN (r_prep) interaction_29/NN (r_dobj) indicates_24/VBZ (l_ccomp) was_8/VBD (l_attr) cause_11/NN (l_prep) of_12/IN (l_pobj) delirium_16/NN
D005424_D003693 CID flecainide_1/JJ (r_compound) concentrations_3/NNS (r_nsubj) cause_5/VB (l_dobj) delirium_6/NN
D017374_D003693 CID paroxetine_18/NNP (r_pobj) with_17/IN (r_prep) interaction_16/NN (r_pobj) of_12/IN (r_prep) role_11/NN (r_appos) Delirium_0/NNP
D017374_D003693 CID paroxetine_16/NNP (r_pobj) with_15/IN (r_prep) interaction_14/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) delirium_8/NN
D017374_D003693 CID paroxetine_24/NNP (l_appos) inhibitor_28/NN (l_conj) reports_35/NNS (l_prep) of_36/IN (l_pobj) delirium_40/NN
D017374_D003693 CID paroxetine_33/NNP (r_conj) flecainide_31/NNP (r_pobj) between_30/IN (r_prep) interaction_29/NN (r_dobj) indicates_24/VBZ (l_ccomp) was_8/VBD (l_attr) cause_11/NN (l_prep) of_12/IN (l_pobj) delirium_16/NN
D005424_D001281 NONE Flecainide_0/NNP (r_nsubjpass) started_3/VBN (l_advmod) prior_6/RB (l_prep) for_7/IN (l_pobj) fibrillation_9/NN
D012964_D003693 NONE sodium_8/NN (r_compound) channels_9/NNS (r_pobj) with_7/IN (r_prep) interact_6/VBP (r_relcl) agents_4/NNS (r_conj) Flecainide_0/NNP (r_nsubj) cause_11/VB (l_dobj) delirium_12/NN
D005424_D064420 NONE flecainide_5/NNP (r_nsubjpass) prescribed_7/VBN (r_advcl) occur_3/VB (l_nsubj) toxicity_1/NN
D005424_D064420 NONE flecainide_16/JJ (r_compound) concentrations_18/NNS (r_nsubjpass) monitored_21/VBN (l_advcl) occur_3/VB (l_nsubj) toxicity_1/NN
D017374_D064420 NONE paroxetine_9/NN (r_pobj) with_8/IN (r_prep) prescribed_7/VBN (r_advcl) occur_3/VB (l_nsubj) toxicity_1/NN
3289726
D005047_D009422 NONE etoposide_7/NN (r_compound) therapy_8/NN (r_pobj) after_3/IN (r_prep) dysfunction_2/NN
D005047_D005910 NONE etoposide_7/NN (r_compound) therapy_8/NN (l_prep) for_9/IN (l_pobj) glioma_11/NN
D005047_D005910 NONE etoposide_13/NN (r_compound) therapy_14/NN (r_pobj) of_9/IN (r_prep) toxicity_8/NN (l_prep) for_15/IN (l_pobj) glioma_17/NN
D005047_D009369 NONE Etoposide_0/NN (r_nsubjpass) used_8/VBN (l_prep) in_9/IN (l_pobj) treatment_11/NN (l_prep) of_12/IN (l_pobj) tumors_15/NNS
D005047_D009369 NONE 213_4/CD (r_appos) Etoposide_0/NN (r_nsubjpass) used_8/VBN (l_prep) in_9/IN (l_pobj) treatment_11/NN (l_prep) of_12/IN (l_pobj) tumors_15/NNS
D005047_D019337 NONE Etoposide_0/NN (r_nsubjpass) used_8/VBN (l_prep) in_9/IN (l_pobj) treatment_11/NN (l_prep) of_12/IN (l_pobj) tumors_15/NNS (l_conj) malignancies_18/NNS
D005047_D019337 NONE 213_4/CD (r_appos) Etoposide_0/NN (r_nsubjpass) used_8/VBN (l_prep) in_9/IN (l_pobj) treatment_11/NN (l_prep) of_12/IN (l_pobj) tumors_15/NNS (l_conj) malignancies_18/NNS
D005047_D064420 NONE etoposide_13/NN (r_compound) therapy_14/NN (r_pobj) of_9/IN (r_prep) toxicity_8/NN
20431083
D014859_D002543 CID warfarin_69/NN (r_amod) users_70/NNS (r_pobj) in_68/IN (r_prep) users_58/NNS (r_pobj) in_56/IN (r_prep) range_50/NN (r_pobj) to_47/IN (r_prep) increased_31/VBD (r_conj) were_14/VBD (l_ccomp) IS_9/VBZ (l_prep) In_0/IN (l_pobj) analysis_3/NN (l_prep) of_4/IN (l_pobj) ICH_6/NNP
D014859_D002543 CID warfarin_69/NN (r_amod) users_70/NNS (r_pobj) in_68/IN (r_prep) users_58/NNS (r_pobj) in_56/IN (r_prep) range_50/NN (r_pobj) to_47/IN (r_prep) increased_31/VBD (r_conj) were_14/VBD (l_acomp) frequent_16/JJ (l_prep) in_17/IN (l_pobj) ICH_18/NNP
D014859_D002543 CID warfarin_8/NN (r_amod) users_9/NNS (l_prep) vs_10/IN (l_pobj) nonusers_11/NNS (l_prep) with_12/IN (l_pobj) ICH_13/NNP
D014859_D002543 CID warfarin_32/NN (r_amod) users_33/NNS (r_pobj) in_31/IN (r_prep) none_30/NN (r_conj) CI_21/NNP (r_attr) was_1/VBD (l_prep) in_7/IN (l_pobj) users_9/NNS (l_prep) vs_10/IN (l_pobj) nonusers_11/NNS (l_prep) with_12/IN (l_pobj) ICH_13/NNP
D014859_D002543 CID warfarin_5/NN (r_amod) users_6/NNS (l_prep) with_7/IN (l_pobj) ICH_8/NNP
D014859_D002543 CID warfarin_5/NN (r_amod) users_6/NNS (r_pobj) in_4/IN (r_prep) excess_1/NN (r_nsubj) suggests_13/VBZ (l_ccomp) increase_16/VB (l_dobj) risk_18/NN (l_prep) of_19/IN (l_pobj) ICH_23/NNP
D014859_D002543 CID warfarin_20/NN (r_advmod) associated_22/VBN (r_amod) ICH_23/NNP (r_pobj) of_19/IN (r_prep) risk_18/NN (r_dobj) increase_16/VB (r_ccomp) suggests_13/VBZ (l_nsubj) excess_1/NN (l_prep) in_4/IN (l_pobj) users_6/NNS (l_prep) with_7/IN (l_pobj) ICH_8/NNP
D014859_D002543 CID warfarin_20/NN (r_advmod) associated_22/VBN (r_amod) ICH_23/NNP
D014859_D002544 NONE warfarin_69/NN (r_amod) users_70/NNS (r_pobj) in_68/IN (r_prep) users_58/NNS (r_pobj) in_56/IN (r_prep) range_50/NN (r_pobj) to_47/IN (r_prep) increased_31/VBD (r_conj) were_14/VBD (l_ccomp) IS_9/VBZ
D014859_D002544 NONE warfarin_69/NN (r_amod) users_70/NNS (r_pobj) in_68/IN (r_prep) users_58/NNS (r_pobj) in_56/IN (r_prep) range_50/NN (r_pobj) to_47/IN (r_prep) increased_31/VBD (r_conj) were_14/VBD (l_attr) TIA_22/NNP (l_nmod) IS_20/VBZ
D014859_D002544 NONE warfarin_8/NN (r_amod) users_9/NNS (r_pobj) in_7/IN (r_prep) was_1/VBD (l_attr) CI_21/NNP (l_conj) none_30/NN (l_prep) in_31/IN (l_pobj) users_33/NNS (l_prep) with_34/IN (l_pobj) CI_45/NNP (l_nmod) TIA_37/NNP (l_nmod) IS_35/VBZ
D014859_D002544 NONE warfarin_32/NN (r_amod) users_33/NNS (l_prep) with_34/IN (l_pobj) CI_45/NNP (l_nmod) TIA_37/NNP (l_nmod) IS_35/VBZ
D014859_D002546 NONE warfarin_69/NN (r_amod) users_70/NNS (r_pobj) in_68/IN (r_prep) users_58/NNS (r_pobj) in_56/IN (r_prep) range_50/NN (r_pobj) to_47/IN (r_prep) increased_31/VBD (r_conj) were_14/VBD (l_ccomp) IS_9/VBZ (l_attr) TIA_11/NNP
D014859_D002546 NONE warfarin_69/NN (r_amod) users_70/NNS (r_pobj) in_68/IN (r_prep) users_58/NNS (r_pobj) in_56/IN (r_prep) range_50/NN (r_pobj) to_47/IN (r_prep) increased_31/VBD (r_conj) were_14/VBD (l_attr) TIA_22/NNP
D014859_D002546 NONE warfarin_8/NN (r_amod) users_9/NNS (r_pobj) in_7/IN (r_prep) was_1/VBD (l_attr) CI_21/NNP (l_conj) none_30/NN (l_prep) in_31/IN (l_pobj) users_33/NNS (l_prep) with_34/IN (l_pobj) CI_45/NNP (l_nmod) TIA_37/NNP
D014859_D002546 NONE warfarin_32/NN (r_amod) users_33/NNS (l_prep) with_34/IN (l_pobj) CI_45/NNP (l_nmod) TIA_37/NNP
D014859_-1 NONE warfarin_69/NN (r_amod) users_70/NNS (r_pobj) in_68/IN (r_prep) users_58/NNS (r_pobj) in_56/IN (r_prep) range_50/NN (r_pobj) to_47/IN (r_prep) increased_31/VBD (r_conj) were_14/VBD (l_nsubj) MB_13/NNP
D014859_-1 NONE warfarin_8/NN (r_amod) users_9/NNS (r_pobj) in_7/IN (r_prep) was_1/VBD (l_attr) excess_4/NN (l_prep) of_5/IN (l_pobj) MB_6/NN
D014859_-1 NONE warfarin_32/NN (r_amod) users_33/NNS (r_pobj) in_31/IN (r_prep) none_30/NN (r_conj) CI_21/NNP (r_attr) was_1/VBD (l_attr) excess_4/NN (l_prep) of_5/IN (l_pobj) MB_6/NN
D014859_-1 NONE warfarin_5/NN (r_amod) users_6/NNS (r_pobj) in_4/IN (r_prep) excess_1/NN (l_prep) of_2/IN (l_pobj) MB_3/NN
D014859_-1 NONE warfarin_5/NN (r_amod) users_6/NNS (r_pobj) in_4/IN (r_prep) excess_1/NN (r_nsubj) suggests_13/VBZ (l_ccomp) increase_16/VB (l_nsubj) MB_15/NN
D014859_-1 NONE warfarin_20/NN (r_advmod) associated_22/VBN (r_amod) ICH_23/NNP (r_pobj) of_19/IN (r_prep) risk_18/NN (r_dobj) increase_16/VB (r_ccomp) suggests_13/VBZ (l_nsubj) excess_1/NN (l_prep) of_2/IN (l_pobj) MB_3/NN
D014859_-1 NONE warfarin_20/NN (r_advmod) associated_22/VBN (r_amod) ICH_23/NNP (r_pobj) of_19/IN (r_prep) risk_18/NN (r_dobj) increase_16/VB (l_nsubj) MB_15/NN
6806735
D002945_D010051 NONE platinum_10/NN (r_pobj) of_7/IN (r_prep) combination_6/NN (r_pobj) with_4/IN (r_prep) Treatment_0/NN (l_prep) of_1/IN (l_pobj) cancer_3/NN
D002945_D010051 NONE cisplatinum_18/NNP (r_pobj) of_17/IN (r_prep) combination_16/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (l_nsubjpass) patients_8/NNS (l_prep) with_9/IN (l_pobj) cancer_11/NN
D004317_D010051 NONE adriamycin_12/NN (r_conj) platinum_10/NN (r_pobj) of_7/IN (r_prep) combination_6/NN (r_pobj) with_4/IN (r_prep) Treatment_0/NN (l_prep) of_1/IN (l_pobj) cancer_3/NN
D004317_D010051 NONE adriamycin_28/NN (r_conj) m2_26/NNP (r_conj) cisplatinum_18/NNP (r_pobj) of_17/IN (r_prep) combination_16/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (l_nsubjpass) patients_8/NNS (l_prep) with_9/IN (l_pobj) cancer_11/NN
D003520_D010051 NONE cyclophosphamide_14/NN (r_conj) adriamycin_12/NN (r_conj) platinum_10/NN (r_pobj) of_7/IN (r_prep) combination_6/NN (r_pobj) with_4/IN (r_prep) Treatment_0/NN (l_prep) of_1/IN (l_pobj) cancer_3/NN
D003520_D010051 NONE cyclophosphamide_35/IN (r_conj) m2_33/NNP (r_conj) adriamycin_28/NN (r_conj) m2_26/NNP (r_conj) cisplatinum_18/NNP (r_pobj) of_17/IN (r_prep) combination_16/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (l_nsubjpass) patients_8/NNS (l_prep) with_9/IN (l_pobj) cancer_11/NN
D006585_D010051 NONE hexamethylmelamine_16/NNP (r_conj) cyclophosphamide_14/NN (r_conj) adriamycin_12/NN (r_conj) platinum_10/NN (r_pobj) of_7/IN (r_prep) combination_6/NN (r_pobj) with_4/IN (r_prep) Treatment_0/NN (l_prep) of_1/IN (l_pobj) cancer_3/NN
D006585_D010051 NONE hexamethylmelamine_47/NNP (r_conj) treated_13/VBN (l_nsubjpass) patients_8/NNS (l_prep) with_9/IN (l_pobj) cancer_11/NN
D006585_D010051 NONE HMM_49/NNP (r_appos) hexamethylmelamine_47/NNP (r_conj) treated_13/VBN (l_nsubjpass) patients_8/NNS (l_prep) with_9/IN (l_pobj) cancer_11/NN
C034868_D010051 NONE CPDD_20/NNP (r_appos) cisplatinum_18/NNP (r_pobj) of_17/IN (r_prep) combination_16/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (l_nsubjpass) patients_8/NNS (l_prep) with_9/IN (l_pobj) cancer_11/NN
D006585_D005767 NONE HMM_0/UH (r_nsubj) necessitated_3/VBD (l_nsubj) toxicity_2/NN
3685052
D005481_D012640 NONE Flurothyl_0/NN (r_compound) thresholds_2/NNS (l_compound) seizure_1/NN
D005481_D012640 NONE Flurothyl_0/NN (r_compound) thresholds_2/NNS (r_nsubj) treated_5/VBD (l_prep) with_7/IN (l_pobj) injection_10/NN (l_prep) of_11/IN (l_pobj) glutamate_13/NN (l_appos) evaluation_18/NN (l_prep) in_22/IN (l_pobj) testing_25/NN (l_compound) seizure_24/NN
D005481_D012640 NONE flurothyl_23/JJ (r_amod) testing_25/NN (r_pobj) in_22/IN (r_prep) evaluation_18/NN (r_appos) glutamate_13/NN (r_pobj) of_11/IN (r_prep) injection_10/NN (r_pobj) with_7/IN (r_prep) treated_5/VBD (l_nsubj) thresholds_2/NNS (l_compound) seizure_1/NN
D005481_D012640 NONE flurothyl_23/JJ (r_amod) testing_25/NN (l_compound) seizure_24/NN
D005481_D012640 NONE flurothyl_1/JJ (r_compound) ether_2/JJ (r_compound) technique_5/NN (l_compound) screening_4/NN (l_compound) seizure_3/NN
D005481_D012640 NONE flurothyl_1/JJ (r_compound) ether_2/JJ (r_compound) technique_5/NN (r_nsubjpass) used_7/VBN (l_xcomp) evaluate_9/VB (l_dobj) susceptibility_11/NN (l_compound) seizure_10/JJ
D005481_D012640 NONE Flurothyl_0/NNP (r_compound) ether_1/NN (r_nsubj) produced_2/VBD (r_ccomp) was_23/VBD (l_nsubj) relationship_17/NN (l_prep) to_20/IN (l_pobj) induction_22/NN (l_compound) seizure_21/NN
D005481_D012640 NONE flurothyl_11/JJ (r_amod) exposure_12/NN (r_pobj) of_10/IN (r_prep) duration_9/NN (r_pobj) with_7/IN (r_prep) correlated_6/VBN (r_relcl) hypothermia_3/NN (r_dobj) produced_2/VBD (r_ccomp) was_23/VBD (l_nsubj) relationship_17/NN (l_prep) to_20/IN (l_pobj) induction_22/NN (l_compound) seizure_21/NN
D005481_D012640 NONE Flurothyl_0/NNP (r_compound) testing_2/NN (l_compound) seizure_1/NN
D005481_D012640 NONE Flurothyl_0/NNP (r_compound) testing_2/NN (r_nsubj) proved_3/VBD (l_xcomp) be_5/VB (l_attr) technique_10/NN (l_relcl) evaluate_14/VB (l_dobj) susceptibility_16/NN (l_compound) seizure_15/NN
D012970_D012640 NONE glutamate_13/NN (r_pobj) of_11/IN (r_prep) injection_10/NN (r_pobj) with_7/IN (r_prep) treated_5/VBD (l_nsubj) thresholds_2/NNS (l_compound) seizure_1/NN
D012970_D012640 NONE glutamate_13/NN (l_appos) evaluation_18/NN (l_prep) in_22/IN (l_pobj) testing_25/NN (l_compound) seizure_24/NN
D012970_D012640 NONE MSG_15/NNP (r_appos) glutamate_13/NN (r_pobj) of_11/IN (r_prep) injection_10/NN (r_pobj) with_7/IN (r_prep) treated_5/VBD (l_nsubj) thresholds_2/NNS (l_compound) seizure_1/NN
D012970_D012640 NONE MSG_15/NNP (r_appos) glutamate_13/NN (l_appos) evaluation_18/NN (l_prep) in_22/IN (l_pobj) testing_25/NN (l_compound) seizure_24/NN
D012970_D012640 NONE glutamate_1/NN (r_nsubj) produces_9/VBZ (l_dobj) convulsions_10/NNS
D012970_D012640 NONE MSG_3/NNP (r_nmod) administration_5/NN (r_appos) glutamate_1/NN (r_nsubj) produces_9/VBZ (l_dobj) convulsions_10/NNS
D012970_D012640 NONE MSG_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_nsubj) produced_11/VBD (l_dobj) alterations_13/NNS (l_prep) in_14/IN (l_pobj) susceptibility_16/NN (l_compound) seizure_15/NN
D012970_D012640 NONE MSG_20/NNP (r_pobj) of_19/IN (r_prep) injections_18/NNS (r_dobj) received_16/VBD (r_relcl) mice_14/NNS (r_pobj) in_12/IN (r_prep) susceptibility_11/NN (r_dobj) evaluate_9/VB (r_xcomp) used_7/VBN (l_nsubjpass) technique_5/NN (l_compound) screening_4/NN (l_compound) seizure_3/NN
D012970_D012640 NONE MSG_20/NNP (r_pobj) of_19/IN (r_prep) injections_18/NNS (r_dobj) received_16/VBD (r_relcl) mice_14/NNS (r_pobj) in_12/IN (r_prep) susceptibility_11/NN (l_compound) seizure_10/JJ
D012970_D012640 NONE MSG_0/NNP (r_compound) treatment_1/NN (r_nsubj) resulted_2/VBD (l_conj) alter_13/VB (l_dobj) threshold_15/NN (l_compound) seizure_14/NN
D012970_D012640 NONE MSG_19/NNP (r_npadvmod) treated_21/VBN (r_amod) mice_22/NNS (r_pobj) of_18/IN (r_prep) control_17/NN (r_pobj) of_15/IN (r_prep) thresholds_14/NNS (l_compound) seizure_13/NN
D004986_D012640 NONE ether_2/JJ (r_compound) technique_5/NN (l_compound) screening_4/NN (l_compound) seizure_3/NN
D004986_D012640 NONE ether_2/JJ (r_compound) technique_5/NN (r_nsubjpass) used_7/VBN (l_xcomp) evaluate_9/VB (l_dobj) susceptibility_11/NN (l_compound) seizure_10/JJ
D004986_D012640 NONE ether_1/NN (r_nsubj) produced_2/VBD (r_ccomp) was_23/VBD (l_nsubj) relationship_17/NN (l_prep) to_20/IN (l_pobj) induction_22/NN (l_compound) seizure_21/NN
D009270_D012640 NONE naloxone_1/NN (r_nsubj) was_7/VBD (l_acomp) ineffective_9/JJ (l_prep) in_10/IN (l_pcomp) altering_11/VBG (l_dobj) thresholds_14/NNS (l_compound) seizure_13/NN
D005481_D007035 CID Flurothyl_0/NNP (r_compound) ether_1/NN (r_nsubj) produced_2/VBD (l_dobj) hypothermia_3/NN
D005481_D007035 CID Flurothyl_0/NNP (r_compound) ether_1/NN (r_nsubj) produced_2/VBD (r_ccomp) was_23/VBD (l_nsubj) relationship_17/NN (l_prep) of_18/IN (l_pobj) hypothermia_19/NN
D005481_D007035 CID flurothyl_11/JJ (r_amod) exposure_12/NN (r_pobj) of_10/IN (r_prep) duration_9/NN (r_pobj) with_7/IN (r_prep) correlated_6/VBN (r_relcl) hypothermia_3/NN
D005481_D007035 CID flurothyl_11/JJ (r_amod) exposure_12/NN (r_pobj) of_10/IN (r_prep) duration_9/NN (r_pobj) with_7/IN (r_prep) correlated_6/VBN (r_relcl) hypothermia_3/NN (r_dobj) produced_2/VBD (r_ccomp) was_23/VBD (l_nsubj) relationship_17/NN (l_prep) of_18/IN (l_pobj) hypothermia_19/NN
D004986_D007035 NONE ether_1/NN (r_nsubj) produced_2/VBD (l_dobj) hypothermia_3/NN
D004986_D007035 NONE ether_1/NN (r_nsubj) produced_2/VBD (r_ccomp) was_23/VBD (l_nsubj) relationship_17/NN (l_prep) of_18/IN (l_pobj) hypothermia_19/NN
1615846
D015248_D006951 NONE Gemfibrozil_0/NN (r_compound) lovastatin_2/NN (r_compound) therapy_3/NN (l_prep) for_4/IN (l_pobj) hyperlipoproteinemias_6/NNP
D008148_D006951 NONE lovastatin_2/NN (r_compound) therapy_3/NN (l_prep) for_4/IN (l_pobj) hyperlipoproteinemias_6/NNP
D015248_D006949 NONE gemfibrozil_30/NN (r_compound) lovastatin_32/NN (r_appos) label_28/NN (r_nmod) treatment_33/NN (l_prep) in_34/IN (l_pobj) patients_36/NNS (l_prep) with_37/IN (l_pobj) hyperlipidemia_40/NN
D015248_D002340 NONE gemfibrozil_30/NN (r_compound) lovastatin_32/NN (r_appos) label_28/NN (r_nmod) treatment_33/NN (l_prep) in_34/IN (l_pobj) patients_36/NNS (l_prep) with_37/IN (l_pobj) hyperlipidemia_40/NN (l_relcl) had_46/VBD (l_dobj) disease_49/NN
D008148_D006949 NONE lovastatin_32/NN (r_appos) label_28/NN (r_nmod) treatment_33/NN (l_prep) in_34/IN (l_pobj) patients_36/NNS (l_prep) with_37/IN (l_pobj) hyperlipidemia_40/NN
D008148_D002340 NONE lovastatin_32/NN (r_appos) label_28/NN (r_nmod) treatment_33/NN (l_prep) in_34/IN (l_pobj) patients_36/NNS (l_prep) with_37/IN (l_pobj) hyperlipidemia_40/NN (l_relcl) had_46/VBD (l_dobj) disease_49/NN
D003401_D009220 NONE creatine_28/NN (r_compound) phosphokinase_29/NN (r_pobj) with_25/IN (r_prep) %_24/NN (r_pobj) in_22/IN (r_prep) had_39/VBD (r_conj) occurred_14/VBD (l_nsubj) Myositis_0/NN
D003401_D012206 NONE creatine_28/NN (r_compound) phosphokinase_29/NN (r_pobj) with_25/IN (r_prep) %_24/NN (r_pobj) in_22/IN (r_prep) had_39/VBD (l_dobj) rhabdomyolysis_40/NN
D003401_D009212 NONE creatine_28/NN (r_compound) phosphokinase_29/NN (r_pobj) with_25/IN (r_prep) %_24/NN (r_pobj) in_22/IN (r_prep) had_39/VBD (l_dobj) rhabdomyolysis_40/NN (l_conj) myoglobinuria_42/NN
9071336
D017239_D001943 NONE Paclitaxel_0/NNP (l_conj) acid_6/NN (l_prep) in_7/IN (l_pobj) cancer_10/NN
D017239_D001943 NONE paclitaxel_4/NN (r_conj) acid_2/NNP (r_nsubj) are_18/VBP (l_attr) therapies_21/NNS (l_prep) for_22/IN (l_pobj) patients_26/NNS (l_compound) cancer_25/NN
D017239_D001943 NONE Taxol_6/NNP (r_nsubj) are_18/VBP (l_attr) therapies_21/NNS (l_prep) for_22/IN (l_pobj) patients_26/NNS (l_compound) cancer_25/NN
D005472_D001943 NONE 5-fluorouracil_2/CD (r_appos) Paclitaxel_0/NNP (l_conj) acid_6/NN (l_prep) in_7/IN (l_pobj) cancer_10/NN
D005472_D001943 NONE 5-fluorouracil_6/CD (r_punct) m2_10/NNP (l_appos) days_18/NNS (l_prep) in_22/IN (l_pobj) women_23/NNS (l_prep) with_24/IN (l_pobj) cancer_27/NN
D002955_D001943 NONE acid_6/NN (l_prep) in_7/IN (l_pobj) cancer_10/NN
D002955_D001943 NONE acid_2/NNP (r_nsubj) are_18/VBP (l_attr) therapies_21/NNS (l_prep) for_22/IN (l_pobj) patients_26/NNS (l_compound) cancer_25/NN
D017239_D064420 NONE Paclitaxel_0/NNP (r_nsubj) have_3/VBP (l_dobj) cytotoxicity_5/NN
D005472_D064420 NONE 5-fluorouracil_2/CD (r_conj) Paclitaxel_0/NNP (r_nsubj) have_3/VBP (l_dobj) cytotoxicity_5/NN
D016179_D009503 NONE factor_54/NN (r_dobj) required_49/VBN (l_ccomp) reported_2/VBN (l_ccomp) associated_32/VBN (l_prep) with_33/IN (l_pobj) neutropenia_36/NN
D016179_D009503 NONE factor_54/NN (l_amod) due_55/IN (l_pobj) neutropenia_57/NN
12165618
D019469_D007674 CID indinavir_5/NNP (r_npadvmod) related_7/VBN (r_amod) nephrotoxicity_8/NN
D019469_D007674 CID indinavir_4/NNP (r_nsubjpass) discontinued_6/VBN (l_prep) because_7/IN (l_pobj) nephrotoxicity_9/NN
D019469_D007674 CID Indinavir_0/NNP (r_npadvmod) associated_2/VBN (r_amod) nephrotoxicity_3/NN
D019469_D015658 NONE indinavir_5/NNP (r_npadvmod) related_7/VBN (r_amod) nephrotoxicity_8/NN (r_dobj) monitor_4/VB (l_prep) in_9/IN (l_pobj) cohort_11/NN (l_prep) of_12/IN (l_pobj) type_17/NN
D003404_-1 NONE creatinine_15/NN (r_compound) ratio_16/NN (r_pobj) in_10/IN (r_prep) increase_9/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (l_nsubjpass) leukocyturia_2/NN
D003404_-1 NONE creatinine_9/NN (r_compound) levels_10/NNS (r_dobj) had_7/VBD (l_nsubj) Children_0/NNS (l_prep) with_1/IN (l_pobj) leukocyturia_4/NN
D003404_-1 NONE creatinine_9/NN (r_compound) levels_10/NNS (r_dobj) had_7/VBD (l_prep) without_19/IN (l_pobj) leukocyturia_22/NN
D003404_-1 NONE creatinine_4/NN (r_compound) levels_5/NNS (r_nsubj) decreased_6/VBD (r_ccomp) returned_14/VBN (l_conj) disappeared_21/VBD (l_nsubj) leukocyturia_20/NN
D003404_-1 NONE creatinine_12/NN (r_compound) ratios_13/NNS (r_nsubj) returned_14/VBN (l_conj) disappeared_21/VBD (l_nsubj) leukocyturia_20/NN
D003404_-1 NONE creatinine_12/NN (r_compound) levels_13/NNS (r_pobj) in_10/IN (r_prep) increase_9/NN (r_dobj) had_7/VBD (l_nsubj) Children_0/NNS (l_prep) with_1/IN (l_pobj) leukocyturia_4/NN
D003404_D006417 NONE creatinine_15/NN (r_compound) ratio_16/NN (r_pobj) in_10/IN (r_prep) increase_9/NN (r_pobj) with_6/IN (l_conj) by_18/IN (l_pobj) hematuria_20/NN
D019469_-1 NONE indinavir_3/NNP (r_pobj) with_2/IN (r_prep) treated_1/VBN (r_acl) Children_0/NNS (r_nsubj) have_4/VBP (l_dobj) incidence_8/NN (l_prep) of_9/IN (l_pobj) leukocyturia_12/NN
D019469_-1 NONE Indinavir_0/NNP (r_npadvmod) associated_2/VBN (r_amod) nephrotoxicity_3/NN (r_nsubjpass) monitored_6/VBN (l_prep) in_10/IN (l_pobj) children_11/NNS (l_prep) with_12/IN (l_pobj) factors_14/NNS (l_prep) as_16/IN (l_pobj) leukocyturia_19/NN
9646784
D006493_D013921 CID Heparin_0/NN (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN
D006493_D013921 CID heparin_13/NN (r_compound) therapy_14/NN (r_pobj) of_12/IN (r_prep) effects_11/NNS (r_conj) thromboembolism_6/NN (r_conj) thrombocytopenia_3/NN
D006493_D013921 CID heparin_4/NN (r_compound) therapy_5/NN (l_prep) including_6/VBG (l_pobj) thrombocytopenia_10/NN
D006493_D013921 CID heparin_4/NN (r_compound) therapy_5/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubjpass) discussed_31/VBN (l_nsubjpass) thrombocytopenia_26/NN
D006493_D013921 CID heparin_7/NN (r_npadvmod) induced_9/VBN (r_amod) thrombocytopenia_10/NN
D006493_D013921 CID heparin_7/NN (r_npadvmod) induced_9/VBN (r_amod) thrombocytopenia_10/NN (r_pobj) including_6/VBG (r_prep) therapy_5/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubjpass) discussed_31/VBN (l_nsubjpass) thrombocytopenia_26/NN
D006493_D013921 CID heparin_12/NN (r_npadvmod) associated_14/VBN (r_amod) osteoporosis_15/NN (r_conj) thrombocytopenia_10/NN
D006493_D013921 CID heparin_12/NN (r_npadvmod) associated_14/VBN (r_amod) osteoporosis_15/NN (r_conj) thrombocytopenia_10/NN (r_pobj) including_6/VBG (r_prep) therapy_5/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubjpass) discussed_31/VBN (l_nsubjpass) thrombocytopenia_26/NN
D006493_D013923 CID Heparin_0/NN (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN (l_conj) thromboembolism_6/NN
D006493_D013923 CID heparin_13/NN (r_compound) therapy_14/NN (r_pobj) of_12/IN (r_prep) effects_11/NNS (r_conj) thromboembolism_6/NN
D006493_D010024 CID heparin_4/NN (r_compound) therapy_5/NN (l_prep) including_6/VBG (l_pobj) thrombocytopenia_10/NN (l_conj) osteoporosis_15/NN
D006493_D010024 CID heparin_7/NN (r_npadvmod) induced_9/VBN (r_amod) thrombocytopenia_10/NN (l_conj) osteoporosis_15/NN
D006493_D010024 CID heparin_12/NN (r_npadvmod) associated_14/VBN (r_amod) osteoporosis_15/NN
D006493_D004802 CID heparin_4/NN (r_compound) therapy_5/NN (l_prep) including_6/VBG (l_pobj) thrombocytopenia_10/NN (l_conj) osteoporosis_15/NN (l_conj) eosinophilia_17/NN
D006493_D004802 CID heparin_7/NN (r_npadvmod) induced_9/VBN (r_amod) thrombocytopenia_10/NN (l_conj) osteoporosis_15/NN (l_conj) eosinophilia_17/NN
D006493_D004802 CID heparin_12/NN (r_npadvmod) associated_14/VBN (r_amod) osteoporosis_15/NN (l_conj) eosinophilia_17/NN
D006493_D012871 CID heparin_4/NN (r_compound) therapy_5/NN (l_prep) including_6/VBG (l_pobj) thrombocytopenia_10/NN (l_conj) osteoporosis_15/NN (l_conj) eosinophilia_17/NN (l_conj) reactions_20/NNS
D006493_D012871 CID heparin_7/NN (r_npadvmod) induced_9/VBN (r_amod) thrombocytopenia_10/NN (l_conj) osteoporosis_15/NN (l_conj) eosinophilia_17/NN (l_conj) reactions_20/NNS
D006493_D012871 CID heparin_12/NN (r_npadvmod) associated_14/VBN (r_amod) osteoporosis_15/NN (l_conj) eosinophilia_17/NN (l_conj) reactions_20/NNS
D006493_D004342 CID heparin_4/NN (r_compound) therapy_5/NN (l_prep) including_6/VBG (l_pobj) thrombocytopenia_10/NN (l_conj) osteoporosis_15/NN (l_conj) eosinophilia_17/NN (l_conj) reactions_20/NNS (l_conj) reactions_23/NNS
D006493_D004342 CID heparin_7/NN (r_npadvmod) induced_9/VBN (r_amod) thrombocytopenia_10/NN (l_conj) osteoporosis_15/NN (l_conj) eosinophilia_17/NN (l_conj) reactions_20/NNS (l_conj) reactions_23/NNS
D006493_D004342 CID heparin_12/NN (r_npadvmod) associated_14/VBN (r_amod) osteoporosis_15/NN (l_conj) eosinophilia_17/NN (l_conj) reactions_20/NNS (l_conj) reactions_23/NNS
D006493_D000505 CID heparin_4/NN (r_compound) therapy_5/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubjpass) discussed_31/VBN (l_nsubjpass) thrombocytopenia_26/NN (l_conj) alopecia_28/NN
D006493_D000505 CID heparin_7/NN (r_npadvmod) induced_9/VBN (r_amod) thrombocytopenia_10/NN (r_pobj) including_6/VBG (r_prep) therapy_5/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubjpass) discussed_31/VBN (l_nsubjpass) thrombocytopenia_26/NN (l_conj) alopecia_28/NN
D006493_D000505 CID heparin_12/NN (r_npadvmod) associated_14/VBN (r_amod) osteoporosis_15/NN (r_conj) thrombocytopenia_10/NN (r_pobj) including_6/VBG (r_prep) therapy_5/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubjpass) discussed_31/VBN (l_nsubjpass) thrombocytopenia_26/NN (l_conj) alopecia_28/NN
17496739
C085143_D012640 NONE tazobactam_2/NNP (r_npadvmod) induced_4/VBN (r_amod) seizure_5/NN
D010878_D020258 NONE piperacillin_4/NNP (l_appos) neurotoxicity_8/NN
D010878_D020258 NONE piperacillin_11/NNP (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) neurotoxicity_8/NN
C085143_D007676 NONE tazobactam_54/NNP (r_pobj) of_51/IN (r_prep) doses_50/NNS (r_nsubjpass) given_61/VBN (r_advcl) report_1/VBP (l_dobj) woman_6/NN (l_prep) with_7/IN (l_pobj) disease_12/NN
C085143_D014202 CID tazobactam_54/NNP (r_pobj) of_51/IN (r_prep) doses_50/NNS (r_nsubjpass) given_61/VBN (r_advcl) report_1/VBP (l_dobj) woman_6/NN (l_relcl) developed_23/VBD (l_dobj) speech_25/NN (l_conj) tremor_27/NN
C085143_D003221 CID tazobactam_54/NNP (r_pobj) of_51/IN (r_prep) doses_50/NNS (r_nsubjpass) given_61/VBN (r_advcl) report_1/VBP (l_dobj) woman_6/NN (l_relcl) developed_23/VBD (l_dobj) speech_25/NN (l_conj) tremor_27/NN (l_conj) behavior_30/NN (l_conj) confusion_34/NN
C085143_D004830 CID tazobactam_54/NNP (r_pobj) of_51/IN (r_prep) doses_50/NNS (r_nsubjpass) given_61/VBN (r_advcl) report_1/VBP (l_dobj) woman_6/NN (l_relcl) developed_23/VBD (l_dobj) speech_25/NN (l_conj) tremor_27/NN (l_conj) behavior_30/NN (l_conj) confusion_34/NN (l_conj) episodes_38/NNS (l_prep) of_39/IN (l_pobj) seizure_44/NN
C085143_D004830 CID tazobactam_54/NNP (r_pobj) of_51/IN (r_prep) doses_50/NNS (r_nsubjpass) given_61/VBN (r_advcl) report_1/VBP (l_dobj) woman_6/NN (l_relcl) developed_23/VBD (l_dobj) speech_25/NN (l_conj) tremor_27/NN (l_conj) behavior_30/NN (l_conj) confusion_34/NN (l_conj) episodes_38/NNS (l_prep) of_39/IN (l_pobj) seizure_44/NN (l_appos) GTCS_46/NNP
C085143_D004830 CID tazobactam_18/NNP (r_pobj) of_15/IN (r_prep) dose_14/NN (r_pobj) after_11/IN (r_prep) recurred_10/VBD (l_nsubj) episode_9/NN (l_compound) GTCS_8/NNP
C085143_D001987 NONE tazobactam_54/NNP (r_pobj) of_51/IN (r_prep) doses_50/NNS (r_nsubjpass) given_61/VBN (l_prep) for_62/IN (l_pobj) bronchiectasis_63/NN
C085143_D060085 NONE tazobactam_54/NNP (r_pobj) of_51/IN (r_prep) doses_50/NNS (r_nsubjpass) given_61/VBN (l_prep) for_62/IN (l_pobj) bronchiectasis_63/NN (l_prep) with_64/IN (l_pobj) infection_66/NN
D000641_D007964 NONE ammonia_8/NN (r_compound) levels_9/NNS (r_conj) electrolyte_6/NN (l_conj) leukocytosis_11/NNP
D010878_D001927 NONE Piperacillin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) encephalopathy_3/NN
D010878_D001927 NONE piperacillin_5/NNP (r_dobj) removing_4/VBG (r_pcomp) in_3/IN (r_prep) inefficient_2/JJ (r_acomp) is_1/VBZ (l_advcl) terminate_11/VB (l_dobj) encephalopathy_16/NN
D010878_D001927 NONE piperacillin_13/NNP (r_npadvmod) induced_15/VBN (r_amod) encephalopathy_16/NN
D010878_D006463 NONE Piperacillin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) encephalopathy_3/NN (r_nsubjpass) considered_6/VBN (l_prep) in_7/IN (l_pobj) patients_10/NNS (l_amod) uremic_9/JJ
20828385
C401859_D020522 NONE temsirolimus_7/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (l_prep) in_8/IN (l_pobj) lymphoma_12/NN
C401859_D020522 NONE temsirolimus_16/NNP (r_pobj) with_15/IN (r_prep) treated_14/VBN (r_advcl) reported_10/VBN (l_prep) in_11/IN (l_pobj) MCL_13/NNP
C401859_D020522 NONE temsirolimus_19/NNP (r_compound) treatment_20/NN (r_pobj) after_18/IN (r_prep) had_13/VBD (r_relcl) MCL_11/NN
C401859_D020522 NONE temsirolimus_4/NNP (r_pobj) of_3/IN (r_prep) effect_2/NN (r_nsubj) contribute_9/VB (l_prep) to_10/IN (l_pobj) efficiency_14/NN (l_prep) in_15/IN (l_pobj) MCL_17/NN
C401859_D009369 NONE temsirolimus_19/NNP (r_compound) treatment_20/NN (r_pobj) after_18/IN (r_prep) had_13/VBD (l_dobj) regression_15/NN (l_compound) tumor_14/NN
C401859_D009369 NONE temsirolimus_7/NNP (r_nsubj) inhibited_8/VBD (l_dobj) proliferation_11/NN (l_compound) cell_10/NN (l_compound) tumor_9/NN
C401859_D009369 NONE temsirolimus_7/NNP (r_nsubj) inhibited_8/VBD (r_ccomp) showed_5/VBD (l_conj) induce_20/VB (l_dobj) change_22/NN (l_prep) in_23/IN (l_pobj) number_25/NN (l_prep) of_26/IN (l_pobj) cells_29/NNS (l_compound) tumor_28/NN
C401859_D009369 NONE temsirolimus_6/NNP (r_nsubj) had_7/VBD (l_dobj) effect_10/NN (l_prep) with_11/IN (l_pobj) decrease_12/NN (l_prep) of_13/IN (l_pobj) density_16/NN (l_compound) microvessel_15/NN (l_compound) tumor_14/NN
C401859_D009369 NONE temsirolimus_2/NNP (r_nsubj) reduced_3/VBD (l_dobj) burden_5/NN (l_compound) tumor_4/NN
C401859_D009369 NONE temsirolimus_4/NNP (l_prep) on_5/IN (l_pobj) tissue_7/NN (l_compound) tumor_6/NN
C401859_D009336 CID temsirolimus_23/NN (r_compound) therapy_24/NN (r_pobj) after_21/IN (r_prep) found_20/VBN (l_nsubjpass) areas_9/NNS (l_amod) compatible_11/JJ (l_prep) with_12/IN (l_pobj) repair_17/NN (l_amod) necrotic_15/JJ
17035713
C004656_D007674 NONE Chloroacetaldehyde_0/NNP (l_prep) as_1/IN (l_pobj) reagent_4/NN (l_appos) role_7/NN (l_prep) of_8/IN (l_pobj) groups_11/NNS (l_prep) in_12/IN (l_pobj) nephropathy_14/NN
C004656_D007674 NONE Chloroacetaldehyde_0/NNP (r_nsubj) is_4/VBZ (l_attr) metabolite_6/NN (l_prep) of_7/IN (l_pobj) agent_10/NN (l_appos) ifosfamide_11/NNP (l_conj) responsible_17/JJ (l_prep) for_18/IN (l_pobj) damage_20/NN
C004656_D007674 NONE CAA_2/NNP (r_appos) Chloroacetaldehyde_0/NNP (r_nsubj) is_4/VBZ (l_attr) metabolite_6/NN (l_prep) of_7/IN (l_pobj) agent_10/NN (l_appos) ifosfamide_11/NNP (l_conj) responsible_17/JJ (l_prep) for_18/IN (l_pobj) damage_20/NN
-1_D007674 NONE sulfhydryl_3/NN (r_compound) reagent_4/NN (l_appos) role_7/NN (l_prep) of_8/IN (l_pobj) groups_11/NNS (l_prep) in_12/IN (l_pobj) nephropathy_14/NN
D013438_D007674 NONE thiol_10/NN (r_compound) groups_11/NNS (l_prep) in_12/IN (l_pobj) nephropathy_14/NN
D007069_D007674 CID ifosfamide_13/NNP (r_compound) nephropathy_14/NN
D007069_D007674 CID ifosfamide_11/NNP (l_conj) responsible_17/JJ (l_prep) for_18/IN (l_pobj) damage_20/NN
D007069_D007674 CID IFO_13/NNP (r_appos) ifosfamide_11/NNP (l_conj) responsible_17/JJ (l_prep) for_18/IN (l_pobj) damage_20/NN
D007069_D007674 CID IFO_27/NNP (r_pobj) with_26/IN (r_prep) therapy_25/NN (r_pobj) following_21/VBG (r_prep) damage_20/NN
D007069_D007674 CID IFO_10/NNP (r_compound) nephropathy_11/NN
C004656_D009369 NONE Chloroacetaldehyde_0/NNP (r_nsubj) is_4/VBZ (l_attr) metabolite_6/NN (l_prep) of_7/IN (l_pobj) agent_10/NN (l_appos) ifosfamide_11/NNP (l_conj) responsible_17/JJ (l_prep) for_18/IN (l_pobj) damage_20/NN (l_prep) following_21/VBG (l_pobj) therapy_25/NN (l_amod) tumor_24/JJ
C004656_D009369 NONE CAA_2/NNP (r_appos) Chloroacetaldehyde_0/NNP (r_nsubj) is_4/VBZ (l_attr) metabolite_6/NN (l_prep) of_7/IN (l_pobj) agent_10/NN (l_appos) ifosfamide_11/NNP (l_conj) responsible_17/JJ (l_prep) for_18/IN (l_pobj) damage_20/NN (l_prep) following_21/VBG (l_pobj) therapy_25/NN (l_amod) tumor_24/JJ
D007069_D009369 NONE ifosfamide_11/NNP (l_conj) responsible_17/JJ (l_prep) for_18/IN (l_pobj) damage_20/NN (l_prep) following_21/VBG (l_pobj) therapy_25/NN (l_amod) tumor_24/JJ
D007069_D009369 NONE IFO_13/NNP (r_appos) ifosfamide_11/NNP (l_conj) responsible_17/JJ (l_prep) for_18/IN (l_pobj) damage_20/NN (l_prep) following_21/VBG (l_pobj) therapy_25/NN (l_amod) tumor_24/JJ
D007069_D009369 NONE IFO_27/NNP (r_pobj) with_26/IN (r_prep) therapy_25/NN (l_amod) tumor_24/JJ
C004656_D064420 NONE CAA_2/NNP (r_pobj) of_1/IN (r_prep) Toxicity_0/NN
C004656_D064420 NONE CAA_2/NNP (r_nsubj) reacts_4/VBZ (l_advcl) mediating_14/VBG (l_dobj) toxicity_16/NN
D014343_D064420 NONE blue_16/JJ (r_amod) assay_18/NN (r_conj) release_13/NN (r_conj) number_10/NN (r_conj) content_7/NN (r_pobj) by_5/IN (r_agent) determined_4/VBN (l_nsubjpass) Toxicity_0/NN
C004656_D009336 NONE CAA_0/NNP (r_nsubj) reduced_1/VBD (l_conj) induced_8/VBD (l_dobj) loss_10/NN (l_conj) increase_17/NN (l_prep) in_18/IN (l_pobj) markers_20/NNS (l_compound) necrosis_19/NN
C004656_D009336 NONE CAA_7/NNP (r_pobj) of_6/IN (r_prep) reaction_5/NN (r_dobj) slowed_3/VBD (r_relcl) Acidification_0/NN (r_nsubj) attenuate_14/VB (l_dobj) effects_15/NNS (l_prep) on_18/IN (l_pobj) markers_20/NNS (l_compound) necrosis_19/NN
C004656_D009336 NONE CAA_17/NNP (r_pobj) of_16/IN (r_prep) effects_15/NNS (l_prep) on_18/IN (l_pobj) markers_20/NNS (l_compound) necrosis_19/NN
D013438_D009336 NONE thiols_14/NNS (r_pobj) in_11/IN (r_prep) loss_10/NN (l_conj) increase_17/NN (l_prep) in_18/IN (l_pobj) markers_20/NNS (l_compound) necrosis_19/NN
D013438_D009336 NONE thiol_9/NN (r_compound) donors_10/NNS (r_pobj) with_8/IN (r_prep) reaction_5/NN (r_dobj) slowed_3/VBD (r_relcl) Acidification_0/NN (r_nsubj) attenuate_14/VB (l_dobj) effects_15/NNS (l_prep) on_18/IN (l_pobj) markers_20/NNS (l_compound) necrosis_19/NN
D013438_D009336 NONE thiol_22/NN (r_compound) depletion_23/NN (r_conj) markers_20/NNS (l_compound) necrosis_19/NN
D003545_D009336 NONE cysteine_25/NN (r_compound) protease_26/NN (r_compound) inhibition_27/NN (r_conj) depletion_23/NN (r_conj) markers_20/NNS (l_compound) necrosis_19/NN
D013438_D064420 NONE thiols_12/NNS (r_conj) protein_7/NN (r_pobj) with_5/IN (r_prep) reacts_4/VBZ (l_advcl) mediating_14/VBG (l_dobj) toxicity_16/NN
24739405
D003687_D012559 NONE dehydroepiandrosterone_2/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) in_3/IN (l_pobj) models_8/NNS (l_compound) schizophrenia_7/NN
D003687_D012559 NONE dehydroepiandrosterone_5/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (l_prep) on_9/IN (l_pobj) models_11/NNS (l_prep) of_12/IN (l_pobj) schizophrenia_13/NN
D003687_D012559 NONE DHEA_7/NNP (r_appos) dehydroepiandrosterone_5/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (l_prep) on_9/IN (l_pobj) models_11/NNS (l_prep) of_12/IN (l_pobj) schizophrenia_13/NN
D003687_D012559 NONE DHEA_3/NNP (r_nsubj) displays_4/VBZ (l_conj) used_14/VBN (l_prep) in_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) schizophrenia_19/NN
D000661_D012559 CID amphetamine_4/NN (r_npadvmod) induced_6/VBN (r_amod) models_8/NNS (l_compound) schizophrenia_7/NN
D000661_D012559 CID Amphetamine_0/NNP (r_nsubj) induced_6/VBD (l_conj) induced_29/VBD (l_ccomp) used_33/VBN (l_prep) as_34/IN (l_pobj) models_36/NNS (l_prep) of_37/IN (l_pobj) schizophrenia_38/NN
D000661_D006948 NONE Amphetamine_0/NNP (r_nsubj) induced_6/VBD (l_dobj) locomotion_8/NN (l_amod) hyper_7/JJ
D000661_D002375 NONE Amphetamine_0/NNP (r_nsubj) induced_6/VBD (l_conj) induced_29/VBD (l_ccomp) used_33/VBN (l_nsubjpass) tests_31/NNS (l_compound) catalepsy_30/NN
D001058_D006948 NONE apomorphine_10/NNP (r_appos) locomotion_8/NN (l_amod) hyper_7/JJ
D001058_D002375 NONE apomorphine_10/NNP (r_appos) locomotion_8/NN (r_dobj) induced_6/VBD (l_conj) induced_29/VBD (l_ccomp) used_33/VBN (l_nsubjpass) tests_31/NNS (l_compound) catalepsy_30/NN
D001058_D012559 CID apomorphine_10/NNP (r_appos) locomotion_8/NN (r_dobj) induced_6/VBD (l_conj) induced_29/VBD (l_ccomp) used_33/VBN (l_prep) as_34/IN (l_pobj) models_36/NNS (l_prep) of_37/IN (l_pobj) schizophrenia_38/NN
D006220_D006948 NONE haloperidol_23/NNP (r_nsubj) induced_29/VBD (r_conj) induced_6/VBD (l_dobj) locomotion_8/NN (l_amod) hyper_7/JJ
D006220_D002375 CID haloperidol_23/NNP (r_nsubj) induced_29/VBD (l_ccomp) used_33/VBN (l_nsubjpass) tests_31/NNS (l_compound) catalepsy_30/NN
D006220_D002375 CID haloperidol_9/NN (r_npadvmod) induced_11/VBN (r_amod) test_13/NN (l_compound) catalepsy_12/NN
D006220_D012559 CID haloperidol_23/NNP (r_nsubj) induced_29/VBD (l_ccomp) used_33/VBN (l_prep) as_34/IN (l_pobj) models_36/NNS (l_prep) of_37/IN (l_pobj) schizophrenia_38/NN
D003687_D002375 NONE DHEA_3/NNP (r_nsubj) reduced_4/VBD (l_conj) catalepsy_9/NN
2358093
D003613_D054179 NONE danazol_6/NN (r_pobj) of_5/IN (r_prep) safety_4/NN (l_prep) in_7/IN (l_pobj) women_8/NNS (l_prep) with_9/IN (l_pobj) angioedema_11/NN
D003613_D054179 NONE danazol_9/NNP (r_pobj) of_8/IN (r_prep) safety_7/NN (r_dobj) investigated_2/VBD (l_prep) by_10/IN (l_pcomp) performing_11/VBG (l_dobj) review_15/NN (l_prep) of_16/IN (l_pobj) patients_19/NNS (l_prep) with_20/IN (l_pobj) angioedema_22/NN
D003613_D054179 NONE danazol_25/NN (r_pobj) with_24/IN (r_prep) treated_23/VBN (r_acl) review_15/NN (l_prep) of_16/IN (l_pobj) patients_19/NNS (l_prep) with_20/IN (l_pobj) angioedema_22/NN
24283660
D016559_D012640 CID Tacrolimus_0/NN (r_npadvmod) related_2/VBN (r_amod) seizure_3/NN
D016559_D012640 CID TAC_5/NNP (r_compound) level_6/NN (r_nsubj) was_7/VBD (l_attr) factor_12/NN (l_acl) associated_13/VBN (l_prep) with_14/IN (l_pobj) seizures_16/NNS
D016559_D012640 CID TAC_2/NN (r_compound) level_3/NN (r_nsubj) was_4/VBD (l_attr) factor_7/NN (l_relcl) contributed_9/VBD (l_prep) to_10/IN (l_pobj) seizures_11/NNS
D016559_D012640 CID TAC_12/NNP (r_npadvmod) related_14/VBN (r_amod) seizures_15/NNS
12699527
D002712_D009224 NONE chloride_14/NN (r_compound) channel_15/NN (r_compound) function_16/NN (r_pobj) in_10/IN (r_prep) defect_9/NN (r_pobj) by_7/IN (r_agent) caused_6/VBN (l_nsubjpass) congenita_1/NN
D002712_D009224 NONE chloride_14/NN (r_compound) channel_15/NN (r_compound) function_16/NN (r_pobj) in_10/IN (r_prep) defect_9/NN (r_pobj) by_7/IN (r_agent) caused_6/VBN (l_nsubjpass) congenita_1/NN (l_appos) MC_3/NNP
D002712_-1 NONE chloride_14/NN (r_compound) channel_15/NN (r_compound) function_16/NN (l_relcl) cause_20/VB (l_dobj) depolarisation_23/NN
D013390_D013035 CID suxamethonium_26/NN (r_pobj) of_25/IN (r_prep) injection_24/NN (r_pobj) following_21/VBG (r_prep) describe_1/VBP (l_dobj) woman_8/NN (l_relcl) developed_10/VBD (l_dobj) spasm_16/NN
11380496
D011441_D006111 NONE propylthiouracil_21/NNP (r_pobj) with_20/IN (r_prep) treated_19/VBN (r_acl) patients_18/NNS (l_compound) disease_17/NN
D011441_D006111 NONE propylthiouracil_22/NNP (r_pobj) with_21/IN (r_prep) treated_20/VBN (r_relcl) disease_17/NN
D011441_D006111 NONE PTU_24/NNP (r_appos) propylthiouracil_22/NNP (r_pobj) with_21/IN (r_prep) treated_20/VBN (r_relcl) disease_17/NN
D011441_D006111 NONE PTU_21/NNP (r_compound) therapy_22/NN (r_pobj) during_20/IN (r_prep) studies_6/NNS (r_attr) been_4/VBN (l_prep) on_25/IN (l_pobj) incidence_27/NN (l_prep) of_28/IN (l_pobj) ANCA_31/NNP (l_prep) in_32/IN (l_pobj) patients_37/NNS (l_compound) disease_36/NN
D011441_D006111 NONE PTU_27/NNP (r_compound) therapy_28/NN (r_dobj) starting_26/VBG (r_pcomp) after_25/IN (r_prep) investigated_1/VBD (l_prep) with_5/IN (l_pobj) hyperthyroidism_6/NN (l_prep) due_7/IN (l_pcomp) to_8/IN (l_pobj) disease_11/NN
D011441_D014657 NONE propylthiouracil_22/NNP (r_pobj) with_21/IN (r_prep) treated_20/VBN (r_relcl) disease_17/NN (r_pobj) with_14/IN (r_prep) patients_13/NNS (r_pobj) in_12/IN (r_prep) reported_11/VBN (l_nsubjpass) vasculitis_8/NN
D011441_D014657 NONE PTU_24/NNP (r_appos) propylthiouracil_22/NNP (r_pobj) with_21/IN (r_prep) treated_20/VBN (r_relcl) disease_17/NN (r_pobj) with_14/IN (r_prep) patients_13/NNS (r_pobj) in_12/IN (r_prep) reported_11/VBN (l_nsubjpass) vasculitis_8/NN
D011441_D014657 NONE PTU_21/NNP (r_compound) therapy_22/NN (r_pobj) during_20/IN (r_prep) studies_6/NNS (l_conj) vasculitis_19/NN
D011441_D014657 NONE PTU_27/NNP (r_compound) therapy_28/NN (r_dobj) starting_26/VBG (r_pcomp) after_25/IN (r_prep) investigated_1/VBD (l_conj) for_21/IN (l_pobj) vasculitis_24/NN
D011441_D014657 NONE PTU_0/NNP (r_compound) therapy_1/NN (r_nsubjpass) related_4/VBN (l_conj) appear_19/VB (l_xcomp) be_21/VB (l_acomp) related_23/VBN (l_prep) to_24/IN (l_pobj) vasculitis_25/NN
D011441_D006980 NONE PTU_27/NNP (r_compound) therapy_28/NN (r_dobj) starting_26/VBG (r_pcomp) after_25/IN (r_prep) investigated_1/VBD (l_prep) with_5/IN (l_pobj) hyperthyroidism_6/NN
D011441_D014652 NONE PTU_24/NNP (r_compound) therapy_25/NN (r_pobj) despite_22/IN (r_prep) increased_11/VBD (l_conj) developed_31/VBD (l_nsubj) disorders_30/NNS
D011441_D005334 CID PTU_36/NNP (r_compound) therapy_37/NN (r_dobj) stopping_35/VBG (r_pcomp) after_34/IN (r_prep) resolved_31/VBD (r_conj) developed_18/VBD (l_dobj) fever_21/NN
D011441_D005334 CID PTU_56/NNP (r_dobj) discontinuing_55/VBG (r_pcomp) after_54/IN (r_prep) decreased_45/VBD (r_conj) resolved_31/VBD (r_conj) developed_18/VBD (l_dobj) fever_21/NN
D011441_D019226 CID PTU_36/NNP (r_compound) therapy_37/NN (r_dobj) stopping_35/VBG (r_pcomp) after_34/IN (r_prep) resolved_31/VBD (r_conj) developed_18/VBD (l_dobj) fever_21/NN (l_conj) ulcers_24/NNS
D011441_D019226 CID PTU_56/NNP (r_dobj) discontinuing_55/VBG (r_pcomp) after_54/IN (r_prep) decreased_45/VBD (r_conj) resolved_31/VBD (r_conj) developed_18/VBD (l_dobj) fever_21/NN (l_conj) ulcers_24/NNS
D011441_D018771 CID PTU_36/NNP (r_compound) therapy_37/NN (r_dobj) stopping_35/VBG (r_pcomp) after_34/IN (r_prep) resolved_31/VBD (r_conj) developed_18/VBD (l_dobj) fever_21/NN (l_conj) ulcers_24/NNS (l_conj) polyarthralgia_26/NNP
D011441_D018771 CID PTU_56/NNP (r_dobj) discontinuing_55/VBG (r_pcomp) after_54/IN (r_prep) decreased_45/VBD (r_conj) resolved_31/VBD (r_conj) developed_18/VBD (l_dobj) fever_21/NN (l_conj) ulcers_24/NNS (l_conj) polyarthralgia_26/NNP
6884395
D003276_D000784 CID contraceptives_19/NNS (r_nsubjpass) reported_21/VBN (l_nsubjpass) case_1/NN (l_prep) of_2/IN (l_pobj) aneurysm_5/NN
D003276_D006973 NONE contraceptives_19/NNS (r_nsubjpass) reported_21/VBN (l_nsubjpass) case_1/NN (l_prep) of_2/IN (l_pobj) aneurysm_5/NN (l_prep) of_6/IN (l_pobj) artery_9/NN (l_prep) in_10/IN (l_pobj) association_11/NN (l_prep) with_12/IN (l_pobj) hypertension_13/NN
D003276_D011782 NONE contraceptives_19/NNS (r_nsubjpass) reported_21/VBN (l_prep) in_22/IN (l_pobj) patient_26/NN (l_prep) with_27/IN (l_pobj) syndrome_32/NN
24894748
D008790_D001919 CID metoprolol_1/NN (r_compound) terbinafine_3/JJ (r_compound) combination_4/NN (r_nsubj) induced_5/VBN (l_dobj) bradycardia_6/NN
C041359_D001919 CID terbinafine_3/JJ (r_compound) combination_4/NN (r_nsubj) induced_5/VBN (l_dobj) bradycardia_6/NN
D008790_D012804 NONE metoprolol_7/NNP (r_pobj) by_6/IN (r_agent) induced_5/VBN (r_acl) bradycardia_4/NN
D008790_D012804 NONE metoprolol_27/NNP (r_pobj) between_26/IN (r_prep) interaction_25/NN (r_conj) bradycardia_21/NN
D008790_D012804 NONE metoprolol_10/NNP (r_poss) clearance_12/NN (r_dobj) decreased_9/VBN (l_advcl) leading_14/VBG (l_prep) in_15/IN (l_pobj) accumulation_17/NN (l_relcl) resulted_20/VBN (l_prep) in_21/IN (l_pobj) bradycardia_25/NN
D008790_D012804 NONE metoprolol_16/NN (r_compound) accumulation_17/NN (l_relcl) resulted_20/VBN (l_prep) in_21/IN (l_pobj) bradycardia_25/NN
C041359_D012804 NONE terbinafine_9/NNP (r_compound) interaction_13/NN (r_conj) metoprolol_7/NNP (r_pobj) by_6/IN (r_agent) induced_5/VBN (r_acl) bradycardia_4/NN
C041359_D012804 NONE terbinafine_29/NN (r_conj) metoprolol_27/NNP (r_pobj) between_26/IN (r_prep) interaction_25/NN (r_conj) bradycardia_21/NN
C041359_D012804 NONE terbinafine_7/NNP (r_nsubj) decreased_9/VBN (l_advcl) leading_14/VBG (l_prep) in_15/IN (l_pobj) accumulation_17/NN (l_relcl) resulted_20/VBN (l_prep) in_21/IN (l_pobj) bradycardia_25/NN
D008790_D003324 NONE metoprolol_8/NNP (r_pobj) on_7/IN (r_prep) man_6/NN (l_prep) for_13/IN (l_pobj) disease_17/NN
D008790_D014009 NONE metoprolol_8/NNP (r_pobj) on_7/IN (r_prep) man_6/NN (r_nsubjpass) prescribed_19/VBN (l_prep) for_30/IN (l_pobj) onychomycosis_31/NNP
C041359_D003324 NONE terbinafine_25/NNP (r_pobj) of_23/IN (r_prep) course_22/NN (r_dobj) prescribed_19/VBN (l_nsubjpass) man_6/NN (l_prep) for_13/IN (l_pobj) disease_17/NN
C041359_D014009 NONE terbinafine_25/NNP (r_pobj) of_23/IN (r_prep) course_22/NN (r_dobj) prescribed_19/VBN (l_prep) for_30/IN (l_pobj) onychomycosis_31/NNP
C041359_D003221 NONE terbinafine_5/NNP (r_compound) therapy_6/NN (r_pobj) of_4/IN (r_prep) day_3/NN (r_pobj) On_0/IN (r_prep) brought_10/VBN (l_prep) for_15/IN (l_pobj) decrease_17/NN (l_prep) of_18/IN (l_pobj) status_22/NN (l_conj) confusion_24/NN
D008790_D064420 NONE metoprolol_27/NNP (r_pobj) between_26/IN (r_prep) interaction_25/NN (r_conj) bradycardia_21/NN (r_pobj) between_16/IN (r_prep) relationship_15/NN (r_dobj) indicates_12/VBZ (l_nsubj) score_1/NN (l_prep) on_4/IN (l_pobj) scale_11/NN (l_compound) probability_10/NN (l_compound) reaction_9/NN
C041359_D064420 NONE terbinafine_29/NN (r_conj) metoprolol_27/NNP (r_pobj) between_26/IN (r_prep) interaction_25/NN (r_conj) bradycardia_21/NN (r_pobj) between_16/IN (r_prep) relationship_15/NN (r_dobj) indicates_12/VBZ (l_nsubj) score_1/NN (l_prep) on_4/IN (l_pobj) scale_11/NN (l_compound) probability_10/NN (l_compound) reaction_9/NN
3746148
D004176_D003324 NONE dipyridamole_14/NNP (r_compound) infusion_15/NN (r_pobj) after_13/IN (r_prep) detection_3/NN (l_prep) of_4/IN (l_pobj) disease_7/NN
D004176_D003324 NONE dipyridamole_4/NN (r_compound) test_6/NN (r_nsubj) is_7/VBZ (l_acomp) useful_9/JJ (l_prep) as_10/IN (l_pobj) test_14/NN (l_prep) for_15/IN (l_pobj) assessment_17/NN (l_prep) of_18/IN (l_pobj) disease_21/NN
D004176_D007511 NONE dipyridamole_1/NNP (r_pobj) After_0/IN (r_prep) observed_15/VBN (l_nsubjpass) depression_7/NN (l_amod) ischemic_3/JJ
D004176_D003866 NONE dipyridamole_1/NNP (r_pobj) After_0/IN (r_prep) observed_15/VBN (l_nsubjpass) depression_7/NN
D004176_D009203 NONE dipyridamole_1/NNP (r_pobj) After_0/IN (r_prep) observed_15/VBN (l_prep) in_16/IN (l_pobj) %_18/NN (l_prep) of_19/IN (l_pobj) group_24/NN (l_amod) MI_23/JJ
D004176_D056988 NONE dipyridamole_1/NNP (r_pobj) After_0/IN (r_prep) observed_15/VBN (l_prep) in_16/IN (l_pobj) %_18/NN (l_appos) %_27/NN (l_prep) of_28/IN (l_pobj) group_33/NN (l_compound) MI_32/NNP
D004176_D056989 NONE dipyridamole_1/NNP (r_pobj) After_0/IN (r_prep) observed_15/VBN (l_prep) in_16/IN (l_pobj) %_18/NN (l_appos) %_27/NN (l_appos) %_36/NN (l_prep) of_37/IN (l_pobj) group_42/NN (l_compound) MI_41/NNP
D004176_D017202 CID dipyridamole_5/NN (r_npadvmod) induced_7/VBN (r_amod) ischemia_9/NN
10401555
C096012_D007859 NONE Nociceptin_0/NNP (r_nmod) orphanin_2/NNP (r_compound) FQ_3/NNP (l_prep) on_6/IN (l_pobj) impairment_10/NN
C096012_D007859 NONE FQ_3/NNP (l_prep) on_6/IN (l_pobj) impairment_10/NN
C096012_D007859 NONE nociceptin_8/NNP (r_nsubj) modulate_15/VB (l_dobj) impairment_16/NN (l_prep) of_17/IN (l_pobj) learning_18/NN (l_conj) memory_20/NN
C096012_D007859 NONE FQ_11/NNP (r_appos) nociceptin_8/NNP (r_nsubj) modulate_15/VB (l_dobj) impairment_16/NN (l_prep) of_17/IN (l_pobj) learning_18/NN (l_conj) memory_20/NN
C096012_D008569 NONE Nociceptin_0/NNP (r_nmod) orphanin_2/NNP (r_compound) FQ_3/NNP (l_prep) on_6/IN (l_pobj) impairment_10/NN
C096012_D008569 NONE FQ_3/NNP (l_prep) on_6/IN (l_pobj) impairment_10/NN
C096012_D008569 NONE nociceptin_8/NNP (r_nsubj) modulate_15/VB (l_dobj) impairment_16/NN (l_prep) of_17/IN (l_pobj) learning_18/NN (l_conj) memory_20/NN
C096012_D008569 NONE FQ_11/NNP (r_appos) nociceptin_8/NNP (r_nsubj) modulate_15/VB (l_dobj) impairment_16/NN (l_prep) of_17/IN (l_pobj) learning_18/NN (l_conj) memory_20/NN
C111148_D007859 NONE nocistatin_5/NNP (r_conj) FQ_3/NNP (l_prep) on_6/IN (l_pobj) impairment_10/NN
C111148_D007859 NONE nocistatin_13/NNP (r_conj) FQ_11/NNP (r_appos) nociceptin_8/NNP (r_nsubj) modulate_15/VB (l_dobj) impairment_16/NN (l_prep) of_17/IN (l_pobj) learning_18/NN (l_conj) memory_20/NN
C111148_D008569 NONE nocistatin_5/NNP (r_conj) FQ_3/NNP (l_prep) on_6/IN (l_pobj) impairment_10/NN
C111148_D008569 NONE nocistatin_13/NNP (r_conj) FQ_11/NNP (r_appos) nociceptin_8/NNP (r_nsubj) modulate_15/VB (l_dobj) impairment_16/NN (l_prep) of_17/IN (l_pobj) learning_18/NN (l_conj) memory_20/NN
D012601_D007859 CID scopolamine_13/NN (r_pobj) by_12/IN (r_agent) induced_11/VBN (r_acl) impairment_10/NN
D012601_D007859 CID scopolamine_23/NN (r_pobj) by_22/IN (r_agent) induced_21/VBN (r_acl) learning_18/NN (l_conj) memory_20/NN
D012601_D008569 CID scopolamine_13/NN (r_pobj) by_12/IN (r_agent) induced_11/VBN (r_acl) impairment_10/NN
D012601_D008569 CID scopolamine_23/NN (r_pobj) by_22/IN (r_agent) induced_21/VBN (r_acl) learning_18/NN (l_conj) memory_20/NN
C111148_D006930 NONE nocistatin_5/NNP (r_nsubjpass) isolated_8/VBN (l_prep) from_9/IN (l_pobj) precursor_12/NN (l_conj) blocks_16/VBZ (l_dobj) allodynia_20/NN
C111148_D006930 NONE nocistatin_5/NNP (r_nsubjpass) isolated_8/VBN (l_prep) from_9/IN (l_pobj) precursor_12/NN (l_conj) blocks_16/VBZ (l_dobj) allodynia_20/NN (l_conj) hyperalgesia_22/NN
C096012_D006930 NONE nociceptin_14/NNP (r_pobj) as_13/IN (r_prep) precursor_12/NN (l_conj) blocks_16/VBZ (l_dobj) allodynia_20/NN
C096012_D006930 NONE nociceptin_14/NNP (r_pobj) as_13/IN (r_prep) precursor_12/NN (l_conj) blocks_16/VBZ (l_dobj) allodynia_20/NN (l_conj) hyperalgesia_22/NN
C096012_D006930 NONE nociceptin_17/NNP (r_npadvmod) induced_19/VBN (r_amod) allodynia_20/NN
C096012_D006930 NONE nociceptin_17/NNP (r_npadvmod) induced_19/VBN (r_amod) allodynia_20/NN (l_conj) hyperalgesia_22/NN
17484470
D011433_D006333 CID propranolol_6/NN (r_nmod) loading_9/VBG (r_pobj) by_5/IN (r_agent) induced_4/VBN (l_nsubjpass) failure_2/NN
D011433_D008944 NONE propranolol_6/NN (r_nmod) loading_9/VBG (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_ccomp) confirmed_21/VBN (l_nsubjpass) absence_17/NN (l_prep) of_18/IN (l_pobj) MR_19/NNP
7018927
D006220_D006966 CID haloperidol_9/NN (r_npadvmod) induced_11/VBN (r_amod) hyperprolactinemia_12/NN
D006220_D006966 CID haloperidol_4/NNP (r_compound) infusions_5/NNS (r_pobj) of_3/IN (r_prep) course_2/NN (r_pobj) During_0/IN (r_prep) found_10/VBN (l_nsubjpass) hyperprolactinemia_8/NN
15987266
D003513_D004827 NONE cycloheximide_16/NN (r_pobj) with_15/IN (r_prep) treated_14/VBN (r_acl) rats_13/NNS (l_amod) epileptic_12/JJ
D010862_D013226 CID pilocarpine_46/NNP (r_pobj) by_45/IN (r_agent) induced_44/VBN (r_acl) epilepticus_43/NN
D010862_D013226 CID Pilo_48/NNP (r_appos) pilocarpine_46/NNP (r_pobj) by_45/IN (r_agent) induced_44/VBN (r_acl) epilepticus_43/NN
D003513_D013226 NONE cycloheximide_56/NN (r_pobj) with_55/IN (r_conj) injected_52/VBN (r_acl) epilepticus_43/NN
D003513_D013226 NONE CHX_58/NNP (r_appos) cycloheximide_56/NN (r_pobj) with_55/IN (r_conj) injected_52/VBN (r_acl) epilepticus_43/NN
2083961
D012293_D058186 CID rifampicin_5/NNS (r_pobj) due_3/IN (r_amod) failure_2/NN
D012293_D009325 NONE Rifampicin_0/NNP (r_nsubjpass) administered_2/VBN (l_conj) time_15/NN (l_relcl) developed_17/VBD (l_dobj) effects_20/NNS (l_prep) like_21/IN (l_pobj) nausea_22/NN
D012293_D014839 NONE Rifampicin_0/NNP (r_nsubjpass) administered_2/VBN (l_conj) time_15/NN (l_relcl) developed_17/VBD (l_dobj) effects_20/NNS (l_prep) like_21/IN (l_pobj) nausea_22/NN (l_conj) vomiting_24/NN
D012293_D005334 NONE Rifampicin_0/NNP (r_nsubjpass) administered_2/VBN (l_conj) time_15/NN (l_relcl) developed_17/VBD (l_dobj) effects_20/NNS (l_prep) like_21/IN (l_pobj) nausea_22/NN (l_conj) vomiting_24/NN (l_conj) fever_26/NN
9382023
D004280_D006973 CID dobutamine_3/JJ (r_compound) stress_4/NN (r_compound) echocardiography_5/NN (r_pobj) during_2/IN (r_prep) response_1/NN (l_amod) Hypertensive_0/JJ
D004280_D006973 CID dobutamine_2/NN (r_nmod) stress_3/NN (r_nmod) studies_5/NNS (r_pobj) Among_0/IN (r_prep) occurred_35/VBD (l_nsubj) response_9/NN (l_amod) hypertensive_8/JJ
D004280_D006973 CID dobutamine_20/NN (r_compound) infusion_21/NN (r_pobj) before_19/IN (r_prep) resting_14/VBG (r_xcomp) had_12/VBD (r_conj) had_6/VBD (l_dobj) history_8/NN (l_prep) of_9/IN (l_pobj) hypertension_10/NN
15625689
D007980_D010300 NONE levodopa_17/NN (r_npadvmod) induced_19/VBN (r_amod) dyskinesia_20/NN (r_pobj) without_16/IN (r_conj) with_14/IN (r_prep) characterize_7/VB (l_dobj) dynamics_10/NNS (l_prep) in_11/IN (l_pobj) patients_13/NNS (l_compound) PD_12/NNP
D007980_D010300 NONE levodopa_6/NN (r_pobj) for_5/IN (r_prep) role_4/NN (r_dobj) suggest_2/VBP (l_conj) confirm_14/VB (l_ccomp) is_17/VBZ (l_attr) predictor_21/NN (l_prep) of_22/IN (l_pobj) alterations_24/NNS (l_prep) in_25/IN (l_pobj) PD_26/NNP
D007980_D004409 CID levodopa_17/NN (r_npadvmod) induced_19/VBN (r_amod) dyskinesia_20/NN
D007980_D004409 CID levodopa_23/NN (r_compound) dose_24/NN (r_pobj) of_20/IN (r_prep) basis_19/NN (r_pobj) on_17/IN (r_prep) explained_16/VBN (r_relcl) function_11/NN (r_dobj) swallowing_10/NN (r_pcomp) in_9/IN (r_prep) performed_7/VBD (l_nsubj) patients_6/NNS (l_compound) dyskinetic_5/JJ
D007980_D003680 NONE levodopa_6/NN (r_pobj) for_5/IN (r_prep) role_4/NN (r_dobj) suggest_2/VBP (l_conj) confirm_14/VB (l_ccomp) is_17/VBZ (l_nsubj) dysphagia_16/NN
6321816
D014667_D006973 NONE Vasopressin_0/NN (l_prep) as_1/IN (l_pobj) contributor_4/NN (l_prep) to_5/IN (l_pobj) hypertension_6/NN
D014667_D006973 NONE vasopressin_3/NN (r_pobj) of_2/IN (r_prep) role_1/NN (l_prep) as_4/IN (l_pobj) agent_7/NN (l_prep) to_8/IN (l_pobj) process_11/NN (l_amod) hypertensive_10/JJ
D014667_D006973 NONE Vasopressin_0/NN (r_nsubj) plays_1/VBZ (l_prep) in_5/IN (l_pobj) pathogenesis_7/NN (l_prep) of_8/IN (l_pobj) hypertension_12/NN
D014667_D006973 NONE vasopressin_6/NN (r_pobj) of_5/IN (r_prep) action_4/NN (r_nsubj) appears_7/VBZ (l_xcomp) be_9/VB (l_prep) in_11/IN (l_pobj) development_13/NN (l_prep) of_14/IN (l_pobj) model_16/NN (l_prep) of_17/IN (l_pobj) hypertension_18/NN
D014667_D006973 NONE vasopressin_6/NN (r_pobj) of_5/IN (r_prep) action_4/NN (r_nsubj) appears_7/VBZ (l_advcl) observed_29/VBN (l_prep) in_30/IN (l_pobj) stage_33/NN (l_prep) of_34/IN (l_pobj) hypertension_35/NN
D014667_D006973 NONE vasopressin_3/NN (r_pobj) of_2/IN (r_prep) secretion_1/NN (r_nsubj) promotes_7/VBZ (l_dobj) function_9/NN (l_prep) as_13/IN (l_pobj) factor_16/NN (l_prep) in_17/IN (l_pobj) hypertension_18/NN
D014667_D006973 NONE vasopressin_5/NN (r_pobj) of_4/IN (r_prep) role_3/NN (r_nsubj) remains_6/VBZ (l_xcomp) determined_9/VBN (l_prep) in_10/IN (l_pobj) hypertension_13/NN
D014667_D003919 NONE Vasopressin_0/NN (r_nsubj) plays_1/VBZ (l_advcl) was_20/VBD (l_prep) in_23/IN (l_pobj) rats_25/NNS (l_prep) with_26/IN (l_pobj) insipidus_31/NN
D003900_D006973 CID DOCA_9/NNP (r_compound) salt_11/NN (r_compound) hypertension_12/NN
D003900_D006973 CID DOCA_33/NNP (r_compound) salt_35/NN (r_compound) treatment_36/NN (r_pobj) after_32/IN (r_prep) was_20/VBD (r_advcl) plays_1/VBZ (l_prep) in_5/IN (l_pobj) pathogenesis_7/NN (l_prep) of_8/IN (l_pobj) hypertension_12/NN
D003900_D003919 NONE DOCA_9/NNP (r_compound) salt_11/NN (r_compound) hypertension_12/NN (r_pobj) of_8/IN (r_prep) pathogenesis_7/NN (r_pobj) in_5/IN (r_prep) plays_1/VBZ (l_advcl) was_20/VBD (l_prep) in_23/IN (l_pobj) rats_25/NNS (l_prep) with_26/IN (l_pobj) insipidus_31/NN
D003900_D003919 NONE DOCA_33/NNP (r_compound) salt_35/NN (r_compound) treatment_36/NN (r_pobj) after_32/IN (r_prep) was_20/VBD (l_prep) in_23/IN (l_pobj) rats_25/NNS (l_prep) with_26/IN (l_pobj) insipidus_31/NN
D008094_D006973 NONE lithium_27/NN (r_npadvmod) treated_29/VBN (r_amod) insipidus_31/NN (r_pobj) with_26/IN (r_prep) rats_25/NNS (r_pobj) in_23/IN (r_prep) was_20/VBD (r_advcl) plays_1/VBZ (l_prep) in_5/IN (l_pobj) pathogenesis_7/NN (l_prep) of_8/IN (l_pobj) hypertension_12/NN
D008094_D003919 CID lithium_27/NN (r_npadvmod) treated_29/VBN (r_amod) insipidus_31/NN
9759693
D018170_D017091 CID sumatriptan_3/NN (r_compound) use_4/NN (r_conj) colitis_1/NN
D018170_D017091 CID sumatriptan_18/NNP (r_pobj) with_17/IN (r_prep) treated_16/VBN (r_ccomp) report_1/VBP (l_prep) on_2/IN (l_pobj) development_4/NN (l_prep) of_5/IN (l_pobj) cases_8/NNS (l_prep) of_9/IN (l_pobj) colitis_11/NN
D018170_D003329 NONE sumatriptan_16/NNP (r_compound) use_17/NN (r_pobj) after_15/IN (r_prep) occurring_14/VBG (r_advcl) published_3/VBN (l_prep) of_4/IN (l_pobj) vasospasm_6/NN
D018170_D017202 NONE sumatriptan_16/NNP (r_compound) use_17/NN (r_pobj) after_15/IN (r_prep) occurring_14/VBG (r_advcl) published_3/VBN (l_prep) of_4/IN (l_pobj) vasospasm_6/NN (l_conj) ischemia_9/NN
D018170_D009203 NONE sumatriptan_16/NNP (r_compound) use_17/NN (r_pobj) after_15/IN (r_prep) occurring_14/VBG (r_advcl) published_3/VBN (l_prep) of_4/IN (l_pobj) vasospasm_6/NN (l_conj) ischemia_9/NN (l_conj) infarction_13/NN
D018170_D008881 NONE sumatriptan_18/NNP (r_pobj) with_17/IN (r_prep) treated_16/VBN (r_ccomp) report_1/VBP (l_prep) on_2/IN (l_pobj) development_4/NN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) migraine_15/NN
11423811
D004280_D002637 NONE dobutamine_8/NNP (r_compound) stress_9/NN (r_pobj) of_7/IN (r_prep) safety_6/NN (r_dobj) assess_4/VB (l_npadvmod) echocardiography_10/NN (l_prep) in_11/IN (l_pobj) evaluation_15/NN (l_prep) of_16/IN (l_pobj) pain_21/NN
D004280_D002637 NONE dobutamine_8/NNP (r_pobj) of_7/IN (r_prep) administration_6/NN (r_pobj) regarding_5/VBG (r_prep) concern_4/NN (r_pobj) Because_0/IN (r_prep) conducted_17/VBD (l_dobj) study_20/NN (l_relcl) assess_22/VB (l_dobj) safety_24/NN (l_prep) in_27/IN (l_pobj) patients_30/NNS (l_prep) with_31/IN (l_pobj) pain_36/NN
D004280_D002637 NONE dobutamine_7/NNP (r_nsubjpass) administered_9/VBN (l_prep) to_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) pain_17/NN
D003042_D002637 CID cocaine_17/NN (r_npadvmod) associated_19/VBN (r_amod) pain_21/NN
D003042_D002637 CID cocaine_6/NN (r_compound) use_7/NN (r_pobj) of_5/IN (r_prep) setting_4/NN (r_pobj) in_2/IN (r_prep) pain_1/NN
D003042_D002637 CID cocaine_13/NN (r_compound) use_14/NN (r_pobj) of_12/IN (r_prep) setting_11/NN (r_pobj) in_9/IN (r_prep) concern_4/NN (r_pobj) Because_0/IN (r_prep) conducted_17/VBD (l_dobj) study_20/NN (l_relcl) assess_22/VB (l_dobj) safety_24/NN (l_prep) in_27/IN (l_pobj) patients_30/NNS (l_prep) with_31/IN (l_pobj) pain_36/NN
D003042_D002637 CID cocaine_32/NN (r_npadvmod) associated_34/VBN (r_amod) pain_36/NN
D003042_D002637 CID cocaine_9/NN (r_dobj) used_8/VBN (l_xcomp) preceding_13/VBG (l_dobj) onset_15/NN (l_prep) of_16/IN (l_pobj) pain_18/NN
D003042_D002637 CID cocaine_13/NN (r_npadvmod) related_15/VBN (r_amod) pain_17/NN
D004280_D007511 NONE Dobutamine_0/JJ (r_nsubj) stress_1/NN (l_ccomp) is_6/VBZ (l_attr) test_12/NN (l_prep) for_13/IN (l_pcomp) evaluating_14/VBG (l_dobj) ischemia_16/NN
D003042_D064420 NONE cocaine_5/NN (r_compound) toxicity_6/NN
10677406
D004280_D018487 CID dobutamine_13/NN (r_nsubj) induced_16/VBN (r_amod) ischaemia_18/NN (r_dobj) occurs_4/VBZ (l_nsubj) dysfunction_3/NN
D004280_D018487 CID dobutamine_7/JJ (r_nsubj) induced_8/VBN (l_dobj) results_10/NNS (l_prep) in_11/IN (l_pobj) dysfunction_16/NN
D004280_D003324 NONE dobutamine_13/NN (r_nsubj) induced_16/VBN (r_amod) ischaemia_18/NN (r_dobj) occurs_4/VBZ (l_prep) in_5/IN (l_pobj) patients_6/NNS (l_prep) with_7/IN (l_pobj) disease_10/NN
D004280_D003324 NONE dobutamine_7/JJ (r_nsubj) induced_8/VBN (l_prep) In_0/IN (l_pobj) patients_1/NNS (l_prep) with_2/IN (l_pobj) disease_5/NN
D004280_D003324 NONE Dobutamine_0/NNP (r_nsubj) induced_1/VBN (l_ccomp) used_6/VBN (l_xcomp) study_8/VB (l_prep) in_15/IN (l_pobj) patients_16/NNS (l_prep) with_17/IN (l_pobj) disease_20/NN
D004280_D017202 NONE dobutamine_13/NN (r_nsubj) induced_16/VBN (r_amod) ischaemia_18/NN
D004280_D007511 NONE dobutamine_17/NN (r_conj) exercise_15/NN (r_nsubj) induced_18/VBN (l_dobj) ischaemia_19/NN
D004280_D007511 NONE dobutamine_7/JJ (r_nsubj) induced_8/VBN (l_dobj) results_10/NNS (l_compound) ischaemia_9/NN
D004280_D007511 NONE Dobutamine_0/NNP (r_nsubj) induced_1/VBN (l_ccomp) used_6/VBN (l_nsubjpass) ischaemia_2/NN
D004280_D017682 CID dobutamine_7/JJ (r_nsubj) induced_8/VBN (l_dobj) results_10/NNS (l_acl) presumed_18/VBN (l_xcomp) be_20/VB (l_acomp) stunning_22/JJ
24100257
C089750_D054549 CID Zolmitriptan_10/NNP (r_pobj) to_9/IN (r_prep) secondary_8/JJ (r_amod) syndrome_1/NN
C089750_D054549 CID Zolmitriptan_10/NNP (r_pobj) to_9/IN (r_prep) secondary_8/JJ (r_amod) syndrome_1/NN (l_conj) syndrome_6/NN
C089750_D054549 CID zolmitriptan_12/NNP (r_pobj) to_11/IN (r_prep) secondary_10/JJ (r_advmod) revealed_3/VBD (l_conj) associated_20/VBN (l_prep) with_21/IN (l_pobj) TS_22/NNP
C089750_D008881 NONE zolmitriptan_9/NNP (r_dobj) took_8/VBD (l_advcl) had_14/VBD (l_dobj) migraines_15/NNS
C089750_D008881 NONE zolmitriptan_8/NNP (r_dobj) taking_7/VBG (l_prep) because_17/IN (l_pobj) headache_22/NN
C089750_D003329 CID zolmitriptan_12/NNP (r_pobj) to_11/IN (r_prep) secondary_10/JJ (r_advmod) revealed_3/VBD (l_dobj) cases_5/NNS (l_prep) of_6/IN (l_pobj) vasospasm_9/NN
17223814
D015251_D054537 CID epirubicin_11/NNP (r_pobj) with_10/IN (r_prep) chemotherapy_9/NN (r_pobj) of_8/IN (r_prep) result_7/NN (r_pobj) as_5/IN (r_prep) block_4/NN
D017239_D054537 CID paclitaxel_13/NN (r_conj) epirubicin_11/NNP (r_pobj) with_10/IN (r_prep) chemotherapy_9/NN (r_pobj) of_8/IN (r_prep) result_7/NN (r_pobj) as_5/IN (r_prep) block_4/NN
2453942
D001556_D020258 NONE Lindane_0/NNP (r_nsubj) is_6/VBZ (l_attr) insecticide_9/NN (l_prep) with_10/IN (l_pobj) effects_13/NNS (l_amod) neurotoxic_12/JJ
D001556_D020258 NONE hexachlorocyclohexane_4/NNP (r_appos) Lindane_0/NNP (r_nsubj) is_6/VBZ (l_attr) insecticide_9/NN (l_prep) with_10/IN (l_pobj) effects_13/NNS (l_amod) neurotoxic_12/JJ
D001556_D012640 CID lindane_5/NNP (r_pobj) of_4/IN (r_prep) effect_3/NN (r_dobj) studied_1/VBD (l_prep) by_16/IN (l_pcomp) measuring_17/VBG (l_prep) at_31/IN (l_pobj) onset_33/NN (l_prep) of_34/IN (l_pobj) seizures_35/NNS
D001556_D012640 CID lindane_11/NNP (r_compound) administration_12/NN (r_pobj) after_10/IN (r_prep) min_9/NN (r_pobj) at_5/IN (r_prep) suffered_2/VBD (l_dobj) convulsions_4/NNS
D005680_D012640 NONE GABA_21/NNP (r_pobj) of_20/IN (r_prep) concentration_19/NN (r_dobj) measuring_17/VBG (l_prep) at_31/IN (l_pobj) onset_33/NN (l_prep) of_34/IN (l_pobj) seizures_35/NNS
D004298_D012640 NONE dopamine_23/NN (r_conj) GABA_21/NNP (r_pobj) of_20/IN (r_prep) concentration_19/NN (r_dobj) measuring_17/VBG (l_prep) at_31/IN (l_pobj) onset_33/NN (l_prep) of_34/IN (l_pobj) seizures_35/NNS
24067251
C418563_D007674 NONE fumarate_17/NNP (r_pobj) to_14/IN (r_prep) exposed_13/VBN (r_acl) persons_12/NNS (r_pobj) in_8/IN (r_prep) injury_7/NN
C418563_D007674 NONE TDF_12/NNP (r_npadvmod) related_14/VBN (r_amod) disease_16/NN
C418563_D007674 NONE TDF_12/NNP (r_npadvmod) related_14/VBN (r_amod) disease_16/NN (r_pobj) for_11/IN (r_prep) criteria_10/NNS (r_nsubj) had_25/VBD (l_dobj) features_26/NNS (l_prep) of_27/IN (l_pobj) dysfunction_30/NN
C418563_D007674 NONE TDF_12/NNP (r_npadvmod) related_14/VBN (r_amod) disease_16/NN (r_pobj) for_11/IN (r_prep) criteria_10/NNS (r_nsubj) had_25/VBD (l_conj) found_38/VBN (l_xcomp) have_40/VB (l_dobj) features_41/NNS (l_prep) of_42/IN (l_pobj) dysfunction_44/NN
C418563_D005198 CID TDF_5/NNP (r_nmod) kidney_6/NN (r_nmod) effects_8/NNS (r_pobj) for_4/IN (r_prep) hospitalisation_3/NN (r_pobj) of_2/IN (r_prep) incidence_1/NN (r_nsubj) was_9/VBD (l_prep) amongst_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) features_16/NNS (l_prep) of_17/IN (l_pobj) syndrome_19/NN
10219427
24778426
D002945_D007674 NONE Cisplatin_8/NNP (r_dobj) Receiving_7/VBG (r_acl) Patients_6/NNS (r_pobj) in_4/IN (r_prep) Toxicity_3/NN
D002945_D007674 NONE cisplatin_6/NN (r_compound) use_7/NN (r_pobj) of_5/IN (r_prep) complications_4/NNS (r_pobj) of_1/IN (r_prep) One_0/CD (r_nsubj) is_8/VBZ (l_attr) nephrotoxicity_12/NN
D002945_D007674 NONE cisplatin_7/NN (r_npadvmod) induced_9/VBN (r_amod) nephrotoxicity_10/NN
D002945_D007674 NONE cisplatin_18/NN (r_dobj) receiving_14/VBG (r_acl) patients_13/NNS (r_pobj) in_11/IN (r_prep) rates_5/NNS (l_prep) of_6/IN (l_pobj) nephrotoxicity_10/NN
D002945_D007674 NONE cisplatin_16/NN (l_conj) are_24/VBP (l_prep) at_25/IN (l_pobj) risk_28/NN (l_prep) of_29/IN (l_pobj) nephrotoxicity_30/NN
D002945_D009369 NONE Cisplatin_8/NNP (r_dobj) Receiving_7/VBG (r_acl) Patients_6/NNS (l_compound) Cancer_5/NN
D002945_D009369 NONE cisplatin_7/NN (r_npadvmod) induced_9/VBN (r_amod) nephrotoxicity_10/NN (r_pobj) of_6/IN (r_prep) rates_5/NNS (l_prep) in_11/IN (l_pobj) patients_13/NNS (l_compound) cancer_12/NN
D002945_D009369 NONE cisplatin_18/NN (r_dobj) receiving_14/VBG (r_acl) patients_13/NNS (l_compound) cancer_12/NN
D002945_D009369 NONE cisplatin_11/NN (r_dobj) receiving_7/VBG (r_acl) patients_6/NNS (l_compound) cancer_5/NN
D002945_D009369 NONE cisplatin_9/NN (r_dobj) received_5/VBD (r_relcl) patients_3/NNS (r_dobj) evaluated_1/VBD (l_conj) had_15/VBD (l_prep) as_20/IN (l_pobj) malignancy_23/NN
D008353_D064420 NONE mannitol_13/NN (r_pobj) of_12/IN (r_prep) use_11/NN (r_pobj) including_9/VBG (r_prep) toxicity_7/NN
D008353_D007674 NONE mannitol_22/NN (r_pobj) without_21/IN (r_conj) with_19/IN (r_prep) receiving_14/VBG (r_acl) patients_13/NNS (r_pobj) in_11/IN (r_prep) rates_5/NNS (l_prep) of_6/IN (l_pobj) nephrotoxicity_10/NN
D008353_D007674 NONE mannitol_5/NN (r_dobj) receive_4/VB (r_relcl) Patients_0/NNS (r_nsubj) were_6/VBD (l_acomp) likely_8/JJ (l_xcomp) develop_10/VB (l_dobj) nephrotoxicity_11/NN
D008353_D007674 NONE mannitol_4/NN (r_pobj) of_3/IN (r_prep) quantities_2/NNS (r_nsubj) are_5/VBP (r_advcl) given_12/VBN (l_prep) at_15/IN (l_pobj) risk_18/NN (l_prep) of_19/IN (l_pobj) nephrotoxicity_20/NN
D008353_D007674 NONE mannitol_38/NN (r_pobj) of_37/IN (r_prep) addition_36/NN (r_pobj) from_34/IN (r_prep) benefit_33/VB (r_conj) are_24/VBP (l_prep) at_25/IN (l_pobj) risk_28/NN (l_prep) of_29/IN (l_pobj) nephrotoxicity_30/NN
D008353_D009369 NONE mannitol_22/NN (r_pobj) without_21/IN (r_conj) with_19/IN (r_prep) receiving_14/VBG (r_acl) patients_13/NNS (l_compound) cancer_12/NN
D002945_D006258 NONE cisplatin_9/NN (r_dobj) received_5/VBD (r_relcl) patients_3/NNS (r_dobj) evaluated_1/VBD (l_conj) had_15/VBD (l_dobj) cancer_19/NN
D002945_D006973 NONE cisplatin_16/NN (l_conj) are_24/VBP (l_nsubj) those_21/DT (l_prep) with_22/IN (l_pobj) hypertension_23/NN
D008353_D006973 NONE mannitol_38/NN (r_pobj) of_37/IN (r_prep) addition_36/NN (r_pobj) from_34/IN (r_prep) benefit_33/VB (r_conj) are_24/VBP (l_nsubj) those_21/DT (l_prep) with_22/IN (l_pobj) hypertension_23/NN
2400986
D002066_D020258 NONE busulfan_8/NN (r_pobj) of_4/IN (r_prep) neurotoxicity_3/NN
D002066_D020258 NONE Busulfan_0/NNP (r_nsubjpass) known_2/VBN (l_xcomp) be_4/VB (l_acomp) neurotoxic_5/JJ
D002066_D020258 NONE Busulfan_0/NNP (r_nsubjpass) known_2/VBN (l_conj) remains_15/VBZ (l_nsubj) neurotoxicity_14/NN
D002066_D020258 NONE busulfan_3/NN (r_compound) dose_4/NN (r_nsubjpass) taken_6/VBN (r_advcl) was_11/VBD (l_attr) difference_14/NN (l_prep) in_15/IN (l_pobj) terms_16/NNS (l_prep) of_17/IN (l_pobj) incidence_19/NN (l_compound) neurotoxicity_18/NN
D002066_D020258 NONE busulfan_4/NNP (r_compound) neurotoxicity_5/NN
D002066_D020258 NONE busulfan_1/NN (r_nsubjpass) followed_21/VBN (l_agent) by_22/IN (l_pobj) neurotoxicity_24/NN
D002066_D020258 NONE busulfan_1/NN (r_nsubjpass) followed_21/VBN (l_agent) by_22/IN (l_pobj) neurotoxicity_24/NN (l_acl) observed_30/VBN (l_nsubj) close_26/JJ (l_prep) to_27/IN (l_pobj) incidence_29/NN (l_compound) neurotoxicity_28/NN
D002066_D009369 NONE busulfan_20/NN (r_dobj) receiving_16/VBG (l_prep) before_24/IN (l_pobj) transplantation_27/NN (l_prep) for_28/IN (l_pobj) tumors_31/NNS
D002066_D001932 NONE busulfan_20/NN (r_dobj) receiving_16/VBG (r_acl) study_5/NN (l_relcl) excluded_35/VBN (l_nsubj) tumors_34/NNS
D002066_D012640 CID busulfan_23/NN (r_compound) course_24/NN (r_pobj) of_21/IN (r_prep) days_20/NNS (r_pobj) during_17/IN (r_prep) seizures_16/NNS
D002066_D009461 NONE busulfan_10/NNP (r_compound) total_11/NN (r_amod) dose_12/NN (r_dobj) given_5/VBN (r_ccomp) had_21/VBD (l_dobj) symptoms_24/NNS
D002998_D009461 NONE clonazepam_18/NN (r_pobj) of_17/IN (r_prep) infusion_16/NN (r_pobj) with_13/IN (r_prep) dose_12/NN (r_dobj) given_5/VBN (r_ccomp) had_21/VBD (l_dobj) symptoms_24/NNS
D002066_D002493 NONE Busulfan_0/NNP (r_compound) levels_1/NNS (r_nsubjpass) measured_3/VBN (l_agent) by_4/IN (l_pobj) assay_11/NN (l_prep) without_21/IN (l_pobj) disease_25/NN
D002066_D002493 NONE busulfan_31/NN (r_pobj) under_26/IN (r_prep) measured_3/VBN (l_agent) by_4/IN (l_pobj) assay_11/NN (l_prep) without_21/IN (l_pobj) disease_25/NN
D002998_D002493 NONE clonazepam_33/NN (r_pobj) with_32/IN (r_prep) measured_3/VBN (l_agent) by_4/IN (l_pobj) assay_11/NN (l_prep) without_21/IN (l_pobj) disease_25/NN
D002998_D020258 NONE clonazepam_16/NN (r_pobj) by_15/IN (r_agent) prevented_14/VBN (r_conj) is_6/VBZ (l_nsubj) neurotoxicity_5/NN
1280054
D014750_D001927 CID vincristine_5/NNP (r_compound) administration_6/NN (r_pobj) due_2/IN (r_prep) myeloencephalopathy_1/NNS
D014750_D001927 CID Vincristine_0/NNP (r_nsubjpass) given_3/VBN (l_advcl) producing_11/VBG (l_dobj) dysfunction_15/NN (l_acl) followed_16/VBN (l_agent) by_17/IN (l_pobj) encephalopathy_18/NN
D014750_D007938 NONE Vincristine_0/NNP (r_nsubjpass) given_3/VBN (l_dative) to_5/IN (l_pobj) child_7/NN (l_prep) with_8/IN (l_pobj) leukaemia_9/NN
D014750_D007049 CID Vincristine_0/NNP (r_nsubjpass) given_3/VBN (l_advcl) producing_11/VBG (l_dobj) dysfunction_15/NN
15627798
D005839_D009395 CID gentamicin_12/NNS (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) nephritis_9/NN
D005839_D009395 CID gentamicin_15/NNS (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) nephritis_12/NN
D005839_D005355 NONE gentamicin_3/NNS (r_pobj) with_2/IN (r_prep) treated_1/VBN (r_acl) Animals_0/NNS (r_nsubj) show_5/VB (l_dobj) areas_7/NNS (l_prep) of_8/IN (l_pobj) fibrosis_10/NN
7644931
D017239_D064420 NONE paclitaxel_14/NN (r_pobj) of_13/IN (r_prep) trial_12/NN (r_relcl) phase_10/NN (r_pobj) in_8/IN (r_prep) cohort_5/NN (r_pobj) with_3/IN (r_prep) compared_2/VBN (l_nsubjpass) Toxicities_0/NNS
D016190_D006402 NONE Carboplatin_0/NNP (r_nsubj) appear_3/VB (l_xcomp) add_5/VB (l_prep) to_6/IN (l_pobj) toxicities_9/NNS
D016190_D006402 NONE carboplatin_16/NNP (r_compound) combination_17/NN (r_nsubjpass) dosed_20/VBN (r_conj) appear_3/VB (l_xcomp) add_5/VB (l_prep) to_6/IN (l_pobj) toxicities_9/NNS
D017239_D006402 CID paclitaxel_14/NNP (r_nmod) carboplatin_16/NNP (r_compound) combination_17/NN (r_nsubjpass) dosed_20/VBN (r_conj) appear_3/VB (l_xcomp) add_5/VB (l_prep) to_6/IN (l_pobj) toxicities_9/NNS
2710809
D001712_D001919 CID biperiden_3/NNP (r_pobj) due_1/JJ (r_prep) Bradycardia_0/NNP
D001712_D001919 CID biperiden_3/NNP (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Bradycardia_0/NN
C036432_D006562 NONE lactate_21/NN (r_pobj) of_17/IN (r_prep) application_16/NN (r_nsubj) led_22/VBD (l_prep) In_0/IN (l_pobj) patient_6/NN (l_acl) suffering_7/NN (l_prep) from_8/IN (l_pobj) postzosteric_11/JJ
C036432_D014277 NONE lactate_21/NN (r_pobj) of_17/IN (r_prep) application_16/NN (r_nsubj) led_22/VBD (l_prep) In_0/IN (l_pobj) patient_6/NN (l_acl) suffering_7/NN (l_prep) from_8/IN (l_pobj) postzosteric_11/JJ (l_appos) neuralgia_13/NN
C036432_D001919 NONE lactate_21/NN (r_pobj) of_17/IN (r_prep) application_16/NN (r_nsubj) led_22/VBD (l_prep) to_23/IN (l_pobj) reaction_29/NN (l_acl) characterized_30/VBN (l_agent) by_31/IN (l_pobj) bradycardia_33/NNS
C036432_D004401 NONE lactate_21/NN (r_pobj) of_17/IN (r_prep) application_16/NN (r_nsubj) led_22/VBD (l_prep) to_23/IN (l_pobj) reaction_29/NN (l_acl) characterized_30/VBN (l_agent) by_31/IN (l_pobj) bradycardia_33/NNS (l_conj) dysarthria_35/NN
C036432_D003680 NONE lactate_21/NN (r_pobj) of_17/IN (r_prep) application_16/NN (r_nsubj) led_22/VBD (l_prep) to_23/IN (l_pobj) reaction_29/NN (l_acl) characterized_30/VBN (l_agent) by_31/IN (l_pobj) bradycardia_33/NNS (l_conj) dysarthria_35/NN (l_conj) dysphagia_38/NN
D001285_D001919 NONE atropine_20/NN (r_npadvmod) like_22/JJ (r_amod) drugs_23/NNS (r_pobj) of_19/IN (r_prep) effect_18/NN (r_pobj) to_12/IN (r_conj) to_6/IN (r_prep) attributed_5/VBN (l_nsubjpass) Bradycardia_0/NN
D009116_D001919 NONE muscarine_25/NNP (r_compound) receptors_26/NNS (r_pobj) on_24/IN (r_prep) effect_18/NN (r_pobj) to_12/IN (r_conj) to_6/IN (r_prep) attributed_5/VBN (l_nsubjpass) Bradycardia_0/NN
20034406
D010862_D013226 CID pilocarpine_12/NN (r_npadvmod) induced_14/VBN (r_amod) status_15/NN (r_compound) epilepticus_16/NN
D010862_D013226 CID pilocarpine_17/NNP (r_compound) injection_18/NN (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) epilepticus_11/NN
D010862_D013226 CID pilocarpine_17/NNP (r_compound) injection_18/NN (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) epilepticus_11/NN (l_appos) SE_13/NNP
D010862_D013226 CID pilocarpine_4/NNP (r_compound) injection_5/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (l_nsubjpass) SE_0/NNP
D010862_D013226 CID pilocarpine_15/NNP (r_npadvmod) induced_17/VBN (r_amod) SE_18/NNP
12950111
D006024_D013547 NONE glycopyrrolate_7/NN (r_pobj) with_5/IN (r_prep) Treatment_0/NN (l_prep) of_1/IN (l_pobj) hyperhidrosis_4/NN
D006024_D013547 NONE glycopyrrolate_3/NN (r_dobj) applying_1/VBG (r_pcomp) After_0/IN (r_prep) was_8/VBD (l_parataxis) sweating_12/NN
D006024_D013547 NONE glycopyrrolate_3/NN (r_dobj) applying_1/VBG (r_pcomp) After_0/IN (r_prep) was_8/VBD (l_conj) sweating_32/NN
D006024_D013547 NONE glycopyrrolate_5/NN (r_amod) pad_6/NN (r_pobj) of_3/IN (r_prep) application_2/NN (r_nsubj) appeared_7/VBD (l_conj) method_20/NN (l_prep) for_23/IN (l_amod) moderate_24/JJ (l_prep) to_25/IN (l_pobj) symptoms_27/NNS (l_prep) of_28/IN (l_pobj) hyperhidrosis_30/NN
D006024_D014987 NONE glycopyrrolate_17/NN (r_amod) patients_13/NNS (r_pobj) in_11/IN (r_prep) throat_10/NN (r_conj) mouth_6/NN
D006024_D014987 NONE glycopyrrolate_29/NN (r_advmod) patient_25/NN (r_pobj) in_23/IN (r_prep) headache_22/NN (r_appos) patients_13/NNS (r_pobj) in_11/IN (r_prep) throat_10/NN (r_conj) mouth_6/NN
D006024_D010612 CID glycopyrrolate_17/NN (r_amod) patients_13/NNS (r_pobj) in_11/IN (r_prep) throat_10/NN
D006024_D010612 CID glycopyrrolate_29/NN (r_advmod) patient_25/NN (r_pobj) in_23/IN (r_prep) headache_22/NN (r_appos) patients_13/NNS (r_pobj) in_11/IN (r_prep) throat_10/NN
D006024_D006261 CID glycopyrrolate_17/NN (r_amod) patients_13/NNS (l_appos) headache_22/NN
D006024_D006261 CID glycopyrrolate_29/NN (r_advmod) patient_25/NN (r_pobj) in_23/IN (r_prep) headache_22/NN
11366874
D019888_D001145 NONE Viracept_0/NNP (l_conj) warning_4/VBG (l_compound) heartbeat_3/NN
D019888_D001145 NONE Viracept_11/NNP (r_appos) inhibitor_10/NN (r_nsubj) cause_13/VB (l_ccomp) beat_17/VBD
D019888_D001919 CID Viracept_11/NNP (r_appos) inhibitor_10/NN (r_nsubj) cause_13/VB (l_ccomp) beat_17/VBD (l_acl) known_19/VBN (l_prep) as_20/IN (l_pobj) bradycardia_21/NN
D019888_D001919 CID Viracept_11/NNP (r_attr) was_10/VBD (r_relcl) patient_8/NN (r_pobj) in_2/IN (r_prep) occurred_1/VBD (l_nsubj) Bradycardia_0/NNP
3383127
D002945_D007022 CID cisplatin_10/NN (r_dobj) receiving_9/VBG (r_acl) patients_8/NNS (r_pobj) in_6/IN (r_prep) manifestation_3/NN (r_pobj) as_1/IN (r_prep) Hypotension_0/NN
D002945_D007022 CID cisplatin_18/NN (r_pobj) with_17/IN (r_prep) treated_16/VBN (r_advcl) developed_6/VBN (r_acl) hypotension_4/NN
D002945_D007022 CID CDDP_20/NNP (r_appos) cisplatin_18/NN (r_pobj) with_17/IN (r_prep) treated_16/VBN (r_advcl) developed_6/VBN (r_acl) hypotension_4/NN
D002945_D066126 NONE cisplatin_10/NN (r_dobj) receiving_9/VBG (r_acl) patients_8/NNS (r_pobj) in_6/IN (r_prep) manifestation_3/NN (l_prep) of_4/IN (l_pobj) cardiotoxicity_5/NN
D002945_D066126 NONE CDDP_27/NNS (r_pobj) by_26/IN (r_agent) influenced_25/VBN (r_relcl) cardiotoxicity_21/NN
D005472_D007022 CID 5-fluorouracil_12/CD (r_dep) ._13/. (r_punct) Hypotension_0/NN
D005472_D007022 CID 5-fluorouracil_23/CD (r_punct) 5-FU_25/CD (r_conj) CDDP_20/NNP (r_appos) cisplatin_18/NN (r_pobj) with_17/IN (r_prep) treated_16/VBN (r_advcl) developed_6/VBN (r_acl) hypotension_4/NN
D005472_D007022 CID 5-FU_25/CD (r_conj) CDDP_20/NNP (r_appos) cisplatin_18/NN (r_pobj) with_17/IN (r_prep) treated_16/VBN (r_advcl) developed_6/VBN (r_acl) hypotension_4/NN
D005472_D066126 NONE 5-fluorouracil_12/CD (r_dep) ._13/. (r_punct) Hypotension_0/NN (l_prep) as_1/IN (l_pobj) manifestation_3/NN (l_prep) of_4/IN (l_pobj) cardiotoxicity_5/NN
D005472_D066126 NONE 5-FU_20/CD (r_compound) cardiotoxicity_21/NN
D002945_D015179 NONE cisplatin_18/NN (r_pobj) with_17/IN (r_prep) treated_16/VBN (r_advcl) developed_6/VBN (l_prep) in_7/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) carcinoma_13/NN
D002945_D015179 NONE CDDP_20/NNP (r_appos) cisplatin_18/NN (r_pobj) with_17/IN (r_prep) treated_16/VBN (r_advcl) developed_6/VBN (l_prep) in_7/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) carcinoma_13/NN
D005472_D015179 NONE 5-fluorouracil_23/CD (r_punct) 5-FU_25/CD (r_conj) CDDP_20/NNP (r_appos) cisplatin_18/NN (r_pobj) with_17/IN (r_prep) treated_16/VBN (r_advcl) developed_6/VBN (l_prep) in_7/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) carcinoma_13/NN
D005472_D015179 NONE 5-FU_25/CD (r_conj) CDDP_20/NNP (r_appos) cisplatin_18/NN (r_pobj) with_17/IN (r_prep) treated_16/VBN (r_advcl) developed_6/VBN (l_prep) in_7/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) carcinoma_13/NN
15609701
D013015_D003329 CID Sotalol_0/NN (r_npadvmod) induced_2/VBN (r_amod) spasm_4/NN
D013015_D003329 CID sotalol_15/NNS (r_pobj) of_14/IN (r_prep) properties_13/NNS (r_pobj) by_5/IN (r_agent) induced_4/VBN (l_nsubjpass) vasospasm_1/NN
D013015_D002311 NONE Sotalol_0/NN (r_npadvmod) induced_2/VBN (r_amod) spasm_4/NN (l_prep) in_5/IN (l_pobj) patient_7/NN (l_prep) with_8/IN (l_pobj) cardiomyopathy_10/NN
D013015_D017180 NONE Sotalol_0/NN (r_npadvmod) induced_2/VBN (r_amod) spasm_4/NN (l_prep) in_5/IN (l_pobj) patient_7/NN (l_prep) with_8/IN (l_pobj) cardiomyopathy_10/NN (l_acl) associated_11/VBN (l_prep) with_12/IN (l_pobj) tachycardia_15/NN
D013015_D017180 NONE sotalol_6/NNP (r_appos) agent_4/NN (r_nsubj) was_8/VBD (l_acomp) effective_10/JJ (l_prep) for_11/IN (l_pobj) prevention_13/NN (l_prep) of_14/IN (l_pobj) VT_15/NNP
C076259_D017180 NONE hydrochloride_5/NNP (r_pobj) of_3/IN (r_prep) administration_2/NN (r_nsubjpass) terminated_10/VBN (l_nsubjpass) VT_8/NNP
15815446
D010656_D002545 NONE phenylephrine_8/NN (r_npadvmod) induced_10/VBN (r_amod) hypertension_11/NN (r_pobj) of_7/IN (r_prep) effect_6/NN (r_appos) ischemia_2/NN
D010656_D006973 CID phenylephrine_8/NN (r_npadvmod) induced_10/VBN (r_amod) hypertension_11/NN
D010656_D006973 CID phenylephrine_17/NN (r_npadvmod) induced_19/VBN (r_amod) hypertension_20/NN (r_pobj) of_16/IN (r_prep) effect_15/NN (r_nsubjpass) determined_32/VBN (l_prep) After_0/IN (l_pobj) min_2/NN (l_prep) of_3/IN (l_pobj) occlusion_8/NN (l_prep) in_9/IN (l_pobj) rats_12/NNS (l_amod) hypertensive_11/JJ
D010656_D006973 CID phenylephrine_17/NN (r_npadvmod) induced_19/VBN (r_amod) hypertension_20/NN
D010656_D020244 NONE phenylephrine_17/NN (r_npadvmod) induced_19/VBN (r_amod) hypertension_20/NN (r_pobj) of_16/IN (r_prep) effect_15/NN (r_nsubjpass) determined_32/VBN (l_prep) After_0/IN (l_pobj) min_2/NN (l_prep) of_3/IN (l_pobj) occlusion_8/NN
D010656_D001930 NONE phenylephrine_17/NN (r_npadvmod) induced_19/VBN (r_amod) hypertension_20/NN (l_prep) on_21/IN (l_pobj) injury_24/NN
C009591_D001930 NONE chloride_18/NN (r_dobj) using_16/VBG (r_acl) tissue_15/NN (r_pobj) by_13/IN (r_agent) evaluated_12/VBN (l_nsubjpass) A_1/NNP (l_prep) for_3/IN (l_pobj) rats_5/NNS (l_prep) in_6/IN (l_pobj) injury_10/NN
C009591_D004487 NONE chloride_18/NN (l_conj) edema_20/NN
D005070_D006973 NONE Blue_1/NNP (r_nsubj) was_9/VBD (l_prep) in_11/IN (l_pobj) group_16/NN (l_compound) HTN_15/NNP
D005070_D006973 NONE Blue_1/NNP (r_nsubj) was_9/VBD (l_prep) in_11/IN (l_pobj) group_16/NN (l_prep) versus_22/IN (l_pobj) group_25/NN (l_relcl) was_33/VBD (l_prep) in_34/IN (l_pobj) turn_35/NN (l_amod) greater_36/JJR (l_prep) than_37/IN (l_pobj) group_42/NN (l_compound) HTN_41/NNP
24897009
D004977_D010523 NONE ethambutol_6/NNP (r_amod) overtreatment_7/NN (r_pobj) due_4/JJ (r_prep) Optochiasmatic_0/JJ (l_conj) neuropathy_3/NN
D004977_D009901 CID Ethambutol_0/NNP (r_nsubjpass) known_2/VBN (l_xcomp) cause_4/VB (l_dobj) neuropathy_6/NN
D004977_D011115 CID Ethambutol_0/NNP (r_nsubjpass) known_2/VBN (l_xcomp) cause_4/VB (l_dobj) polyneuropathy_13/NNS
D004977_D014786 CID ethambutol_32/NNP (r_pobj) of_31/IN (r_prep) dose_30/NN (r_pobj) to_27/IN (r_prep) exposure_26/NN (r_pobj) of_25/IN (r_prep) weeks_24/NNS (r_pobj) after_22/IN (r_prep) developed_17/VBD (l_dobj) loss_19/NN
D004977_D010292 CID ethambutol_32/NNP (r_pobj) of_31/IN (r_prep) dose_30/NN (r_pobj) to_27/IN (r_prep) exposure_26/NN (r_pobj) of_25/IN (r_prep) weeks_24/NNS (r_pobj) after_22/IN (r_prep) developed_17/VBD (l_dobj) loss_19/NN (l_conj) paresthesias_21/NNS
D004977_D064420 NONE ethambutol_15/NNP (r_compound) toxicity_16/NN
3812624
D002220_D009759 NONE carbamazepine_9/NN (r_pobj) with_8/IN (r_prep) associated_7/VBN (r_acl) nystagmus_4/NN
D002220_D009759 NONE carbamazepine_14/NN (r_compound) therapy_15/NN (r_pobj) to_13/IN (r_prep) related_12/VBN (r_acl) nystagmus_11/NN
D002220_D009759 NONE carbamazepine_11/NN (r_compound) levels_12/NNS (r_pobj) of_8/IN (r_prep) reduction_7/NN (r_pobj) after_6/IN (r_prep) resolved_5/VBN (l_nsubj) nystagmus_1/NN
D002220_D015835 CID carbamazepine_9/NN (r_pobj) with_8/IN (r_prep) associated_7/VBN (r_acl) nystagmus_4/NN (l_conj) oscillopsia_6/NNP
15630069
D005947_D012559 NONE Glucose_0/NN (l_prep) in_2/IN (l_pobj) patients_3/NNS (l_prep) with_4/IN (l_pobj) schizophrenia_5/NN
D005947_D012559 NONE glucose_16/NN (r_compound) tolerance_17/NN (r_compound) test_18/NN (r_appos) Glucose_0/NN (l_prep) in_2/IN (l_pobj) patients_3/NNS (l_prep) with_4/IN (l_pobj) schizophrenia_5/NN
D005947_D012559 NONE glucose_32/NN (r_compound) metabolism_33/NN (r_dobj) affecting_31/VBG (r_ccomp) remains_24/VBZ (l_advcl) increasing_11/VBG (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) schizophrenia_15/NN
D005947_D012559 NONE glucose_18/NN (r_compound) tolerance_19/NN (r_compound) test_20/NN (r_dobj) using_13/VBG (r_xcomp) evaluated_12/VBN (l_nsubj) patients_9/NNS (l_prep) with_10/IN (l_pobj) schizophrenia_11/NN
D005947_D003920 NONE glucose_32/NN (r_compound) metabolism_33/NN (r_dobj) affecting_31/VBG (r_ccomp) remains_24/VBZ (l_advcl) increasing_11/VBG (l_nsubj) mellitus_8/NN
D005947_D003920 NONE glucose_32/NN (r_compound) metabolism_33/NN (l_conj) increasing_36/VBG (l_dobj) factors_39/NNS (l_prep) for_40/IN (l_pobj) diabetes_41/NN
D003024_D012559 NONE clozapine_20/NN (r_pobj) with_18/IN (r_prep) treated_17/VBN (r_conj) matched_11/VBN (r_acl) subjects_4/NNS (l_prep) with_5/IN (l_pobj) schizophrenia_6/NN
D003024_D011618 NONE clozapine_20/NN (r_pobj) with_18/IN (r_prep) treated_17/VBN (r_conj) matched_11/VBN (r_acl) subjects_4/NNS (l_prep) with_5/IN (l_pobj) schizophrenia_6/NN (l_conj) disorder_9/NN
C076029_D012559 NONE olanzapine_22/NN (r_conj) clozapine_20/NN (r_pobj) with_18/IN (r_prep) treated_17/VBN (r_conj) matched_11/VBN (r_acl) subjects_4/NNS (l_prep) with_5/IN (l_pobj) schizophrenia_6/NN
C076029_D011618 NONE olanzapine_22/NN (r_conj) clozapine_20/NN (r_pobj) with_18/IN (r_prep) treated_17/VBN (r_conj) matched_11/VBN (r_acl) subjects_4/NNS (l_prep) with_5/IN (l_pobj) schizophrenia_6/NN (l_conj) disorder_9/NN
D018967_D012559 NONE risperidone_25/NNP (r_conj) olanzapine_22/NN (r_conj) clozapine_20/NN (r_pobj) with_18/IN (r_prep) treated_17/VBN (r_conj) matched_11/VBN (r_acl) subjects_4/NNS (l_prep) with_5/IN (l_pobj) schizophrenia_6/NN
D018967_D011618 NONE risperidone_25/NNP (r_conj) olanzapine_22/NN (r_conj) clozapine_20/NN (r_pobj) with_18/IN (r_prep) treated_17/VBN (r_conj) matched_11/VBN (r_acl) subjects_4/NNS (l_prep) with_5/IN (l_pobj) schizophrenia_6/NN (l_conj) disorder_9/NN
D005947_D007333 NONE glucose_2/NN (l_conj) fasting_4/VBG (l_dobj) levels_7/NNS (l_conj) index_11/NN (l_compound) sensitivity_10/NN
D005947_D007333 NONE glucose_2/NN (l_conj) fasting_4/VBG (l_dobj) levels_7/NNS (l_conj) index_11/NN (l_conj) assessment_15/NN (l_prep) of_16/IN (l_pobj) resistance_18/NN
D005947_D007333 NONE glucose_21/VB (r_conj) Fasting_0/VBG (l_dobj) glucose_2/NN (l_conj) fasting_4/VBG (l_dobj) levels_7/NNS (l_conj) index_11/NN (l_compound) sensitivity_10/NN
D005947_D007333 NONE glucose_21/VB (r_conj) Fasting_0/VBG (l_dobj) glucose_2/NN (l_conj) fasting_4/VBG (l_dobj) levels_7/NNS (l_conj) index_11/NN (l_conj) assessment_15/NN (l_prep) of_16/IN (l_pobj) resistance_18/NN
D005947_D007333 NONE glucose_15/NN (r_compound) effectiveness_16/NN (r_pobj) of_14/IN (r_prep) resistance_11/NN
D003024_D007333 CID clozapine_3/FW (r_nmod) risperidone_7/NNP (r_appos) P<.001_0/LS (l_prep) with_10/IN (l_pobj) subjects_11/NNS (l_relcl) received_13/VBD (l_advcl) exhibiting_17/VBG (l_dobj) resistance_20/NN
D003024_D007333 CID clozapine_14/NN (r_dobj) received_13/VBD (l_advcl) exhibiting_17/VBG (l_dobj) resistance_20/NN
D003024_D007333 CID clozapine_30/NNP (r_appos) risperidone_28/NNP (r_pobj) with_27/IN (r_prep) treated_26/VBN (r_relcl) subjects_23/NNS (r_pobj) with_22/IN (r_prep) compared_21/VBN (r_prep) received_13/VBD (l_advcl) exhibiting_17/VBG (l_dobj) resistance_20/NN
D003024_D007333 CID clozapine-_2/NNP (r_case) nonobese_1/NNP (r_amod) groups_7/NNS (r_nsubj) displayed_8/VBD (l_dobj) resistance_11/NN
D003024_D007333 CID clozapine_2/NN (r_dobj) taking_1/VBG (r_acl) Patients_0/NNS (r_nsubjpass) examined_7/VBN (l_prep) for_8/IN (l_pobj) resistance_10/NN
C076029_D007333 CID olanzapine_5/NNP (r_nmod) risperidone_7/NNP (r_appos) P<.001_0/LS (l_prep) with_10/IN (l_pobj) subjects_11/NNS (l_relcl) received_13/VBD (l_advcl) exhibiting_17/VBG (l_dobj) resistance_20/NN
C076029_D007333 CID olanzapine_16/NN (r_conj) clozapine_14/NN (r_dobj) received_13/VBD (l_advcl) exhibiting_17/VBG (l_dobj) resistance_20/NN
C076029_D007333 CID olanzapine_4/NN (r_npadvmod) treated_6/VBN (r_amod) groups_7/NNS (r_nsubj) displayed_8/VBD (l_dobj) resistance_11/NN
C076029_D007333 CID olanzapine_4/NN (r_conj) clozapine_2/NN (r_dobj) taking_1/VBG (r_acl) Patients_0/NNS (r_nsubjpass) examined_7/VBN (l_prep) for_8/IN (l_pobj) resistance_10/NN
D018967_D007333 NONE risperidone_7/NNP (r_appos) P<.001_0/LS (l_prep) with_10/IN (l_pobj) subjects_11/NNS (l_relcl) received_13/VBD (l_advcl) exhibiting_17/VBG (l_dobj) resistance_20/NN
D018967_D007333 NONE risperidone_28/NNP (r_pobj) with_27/IN (r_prep) treated_26/VBN (r_relcl) subjects_23/NNS (r_pobj) with_22/IN (r_prep) compared_21/VBN (r_prep) received_13/VBD (l_advcl) exhibiting_17/VBG (l_dobj) resistance_20/NN
D018967_D007333 NONE risperidone_32/NNP (r_pobj) vs_31/IN (r_prep) clozapine_30/NNP (r_appos) risperidone_28/NNP (r_pobj) with_27/IN (r_prep) treated_26/VBN (r_relcl) subjects_23/NNS (r_pobj) with_22/IN (r_prep) compared_21/VBN (r_prep) received_13/VBD (l_advcl) exhibiting_17/VBG (l_dobj) resistance_20/NN
D018967_D007333 NONE risperidone_19/NN (r_npadvmod) treated_21/VBN (r_amod) subjects_22/NNS (r_pobj) with_18/IN (r_prep) compared_17/VBN (r_prep) displayed_8/VBD (l_dobj) resistance_11/NN
4010471
D009538_D012640 CID nicotine_2/NN (r_npadvmod) induced_4/VBN (r_amod) seizures_5/NNS
D009538_D012640 CID nicotine_15/NN (r_npadvmod) induced_17/VBN (r_amod) seizures_18/NNS
D009538_D012640 CID nicotine_7/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_pobj) to_2/IN (r_prep) sensitive_1/JJ (r_amod) Mice_0/NNS (r_nsubj) had_8/VBD (l_dobj) binding_13/VBG (l_prep) than_17/IN (l_pobj) mice_20/NNS (l_nmod) seizure_18/NN
D004229_D012640 NONE dithiothreitol_15/NNP (r_pobj) with_14/IN (r_prep) treatment_13/NN (r_pobj) by_12/IN (r_agent) affected_11/VBN (l_nsubjpass) sites_2/NNS (l_prep) from_3/IN (l_pobj) mice_8/NNS (l_amod) sensitive_5/JJ (l_npadvmod) seizure_4/NN
3990093
D011692_D007674 NONE aminonucleoside_8/JJ (r_compound) nephrosis_9/NN (r_pobj) with_7/IN (r_prep) rats_6/NNS (r_pobj) in_5/IN (r_prep) sclerosis_4/NN
D011692_D007674 NONE aminonucleoside_16/NNP (r_nmod) model_20/NN (r_npadvmod) studied_12/VBN (l_nsubjpass) relationship_2/NN (l_prep) between_3/IN (l_pobj) dysfunction_5/NN
D011692_D007674 NONE aminonucleoside_16/NNP (r_nmod) model_20/NN (r_npadvmod) studied_12/VBN (l_nsubjpass) relationship_2/NN (l_prep) between_3/IN (l_pobj) dysfunction_5/NN (l_prep) of_8/IN (l_pobj) sclerosis_10/NN
D011692_D007674 NONE PAN_18/NNP (r_nmod) model_20/NN (r_npadvmod) studied_12/VBN (l_nsubjpass) relationship_2/NN (l_prep) between_3/IN (l_pobj) dysfunction_5/NN
D011692_D007674 NONE PAN_18/NNP (r_nmod) model_20/NN (r_npadvmod) studied_12/VBN (l_nsubjpass) relationship_2/NN (l_prep) between_3/IN (l_pobj) dysfunction_5/NN (l_prep) of_8/IN (l_pobj) sclerosis_10/NN
D011692_D007674 NONE PAN_16/NNP (r_compound) rats_17/NNS (r_pobj) of_15/IN (r_prep) glomeruli_14/NNS (r_pobj) of_12/IN (r_prep) %_11/NN (r_pobj) in_7/IN (r_prep) found_6/VBN (l_nsubjpass) sclerosis_4/NN
D011692_D007674 NONE PAN_7/NNP (r_compound) nephrosis_8/NN (r_pobj) in_6/IN (r_prep) model_5/NN (r_pobj) to_1/IN (r_prep) Similar_0/JJ (r_advcl) related_16/VBN (l_nsubjpass) development_10/NN (l_prep) of_11/IN (l_pobj) sclerosis_13/NN
D011692_D009401 NONE aminonucleoside_8/JJ (r_compound) nephrosis_9/NN
D011692_D009401 NONE PAN_7/NNP (r_compound) nephrosis_8/NN
D011692_D011507 CID PAN_4/NNP (r_compound) rats_5/NNS (r_nsubj) were_6/VBD (l_acomp) proteinuric_8/JJ
D002244_D011507 NONE carbon_23/NN (r_dobj) given_21/VBN (r_conj) were_6/VBD (l_acomp) proteinuric_8/JJ
D011692_D012598 NONE PAN_12/NNP (r_compound) treatment_13/NN (r_pobj) during_10/IN (r_prep) change_9/VB (r_advcl) conclude_16/VBP (l_ccomp) caused_26/VBN (l_prep) in_35/IN (l_pobj) areas_38/NNS (l_relcl) develop_42/VB (l_nsubj) sclerosis_40/NN
15696449
D008558_D058186 CID melphalan_7/NN (r_pobj) after_3/IN (r_prep) insufficiency_2/NN
D008558_D058186 CID melphalan_12/NNP (r_compound) conditioning_13/NN (r_pobj) after_11/IN (r_prep) development_5/NN (l_prep) of_6/IN (l_pobj) insufficiency_9/NN
D008558_D058186 CID melphalan_10/NNP (r_pobj) after_6/IN (r_prep) insufficiency_2/NN
D008558_D058186 CID melphalan_10/NNP (r_pobj) after_6/IN (r_prep) insufficiency_2/NN (l_appos) ARI_4/NNP
D008558_D058186 CID melphalan_18/NN (r_pobj) after_14/IN (r_prep) developed_7/VBD (l_nsubj) ARI_6/NNP
D008558_D058186 CID melphalan_8/NNP (r_pobj) after_4/IN (r_prep) had_2/VBD (l_dobj) ARI_3/NNP
D008558_D058186 CID melphalan_7/NNP (r_dobj) suggests_6/VBZ (l_nsubj) timing_1/NN (l_prep) of_2/IN (l_pobj) injury_4/NN
D008558_D058186 CID melphalan_11/NNP (r_pobj) by_10/IN (r_prep) injury_9/NN
D008558_C531616 NONE melphalan_7/NN (r_pobj) after_3/IN (r_prep) insufficiency_2/NN (l_prep) in_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) amyloidosis_13/NN
D003404_D058186 NONE creatinine_31/NN (r_compound) level_32/NN (r_pobj) in_28/IN (r_prep) increase_16/NN (r_pobj) by_13/IN (r_agent) defined_12/VBN (l_nsubjpass) insufficiency_2/NN
D003404_D058186 NONE creatinine_31/NN (r_compound) level_32/NN (r_pobj) in_28/IN (r_prep) increase_16/NN (r_pobj) by_13/IN (r_agent) defined_12/VBN (l_nsubjpass) insufficiency_2/NN (l_appos) ARI_4/NNP
D008558_-1 NONE melphalan_11/NNP (r_pobj) by_10/IN (r_prep) injury_9/NN (r_pobj) for_7/IN (r_prep) prerequisite_6/NN (r_attr) be_4/VB (l_nsubj) injury_2/NN
1837756
D012701_D010259 NONE Serotonin_0/NN (r_compound) inhibitors_2/NNS (l_conj) paranoia_4/NN
D012701_D010259 NONE serotonin_7/NNS (r_compound) inhibitors_9/NNS (r_pobj) with_5/IN (r_prep) exacerbation_4/NN (l_amod) paranoid_3/JJ
D012701_D010259 NONE serotonin_37/NN (r_compound) inhibitors_39/NNS (r_pobj) with_36/IN (r_prep) associated_35/VBN (r_acl) exacerbations_34/NNS (l_amod) paranoid_33/JJ
D012701_D010259 NONE serotonin_9/NN (r_compound) blockers_11/NNS (r_pobj) with_8/IN (r_prep) exacerbations_7/NNS (l_amod) paranoid_6/JJ
D012701_D010259 NONE serotonin_9/NN (r_compound) blockers_11/NNS (r_pobj) with_8/IN (r_prep) exacerbations_7/NNS (r_pobj) to_4/IN (r_prep) call_2/VBP (l_conj) raise_16/VB (l_dobj) considerations_18/NNS (l_prep) regarding_19/VBG (l_pobj) paranoia_20/NN
D005473_D010259 CID fluoxetine_10/NNP (r_appos) inhibitors_9/NNS (r_pobj) with_5/IN (r_prep) exacerbation_4/NN (l_amod) paranoid_3/JJ
D000639_D010259 CID amitriptyline_12/NN (r_conj) fluoxetine_10/NNP (r_appos) inhibitors_9/NNS (r_pobj) with_5/IN (r_prep) exacerbation_4/NN (l_amod) paranoid_3/JJ
D012701_D003866 NONE serotonin_37/NN (r_compound) inhibitors_39/NNS (r_pobj) with_36/IN (r_prep) associated_35/VBN (r_acl) exacerbations_34/NNS (r_pobj) to_32/IN (r_prep) vulnerability_31/NN (r_dobj) present_29/VB (l_nsubj) disorders_2/NNS
D012701_D011605 NONE serotonin_37/NN (r_compound) inhibitors_39/NNS (r_pobj) with_36/IN (r_prep) associated_35/VBN (r_acl) exacerbations_34/NNS (r_pobj) to_32/IN (r_prep) vulnerability_31/NN (r_dobj) present_29/VB (l_nsubj) disorders_2/NNS (l_prep) including_4/VBG (l_pobj) atypicality_5/NN (l_conj) chronicity_11/NN (l_conj) psychosis_13/NN
D012701_D011605 NONE serotonin_37/NN (r_compound) inhibitors_39/NNS (r_pobj) with_36/IN (r_prep) associated_35/VBN (r_acl) exacerbations_34/NNS (r_pobj) to_32/IN (r_prep) vulnerability_31/NN (r_dobj) present_29/VB (l_nsubj) disorders_2/NNS (l_prep) in_20/IN (l_pobj) course_22/NN (l_prep) of_23/IN (l_pobj) psychosis_26/NN
D004298_D010259 NONE dopamine_18/NN (r_compound) release_19/NN (r_pobj) including_13/VBG (r_prep) mechanisms_11/NNS (r_npadvmod) remain_7/VBP (l_nsubj) pharmacology_2/NN (l_prep) of_5/IN (l_pobj) paranoia_6/NN
6316193
D010852_D012640 CID picrotoxin_12/NNP (r_npadvmod) induced_14/VBN (r_amod) seizures_15/NNS
D010852_D012640 CID picrotoxin_10/NNP (r_pobj) by_9/IN (r_agent) induced_8/VBN (r_acl) seizures_7/NNS
D010852_D012640 CID picrotoxin_31/NN (r_npadvmod) induced_33/VBN (r_amod) seizures_34/NNS
D002766_D012640 NONE cholecystokinin_17/NN (r_pobj) by_16/IN (r_prep) antagonism_10/NN (l_prep) of_11/IN (l_pobj) seizures_15/NNS
D002766_D012640 NONE cholecystokinin_23/NN (r_pobj) of_22/IN (r_prep) fragments_19/NNS (r_conj) cholecystokinin_17/NN (r_pobj) by_16/IN (r_prep) antagonism_10/NN (l_prep) of_11/IN (l_pobj) seizures_15/NNS
D012844_D012640 NONE CCK-8-NS_1/NNP (r_intj) enhanced_3/VBD (l_dobj) latency_5/NN (l_prep) of_6/IN (l_pobj) seizures_7/NNS
D003975_D012640 NONE diazepam_27/NN (r_appos) drug_25/NN (r_pobj) of_22/IN (r_prep) doses_21/NNS (r_conj) kg_18/NNS (r_appos) octapeptides_13/NNS (r_pobj) to_11/IN (r_prep) comparison_10/NN (r_pobj) in_9/IN (r_prep) had_5/VBD (r_ccomp) prevented_30/VBD (l_dobj) seizures_34/NNS
24691439
D003907_D012173 NONE dexamethasone_9/NN (r_pobj) with_4/IN (r_prep) mice_3/NNS (r_pobj) of_1/IN (r_prep) Treatment_0/NN (r_nsubj) led_10/VBD (l_dobj) loss_23/NN (l_prep) of_24/IN (l_pobj) cells_27/NNS (l_compound) ganglion_26/NN
D003907_D009410 CID dexamethasone_9/NN (r_pobj) with_4/IN (r_prep) mice_3/NNS (r_pobj) of_1/IN (r_prep) Treatment_0/NN (r_nsubj) led_10/VBD (l_dobj) loss_23/NN (l_conj) degeneration_31/NN
D003907_D005901 CID dexamethasone_9/NN (r_pobj) with_4/IN (r_prep) mice_3/NNS (r_pobj) of_1/IN (r_prep) Treatment_0/NN (r_nsubj) led_10/VBD (l_advcl) resembling_33/VBG (l_dobj) glaucoma_37/NN
D003907_D009798 CID dexamethasone_2/NN (r_npadvmod) induced_4/VBN (r_amod) hypertension_6/NN
D003907_D009798 CID Dexamethasone_0/NN (r_nsubj) induced_1/VBD (l_ccomp) reduced_23/VBN (l_conj) prevented_30/VBD (l_dobj) hypertension_35/NN
D003907_D009798 CID dexamethasone_31/NN (r_npadvmod) induced_33/VBN (r_amod) hypertension_35/NN
D003907_D009798 CID dexamethasone_13/NN (r_npadvmod) induced_15/VBN (r_amod) hypertension_17/NN
C075773_D009798 NONE 4-phenylbutyrate_11/CD (r_pobj) with_9/IN (r_prep) reduction_2/NN (r_nsubj) prevented_12/VBD (l_dobj) hypertension_17/NN
18341442
C026098_C562694 NONE Levetiracetam_0/NNS (l_prep) as_1/IN (l_pobj) adjunct_3/NN (l_prep) to_4/IN (l_pobj) treatment_6/NN (l_prep) in_7/IN (l_pobj) cats_8/NNS (l_prep) with_9/IN (l_pobj) epilepsy_12/NN
C026098_C562694 NONE levetiracetam_10/NNS (r_pobj) of_8/IN (r_prep) efficacy_4/NN (r_conj) pharmacokinetics_2/NNS (r_dobj) assess_1/VB (r_advcl) administered_11/VBD (l_prep) as_12/IN (l_pobj) adjunct_14/NN (l_prep) to_15/IN (l_pobj) treatment_17/NN (l_prep) in_18/IN (l_pobj) cats_19/NNS (l_prep) with_20/IN (l_pobj) epilepsy_25/NN
C026098_C562694 NONE levetiracetam_3/NNP (r_nsubjpass) tolerated_6/VBN (l_conj) be_11/VB (l_acomp) useful_12/JJ (l_prep) as_13/IN (l_pobj) adjunct_15/NN (l_prep) to_16/IN (l_pobj) treatment_18/NN (l_prep) in_19/IN (l_pobj) cats_20/NNS (l_prep) with_21/IN (l_pobj) epilepsy_23/NN
D010634_C562694 NONE phenobarbital_5/JJ (r_amod) treatment_6/NN (l_prep) in_7/IN (l_pobj) cats_8/NNS (l_prep) with_9/IN (l_pobj) epilepsy_12/NN
D010634_C562694 NONE phenobarbital_16/JJ (r_amod) treatment_17/NN (l_prep) in_18/IN (l_pobj) cats_19/NNS (l_prep) with_20/IN (l_pobj) epilepsy_25/NN
D010634_C562694 NONE phenobarbital_14/NN (r_pobj) with_13/IN (r_prep) controlled_12/VBN (r_relcl) epilepsy_8/NN
D010634_C562694 NONE phenobarbital_24/NN (r_pobj) with_23/IN (r_prep) treated_22/VBN (r_advcl) had_17/VBD (r_conj) controlled_12/VBN (r_relcl) epilepsy_8/NN
D010634_C562694 NONE phenobarbital_17/JJ (r_amod) treatment_18/NN (l_prep) in_19/IN (l_pobj) cats_20/NNS (l_prep) with_21/IN (l_pobj) epilepsy_23/NN
C026098_D012640 NONE levetiracetam_7/NNP (r_compound) treatment_8/NN (r_pobj) of_6/IN (r_prep) initiation_5/NN (r_pobj) after_4/IN (r_conj) before_2/IN (r_prep) frequencies_1/NNS (l_compound) Seizure_0/NN
C026098_D012640 NONE levetiracetam_7/NNP (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) to_4/IN (r_prep) prior_3/RB (r_advmod) frequency_2/NN (l_compound) seizure_1/NN
C026098_D012640 NONE levetiracetam_16/NNP (r_compound) treatment_17/NN (r_pobj) of_15/IN (r_prep) initiation_14/NN (r_pobj) after_13/IN (r_prep) was_6/VBD (l_nsubj) seizures_2/NNS
C026098_D012640 NONE levetiracetam_16/NNP (r_compound) treatment_17/NN (r_pobj) of_15/IN (r_prep) initiation_14/NN (r_pobj) after_13/IN (r_prep) was_6/VBD (l_acomp) higher_8/JJR (l_prep) than_9/IN (l_pobj) frequency_12/NN (l_compound) seizure_11/NN
C026098_D012640 NONE levetiracetam_16/NNP (r_compound) treatment_17/NN (r_pobj) of_15/IN (r_prep) initiation_14/NN (r_pobj) after_13/IN (r_prep) was_6/VBD (l_dep) seizures_20/NNS
C026098_D012640 NONE levetiracetam_16/NNP (r_compound) treatment_17/NN (r_pobj) of_15/IN (r_prep) initiation_14/NN (r_pobj) after_13/IN (r_prep) was_6/VBD (l_dep) seizures_20/NNS (l_appos) reduction_41/NN (l_prep) in_42/IN (l_pobj) frequency_44/NN (l_compound) seizure_43/NN
C026098_D012640 NONE levetiracetam_36/NNS (r_xcomp) responded_34/VBN (r_pcomp) as_32/IN (r_prep) classified_31/VBN (r_conj) seizures_20/NNS (r_dep) was_6/VBD (l_nsubj) seizures_2/NNS
C026098_D012640 NONE levetiracetam_36/NNS (r_xcomp) responded_34/VBN (r_pcomp) as_32/IN (r_prep) classified_31/VBN (r_conj) seizures_20/NNS (r_dep) was_6/VBD (l_acomp) higher_8/JJR (l_prep) than_9/IN (l_pobj) frequency_12/NN (l_compound) seizure_11/NN
C026098_D012640 NONE levetiracetam_36/NNS (r_xcomp) responded_34/VBN (r_pcomp) as_32/IN (r_prep) classified_31/VBN (r_conj) seizures_20/NNS
C026098_D012640 NONE levetiracetam_36/NNS (r_xcomp) responded_34/VBN (r_pcomp) as_32/IN (r_prep) classified_31/VBN (r_conj) seizures_20/NNS (l_appos) reduction_41/NN (l_prep) in_42/IN (l_pobj) frequency_44/NN (l_compound) seizure_43/NN
24753331
C083440_D020964 CID S-23121_0/NNS (r_nsubj) are_1/VBP (l_attr) herbicides_5/NNS (l_conj) embryolethality_8/NN
C083440_D020964 CID S-23121_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) incidence_11/NN (l_prep) of_12/IN (l_pobj) death_14/NN
C083440_D020964 CID S-23121_34/NNP (r_pobj) to_33/IN (r_prep) exposure_32/NN (r_dobj) following_30/VBG (r_advcl) observed_26/VBN (r_conj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) incidence_11/NN (l_prep) of_12/IN (l_pobj) death_14/NN
C083440_D064793 CID S-23121_0/NNS (r_nsubj) are_1/VBP (l_attr) herbicides_5/NNS (l_conj) embryolethality_8/NN (l_conj) teratogenicity_10/NN
C083440_D064793 CID S-23121_0/NNS (r_nsubj) were_1/VBD (l_acomp) teratogenic_2/JJ
C083440_D006345 CID S-23121_0/NNS (r_nsubj) are_1/VBP (l_attr) herbicides_5/NNS (l_conj) embryolethality_8/NN (l_conj) teratogenicity_10/NN (l_parataxis) defects_15/NNS
C083440_D006345 CID S-23121_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) incidence_11/NN (l_prep) of_12/IN (l_pobj) death_14/NN (l_conj) defect_18/NN
C083440_D006345 CID S-23121_34/NNP (r_pobj) to_33/IN (r_prep) exposure_32/NN (r_dobj) following_30/VBG (r_advcl) observed_26/VBN (r_conj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) incidence_11/NN (l_prep) of_12/IN (l_pobj) death_14/NN (l_conj) defect_18/NN
C083440_D005317 CID S-23121_0/NNS (r_nsubj) are_1/VBP (l_attr) herbicides_5/NNS (l_conj) embryolethality_8/NN (l_conj) teratogenicity_10/NN (l_parataxis) defects_15/NNS (l_conj) retardation_23/NN
C083440_D064420 NONE S-23121_0/NNS (r_nsubj) are_1/VBP (l_attr) herbicides_5/NNS (l_conj) embryolethality_8/NN (l_conj) teratogenicity_10/NN (l_parataxis) defects_15/NNS (l_prep) in_24/IN (l_pobj) rats_25/NNS (l_prep) in_26/IN (l_pobj) studies_31/NNS (l_compound) toxicity_30/NN
C106487_D064420 NONE S-53482_5/NN (r_pobj) to_4/IN (r_prep) exposure_1/NN (l_prep) at_6/IN (l_pobj) patterns_10/NNS (l_prep) of_11/IN (l_pobj) toxicity_13/NN
3864191
D012459_D007674 NONE Salicylate_0/NN (r_compound) nephropathy_1/NN
D011453_D007674 NONE prostaglandins_10/NNS (r_pobj) of_9/IN (r_prep) role_8/NN (r_appos) nephropathy_1/NN
D011453_D007674 NONE prostaglandins_6/NNS (r_pobj) of_5/IN (r_prep) role_4/NN (l_prep) in_7/IN (l_pobj) development_9/NN (l_prep) of_10/IN (l_pobj) nephropathy_12/NN
D011453_D007674 NONE prostaglandin_4/JJ (r_amod) synthesis_5/NN (r_pobj) in_2/IN (r_prep) changes_1/NNS (r_nsubjpass) accompanied_7/VBN (l_agent) by_8/IN (l_pobj) evidence_9/NN (l_prep) of_10/IN (l_pobj) damage_12/NN
D011453_D007674 NONE prostaglandin_5/NN (r_amod) synthesis_6/NN (r_nsubj) contributes_7/VBZ (l_conj) lead_24/VB (l_prep) to_25/IN (l_pobj) lesions_29/NNS (l_conj) deterioration_31/NN (l_prep) of_32/IN (l_pobj) function_34/NN
D011453_D007674 NONE prostaglandin_21/JJ (r_amod) synthesis_22/NN (r_pobj) of_20/IN (r_prep) inhibition_19/NN (r_nsubj) lead_24/VB (l_prep) to_25/IN (l_pobj) lesions_29/NNS (l_conj) deterioration_31/NN (l_prep) of_32/IN (l_pobj) function_34/NN
-1_D006932 NONE glucuronyl_12/NN (r_compound) transferase_13/NN (r_pobj) of_11/IN (r_prep) absence_10/NN (r_pobj) due_7/IN (r_prep) have_4/VBP (l_dobj) hyperbilirubinemia_6/NN
D001663_D006932 NONE bilirubin_18/NN (r_amod) deposition_19/NN (r_pobj) to_16/IN (r_prep) leading_15/VBG (r_advcl) have_4/VBP (l_dobj) hyperbilirubinemia_6/NN
D011453_D006417 NONE prostaglandin_4/JJ (r_amod) synthesis_5/NN (r_pobj) in_2/IN (r_prep) changes_1/NNS (r_nsubjpass) accompanied_7/VBN (l_agent) by_8/IN (l_pobj) evidence_9/NN (l_conj) rats_21/NNS (l_advcl) evidenced_23/VBN (l_agent) by_24/IN (l_pobj) incidence_27/NN (l_prep) of_30/IN (l_pobj) hematuria_31/NN
D001241_D007674 CID aspirin_14/NN (r_npadvmod) treated_16/VBN (r_amod) jj_17/NN (r_pobj) in_13/IN (r_prep) damage_12/NN
D001241_D007674 CID aspirin_69/NN (r_npadvmod) treated_71/VBN (r_amod) jJ_72/NNP (r_conj) jj_67/NN (r_pobj) to_62/IN (r_prep) compared_61/VBN (r_prep) increase_50/VB (r_conj) creatinine_41/NN (r_conj) rats_21/NNS (r_conj) evidence_9/NN (l_prep) of_10/IN (l_pobj) damage_12/NN
D001241_D006417 NONE aspirin_14/NN (r_npadvmod) treated_16/VBN (r_amod) jj_17/NN (r_pobj) in_13/IN (r_prep) damage_12/NN (r_pobj) of_10/IN (r_prep) evidence_9/NN (l_conj) rats_21/NNS (l_advcl) evidenced_23/VBN (l_agent) by_24/IN (l_pobj) incidence_27/NN (l_prep) of_30/IN (l_pobj) hematuria_31/NN
D001241_D006417 NONE aspirin_69/NN (r_npadvmod) treated_71/VBN (r_amod) jJ_72/NNP (r_conj) jj_67/NN (r_pobj) to_62/IN (r_prep) compared_61/VBN (r_prep) increase_50/VB (r_conj) creatinine_41/NN (r_conj) rats_21/NNS (l_advcl) evidenced_23/VBN (l_agent) by_24/IN (l_pobj) incidence_27/NN (l_prep) of_30/IN (l_pobj) hematuria_31/NN
D003404_D007674 NONE creatinine_41/NN (r_conj) rats_21/NNS (r_conj) evidence_9/NN (l_prep) of_10/IN (l_pobj) damage_12/NN
D003404_D006417 NONE creatinine_41/NN (r_conj) rats_21/NNS (l_advcl) evidenced_23/VBN (l_agent) by_24/IN (l_pobj) incidence_27/NN (l_prep) of_30/IN (l_pobj) hematuria_31/NN
D011453_D058186 NONE prostaglandin_5/NN (r_amod) synthesis_6/NN (r_nsubj) contributes_7/VBZ (l_conj) lead_24/VB (l_prep) to_25/IN (l_pobj) lesions_29/NNS
D011453_D058186 NONE prostaglandin_21/JJ (r_amod) synthesis_22/NN (r_pobj) of_20/IN (r_prep) inhibition_19/NN (r_nsubj) lead_24/VB (l_prep) to_25/IN (l_pobj) lesions_29/NNS
20495512
D006493_D013921 CID Heparin_0/NN (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN
D006493_D013921 CID Heparin_0/NN (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN
D006493_D013921 CID Heparin_0/NN (r_npadvmod) induced_2/VBN (r_amod) thrombocytopenia_3/NN (l_appos) HIT_5/NN
D006493_D013921 CID heparin_16/NN (r_compound) exposure_17/NN (r_pobj) after_15/IN (r_prep) occurs_14/VBZ (r_ccomp) suspected_11/VBN (r_conj) acknowledged_3/VBN (l_nsubjpass) HIT_0/NN
D006493_D013921 CID heparin_10/NN (r_compound) exposure_11/NN (r_pobj) of_8/IN (r_prep) cessation_7/NN (l_nsubj) treatment_1/NN (l_prep) of_2/IN (l_pobj) mandates_4/VBZ (l_compound) HIT_3/NN
D006493_D013921 CID heparin_11/NN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) history_16/NN (l_prep) of_17/IN (l_pobj) HIT_18/NN
D006493_D013921 CID heparin_1/NN (r_nsubj) remains_2/VBZ (l_prep) with_11/IN (l_pobj) potential_12/NN (l_prep) for_13/IN (l_pobj) HIT_14/NN
D006493_D013921 CID heparin_17/NN (r_compound) exposure_18/NN (r_pobj) with_15/IN (r_prep) HIT_14/NN
D006493_D013921 CID heparin_30/NN (r_nsubjpass) initiated_32/VBN (r_advcl) practiced_28/VBN (l_advcl) remains_2/VBZ (l_prep) with_11/IN (l_pobj) potential_12/NN (l_prep) for_13/IN (l_pobj) HIT_14/NN
D006493_D013927 CID heparin_16/NN (r_compound) exposure_17/NN (r_pobj) after_15/IN (r_prep) occurs_14/VBZ (r_ccomp) suspected_11/VBN (r_conj) acknowledged_3/VBN (l_prep) for_4/IN (l_pobj) predilection_7/NN (l_prep) for_8/IN (l_pobj) thrombosis_9/NN
D006493_D013927 CID heparin_16/NN (r_compound) exposure_17/NN (r_pobj) after_15/IN (r_prep) occurs_14/VBZ (l_nsubj) thrombosis_13/NN
D000991_D013921 NONE inhibitor_26/NN (r_dobj) using_22/VBG (r_advcl) cessation_7/NN (l_nsubj) treatment_1/NN (l_prep) of_2/IN (l_pobj) mandates_4/VBZ (l_compound) HIT_3/NN
D000991_D013921 NONE inhibitors_2/NNS (r_nsubj) are_3/VBP (l_attr) alternatives_9/NNS (l_relcl) heparin_11/NN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) history_16/NN (l_prep) of_17/IN (l_pobj) HIT_18/NN
7173007
C025504_D009325 CID X_3/NN (r_compound) group_4/NN (r_nsubj) had_5/VBD (l_dobj) incidence_8/NN (l_prep) of_9/IN (l_pobj) nausea_10/NN
C025504_D004244 CID X_3/NN (r_compound) group_4/NN (r_nsubj) had_5/VBD (l_dobj) incidence_8/NN (l_prep) of_9/IN (l_pobj) nausea_10/NN (l_conj) dizziness_12/NN
C006753_D015746 CID Endografine_1/NNP (r_compound) group_2/NN (r_nsubj) had_3/VBD (l_dobj) incidence_6/NN (l_prep) of_7/IN (l_pobj) pain_9/NN
D007485_D064420 NONE Hexabrix_0/NNP (r_nmod) polyvidone_3/NN (r_nsubjpass) considered_5/VBN (l_conj) preferred_22/VBN (l_prep) because_14/IN (l_pobj) Hexabrix_19/NNP (l_compound) toxicity_18/NN
D007485_D064420 NONE Hexabrix_19/NNP (l_compound) toxicity_18/NN
D000100_D064420 NONE polyvidone_3/NN (r_nsubjpass) considered_5/VBN (l_conj) preferred_22/VBN (l_prep) because_14/IN (l_pobj) Hexabrix_19/NNP (l_compound) toxicity_18/NN
D003287_D064420 NONE media_9/NNS (r_oprd) considered_5/VBN (l_conj) preferred_22/VBN (l_prep) because_14/IN (l_pobj) Hexabrix_19/NNP (l_compound) toxicity_18/NN
24220752
D003287_D007674 CID contrast_2/NN (r_npadvmod) induced_4/VBN (r_amod) nephropathy_5/NN
D003287_D007674 CID contrast_10/NN (r_npadvmod) induced_12/VBN (r_amod) nephropathy_13/NN
D003287_D007674 CID Contrast_0/NN (r_npadvmod) induced_2/VBN (r_amod) nephropathy_3/NN
D003287_D009369 NONE contrast_2/NN (r_npadvmod) induced_4/VBN (r_amod) nephropathy_5/NN (l_prep) in_6/IN (l_pobj) patients_8/NNS (l_prep) with_9/IN (l_pobj) cancer_10/NN
D003287_D009369 NONE contrast_10/NN (r_npadvmod) induced_12/VBN (r_amod) nephropathy_13/NN (r_pobj) to_9/IN (r_prep) related_8/VBN (l_prep) in_17/IN (l_pobj) patients_19/NNS (l_prep) with_20/IN (l_pobj) cancer_21/NN
-1_D006973 NONE bevacizumab_7/NNP (r_nmod) irinotecan_9/NNP (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) after_4/IN (l_conj) in_16/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) hypertension_19/NN
-1_D006973 NONE bevacizumab_5/NNP (r_nmod) irinotecan_7/NNP (r_pobj) of_4/IN (r_prep) combination_3/NN (r_conj) Hypertension_0/NN
-1_D006973 NONE bevacizumab_4/NNP (r_pobj) with_3/IN (r_prep) treatment_2/NN (r_conj) Hypertension_0/NN
C051890_D006973 NONE irinotecan_9/NNP (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) after_4/IN (l_conj) in_16/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) hypertension_19/NN
C051890_D006973 NONE irinotecan_7/NNP (r_pobj) of_4/IN (r_prep) combination_3/NN (r_conj) Hypertension_0/NN
17346443
D010396_D017512 CID Penicillamine_0/NNP (r_npadvmod) related_2/VBN (r_amod) dermatitis_4/NN
D010396_D017512 CID penicillamine_9/NNP (r_nsubjpass) interrupted_11/VBN (l_prep) after_12/IN (l_pobj) appearance_14/NN (l_prep) of_15/IN (l_pobj) dermatitis_18/NN
D010396_D006527 NONE Penicillamine_0/NNP (r_npadvmod) related_2/VBN (r_amod) dermatitis_4/NN (l_prep) in_10/IN (l_pobj) patient_14/NN (l_compound) disease_13/NN
D010396_D006527 NONE penicillamine_20/NN (r_npadvmod) related_22/VBN (r_amod) effects_24/NNS (r_nsubj) appeared_25/VBD (r_relcl) patient_17/NN (l_compound) disease_16/NN
D010396_D006527 NONE penicillamine_6/NN (r_npadvmod) treated_8/VBN (r_amod) patients_9/NNS (l_nmod) disease_5/NN
D010396_D001008 NONE Penicillamine_0/NNP (r_npadvmod) related_2/VBN (r_amod) dermatitis_4/NN (l_prep) in_10/IN (l_pobj) patient_14/NN (l_prep) with_15/IN (l_pobj) presentation_17/NN (l_appos) abnormalities_22/NNS (l_nmod) anxiety_19/NN
D019345_D017512 NONE acetate_9/NN (r_pobj) of_7/IN (r_prep) utility_6/NN (r_conj) dermatitis_4/NN
D019345_D017512 NONE acetate_22/NN (r_nsubj) permitted_23/VBD (r_conj) interrupted_11/VBN (l_prep) after_12/IN (l_pobj) appearance_14/NN (l_prep) of_15/IN (l_pobj) dermatitis_18/NN
D019345_D006527 NONE acetate_9/NN (r_pobj) of_7/IN (r_prep) utility_6/NN (r_conj) dermatitis_4/NN (l_prep) in_10/IN (l_pobj) patient_14/NN (l_compound) disease_13/NN
D019345_D006527 NONE acetate_7/NN (r_pobj) with_5/IN (r_prep) therapy_4/NN (r_nsubj) represented_8/VBD (l_dobj) treatment_11/NN (l_prep) for_12/IN (l_pobj) patient_17/NN (l_compound) disease_16/NN
D019345_D006527 NONE acetate_5/NN (r_pobj) of_2/IN (r_prep) safety_1/NN (r_nsubj) allowed_6/VBD (r_ccomp) is_18/VBZ (l_prep) in_19/IN (l_pobj) line_20/NN (l_prep) with_21/IN (l_pobj) evidence_24/NN (l_prep) on_25/IN (l_pobj) efficacy_27/NN (l_prep) in_31/IN (l_pobj) treatment_33/NN (l_prep) of_34/IN (l_pobj) disease_37/NN
D019345_D001008 NONE acetate_9/NN (r_pobj) of_7/IN (r_prep) utility_6/NN (r_conj) dermatitis_4/NN (l_prep) in_10/IN (l_pobj) patient_14/NN (l_prep) with_15/IN (l_pobj) presentation_17/NN (l_appos) abnormalities_22/NNS (l_nmod) anxiety_19/NN
D003300_D006527 NONE copper_10/NN (r_compound) metabolism_11/NN (r_pobj) of_8/IN (r_prep) disorder_7/NN (r_attr) is_3/VBZ (l_nsubj) disease_2/NN
D003300_D006527 NONE copper_14/NN (r_compound) accumulation_15/NN (r_pobj) with_12/IN (r_prep) disorder_7/NN (r_attr) is_3/VBZ (l_nsubj) disease_2/NN
D003300_D064420 NONE copper_10/NN (r_compound) metabolism_11/NN (r_pobj) of_8/IN (r_prep) disorder_7/NN (l_prep) with_12/IN (l_pobj) accumulation_15/NN (l_conj) toxicity_17/NN
D003300_D064420 NONE copper_14/NN (r_compound) accumulation_15/NN (l_conj) toxicity_17/NN
D003300_D056486 NONE copper_10/NN (r_compound) metabolism_11/NN (r_pobj) of_8/IN (r_prep) disorder_7/NN (l_prep) in_18/IN (l_pobj) tissues_20/NNS (l_conj) disorders_28/NNS
D003300_D056486 NONE copper_14/NN (r_compound) accumulation_15/NN (r_pobj) with_12/IN (r_prep) disorder_7/NN (l_prep) in_18/IN (l_pobj) tissues_20/NNS (l_conj) disorders_28/NNS
D003300_D009422 NONE copper_10/NN (r_compound) metabolism_11/NN (r_pobj) of_8/IN (r_prep) disorder_7/NN (l_prep) in_18/IN (l_pobj) tissues_20/NNS (l_conj) disorders_28/NNS
D003300_D009422 NONE copper_14/NN (r_compound) accumulation_15/NN (r_pobj) with_12/IN (r_prep) disorder_7/NN (l_prep) in_18/IN (l_pobj) tissues_20/NNS (l_conj) disorders_28/NNS
D003300_D001523 NONE copper_10/NN (r_compound) metabolism_11/NN (r_pobj) of_8/IN (r_prep) disorder_7/NN (l_prep) in_18/IN (l_pobj) tissues_20/NNS (l_conj) disorders_28/NNS
D003300_D001523 NONE copper_14/NN (r_compound) accumulation_15/NN (r_pobj) with_12/IN (r_prep) disorder_7/NN (l_prep) in_18/IN (l_pobj) tissues_20/NNS (l_conj) disorders_28/NNS
D010396_D012871 NONE penicillamine_6/NN (r_npadvmod) treated_8/VBN (r_amod) patients_9/NNS (r_pobj) of_2/IN (r_prep) most_1/JJS (r_nsubj) seem_12/VB (l_xcomp) develop_14/VB (l_dobj) lesion_17/NN
978847
D006145_D006973 NONE guanethidine_13/NNP (r_pobj) of_12/IN (r_prep) injection_11/NN (r_pobj) by_5/IN (r_agent) reduced_4/VBN (l_conj) hexamethonium_19/NNP (l_conj) potentiated_34/VBN (l_advcl) inhibited_51/VBD (l_dobj) enlargement_53/NN (l_prep) of_54/IN (l_pobj) pressure_56/NN
D006145_D013610 NONE guanethidine_13/NNP (r_pobj) of_12/IN (r_prep) injection_11/NN (r_pobj) by_5/IN (r_agent) reduced_4/VBN (l_conj) hexamethonium_19/NNP (l_conj) potentiated_34/VBN (l_advcl) inhibited_51/VBD (l_dobj) enlargement_53/NN (l_conj) tachycardia_59/NN
D018738_D006973 NONE hexamethonium_19/NNP (l_conj) potentiated_34/VBN (l_advcl) inhibited_51/VBD (l_dobj) enlargement_53/NN (l_prep) of_54/IN (l_pobj) pressure_56/NN
D018738_D013610 NONE hexamethonium_19/NNP (l_conj) potentiated_34/VBN (l_advcl) inhibited_51/VBD (l_dobj) enlargement_53/NN (l_conj) tachycardia_59/NN
D010646_D006973 NONE phentolamine_25/NN (r_conj) hexamethonium_19/NNP (l_conj) potentiated_34/VBN (l_advcl) inhibited_51/VBD (l_dobj) enlargement_53/NN (l_prep) of_54/IN (l_pobj) pressure_56/NN
D010646_D013610 NONE phentolamine_25/NN (r_conj) hexamethonium_19/NNP (l_conj) potentiated_34/VBN (l_advcl) inhibited_51/VBD (l_dobj) enlargement_53/NN (l_conj) tachycardia_59/NN
D003891_D006973 CID desmethylimipramine_37/NN (r_pobj) by_35/IN (r_agent) potentiated_34/VBN (l_advcl) inhibited_51/VBD (l_dobj) enlargement_53/NN (l_prep) of_54/IN (l_pobj) pressure_56/NN
D003891_D013610 NONE desmethylimipramine_37/NN (r_pobj) by_35/IN (r_agent) potentiated_34/VBN (l_advcl) inhibited_51/VBD (l_dobj) enlargement_53/NN (l_conj) tachycardia_59/NN
D011433_D006973 NONE propranolol_44/NNS (r_nsubj) inhibited_51/VBD (l_dobj) enlargement_53/NN (l_prep) of_54/IN (l_pobj) pressure_56/NN
D011433_D013610 NONE propranolol_44/NNS (r_nsubj) inhibited_51/VBD (l_dobj) enlargement_53/NN (l_conj) tachycardia_59/NN
D002217_D006973 CID carbachol_62/NNP (r_pobj) following_60/VBG (r_prep) inhibited_51/VBD (l_dobj) enlargement_53/NN (l_prep) of_54/IN (l_pobj) pressure_56/NN
D002217_D013610 CID carbachol_62/NNP (r_pobj) following_60/VBG (r_prep) inhibited_51/VBD (l_dobj) enlargement_53/NN (l_conj) tachycardia_59/NN
1420650
D002220_D020820 NONE carbamazepine_3/NN (r_compound) therapy_4/NN (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Asterixis_0/NNP
D002220_D020820 NONE carbamazepine_24/NN (r_dobj) adding_23/VBG (r_pcomp) by_22/IN (r_prep) triggered_20/VBN (l_nsubjpass) asterixis_18/NN
D002220_D020820 NONE CBZ_26/NNP (r_appos) carbamazepine_24/NN (r_dobj) adding_23/VBG (r_pcomp) by_22/IN (r_prep) triggered_20/VBN (l_nsubjpass) asterixis_18/NN
D002220_D020820 NONE CBZ_35/NNP (r_pobj) with_34/IN (r_prep) combination_33/NN (r_pobj) in_32/IN (r_prep) used_31/VBN (r_advcl) consider_1/VBP (l_ccomp) be_4/VB (l_nsubj) asterixis_2/NN
D008094_D020820 CID lithium_27/NN (r_pobj) as_26/IN (r_prep) drugs_25/NNS (r_nsubjpass) used_31/VBN (r_advcl) consider_1/VBP (l_ccomp) be_4/VB (l_nsubj) asterixis_2/NN
D008094_D020258 NONE lithium_27/NN (r_pobj) as_26/IN (r_prep) drugs_25/NNS (r_nsubjpass) used_31/VBN (r_advcl) consider_1/VBP (l_ccomp) be_4/VB (l_attr) sign_8/NN (l_prep) of_9/IN (l_pobj) neurotoxicity_10/NN
D003024_D020820 CID clozapine_29/NN (r_conj) lithium_27/NN (r_pobj) as_26/IN (r_prep) drugs_25/NNS (r_nsubjpass) used_31/VBN (r_advcl) consider_1/VBP (l_ccomp) be_4/VB (l_nsubj) asterixis_2/NN
D003024_D020258 NONE clozapine_29/NN (r_conj) lithium_27/NN (r_pobj) as_26/IN (r_prep) drugs_25/NNS (r_nsubjpass) used_31/VBN (r_advcl) consider_1/VBP (l_ccomp) be_4/VB (l_attr) sign_8/NN (l_prep) of_9/IN (l_pobj) neurotoxicity_10/NN
D002220_D020258 NONE CBZ_35/NNP (r_pobj) with_34/IN (r_prep) combination_33/NN (r_pobj) in_32/IN (r_prep) used_31/VBN (r_advcl) consider_1/VBP (l_ccomp) be_4/VB (l_attr) sign_8/NN (l_prep) of_9/IN (l_pobj) neurotoxicity_10/NN
2782734
D000420_D001249 NONE salbutamol_15/NN (l_prep) in_16/IN (l_pobj) asthmatics_17/NNS
D000420_D001249 NONE salbutamol_4/JJ (r_pobj) of_2/IN (r_prep) doses_1/NNS (r_nsubj) produce_5/VB (l_dobj) improvements_7/NNS (l_prep) in_8/IN (l_pobj) response_10/NN (l_prep) in_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) asthma_14/NN
D000420_D001249 NONE salbutamol_34/NN (r_pobj) with_30/IN (r_prep) treatment_29/NN (r_dobj) given_26/VBN (l_parataxis) predicted_10/VBN (l_nsubj) patients_2/NNS (l_amod) asthmatic_1/JJ
D000420_D001249 NONE salbutamol_46/NN (r_appos) treatment_29/NN (r_dobj) given_26/VBN (l_parataxis) predicted_10/VBN (l_nsubj) patients_2/NNS (l_amod) asthmatic_1/JJ
D011188_D014202 NONE K_38/NNP (r_nmod) Glu_40/NNP (r_dep) )_41/-RRB- (r_punct) metabolic_36/JJ (r_conj) tremor_33/NN
D005947_D014202 NONE Glu_40/NNP (r_dep) )_41/-RRB- (r_punct) metabolic_36/JJ (r_conj) tremor_33/NN
19178808
D015742_D006470 NONE propofol_54/NN (r_nmod) remifentanil_56/NNP (r_nmod) anesthesia_59/NN (r_pobj) by_53/IN (r_agent) induced_52/VBN (r_acl) anesthesia_51/NN (r_dobj) maintaining_48/VBG (r_pcomp) in_47/IN (r_prep) using_32/VBG (r_advcl) compare_7/VB (l_dobj) conditions_9/NNS (l_prep) including_11/VBG (l_pobj) amount_13/NN (l_prep) of_14/IN (l_pobj) bleeding_16/NN
D015742_D007022 CID propofol_54/NN (r_nmod) remifentanil_56/NNP (r_nmod) anesthesia_59/NN (r_pobj) by_53/IN (r_agent) induced_52/VBN (r_acl) anesthesia_51/NN (l_compound) hypotension_50/NN
D015742_D007022 CID propofol_10/NN (r_compound) remifentanil_12/NN (r_compound) TIVA_14/NNP (r_pobj) by_9/IN (r_agent) caused_8/VBN (r_acl) anesthesia_7/NN (l_compound) hypotension_6/NN
C071741_D006470 NONE remifentanil_56/NNP (r_nmod) anesthesia_59/NN (r_pobj) by_53/IN (r_agent) induced_52/VBN (r_acl) anesthesia_51/NN (r_dobj) maintaining_48/VBG (r_pcomp) in_47/IN (r_prep) using_32/VBG (r_advcl) compare_7/VB (l_dobj) conditions_9/NNS (l_prep) including_11/VBG (l_pobj) amount_13/NN (l_prep) of_14/IN (l_pobj) bleeding_16/NN
C071741_D007022 CID remifentanil_56/NNP (r_nmod) anesthesia_59/NN (r_pobj) by_53/IN (r_agent) induced_52/VBN (r_acl) anesthesia_51/NN (l_compound) hypotension_50/NN
C071741_D007022 CID remifentanil_12/NN (r_compound) TIVA_14/NNP (r_pobj) by_9/IN (r_agent) caused_8/VBN (r_acl) anesthesia_7/NN (l_compound) hypotension_6/NN
C071741_D007022 CID remifentanil_15/NN (r_compound) infusion_16/NN (r_pobj) of_14/IN (r_prep) rates_13/NNS (r_dobj) using_11/VBG (r_xcomp) using_8/VBG (r_acl) period_7/NN (r_pobj) within_4/IN (r_prep) achieved_3/VBN (l_nsubjpass) hypotension_1/NN
C071741_D007022 CID remifentanil_22/NN (r_pobj) of_21/IN (r_prep) dose_20/NN (r_conj) infusion_16/NN (r_pobj) of_14/IN (r_prep) rates_13/NNS (r_dobj) using_11/VBG (r_xcomp) using_8/VBG (r_acl) period_7/NN (r_pobj) within_4/IN (r_prep) achieved_3/VBN (l_nsubjpass) hypotension_1/NN
C071741_D007022 CID remifentanil_39/NN (r_pobj) of_38/IN (r_prep) doses_37/NNS (r_pobj) with_35/IN (r_prep) hypotension_34/NN (r_pobj) for_31/IN (r_prep) allowed_30/VBN (r_conj) provided_15/VBN (r_acl) anesthesia_14/NN (l_compound) hypotension_13/NN
C071741_D007022 CID remifentanil_39/NN (r_pobj) of_38/IN (r_prep) doses_37/NNS (r_pobj) with_35/IN (r_prep) hypotension_34/NN
1905439
D016595_D003693 CID misoprostol_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) woman_4/NN (r_pobj) in_1/IN (r_prep) Delirium_0/NNP
D016595_D003693 CID misoprostol_5/NNP (r_nsubjpass) discontinued_7/VBN (r_advcl) improved_3/VBD (l_nsubj) delirium_1/NN
D016595_D003693 CID misoprostol_20/NNP (r_compound) therapy_21/NN (r_pobj) from_19/IN (r_prep) resulted_18/VBD (l_nsubj) delirium_12/NN
D016595_D006261 NONE Misoprostol_0/NNP (r_nsubjpass) associated_3/VBN (l_prep) with_4/IN (l_pobj) reactions_6/NNS (l_prep) including_8/VBG (l_pobj) symptoms_10/NNS (l_conj) problems_13/NNS (l_conj) headache_16/NN
3831029
C037293_D006333 NONE denopamine_2/NNP (l_prep) of_6/IN (l_pobj) failure_11/NN
C037293_D006333 NONE TA-064_4/NNP (r_dep) )_5/-RRB- (r_punct) denopamine_2/NNP (l_prep) of_6/IN (l_pobj) failure_11/NN
C037293_D006333 NONE denopamine_3/NNP (r_pobj) of_2/IN (r_prep) efficacy_1/NN (l_prep) in_12/IN (l_pcomp) improving_13/VBG (l_dobj) failure_15/NN
C037293_D006333 NONE denopamine_6/NN (r_pobj) of_5/IN (r_prep) trials_4/NNS (r_dobj) warrant_2/VBP (l_prep) in_7/IN (l_pobj) treatment_9/NN (l_prep) of_10/IN (l_pobj) failure_12/NN
D010424_D006333 CID pentobarbital_7/NN (r_npadvmod) induced_9/VBN (r_amod) failure_11/NN
C037293_D001145 NONE denopamine_8/NNP (r_pobj) of_7/IN (r_prep) doses_6/NNS (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_nsubjpass) arrhythmias_1/NNS
3155884
D007545_D066126 NONE isoproterenol_11/NN (r_pobj) of_10/IN (r_prep) effect_9/NN (l_amod) cardiotoxic_8/JJ
D007545_D066126 NONE isoproterenol_23/NN (r_pobj) of_22/IN (r_prep) doses_21/NNS (r_pobj) of_19/IN (r_prep) effect_18/NN (l_amod) cardiotoxic_17/JJ
D007545_D066126 NONE ISO_25/NNP (r_appos) isoproterenol_23/NN (r_pobj) of_22/IN (r_prep) doses_21/NNS (r_pobj) of_19/IN (r_prep) effect_18/NN (l_amod) cardiotoxic_17/JJ
D007545_D003920 NONE isoproterenol_11/NN (l_prep) in_12/IN (l_pobj) rats_15/NNS (l_amod) diabetic_14/JJ
D007545_D003920 NONE isoproterenol_23/NN (r_pobj) of_22/IN (r_prep) doses_21/NNS (r_pobj) of_19/IN (r_prep) effect_18/NN (r_pobj) against_15/IN (r_prep) diabetes_14/NN
D007545_D003920 NONE ISO_25/NNP (r_appos) isoproterenol_23/NN (r_pobj) of_22/IN (r_prep) doses_21/NNS (r_pobj) of_19/IN (r_prep) effect_18/NN (r_pobj) against_15/IN (r_prep) diabetes_14/NN
D007545_D003920 NONE ISO_15/NN (r_compound) resistance_16/NN (l_prep) towards_19/IN (l_pobj) effect_23/NN (l_prep) on_24/IN (l_pobj) sensitivity_27/NN (l_prep) in_28/IN (l_pobj) rats_30/NNS (l_amod) diabetic_29/JJ
D013311_D066126 NONE streptozotocin_13/NNP (r_compound) rats_15/NNS (r_pobj) in_12/IN (r_prep) isoproterenol_11/NN (r_pobj) of_10/IN (r_prep) effect_9/NN (l_amod) cardiotoxic_8/JJ
D013311_D066126 NONE streptozotocin_13/NNP (r_compound) diabetes_14/NN (l_prep) against_15/IN (l_pobj) effect_18/NN (l_amod) cardiotoxic_17/JJ
D013311_D003920 CID streptozotocin_13/NNP (r_compound) rats_15/NNS (l_amod) diabetic_14/JJ
D013311_D003920 CID streptozotocin_13/NNP (r_compound) diabetes_14/NN
D013311_D003920 CID streptozotocin_10/NNS (r_nsubj) causes_13/VBZ (l_dobj) resistance_16/NN (l_prep) towards_19/IN (l_pobj) effect_23/NN (l_prep) on_24/IN (l_pobj) sensitivity_27/NN (l_prep) in_28/IN (l_pobj) rats_30/NNS (l_amod) diabetic_29/JJ
D007545_D005355 CID isoproterenol_4/NNP (r_pobj) of_3/IN (r_prep) study_2/NN (r_nsubj) induced_5/VBN (l_dobj) fibrosis_7/NN
D007545_D005355 CID ISO_11/NNP (r_nsubjpass) given_13/VBN (l_conj) analyzed_25/VBN (l_nsubjpass) fibrosis_19/NN
D007545_D005355 CID ISO_17/NN (r_nsubj) induced_18/VBD (r_advcl) analyzed_25/VBN (l_nsubjpass) fibrosis_19/NN
D005947_D005355 NONE glucose_52/NN (r_pobj) in_50/IN (r_prep) fall_49/NN (r_pobj) of_47/IN (r_prep) slope_46/NN (r_pobj) to_44/IN (r_prep) correlation_33/NN (r_conj) analyzed_25/VBN (l_nsubjpass) fibrosis_19/NN
D002395_D003920 NONE catecholamines_4/NNS (r_pobj) of_3/IN (r_prep) content_2/NN (r_nsubjpass) estimated_6/VBN (l_prep) in_7/IN (l_pobj) rats_12/NNS (l_amod) diabetic_11/JJ
D002395_D003920 NONE catecholamine_26/NN (r_compound) sensitivity_27/NN (l_prep) in_28/IN (l_pobj) rats_30/NNS (l_amod) diabetic_29/JJ
16723784
D015764_D001281 NONE bepridil_6/NNP (r_compound) administration_7/NN (l_prep) for_8/IN (l_pobj) fibrillation_10/NN (l_conj) flutter_12/NN
D015764_D001281 NONE hydrochloride_1/NN (r_nsubj) attracted_6/VBN (l_prep) as_8/IN (l_pobj) drug_11/NN (l_prep) for_12/IN (l_pobj) fibrillation_14/NN
D015764_D001281 NONE hydrochloride_1/NN (r_nsubj) attracted_6/VBN (l_prep) as_8/IN (l_pobj) drug_11/NN (l_prep) for_12/IN (l_pobj) fibrillation_14/NN (l_appos) AF_16/NNP
D015764_D001281 NONE Bpd_3/NNP (r_appos) hydrochloride_1/NN (r_nsubj) attracted_6/VBN (l_prep) as_8/IN (l_pobj) drug_11/NN (l_prep) for_12/IN (l_pobj) fibrillation_14/NN
D015764_D001281 NONE Bpd_3/NNP (r_appos) hydrochloride_1/NN (r_nsubj) attracted_6/VBN (l_prep) as_8/IN (l_pobj) drug_11/NN (l_prep) for_12/IN (l_pobj) fibrillation_14/NN (l_appos) AF_16/NNP
D015764_D001281 NONE Bpd_0/NNP (r_nsubjpass) administered_2/VBN (l_prep) to_3/IN (l_pobj) patients_5/NNS (l_acl) comprising_14/VBG (l_dobj) AF_16/NNP
D015764_D001282 NONE bepridil_6/NNP (r_compound) administration_7/NN (l_prep) for_8/IN (l_pobj) fibrillation_10/NN (l_conj) flutter_12/NN
D015764_D001282 NONE hydrochloride_1/NN (r_nsubj) attracted_6/VBN (l_prep) as_8/IN (l_pobj) drug_11/NN (l_conj) flutter_20/NN
D015764_D001282 NONE hydrochloride_1/NN (r_nsubj) attracted_6/VBN (l_prep) as_8/IN (l_pobj) drug_11/NN (l_conj) flutter_20/NN (l_appos) AFL_22/NNP
D015764_D001282 NONE Bpd_3/NNP (r_appos) hydrochloride_1/NN (r_nsubj) attracted_6/VBN (l_prep) as_8/IN (l_pobj) drug_11/NN (l_conj) flutter_20/NN
D015764_D001282 NONE Bpd_3/NNP (r_appos) hydrochloride_1/NN (r_nsubj) attracted_6/VBN (l_prep) as_8/IN (l_pobj) drug_11/NN (l_conj) flutter_20/NN (l_appos) AFL_22/NNP
D015764_D001282 NONE Bpd_0/NNP (r_nsubjpass) administered_2/VBN (l_prep) to_3/IN (l_pobj) patients_5/NNS (l_acl) comprising_14/VBG (l_dobj) AF_16/NNP (l_conj) cases_20/NNS (l_compound) AFL_19/NNP
439781
D007213_D007022 CID Indomethacin_0/NN (r_nsubj) induced_1/VBN (l_dobj) hypotension_2/NN
D012964_D007022 NONE sodium_4/NN (r_pobj) in_3/IN (r_prep) hypotension_2/NN
24641119
D007654_-1 NONE ketoconazole_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) syndrome_1/NN
D007654_-1 NONE ketoconazole_21/NN (r_pobj) to_19/IN (r_prep) sensitivity_18/NN (r_dobj) included_16/VBD (r_relcl) history_13/NN (r_pobj) on_11/IN (r_prep) based_10/VBN (r_acl) syndrome_9/NN
D007654_-1 NONE ketoconazole_14/NN (r_npadvmod) induced_16/VBN (r_amod) syndrome_18/NN
D007654_D003875 CID ketoconazole_20/NN (r_dobj) using_18/VBG (r_pcomp) after_17/IN (r_prep) presented_6/VBN (l_prep) with_7/IN (l_pobj) eruption_10/NN
10713017
D005277_D006976 CID fenfluramines_9/NNPS (r_nsubj) had_10/VBD (l_dobj) association_14/NN (l_prep) with_15/IN (l_pobj) PPH_16/NNP
D005277_D006976 CID fenfluramines_22/NNS (r_pobj) for_21/IN (r_prep) specificity_20/NN (r_conj) increase_9/NN (r_appos) magnitude_1/NN (l_prep) of_2/IN (l_pobj) association_4/NN (l_prep) with_5/IN (l_pobj) PPH_6/NNP
D005277_D006976 CID fenfluramines_22/NNS (r_pobj) for_21/IN (r_prep) specificity_20/NN (r_conj) increase_9/NN (r_appos) magnitude_1/NN (r_nsubj) are_23/VBP (l_acomp) consistent_24/JJ (l_prep) with_25/IN (l_pobj) studies_27/NNS (l_acl) indicating_28/VBG (l_ccomp) are_31/VBP (l_acomp) related_33/JJ (l_prep) to_34/IN (l_pobj) PPH_35/NN
D005277_D006976 CID fenfluramines_30/NNS (r_nsubj) are_31/VBP (r_ccomp) indicating_28/VBG (r_acl) studies_27/NNS (r_pobj) with_25/IN (r_prep) consistent_24/JJ (r_acomp) are_23/VBP (l_nsubj) magnitude_1/NN (l_prep) of_2/IN (l_pobj) association_4/NN (l_prep) with_5/IN (l_pobj) PPH_6/NNP
D005277_D006976 CID fenfluramines_30/NNS (r_nsubj) are_31/VBP (l_acomp) related_33/JJ (l_prep) to_34/IN (l_pobj) PPH_35/NN
25907210
D010755_D009369 NONE organophosphate_10/NN (r_compound) diazinon_12/NN (r_pobj) to_8/IN (r_prep) exposed_7/VBN (r_acl) applicators_6/NNS (r_pobj) among_4/IN (r_prep) tumours_3/NNS
D010755_D009369 NONE organophosphate_4/NN (r_compound) insecticide_5/NN (r_appos) Diazinon_0/NNP (r_nsubjpass) associated_12/VBN (l_conj) examined_32/VBN (l_dobj) risk_37/NN (l_compound) cancer_36/NN
D003976_D009369 NONE diazinon_12/NN (r_pobj) to_8/IN (r_prep) exposed_7/VBN (r_acl) applicators_6/NNS (r_pobj) among_4/IN (r_prep) tumours_3/NNS
D003976_D009369 NONE Diazinon_0/NNP (r_nsubjpass) associated_12/VBN (l_conj) examined_32/VBN (l_dobj) risk_37/NN (l_compound) cancer_36/NN
D003976_D009369 NONE diazinon_33/NN (r_npadvmod) associated_35/VBN (r_amod) risk_37/NN (l_compound) cancer_36/NN
D003976_D009369 NONE diazinon_3/NNP (r_compound) exposure_4/NN (l_conj) information_8/NN (l_compound) incidence_7/NN (l_compound) cancer_6/NN
D003976_D009369 NONE diazinon_3/NNP (r_compound) exposure_4/NN (r_dobj) used_1/VBD (l_xcomp) evaluate_10/VB (l_dobj) risk_13/NN (l_compound) tumour_12/NN
D003976_D009369 NONE diazinon_10/NNP (r_compound) use_11/NN (r_dobj) reported_8/VBD (r_ccomp) assessed_32/VBN (l_nsubjpass) incidence_30/NN (l_compound) cancer_29/NN
D003976_D008175 CID Diazinon_0/NNP (r_nsubjpass) associated_12/VBN (l_prep) with_13/IN (l_pobj) cancer_15/NN
D003976_D008175 CID diazinon_33/NN (r_npadvmod) associated_35/VBN (r_amod) risk_37/NN (r_dobj) examined_32/VBN (r_conj) associated_12/VBN (l_prep) with_13/IN (l_pobj) cancer_15/NN
D003976_D008175 CID diazinon_33/NNP (r_compound) use_34/NN (r_pobj) of_32/IN (r_prep) days_31/NNS (r_conj) observed_1/VBD (l_dobj) risks_5/NNS (l_compound) cancer_4/NN
D003976_D008175 CID diazinon_4/NNP (r_pobj) of_3/IN (r_prep) evaluation_2/NN (r_nsubj) provides_5/VBZ (l_dobj) evidence_7/NN (l_prep) of_8/IN (l_pobj) association_10/NN (l_prep) with_11/IN (l_pobj) risk_14/NN (l_compound) cancer_13/NN
D010755_D008175 NONE organophosphate_4/NN (r_compound) insecticide_5/NN (r_appos) Diazinon_0/NNP (r_nsubjpass) associated_12/VBN (l_prep) with_13/IN (l_pobj) cancer_15/NN
10087562
D004280_D016171 CID dobutamine_9/JJ (r_compound) treatment_10/NN (r_pobj) during_5/IN (r_prep) tachycardia_4/NN (l_nmod) pointes_2/FW
D004280_D016171 CID dobutamine_52/NNP (r_pobj) of_40/IN (r_prep) cycle_39/NN (r_pobj) during_37/IN (r_prep) developed_28/VBD (l_dobj) prolongation_30/NN (l_conj) tachycardia_36/VBD (l_amod) ventricular_35/JJ (l_npadvmod) pointes_34/FW
D004280_D016171 CID dobutamine_10/NN (r_pobj) during_8/IN (r_prep) report_1/NN (l_prep) of_2/IN (l_pobj) tachycardia_7/NN (l_nmod) pointes_5/FW
D004280_D017180 NONE dobutamine_9/JJ (r_compound) treatment_10/NN (r_pobj) during_5/IN (r_prep) tachycardia_4/NN
D004280_D017180 NONE dobutamine_52/NNP (r_pobj) of_40/IN (r_prep) cycle_39/NN (r_pobj) during_37/IN (r_prep) developed_28/VBD (l_dobj) prolongation_30/NN (l_conj) tachycardia_36/VBD
D004280_D017180 NONE dobutamine_10/NN (r_pobj) during_8/IN (r_prep) report_1/NN (l_prep) of_2/IN (l_pobj) tachycardia_7/NN
D004280_D002311 NONE dobutamine_9/JJ (r_compound) treatment_10/NN (l_prep) in_11/IN (l_pobj) patient_13/NN (l_prep) with_14/IN (l_pobj) cardiomyopathy_16/NN
D004280_D002311 NONE dobutamine_52/NNP (r_pobj) of_40/IN (r_prep) cycle_39/NN (r_pobj) during_37/IN (r_prep) developed_28/VBD (r_relcl) arrhythmias_26/NNS (r_pobj) of_23/IN (r_prep) absence_22/NN (r_conj) cardiomyopathy_20/NN
D004280_D006333 NONE dobutamine_9/JJ (r_compound) treatment_10/NN (l_prep) in_11/IN (l_pobj) patient_13/NN (l_prep) with_14/IN (l_pobj) cardiomyopathy_16/NN (l_conj) failure_20/NN
D004280_D006333 NONE dobutamine_52/NNP (r_pobj) of_40/IN (r_prep) cycle_39/NN (r_pobj) during_37/IN (r_prep) developed_28/VBD (r_relcl) arrhythmias_26/NNS (r_pobj) of_23/IN (r_prep) absence_22/NN (r_conj) cardiomyopathy_20/NN (r_pobj) to_18/IN (r_prep) secondary_17/JJ (r_amod) failure_16/NN
D004280_D001145 NONE dobutamine_52/NNP (r_pobj) of_40/IN (r_prep) cycle_39/NN (r_pobj) during_37/IN (r_prep) developed_28/VBD (r_relcl) arrhythmias_26/NNS
D004280_D001145 NONE dobutamine_10/NN (r_pobj) during_8/IN (r_prep) report_1/NN (r_nsubj) supports_11/VBZ (l_dobj) hypothesis_13/NN (l_acl) occur_19/VB (l_nsubj) arrhythmias_17/NNS
D004280_D008133 NONE dobutamine_52/NNP (r_pobj) of_40/IN (r_prep) cycle_39/NN (r_pobj) during_37/IN (r_prep) developed_28/VBD (l_dobj) prolongation_30/NN
17356399
C042705_D020803 NONE asparaginase_11/NNP (r_pobj) including_8/VBG (r_prep) chemotherapy_7/NN (r_pobj) after_5/IN (r_prep) encephalopathy_1/NN
C042705_D020301 CID asparaginase_11/NNP (r_pobj) including_8/VBG (r_prep) chemotherapy_7/NN (r_pobj) after_5/IN (r_prep) encephalopathy_1/NN (l_conj) vasospasm_4/NN
C042705_D054198 NONE asparaginase_11/NNP (r_pobj) including_8/VBG (r_prep) chemotherapy_7/NN (l_prep) for_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) leukemia_21/NN
D003561_D020803 NONE cytarabine_14/NN (r_conj) asparaginase_11/NNP (r_pobj) including_8/VBG (r_prep) chemotherapy_7/NN (r_pobj) after_5/IN (r_prep) encephalopathy_1/NN
D003561_D020803 NONE cytarabine_35/NNP (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) after_30/IN (r_prep) evidenced_5/VBN (r_acl) encephalopathy_4/NN
D003561_D020301 CID cytarabine_14/NN (r_conj) asparaginase_11/NNP (r_pobj) including_8/VBG (r_prep) chemotherapy_7/NN (r_pobj) after_5/IN (r_prep) encephalopathy_1/NN (l_conj) vasospasm_4/NN
D003561_D020301 CID cytarabine_35/NNP (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) after_30/IN (r_prep) evidenced_5/VBN (l_prep) with_22/IN (l_pobj) vasospasm_25/NN
D003561_D054198 NONE cytarabine_14/NN (r_conj) asparaginase_11/NNP (r_pobj) including_8/VBG (r_prep) chemotherapy_7/NN (l_prep) for_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) leukemia_21/NN
D003561_D001037 CID cytarabine_35/NNP (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) after_30/IN (r_prep) evidenced_5/VBN (l_agent) by_6/IN (l_pobj) changes_8/NNS (l_conj) aphasia_10/NN
D003561_D014549 CID cytarabine_35/NNP (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) after_30/IN (r_prep) evidenced_5/VBN (l_agent) by_6/IN (l_pobj) changes_8/NNS (l_conj) aphasia_10/NN (l_conj) incontinence_12/NN
D003561_D006212 CID cytarabine_35/NNP (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) after_30/IN (r_prep) evidenced_5/VBN (l_agent) by_6/IN (l_pobj) changes_8/NNS (l_conj) aphasia_10/NN (l_conj) incontinence_12/NN (l_conj) hallucinations_15/NNS
D003561_D018908 CID cytarabine_35/NNP (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) after_30/IN (r_prep) evidenced_5/VBN (l_agent) by_6/IN (l_pobj) changes_8/NNS (l_conj) aphasia_10/NN (l_conj) incontinence_12/NN (l_conj) hallucinations_15/NNS (l_conj) weakness_21/NN
25951420
D010126_D010300 CID Ozone_2/NNP (l_conj) Concentrations_5/NNPS (l_prep) With_6/IN (l_pobj) Disease_9/NNP
D010126_D010300 CID ozone_5/NN (r_nmod) matter_9/NN (r_pobj) of_4/IN (r_prep) associations_3/NNS (l_prep) with_10/IN (l_pobj) disease_13/NN
D010126_D010300 CID ozone_9/NN (r_pobj) with_8/IN (r_prep) disease_7/NN
D052638_D010300 CID matter_9/NN (r_pobj) of_4/IN (r_prep) associations_3/NNS (l_prep) with_10/IN (l_pobj) disease_13/NN
D052638_D010300 CID matter_27/NN (r_conj) CI_18/NNP (r_appos) associations_3/NNS (l_prep) of_4/IN (l_pobj) disease_7/NN
24341598
D012965_D007674 NONE chloride_6/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) in_9/IN (l_pobj) prevention_10/NN (l_prep) of_11/IN (l_pobj) nephropathy_15/NN
D004110_D007674 NONE diltiazem_8/NN (r_pobj) with_7/IN (r_prep) effects_2/NNS (l_prep) in_9/IN (l_pobj) prevention_10/NN (l_prep) of_11/IN (l_pobj) nephropathy_15/NN
D003287_D007674 NONE contrast_12/NN (r_npadvmod) induced_14/VBN (r_amod) nephropathy_15/NN
D003287_D007674 NONE Contrast_0/NN (r_npadvmod) induced_2/VBN (r_amod) nephropathy_3/NN
D003287_D058186 CID contrast_25/NN (r_compound) material_26/NN (r_nsubjpass) injected_28/VBN (r_advcl) day_23/NN (r_pobj) on_20/IN (r_prep) developed_13/VBD (l_dobj) failure_16/NN
D003287_D058186 CID contrast_25/NN (r_compound) material_26/NN (r_nsubjpass) injected_28/VBN (r_advcl) day_23/NN (r_pobj) on_20/IN (r_prep) developed_13/VBD (l_dobj) failure_16/NN (l_appos) ARF_18/NNP
2907577
-1_D058186 NONE alkylxanthines_2/NNS (l_prep) on_3/IN (l_pobj) failure_9/NN
-1_D058186 NONE alkylxanthines_9/NNS (r_pobj) of_7/IN (r_prep) effects_6/NNS (r_nsubjpass) examined_23/VBN (l_prep) in_24/IN (l_pobj) rats_25/NNS (l_acl) developing_26/VBG (l_dobj) failure_29/NN
-1_D058186 NONE alkylxanthines_10/NNS (r_pobj) with_8/IN (r_prep) noted_7/VBN (l_ccomp) indicates_16/VBZ (l_ccomp) plays_19/VBZ (l_dobj) role_26/NN (l_prep) in_27/IN (l_pobj) ARF_31/NN
D005839_D058186 CID gentamicin_4/NN (r_npadvmod) induced_6/VBN (r_amod) failure_9/NN
D005839_D058186 CID gentamicin_35/NNS (r_pobj) of_34/IN (r_prep) injections_33/NNS (r_pobj) after_30/IN (r_prep) examined_23/VBN (l_prep) in_24/IN (l_pobj) rats_25/NNS (l_acl) developing_26/VBG (l_dobj) failure_29/NN
D005839_D058186 CID gentamicin_28/NN (r_npadvmod) induced_30/VBN (r_amod) ARF_31/NN
D000241_D007511 NONE Adenosine_0/NN (r_compound) antagonists_1/NNS (r_nsubjpass) shown_5/VBN (l_xcomp) be_7/VB (l_prep) in_10/IN (l_pobj) models_15/NNS (l_amod) ischaemic_12/JJ
D000241_D007674 NONE Adenosine_0/NN (r_compound) antagonists_1/NNS (r_nsubjpass) shown_5/VBN (l_xcomp) be_7/VB (l_prep) in_10/IN (l_pobj) models_15/NNS (l_amod) ischaemic_12/JJ (l_conj) nephrotoxic_14/JJ
D000241_D058186 NONE Adenosine_0/NN (r_compound) antagonists_1/NNS (r_nsubjpass) shown_5/VBN (l_xcomp) be_7/VB (l_prep) in_10/IN (l_pobj) models_15/NNS (l_prep) of_16/IN (l_pobj) failure_19/NN
D000241_D058186 NONE Adenosine_0/NN (r_compound) antagonists_1/NNS (r_nsubjpass) shown_5/VBN (l_xcomp) be_7/VB (l_prep) in_10/IN (l_pobj) models_15/NNS (l_prep) of_16/IN (l_pobj) failure_19/NN (l_appos) ARF_21/NNP
D000241_D058186 NONE adenosine_14/NN (r_compound) antagonists_15/NNS (r_pobj) as_13/IN (r_prep) potencies_12/NNS (r_pobj) with_10/IN (r_prep) alkylxanthines_9/NNS (r_pobj) of_7/IN (r_prep) effects_6/NNS (r_nsubjpass) examined_23/VBN (l_prep) in_24/IN (l_pobj) rats_25/NNS (l_acl) developing_26/VBG (l_dobj) failure_29/NN
D000241_D058186 NONE adenosine_18/NN (r_nsubj) plays_19/VBZ (l_dobj) role_26/NN (l_prep) in_27/IN (l_pobj) ARF_31/NN
C028322_D058186 NONE 8-phenyltheophylline_16/CD (r_appos) antagonists_15/NNS (r_pobj) as_13/IN (r_prep) potencies_12/NNS (r_pobj) with_10/IN (r_prep) alkylxanthines_9/NNS (r_pobj) of_7/IN (r_prep) effects_6/NNS (r_nsubjpass) examined_23/VBN (l_prep) in_24/IN (l_pobj) rats_25/NNS (l_acl) developing_26/VBG (l_dobj) failure_29/NN
D013806_D058186 NONE theophylline_18/NN (r_conj) 8-phenyltheophylline_16/CD (r_appos) antagonists_15/NNS (r_pobj) as_13/IN (r_prep) potencies_12/NNS (r_pobj) with_10/IN (r_prep) alkylxanthines_9/NNS (r_pobj) of_7/IN (r_prep) effects_6/NNS (r_nsubjpass) examined_23/VBN (l_prep) in_24/IN (l_pobj) rats_25/NNS (l_acl) developing_26/VBG (l_dobj) failure_29/NN
C034347_D058186 NONE enprofylline_20/NN (r_conj) theophylline_18/NN (r_conj) 8-phenyltheophylline_16/CD (r_appos) antagonists_15/NNS (r_pobj) as_13/IN (r_prep) potencies_12/NNS (r_pobj) with_10/IN (r_prep) alkylxanthines_9/NNS (r_pobj) of_7/IN (r_prep) effects_6/NNS (r_nsubjpass) examined_23/VBN (l_prep) in_24/IN (l_pobj) rats_25/NNS (l_acl) developing_26/VBG (l_dobj) failure_29/NN
D014508_D009336 NONE urea_8/NN (r_pobj) by_4/IN (r_agent) assessed_3/VBN (l_nsubjpass) function_1/NN (l_appos) analysis_16/NN (l_conj) degree_31/NN (l_prep) of_32/IN (l_pobj) indices_35/NNS (l_nmod) necrosis_33/NN
D003404_D009336 NONE creatinine_10/NN (r_conj) urea_8/NN (r_pobj) by_4/IN (r_agent) assessed_3/VBN (l_nsubjpass) function_1/NN (l_appos) analysis_16/NN (l_conj) degree_31/NN (l_prep) of_32/IN (l_pobj) indices_35/NNS (l_nmod) necrosis_33/NN
D010130_D009336 NONE acid_25/NN (r_compound) clearances_26/NNS (r_conj) 3H]inulin_19/CD (r_conj) analysis_16/NN (l_conj) degree_31/NN (l_prep) of_32/IN (l_pobj) indices_35/NNS (l_nmod) necrosis_33/NN
6893265
D011441_D056486 CID Propylthiouracil_0/NNP (r_npadvmod) induced_2/VBN (r_amod) damage_4/NN
D011441_D056486 CID propylthiouracil_3/NN (r_npadvmod) induced_5/VBN (r_amod) damage_7/NN
19655282
D003042_D002637 CID cocaine_13/NN (r_npadvmod) associated_15/VBN (r_amod) pain_17/NN
D003042_D002637 CID cocaine_10/NN (r_npadvmod) associated_12/VBN (r_amod) pain_14/NN
D003042_D002637 CID cocaine_12/NN (r_npadvmod) associated_14/VBN (r_amod) pain_16/NN
D003042_D002637 CID cocaine_10/NN (r_npadvmod) associated_12/VBN (r_amod) pain_14/NN
D003042_D002637 CID cocaine_6/NN (r_npadvmod) associated_8/VBN (r_amod) pain_10/NN
D003042_D002637 CID cocaine_1/NN (r_npadvmod) associated_3/VBN (r_amod) ischemia_5/NN (r_nsubj) result_7/VB (r_advcl) discharged_35/VBN (l_nsubjpass) patients_12/NNS (l_prep) with_13/IN (l_pobj) pain_17/NN
D003042_D002637 CID cocaine_14/NN (r_compound) pain_17/NN
D003042_D054058 NONE cocaine_10/NN (r_npadvmod) associated_12/VBN (r_amod) pain_14/NN (r_pobj) with_9/IN (r_prep) presenting_2/VBG (r_acl) patients_1/NNS (r_nsubjpass) admitted_16/VBN (l_conj) receive_23/VB (l_dobj) protocol_32/NN (l_nmod) syndrome_30/NN
D003042_D003329 NONE cocaine_12/NN (r_npadvmod) associated_14/VBN (r_amod) pain_16/NN (r_pobj) in_11/IN (r_prep) efficacious_10/JJ (r_acomp) be_9/VB (l_advcl) account_22/VB (l_nsubj) vasospasm_20/NN
D003042_D007511 NONE cocaine_12/NN (r_npadvmod) associated_14/VBN (r_amod) pain_16/NN (r_pobj) in_11/IN (r_prep) efficacious_10/JJ (r_acomp) be_9/VB (l_advcl) account_22/VB (l_prep) for_23/IN (l_pobj) some_24/DT (l_prep) of_25/IN (l_pobj) ischemia_27/NN
D003042_D007511 NONE cocaine_1/NN (r_npadvmod) associated_3/VBN (r_amod) ischemia_5/NN (r_nsubj) result_7/VB (r_advcl) discharged_35/VBN (l_nsubjpass) patients_12/NNS (l_prep) with_13/IN (l_pobj) pain_17/NN (l_conj) ECG_23/NNP (l_amod) ischemic_22/JJ
D003042_D007511 NONE cocaine_14/NN (r_compound) pain_17/NN (l_conj) ECG_23/NNP (l_amod) ischemic_22/JJ
D003042_D017202 CID cocaine_1/NN (r_npadvmod) associated_3/VBN (r_amod) ischemia_5/NN
D003042_D017202 CID cocaine_14/NN (r_compound) pain_17/NN (r_pobj) with_13/IN (r_prep) patients_12/NNS (r_nsubjpass) discharged_35/VBN (l_advcl) result_7/VB (l_nsubj) ischemia_5/NN
11425091
D003042_D007235 CID cocaine_1/NN (r_compound) exposure_2/NN (l_conj) findings_6/NNS (l_prep) in_7/IN (l_pobj) infants_9/NNS
D003042_D007235 CID cocaine_6/NN (r_compound) exposure_7/NN (r_nsubj) increases_8/VBZ (l_dobj) incidence_10/NN (l_prep) in_14/IN (l_pobj) infants_16/NNS
D003042_D007235 CID cocaine_16/NN (r_pobj) to_15/IN (r_prep) exposed_14/VBN (r_relcl) infants_11/NNS
D003042_D006470 NONE cocaine_1/NN (r_compound) exposure_2/NN (r_nsubjpass) linked_5/VBN (l_prep) with_6/IN (l_pobj) hemorrhage_8/NN
D003042_D003560 CID cocaine_1/NN (r_compound) exposure_2/NN (r_nsubjpass) linked_5/VBN (l_prep) with_6/IN (l_pobj) hemorrhage_8/NN (l_conj) formation_11/NN (l_prep) of_12/IN (l_pobj) cysts_13/NNS
D003042_D003560 CID cocaine_6/NN (r_compound) exposure_7/NN (r_nsubj) increases_8/VBZ (l_dobj) incidence_10/NN (l_prep) of_11/IN (l_pobj) cysts_13/NNS
D003042_D003560 CID cocaine_9/NN (r_pobj) to_8/IN (r_prep) exposed_7/VBN (r_acl) infants_6/NNS (r_pobj) in_5/IN (r_prep) cysts_4/NNS
D003042_D003560 CID cocaine_16/NN (r_pobj) to_15/IN (r_prep) exposed_14/VBN (r_relcl) infants_11/NNS (r_pobj) in_9/IN (r_prep) formation_8/NN (l_compound) cyst_7/NN
D003042_D001927 CID cocaine_6/NN (r_compound) exposure_7/NN (r_nsubj) increases_8/VBZ (l_dobj) incidence_10/NN (l_prep) of_11/IN (l_pobj) cysts_13/NNS
D003042_D001927 CID cocaine_9/NN (r_pobj) to_8/IN (r_prep) exposed_7/VBN (r_acl) infants_6/NNS (r_pobj) in_5/IN (r_prep) cysts_4/NNS
D003042_D001927 CID cocaine_16/NN (r_pobj) to_15/IN (r_prep) exposed_14/VBN (r_relcl) infants_11/NNS (r_pobj) in_9/IN (r_prep) formation_8/NN (l_compound) cyst_7/NN
D003042_D019970 NONE cocaine_5/NN (r_npadvmod) exposed_7/VBN (r_amod) group_8/NN (r_pobj) to_3/IN (r_prep) assigned_2/VBN (l_advcl) was_11/VBD (l_attr) history_14/NN (l_prep) of_15/IN (l_pobj) abuse_17/NN
16920333
C416835_D012640 NONE acetate_4/NN (l_prep) on_11/IN (l_pobj) seizures_12/NNS
C416835_D012640 NONE 093_9/CD (r_appos) acetate_4/NN (l_prep) on_11/IN (l_pobj) seizures_12/NNS
C416835_D012640 NONE acetate_10/NN (l_prep) on_11/IN (l_pobj) model_16/NN (l_relcl) elicited_23/VBN (l_nsubjpass) seizures_20/NNS
C416835_D012640 NONE acetate_10/NN (l_prep) on_11/IN (l_pobj) model_16/NN (l_relcl) elicited_23/VBN (l_prep) without_28/IN (l_pobj) changes_29/NNS (l_prep) in_30/IN (l_pobj) patterns_34/NNS (l_nmod) threshold_31/NN (l_conj) seizure_33/NN
D010852_D012640 CID picrotoxin_17/NNP (r_pobj) of_16/IN (r_prep) microperfusion_15/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) seizures_12/NNS
D010852_D012640 CID picrotoxin_8/NNP (r_pobj) of_7/IN (r_prep) doses_6/NNS (r_pobj) with_4/IN (r_prep) treated_3/VBN (r_acl) animals_2/NNS (r_pobj) In_0/IN (r_prep) was_15/VBD (l_nsubj) number_12/NN (l_prep) of_13/IN (l_pobj) seizures_14/NNS
D010852_D012640 CID picrotoxin_8/NNP (r_pobj) of_7/IN (r_prep) doses_6/NNS (r_pobj) with_4/IN (r_prep) treated_3/VBN (r_acl) animals_2/NNS (r_pobj) In_0/IN (r_prep) was_15/VBD (l_conj) was_22/VBD (l_nsubj) duration_21/NN (l_compound) seizure_20/NN
D010852_D012640 CID picrotoxin_11/NNP (r_compound) microperfusion_12/NN (r_nsubj) prevented_13/VBD (l_dobj) seizures_14/NNS
1423336
D007980_D007022 CID levodopa_6/NNP (r_pobj) of_5/IN (r_prep) effect_4/NN (l_amod) hypotensive_3/JJ
D007980_D007022 CID levodopa_7/NNP (r_pobj) of_6/IN (r_prep) effect_5/NN (l_amod) hypotensive_4/JJ
D007980_D007022 CID levodopa_12/NNP (r_pobj) with_11/IN (r_prep) competing_10/VBG (r_acl) amino_5/NN (r_appos) Phenylalanine_0/NNP (r_nsubj) reduced_22/VBD (l_dobj) effects_27/NNS (l_amod) hypotensive_24/JJ
D007980_D007022 CID levodopa_29/NN (r_pobj) of_28/IN (r_prep) effects_27/NNS (l_amod) hypotensive_24/JJ
D007980_D007022 CID levodopa_3/NNP (r_nsubj) has_4/VBZ (l_dobj) action_8/NN (l_amod) hypotensive_7/JJ
D007980_D010300 NONE levodopa_6/NNP (r_pobj) of_5/IN (r_prep) effect_4/NN (l_prep) in_7/IN (l_pobj) patients_9/NNS (l_amod) parkinsonian_8/NNP
D007980_D010300 NONE levodopa_5/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubjpass) examined_7/VBN (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_amod) parkinsonian_9/NNP
D007980_D010300 NONE levodopa_17/NNP (r_pobj) to_16/IN (r_prep) responses_15/NNS (r_pobj) with_11/IN (r_prep) examined_7/VBN (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_amod) parkinsonian_9/NNP
D010649_D007022 NONE Phenylalanine_0/NNP (r_nsubj) reduced_22/VBD (l_dobj) effects_27/NNS (l_amod) hypotensive_24/JJ
D000596_D007022 NONE acid_6/NN (r_appos) amino_5/NN (r_appos) Phenylalanine_0/NNP (r_nsubj) reduced_22/VBD (l_dobj) effects_27/NNS (l_amod) hypotensive_24/JJ
19920070
D010634_D006529 CID phenobarbital_21/NNP (r_compound) administration_22/NN (r_pobj) after_20/IN (r_prep) ablation_3/NN (l_prep) in_9/IN (l_pobj) results_11/NNS (l_prep) in_12/IN (l_pobj) proliferation_17/NN (l_conj) hepatomegaly_19/NNP
11936424
C055603_D007674 NONE Temocapril_0/NNP (r_nsubj) modulates_15/VBZ (l_dobj) injury_17/NN
C055603_D009401 NONE Temocapril_0/NNP (r_nsubj) modulates_15/VBZ (l_dobj) injury_17/NN (l_prep) in_18/IN (l_pobj) nephrosis_22/NN
C055603_D009401 NONE temocapril_3/NNP (r_nsubj) was_4/VBD (l_acomp) effective_5/JJ (l_prep) in_6/IN (l_pcomp) retarding_7/VBG (l_conj) protected_11/VBN (l_dobj) function_13/NN (l_prep) in_14/IN (l_pobj) rats_17/NNS (l_compound) neprotic_16/JJ
D000809_D007674 NONE angiotensin_10/NN (r_appos) Temocapril_0/NNP (r_nsubj) modulates_15/VBZ (l_dobj) injury_17/NN
D000809_D009401 NONE angiotensin_10/NN (r_appos) Temocapril_0/NNP (r_nsubj) modulates_15/VBZ (l_dobj) injury_17/NN (l_prep) in_18/IN (l_pobj) nephrosis_22/NN
D011692_D007674 NONE aminonucleoside_21/JJ (r_compound) nephrosis_22/NN (r_pobj) in_18/IN (r_prep) injury_17/NN
D011692_D009401 CID aminonucleoside_21/JJ (r_compound) nephrosis_22/NN
D011692_D009401 CID PAN_6/NNP (r_pobj) of_5/IN (r_prep) injection_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (l_nsubjpass) Nephrosis_0/NNP
D011692_D009401 CID PAN_15/NNP (r_compound) rats_17/NNS (l_compound) neprotic_16/JJ
C055603_D011507 NONE temocapril_13/NNP (r_pobj) of_12/IN (r_prep) administration_11/NN (l_appos) inhibitor_29/NN (l_conj) proteinuria_32/NN
C055603_D011507 NONE Temocapril_0/NNP (r_nsubj) attenuate_3/VB (l_dobj) proteinuria_4/NN
C055603_D006984 NONE temocapril_13/NNP (r_pobj) of_12/IN (r_prep) administration_11/NN (l_appos) inhibitor_29/NN (l_conj) proteinuria_32/NN (l_conj) hypertrophy_36/NN
C055603_D005921 NONE temocapril_13/NNP (r_pobj) of_12/IN (r_prep) administration_11/NN (r_nsubj) prevented_38/VBD (l_dobj) glomerulosclerosis_39/NN
C055603_D009404 NONE temocapril_13/NNP (r_pobj) of_12/IN (r_prep) administration_11/NN (r_nsubj) prevented_38/VBD (l_dobj) rats_50/NNS (l_amod) nephrotic_49/JJ
D000809_D011507 NONE angiotensin_23/NN (r_punct) acting_18/VBG (r_amod) inhibitor_29/NN (l_conj) proteinuria_32/NN
D000809_D006984 NONE angiotensin_23/NN (r_punct) acting_18/VBG (r_amod) inhibitor_29/NN (l_conj) proteinuria_32/NN (l_conj) hypertrophy_36/NN
D000809_D005921 NONE angiotensin_23/NN (r_punct) acting_18/VBG (r_amod) inhibitor_29/NN (r_appos) administration_11/NN (r_nsubj) prevented_38/VBD (l_dobj) glomerulosclerosis_39/NN
D000809_D009404 NONE angiotensin_23/NN (r_punct) acting_18/VBG (r_amod) inhibitor_29/NN (r_appos) administration_11/NN (r_nsubj) prevented_38/VBD (l_dobj) rats_50/NNS (l_amod) nephrotic_49/JJ
D011692_D011507 CID aminonucleoside_43/RB (r_nmod) rats_50/NNS (r_dobj) prevented_38/VBD (l_nsubj) administration_11/NN (l_appos) inhibitor_29/NN (l_conj) proteinuria_32/NN
D011692_D011507 CID PAN_45/NNP (r_npadvmod) induced_48/VBN (r_amod) rats_50/NNS (r_dobj) prevented_38/VBD (l_nsubj) administration_11/NN (l_appos) inhibitor_29/NN (l_conj) proteinuria_32/NN
D011692_D006984 NONE aminonucleoside_43/RB (r_nmod) rats_50/NNS (r_dobj) prevented_38/VBD (l_nsubj) administration_11/NN (l_appos) inhibitor_29/NN (l_conj) proteinuria_32/NN (l_conj) hypertrophy_36/NN
D011692_D006984 NONE PAN_45/NNP (r_npadvmod) induced_48/VBN (r_amod) rats_50/NNS (r_dobj) prevented_38/VBD (l_nsubj) administration_11/NN (l_appos) inhibitor_29/NN (l_conj) proteinuria_32/NN (l_conj) hypertrophy_36/NN
D011692_D005921 NONE aminonucleoside_43/RB (r_nmod) rats_50/NNS (r_dobj) prevented_38/VBD (l_dobj) glomerulosclerosis_39/NN
D011692_D005921 NONE PAN_45/NNP (r_npadvmod) induced_48/VBN (r_amod) rats_50/NNS (r_dobj) prevented_38/VBD (l_dobj) glomerulosclerosis_39/NN
D011692_D005921 NONE PAN_26/NNP (r_compound) group_27/NN (r_pobj) in_24/IN (r_prep) weeks_23/NNS (r_pobj) at_19/IN (r_prep) was_6/VBD (l_nsubj) index_2/NN (l_compound) glomerulosclerosis_1/NN
D011692_D009404 NONE aminonucleoside_43/RB (r_nmod) rats_50/NNS (l_amod) nephrotic_49/JJ
D011692_D009404 NONE PAN_45/NNP (r_npadvmod) induced_48/VBN (r_amod) rats_50/NNS (l_amod) nephrotic_49/JJ
16810074
D009569_D006973 CID oxide_6/NN (r_nmod) deficiency_10/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (r_acl) Mechanisms_0/NNS (l_prep) of_1/IN (l_pobj) hypertension_2/NN
D009569_D006973 CID NO_8/JJ (r_nmod) deficiency_10/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (r_acl) Mechanisms_0/NNS (l_prep) of_1/IN (l_pobj) hypertension_2/NN
D009569_D006973 CID oxide_7/NN (r_pobj) of_1/IN (r_prep) Loss_0/NN (l_prep) in_11/IN (l_pobj) hypertension_12/NN
D009569_D006973 CID NO_9/UH (r_intj) Loss_0/NN (l_prep) in_11/IN (l_pobj) hypertension_12/NN
D009569_D006973 CID NO_7/NNP (r_pobj) of_6/IN (r_prep) removal_5/NN (r_pobj) by_3/IN (r_agent) created_2/VBN (r_acl) hypertension_1/NN
D009569_D006973 CID NO_5/DT (r_det) deficiency_6/NN (r_nsubj) increases_7/VBZ (r_advcl) make_26/VB (l_dobj) contribution_29/NN (l_prep) to_30/IN (l_pobj) form_32/NN (l_prep) of_33/IN (l_pobj) hypertension_34/NN
D009569_D018754 NONE oxide_7/NN (r_pobj) of_1/IN (r_prep) Loss_0/NN (r_nsubj) is_13/VBZ (l_attr) hallmark_15/NN (l_prep) of_16/IN (l_pobj) dysfunction_18/NN
D009569_D018754 NONE NO_9/UH (r_intj) Loss_0/NN (r_nsubj) is_13/VBZ (l_attr) hallmark_15/NN (l_prep) of_16/IN (l_pobj) dysfunction_18/NN
D019335_D006973 NONE arginine_21/NN (l_appos) hypertension_25/NN
D019335_D006973 NONE LNNA_23/NNP (r_nmod) hypertension_25/NN
D019335_D006973 NONE LNNA_17/NNP (r_compound) hypertension_18/NN
D019335_D006973 NONE LNNA_25/NNP (r_pobj) after_24/IN (r_prep) elevated_15/VBN (l_prep) in_16/IN (l_pobj) hypertension_18/NN
D019335_D006973 NONE LNNA_12/NNP (r_nmod) rats_14/NNS (l_amod) hypertensive_13/JJ
D018738_D006973 NONE hexamethonium_5/NNP (r_pobj) with_4/IN (r_prep) blockade_3/NN (r_nsubj) caused_6/VBD (l_dobj) fall_10/NN (l_prep) in_11/IN (l_pobj) rats_14/NNS (l_amod) hypertensive_13/JJ
24664478
C104457_D020258 NONE Nelarabine_0/JJ (r_compound) neurotoxicity_1/NN
C104457_D020258 NONE nelarabine_1/JJ (r_compound) neurotoxicity_2/NN
C104457_D020258 NONE nelarabine_16/NNP (r_pobj) by_15/IN (r_agent) caused_14/VBN (r_acl) neurotoxicity_13/NN
12677626
C476513_D020258 NONE levobupivacaine_8/NNP (r_pobj) of_7/IN (r_prep) administration_6/NN (r_pobj) following_4/VBG (r_prep) toxicity_3/NN
C476513_D004830 CID levobupivacaine_13/NN (r_pobj) of_12/IN (r_prep) injection_11/NN (r_pobj) following_8/VBG (r_prep) describe_1/VBP (l_dobj) cases_3/NNS (l_prep) of_4/IN (l_pobj) seizures_7/NNS
C476513_D004830 CID levobupivacaine_5/NNP (r_pobj) of_4/IN (r_prep) administration_3/NN (r_pobj) after_1/IN (r_prep) developed_17/VBD (l_dobj) seizures_20/NNS
D004837_D004830 NONE epinephrine_9/NN (r_pobj) with_8/IN (r_prep) levobupivacaine_5/NNP (r_pobj) of_4/IN (r_prep) administration_3/NN (r_pobj) after_1/IN (r_prep) developed_17/VBD (l_dobj) seizures_20/NNS
D004837_D004830 NONE epinephrine_33/NN (r_compound) administration_34/NN (r_pobj) of_31/IN (r_prep) signs_30/NNS (r_conj) aspiration_24/NN (r_pobj) despite_22/IN (r_prep) developed_17/VBD (l_dobj) seizures_20/NNS
D013874_D012640 NONE thiopental_7/NN (r_pobj) with_5/IN (r_prep) treated_4/VBN (l_nsubjpass) seizures_1/NNS
D013390_D012640 NONE succinylcholine_11/NN (r_pobj) to_10/IN (r_prep) addition_9/NN (r_pobj) in_8/IN (r_prep) treated_4/VBN (l_nsubjpass) seizures_1/NNS
C476513_D066126 NONE levobupivacaine_1/NNP (r_nsubj) have_3/VB (l_dobj) profile_8/NN (l_compound) toxicity_7/NN
C476513_D066126 NONE levobupivacaine_17/NNP (r_pobj) of_16/IN (r_prep) amounts_15/NNS (r_nsubj) reach_18/VBP (r_advcl) result_24/VB (l_advcl) have_3/VB (l_dobj) profile_8/NN (l_compound) toxicity_7/NN
C476513_D012640 NONE levobupivacaine_1/NNP (r_nsubj) have_3/VB (r_advcl) result_24/VB (l_prep) in_25/IN (l_pobj) convulsions_26/NNS
C476513_D012640 NONE levobupivacaine_17/NNP (r_pobj) of_16/IN (r_prep) amounts_15/NNS (r_nsubj) reach_18/VBP (r_advcl) result_24/VB (l_prep) in_25/IN (l_pobj) convulsions_26/NNS
D002045_D066126 NONE bupivacaine_11/NNP (r_pobj) than_9/IN (r_prep) profile_8/NN (l_compound) toxicity_7/NN
D002045_D012640 NONE bupivacaine_11/NNP (r_pobj) than_9/IN (r_prep) profile_8/NN (r_dobj) have_3/VB (r_advcl) result_24/VB (l_prep) in_25/IN (l_pobj) convulsions_26/NNS
851038
D007980_D010300 NONE dopa_5/NNP (r_compound) treatment_6/NN (l_prep) in_7/IN (l_pobj) patients_9/NNS (l_amod) parkinsonian_8/NNP
D007980_D010300 NONE dopa_11/NNP (r_npadvmod) treated_13/VBN (r_amod) patients_15/NNS (l_amod) parkinsonian_14/NN
D007980_D007008 CID dopa_11/NNP (r_npadvmod) treated_13/VBN (r_amod) patients_15/NNS (r_pobj) in_7/IN (r_prep) observed_6/VBN (l_nsubjpass) Hypokalemia_0/NNP
D007980_D007008 CID dopa_5/NNP (r_pobj) of_2/IN (r_prep) influence_1/NN (r_nsubjpass) studied_13/VBN (l_prep) with_17/IN (l_pobj) hypokalemia_18/NN
D011188_D007008 NONE potassium_11/NN (r_pobj) of_10/IN (r_prep) excretion_9/NN (r_pobj) on_6/IN (r_prep) influence_1/NN (r_nsubjpass) studied_13/VBN (l_prep) with_17/IN (l_pobj) hypokalemia_18/NN
D011188_D007008 NONE potassium_38/NN (r_pobj) of_37/IN (r_prep) concentration_36/NN (r_conj) rate_33/NN (r_appos) influence_1/NN (r_nsubjpass) studied_13/VBN (l_prep) with_17/IN (l_pobj) hypokalemia_18/NN
D011188_D007008 NONE potassium_47/NN (r_pobj) of_46/IN (r_prep) excretion_45/NN (r_conj) concentration_36/NN (r_conj) rate_33/NN (r_appos) influence_1/NN (r_nsubjpass) studied_13/VBN (l_prep) with_17/IN (l_pobj) hypokalemia_18/NN
D012964_D007008 NONE sodium_40/NN (r_conj) potassium_38/NN (r_pobj) of_37/IN (r_prep) concentration_36/NN (r_conj) rate_33/NN (r_appos) influence_1/NN (r_nsubjpass) studied_13/VBN (l_prep) with_17/IN (l_pobj) hypokalemia_18/NN
D012964_D007008 NONE sodium_49/NN (r_conj) potassium_47/NN (r_pobj) of_46/IN (r_prep) excretion_45/NN (r_conj) concentration_36/NN (r_conj) rate_33/NN (r_appos) influence_1/NN (r_nsubjpass) studied_13/VBN (l_prep) with_17/IN (l_pobj) hypokalemia_18/NN
D000450_D007008 NONE aldosterone_51/NN (r_conj) sodium_49/NN (r_conj) potassium_47/NN (r_pobj) of_46/IN (r_prep) excretion_45/NN (r_conj) concentration_36/NN (r_conj) rate_33/NN (r_appos) influence_1/NN (r_nsubjpass) studied_13/VBN (l_prep) with_17/IN (l_pobj) hypokalemia_18/NN
10427794
C065757_D056486 CID Meloxicam_0/NNP (r_npadvmod) induced_2/VBN (r_amod) toxicity_4/NN
C065757_D056486 CID meloxicam_18/NNP (r_pobj) to_17/IN (r_pcomp) due_16/IN (r_prep) developed_12/VBD (l_dobj) hepatitis_15/NN
C065757_D056486 CID meloxicam_7/NNP (r_compound) administration_8/NN (r_pobj) after_6/IN (r_prep) occurred_4/VBD (l_nsubj) hepatitis_3/NN
C065757_D056486 CID meloxicam_4/NN (r_nmod) toxicity_7/NN
C065757_D056486 CID meloxicam_4/NN (r_nmod) toxicity_7/NN (r_pobj) of_3/IN (r_prep) case_2/NN (r_nsubj) demonstrates_8/VBZ (l_advcl) induce_15/VB (l_dobj) damage_17/NN
C065757_D001172 NONE meloxicam_18/NNP (r_pobj) to_17/IN (r_pcomp) due_16/IN (r_prep) developed_12/VBD (r_relcl) patient_7/NN (l_prep) with_8/IN (l_pobj) arthritis_10/NN
C065757_D004342 CID meloxicam_7/NNP (r_compound) administration_8/NN (r_pobj) after_6/IN (r_prep) occurred_4/VBD (l_conj) associated_11/VBN (l_prep) with_12/IN (l_pobj) development_14/NN (l_prep) of_15/IN (l_pobj) antibodies_17/NNS (l_acl) suggesting_18/VBG (l_dobj) mechanism_21/NN (l_compound) hypersensitivity_20/NN
23846525
C055162_D056486 CID clopidogrel_4/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) hepatitis_1/NN
C055162_D056486 CID clopidogrel_5/RB (r_npadvmod) related_7/VBN (r_amod) hepatitis_9/NN
C055162_D056486 CID clopidogrel_7/NN (r_pobj) due_5/JJ (r_amod) hepatotoxicity_4/NN
C055162_D056486 CID clopidogrel_19/NNP (r_nsubjpass) prescribed_21/VBN (r_relcl) injury_17/NN
3191389
D010862_D012640 CID pilocarpine_14/NNP (r_pobj) by_13/IN (r_agent) produced_12/VBN (r_acl) seizures_11/NNS
D010862_D012640 CID pilocarpine_4/NN (r_nsubj) induces_5/VBZ (l_prep) in_6/IN (l_pobj) seizures_8/NNS
D010862_D012640 CID pilocarpine_35/NNP (r_pobj) by_34/IN (r_agent) produced_33/VBN (r_acl) seizures_32/NNS
D010862_D012640 CID pilocarpine_21/NNP (r_pobj) by_20/IN (r_agent) produced_19/VBN (r_acl) seizures_18/NNS
D010862_D012640 CID pilocarpine_24/NNP (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) damage_21/NN (r_pobj) from_16/IN (r_prep) protected_14/VBN (r_conj) prevented_11/VBN (l_dobj) seizures_12/NNS
D010862_D012640 CID pilocarpine_24/NNP (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) damage_21/NN (l_amod) related_19/VBN (l_npadvmod) seizure_17/NN
D010862_D012640 CID pilocarpine_16/NN (r_npadvmod) induced_18/VBN (r_amod) seizures_19/NNS
D010862_D013226 CID pilocarpine_4/NN (r_nsubj) induces_5/VBZ (l_conj) epilepticus_11/NN
D012980_D012640 CID salicylate_20/NN (r_appos) drugs_17/NNS (r_pobj) of_9/IN (r_prep) effect_8/NN (r_dobj) investigate_6/VB (l_prep) on_31/IN (l_pobj) seizures_32/NNS
D010653_D012640 CID phenylbutazone_22/NN (r_conj) salicylate_20/NN (r_appos) drugs_17/NNS (r_pobj) of_9/IN (r_prep) effect_8/NN (r_dobj) investigate_6/VB (l_prep) on_31/IN (l_pobj) seizures_32/NNS
D007213_D012640 NONE indomethacin_24/NN (r_conj) phenylbutazone_22/NN (r_conj) salicylate_20/NN (r_appos) drugs_17/NNS (r_pobj) of_9/IN (r_prep) effect_8/NN (r_dobj) investigate_6/VB (l_prep) on_31/IN (l_pobj) seizures_32/NNS
D007213_D012640 NONE Indomethacin_0/NNS (r_nsubj) failed_15/VBD (l_xcomp) modulate_17/VB (l_dobj) seizures_18/NNS
D007052_D012640 NONE ibuprofen_26/NN (r_conj) indomethacin_24/NN (r_conj) phenylbutazone_22/NN (r_conj) salicylate_20/NN (r_appos) drugs_17/NNS (r_pobj) of_9/IN (r_prep) effect_8/NN (r_dobj) investigate_6/VB (l_prep) on_31/IN (l_pobj) seizures_32/NNS
D007052_D012640 NONE ibuprofen_8/NN (r_nsubj) failed_15/VBD (l_xcomp) modulate_17/VB (l_dobj) seizures_18/NNS
D008528_D012640 NONE acid_29/NN (r_conj) ibuprofen_26/NN (r_conj) indomethacin_24/NN (r_conj) phenylbutazone_22/NN (r_conj) salicylate_20/NN (r_appos) drugs_17/NNS (r_pobj) of_9/IN (r_prep) effect_8/NN (r_dobj) investigate_6/VB (l_prep) on_31/IN (l_pobj) seizures_32/NNS
D008528_D012640 NONE acid_1/NN (r_nsubj) prevented_11/VBN (l_dobj) seizures_12/NNS
D008528_D012640 NONE acid_1/NN (r_nsubj) prevented_11/VBN (l_conj) protected_14/VBN (l_prep) from_16/IN (l_pobj) damage_21/NN (l_amod) related_19/VBN (l_npadvmod) seizure_17/NN
D008528_D001930 NONE acid_1/NN (r_nsubj) prevented_11/VBN (l_conj) protected_14/VBN (l_prep) from_16/IN (l_pobj) damage_21/NN
D010862_D001930 NONE pilocarpine_24/NNP (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) damage_21/NN
24275640
D004317_D066126 CID doxorubicin_12/NNS (r_pobj) of_11/IN (r_prep) doses_10/NNS (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) after_4/IN (r_prep) stress_1/NN (l_prep) on_2/IN (l_pobj) cardiotoxicity_3/NN
D004317_D066126 CID doxorubicin_3/NNS (r_pobj) of_2/IN (r_prep) mechanism_1/NN (l_parataxis) remains_7/VBZ (l_nsubj) cardiotoxicity_6/NN
D004317_D066126 CID DOX)-induced_5/VBN (r_compound) cardiotoxicity_6/NN
D004317_D066126 CID DOX_17/NNP (r_pobj) of_16/IN (r_prep) dose_15/NN (r_pobj) by_12/IN (r_agent) induced_11/VBN (r_acl) cardiotoxicity_10/NN
D004317_D006331 NONE DOX_3/NNP (r_pobj) of_2/IN (r_prep) dose_1/NN (r_nsubjpass) associated_5/VBN (l_prep) with_6/IN (l_pobj) disarrangement_9/NN
D004317_D009336 CID DOX_3/NNP (r_pobj) of_2/IN (r_prep) dose_1/NN (r_nsubjpass) associated_5/VBN (l_prep) with_6/IN (l_pobj) disarrangement_9/NN (l_conj) necrosis_11/NN
7176945
D013390_D010146 CID suxamethonium_2/JJ (r_amod) pains_3/NNS
D013390_D010146 CID scoline_8/NNP (r_compound) pain_9/NN
D013390_D010146 CID scoline_9/JJ (r_amod) pain_10/NN
D013390_D010146 CID scoline_20/NNP (r_amod) pain_21/NN
D013390_D010146 CID suxamethonium_16/NNP (r_pobj) of_15/IN (r_prep) preparation_14/NN (r_conj) type_2/NN (r_nsubj) affected_24/VBD (l_dobj) incidence_26/NN (l_prep) of_27/IN (l_pobj) pain_29/NN
D013390_D010146 CID scoline_28/NNP (r_compound) pain_29/NN
C084773_D005207 NONE Fazadinium_12/NNP (r_pobj) of_11/IN (r_prep) dose_10/NN (r_pobj) by_6/IN (r_prep) abolition_1/NN (l_prep) of_2/IN (l_pobj) fasciculations_4/NNS
C084773_D010146 NONE Fazadinium_12/NNP (r_pobj) of_11/IN (r_prep) dose_10/NN (r_pobj) by_6/IN (r_prep) abolition_1/NN (r_nsubj) influence_16/VB (l_dobj) occurrence_18/NN (l_prep) of_19/IN (l_pobj) pain_21/NN
D013390_D005207 CID scoline_20/NNP (r_amod) pain_21/NN (r_pobj) of_19/IN (r_prep) occurrence_18/NN (r_dobj) influence_16/VB (l_nsubj) abolition_1/NN (l_prep) of_2/IN (l_pobj) fasciculations_4/NNS
D000530_D010146 NONE Althesin_7/NNP (r_appos) agent_5/NN (r_pobj) of_3/IN (r_prep) type_2/NN (r_nsubj) affected_24/VBD (l_dobj) incidence_26/NN (l_prep) of_27/IN (l_pobj) pain_29/NN
D013874_D010146 NONE Thiopentone_9/NNP (r_conj) Althesin_7/NNP (r_appos) agent_5/NN (r_pobj) of_3/IN (r_prep) type_2/NN (r_nsubj) affected_24/VBD (l_dobj) incidence_26/NN (l_prep) of_27/IN (l_pobj) pain_29/NN
D002712_D010146 NONE chloride_19/NN (r_appos) suxamethonium_16/NNP (r_pobj) of_15/IN (r_prep) preparation_14/NN (r_conj) type_2/NN (r_nsubj) affected_24/VBD (l_dobj) incidence_26/NN (l_prep) of_27/IN (l_pobj) pain_29/NN
D001965_D010146 NONE bromide_21/NN (r_conj) chloride_19/NN (r_appos) suxamethonium_16/NNP (r_pobj) of_15/IN (r_prep) preparation_14/NN (r_conj) type_2/NN (r_nsubj) affected_24/VBD (l_dobj) incidence_26/NN (l_prep) of_27/IN (l_pobj) pain_29/NN
4082192
C026729_D007674 NONE aminophenol_5/NNP (r_pobj) of_2/IN (r_prep) role_1/NN (l_prep) in_6/IN (l_pobj) nephrotoxicity_10/NN
C026729_D007674 NONE aminophenol_5/NNP (r_pobj) of_2/IN (r_prep) role_1/NN (l_appos) effect_12/NN (l_prep) of_13/IN (l_pobj) phosphate_18/NN (l_conj) nephrotoxicity_25/NN
C026729_D007674 NONE aminophenol_24/NN (r_compound) nephrotoxicity_25/NN (r_conj) phosphate_18/NN (r_pobj) of_13/IN (r_prep) effect_12/NN (r_appos) role_1/NN (l_prep) in_6/IN (l_pobj) nephrotoxicity_10/NN
C026729_D007674 NONE aminophenol_24/NN (r_compound) nephrotoxicity_25/NN
C026729_D007674 NONE PAP_9/NN (r_compound) formation_10/NN (r_nsubj) is_11/VBZ (l_attr) step_14/NN (l_prep) in_15/IN (l_pobj) nephrotoxicity_19/NN
C026729_D007674 NONE PAP_21/NNP (r_compound) nephrotoxicity_22/NN
C026729_D007674 NONE PAP_9/NNP (r_compound) administration_10/NN (r_conj) APAP_7/NNP (r_pobj) to_6/IN (r_prep) prior_5/RB (r_advmod) Pretreatment_0/NN (r_nsubj) resulted_11/VBD (l_prep) in_12/IN (l_pobj) reduction_14/NN (l_prep) of_15/IN (l_pobj) APAP_16/NNP (l_appos) nephrotoxicity_21/NN
C026729_D007674 NONE PAP_9/NNP (r_compound) administration_10/NN (r_conj) APAP_7/NNP (r_pobj) to_6/IN (r_prep) prior_5/RB (r_advmod) Pretreatment_0/NN (r_nsubj) resulted_11/VBD (l_prep) in_12/IN (l_pobj) reduction_14/NN (l_prep) of_15/IN (l_pobj) APAP_16/NNP (l_appos) nephrotoxicity_21/NN (l_conj) nephrotoxicity_25/NN
C026729_D007674 NONE PAP_24/NNP (r_compound) nephrotoxicity_25/NN (r_conj) nephrotoxicity_21/NN
C026729_D007674 NONE PAP_24/NNP (r_compound) nephrotoxicity_25/NN
D000082_D007674 NONE acetaminophen_7/NN (r_advmod) induced_9/VBN (r_amod) nephrotoxicity_10/NN
D000082_D007674 NONE acetaminophen_7/NN (r_advmod) induced_9/VBN (r_amod) nephrotoxicity_10/NN (r_pobj) in_6/IN (r_prep) role_1/NN (l_appos) effect_12/NN (l_prep) of_13/IN (l_pobj) phosphate_18/NN (l_conj) nephrotoxicity_25/NN
D000082_D007674 NONE acetaminophen_20/NN (r_pobj) on_19/IN (r_prep) phosphate_18/NN (r_pobj) of_13/IN (r_prep) effect_12/NN (r_appos) role_1/NN (l_prep) in_6/IN (l_pobj) nephrotoxicity_10/NN
D000082_D007674 NONE acetaminophen_20/NN (r_pobj) on_19/IN (r_prep) phosphate_18/NN (l_conj) nephrotoxicity_25/NN
D000082_D007674 NONE APAP_16/NNP (r_npadvmod) induced_18/VBN (r_amod) nephrotoxicity_19/NN
D000082_D007674 NONE APAP_19/NNP (l_conj) nephrotoxicity_22/NN
D000082_D007674 NONE APAP_7/NNP (r_pobj) to_6/IN (r_prep) prior_5/RB (r_advmod) Pretreatment_0/NN (r_nsubj) resulted_11/VBD (l_prep) in_12/IN (l_pobj) reduction_14/NN (l_prep) of_15/IN (l_pobj) APAP_16/NNP (l_appos) nephrotoxicity_21/NN
D000082_D007674 NONE APAP_7/NNP (r_pobj) to_6/IN (r_prep) prior_5/RB (r_advmod) Pretreatment_0/NN (r_nsubj) resulted_11/VBD (l_prep) in_12/IN (l_pobj) reduction_14/NN (l_prep) of_15/IN (l_pobj) APAP_16/NNP (l_appos) nephrotoxicity_21/NN (l_conj) nephrotoxicity_25/NN
D000082_D007674 NONE APAP_16/NNP (l_appos) nephrotoxicity_21/NN
D000082_D007674 NONE APAP_16/NNP (l_appos) nephrotoxicity_21/NN (l_conj) nephrotoxicity_25/NN
D000082_D007674 NONE APAP_8/NNP (r_npadvmod) induced_10/VBN (r_amod) nephrotoxicity_11/NN
D000082_D007674 NONE APAP_19/NNP (r_compound) deacetylation_20/NN (r_pobj) of_18/IN (r_prep) inhibition_17/NN (r_pobj) to_16/IN (r_prep) due_15/IN (r_acomp) be_14/VB (r_xcomp) appears_12/VBZ (l_nsubj) reduction_6/NN (l_prep) in_7/IN (l_pobj) nephrotoxicity_11/NN
C002887_D007674 NONE phosphate_18/NN (r_pobj) of_13/IN (r_prep) effect_12/NN (r_appos) role_1/NN (l_prep) in_6/IN (l_pobj) nephrotoxicity_10/NN
C002887_D007674 NONE phosphate_18/NN (l_conj) nephrotoxicity_25/NN
C002887_D007674 NONE phosphate_9/NN (l_prep) on_18/IN (l_pobj) APAP_19/NNP (l_conj) nephrotoxicity_22/NN
C002887_D007674 NONE BNPP_11/NNP (r_appos) phosphate_9/NN (l_prep) on_18/IN (l_pobj) APAP_19/NNP (l_conj) nephrotoxicity_22/NN
C002887_D007674 NONE BNPP_4/NNP (r_pobj) with_3/IN (r_prep) animals_2/NNS (r_pobj) of_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) resulted_11/VBD (l_prep) in_12/IN (l_pobj) reduction_14/NN (l_prep) of_15/IN (l_pobj) APAP_16/NNP (l_appos) nephrotoxicity_21/NN
C002887_D007674 NONE BNPP_4/NNP (r_pobj) with_3/IN (r_prep) animals_2/NNS (r_pobj) of_1/IN (r_prep) Pretreatment_0/NN (r_nsubj) resulted_11/VBD (l_prep) in_12/IN (l_pobj) reduction_14/NN (l_prep) of_15/IN (l_pobj) APAP_16/NNP (l_appos) nephrotoxicity_21/NN (l_conj) nephrotoxicity_25/NN
C002887_D007674 NONE BNPP_3/NNP (r_npadvmod) induced_5/VBN (r_amod) reduction_6/NN (l_prep) in_7/IN (l_pobj) nephrotoxicity_11/NN
D000082_D007683 CID Acetaminophen_0/NNP (r_nsubj) produces_4/VBZ (l_dobj) necrosis_7/NN
D000082_D007683 CID APAP_2/NNP (r_appos) Acetaminophen_0/NNP (r_nsubj) produces_4/VBZ (l_dobj) necrosis_7/NN
D000082_D007683 CID APAP_18/NNP (r_npadvmod) induced_20/VBN (r_amod) necrosis_23/NN
C026729_D007683 CID PAP_4/NN (r_compound) formation_5/NN (r_nsubj) accounts_10/NNS (l_prep) for_17/IN (l_pobj) necrosis_23/NN
24881749
D013747_D009459 CID tetrabenazine_8/NNP (r_pobj) with_7/IN (r_prep) therapy_6/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (r_acl) syndrome_2/NN
D013747_D009459 CID tetrabenazine_35/NNP (r_conj) initiation_22/NN (r_pobj) after_20/IN (r_prep) occurred_17/VBD (r_relcl) woman_11/NN (l_prep) with_12/IN (l_pobj) syndrome_15/NN
D013747_D009459 CID tetrabenazine_18/NNP (r_pobj) with_17/IN (r_prep) therapy_16/NN (r_pobj) due_13/IN (r_prep) occurrence_8/NN (l_prep) of_9/IN (l_pobj) syndrome_12/NN
D013747_D006816 NONE tetrabenazine_8/NNP (r_pobj) with_7/IN (r_prep) therapy_6/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_prep) in_11/IN (l_pobj) patient_14/NN (l_prep) with_15/IN (l_pobj) disease_18/NN
D013747_D006816 NONE tetrabenazine_35/NNP (r_conj) initiation_22/NN (l_prep) for_42/IN (l_pobj) disease_45/NN
D013747_D001943 NONE tetrabenazine_8/NNP (r_pobj) with_7/IN (r_prep) therapy_6/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_prep) in_11/IN (l_pobj) patient_14/NN (l_prep) with_15/IN (l_pobj) disease_18/NN (l_prep) at_19/IN (l_pobj) stage_22/NN (l_prep) of_23/IN (l_pobj) cancer_26/NN
D063325_D009459 CID tiapride_10/NNP (r_conj) tetrabenazine_8/NNP (r_pobj) with_7/IN (r_prep) therapy_6/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (r_acl) syndrome_2/NN
D063325_D009459 CID tiapride_27/NNP (r_pobj) with_26/IN (r_prep) therapy_25/NN (r_pobj) of_23/IN (r_prep) initiation_22/NN (r_pobj) after_20/IN (r_prep) occurred_17/VBD (r_relcl) woman_11/NN (l_prep) with_12/IN (l_pobj) syndrome_15/NN
D063325_D009459 CID tiapride_20/NNP (r_conj) tetrabenazine_18/NNP (r_pobj) with_17/IN (r_prep) therapy_16/NN (r_pobj) due_13/IN (r_prep) occurrence_8/NN (l_prep) of_9/IN (l_pobj) syndrome_12/NN
D063325_D006816 NONE tiapride_10/NNP (r_conj) tetrabenazine_8/NNP (r_pobj) with_7/IN (r_prep) therapy_6/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_prep) in_11/IN (l_pobj) patient_14/NN (l_prep) with_15/IN (l_pobj) disease_18/NN
D063325_D006816 NONE tiapride_27/NNP (r_pobj) with_26/IN (r_prep) therapy_25/NN (r_pobj) of_23/IN (r_prep) initiation_22/NN (l_prep) for_42/IN (l_pobj) disease_45/NN
D063325_D001943 NONE tiapride_10/NNP (r_conj) tetrabenazine_8/NNP (r_pobj) with_7/IN (r_prep) therapy_6/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_prep) in_11/IN (l_pobj) patient_14/NN (l_prep) with_15/IN (l_pobj) disease_18/NN (l_prep) at_19/IN (l_pobj) stage_22/NN (l_prep) of_23/IN (l_pobj) cancer_26/NN
3297909
D013827_D001649 NONE thiabendazole_5/NNP (r_compound) administration_6/NN (r_pobj) after_4/IN (r_prep) injury_3/NN
D013827_D007565 NONE thiabendazole_12/NNP (r_pobj) to_11/IN (r_prep) exposure_10/NN (r_pobj) after_9/IN (r_prep) developed_5/VBD (l_dobj) jaundice_6/NN
24126708
D007980_D010300 NONE levodopa_9/JJ (r_nmod) effects_11/NNS (l_prep) in_12/IN (l_pobj) patients_16/NNS (l_compound) disease_15/NN
D007980_D010300 NONE Levodopa_0/NNP (r_nsubj) is_1/VBZ (l_attr) therapy_6/NN (l_prep) for_7/IN (l_pobj) disease_10/NN
D007980_D004409 CID Levodopa_0/NNP (r_nsubj) is_1/VBZ (l_conj) lead_17/VB (l_prep) to_18/IN (l_pobj) outcomes_21/NNS (l_prep) as_24/IN (l_pobj) fluctuations_26/NNS (l_conj) dyskinesia_28/NN
D007980_D006212 CID Levodopa_0/NNP (r_nsubj) is_1/VBZ (l_conj) lead_17/VB (l_prep) to_18/IN (l_pobj) outcomes_21/NNS (l_prep) as_24/IN (l_pobj) fluctuations_26/NNS (l_conj) dyskinesia_28/NN (l_conj) hallucinations_31/NNS
6631522
C013102_D066126 NONE HA_16/NNP (r_pobj) with_14/IN (r_prep) alteration_9/NN (r_pobj) to_7/IN (r_prep) leading_6/VBG (r_acl) changes_5/NNS (r_nsubj) are_17/VBP (l_attr) factor_21/NN (l_prep) in_22/IN (l_pobj) cardiotoxicity_24/NN
D004317_D066126 CID doxorubicin_23/NN (r_compound) cardiotoxicity_24/NN
24842192
D008687_D018487 NONE metformin_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_nsubj) suppresses_4/VBZ (l_conj) attenuates_12/VBZ (l_dobj) dysfunction_15/NN
D008687_D018487 NONE metformin_18/NN (r_pobj) of_17/IN (r_prep) kg_16/NNS (r_pobj) with_11/IN (r_prep) treated_10/VBN (r_acl) groups_9/NNS (r_pobj) in_7/IN (r_prep) was_4/VBD (l_nsubj) dysfunction_3/NN
D008687_D009203 NONE metformin_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_nsubj) suppresses_4/VBZ (l_conj) attenuates_12/VBZ (l_dobj) dysfunction_15/NN (l_prep) following_16/VBG (l_pobj) infarction_18/NN
D008687_D009203 NONE metformin_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_nsubj) has_4/VBZ (l_dobj) effect_7/NN (l_prep) in_8/IN (l_pobj) infarction_10/NN
D008687_D009203 NONE metformin_13/NN (r_pobj) with_12/IN (r_prep) treatment_11/NN (r_pobj) of_7/IN (r_prep) effect_6/NN (l_appos) activities_26/NNS (l_acl) following_27/VBG (l_pobj) infarction_29/NN
D008687_D009203 NONE metformin_5/NN (r_pobj) with_4/IN (r_prep) treatment_3/NN (r_nsubj) reduces_6/VBZ (l_dobj) dysfunction_12/NN (l_nmod) infarction_10/NN
D000667_D009203 NONE AMP_20/NN (r_npadvmod) activated_22/VBN (r_amod) kinase_24/NN (r_pobj) of_19/IN (r_prep) activation_18/NN (r_pobj) due_16/JJ (r_prep) has_4/VBZ (l_dobj) effect_7/NN (l_prep) in_8/IN (l_pobj) infarction_10/NN
D008687_D006331 NONE metformin_13/NN (r_pobj) with_12/IN (r_prep) treatment_11/NN (l_prep) on_14/IN (l_pobj) dysfunction_16/NN
D007545_D009203 CID Isoproterenol_0/NNP (r_nsubjpass) injected_7/VBN (l_advcl) induce_16/VB (l_dobj) infarction_19/NN
D007545_D009369 NONE isoproterenol_3/NN (r_npadvmod) induced_5/VBN (r_amod) elevation_6/NN (l_conj) protein_16/NN (l_appos) factor_24/NN (l_compound) necrosis_23/NN (l_compound) tumor_22/NN
D007545_D009336 NONE isoproterenol_3/NN (r_npadvmod) induced_5/VBN (r_amod) elevation_6/NN (l_conj) protein_16/NN (l_appos) factor_24/NN (l_compound) necrosis_23/NN
11988250
D007052_D006976 CID ibuprofen_3/NN (r_compound) prophylaxis_4/NN (r_pobj) after_2/IN (r_prep) hypertension_1/NN
D007052_D000860 CID ibuprofen_8/NNP (r_compound) administration_9/NNP (r_pobj) after_7/IN (r_prep) report_1/VBP (l_dobj) cases_3/NNS (l_prep) of_4/IN (l_pobj) hypoxaemia_6/NN
D007052_D000860 CID ibuprofen_23/NN (r_pobj) with_22/IN (r_prep) trial_14/NN (r_pobj) during_10/IN (r_prep) administration_9/NNP (r_pobj) after_7/IN (r_prep) report_1/VBP (l_dobj) cases_3/NNS (l_prep) of_4/IN (l_pobj) hypoxaemia_6/NN
D007052_D000860 CID ibuprofen_21/NNP (r_pobj) of_20/IN (r_prep) administration_19/NN (r_pobj) after_17/IN (r_prep) occurs_16/VBZ (l_nsubj) hypoxaemia_15/NN
D007052_D004374 NONE ibuprofen_8/NNP (r_compound) administration_9/NNP (l_prep) during_10/IN (l_pobj) trial_14/NN (l_prep) of_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) arteriosus_21/NN
D007052_D004374 NONE ibuprofen_23/NN (r_pobj) with_22/IN (r_prep) trial_14/NN (l_prep) of_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) arteriosus_21/NN
D009569_D000860 NONE oxide_6/NN (r_compound) therapy_7/NN (r_pobj) on_3/IN (r_prep) resolved_1/VBD (l_nsubj) Hypoxaemia_0/NNP
24088636
C098010_D009901 CID Linezolid_0/NNP (r_npadvmod) induced_2/VBN (r_amod) neuropathy_4/NN
C098010_D014786 NONE linezolid_11/NNP (r_compound) therapy_12/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) vision_8/NN
C098010_D014786 NONE linezolid_20/NNP (r_pobj) including_19/VBG (r_prep) drugs_18/NNS (r_pobj) with_10/IN (r_prep) treatment_9/NN (r_pobj) on_8/IN (r_prep) was_7/VBD (r_relcl) patient_5/NN (r_nsubj) presented_34/VBN (l_prep) with_37/IN (l_pobj) loss_40/NN (l_prep) of_41/IN (l_pobj) vision_42/NN
C098010_D054908 NONE linezolid_20/NNP (l_conj) ethambutol_22/NNP (l_prep) for_23/IN (l_pobj) tuberculosis_28/NN
C098010_D054908 NONE linezolid_20/NNP (l_conj) ethambutol_22/NNP (l_prep) for_23/IN (l_pobj) tuberculosis_28/NN (l_appos) TB_32/NNP
D004977_D054908 NONE ethambutol_22/NNP (l_prep) for_23/IN (l_pobj) tuberculosis_28/NN
D004977_D054908 NONE ethambutol_22/NNP (l_prep) for_23/IN (l_pobj) tuberculosis_28/NN (l_appos) TB_32/NNP
D004977_D014786 NONE ethambutol_22/NNP (r_conj) linezolid_20/NNP (r_pobj) including_19/VBG (r_prep) drugs_18/NNS (r_pobj) with_10/IN (r_prep) treatment_9/NN (r_pobj) on_8/IN (r_prep) was_7/VBD (r_relcl) patient_5/NN (r_nsubj) presented_34/VBN (l_prep) with_37/IN (l_pobj) loss_40/NN (l_prep) of_41/IN (l_pobj) vision_42/NN
D004977_D009901 NONE Ethambutol_0/NNP (r_npadvmod) induced_2/VBN (r_amod) neuropathy_5/NN
D004977_D009901 NONE ethambutol_10/NNP (r_nsubjpass) withdrawn_12/VBN (r_conj) suspected_7/VBN (l_nsubjpass) neuropathy_5/NN
D004977_D015354 NONE ethambutol_7/NNP (r_pobj) of_6/IN (r_prep) withdrawal_5/NN (r_pobj) despite_4/IN (r_prep) occurred_3/VBD (l_nsubj) Deterioration_0/NN (l_prep) of_1/IN (l_pobj) vision_2/NN
18987260
D004317_D007674 NONE adriamycin_3/NN (r_compound) nephropathy_4/NN
D004317_D007674 NONE adriamycin_37/FW (r_pobj) with_36/IN (r_prep) slowing_24/VBG (l_dobj) progression_28/NN (l_compound) disease_27/NN
D004317_D007674 NONE adriamycin_37/FW (l_appos) nephropathy_41/NN
D004317_D007674 NONE ADR_39/NNP (r_nmod) nephropathy_41/NN (r_appos) adriamycin_37/FW (r_pobj) with_36/IN (r_prep) slowing_24/VBG (l_dobj) progression_28/NN (l_compound) disease_27/NN
D004317_D007674 NONE ADR_39/NNP (r_nmod) nephropathy_41/NN
D004317_D007674 NONE ADR_9/NNP (r_compound) nephropathy_10/NN
D004317_D007674 NONE ADR_15/NNP (r_compound) nephropathy_16/NN
D004317_D006973 NONE adriamycin_3/NN (r_compound) nephropathy_4/NN (r_pobj) of_2/IN (r_prep) progression_1/NN (l_prep) in_5/IN (l_pobj) rats_8/NNS (l_amod) hypertensive_7/JJ
D004317_D006973 NONE adriamycin_37/FW (r_pobj) with_36/IN (r_prep) slowing_24/VBG (l_prep) in_29/IN (l_pobj) rats_32/NNS (l_amod) hypertensive_31/JJ
D004317_D006973 NONE ADR_39/NNP (r_nmod) nephropathy_41/NN (r_appos) adriamycin_37/FW (r_pobj) with_36/IN (r_prep) slowing_24/VBG (l_prep) in_29/IN (l_pobj) rats_32/NNS (l_amod) hypertensive_31/JJ
D019808_D007674 NONE losartan_11/NN (r_pobj) by_10/IN (r_agent) treated_9/VBN (r_acl) rats_8/NNS (r_pobj) in_5/IN (r_prep) progression_1/NN (l_prep) of_2/IN (l_pobj) nephropathy_4/NN
D019808_D007674 NONE losartan_18/NNP (l_conj) potential_22/NN (l_prep) in_23/IN (l_pcomp) slowing_24/VBG (l_dobj) progression_28/NN (l_compound) disease_27/NN
D019808_D007674 NONE losartan_18/NNP (l_conj) potential_22/NN (l_prep) in_23/IN (l_pcomp) slowing_24/VBG (l_prep) with_36/IN (l_pobj) adriamycin_37/FW (l_appos) nephropathy_41/NN
D019808_D007674 NONE Losartan_0/NNP (r_nsubj) reduced_1/VBD (l_conj) clearance_6/NN (l_prep) in_7/IN (l_pobj) nephropathy_10/NN
D019808_D007674 NONE losartan_4/NN (r_nsubj) prevent_6/VB (l_dobj) atrophy_8/NN (l_conj) infiltration_11/NN (l_prep) in_14/IN (l_pobj) nephropathy_16/NN
D019808_D006973 NONE losartan_11/NN (r_pobj) by_10/IN (r_agent) treated_9/VBN (r_acl) rats_8/NNS (l_amod) hypertensive_7/JJ
D019808_D006973 NONE losartan_18/NNP (l_conj) potential_22/NN (l_prep) in_23/IN (l_pcomp) slowing_24/VBG (l_prep) in_29/IN (l_pobj) rats_32/NNS (l_amod) hypertensive_31/JJ
D000804_D007674 NONE II_13/NNP (r_compound) type-1_14/NN (r_compound) blocker_16/NN (l_conj) losartan_18/NNP (l_conj) potential_22/NN (l_prep) in_23/IN (l_pcomp) slowing_24/VBG (l_dobj) progression_28/NN (l_compound) disease_27/NN
D000804_D007674 NONE II_13/NNP (r_compound) type-1_14/NN (r_compound) blocker_16/NN (l_conj) losartan_18/NNP (l_conj) potential_22/NN (l_prep) in_23/IN (l_pcomp) slowing_24/VBG (l_prep) with_36/IN (l_pobj) adriamycin_37/FW (l_appos) nephropathy_41/NN
D000804_D006973 NONE II_13/NNP (r_compound) type-1_14/NN (r_compound) blocker_16/NN (l_conj) losartan_18/NNP (l_conj) potential_22/NN (l_prep) in_23/IN (l_pcomp) slowing_24/VBG (l_prep) in_29/IN (l_pobj) rats_32/NNS (l_amod) hypertensive_31/JJ
D019808_D005921 NONE losartan_3/NNP (r_compound) treatment_4/NN (r_nsubj) improved_10/VBD (l_conj) ameliorated_15/VBD (l_dobj) glomerulosclerosis_16/NN
D019808_D005921 NONE losartan_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_nsubj) showed_4/VBD (l_dobj) reduction_6/NN (l_prep) of_7/IN (l_pobj) glomerulosclerosis_8/NNP
D019808_D011507 NONE losartan_3/NNP (r_compound) treatment_4/NN (r_nsubj) improved_10/VBD (l_conj) ameliorated_15/VBD (l_dobj) glomerulosclerosis_16/NN (l_acl) resulting_17/VBG (l_prep) in_18/IN (l_pobj) proteinuria_20/NN
D019808_D011507 NONE losartan_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_nsubj) showed_4/VBD (l_advcl) preventing_21/VBG (l_dobj) proteinuria_23/NN
D019808_D001284 NONE losartan_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_nsubj) showed_4/VBD (l_dobj) reduction_6/NN (l_prep) of_7/IN (l_pobj) glomerulosclerosis_8/NNP (l_acl) associated_9/VBN (l_prep) with_10/IN (l_pobj) progression_12/NN (l_prep) of_13/IN (l_pobj) atrophy_15/NN
D019808_D001284 NONE losartan_4/NN (r_nsubj) prevent_6/VB (l_dobj) atrophy_8/NN
D019808_D005355 NONE losartan_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_nsubj) showed_4/VBD (l_dobj) reduction_6/NN (l_prep) of_7/IN (l_pobj) glomerulosclerosis_8/NNP (l_acl) associated_9/VBN (l_prep) with_10/IN (l_pobj) progression_12/NN (l_prep) of_13/IN (l_pobj) atrophy_15/NN (l_conj) fibrosis_18/NN
D019808_D005355 NONE losartan_4/NN (r_nsubj) prevent_6/VB (l_dobj) atrophy_8/NN (l_conj) infiltration_11/NN (l_conj) fibrosis_13/NN
D019808_D007676 NONE losartan_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_nsubj) showed_4/VBD (l_advcl) preventing_21/VBG (l_dobj) proteinuria_23/NN (l_conj) failure_27/NN
D019808_D007676 NONE Losartan_0/NNP (r_nsubj) reduces_1/VBZ (l_prep) to_13/IN (l_pobj) disease_18/NN
D019808_D014511 NONE Losartan_0/NNP (r_nsubj) reduced_1/VBD (l_dobj) uraemia_2/NN
D014508_D014511 NONE urea_5/NN (r_compound) clearance_6/NN (r_conj) reduced_1/VBD (l_dobj) uraemia_2/NN
D014508_D007674 NONE urea_5/NN (r_compound) clearance_6/NN (l_prep) in_7/IN (l_pobj) nephropathy_10/NN
D004317_D014511 CID ADR_9/NNP (r_compound) nephropathy_10/NN (r_pobj) in_7/IN (r_prep) clearance_6/NN (r_conj) reduced_1/VBD (l_dobj) uraemia_2/NN
D004317_D001284 NONE ADR_15/NNP (r_compound) nephropathy_16/NN (r_pobj) in_14/IN (r_prep) infiltration_11/NN (r_conj) atrophy_8/NN
D004317_D005355 NONE ADR_15/NNP (r_compound) nephropathy_16/NN (r_pobj) in_14/IN (r_prep) infiltration_11/NN (l_conj) fibrosis_13/NN
D019808_D005923 NONE Losartan_0/NNP (r_nsubj) reduces_1/VBZ (l_dobj) rate_3/NN (l_prep) of_4/IN (l_pobj) progression_5/NN (l_prep) of_6/IN (l_pobj) glomerulosclerosis_12/NN
D004317_D005923 CID ADR_7/NN (r_npadvmod) induced_9/VBN (r_amod) glomerulosclerosis_12/NN
D004317_D007676 NONE ADR_7/NN (r_npadvmod) induced_9/VBN (r_amod) glomerulosclerosis_12/NN (r_pobj) of_6/IN (r_prep) progression_5/NN (r_pobj) of_4/IN (r_prep) rate_3/NN (r_dobj) reduces_1/VBZ (l_prep) to_13/IN (l_pobj) disease_18/NN
15094729
D020888_D014786 CID Vigabatrin_4/NNP (r_nmod) defects_8/NNS
D020888_D014786 CID Vigabatrin_17/NNP (r_npadvmod) associated_19/VBN (r_amod) changes_20/NNS (r_dobj) have_16/VB (r_xcomp) known_14/VBN (r_acl) patients_13/NNS (r_pobj) of_12/IN (r_prep) group_11/NN (r_pobj) in_9/IN (r_prep) defects_8/NNS
D020888_D014786 CID Vigabatrin_9/NNP (r_compound) therapy_10/NN (r_pobj) to_8/IN (r_prep) due_7/IN (r_acomp) be_6/VB (r_xcomp) presumed_4/VBN (l_nsubj) defects_3/NNS
D020888_D014786 CID Vigabatrin_11/NNP (r_npadvmod) associated_13/VBN (r_amod) defects_16/NNS
D020888_D012640 NONE Vigabatrin_17/NNP (r_npadvmod) associated_19/VBN (r_amod) changes_20/NNS (l_relcl) elected_22/VBD (l_prep) because_27/IN (l_pobj) control_31/NN (l_compound) seizure_30/NN
D020888_D064420 NONE Vigabatrin_11/NNP (r_npadvmod) associated_13/VBN (r_amod) defects_16/NNS (r_pobj) of_10/IN (r_prep) pathogenesis_9/NN (r_nsubj) be_18/VB (l_attr) reaction_23/NN (l_conj) toxicity_29/NN
24595967
D018817_D008569 CID ecstasy_5/NN (r_compound) users_6/NNS (r_pobj) in_4/IN (r_prep) consolidation_3/NN (l_compound) memory_2/NN
D018817_D008569 CID Ecstasy_0/NN (r_compound) users_1/NNS (r_nsubj) demonstrated_2/VBD (l_dobj) consolidation_6/NN (l_compound) memory_5/NN
D018817_D008569 CID ecstasy_3/NN (r_npadvmod) associated_5/VBN (r_amod) dysfunction_6/NN (r_nsubj) underlie_13/VB (l_dobj) impairments_17/NNS
D018817_D008569 CID ecstasy_20/NN (r_compound) users_21/NNS (r_pobj) in_18/IN (r_prep) impairments_17/NNS
D018817_D012893 CID ecstasy_4/NN (r_compound) users_5/NNS (r_nsubj) marked_7/VBN (l_dobj) impairments_15/NNS
8755612
D004967_D009369 NONE estrogen_10/NN (r_npadvmod) induced_12/VBN (r_amod) tumor_13/NN (r_pobj) in_8/IN (r_prep) separation_1/NN (l_prep) of_2/IN (l_pobj) growth_4/NN (l_compound) tumor_3/NN
D004967_D009369 NONE estrogen_10/NN (r_npadvmod) induced_12/VBN (r_amod) tumor_13/NN
D004967_D006470 NONE estrogen_10/NN (r_npadvmod) induced_12/VBN (r_amod) tumor_13/NN (r_pobj) in_8/IN (r_prep) separation_1/NN (l_prep) of_2/IN (l_pobj) growth_4/NN (l_conj) phenotypes_7/NNS (l_amod) hemorrhagic_6/JJ
D004967_D006470 NONE estrogen_3/NN (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) induces_12/VBZ (l_dobj) growth_13/NN (l_prep) of_14/IN (l_pobj) tumors_19/NNS (l_amod) hemorrhagic_17/JJ
D004967_D010911 NONE estrogen_3/NN (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) induces_12/VBZ (l_dobj) growth_13/NN (l_prep) of_14/IN (l_pobj) tumors_19/NNS
D004054_D006470 NONE diethylstilbestrol_3/NN (r_nmod) treatment_7/NN (r_pobj) of_2/IN (r_prep) weeks_1/NNS (r_nsubj) caused_8/VBD (l_ccomp) grow_14/VB (l_prep) versus_28/IN (l_conj) become_39/VB (l_acomp) hemorrhagic_41/JJ
D004054_D006470 NONE DES_5/NNP (r_nmod) treatment_7/NN (r_pobj) of_2/IN (r_prep) weeks_1/NNS (r_nsubj) caused_8/VBD (l_ccomp) grow_14/VB (l_prep) versus_28/IN (l_conj) become_39/VB (l_acomp) hemorrhagic_41/JJ
D004054_D006470 NONE DES_3/NNP (r_npadvmod) induced_5/VBN (r_amod) growth_7/NN (r_nsubj) exhibited_8/VBD (r_advcl) exhibited_17/VBD (l_nsubj) phenotype_16/NN (l_amod) hemorrhagic_15/JJ
15991002
D009538_D001008 NONE nicotine_7/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (l_prep) on_8/IN (l_pobj) anxiety_9/NN
D009538_D001008 NONE Nicotine_0/NN (r_nsubj) blocked_6/VBD (l_dobj) anxiety_14/NN
D009538_D001008 NONE nicotine_9/NN (r_pobj) of_8/IN (r_prep) effect_7/NN (l_prep) on_10/IN (l_pobj) anxiety_14/NN
D002110_D001008 CID caffeine_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) anxiety_9/NN
D002110_D001008 CID caffeine-_8/NN (r_amod) anxiety_14/NN
D002110_D001008 CID caffeine_11/NN (r_npadvmod) induced_13/VBN (r_amod) anxiety_14/NN
D002110_D001008 CID caffeine_18/NN (r_pobj) to_17/IN (r_prep) specific_16/JJ (r_acomp) is_15/VBZ (l_nsubj) effect_7/NN (l_prep) on_10/IN (l_pobj) anxiety_14/NN
D010433_D001008 CID pentylenetetrazole_18/NNP (r_appos) drug_16/NN (r_conj) caffeine_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) anxiety_9/NN
D010433_D001008 CID pentylenetetrazole_11/NNP (r_npadvmod) induced_13/VBN (r_amod) anxiety_14/NN
2884595
D006632_D014917 NONE histamine_2/JJ (r_compound) receptors_4/NNS (r_pobj) of_1/IN (r_prep) Blockade_0/NN (r_nsubj) reduce_6/VB (l_dobj) mortality_7/NN (l_prep) in_8/IN (l_pobj) encephalopathy_13/NN (l_nmod) pertussis_9/NN
D006632_D001927 NONE histamine_2/JJ (r_compound) receptors_4/NNS (r_pobj) of_1/IN (r_prep) Blockade_0/NN (r_nsubj) reduce_6/VB (l_dobj) mortality_7/NN (l_prep) in_8/IN (l_pobj) encephalopathy_13/NN
20408947
D000082_D017114 CID acetaminophen_8/NN (r_advmod) induced_10/VBN (r_amod) failure_13/NN
D000082_D017114 CID Acetaminophen_0/NN (r_advmod) induced_2/VBN (r_amod) hepatotoxicity_3/NN (r_nsubj) is_4/VBZ (l_attr) cause_8/NN (l_prep) of_9/IN (l_pobj) failure_12/NN
D000082_D017114 CID Acetaminophen_0/NN (r_advmod) induced_2/VBN (r_amod) hepatotoxicity_3/NN (r_nsubj) is_4/VBZ (l_attr) cause_8/NN (l_prep) of_9/IN (l_pobj) failure_12/NN (l_appos) ALF_14/NNP
D000082_D017114 CID acetaminophen_34/NN (r_npadvmod) induced_36/VBN (r_amod) ALF_37/NNP
D000082_D017114 CID acetaminophen_34/NN (r_npadvmod) induced_36/VBN (r_amod) ALF_37/NNP (l_prep) with_41/IN (l_pcomp) undergoing_48/VBG (l_prep) for_51/IN (l_pobj) ALF_57/NNP
D000082_D017114 CID acetaminophen_54/JJ (r_advmod) induced_56/VBN (r_amod) ALF_57/NNP (r_pobj) for_51/IN (r_prep) undergoing_48/VBG (r_pcomp) with_41/IN (r_prep) ALF_37/NNP
D000082_D017114 CID acetaminophen_54/JJ (r_advmod) induced_56/VBN (r_amod) ALF_57/NNP
D000082_D017114 CID Acetaminophen_0/NN (r_advmod) induced_2/VBN (r_amod) patients_4/NNS (l_compound) ALF_3/NNP
D000082_D017114 CID acetaminophen_0/NN (r_advmod) induced_2/VBN (r_amod) patients_4/NNS (l_compound) ALF_3/NNP
D000082_D017114 CID acetaminophen_0/NN (r_advmod) induced_2/VBN (r_amod) patients_4/NNS (r_nsubj) had_5/VBD (l_prep) before_10/IN (l_pobj) ALF=0/35_18/NNP
D000082_D017114 CID acetaminophen_15/JJ (r_advmod) induced_17/VBN (r_amod) ALF=0/35_18/NNP (r_pobj) before_10/IN (r_prep) had_5/VBD (l_nsubj) patients_4/NNS (l_compound) ALF_3/NNP
D000082_D017114 CID acetaminophen_15/JJ (r_advmod) induced_17/VBN (r_amod) ALF=0/35_18/NNP
D000082_D017114 CID acetaminophen_31/NN (r_advmod) induced_33/VBN (r_amod) ALF_34/NNP
D000082_D017114 CID acetaminophen_31/NN (r_advmod) induced_33/VBN (r_amod) ALF_34/NNP (r_appos) groups_29/NNS (l_appos) ALF_50/NNP
D000082_D017114 CID acetaminophen_47/RB (r_npadvmod) induced_49/VBN (r_amod) ALF_50/NNP (r_appos) groups_29/NNS (l_appos) ALF_34/NNP
D000082_D017114 CID acetaminophen_47/RB (r_npadvmod) induced_49/VBN (r_amod) ALF_50/NNP
D000082_D017114 CID acetaminophen_1/NN (r_advmod) induced_3/VBN (r_amod) patients_5/NNS (l_compound) ALF_4/NNP
D000082_D017114 CID acetaminophen_14/NN (r_advmod) induced_16/VBN (r_amod) ALF_17/NNP
D000082_D017114 CID acetaminophen_14/NN (r_advmod) induced_16/VBN (r_amod) ALF_17/NNP (r_pobj) for_13/IN (r_prep) transplanted_11/VBN (r_acl) patients_10/NNS (r_pobj) for_9/IN (r_prep) outcomes_8/NNS (r_nsubj) were_18/VBD (l_acomp) comparable_19/JJ (l_prep) to_20/IN (l_pobj) those_21/DT (l_acl) transplanted_22/VBN (l_prep) for_23/IN (l_pobj) ALF_29/NNP
D000082_D017114 CID acetaminophen_26/JJ (r_advmod) induced_28/VBN (r_amod) ALF_29/NNP (r_pobj) for_23/IN (r_prep) transplanted_22/VBN (r_acl) those_21/DT (r_pobj) to_20/IN (r_prep) comparable_19/JJ (r_acomp) were_18/VBD (l_nsubj) outcomes_8/NNS (l_prep) for_9/IN (l_pobj) patients_10/NNS (l_acl) transplanted_11/VBN (l_prep) for_13/IN (l_pobj) ALF_17/NNP
D000082_D017114 CID acetaminophen_26/JJ (r_advmod) induced_28/VBN (r_amod) ALF_29/NNP
D000082_D056486 CID Acetaminophen_0/NN (r_advmod) induced_2/VBN (r_amod) hepatotoxicity_3/NN
D000082_D008107 NONE acetaminophen_34/NN (r_npadvmod) induced_36/VBN (r_amod) ALF_37/NNP (l_prep) with_41/IN (l_pcomp) undergoing_48/VBG (l_prep) for_51/IN (l_pobj) ALF_57/NNP (l_conj) LT_63/NN (l_prep) for_64/IN (l_pobj) disease_67/NN
D000082_D008107 NONE acetaminophen_34/NN (r_npadvmod) induced_36/VBN (r_amod) ALF_37/NNP (l_prep) with_41/IN (l_pcomp) undergoing_48/VBG (l_prep) for_51/IN (l_pobj) ALF_57/NNP (l_conj) LT_63/NN (l_appos) CLD_69/NNP
D000082_D008107 NONE acetaminophen_54/JJ (r_advmod) induced_56/VBN (r_amod) ALF_57/NNP (l_conj) LT_63/NN (l_prep) for_64/IN (l_pobj) disease_67/NN
D000082_D008107 NONE acetaminophen_54/JJ (r_advmod) induced_56/VBN (r_amod) ALF_57/NNP (l_conj) LT_63/NN (l_appos) CLD_69/NNP
D000082_D008107 NONE acetaminophen_0/NN (r_advmod) induced_2/VBN (r_amod) patients_4/NNS (r_nsubj) had_5/VBD (l_prep) before_10/IN (l_pobj) ALF=0/35_18/NNP (l_appos) CLD=2/34_20/NNP
D000082_D008107 NONE acetaminophen_15/JJ (r_advmod) induced_17/VBN (r_amod) ALF=0/35_18/NNP (l_appos) CLD=2/34_20/NNP
D000082_D008107 NONE acetaminophen_31/NN (r_advmod) induced_33/VBN (r_amod) ALF_34/NNP (r_appos) groups_29/NNS (r_pobj) between_27/IN (r_prep) failure_24/NN (r_attr) were_11/VBD (l_conj) CLD_57/NNP
D000082_D008107 NONE acetaminophen_47/RB (r_npadvmod) induced_49/VBN (r_amod) ALF_50/NNP (r_appos) groups_29/NNS (r_pobj) between_27/IN (r_prep) failure_24/NN (r_attr) were_11/VBD (l_conj) CLD_57/NNP
D000082_D008107 NONE acetaminophen_14/NN (r_advmod) induced_16/VBN (r_amod) ALF_17/NNP (r_pobj) for_13/IN (r_prep) transplanted_11/VBN (r_acl) patients_10/NNS (r_pobj) for_9/IN (r_prep) outcomes_8/NNS (r_nsubj) were_18/VBD (l_acomp) comparable_19/JJ (l_prep) to_20/IN (l_pobj) those_21/DT (l_acl) transplanted_22/VBN (l_conj) electively_31/RB (l_prep) for_32/IN (l_pobj) CLD_33/NNP
D000082_D008107 NONE acetaminophen_26/JJ (r_advmod) induced_28/VBN (r_amod) ALF_29/NNP (r_pobj) for_23/IN (r_prep) transplanted_22/VBN (l_conj) electively_31/RB (l_prep) for_32/IN (l_pobj) CLD_33/NNP
12523489
D003042_D006948 NONE Cocaine_0/NN (r_npadvmod) induced_2/VBN (r_amod) hyperactivity_3/NN
D003042_D006948 NONE Cocaine_0/NN (r_npadvmod) induced_2/VBN (r_amod) hyperactivity_3/NN (r_nsubjpass) influenced_6/VBN (l_prep) than_11/IN (l_pobj) hyperactivity_15/NN
D003042_D006948 NONE cocaine_9/NN (r_nmod) hyperactivity_15/NN
D003042_D006948 NONE cocaine_23/NN (r_npadvmod) induced_25/VBN (r_amod) hyperactivity_26/NN (r_pobj) in_22/IN (r_prep) active_21/JJ (r_acomp) were_20/VBD (r_relcl) those_18/DT (r_pobj) than_17/IN (r_prep) doses_16/NNS (r_pobj) at_13/IN (r_conj) decreased_6/VBD (l_dobj) hyperactivity_10/NN
D003042_D006948 NONE cocaine_23/NN (r_npadvmod) induced_25/VBN (r_amod) hyperactivity_26/NN
D003042_D006948 NONE cocaine-_15/JJ (r_dep) and_16/CC (r_cc) amphetamine_17/NN (r_npadvmod) induced_19/VBN (r_amod) activity_21/NN (r_dobj) reduce_14/VB (r_conj) adenosine_6/NN (l_conj) indicate_23/VBP (l_ccomp) influenced_31/VBN (l_nsubjpass) hyperactivity_28/NN
D003042_D006948 NONE cocaine-_15/JJ (r_dep) and_16/CC (r_cc) amphetamine_17/NN (r_npadvmod) induced_19/VBN (r_amod) activity_21/NN (r_dobj) reduce_14/VB (r_conj) adenosine_6/NN (l_conj) indicate_23/VBP (l_ccomp) influenced_31/VBN (l_agent) by_32/IN (l_pobj) agonists_35/NNS (l_prep) than_41/IN (l_pobj) hyperactivity_45/NN
D003042_D006948 NONE cocaine_25/NN (r_npadvmod) induced_27/VBN (r_amod) hyperactivity_28/NN
D003042_D006948 NONE cocaine_25/NN (r_npadvmod) induced_27/VBN (r_amod) hyperactivity_28/NN (r_nsubjpass) influenced_31/VBN (l_agent) by_32/IN (l_pobj) agonists_35/NNS (l_prep) than_41/IN (l_pobj) hyperactivity_45/NN
D000241_D006948 NONE adenosine_8/NN (r_amod) agonists_10/NNS (r_pobj) by_7/IN (r_agent) influenced_6/VBN (l_nsubjpass) hyperactivity_3/NN
D000241_D006948 NONE adenosine_8/NN (r_amod) agonists_10/NNS (r_pobj) by_7/IN (r_agent) influenced_6/VBN (l_prep) than_11/IN (l_pobj) hyperactivity_15/NN
D000241_D006948 NONE adenosine_3/NN (r_compound) agonists_5/NNS (l_conj) antagonists_7/NNS (l_prep) on_8/IN (l_pobj) hyperactivity_15/NN
D000241_D006948 NONE adenosine_3/NN (r_compound) agonists_5/NNS (r_nsubj) decreased_6/VBD (l_dobj) hyperactivity_10/NN
D000241_D006948 NONE adenosine_3/NN (r_compound) agonists_5/NNS (r_nsubj) decreased_6/VBD (l_conj) at_13/IN (l_pobj) doses_16/NNS (l_prep) than_17/IN (l_pobj) those_18/DT (l_relcl) were_20/VBD (l_acomp) active_21/JJ (l_prep) in_22/IN (l_pobj) hyperactivity_26/NN
D000241_D006948 NONE adenosine_6/NN (l_conj) indicate_23/VBP (l_ccomp) influenced_31/VBN (l_nsubjpass) hyperactivity_28/NN
D000241_D006948 NONE adenosine_6/NN (l_conj) indicate_23/VBP (l_ccomp) influenced_31/VBN (l_agent) by_32/IN (l_pobj) agonists_35/NNS (l_prep) than_41/IN (l_pobj) hyperactivity_45/NN
D000241_D006948 NONE adenosine_33/NN (r_compound) agonists_35/NNS (r_pobj) by_32/IN (r_agent) influenced_31/VBN (l_nsubjpass) hyperactivity_28/NN
D000241_D006948 NONE adenosine_33/NN (r_compound) agonists_35/NNS (l_prep) than_41/IN (l_pobj) hyperactivity_45/NN
D000661_D006948 NONE amphetamine_12/NN (r_npadvmod) induced_14/VBN (r_amod) hyperactivity_15/NN (r_pobj) than_11/IN (r_prep) influenced_6/VBN (l_nsubjpass) hyperactivity_3/NN
D000661_D006948 NONE amphetamine_12/NN (r_npadvmod) induced_14/VBN (r_amod) hyperactivity_15/NN
D000661_D006948 NONE amphetamine_12/NN (r_npadvmod) induced_14/VBN (r_amod) hyperactivity_15/NN
D000661_D006948 NONE amphetamine_7/NN (r_npadvmod) induced_9/VBN (r_amod) hyperactivity_10/NN
D000661_D006948 NONE amphetamine_7/NN (r_npadvmod) induced_9/VBN (r_amod) hyperactivity_10/NN (r_dobj) decreased_6/VBD (l_conj) at_13/IN (l_pobj) doses_16/NNS (l_prep) than_17/IN (l_pobj) those_18/DT (l_relcl) were_20/VBD (l_acomp) active_21/JJ (l_prep) in_22/IN (l_pobj) hyperactivity_26/NN
D000661_D006948 NONE amphetamine_17/NN (r_npadvmod) induced_19/VBN (r_amod) activity_21/NN (r_dobj) reduce_14/VB (r_conj) adenosine_6/NN (l_conj) indicate_23/VBP (l_ccomp) influenced_31/VBN (l_nsubjpass) hyperactivity_28/NN
D000661_D006948 NONE amphetamine_17/NN (r_npadvmod) induced_19/VBN (r_amod) activity_21/NN (r_dobj) reduce_14/VB (r_conj) adenosine_6/NN (l_conj) indicate_23/VBP (l_ccomp) influenced_31/VBN (l_agent) by_32/IN (l_pobj) agonists_35/NNS (l_prep) than_41/IN (l_pobj) hyperactivity_45/NN
D000661_D006948 NONE amphetamine_42/NN (r_npadvmod) induced_44/VBN (r_amod) hyperactivity_45/NN (r_pobj) than_41/IN (r_prep) agonists_35/NNS (r_pobj) by_32/IN (r_agent) influenced_31/VBN (l_nsubjpass) hyperactivity_28/NN
D000661_D006948 NONE amphetamine_42/NN (r_npadvmod) induced_44/VBN (r_amod) hyperactivity_45/NN
D000241_D004409 NONE adenosine_1/NN (r_compound) agonists_3/NNS (r_nsubj) decreased_5/VBD (l_dobj) activity_8/NN
1117341
D015119_D006943 CID amino_3/NN (r_compound) compounds_4/NNS (r_pobj) of_2/IN (r_prep) effect_1/NN (l_amod) Hyperglycemic_0/JJ
D015119_D006943 CID amino_17/NN (r_compound) derivatives_18/NNS (r_pobj) of_15/IN (r_prep) amounts_5/NNS (r_pobj) of_3/IN (r_prep) feeding_2/NN (r_nsubj) resulted_21/VBD (l_prep) in_22/IN (l_pobj) hyperglycemia_23/NN
C037652_D006943 NONE caproate_8/NNP (r_pobj) to_7/IN (r_prep) related_6/JJ (r_acl) compounds_4/NNS (r_pobj) of_2/IN (r_prep) effect_1/NN (l_amod) Hyperglycemic_0/JJ
C037652_D006943 NONE caproate_20/NNP (r_pobj) of_19/IN (r_prep) derivatives_18/NNS (r_pobj) of_15/IN (r_prep) amounts_5/NNS (r_pobj) of_3/IN (r_prep) feeding_2/NN (r_nsubj) resulted_21/VBD (l_prep) in_22/IN (l_pobj) hyperglycemia_23/NN
D015119_D006030 NONE amino_17/NN (r_compound) derivatives_18/NNS (r_pobj) of_15/IN (r_prep) amounts_5/NNS (r_pobj) of_3/IN (r_prep) feeding_2/NN (r_nsubj) resulted_21/VBD (l_conj) glucosuria_34/NNP
C037652_D006030 NONE caproate_20/NNP (r_pobj) of_19/IN (r_prep) derivatives_18/NNS (r_pobj) of_15/IN (r_prep) amounts_5/NNS (r_pobj) of_3/IN (r_prep) feeding_2/NN (r_nsubj) resulted_21/VBD (l_conj) glucosuria_34/NNP
D005947_D006943 NONE glucose_27/NN (r_compound) tolerance_28/NN (r_compound) curve_29/NN (r_appos) hyperglycemia_23/NN
D005947_D006030 NONE glucose_27/NN (r_compound) tolerance_28/NN (r_compound) curve_29/NN (r_appos) hyperglycemia_23/NN (r_pobj) in_22/IN (r_prep) resulted_21/VBD (l_conj) glucosuria_34/NNP
1280707
D002045_D001145 CID bupivacaine_3/NN (r_dobj) determining_1/VBG (l_npadvmod) AD50_4/NNP (l_parataxis) concentration_7/NN (l_relcl) caused_11/VBD (l_ccomp) beating_16/VBG (l_xcomp) become_22/VB (l_acomp) arrhythmic_23/JJ
D002045_D001145 CID bupivacaine_9/NNP (r_pobj) of_8/IN (r_prep) concentration_7/NN (l_relcl) caused_11/VBD (l_ccomp) beating_16/VBG (l_xcomp) become_22/VB (l_acomp) arrhythmic_23/JJ
D002045_D001145 CID bupivacaine_2/NNP (r_compound) arrhythmia_3/NN
D011374_D001145 CID progesterone_32/NN (r_compound) HCl_33/NNP (r_compound) exposure_34/NN (r_pobj) of_30/IN (r_prep) effect_29/NN (r_dobj) determined_27/VBD (l_prep) After_0/IN (l_pcomp) determining_1/VBG (l_npadvmod) AD50_4/NNP (l_parataxis) concentration_7/NN (l_relcl) caused_11/VBD (l_ccomp) beating_16/VBG (l_xcomp) become_22/VB (l_acomp) arrhythmic_23/JJ
D006851_D001145 NONE HCl_33/NNP (r_compound) exposure_34/NN (r_pobj) of_30/IN (r_prep) effect_29/NN (r_dobj) determined_27/VBD (l_prep) After_0/IN (l_pcomp) determining_1/VBG (l_npadvmod) AD50_4/NNP (l_parataxis) concentration_7/NN (l_relcl) caused_11/VBD (l_ccomp) beating_16/VBG (l_xcomp) become_22/VB (l_acomp) arrhythmic_23/JJ
20589632
D014295_D000743 CID Trimethoprim_0/NNP (r_npadvmod) induced_2/VBN (r_amod) anemia_5/NN
6453500
D004221_D056486 CID disulfiram_4/NNP (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) hepatitis_1/NN
D004221_D056486 CID disulfiram_15/NNP (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) woman_12/NN (r_pobj) in_7/IN (r_prep) observed_6/VBN (l_nsubjpass) damage_4/NN
15953230
C012052_D062787 NONE amisulpride_3/JJ (r_compound) overdose_4/NN
C012052_D008133 CID amisulpride_3/JJ (r_compound) overdose_4/NN (r_pobj) of_2/IN (r_prep) cases_1/NNS (l_appos) cause_7/NN (l_prep) for_8/IN (l_pobj) syndrome_11/NN
C012052_D011041 NONE amisulpride_14/NNP (r_pobj) of_13/IN (r_prep) g_12/NN (r_conj) poisoning_6/NN
D002125_D008133 NONE gluconate_11/NN (r_pobj) of_8/IN (r_prep) administration_7/NN (r_pobj) to_6/IN (r_prep) respond_5/VB (r_xcomp) appeared_3/VBD (l_nsubj) prolongation_2/NN
17828434
C002647_D012640 NONE MIP_4/NNP (r_compound) synthase_5/NN (r_compound) inhibition_6/NN (r_nsubj) replicate_9/VB (l_conj) augment_11/VB (l_dobj) effects_13/NNS (l_prep) in_16/IN (l_pobj) model_24/NN (l_compound) seizures_23/NNS
D008094_D012640 NONE lithium_15/NN (r_pobj) of_14/IN (r_prep) effects_13/NNS (l_prep) in_16/IN (l_pobj) model_24/NN (l_compound) seizures_23/NNS
D007294_D012640 NONE inositol_18/NN (r_nmod) model_24/NN (l_compound) seizures_23/NNS
D010862_D012640 CID pilocarpine_20/NN (r_npadvmod) induced_22/VBN (r_amod) seizures_23/NNS
6728873
D002110_D012640 CID caffeine_28/NN (r_compound) doses_29/NNS (r_pobj) at_26/IN (r_prep) scored_25/VBN (l_nsubjpass) characteristics_2/NNS (l_acl) righting_7/VBG (l_dobj) ability_8/NN (l_conj) induction_12/NN (l_compound) seizure_11/NN
-1_D064420 NONE alkylxanthines_8/NNS (r_pobj) of_7/IN (r_prep) testing_6/NN (l_compound) toxicity_5/NN
11135381
D008729_D014550 NONE methoxamine_2/NNP (r_pobj) of_1/IN (r_prep) Effect_0/NN (l_prep) on_3/IN (l_pobj) pressure_6/NN (l_prep) in_7/IN (l_pobj) women_8/NNS (l_prep) with_9/IN (l_pobj) incontinence_12/NN
D008729_D014550 NONE methoxamine_4/NN (r_pobj) of_2/IN (r_prep) doses_1/NNS (r_nsubjpass) administered_11/VBN (l_prep) with_17/IN (l_pobj) incontinence_20/NN
D008729_D006973 CID Methoxamine_0/NNP (r_nsubj) evoked_1/VBD (l_conj) caused_13/VBD (l_dobj) rise_16/NN (l_prep) in_17/IN (l_pobj) pressure_20/NN
946593
D008727_D010264 CID methotrexate_3/NN (r_pobj) following_1/VBG (r_acl) Paraplegia_0/NN
D008727_D010264 CID methotrexate_10/NNP (r_pobj) of_9/IN (r_prep) instillation_8/NN (r_pobj) following_5/VBG (r_prep) developed_3/VBD (l_dobj) paraplegia_4/NN
D008727_D002493 NONE methothexate_21/NN (r_compound) concentration_22/NN (r_conj) leakage_16/NN (r_conj) leukemia_11/NN
D008727_D002493 NONE methotrexate_33/NNP (r_compound) doses_34/NNS (r_pobj) to_30/TO (r_conj) concentration_22/NN (r_conj) leakage_16/NN (r_conj) leukemia_11/NN
D008727_D002493 NONE methotrexate_55/NNP (r_compound) preparations_56/NNS (r_pobj) in_52/IN (r_prep) presence_48/NN (r_conj) concentration_22/NN (r_conj) leakage_16/NN (r_conj) leukemia_11/NN
D008727_D002493 NONE methotrexate_64/NNP (r_compound) diluents_65/NNS (r_pobj) of_63/IN (r_prep) use_62/NN (r_conj) presence_48/NN (r_conj) concentration_22/NN (r_conj) leakage_16/NN (r_conj) leukemia_11/NN
D008727_D002493 NONE methotrexate_12/NN (r_pobj) of_11/IN (r_prep) doses_10/NNS (r_dobj) employing_8/VBG (l_prep) in_13/IN (l_pobj) presence_15/NN (l_prep) of_16/IN (l_pobj) leukemia_20/NN
D008727_D020258 NONE methothexate_21/NN (r_compound) concentration_22/NN (l_conj) presence_48/NN (l_prep) of_49/IN (l_pobj) preservatives_51/NNS (l_amod) neurotoxic_50/JJ
D008727_D020258 NONE methotrexate_33/NNP (r_compound) doses_34/NNS (r_pobj) to_30/TO (r_conj) concentration_22/NN (l_conj) presence_48/NN (l_prep) of_49/IN (l_pobj) preservatives_51/NNS (l_amod) neurotoxic_50/JJ
D008727_D020258 NONE methotrexate_55/NNP (r_compound) preparations_56/NNS (r_pobj) in_52/IN (r_prep) presence_48/NN (l_prep) of_49/IN (l_pobj) preservatives_51/NNS (l_amod) neurotoxic_50/JJ
D008727_D020258 NONE methotrexate_64/NNP (r_compound) diluents_65/NNS (r_pobj) of_63/IN (r_prep) use_62/NN (r_conj) presence_48/NN (l_prep) of_49/IN (l_pobj) preservatives_51/NNS (l_amod) neurotoxic_50/JJ
D008727_D020258 NONE methotrexate_12/NN (r_pobj) of_11/IN (r_prep) doses_10/NNS (r_dobj) employing_8/VBG (r_pcomp) by_7/IN (r_prep) reduced_6/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_2/IN (l_pobj) neurotoxicity_3/NN
D008727_D020258 NONE methotrexate_5/NNP (r_compound) levels_6/NNS (r_pobj) of_2/IN (r_prep) monitoring_1/NN (r_nsubj) be_8/VB (l_attr) predictive_9/JJ (l_prep) of_10/IN (l_pobj) development_12/NN (l_prep) of_13/IN (l_pobj) neurotoxicity_15/NN
D008727_C536409 NONE methotrexate_3/NNP (r_compound) contaminants_4/NNS (l_conj) deficiency_8/NN
D008727_C536409 NONE methotrexate_18/NN (r_compound) toxicity_19/NN (r_pobj) of_16/IN (r_prep) pathogenesis_15/NN (r_pobj) in_13/IN (r_prep) irradiation_12/NN (r_conj) deficiency_8/NN
D008727_D064420 NONE methotrexate_3/NNP (r_compound) contaminants_4/NNS (l_conj) deficiency_8/NN (l_conj) irradiation_12/NN (l_prep) in_13/IN (l_pobj) pathogenesis_15/NN (l_prep) of_16/IN (l_pobj) toxicity_19/NN
D008727_D064420 NONE methotrexate_18/NN (r_compound) toxicity_19/NN
19553912
D020123_D000740 CID sirolimus_6/NN (r_pobj) of_5/IN (r_prep) role_4/NN (r_appos) anemia_1/NN
D020123_D000740 CID Sirolimus_0/NNP (r_nsubjpass) implicated_11/VBN (l_prep) as_12/IN (l_pcomp) playing_13/VBG (l_prep) in_17/IN (l_pobj) anemia_19/NN
D020123_D000740 CID rapamycin_6/NN (r_amod) inhibitor_7/NN (r_pobj) of_5/IN (r_prep) target_4/NN (r_appos) Sirolimus_0/NNP (r_nsubjpass) implicated_11/VBN (l_prep) as_12/IN (l_pcomp) playing_13/VBG (l_prep) in_17/IN (l_pobj) anemia_19/NN
D020123_D000740 CID sirolimus_6/NNP (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) anemia_3/NN
15321332
D004329_D001008 CID droperidol_9/NNP (r_pobj) due_5/IN (r_prep) case_1/NN (l_prep) of_2/IN (l_pobj) anxiety_4/NN
D004329_D001008 CID droperidol_3/NN (r_npadvmod) induced_5/VBN (r_amod) disturbance_7/NN
12644816
D013792_D011471 NONE thalidomide_11/NN (r_pobj) of_7/IN (r_prep) study_6/NN (l_prep) in_12/IN (l_pobj) cancer_17/NN
D000728_D011471 NONE androgen_13/NN (r_npadvmod) independent_15/JJ (r_amod) cancer_17/NN
D000728_D011471 NONE androgen_13/JJ (r_npadvmod) independent_15/JJ (r_amod) cancer_17/NN
D013792_D019337 NONE thalidomide_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubjpass) assessed_7/VBN (l_prep) in_8/IN (l_pobj) trials_10/NNS (l_prep) in_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) malignancies_18/NNS
D013792_D010523 CID thalidomide_9/NN (r_pobj) on_8/IN (r_prep) months_7/NNS (r_dobj) completed_5/VBD (r_relcl) men_3/NNS (r_pobj) In_0/IN (r_prep) found_17/VBN (l_nsubjpass) evidence_12/NN (l_prep) of_13/IN (l_pobj) neuropathy_15/NN
D013792_D010523 CID thalidomide_4/NN (r_nsubj) be_6/VB (l_conj) maintained_25/VBN (l_prep) for_26/IN (l_pobj) development_27/NN (l_prep) of_28/IN (l_pobj) neuropathy_30/NN
24091473
D004837_D066126 NONE epinephrine_4/NN (r_conj) lipid_2/NN (r_pobj) with_1/IN (r_prep) Resuscitation_0/NN (l_prep) in_8/IN (l_pobj) toxicity_13/NN
C476513_D066126 NONE levobupivacaine_9/NN (r_npadvmod) induced_11/VBN (r_amod) toxicity_13/NN
D004837_D064420 NONE epinephrine_8/NN (r_conj) emulsion_6/NN (r_pobj) of_4/IN (r_prep) regimens_3/NNS (r_nsubj) are_12/VBP (l_acomp) determined_15/VBN (l_prep) in_18/IN (l_pobj) cases_19/NNS (l_prep) of_20/IN (l_pobj) toxicity_24/NN
C476513_D002318 CID levobupivacaine_3/NN (r_dobj) received_2/VBD (l_advcl) occurred_7/VBD (l_nsubj) collapse_6/NN
24309294
D012844_D000647 NONE CCK-8_5/NNP (r_nsubj) alleviated_7/VBD (l_dobj) amnesia_11/NN
D009020_D000647 CID morphine_8/NN (r_npadvmod) induced_10/VBN (r_amod) amnesia_11/NN
D009020_D000647 CID morphine_25/NN (r_npadvmod) treated_27/VBN (r_amod) animals_28/NNS (r_pobj) in_24/IN (r_prep) decreases_16/VBZ (r_dobj) reversed_13/JJ (r_conj) alleviated_7/VBD (l_dobj) amnesia_11/NN
D012844_D008569 NONE CCK-8_5/NN (r_nsubj) attenuates_6/VBZ (l_conj) suggest_18/VBP (l_dobj) function_21/NN (l_prep) on_24/IN (l_pobj) impairment_29/NN
D012844_D008569 NONE CCK-8_23/NN (r_pobj) of_22/IN (r_prep) function_21/NN (l_prep) on_24/IN (l_pobj) impairment_29/NN
D009020_D008569 NONE morphine_10/NN (r_pobj) of_9/IN (r_prep) effect_8/NN (r_dobj) attenuates_6/VBZ (l_conj) suggest_18/VBP (l_dobj) function_21/NN (l_prep) on_24/IN (l_pobj) impairment_29/NN
D009020_D008569 NONE morphine_25/NN (r_npadvmod) induced_27/VBN (r_amod) impairment_29/NN
11026989
D014331_D015878 CID tropicamide_6/NN (r_pobj) with_5/IN (r_prep) dilation_4/NN
D014331_D015878 CID tropicamide_28/NNP (r_dep) performed_15/VBN (l_advmod) before_21/RB (l_conj) after_23/IN (l_pobj) dilation_25/NN
9272404
D002245_D010146 NONE CO2_10/NNP (r_pobj) of_9/IN (r_prep) pulses_8/NNS (r_pobj) of_6/IN (r_prep) means_5/NNS (r_pobj) by_4/IN (r_agent) applied_3/VBN (l_nsubjpass) pain_1/NN
D002245_D010146 NONE CO2_17/NNP (r_compound) stimuli_18/NNS (r_pobj) to_15/IN (r_prep) response_14/NN (r_pobj) in_13/IN (r_prep) obtained_12/VBN (l_nsubjpass) CSSEPs_1/NNS (l_prep) as_6/IN (l_pobj) correlates_8/NNS (l_prep) of_9/IN (l_pobj) pain_10/NN
D007052_D010146 CID ibuprofen_6/NNP (r_pobj) of_5/IN (r_prep) administration_4/NN (r_nsubjpass) followed_8/VBN (l_agent) by_9/IN (l_pobj) decrease_11/NN (l_prep) in_12/IN (l_pobj) pain_14/NN
D007052_D010146 CID ibuprofen_13/NN (r_pobj) of_12/IN (r_prep) effect_11/NN (r_dobj) indicating_8/VBG (r_acl) increase_1/NN (l_prep) in_2/IN (l_pobj) correlates_3/NNS (l_prep) of_4/IN (l_pobj) pain_6/NN
D007052_D010146 CID ibuprofen_13/NN (r_pobj) of_12/IN (r_prep) effect_11/NN (l_prep) on_14/IN (l_pobj) interaction_16/NN (l_prep) between_17/IN (l_pobj) stimuli_20/NNS (l_compound) pain_19/NN
17069550
D005702_D001321 NONE galantamine_8/NNP (r_pobj) of_7/IN (r_prep) trial_6/NN (l_prep) in_9/IN (l_pobj) disorder_11/NN
D005702_D001321 NONE galantamine_11/NNP (r_pobj) of_10/IN (r_prep) use_9/NN (l_prep) in_21/IN (l_pobj) treatment_23/NN (l_prep) of_24/IN (l_pcomp) interfering_25/VBG (l_prep) with_29/IN (l_pobj) autism_30/NN
D005702_D001321 NONE galantamine_26/NNP (r_pobj) of_25/IN (r_prep) trial_24/NN (r_pobj) in_17/IN (r_prep) participated_16/VBD (l_nsubj) children_4/NNS (l_prep) with_5/IN (l_pobj) autism_6/NN
D005702_D001321 NONE galantamine_5/NNP (r_nsubj) was_6/VBD (l_conj) appeared_11/VBD (l_xcomp) be_13/VB (l_acomp) beneficial_14/JJ (l_prep) for_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pcomp) interfering_19/VBG (l_dobj) behaviors_20/NNS (l_prep) in_21/IN (l_pobj) children_22/NNS (l_prep) with_23/IN (l_pobj) autism_24/NN
D005702_D006261 CID galantamine_2/NNP (r_nsubj) was_3/VBD (l_prep) with_8/IN (l_pobj) effects_12/NNS (l_advmod) apart_13/RB (l_prep) from_14/IN (l_pobj) headaches_15/NNS
D005702_D001523 NONE galantamine_5/NNP (r_nsubj) was_6/VBD (l_conj) appeared_11/VBD (l_xcomp) be_13/VB (l_acomp) beneficial_14/JJ (l_prep) for_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) aggression_27/NN
D005702_D002653 NONE galantamine_5/NNP (r_nsubj) was_6/VBD (l_conj) appeared_11/VBD (l_xcomp) be_13/VB (l_acomp) beneficial_14/JJ (l_prep) for_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) aggression_27/NN (l_conj) dyscontrol_30/NN
D005702_D019958 NONE galantamine_5/NNP (r_nsubj) was_6/VBD (l_conj) appeared_11/VBD (l_xcomp) be_13/VB (l_acomp) beneficial_14/JJ (l_prep) for_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) aggression_27/NN (l_conj) dyscontrol_30/NN (l_conj) inattention_33/NN
23864035
C400082_D009101 NONE Bortezomib_0/NNP (l_prep) as_3/IN (l_pobj) therapy_5/NN (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_prep) with_8/IN (l_pobj) myeloma_13/NN
C400082_D009101 NONE Bortezomib_0/NNP (r_nsubj) is_6/VBZ (l_attr) therapy_9/NN (l_prep) for_10/IN (l_pobj) myeloma_20/NN
C400082_D009101 NONE Bortezomib_0/NNP (r_nsubj) is_6/VBZ (l_attr) therapy_9/NN (l_prep) for_10/IN (l_pobj) myeloma_20/NN (l_appos) MM_22/NNP
C400082_D009101 NONE bort)-dexamethasone_2/NNP (r_nmod) dex_4/NNP (r_appos) Bortezomib_0/NNP (r_nsubj) is_6/VBZ (l_attr) therapy_9/NN (l_prep) for_10/IN (l_pobj) myeloma_20/NN
C400082_D009101 NONE bort)-dexamethasone_2/NNP (r_nmod) dex_4/NNP (r_appos) Bortezomib_0/NNP (r_nsubj) is_6/VBZ (l_attr) therapy_9/NN (l_prep) for_10/IN (l_pobj) myeloma_20/NN (l_appos) MM_22/NNP
C400082_D009101 NONE bort_7/NNP (r_pobj) of_6/IN (r_prep) combination_5/NN (r_dobj) investigated_3/VBD (l_conj) 11_23/CD (l_conj) dex_29/NN (l_parataxis) mg_32/NNS (l_prep) on_33/IN (l_pobj) day_35/NN (l_conj) day_39/NN (l_prep) as_43/IN (l_pobj) treatment_45/NN (l_prep) in_46/IN (l_pobj) patients_48/NNS (l_prep) with_49/IN (l_pobj) MM_53/NNP
C400082_D009101 NONE bort_41/NNP (r_pobj) after_40/IN (r_prep) day_39/NN (l_prep) as_43/IN (l_pobj) treatment_45/NN (l_prep) in_46/IN (l_pobj) patients_48/NNS (l_prep) with_49/IN (l_pobj) MM_53/NNP
C400082_D009101 NONE Bort_0/NNP (r_compound) dex_2/NNP (r_nsubj) was_3/VBD (l_attr) treatment_7/NN (l_prep) for_8/IN (l_pobj) patients_10/NNS (l_compound) MM_9/NNP
D003907_D009101 NONE dexamethasone_2/NN (r_conj) Bortezomib_0/NNP (l_prep) as_3/IN (l_pobj) therapy_5/NN (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_prep) with_8/IN (l_pobj) myeloma_13/NN
D003907_D009101 NONE bort)-dexamethasone_2/NNP (r_nmod) dex_4/NNP (r_appos) Bortezomib_0/NNP (r_nsubj) is_6/VBZ (l_attr) therapy_9/NN (l_prep) for_10/IN (l_pobj) myeloma_20/NN
D003907_D009101 NONE bort)-dexamethasone_2/NNP (r_nmod) dex_4/NNP (r_appos) Bortezomib_0/NNP (r_nsubj) is_6/VBZ (l_attr) therapy_9/NN (l_prep) for_10/IN (l_pobj) myeloma_20/NN (l_appos) MM_22/NNP
D003907_D009101 NONE dex_4/NNP (r_appos) Bortezomib_0/NNP (r_nsubj) is_6/VBZ (l_attr) therapy_9/NN (l_prep) for_10/IN (l_pobj) myeloma_20/NN
D003907_D009101 NONE dex_4/NNP (r_appos) Bortezomib_0/NNP (r_nsubj) is_6/VBZ (l_attr) therapy_9/NN (l_prep) for_10/IN (l_pobj) myeloma_20/NN (l_appos) MM_22/NNP
D003907_D009101 NONE dex_29/NN (l_parataxis) mg_32/NNS (l_prep) on_33/IN (l_pobj) day_35/NN (l_conj) day_39/NN (l_prep) as_43/IN (l_pobj) treatment_45/NN (l_prep) in_46/IN (l_pobj) patients_48/NNS (l_prep) with_49/IN (l_pobj) MM_53/NNP
D003907_D009101 NONE dex_2/NNP (r_nsubj) was_3/VBD (l_attr) treatment_7/NN (l_prep) for_8/IN (l_pobj) patients_10/NNS (l_compound) MM_9/NNP
8312343
D004317_D002311 NONE doxorubicin_49/NN (r_compound) cardiomyopathy_50/NN (r_conj) disease_42/NN (r_conj) cardiomyopathy_34/NN (r_appos) cardiomyopathy_5/NN
D004317_D006331 NONE doxorubicin_49/NN (r_compound) cardiomyopathy_50/NN (r_conj) disease_42/NN (r_conj) cardiomyopathy_34/NN (r_appos) cardiomyopathy_5/NN (l_appos) disease_13/NN
D004317_D002312 NONE doxorubicin_49/NN (r_compound) cardiomyopathy_50/NN (r_conj) disease_42/NN (r_conj) cardiomyopathy_34/NN
D004317_D006349 NONE doxorubicin_49/NN (r_compound) cardiomyopathy_50/NN (r_conj) disease_42/NN
D004317_D009202 CID doxorubicin_49/NN (r_compound) cardiomyopathy_50/NN
D015774_D003586 NONE ganciclovir_6/NNS (r_pobj) with_5/IN (r_prep) treated_3/VBN (l_nsubjpass) infections_1/NNS
20009434
D008727_D058186 CID methotrexate_7/NNP (r_compound) therapy_8/NN (r_pobj) after_3/IN (r_prep) failure_2/NN
D008727_D058186 CID MTX_11/NNP (r_compound) therapy_12/NN (r_pobj) after_8/IN (r_prep) case_3/NN (l_prep) of_4/IN (l_pobj) failure_7/NN
D008727_D058186 CID MTX_3/NNP (r_compound) therapy_4/NN (r_nsubj) caused_5/VBD (l_dobj) failure_8/NN
D008727_D002051 NONE methotrexate_3/NN (r_nsubj) is_9/VBZ (l_attr) treatment_12/NN (l_prep) for_13/IN (l_pobj) lymphoma_15/NN
D008727_D002051 NONE MTX_7/NNP (r_appos) methotrexate_3/NN (r_nsubj) is_9/VBZ (l_attr) treatment_12/NN (l_prep) for_13/IN (l_pobj) lymphoma_15/NN
D008727_D056486 NONE methotrexate_3/NN (r_nsubj) is_9/VBZ (l_conj) cause_19/VB (l_dobj) toxicity_23/NN
D008727_D056486 NONE MTX_7/NNP (r_appos) methotrexate_3/NN (r_nsubj) is_9/VBZ (l_conj) cause_19/VB (l_dobj) toxicity_23/NN
D008727_D007674 NONE methotrexate_3/NN (r_nsubj) is_9/VBZ (l_conj) cause_19/VB (l_dobj) toxicity_23/NN
D008727_D007674 NONE MTX_7/NNP (r_appos) methotrexate_3/NN (r_nsubj) is_9/VBZ (l_conj) cause_19/VB (l_dobj) toxicity_23/NN
D008727_D001656 NONE MTX_11/NNP (r_compound) therapy_12/NN (r_pobj) after_8/IN (r_prep) case_3/NN (r_dobj) report_1/VBP (r_ccomp) was_21/VBD (l_attr) boy_26/NN (l_relcl) received_29/VBN (l_prep) for_36/IN (l_pobj) atresia_39/NN
10975596
C118667_D009203 NONE dronedarone_5/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (l_prep) with_10/IN (l_pobj) infarction_14/NN
C118667_D009203 NONE dronedarone_6/NN (r_pobj) of_5/IN (r_prep) effects_4/NNS (r_nsubjpass) compared_17/VBN (l_prep) with_18/IN (l_pobj) those_19/DT (l_prep) at_28/IN (l_conj) during_31/IN (l_pobj) stimulation_33/NN (l_prep) in_34/IN (l_pobj) dogs_36/NNS (l_prep) with_37/IN (l_pobj) infarction_41/NN
D000638_D009203 NONE amiodarone_7/NN (r_conj) dronedarone_5/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (l_prep) with_10/IN (l_pobj) infarction_14/NN
D000638_D009203 NONE amiodarone_14/NN (r_pobj) to_13/IN (r_prep) related_12/VBN (r_amod) compound_10/NN (r_appos) dronedarone_6/NN (r_pobj) of_5/IN (r_prep) effects_4/NNS (r_nsubjpass) compared_17/VBN (l_prep) with_18/IN (l_pobj) those_19/DT (l_prep) at_28/IN (l_conj) during_31/IN (l_pobj) stimulation_33/NN (l_prep) in_34/IN (l_pobj) dogs_36/NNS (l_prep) with_37/IN (l_pobj) infarction_41/NN
D000638_D009203 NONE amiodarone_21/NN (r_pobj) of_20/IN (r_prep) those_19/DT (l_prep) at_28/IN (l_conj) during_31/IN (l_pobj) stimulation_33/NN (l_prep) in_34/IN (l_pobj) dogs_36/NNS (l_prep) with_37/IN (l_pobj) infarction_41/NN
C118667_D013610 NONE dronedarone_1/NN (r_nsubj) reduced_5/VBD (l_dobj) tachycardia_10/NN
C118667_D013610 NONE dronedarone_1/NN (r_nsubj) reduced_5/VBD (l_conj) decreased_18/VBD (l_dobj) tachycardia_23/NN
D000638_D013610 NONE amiodarone_3/NNP (r_conj) dronedarone_1/NN (r_nsubj) reduced_5/VBD (l_dobj) tachycardia_10/NN
D000638_D013610 NONE amiodarone_3/NNP (r_conj) dronedarone_1/NN (r_nsubj) reduced_5/VBD (l_conj) decreased_18/VBD (l_dobj) tachycardia_23/NN
D007545_D013610 CID isoproterenol_20/NN (r_npadvmod) induced_22/VBN (r_amod) tachycardia_23/NN (r_dobj) decreased_18/VBD (r_conj) reduced_5/VBD (l_dobj) tachycardia_10/NN
D007545_D013610 CID isoproterenol_20/NN (r_npadvmod) induced_22/VBN (r_amod) tachycardia_23/NN
C118667_D001145 NONE dronedarone_2/NN (r_nsubj) be_4/VB (l_acomp) suitable_6/JJ (l_prep) for_7/IN (l_pobj) treatment_9/NN (l_prep) of_12/IN (l_pobj) arrhythmias_15/NNS
16731636
D007545_D006332 CID isoproterenol_1/NN (r_npadvmod) induced_3/VBN (r_amod) hypertrophy_5/NN
D007545_D006332 CID Iso_4/NN (r_compound) treatment_5/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) hypertrophy_1/NN
9323412
D017294_D003866 NONE ondansetron_7/NNP (r_pobj) following_3/VBG (r_acl) depression_2/NN
D017294_D020250 NONE ondansetron_25/NNP (r_compound) prophylaxis_26/NN (r_nsubjpass) used_29/VBN (r_relcl) anaesthetic_23/NN (r_pobj) after_20/IN (r_prep) woman_4/NN (l_prep) with_5/IN (l_pobj) history_8/NN (l_prep) of_9/IN (l_pobj) nausea_11/NN (l_conj) vomiting_13/NN
D012701_D003865 NONE serotonin_20/NN (r_compound) antagonist_21/NN (r_pobj) of_18/IN (r_prep) use_17/NN (r_pobj) to_15/IN (r_prep) related_14/VBN (r_advcl) developed_2/VBN (l_dobj) disorder_8/NN
D015742_D009325 NONE propofol_3/NN (r_compound) infusion_4/NN (r_pobj) with_1/IN (r_prep) Anaesthesia_0/NN (r_nsubj) provided_10/VBD (l_dobj) course_16/NN (l_amod) free_14/JJ (l_npadvmod) nausea_12/NN
D015742_D003866 NONE propofol_3/NN (r_compound) infusion_4/NN (r_pobj) with_1/IN (r_prep) Anaesthesia_0/NN (r_nsubj) provided_10/VBD (l_prep) without_17/IN (l_pobj) exacerbation_18/NN (l_prep) of_19/IN (l_pobj) disorder_22/NN
D012701_D009325 NONE serotonin_8/NN (r_compound) antagonists_9/NNS (r_pobj) of_7/IN (r_prep) infusion_4/NN (r_pobj) with_1/IN (r_prep) Anaesthesia_0/NN (r_nsubj) provided_10/VBD (l_dobj) course_16/NN (l_amod) free_14/JJ (l_npadvmod) nausea_12/NN
D012701_D003866 NONE serotonin_8/NN (r_compound) antagonists_9/NNS (r_pobj) of_7/IN (r_prep) infusion_4/NN (r_pobj) with_1/IN (r_prep) Anaesthesia_0/NN (r_nsubj) provided_10/VBD (l_prep) without_17/IN (l_pobj) exacerbation_18/NN (l_prep) of_19/IN (l_pobj) disorder_22/NN
2765447
D019793_D012640 NONE fluorescein_3/NNP (r_compound) angiography_4/NN (r_pobj) following_1/VBG (r_prep) Convulsion_0/NN
D019793_D004830 CID fluorescein_6/JJ (r_amod) injection_7/NN (r_dobj) followed_4/VBD (l_nsubj) seizures_3/NNS
12948256
D004977_D009901 CID Ethambutol_0/NNP (r_nmod) neuropathy_3/NN
D004977_D009901 CID ethambutol_7/NNP (r_nmod) neuropathy_10/NN
D004977_D009901 CID ethambutol_10/NNP (r_pobj) with_9/IN (r_prep) treated_8/VBN (r_pcomp) after_6/IN (r_prep) developed_3/VBD (l_dobj) neuropathy_5/NN
D004977_D009901 CID ethambutol_18/NNP (r_compound) therapy_19/NN (r_dobj) starting_17/VBG (r_pcomp) after_16/IN (r_prep) had_2/VBD (l_dobj) neuropathy_4/NN
D004977_D009901 CID ethambutol_11/NNP (r_compound) therapy_12/NN (r_pobj) with_10/IN (r_prep) patients_9/NNS (r_pobj) in_8/IN (r_prep) considered_7/VBN (l_nsubjpass) recognition_1/NN (l_prep) of_2/IN (l_pobj) neuropathy_4/NN
D004977_D014397 NONE ethambutol_10/NNP (r_pobj) with_9/IN (r_prep) treated_8/VBN (l_prep) for_11/IN (l_pobj) tuberculosis_12/NN (l_prep) of_13/IN (l_pobj) node_18/NN
D004977_D014388 NONE ethambutol_10/NNP (r_pobj) with_9/IN (r_prep) treated_8/VBN (l_prep) for_11/IN (l_pobj) tuberculosis_12/NN (l_prep) of_13/IN (l_pobj) node_18/NN
11745287
D016190_D002294 NONE carboplatin_4/NNP (r_pobj) of_3/IN (r_prep) study_2/NN (r_nsubj) doxorubicin_7/NNS (l_prep) in_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) carcinoma_14/NN (l_prep) of_15/IN (l_pobj) cervix_17/NN
D016190_D002294 NONE carboplatin_3/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) administered_32/VBN (l_prep) to_37/IN (l_pobj) patients_39/NNS (l_prep) with_40/IN (l_pobj) carcinoma_45/NN
D016190_D002583 NONE carboplatin_4/NNP (r_pobj) of_3/IN (r_prep) study_2/NN (r_nsubj) doxorubicin_7/NNS (l_prep) in_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) carcinoma_14/NN (l_prep) of_15/IN (l_pobj) cervix_17/NN
D016190_D002583 NONE carboplatin_6/NNP (r_pobj) of_5/IN (r_prep) combination_4/NN (r_pobj) of_2/IN (r_prep) activity_1/NN (r_nsubjpass) tested_11/VBN (l_prep) in_12/IN (l_pobj) study_16/NN (l_prep) of_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) carcinoma_22/NN
D016190_D002583 NONE carboplatin_3/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) administered_32/VBN (l_prep) to_37/IN (l_pobj) patients_39/NNS (l_prep) with_40/IN (l_pobj) carcinoma_45/NN
D016190_D002583 NONE carboplatin_3/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubj) has_7/VBZ (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) carcinoma_15/NN
D004317_D002294 NONE doxorubicin_7/NNS (l_prep) in_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) carcinoma_14/NN (l_prep) of_15/IN (l_pobj) cervix_17/NN
D004317_D002294 NONE doxorubicin_18/NNS (r_conj) carboplatin_3/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) administered_32/VBN (l_prep) to_37/IN (l_pobj) patients_39/NNS (l_prep) with_40/IN (l_pobj) carcinoma_45/NN
D004317_D002294 NONE Doxil_20/NNP (r_appos) doxorubicin_18/NNS (r_conj) carboplatin_3/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) administered_32/VBN (l_prep) to_37/IN (l_pobj) patients_39/NNS (l_prep) with_40/IN (l_pobj) carcinoma_45/NN
D004317_D002583 NONE doxorubicin_7/NNS (l_prep) in_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) carcinoma_14/NN (l_prep) of_15/IN (l_pobj) cervix_17/NN
D004317_D002583 NONE doxorubicin_9/NNS (r_conj) carboplatin_6/NNP (r_pobj) of_5/IN (r_prep) combination_4/NN (r_pobj) of_2/IN (r_prep) activity_1/NN (r_nsubjpass) tested_11/VBN (l_prep) in_12/IN (l_pobj) study_16/NN (l_prep) of_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) carcinoma_22/NN
D004317_D002583 NONE doxorubicin_18/NNS (r_conj) carboplatin_3/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) administered_32/VBN (l_prep) to_37/IN (l_pobj) patients_39/NNS (l_prep) with_40/IN (l_pobj) carcinoma_45/NN
D004317_D002583 NONE Doxil_20/NNP (r_appos) doxorubicin_18/NNS (r_conj) carboplatin_3/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) administered_32/VBN (l_prep) to_37/IN (l_pobj) patients_39/NNS (l_prep) with_40/IN (l_pobj) carcinoma_45/NN
D004317_D002583 NONE doxorubicin_6/NNS (r_conj) carboplatin_3/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubj) has_7/VBZ (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) carcinoma_15/NN
D016190_D064420 NONE carboplatin_3/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) administered_32/VBN (l_advcl) determine_47/VB (l_dobj) activity_49/NN (l_conj) profile_52/NN (l_compound) toxicity_51/NN
D004317_D064420 NONE doxorubicin_18/NNS (r_conj) carboplatin_3/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) administered_32/VBN (l_advcl) determine_47/VB (l_dobj) activity_49/NN (l_conj) profile_52/NN (l_compound) toxicity_51/NN
D004317_D064420 NONE Doxil_20/NNP (r_appos) doxorubicin_18/NNS (r_conj) carboplatin_3/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) administered_32/VBN (l_advcl) determine_47/VB (l_dobj) activity_49/NN (l_conj) profile_52/NN (l_compound) toxicity_51/NN
7147232
D000255_D007022 CID triphosphate_7/NN (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) hypotension_3/NN
D000255_D007022 CID triphosphate_1/NN (r_nsubjpass) administered_12/VBN (l_advcl) induce_16/VB (l_dobj) hypotension_19/NN
D000255_D007022 CID ATP_3/NNP (r_appos) triphosphate_1/NN (r_nsubjpass) administered_12/VBN (l_advcl) induce_16/VB (l_dobj) hypotension_19/NN
D000255_D007022 CID ATP_3/NNP (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Hypotension_0/NN
D000255_D007022 CID ATP_94/NNP (r_nsubjpass) stopped_96/VBN (r_advcl) returned_88/VBD (l_ccomp) left_31/VBD (l_ccomp) accompanied_5/VBN (l_nsubjpass) Hypotension_0/NN
D009599_D007022 CID nitroprusside_10/RB (r_appos) triphosphate_7/NN (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) hypotension_3/NN
D009599_D007022 CID nitroprusside_7/NNP (r_conj) triphosphate_1/NN (r_nsubjpass) administered_12/VBN (l_advcl) induce_16/VB (l_dobj) hypotension_19/NN
D009599_D007022 CID SNP_9/NNP (r_appos) nitroprusside_7/NNP (r_conj) triphosphate_1/NN (r_nsubjpass) administered_12/VBN (l_advcl) induce_16/VB (l_dobj) hypotension_19/NN
D009599_D007022 CID SNP_4/NNP (r_nmod) decreases_6/NNS (r_pobj) by_3/IN (r_agent) produced_2/VBN (r_acl) hypotension_1/NN
D010100_D007022 NONE oxygen_66/NN (r_compound) consumption_67/NN (r_intj) ,_63/, (r_punct) left_31/VBD (l_ccomp) accompanied_5/VBN (l_nsubjpass) Hypotension_0/NN
D010100_D007022 NONE oxygen_65/NN (r_compound) content_66/NN (r_compound) difference_67/NN (r_conj) resistance_46/NN (r_intj) ,_43/, (r_punct) observed_8/VBN (l_prep) During_0/IN (l_pobj) hypotension_1/NN
21195121
D009569_D012640 NONE oxide_4/NN (l_prep) in_5/IN (l_pobj) convulsions_6/NNS
D009569_D012640 NONE NO_6/NNP (r_nsubj) plays_7/VBZ (l_dobj) role_9/NN (l_prep) in_13/IN (l_pobj) model_15/NN (l_prep) of_16/IN (l_pobj) seizures_18/NNS
D001556_D012640 CID lindane_9/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) convulsions_6/NNS
D001556_D012640 CID lindane_37/NN (r_compound) dose_38/NN (r_pobj) by_35/IN (r_agent) elicited_34/VBN (r_acl) convulsion_33/NN (r_pobj) to_31/IN (r_prep) time_30/NN (r_conj) increased_22/VBD (l_dobj) incidence_24/NN (l_compound) convulsion_23/NN
D001556_D012640 CID lindane_37/NN (r_compound) dose_38/NN (r_pobj) by_35/IN (r_agent) elicited_34/VBN (r_acl) convulsion_33/NN
D001556_D012640 CID lindane_37/NNP (r_pobj) of_36/IN (r_prep) dose_35/NN (r_pobj) with_32/IN (r_prep) decreased_19/VBD (l_dobj) incidence_21/NN (l_compound) convulsion_20/NN
D001556_D012640 CID lindane_37/NNP (r_pobj) of_36/IN (r_prep) dose_35/NN (r_pobj) with_32/IN (r_prep) decreased_19/VBD (l_prep) to_28/IN (l_pobj) convulsion_29/NN
D001556_D012640 CID lindane_37/NNP (r_pobj) of_36/IN (r_prep) dose_35/NN (l_amod) convulsive_34/JJ
D001556_D012640 CID lindane_17/NN (r_compound) seizures_18/NNS
D005680_D012640 NONE GABA(A_8/DT (r_pobj) of_7/IN (r_prep) blockage_6/NN (r_dobj) trough_4/IN (r_prep) evokes_1/VBZ (l_dobj) convulsions_2/NNS
D009569_D004827 NONE oxide_1/NN (r_nsubj) has_9/VBZ (l_conj) observed_39/VBN (l_prep) in_40/IN (l_pobj) models_43/NNS (l_compound) epilepsy_42/NN
D009569_D004827 NONE NO_3/NN (r_intj) oxide_1/NN (r_nsubj) has_9/VBZ (l_conj) observed_39/VBN (l_prep) in_40/IN (l_pobj) models_43/NNS (l_compound) epilepsy_42/NN
D009569_D004827 NONE NO_25/DT (r_amod) syntheses_26/NNS (r_pobj) of_24/IN (r_prep) precursor_23/NN (r_dobj) has_9/VBZ (l_conj) observed_39/VBN (l_prep) in_40/IN (l_pobj) models_43/NNS (l_compound) epilepsy_42/NN
D009569_D004827 NONE NO_12/NN (r_pobj) of_11/IN (r_prep) effects_10/NNS (l_prep) on_13/IN (l_pobj) characteristics_18/NNS (l_prep) of_19/IN (l_pobj) epilepsy_23/NN
D001120_D004827 NONE arginine_21/NN (r_pobj) of_18/IN (r_prep) effects_17/NNS (r_pobj) due_14/IN (r_prep) has_9/VBZ (l_conj) observed_39/VBN (l_prep) in_40/IN (l_pobj) models_43/NNS (l_compound) epilepsy_42/NN
D019331_D004827 NONE NAME_34/NNP (r_nsubj) observed_39/VBN (l_prep) in_40/IN (l_pobj) models_43/NNS (l_compound) epilepsy_42/NN
D001556_D004827 NONE lindane_20/NN (r_npadvmod) induced_22/VBN (r_amod) epilepsy_23/NN
D001120_D012640 NONE arginine_5/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) increased_22/VBD (l_dobj) incidence_24/NN (l_compound) convulsion_23/NN
D001120_D012640 NONE arginine_5/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) increased_22/VBD (l_conj) time_30/NN (l_prep) to_31/IN (l_pobj) convulsion_33/NN
D019331_D012640 NONE NAME_8/NNP (r_pobj) with_5/IN (r_prep) pretreatment_4/NN (r_nsubj) decreased_19/VBD (l_dobj) incidence_21/NN (l_compound) convulsion_20/NN
D019331_D012640 NONE NAME_8/NNP (r_pobj) with_5/IN (r_prep) pretreatment_4/NN (r_nsubj) decreased_19/VBD (l_prep) to_28/IN (l_pobj) convulsion_29/NN
D019331_D012640 NONE NAME_8/NNP (r_pobj) with_5/IN (r_prep) pretreatment_4/NN (r_nsubj) decreased_19/VBD (l_prep) with_32/IN (l_pobj) dose_35/NN (l_amod) convulsive_34/JJ
2173761
D019806_D007022 CID cromakalim_11/NNP (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) vessels_6/NNS (l_conj) hypotension_8/NN
D019806_D013610 CID cromakalim_11/NNP (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) vessels_6/NNS (r_pobj) of_1/IN (r_prep) Vasodilation_0/NNP (r_nsubjpass) affected_16/VBN (l_agent) by_17/IN (l_pobj) blockade_25/NN (l_conj) tachycardia_30/NN
D020110_D007022 CID pinacidil_13/NNP (r_conj) cromakalim_11/NNP (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) vessels_6/NNS (l_conj) hypotension_8/NN
D020110_D013610 CID pinacidil_13/NNP (r_conj) cromakalim_11/NNP (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) vessels_6/NNS (r_pobj) of_1/IN (r_prep) Vasodilation_0/NNP (r_nsubjpass) affected_16/VBN (l_agent) by_17/IN (l_pobj) blockade_25/NN (l_conj) tachycardia_30/NN
D000319_D007022 NONE blockade_25/NN (r_pobj) by_17/IN (r_agent) affected_16/VBN (l_nsubjpass) Vasodilation_0/NNP (l_prep) of_1/IN (l_pobj) vessels_6/NNS (l_conj) hypotension_8/NN
D018727_D007022 NONE blockade_25/NN (r_pobj) by_17/IN (r_agent) affected_16/VBN (l_nsubjpass) Vasodilation_0/NNP (l_prep) of_1/IN (l_pobj) vessels_6/NNS (l_conj) hypotension_8/NN
D000319_D013610 NONE blockade_25/NN (l_conj) tachycardia_30/NN
D018727_D013610 NONE blockade_25/NN (l_conj) tachycardia_30/NN
17028363
D000880_D058186 NONE anthraquinones_11/NNS (r_dobj) containing_10/VBG (r_acl) pills_9/NNS (r_pobj) of_7/IN (r_prep) intake_6/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (r_acl) failure_2/NN
D000880_D058186 NONE anthraquinone_24/NN (r_compound) derivatives_25/NNS (r_dobj) contained_23/VBD (r_relcl) pill_21/NN (r_pobj) of_15/IN (r_prep) use_14/NN (r_pobj) following_12/VBG (r_prep) developed_8/VBD (l_dobj) failure_11/NN
D000880_D058186 NONE anthraquinone_9/NN (r_npadvmod) containing_11/VBG (r_amod) agent_13/NN (l_conj) injury_16/NN
D004365_D007674 NONE herbs_4/NNS (r_pobj) by_2/IN (r_agent) caused_1/VBN (r_acl) Nephropathy_0/NNP
D034341_D007674 NONE acids_16/NNS (r_pobj) of_14/IN (r_prep) use_13/NN (r_dobj) involving_11/VBG (r_advcl) reported_8/VBN (l_nsubjpass) Nephropathy_0/NNP
D004365_D058186 CID herbal_19/JJ (r_amod) slimming_20/NN (r_compound) pill_21/NN (r_pobj) of_15/IN (r_prep) use_14/NN (r_pobj) following_12/VBG (r_prep) developed_8/VBD (l_dobj) failure_11/NN
D004008_D058186 CID diclofenac_20/NN (r_appos) drug_18/NN (r_pobj) of_10/IN (r_prep) intake_9/NN (r_pobj) by_6/IN (r_agent) aggravated_5/VBN (l_nsubjpass) injury_2/NN
D000880_D007674 NONE anthraquinone_9/NN (r_npadvmod) containing_11/VBG (r_amod) agent_13/NN (r_pobj) of_7/IN (r_prep) use_6/NN (r_pobj) between_4/IN (r_prep) relationship_3/NN (r_nsubj) remains_17/VBZ (r_advcl) considered_29/VBN (l_nsubjpass) nephropathy_26/NN
D000880_D051437 NONE anthraquinone_9/NN (r_npadvmod) containing_11/VBG (r_amod) agent_13/NN (r_pobj) of_7/IN (r_prep) use_6/NN (r_pobj) between_4/IN (r_prep) relationship_3/NN (r_nsubj) remains_17/VBZ (r_advcl) considered_29/VBN (l_prep) in_30/IN (l_pobj) patients_31/NNS (l_relcl) present_33/VBP (l_prep) with_34/IN (l_pobj) failure_37/NN
24671324
C400082_D019115 CID bortezomib_3/NNP (r_pobj) after_2/IN (r_prep) fasciitis_1/NN
C400082_D019115 CID bortezomib_24/NNP (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_19/IN (r_prep) suffered_14/VBD (l_dobj) fasciitis_16/NN
C400082_D008258 NONE bortezomib_3/NNP (l_prep) in_9/IN (l_pobj) patient_12/NN (l_prep) of_13/IN (l_pobj) macroglobulinaemia_15/NN
C400082_D008258 NONE bortezomib_24/NNP (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_19/IN (r_prep) suffered_14/VBD (r_relcl) man_9/NN (l_prep) with_10/IN (l_pobj) macroglobulinaemia_12/NN
D003907_D019115 CID dexamethasone_5/NN (r_npadvmod) containing_7/VBG (r_amod) regimen_8/NN (r_conj) bortezomib_3/NNP (r_pobj) after_2/IN (r_prep) fasciitis_1/NN
D003907_D019115 CID dexamethasone_29/NN (r_conj) bortezomib_24/NNP (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_19/IN (r_prep) suffered_14/VBD (l_dobj) fasciitis_16/NN
D003907_D008258 NONE dexamethasone_5/NN (r_npadvmod) containing_7/VBG (r_amod) regimen_8/NN (r_conj) bortezomib_3/NNP (l_prep) in_9/IN (l_pobj) patient_12/NN (l_prep) of_13/IN (l_pobj) macroglobulinaemia_15/NN
D003907_D008258 NONE dexamethasone_29/NN (r_conj) bortezomib_24/NNP (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_19/IN (r_prep) suffered_14/VBD (r_relcl) man_9/NN (l_prep) with_10/IN (l_pobj) macroglobulinaemia_12/NN
C400082_D001424 NONE Bortezomib_0/NNP (r_nsubjpass) considered_10/VBN (l_xcomp) be_12/VB (l_acomp) tolerable_14/JJ (l_prep) with_15/IN (l_pobj) infections_19/NNS
C400082_D001424 NONE bortezomib_11/NNP (r_pobj) to_10/IN (r_prep) related_9/VBN (r_acl) infections_8/NNS
C400082_D009369 NONE Bortezomib_0/NNP (r_nsubjpass) considered_10/VBN (l_xcomp) be_12/VB (l_acomp) tolerable_14/JJ (l_prep) with_15/IN (l_pobj) infections_19/NNS (l_prep) in_20/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) malignancies_26/NNS
D003907_D001424 NONE dexamethasone_5/NN (r_npadvmod) containing_7/VBG (r_amod) regimens_8/NNS (r_conj) Bortezomib_0/NNP (r_nsubjpass) considered_10/VBN (l_xcomp) be_12/VB (l_acomp) tolerable_14/JJ (l_prep) with_15/IN (l_pobj) infections_19/NNS
D003907_D001424 NONE dexamethasone_16/NN (r_conj) bortezomib_11/NNP (r_pobj) to_10/IN (r_prep) related_9/VBN (r_acl) infections_8/NNS
D003907_D009369 NONE dexamethasone_5/NN (r_npadvmod) containing_7/VBG (r_amod) regimens_8/NNS (r_conj) Bortezomib_0/NNP (r_nsubjpass) considered_10/VBN (l_xcomp) be_12/VB (l_acomp) tolerable_14/JJ (l_prep) with_15/IN (l_pobj) infections_19/NNS (l_prep) in_20/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) malignancies_26/NNS
C400082_D009503 NONE bortezomib_24/NNP (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_19/IN (r_prep) suffered_14/VBD (l_prep) without_17/IN (l_pobj) neutropenia_18/NN
D003907_D009503 NONE dexamethasone_29/NN (r_conj) bortezomib_24/NNP (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_19/IN (r_prep) suffered_14/VBD (l_prep) without_17/IN (l_pobj) neutropenia_18/NN
1563460
D014859_D020758 CID coumadin_4/NNP (r_compound) therapy_6/NN (r_pobj) to_3/IN (r_prep) secondary_2/JJ (r_amod) hematomyelia_1/NNS
11915580
D005996_D004412 NONE trinitrate_4/NNP (l_prep) for_7/IN (l_pobj) treatment_9/NN (l_prep) of_10/IN (l_pobj) dysmenorrhea_12/NN
D005996_D004412 NONE trinitrate_13/NNP (r_pobj) of_11/IN (r_prep) efficacy_10/NN (l_prep) in_22/IN (l_pobj) resolution_24/NN (l_prep) of_25/IN (l_pobj) dysmenorrhea_27/NN
D005996_D004412 NONE GTN_15/NNP (r_appos) trinitrate_13/NNP (r_pobj) of_11/IN (r_prep) efficacy_10/NN (l_prep) in_22/IN (l_pobj) resolution_24/NN (l_prep) of_25/IN (l_pobj) dysmenorrhea_27/NN
D005996_D004412 NONE GTN_4/NNP (r_nsubj) has_5/VBZ (l_dobj) efficacy_8/NN (l_prep) by_11/IN (l_pobj) comparison_12/NN (l_prep) in_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) dysmenorrhea_20/NN
D004008_D004412 NONE diclofenac_6/NN (r_pobj) with_5/IN (r_prep) trinitrate_4/NNP (l_prep) for_7/IN (l_pobj) treatment_9/NN (l_prep) of_10/IN (l_pobj) dysmenorrhea_12/NN
D004008_D004412 NONE diclofenac_31/NN (r_nmod) DCF_33/NNP (r_pobj) with_30/IN (r_prep) comparison_29/NN (r_pobj) in_28/IN (r_prep) resolution_24/NN (l_prep) of_25/IN (l_pobj) dysmenorrhea_27/NN
D004008_D004412 NONE DCF_33/NNP (r_pobj) with_30/IN (r_prep) comparison_29/NN (r_pobj) in_28/IN (r_prep) resolution_24/NN (l_prep) of_25/IN (l_pobj) dysmenorrhea_27/NN
D004008_D004412 NONE DCF_14/NNP (r_pobj) with_13/IN (r_prep) comparison_12/NN (l_prep) in_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) dysmenorrhea_20/NN
D011453_D004412 NONE prostaglandins_16/NNS (r_pobj) of_14/IN (r_prep) hypersecretion_13/NN (r_pobj) by_11/IN (r_agent) caused_10/VBN (r_acl) contractility_9/NN (r_pobj) by_6/IN (r_agent) characterized_5/VBN (r_acl) syndrome_4/NN (r_attr) is_2/VBZ (l_nsubj) dysmenorrhea_1/NN
D009569_D004412 NONE NO_19/JJ (r_amod) donor_20/NN (r_appos) trinitrate_13/NNP (r_pobj) of_11/IN (r_prep) efficacy_10/NN (l_prep) in_22/IN (l_pobj) resolution_24/NN (l_prep) of_25/IN (l_pobj) dysmenorrhea_27/NN
D004008_D017699 NONE DCF_2/NNP (r_nsubj) continued_3/VBD (l_xcomp) be_5/VB (l_acomp) effective_6/JJ (l_prep) in_7/IN (l_pcomp) reducing_8/VBG (l_dobj) pain_10/NN
D005996_D017699 NONE GTN_16/NNP (r_compound) scores_17/NNS (r_nsubj) remained_18/VBD (r_advcl) continued_3/VBD (l_xcomp) be_5/VB (l_acomp) effective_6/JJ (l_prep) in_7/IN (l_pcomp) reducing_8/VBG (l_dobj) pain_10/NN
D005996_D017699 NONE GTN_38/NNP (r_npadvmod) continued_3/VBD (l_xcomp) be_5/VB (l_acomp) effective_6/JJ (l_prep) in_7/IN (l_pcomp) reducing_8/VBG (l_dobj) pain_10/NN
D005996_D006261 CID GTN_5/NNP (r_pobj) by_4/IN (r_agent) increased_3/VBN (l_nsubjpass) Headache_0/NN
D005996_D006261 CID GTN_4/NNP (r_dobj) using_3/VBG (r_xcomp) stopped_2/VBD (l_advcl) became_13/VBD (l_nsubj) headache_6/NN
D004008_D006261 NONE DCF_9/NNP (r_pobj) by_8/IN (r_agent) increased_3/VBN (l_nsubjpass) Headache_0/NN
16083708
D019980_D056486 CID clavulanate_2/NNP (r_nsubj) stands_3/VBZ (l_prep) as_5/IN (l_pobj) drug_9/NN (l_acl) related_10/VBN (l_prep) to_11/IN (l_pobj) DILI_12/NNP
17554526
D003042_D001925 CID cocaine_6/NN (r_compound) users_7/NNS (r_pobj) in_3/IN (r_prep) recognition_2/NN
D003042_D001925 CID cocaine_21/NN (r_pobj) of_20/IN (r_prep) effects_19/NNS (r_pobj) by_16/IN (r_agent) explained_15/VBN (l_nsubjpass) deficit_2/NN (l_prep) in_3/IN (l_pobj) accuracy_6/NN (l_compound) recognition_5/NN
D018817_D001925 NONE ecstasy_24/NN (r_conj) cocaine_21/NN (r_pobj) of_20/IN (r_prep) effects_19/NNS (r_pobj) by_16/IN (r_agent) explained_15/VBN (l_nsubjpass) deficit_2/NN (l_prep) in_3/IN (l_pobj) accuracy_6/NN (l_compound) recognition_5/NN
9428298
D000420_D001249 NONE albuterol_2/NN (r_dobj) nebulized_1/VBN (l_prep) in_3/IN (l_pobj) exacerbations_5/NNS (l_prep) of_6/IN (l_pobj) asthma_7/NN
D000420_D001249 NONE albuterol_25/NN (r_dobj) received_22/VBD (r_relcl) exacerbations_18/NNS (l_prep) of_19/IN (l_pobj) asthma_20/NN
D000420_D001249 NONE albuterol_31/NN (r_nmod) treatments_35/NNS (r_pobj) versus_29/IN (r_prep) received_22/VBD (r_relcl) exacerbations_18/NNS (l_prep) of_19/IN (l_pobj) asthma_20/NN
24190587
D018817_D008107 NONE Ecstasy_0/NNP (r_nsubj) is_4/VBZ (l_attr) drug_7/NN (l_relcl) associated_11/VBN (l_prep) with_12/IN (l_pobj) dysfunction_14/NN
D018817_D008107 NONE MDMA_2/NNP (r_appos) Ecstasy_0/NNP (r_nsubj) is_4/VBZ (l_attr) drug_7/NN (l_relcl) associated_11/VBN (l_prep) with_12/IN (l_pobj) dysfunction_14/NN
D018817_D001008 NONE ecstasy_14/NN (r_compound) polydrug_16/NN (r_compound) users_17/NNS (r_pobj) in_12/IN (r_prep) observations_11/NNS (r_pobj) with_9/IN (r_prep) line_8/NN (r_pobj) in_7/IN (r_prep) are_6/VBP (l_nsubj) increases_1/NNS (l_prep) in_2/IN (l_pobj) anxiety_3/NN
D018817_D003866 CID ecstasy_14/NN (r_compound) polydrug_16/NN (r_compound) users_17/NNS (r_pobj) in_12/IN (r_prep) observations_11/NNS (r_pobj) with_9/IN (r_prep) line_8/NN (r_pobj) in_7/IN (r_prep) are_6/VBP (l_nsubj) increases_1/NNS (l_prep) in_2/IN (l_pobj) anxiety_3/NN (l_conj) depression_5/NN
7492040
D008012_D009203 NONE lidocaine_3/NN (r_pobj) of_2/IN (r_prep) safety_1/NN (l_prep) in_4/IN (l_pobj) patients_5/NNS (l_prep) with_6/IN (l_pobj) infarction_11/NN
D008012_D009203 NONE lidocaine_5/NN (r_pobj) of_4/IN (r_prep) safety_3/NN (r_dobj) evaluate_1/VB (l_prep) in_6/IN (l_pobj) setting_8/NN (l_prep) of_9/IN (l_pobj) infarction_14/NN
D008012_D009203 NONE lidocaine_5/NN (r_pobj) of_4/IN (r_prep) safety_3/NN (r_dobj) evaluate_1/VB (l_prep) in_6/IN (l_pobj) setting_8/NN (l_prep) of_9/IN (l_pobj) infarction_14/NN (l_appos) MI_16/NNP
D008012_D009203 NONE lidocaine_8/NN (r_dobj) received_7/VBD (r_relcl) MI_5/NNP
D008012_D009203 NONE lidocaine_5/NN (r_dobj) received_4/VBD (l_prep) in_6/IN (l_pobj) setting_8/NN (l_prep) of_9/IN (l_pobj) MI_13/NNP
D008012_D009203 NONE lidocaine_35/NNP (r_pobj) of_34/IN (r_prep) administration_33/NN (r_pobj) after_32/IN (r_prep) seizures_31/NNS (r_conj) exhibited_19/VBD (r_conj) died_17/VBD (l_prep) Of_0/IN (l_pobj) patients_2/NNS (l_relcl) received_4/VBD (l_prep) in_6/IN (l_pobj) setting_8/NN (l_prep) of_9/IN (l_pobj) MI_13/NNP
D008012_D009203 NONE lidocaine_4/NN (r_nsubj) enhance_6/VB (r_acl) concerns_2/NNS (r_pobj) Despite_0/IN (r_prep) associated_23/VBN (l_nsubjpass) use_11/NN (l_prep) in_14/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) MI_20/NNP
D008012_D009203 NONE lidocaine_13/NN (r_pobj) of_12/IN (r_prep) use_11/NN (l_prep) in_14/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) MI_20/NNP
D003042_D009203 CID cocaine_7/NN (r_npadvmod) associated_9/VBN (r_amod) infarction_11/NN
D003042_D009203 CID cocaine_10/NN (r_npadvmod) induced_12/VBN (r_amod) infarction_14/NN
D003042_D009203 CID cocaine_10/NN (r_npadvmod) induced_12/VBN (r_amod) infarction_14/NN (l_appos) MI_16/NNP
D003042_D009203 CID cocaine_2/NN (r_npadvmod) associated_4/VBN (r_amod) MI_5/NNP
D003042_D009203 CID cocaine_10/NN (r_npadvmod) associated_12/VBN (r_amod) MI_13/NNP
D003042_D009203 CID cocaine_7/NN (r_compound) toxicity_8/NN (r_dobj) enhance_6/VB (r_acl) concerns_2/NNS (r_pobj) Despite_0/IN (r_prep) associated_23/VBN (l_nsubjpass) use_11/NN (l_prep) in_14/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) MI_20/NNP
D003042_D009203 CID cocaine_17/NN (r_npadvmod) associated_19/VBN (r_amod) MI_20/NNP
D008012_D001919 NONE lidocaine_5/NN (r_dobj) received_4/VBD (r_relcl) patients_2/NNS (r_pobj) Of_0/IN (r_prep) died_17/VBD (l_conj) exhibited_19/VBD (l_dobj) bradydysrhythmias_20/NNP
D008012_D001919 NONE lidocaine_35/NNP (r_pobj) of_34/IN (r_prep) administration_33/NN (r_pobj) after_32/IN (r_prep) seizures_31/NNS (r_conj) exhibited_19/VBD (l_dobj) bradydysrhythmias_20/NNP
D008012_D017180 NONE lidocaine_5/NN (r_dobj) received_4/VBD (r_relcl) patients_2/NNS (r_pobj) Of_0/IN (r_prep) died_17/VBD (l_conj) exhibited_19/VBD (l_dobj) bradydysrhythmias_20/NNP (l_conj) tachycardia_23/NN
D008012_D017180 NONE lidocaine_35/NNP (r_pobj) of_34/IN (r_prep) administration_33/NN (r_pobj) after_32/IN (r_prep) seizures_31/NNS (r_conj) exhibited_19/VBD (l_dobj) bradydysrhythmias_20/NNP (l_conj) tachycardia_23/NN
D008012_D014693 NONE lidocaine_5/NN (r_dobj) received_4/VBD (r_relcl) patients_2/NNS (r_pobj) Of_0/IN (r_prep) died_17/VBD (l_conj) exhibited_19/VBD (l_dobj) bradydysrhythmias_20/NNP (l_conj) tachycardia_23/NN (l_conj) fibrillation_27/NN
D008012_D014693 NONE lidocaine_35/NNP (r_pobj) of_34/IN (r_prep) administration_33/NN (r_pobj) after_32/IN (r_prep) seizures_31/NNS (r_conj) exhibited_19/VBD (l_dobj) bradydysrhythmias_20/NNP (l_conj) tachycardia_23/NN (l_conj) fibrillation_27/NN
D008012_D012640 NONE lidocaine_5/NN (r_dobj) received_4/VBD (r_relcl) patients_2/NNS (r_pobj) Of_0/IN (r_prep) died_17/VBD (l_conj) exhibited_19/VBD (l_conj) seizures_31/NNS
D008012_D012640 NONE lidocaine_35/NNP (r_pobj) of_34/IN (r_prep) administration_33/NN (r_pobj) after_32/IN (r_prep) seizures_31/NNS
D003042_D001919 NONE cocaine_10/NN (r_npadvmod) associated_12/VBN (r_amod) MI_13/NNP (r_pobj) of_9/IN (r_prep) setting_8/NN (r_pobj) in_6/IN (r_prep) received_4/VBD (r_relcl) patients_2/NNS (r_pobj) Of_0/IN (r_prep) died_17/VBD (l_conj) exhibited_19/VBD (l_dobj) bradydysrhythmias_20/NNP
D003042_D017180 NONE cocaine_10/NN (r_npadvmod) associated_12/VBN (r_amod) MI_13/NNP (r_pobj) of_9/IN (r_prep) setting_8/NN (r_pobj) in_6/IN (r_prep) received_4/VBD (r_relcl) patients_2/NNS (r_pobj) Of_0/IN (r_prep) died_17/VBD (l_conj) exhibited_19/VBD (l_dobj) bradydysrhythmias_20/NNP (l_conj) tachycardia_23/NN
D003042_D014693 NONE cocaine_10/NN (r_npadvmod) associated_12/VBN (r_amod) MI_13/NNP (r_pobj) of_9/IN (r_prep) setting_8/NN (r_pobj) in_6/IN (r_prep) received_4/VBD (r_relcl) patients_2/NNS (r_pobj) Of_0/IN (r_prep) died_17/VBD (l_conj) exhibited_19/VBD (l_dobj) bradydysrhythmias_20/NNP (l_conj) tachycardia_23/NN (l_conj) fibrillation_27/NN
D003042_D012640 NONE cocaine_10/NN (r_npadvmod) associated_12/VBN (r_amod) MI_13/NNP (r_pobj) of_9/IN (r_prep) setting_8/NN (r_pobj) in_6/IN (r_prep) received_4/VBD (r_relcl) patients_2/NNS (r_pobj) Of_0/IN (r_prep) died_17/VBD (l_conj) exhibited_19/VBD (l_conj) seizures_31/NNS
D008012_D064420 NONE lidocaine_4/NN (r_nsubj) enhance_6/VB (l_dobj) toxicity_8/NN
D008012_D064420 NONE lidocaine_13/NN (r_pobj) of_12/IN (r_prep) use_11/NN (r_nsubjpass) associated_23/VBN (l_prep) Despite_0/IN (l_pobj) concerns_2/NNS (l_acl) enhance_6/VB (l_dobj) toxicity_8/NN
D008012_D002318 NONE lidocaine_4/NN (r_nsubj) enhance_6/VB (r_acl) concerns_2/NNS (r_pobj) Despite_0/IN (r_prep) associated_23/VBN (l_prep) with_24/IN (l_pobj) toxicity_31/NN
D008012_D002318 NONE lidocaine_13/NN (r_pobj) of_12/IN (r_prep) use_11/NN (r_nsubjpass) associated_23/VBN (l_prep) with_24/IN (l_pobj) toxicity_31/NN
D008012_D002493 NONE lidocaine_4/NN (r_nsubj) enhance_6/VB (r_acl) concerns_2/NNS (r_pobj) Despite_0/IN (r_prep) associated_23/VBN (l_prep) with_24/IN (l_pobj) toxicity_31/NN
D008012_D002493 NONE lidocaine_13/NN (r_pobj) of_12/IN (r_prep) use_11/NN (r_nsubjpass) associated_23/VBN (l_prep) with_24/IN (l_pobj) toxicity_31/NN
D003042_D064420 NONE cocaine_7/NN (r_compound) toxicity_8/NN
D003042_D064420 NONE cocaine_17/NN (r_npadvmod) associated_19/VBN (r_amod) MI_20/NNP (r_pobj) with_16/IN (r_prep) patients_15/NNS (r_pobj) in_14/IN (r_prep) use_11/NN (r_nsubjpass) associated_23/VBN (l_prep) Despite_0/IN (l_pobj) concerns_2/NNS (l_acl) enhance_6/VB (l_dobj) toxicity_8/NN
D003042_D002318 NONE cocaine_7/NN (r_compound) toxicity_8/NN (r_dobj) enhance_6/VB (r_acl) concerns_2/NNS (r_pobj) Despite_0/IN (r_prep) associated_23/VBN (l_prep) with_24/IN (l_pobj) toxicity_31/NN
D003042_D002318 NONE cocaine_17/NN (r_npadvmod) associated_19/VBN (r_amod) MI_20/NNP (r_pobj) with_16/IN (r_prep) patients_15/NNS (r_pobj) in_14/IN (r_prep) use_11/NN (r_nsubjpass) associated_23/VBN (l_prep) with_24/IN (l_pobj) toxicity_31/NN
D003042_D002493 NONE cocaine_7/NN (r_compound) toxicity_8/NN (r_dobj) enhance_6/VB (r_acl) concerns_2/NNS (r_pobj) Despite_0/IN (r_prep) associated_23/VBN (l_prep) with_24/IN (l_pobj) toxicity_31/NN
D003042_D002493 NONE cocaine_17/NN (r_npadvmod) associated_19/VBN (r_amod) MI_20/NNP (r_pobj) with_16/IN (r_prep) patients_15/NNS (r_pobj) in_14/IN (r_prep) use_11/NN (r_nsubjpass) associated_23/VBN (l_prep) with_24/IN (l_pobj) toxicity_31/NN
8188982
D001127_D006973 CID AVP_4/NNP (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) in_7/IN (l_pobj) normotensive_8/NN (l_conj) hypertensive_11/JJ
D001127_D006973 CID vasopressin_13/NN (r_pobj) of_10/IN (r_prep) influence_9/NN (l_prep) in_40/IN (l_pobj) rats_51/NNS (l_amod) hypertensive_47/JJ
D001127_D006973 CID AVP_15/NNP (r_appos) vasopressin_13/NN (r_pobj) of_10/IN (r_prep) influence_9/NN (l_prep) in_40/IN (l_pobj) rats_51/NNS (l_amod) hypertensive_47/JJ
D010656_D006973 CID phenylephrine_36/NNP (l_conj) hypertension_39/NN
D010656_D006973 CID Phe)-induced_38/VBN (r_amod) hypertension_39/NN
D010656_D007022 NONE phenylephrine_36/NNP (l_appos) hypotension_45/NN
D010656_D007022 NONE Phe)-induced_38/VBN (r_amod) hypertension_39/NN (r_conj) phenylephrine_36/NNP (l_appos) hypotension_45/NN
D009599_D006973 NONE nitroprusside_42/JJ (r_conj) hypertension_39/NN
D009599_D006973 NONE SN)-induced_44/JJ (r_nummod) hypotension_45/NN (r_appos) phenylephrine_36/NNP (l_conj) hypertension_39/NN
D009599_D007022 CID nitroprusside_42/JJ (r_conj) hypertension_39/NN (r_conj) phenylephrine_36/NNP (l_appos) hypotension_45/NN
D009599_D007022 CID SN)-induced_44/JJ (r_nummod) hypotension_45/NN
D009599_D007022 CID SN_13/NNP (r_npadvmod) induced_15/VBN (r_amod) hypotension_16/NN
D001127_D007022 NONE AVP_11/NNP (r_pobj) of_10/IN (r_prep) administration_9/NN (l_prep) during_12/IN (l_pobj) hypotension_16/NN
6985297
D015764_D001919 CID bepridil_6/NNP (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) bradycardia_3/NNS
D015764_D001919 CID Bepridil_0/NNP (r_nsubj) induced_13/VBN (l_dobj) bradycardia_15/NNS
D015764_D000787 NONE Bepridil_0/NNP (l_appos) compound_5/NN (l_prep) for_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) attacks_11/NNS
D015764_D013610 NONE Bepridil_0/NNP (r_nsubj) induced_13/VBN (l_dobj) bradycardia_15/NNS (l_conj) effect_24/NN (l_amod) tachycardial_23/JJ
17384765
D004113_D003072 CID Succimer_0/NNP (r_compound) chelation_1/NN (r_nsubj) improves_2/VBZ (l_conj) produces_16/VBZ (l_dobj) impairment_19/NN
D004113_D003072 NONE succimer_3/JJ (r_compound) treatment_4/NN (r_nsubjpass) exposed_9/VBN (r_nsubj) produced_12/VBD (l_dobj) dysfunction_19/NN
D007854_D003072 NONE lead_11/NN (r_npadvmod) exposed_13/VBN (r_amod) rats_14/NNS (r_pobj) in_10/IN (r_prep) learning_3/NN (r_dobj) improves_2/VBZ (l_conj) produces_16/VBZ (l_dobj) impairment_19/NN
D007854_D003072 NONE lead_24/JJ (r_amod) exposure_25/NN (r_pobj) of_23/IN (r_prep) absence_22/NN (r_pobj) in_20/IN (r_prep) produces_16/VBZ (l_dobj) impairment_19/NN
D007854_D003072 NONE Pb_11/NNP (r_pobj) to_10/IN (r_prep) exposed_9/VBN (r_nsubj) produced_12/VBD (l_dobj) dysfunction_19/NN
D007854_D003072 NONE Pb_29/NNP (r_compound) exposure_30/NN (r_compound) regimen_31/NN (r_pobj) by_26/IN (r_agent) produced_25/VBN (r_acl) that_24/DT (r_pobj) to_23/IN (r_prep) magnitude_22/NN (r_pobj) in_21/IN (r_prep) comparable_20/JJ (r_amod) dysfunction_19/NN
D007854_D003072 NONE Pb_24/NNP (r_compound) exposure_25/NN (r_pobj) to_23/IN (r_prep) due_22/JJ (r_amod) deficits_21/NNS
D007854_D007855 NONE Pb_17/NNP (r_compound) exposure_18/NN (l_prep) with_21/IN (l_pobj) succimer_22/NNP (l_appos) agent_28/NN (l_prep) for_29/IN (l_pobj) treatment_31/NN (l_prep) of_32/IN (l_pobj) poisoning_34/NN
D004113_D007855 NONE succimer_22/NNP (l_appos) agent_28/NN (l_prep) for_29/IN (l_pobj) treatment_31/NN (l_prep) of_32/IN (l_pobj) poisoning_34/NN
D007854_D007859 CID Pb_0/NNP (r_compound) exposure_1/NN (r_nsubj) produced_2/VBD (l_dobj) impairments_4/NNS (l_prep) in_5/IN (l_pobj) learning_6/NN (l_conj) attention_8/NN (l_conj) control_11/NN (l_conj) regulation_15/NN
D007854_D007859 CID Pb_24/NNP (r_npadvmod) exposed_26/VBN (r_amod) children_27/NNS (r_pobj) in_23/IN (r_prep) seen_22/VBN (r_acl) dysfunction_21/NN (r_pobj) of_20/IN (r_prep) areas_19/NNS (r_dobj) paralleling_17/VBG (r_advcl) produced_2/VBD (l_dobj) impairments_4/NNS (l_prep) in_5/IN (l_pobj) learning_6/NN (l_conj) attention_8/NN (l_conj) control_11/NN (l_conj) regulation_15/NN
D007854_D019958 CID Pb_0/NNP (r_compound) exposure_1/NN (r_nsubj) produced_2/VBD (l_dobj) impairments_4/NNS (l_prep) in_5/IN (l_pobj) learning_6/NN (l_conj) attention_8/NN (l_conj) control_11/NN (l_conj) regulation_15/NN
D007854_D019958 CID Pb_24/NNP (r_npadvmod) exposed_26/VBN (r_amod) children_27/NNS (r_pobj) in_23/IN (r_prep) seen_22/VBN (r_acl) dysfunction_21/NN (r_pobj) of_20/IN (r_prep) areas_19/NNS (r_dobj) paralleling_17/VBG (r_advcl) produced_2/VBD (l_dobj) impairments_4/NNS (l_prep) in_5/IN (l_pobj) learning_6/NN (l_conj) attention_8/NN (l_conj) control_11/NN (l_conj) regulation_15/NN
D004113_D019964 NONE succimer_3/JJ (r_compound) treatment_4/NN (r_nsubjpass) exposed_9/VBN (r_nsubj) produced_12/VBD (l_dobj) dysfunction_19/NN
D007854_D019964 NONE Pb_11/NNP (r_pobj) to_10/IN (r_prep) exposed_9/VBN (r_nsubj) produced_12/VBD (l_dobj) dysfunction_19/NN
D007854_D019964 NONE Pb_29/NNP (r_compound) exposure_30/NN (r_compound) regimen_31/NN (r_pobj) by_26/IN (r_agent) produced_25/VBN (r_acl) that_24/DT (r_pobj) to_23/IN (r_prep) magnitude_22/NN (r_pobj) in_21/IN (r_prep) comparable_20/JJ (r_amod) dysfunction_19/NN
20024739
D000431_D015658 NONE alcohol_3/NN (r_compound) use_4/NN (l_prep) with_5/IN (l_pobj) progression_8/NN (l_compound) disease_7/NN
D000431_D015658 NONE alcohol_5/NN (r_compound) consumption_6/NN (r_pobj) of_4/IN (r_prep) association_3/NN (r_dobj) evaluated_1/VBD (l_conj) effects_12/NNS (l_prep) on_13/IN (l_pobj) progression_16/NN (l_compound) disease_15/NN
D000431_D003866 CID alcohol_5/NN (r_compound) consumption_6/NN (l_conj) depression_8/NN
D000431_D003866 CID alcohol_39/NN (r_compound) use_40/NN (r_compound) assessment_41/NN (r_dobj) had_2/VBD (l_dobj) examination_4/NN (l_conj) extraction_8/NN (l_conj) determination_17/NN (l_conj) measurement_19/NN (l_prep) of_20/IN (l_pobj) symptoms_22/NNS (l_compound) depression_21/NN
D000431_D003866 CID alcohol_39/NN (r_compound) use_40/NN (r_compound) assessment_41/NN (r_dobj) had_2/VBD (l_advcl) using_24/VBG (l_dobj) Center_29/NNP (l_prep) for_30/IN (l_pobj) Scale_35/NNP (l_compound) Depression_34/NNP
D000431_D003866 CID alcohol_3/NN (r_compound) consumption_4/NN (l_conj) depression_6/NN
D000431_D003866 CID alcohol_4/NN (r_compound) consumption_5/NN (r_nsubj) has_6/VBZ (l_dobj) association_9/NN (l_prep) with_10/IN (l_pobj) depression_11/NN
2904523
D004837_D006973 CID adrenaline_2/NN (r_compound) hypertension_4/NN
D004837_D006973 CID adrenaline_14/NN (r_compound) infusion_15/NN (r_pobj) after_11/IN (r_prep) effect_10/NN (r_appos) Support_0/NN (l_prep) for_1/IN (l_pobj) hypothesis_5/NN (l_compound) hypertension_4/NN
D004837_D006973 CID adrenaline_7/NN (r_compound) hypertension_9/NN
25080425
D001622_D009202 NONE betaine_13/NN (r_pobj) by_12/IN (r_prep) Regulation_0/NN (r_nsubj) attenuates_14/VBZ (l_dobj) injury_20/NN
D001622_D009202 NONE betaine_4/NN (l_prep) on_5/IN (l_pobj) damage_7/NN
D007545_D009202 NONE isoproterenol_15/NN (r_npadvmod) induced_17/VBN (r_amod) injury_20/NN
D001622_D017202 NONE betaine_11/NN (r_pobj) of_10/IN (r_prep) effects_9/NNS (r_dobj) investigate_6/VB (l_prep) on_12/IN (l_pobj) ischemia_15/NN
D001622_D017202 NONE betaine_7/NN (r_compound) pretreatment_8/NN (r_nsubj) attenuated_9/VBD (l_dobj) ischemia_15/NN
D007545_D017202 CID isoproterenol_12/NNP (r_pobj) of_11/IN (r_prep) injection_10/NN (r_pobj) by_8/IN (r_agent) induced_5/VBN (l_nsubjpass) injury_3/NN
D007545_D017202 CID isoproterenol_10/NN (r_npadvmod) induced_12/VBN (r_amod) ischemia_15/NN
D001622_D020257 NONE betaine_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) reduced_11/VBD (l_conj) prevented_22/VBN (l_xcomp) left_23/VBN (l_oprd) remodeling_25/NN
8184922
D007545_D006332 CID isoproterenol_17/NN (r_npadvmod) induced_19/VBN (r_amod) hypertrophy_21/NN
19967075
D012964_D007674 NONE Na_3/NNP (r_nmod) ATPase_7/NNP (r_pobj) of_2/IN (r_prep) Expression_1/NN (l_prep) in_16/IN (l_pobj) Nephropathy_20/NNP
D012964_D007674 NONE Na(+)/K(+)-ATPase_17/NNP (r_pobj) of_16/IN (r_prep) expression_15/NN (r_pobj) with_12/IN (r_prep) related_11/VBN (l_nsubjpass) nephropathy_3/NN
D011188_D007674 NONE K_5/NNP (r_compound) ATPase_7/NNP (r_pobj) of_2/IN (r_prep) Expression_1/NN (l_prep) in_16/IN (l_pobj) Nephropathy_20/NNP
D011188_D007674 NONE Na(+)/K(+)-ATPase_17/NNP (r_pobj) of_16/IN (r_prep) expression_15/NN (r_pobj) with_12/IN (r_prep) related_11/VBN (l_nsubjpass) nephropathy_3/NN
D005839_D007674 CID Gentamicin_17/NN (r_npadvmod) induced_19/VBN (r_amod) Nephropathy_20/NNP
D005839_D007674 CID gentamicin_17/NN (r_npadvmod) induced_19/VBN (r_amod) nephropathy_20/NN
D005839_D007674 CID Gentamicin_0/NN (r_npadvmod) induced_2/VBN (r_amod) nephropathy_3/NN
931801
D005937_D007674 NONE Glucarates_4/NNPS (r_pobj) of_1/IN (r_prep) Effect_0/NN (l_prep) on_5/IN (l_pobj) damage_11/NN
D005937_D007674 NONE Glucarates_2/NNPS (r_nsubj) were_3/VBD (l_acomp) effective_4/JJ (l_prep) against_5/IN (l_pobj) damage_7/NN
D005937_D007674 NONE glucarate_4/NN (r_pobj) With_0/IN (r_prep) obtained_19/VBN (l_prep) against_20/IN (l_pobj) damages_22/NNS
D005937_D007674 NONE Glucarates_2/NNPS (r_nsubj) had_3/VBD (l_dobj) ability_5/NN (l_acl) prevent_7/VB (l_dobj) damage_9/NN
D005937_D007674 NONE glucarates_6/NNS (r_pobj) of_3/IN (r_prep) effect_2/NN (l_prep) against_7/IN (l_pobj) nephrotoxicity_8/NN
D000617_D003681 NONE aminoglycoside_11/JJ (r_compound) antibiotics_12/NNS (r_pobj) of_10/IN (r_prep) injection_9/NN (r_pobj) following_7/VBG (r_prep) develop_3/VBP (l_nsubj) rats_1/NNS (l_amod) Dehydrated_0/JJ
D000617_D058186 CID aminoglycoside_11/JJ (r_compound) antibiotics_12/NNS (r_pobj) of_10/IN (r_prep) injection_9/NN (r_pobj) following_7/VBG (r_prep) develop_3/VBP (l_dobj) failure_6/NN
C038936_D051437 NONE 6,3-dilactone_13/CD (r_nummod) D_9/NNP (r_nmod) rats_15/NNS (l_prep) against_16/IN (l_pobj) failure_18/NN
D007612_D051437 NONE kanamycin_21/NN (r_npadvmod) dextran_23/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) failure_18/NN
D000617_D007674 NONE aminoglycoside_16/NN (r_compound) antibitocis_17/NNS (r_conj) antibiotics_11/NNS (r_pobj) by_9/IN (r_agent) induced_8/VBN (r_acl) damage_7/NN
D009005_D007674 NONE monosaccharides_12/NNS (r_pobj) by_11/IN (r_prep) lesions_10/NNS
2933998
D017265_D001249 NONE Procaterol_0/NNP (l_conj) terbutaline_2/NN (l_prep) in_3/IN (l_pobj) asthma_5/NN
D017265_D001249 NONE Procaterol_0/NNP (r_nsubjpass) studied_9/VBN (l_prep) in_10/IN (l_pobj) trial_23/NN (l_prep) in_24/IN (l_pobj) patients_25/NNS (l_prep) with_26/IN (l_pobj) asthma_28/NN
D017265_D001249 NONE procaterol_8/JJ (r_pobj) of_7/IN (r_prep) effects_6/NNS (l_amod) asthmatic_3/JJ
D013726_D001249 NONE terbutaline_2/NN (l_prep) in_3/IN (l_pobj) asthma_5/NN
D017265_D014202 CID procaterol_8/JJ (r_pobj) of_7/IN (r_prep) effects_6/NNS (l_amod) asthmatic_3/JJ (l_conj) tremorgenic_5/JJ
24975837
D002945_D058186 CID cisplatin_7/NN (r_npadvmod) induced_9/VBN (r_amod) injury_12/NN
D002945_D058186 CID Cisplatin_0/JJ (r_compound) treatment_1/NN (r_nsubjpass) adopted_4/VBN (r_ccomp) induce_14/VB (l_dobj) injury_17/NN
D002945_D058186 CID cisplatin_10/NN (r_npadvmod) induced_12/VBN (r_amod) injury_15/NN
D002945_D058186 CID cisplatin_25/NN (r_pobj) with_24/IN (r_prep) challenged_23/VBN (l_advcl) examine_1/VB (l_dobj) role_3/NN (l_prep) of_4/IN (l_pobj) receptor_8/NN (l_prep) in_9/IN (l_pobj) injury_15/NN
D002945_D058186 CID cisplatin_13/NN (r_npadvmod) induced_15/VBN (r_amod) injury_18/NN
D002945_D007683 CID Cisplatin_0/JJ (r_compound) treatment_1/NN (r_nsubjpass) adopted_4/VBN (r_ccomp) induce_14/VB (l_conj) augment_27/VB (l_conj) increase_35/VB (l_dobj) score_40/NN (l_compound) necrosis_39/NN
D003404_D058186 NONE creatinine_31/NN (r_pobj) of_30/IN (r_prep) levels_29/NNS (r_dobj) augment_27/VB (r_conj) induce_14/VB (l_dobj) injury_17/NN
D003404_D007683 NONE creatinine_31/NN (r_pobj) of_30/IN (r_prep) levels_29/NNS (r_dobj) augment_27/VB (l_conj) increase_35/VB (l_dobj) score_40/NN (l_compound) necrosis_39/NN
D014508_D058186 NONE urea_33/NN (r_conj) creatinine_31/NN (r_pobj) of_30/IN (r_prep) levels_29/NNS (r_dobj) augment_27/VB (r_conj) induce_14/VB (l_dobj) injury_17/NN
D014508_D007683 NONE urea_33/NN (r_conj) creatinine_31/NN (r_pobj) of_30/IN (r_prep) levels_29/NNS (r_dobj) augment_27/VB (l_conj) increase_35/VB (l_dobj) score_40/NN (l_compound) necrosis_39/NN
D002945_D009336 NONE cisplatin_13/NN (r_npadvmod) induced_15/VBN (r_amod) injury_18/NN (r_pobj) in_12/IN (r_prep) involved_11/VBN (l_prep) by_19/IN (l_pcomp) mediating_20/VBG (l_dobj) process_23/NN (l_amod) necrotic_22/JJ
D002945_D007674 NONE cisplatin_15/NN (r_compound) therapy_16/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) nephrotoxicity_12/NN
20959502
D017576_D008581 NONE daptomycin_7/NNS (r_pobj) of_3/IN (r_prep) penetration_2/NN (l_prep) in_8/IN (l_pobj) meningitis_12/NN
D017576_D008581 NONE daptomycin_23/NNS (r_pobj) with_19/IN (r_prep) treated_18/VBN (r_acl) case_3/NN (l_prep) of_4/IN (l_pobj) aureus_9/NN (l_appos) bacteremia_13/NN (l_prep) with_14/IN (l_pobj) meningitis_17/NN
D017576_D008581 NONE daptomycin_4/NNP (r_nsubjpass) initiated_9/VBN (l_prep) for_10/IN (l_pobj) meningitis_12/NN
D008712_D016470 NONE methicillin_5/NN (r_npadvmod) sensitive_7/JJ (r_amod) aureus_9/NN (l_appos) bacteremia_13/NN
D008712_D008581 NONE methicillin_5/NN (r_npadvmod) sensitive_7/JJ (r_amod) aureus_9/NN (l_appos) bacteremia_13/NN (l_prep) with_14/IN (l_pobj) meningitis_17/NN
D017576_D016470 NONE daptomycin_23/NNS (r_pobj) with_19/IN (r_prep) treated_18/VBN (r_acl) case_3/NN (l_prep) of_4/IN (l_pobj) aureus_9/NN (l_appos) bacteremia_13/NN
D017576_D016470 NONE Daptomycin_0/NNP (r_nsubjpass) initiated_2/VBN (l_advmod) secondary_6/JJ (l_prep) to_7/IN (l_pobj) nephritis_14/NN (l_conj) bacteremia_17/NN
D017576_D016470 NONE daptomycin_3/NN (r_nsubj) be_5/VB (l_attr) option_8/NN (l_prep) for_9/IN (l_pobj) bacteremia_11/NN
D003404_D058186 NONE creatinine_12/NN (r_appos) failure_9/NN
D009254_D008581 NONE Nafcillin_0/NNP (r_nsubj) was_1/VBD (r_auxpass) discontinued_2/VBN (l_conj) initiated_9/VBN (l_prep) for_10/IN (l_pobj) meningitis_12/NN
D017576_D009395 NONE Daptomycin_0/NNP (r_nsubjpass) initiated_2/VBN (l_advmod) secondary_6/JJ (l_prep) to_7/IN (l_pobj) nephritis_14/NN
D009254_D009395 CID nafcillin_9/NN (r_npadvmod) induced_11/VBN (r_amod) nephritis_14/NN
D009254_D016470 NONE nafcillin_9/NN (r_npadvmod) induced_11/VBN (r_amod) nephritis_14/NN (l_conj) bacteremia_17/NN
9197951
D003042_D001714 NONE cocaine_4/NN (r_npadvmod) dependent_6/JJ (r_amod) man_7/NN (r_nsubj) became_27/VBD (l_acomp) manic_28/JJ
D004053_D001714 CID diethylpropion_23/NN (r_pobj) of_19/IN (r_prep) efficacy_18/NN (r_dobj) evaluating_15/VBG (r_acl) study_14/NN (r_pobj) in_12/IN (r_prep) subject_11/NN (r_attr) was_9/VBD (r_relcl) man_7/NN (r_nsubj) became_27/VBD (l_acomp) manic_28/JJ
D004053_D001714 CID DEP_25/NNP (r_appos) diethylpropion_23/NN (r_pobj) of_19/IN (r_prep) efficacy_18/NN (r_dobj) evaluating_15/VBG (r_acl) study_14/NN (r_pobj) in_12/IN (r_prep) subject_11/NN (r_attr) was_9/VBD (r_relcl) man_7/NN (r_nsubj) became_27/VBD (l_acomp) manic_28/JJ
D004053_D001714 CID DEP_4/NNP (r_pobj) on_3/IN (r_prep) changes_1/NNS (r_nsubj) changes_7/VBZ (r_nsubj) were_16/VBD (l_acomp) different_18/JJ (l_prep) than_19/IN (l_pobj) those_20/DT (l_acl) observed_21/VBN (l_prep) in_22/IN (l_pobj) subjects_27/NNS (l_relcl) become_31/VB (l_acomp) manic_32/JJ
D004053_D011681 NONE DEP_4/NNP (r_pobj) on_3/IN (r_prep) changes_1/NNS (r_nsubj) changes_7/VBZ (l_prep) in_8/IN (l_pobj) power_11/NN (l_prep) of_12/IN (l_pobj) oscillation_14/NN
3088653
D012601_D000647 CID scopolamine_2/NN (r_npadvmod) induced_4/VBN (r_amod) amnesia_5/NN
D012601_D000647 CID Scopolamine_0/NN (r_nsubj) induced_13/VBD (l_dobj) amnesia_15/NN
D012601_D000647 CID scopolamine_21/NN (r_npadvmod) induced_23/VBN (r_amod) amnesia_24/NN
D009270_D000647 NONE naloxone_15/NN (r_pobj) by_9/IN (r_prep) avoidance_8/NN (r_pobj) of_6/IN (r_prep) amnesia_5/NN
D009270_D000647 NONE naloxone_5/NNP (r_pobj) of_4/IN (r_prep) administration_3/NN (r_nsubj) attenuated_19/VBD (l_dobj) amnesia_24/NN
D009270_D008569 NONE naloxone_11/NN (r_pobj) of_10/IN (r_prep) role_9/NN (l_prep) on_12/IN (l_pobj) deficit_18/NN
D009270_D008569 NONE Naloxone_0/NNP (r_nsubj) attenuated_16/VBD (l_dobj) deficit_19/NN
D009270_D008569 NONE naloxone_14/NN (r_appos) sensitivity_9/NN (r_pobj) in_7/IN (r_prep) increase_6/NN (r_nsubj) appear_27/VB (l_xcomp) be_29/VB (l_acomp) responsible_30/JJ (l_prep) for_31/IN (l_pobj) influence_33/NN (l_prep) on_36/IN (l_pobj) deficit_42/NN
D009270_D008569 NONE naloxone_25/NN (r_appos) state_20/NN (r_conj) increase_6/NN (r_nsubj) appear_27/VB (l_xcomp) be_29/VB (l_acomp) responsible_30/JJ (l_prep) for_31/IN (l_pobj) influence_33/NN (l_prep) on_36/IN (l_pobj) deficit_42/NN
D009270_D008569 NONE naloxone_35/NN (r_pobj) of_34/IN (r_prep) influence_33/NN (l_prep) on_36/IN (l_pobj) deficit_42/NN
D012601_D008569 NONE scopolamine_14/NN (r_npadvmod) induced_16/VBN (r_amod) deficit_18/NN
D012601_D008569 NONE scopolamine_38/NN (r_npadvmod) induced_40/VBN (r_amod) deficit_42/NN
D019832_D000647 NONE scopolamine_5/NN (r_conj) Scopolamine_0/NN (r_nsubj) induced_13/VBD (l_dobj) amnesia_15/NN
D009270_D010146 NONE naloxone_14/NN (r_appos) sensitivity_9/NN (l_compound) pain_8/NN
D009270_D010146 NONE naloxone_25/NN (r_appos) state_20/NN (r_conj) increase_6/NN (l_prep) in_7/IN (l_pobj) sensitivity_9/NN (l_compound) pain_8/NN
D009270_D010146 NONE naloxone_35/NN (r_pobj) of_34/IN (r_prep) influence_33/NN (r_pobj) for_31/IN (r_prep) responsible_30/JJ (r_acomp) be_29/VB (r_xcomp) appear_27/VB (l_nsubj) increase_6/NN (l_prep) in_7/IN (l_pobj) sensitivity_9/NN (l_compound) pain_8/NN
D012601_D010146 NONE scopolamine_38/NN (r_npadvmod) induced_40/VBN (r_amod) deficit_42/NN (r_pobj) on_36/IN (r_prep) influence_33/NN (r_pobj) for_31/IN (r_prep) responsible_30/JJ (r_acomp) be_29/VB (r_xcomp) appear_27/VB (l_nsubj) increase_6/NN (l_prep) in_7/IN (l_pobj) sensitivity_9/NN (l_compound) pain_8/NN
24132704
C029036_D006949 NONE Crocin_0/NNP (r_nsubj) reduced_1/VBD (l_dobj) inhibition_2/NN (l_prep) of_3/IN (l_pobj) activation_5/NN (l_conj) hyperlipemia_10/NN
C029036_D006949 NONE Crocin_0/NNP (r_nsubjpass) considered_3/VBN (l_prep) as_4/IN (l_pobj) agent_8/NN (l_prep) in_9/IN (l_pobj) hyperlipemia_13/NN
D003976_D006949 CID diazinon_7/NN (r_npadvmod) induced_9/VBN (r_amod) hyperlipemia_10/NN
D003976_D006949 CID diazinon_10/NNP (r_npadvmod) induced_12/VBN (r_amod) hyperlipemia_13/NN
1361574
D002243_D012640 NONE carboline_8/NN (r_pobj) of_4/IN (r_prep) mg/kg_3/CD (r_nsubj) reduced_9/VBD (l_dobj) increase_12/NN (l_prep) of_13/IN (l_pobj) binding_16/VBG (l_conj) convulsions_19/NNS
C037476_D012640 NONE 35S]TBPS_15/CD (r_nummod) binding_16/VBG (l_conj) convulsions_19/NNS
D007538_D012640 CID isoniazid_22/NNP (r_pobj) by_21/IN (r_agent) induced_20/VBN (r_acl) convulsions_19/NNS
2983630
D002110_D016584 NONE caffeine_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) in_5/IN (l_pobj) disorders_7/NNS
D002110_D016584 NONE caffeine_6/NNP (r_pobj) of_5/IN (r_prep) administration_4/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) determined_31/VBN (l_prep) in_32/IN (l_pobj) subjects_35/NNS (l_conj) patients_38/NNS (l_acl) meeting_39/VBG (l_prep) with_46/IN (l_pobj) attacks_48/NNS
D002110_D016584 NONE caffeine_6/NNP (r_pobj) of_5/IN (r_prep) administration_4/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) determined_31/VBN (l_prep) in_32/IN (l_pobj) subjects_35/NNS (l_conj) patients_38/NNS (l_acl) meeting_39/VBG (l_prep) with_46/IN (l_pobj) attacks_48/NNS (l_conj) disorder_51/NN
D002110_D016584 NONE caffeine_13/NN (r_pobj) of_12/IN (r_prep) effects_11/NNS (r_nsubj) were_14/VBD (l_acomp) similar_15/JJ (l_prep) to_16/IN (l_pobj) those_17/DT (l_acl) experienced_18/VBN (l_prep) during_19/IN (l_pobj) attacks_21/NNS
D002110_D016584 NONE caffeine_1/NN (r_nsubj) is_2/VBZ (r_advcl) suggest_10/VBP (l_ccomp) have_17/VB (l_nsubj) patients_15/NNS (l_compound) disorder_14/NN
D002110_D000379 NONE caffeine_6/NNP (r_pobj) of_5/IN (r_prep) administration_4/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) determined_31/VBN (l_prep) in_32/IN (l_pobj) subjects_35/NNS (l_conj) patients_38/NNS (l_acl) meeting_39/VBG (l_dobj) criteria_43/NNS (l_prep) for_44/IN (l_pobj) agoraphobia_45/NN
D008734_D000379 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24/CD (r_nummod) MHPG_26/NNP (r_pobj) of_23/IN (r_prep) levels_22/NNS (r_conj) pressure_19/NN (r_conj) symptoms_16/NNS (r_conj) ratings_13/NNS (r_pobj) on_11/IN (r_prep) effects_1/NNS (r_nsubjpass) determined_31/VBN (l_prep) in_32/IN (l_pobj) subjects_35/NNS (l_conj) patients_38/NNS (l_acl) meeting_39/VBG (l_dobj) criteria_43/NNS (l_prep) for_44/IN (l_pobj) agoraphobia_45/NN
D008734_D000379 NONE MHPG_26/NNP (r_pobj) of_23/IN (r_prep) levels_22/NNS (r_conj) pressure_19/NN (r_conj) symptoms_16/NNS (r_conj) ratings_13/NNS (r_pobj) on_11/IN (r_prep) effects_1/NNS (r_nsubjpass) determined_31/VBN (l_prep) in_32/IN (l_pobj) subjects_35/NNS (l_conj) patients_38/NNS (l_acl) meeting_39/VBG (l_dobj) criteria_43/NNS (l_prep) for_44/IN (l_pobj) agoraphobia_45/NN
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24/CD (r_nummod) MHPG_26/NNP (r_pobj) of_23/IN (r_prep) levels_22/NNS (r_conj) pressure_19/NN (r_conj) symptoms_16/NNS (r_conj) ratings_13/NNS (r_pobj) on_11/IN (r_prep) effects_1/NNS (r_nsubjpass) determined_31/VBN (l_prep) in_32/IN (l_pobj) subjects_35/NNS (l_conj) patients_38/NNS (l_acl) meeting_39/VBG (l_prep) with_46/IN (l_pobj) attacks_48/NNS
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24/CD (r_nummod) MHPG_26/NNP (r_pobj) of_23/IN (r_prep) levels_22/NNS (r_conj) pressure_19/NN (r_conj) symptoms_16/NNS (r_conj) ratings_13/NNS (r_pobj) on_11/IN (r_prep) effects_1/NNS (r_nsubjpass) determined_31/VBN (l_prep) in_32/IN (l_pobj) subjects_35/NNS (l_conj) patients_38/NNS (l_acl) meeting_39/VBG (l_prep) with_46/IN (l_pobj) attacks_48/NNS (l_conj) disorder_51/NN
D008734_D016584 NONE MHPG_26/NNP (r_pobj) of_23/IN (r_prep) levels_22/NNS (r_conj) pressure_19/NN (r_conj) symptoms_16/NNS (r_conj) ratings_13/NNS (r_pobj) on_11/IN (r_prep) effects_1/NNS (r_nsubjpass) determined_31/VBN (l_prep) in_32/IN (l_pobj) subjects_35/NNS (l_conj) patients_38/NNS (l_acl) meeting_39/VBG (l_prep) with_46/IN (l_pobj) attacks_48/NNS
D008734_D016584 NONE MHPG_26/NNP (r_pobj) of_23/IN (r_prep) levels_22/NNS (r_conj) pressure_19/NN (r_conj) symptoms_16/NNS (r_conj) ratings_13/NNS (r_pobj) on_11/IN (r_prep) effects_1/NNS (r_nsubjpass) determined_31/VBN (l_prep) in_32/IN (l_pobj) subjects_35/NNS (l_conj) patients_38/NNS (l_acl) meeting_39/VBG (l_prep) with_46/IN (l_pobj) attacks_48/NNS (l_conj) disorder_51/NN
D006854_D000379 NONE cortisol_29/NN (r_conj) pressure_19/NN (r_conj) symptoms_16/NNS (r_conj) ratings_13/NNS (r_pobj) on_11/IN (r_prep) effects_1/NNS (r_nsubjpass) determined_31/VBN (l_prep) in_32/IN (l_pobj) subjects_35/NNS (l_conj) patients_38/NNS (l_acl) meeting_39/VBG (l_dobj) criteria_43/NNS (l_prep) for_44/IN (l_pobj) agoraphobia_45/NN
D006854_D016584 NONE cortisol_29/NN (r_conj) pressure_19/NN (r_conj) symptoms_16/NNS (r_conj) ratings_13/NNS (r_pobj) on_11/IN (r_prep) effects_1/NNS (r_nsubjpass) determined_31/VBN (l_prep) in_32/IN (l_pobj) subjects_35/NNS (l_conj) patients_38/NNS (l_acl) meeting_39/VBG (l_prep) with_46/IN (l_pobj) attacks_48/NNS
D006854_D016584 NONE cortisol_29/NN (r_conj) pressure_19/NN (r_conj) symptoms_16/NNS (r_conj) ratings_13/NNS (r_pobj) on_11/IN (r_prep) effects_1/NNS (r_nsubjpass) determined_31/VBN (l_prep) in_32/IN (l_pobj) subjects_35/NNS (l_conj) patients_38/NNS (l_acl) meeting_39/VBG (l_prep) with_46/IN (l_pobj) attacks_48/NNS (l_conj) disorder_51/NN
D002110_D001008 CID Caffeine_0/NN (r_nsubj) produced_1/VBD (l_dobj) increases_4/NNS (l_prep) in_5/IN (l_pobj) fear_13/NN (l_nmod) anxiety_9/NN
D002110_D001008 CID caffeine_8/NN (r_npadvmod) containing_10/VBG (r_amod) foods_11/NNS (r_dobj) avoiding_7/VBG (r_pcomp) by_6/IN (r_prep) benefit_5/VB (l_nsubj) Patients_0/NNS (l_prep) with_1/IN (l_pobj) disorders_3/NNS
D002110_D009325 CID Caffeine_0/NN (r_nsubj) produced_1/VBD (l_dobj) increases_4/NNS (l_prep) in_5/IN (l_pobj) fear_13/NN (l_conj) nausea_15/NN
D002110_-1 NONE Caffeine_0/NN (r_nsubj) produced_1/VBD (l_dobj) increases_4/NNS (l_prep) in_5/IN (l_pobj) fear_13/NN (l_conj) nausea_15/NN (l_conj) palpitations_17/NNS
D002110_D011595 NONE Caffeine_0/NN (r_nsubj) produced_1/VBD (l_dobj) increases_4/NNS (l_prep) in_5/IN (l_pobj) fear_13/NN (l_conj) nausea_15/NN (l_conj) palpitations_17/NNS (l_conj) restlessness_19/NN
D002110_D014202 CID Caffeine_0/NN (r_nsubj) produced_1/VBD (l_dobj) increases_4/NNS (l_prep) in_5/IN (l_pobj) fear_13/NN (l_conj) nausea_15/NN (l_conj) palpitations_17/NNS (l_conj) restlessness_19/NN (l_conj) tremors_22/NNS
D002110_D009421 NONE caffeine_1/NN (r_nsubj) is_2/VBZ (r_advcl) suggest_10/VBP (l_ccomp) have_17/VB (l_dobj) abnormalities_18/NNS (l_prep) in_19/IN (l_pobj) systems_21/NNS
D000241_D016584 NONE adenosine_4/NN (r_compound) receptor_5/NN (r_compound) antagonist_6/NN (r_attr) is_2/VBZ (r_advcl) suggest_10/VBP (l_ccomp) have_17/VB (l_nsubj) patients_15/NNS (l_compound) disorder_14/NN
D000241_D016584 NONE adenosine_23/NN (r_dobj) involving_22/VBG (r_acl) systems_21/NNS (r_pobj) in_19/IN (r_prep) abnormalities_18/NNS (r_dobj) have_17/VB (l_nsubj) patients_15/NNS (l_compound) disorder_14/NN
D000241_D009421 NONE adenosine_4/NN (r_compound) receptor_5/NN (r_compound) antagonist_6/NN (r_attr) is_2/VBZ (r_advcl) suggest_10/VBP (l_ccomp) have_17/VB (l_dobj) abnormalities_18/NNS (l_prep) in_19/IN (l_pobj) systems_21/NNS
D000241_D009421 NONE adenosine_23/NN (r_dobj) involving_22/VBG (r_acl) systems_21/NNS
24284476
D047310_D000647 NONE apigenin_2/NNP (r_nsubj) prevent_5/VB (l_dobj) amnesia_7/NN
D012601_D000647 CID scopolamine_10/NN (r_pobj) by_9/IN (r_agent) induced_8/VBN (r_acl) amnesia_7/NN
7121659
D012293_D051437 NONE rifampicin_4/NNS (r_npadvmod) associated_6/VBN (r_amod) failure_8/NN
D012293_D058186 NONE rifampicin_18/NNS (r_pobj) of_17/IN (r_prep) reintroduction_16/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) 3_7/CD (r_appos) patients_1/NNS (l_prep) with_2/IN (l_pobj) failure_5/NN
D012293_D013921 CID rifampicin_18/NNS (r_pobj) of_17/IN (r_prep) reintroduction_16/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) 3_7/CD (l_prep) with_8/IN (l_pobj) thrombopenia_9/NNP
D012293_D006461 CID rifampicin_18/NNS (r_pobj) of_17/IN (r_prep) reintroduction_16/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) 3_7/CD (l_prep) with_8/IN (l_pobj) thrombopenia_9/NNP (l_conj) hemolysis_11/NN
19263707
D002231_D056648 CID Carbimazole_0/NNP (r_nsubj) induced_1/VBD (l_dobj) vasculitis_4/NN
D013956_D006980 NONE drugs_3/NNS (r_nsubjpass) prescribed_14/VBN (l_prep) for_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) hyperthyroidism_19/NN
D002231_D006980 NONE carbimazole_6/NNP (r_pobj) like_5/IN (r_prep) drugs_3/NNS (r_nsubjpass) prescribed_14/VBN (l_prep) for_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) hyperthyroidism_19/NN
D011441_D006980 NONE propylthiouracil_8/NNP (r_conj) carbimazole_6/NNP (r_pobj) like_5/IN (r_prep) drugs_3/NNS (r_nsubjpass) prescribed_14/VBN (l_prep) for_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) hyperthyroidism_19/NN
D011441_D006980 NONE PTU_10/NNP (r_appos) propylthiouracil_8/NNP (r_conj) carbimazole_6/NNP (r_pobj) like_5/IN (r_prep) drugs_3/NNS (r_nsubjpass) prescribed_14/VBN (l_prep) for_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) hyperthyroidism_19/NN
D013956_D056648 CID antithyroidmedications_15/NNS (r_pobj) of_14/IN (r_prep) effect_13/NN (r_attr) is_6/VBZ (l_nsubj) antibody_2/NN (l_appos) vasculitis_5/NN
D002231_D006111 NONE carbimazole_12/NNP (r_npadvmod) induced_13/VBD (r_amod) vasculitis_14/NN (r_dobj) developed_9/VBD (r_relcl) patient_3/NN (l_prep) with_4/IN (l_pobj) disease_7/NN
D002231_D014657 NONE carbimazole_12/NNP (r_npadvmod) induced_13/VBD (r_amod) vasculitis_14/NN
D002231_D014657 NONE carbimazole_6/NN (r_nsubj) induced_7/VBD (r_amod) case_9/NN (l_amod) vasculitis_8/JJ
3533179
D003520_D066126 NONE Cyclophosphamide_0/NNP (r_compound) cardiotoxicity_1/NN
D003520_D066126 NONE CYA_5/NNP (r_pobj) of_4/IN (r_prep) doses_3/NNS (r_pobj) At_0/IN (r_prep) occur_10/VB (l_nsubj) cardiotoxicity_8/NN
D003520_D066126 NONE CYA_5/NNP (r_pobj) of_4/IN (r_prep) doses_3/NNS (r_pobj) At_0/IN (r_prep) occur_10/VB (l_conj) described_25/VBN (l_nsubjpass) factors_15/NNS (l_prep) for_16/IN (l_pobj) development_18/NN (l_prep) of_19/IN (l_pobj) cardiotoxicity_21/NN
D003520_D066126 NONE CYA_19/NN (r_pobj) of_18/IN (r_prep) dose_17/NN (l_prep) in_20/IN (l_pobj) patients_21/NNS (l_acl) transplanted_22/VBN (l_advcl) determine_27/VB (l_ccomp) correlated_34/VBN (l_nsubj) incidence_30/NN (l_prep) of_31/IN (l_pobj) cardiotoxicity_33/NN
D003520_D066126 NONE CYA_32/NNP (r_compound) cardiotoxicity_33/NN
D003520_D066126 NONE CYA_14/JJ (r_compound) cardiotoxicity_15/NN
D003520_D066126 NONE CYA_26/NNP (r_pobj) of_25/IN (r_prep) doses_24/NNS (r_dobj) receiving_20/VBG (r_pcomp) of_19/IN (r_prep) days_18/NNS (r_pobj) within_16/IN (r_prep) had_8/VBD (l_dobj) symptoms_9/NNS (l_conj) signs_11/NNS (l_amod) consistent_12/JJ (l_prep) with_13/IN (l_pobj) cardiotoxicity_15/NN
D003520_D066126 NONE CYA_8/NNP (r_pobj) to_7/IN (r_prep) related_6/VBN (r_xcomp) thought_3/VBN (r_relcl) Cardiotoxicity_0/NNP
D003520_D066126 NONE CYA_4/NNP (r_compound) cardiotoxicity_5/NN
D003520_D066126 NONE CYA_4/NNP (r_compound) cardiotoxicity_5/NN (r_nsubj) correlates_6/VBZ (l_conj) prepared_28/VBN (l_prep) for_29/IN (l_pobj) grafting_32/NN (l_prep) with_47/IN (l_pobj) incidence_50/NN (l_prep) of_51/IN (l_pobj) cardiotoxicity_52/NN
D003520_D066126 NONE CYA_8/JJ (r_compound) dosage_9/NN (r_pobj) with_7/IN (r_prep) correlates_6/VBZ (l_nsubj) cardiotoxicity_5/NN
D003520_D066126 NONE CYA_8/JJ (r_compound) dosage_9/NN (r_pobj) with_7/IN (r_prep) correlates_6/VBZ (l_conj) prepared_28/VBN (l_prep) for_29/IN (l_pobj) grafting_32/NN (l_prep) with_47/IN (l_pobj) incidence_50/NN (l_prep) of_51/IN (l_pobj) cardiotoxicity_52/NN
D003520_D066126 NONE CYA_35/NNP (r_compound) dose_36/NN (r_pobj) at_33/IN (r_prep) grafting_32/NN (r_pobj) for_29/IN (r_prep) prepared_28/VBN (r_conj) correlates_6/VBZ (l_nsubj) cardiotoxicity_5/NN
D003520_D066126 NONE CYA_35/NNP (r_compound) dose_36/NN (r_pobj) at_33/IN (r_prep) grafting_32/NN (l_prep) with_47/IN (l_pobj) incidence_50/NN (l_prep) of_51/IN (l_pobj) cardiotoxicity_52/NN
D003520_D066126 NONE CYA_56/JJ (r_compound) dosage_57/NN (r_nsubjpass) calculated_59/VBN (r_relcl) patients_54/NNS (r_pobj) than_53/IN (r_prep) incidence_50/NN (r_pobj) with_47/IN (r_prep) grafting_32/NN (r_pobj) for_29/IN (r_prep) prepared_28/VBN (r_conj) correlates_6/VBZ (l_nsubj) cardiotoxicity_5/NN
D003520_D066126 NONE CYA_56/JJ (r_compound) dosage_57/NN (r_nsubjpass) calculated_59/VBN (r_relcl) patients_54/NNS (r_pobj) than_53/IN (r_prep) incidence_50/NN (l_prep) of_51/IN (l_pobj) cardiotoxicity_52/NN
D003520_D064420 NONE CYA_19/NN (r_pobj) of_18/IN (r_prep) dose_17/NN (r_dobj) calculated_15/VBD (l_advcl) correlates_5/VBZ (l_nsubj) toxicity_3/NN
D003520_D064420 NONE CYA_32/NNP (r_compound) cardiotoxicity_33/NN (r_pobj) of_31/IN (r_prep) incidence_30/NN (r_nsubj) correlated_34/VBN (r_ccomp) determine_27/VB (r_advcl) transplanted_22/VBN (r_acl) patients_21/NNS (r_pobj) in_20/IN (r_prep) dose_17/NN (r_dobj) calculated_15/VBD (l_advcl) correlates_5/VBZ (l_nsubj) toxicity_3/NN
D003520_D000741 NONE CYA_6/NNP (r_dobj) receive_5/VB (r_xcomp) were_3/VBD (r_relcl) patients_1/NNS (r_nsubj) underwent_21/VBD (l_dobj) total_23/NN (l_prep) of_24/IN (l_pobj) transplants_26/NNS (l_prep) for_27/IN (l_pobj) anemia_29/NN
D003520_D000741 NONE CYA_4/NNP (r_compound) cardiotoxicity_5/NN (r_nsubj) correlates_6/VBZ (l_conj) prepared_28/VBN (l_nsubjpass) patients_19/NNS (l_prep) with_20/IN (l_pobj) anemia_22/NN
D003520_D000741 NONE CYA_8/JJ (r_compound) dosage_9/NN (r_pobj) with_7/IN (r_prep) correlates_6/VBZ (l_conj) prepared_28/VBN (l_nsubjpass) patients_19/NNS (l_prep) with_20/IN (l_pobj) anemia_22/NN
D003520_D000741 NONE CYA_35/NNP (r_compound) dose_36/NN (r_pobj) at_33/IN (r_prep) grafting_32/NN (r_pobj) for_29/IN (r_prep) prepared_28/VBN (l_nsubjpass) patients_19/NNS (l_prep) with_20/IN (l_pobj) anemia_22/NN
D003520_D000741 NONE CYA_56/JJ (r_compound) dosage_57/NN (r_nsubjpass) calculated_59/VBN (r_relcl) patients_54/NNS (r_pobj) than_53/IN (r_prep) incidence_50/NN (r_pobj) with_47/IN (r_prep) grafting_32/NN (r_pobj) for_29/IN (r_prep) prepared_28/VBN (l_nsubjpass) patients_19/NNS (l_prep) with_20/IN (l_pobj) anemia_22/NN
D003520_D014923 NONE CYA_6/NNP (r_dobj) receive_5/VB (r_xcomp) were_3/VBD (r_relcl) patients_1/NNS (r_nsubj) underwent_21/VBD (l_dobj) total_23/NN (l_appos) syndrome_34/NN
D003520_D016511 NONE CYA_6/NNP (r_dobj) receive_5/VB (r_xcomp) were_3/VBD (r_relcl) patients_1/NNS (r_nsubj) underwent_21/VBD (l_dobj) total_23/NN (l_appos) syndrome_34/NN (l_conj) syndrome_40/NN
D003520_D007153 NONE CYA_4/NNP (r_compound) cardiotoxicity_5/NN (r_nsubj) correlates_6/VBZ (l_conj) prepared_28/VBN (l_nsubjpass) patients_19/NNS (l_prep) with_20/IN (l_pobj) anemia_22/NN (l_conj) immunodeficiencies_24/NN
D003520_D007153 NONE CYA_8/JJ (r_compound) dosage_9/NN (r_pobj) with_7/IN (r_prep) correlates_6/VBZ (l_conj) prepared_28/VBN (l_nsubjpass) patients_19/NNS (l_prep) with_20/IN (l_pobj) anemia_22/NN (l_conj) immunodeficiencies_24/NN
D003520_D007153 NONE CYA_35/NNP (r_compound) dose_36/NN (r_pobj) at_33/IN (r_prep) grafting_32/NN (r_pobj) for_29/IN (r_prep) prepared_28/VBN (l_nsubjpass) patients_19/NNS (l_prep) with_20/IN (l_pobj) anemia_22/NN (l_conj) immunodeficiencies_24/NN
D003520_D007153 NONE CYA_56/JJ (r_compound) dosage_57/NN (r_nsubjpass) calculated_59/VBN (r_relcl) patients_54/NNS (r_pobj) than_53/IN (r_prep) incidence_50/NN (r_pobj) with_47/IN (r_prep) grafting_32/NN (r_pobj) for_29/IN (r_prep) prepared_28/VBN (l_nsubjpass) patients_19/NNS (l_prep) with_20/IN (l_pobj) anemia_22/NN (l_conj) immunodeficiencies_24/NN
24114426
D018817_D003866 CID 3,4-methylenedioxymethamphetamine_15/CD (r_nummod) ecstasy_19/NN (r_pobj) of_14/IN (r_prep) users_13/NNS (r_pobj) in_8/IN (r_prep) Depression_0/NN
D018817_D003866 CID MDMA_17/NNP (r_nmod) ecstasy_19/NN (r_pobj) of_14/IN (r_prep) users_13/NNS (r_pobj) in_8/IN (r_prep) Depression_0/NN
D018817_D003866 CID ecstasy_19/NN (r_pobj) of_14/IN (r_prep) users_13/NNS (r_pobj) in_8/IN (r_prep) Depression_0/NN
D018817_D003866 CID ecstasy_26/NN (r_compound) users_27/NNS (r_pobj) of_25/IN (r_prep) generation_24/NN (r_pobj) for_21/IN (r_prep) prognosis_20/NN (r_nsubj) is_28/VBZ (l_prep) Given_0/VBN (l_pobj) record_2/NN (l_prep) of_3/IN (l_pobj) memory_5/NN (l_conj) levels_9/NNS (l_prep) of_10/IN (l_pobj) depression_11/NN
D018817_D010554 CID 3,4-methylenedioxymethamphetamine_15/CD (r_nummod) ecstasy_19/NN (r_pobj) of_14/IN (r_prep) users_13/NNS (r_pobj) in_8/IN (r_prep) Depression_0/NN (l_conj) impulsiveness_2/NN
D018817_D010554 CID MDMA_17/NNP (r_nmod) ecstasy_19/NN (r_pobj) of_14/IN (r_prep) users_13/NNS (r_pobj) in_8/IN (r_prep) Depression_0/NN (l_conj) impulsiveness_2/NN
D018817_D010554 CID ecstasy_19/NN (r_pobj) of_14/IN (r_prep) users_13/NNS (r_pobj) in_8/IN (r_prep) Depression_0/NN (l_conj) impulsiveness_2/NN
D018817_D010554 CID ecstasy_26/NN (r_compound) users_27/NNS (r_pobj) of_25/IN (r_prep) generation_24/NN (r_pobj) for_21/IN (r_prep) prognosis_20/NN (r_nsubj) is_28/VBZ (l_prep) Given_0/VBN (l_pobj) record_2/NN (l_prep) of_3/IN (l_pobj) memory_5/NN (l_conj) levels_9/NNS (l_prep) of_10/IN (l_pobj) depression_11/NN (l_conj) impulsiveness_13/NN
D018817_D008569 NONE ecstasy_26/NN (r_compound) users_27/NNS (r_pobj) of_25/IN (r_prep) generation_24/NN (r_pobj) for_21/IN (r_prep) prognosis_20/NN (r_nsubj) is_28/VBZ (l_prep) Given_0/VBN (l_pobj) record_2/NN (l_prep) of_3/IN (l_pobj) memory_5/NN
D018817_D020920 CID ecstasy_26/NN (r_compound) users_27/NNS (r_pobj) of_25/IN (r_prep) generation_24/NN (r_pobj) for_21/IN (r_prep) prognosis_20/NN (r_nsubj) is_28/VBZ (l_prep) Given_0/VBN (l_pobj) record_2/NN (l_prep) of_3/IN (l_pobj) memory_5/NN (l_conj) levels_9/NNS (l_prep) of_10/IN (l_pobj) depression_11/NN (l_conj) impulsiveness_13/NN (l_conj) disturbance_17/NN
15096374
D016559_D003872 NONE tacrolimus_11/NN (r_compound) ointment_12/NN (r_pobj) with_10/IN (r_prep) treatment_5/NN (r_pobj) during_4/IN (r_prep) Induction_0/NN (l_prep) of_1/IN (l_pobj) dermatitis_3/NN
D016559_D003872 NONE tacrolimus_11/NN (r_compound) ointment_12/NN (r_pobj) with_10/IN (r_prep) treatment_9/NN (r_pobj) of_8/IN (r_prep) complication_7/NN (r_pobj) as_5/IN (r_prep) report_1/VBP (l_prep) on_2/IN (l_pobj) dermatitis_4/NN
D016559_D003872 NONE tacrolimus_15/NN (r_compound) ointment_16/NN (r_pobj) with_14/IN (r_prep) treatment_13/NN (r_pobj) of_12/IN (r_prep) complication_11/NN (r_pobj) as_9/IN (r_prep) spectrum_5/NNP (l_prep) of_6/IN (l_pobj) dermatitis_8/NN
D016559_D005148 NONE tacrolimus_11/NN (r_compound) ointment_12/NN (r_pobj) with_10/IN (r_prep) treatment_5/NN (l_prep) of_6/IN (l_pobj) dermatoses_9/NNS
D016559_D005148 NONE tacrolimus_10/NN (r_compound) ointment_11/NN (r_pobj) with_9/IN (r_prep) treated_8/VBN (l_nsubjpass) patients_2/NNS (l_prep) with_3/IN (l_pobj) dermatoses_6/NNS
D016559_D012393 CID Tacrolimus_0/NN (r_compound) ointment_1/NN (r_nsubjpass) used_4/VBN (l_conj) indicate_21/VBP (l_ccomp) is_25/VBZ (l_prep) in_27/IN (l_pobj) rosacea_31/NN
D016559_D019557 NONE Tacrolimus_0/NN (r_compound) ointment_1/NN (r_nsubjpass) used_4/VBN (l_conj) indicate_21/VBP (l_ccomp) is_25/VBZ (l_prep) in_27/IN (l_pobj) rosacea_31/NN (l_conj) dermatitis_34/NN
D013256_D012393 NONE steroid_28/NN (r_npadvmod) aggravated_30/VBN (r_amod) rosacea_31/NN
D013256_D019557 NONE steroid_28/NN (r_npadvmod) aggravated_30/VBN (r_amod) rosacea_31/NN (l_conj) dermatitis_34/NN
448423
D000614_D013345 NONE acid_6/NN (r_compound) therapy_7/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (r_acl) hemorrhage_2/NN
D000614_D007674 NONE acid_6/NN (r_compound) therapy_7/NN (l_conj) thrombosis_12/NN
D015119_D013345 CID acid_2/NN (r_nsubjpass) used_8/VBN (l_xcomp) prevent_10/VB (l_dobj) rebleeding_11/NN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) hemorrhage_16/NN
D015119_D013345 CID acid_2/NN (r_nsubjpass) used_8/VBN (l_xcomp) prevent_10/VB (l_dobj) rebleeding_11/NN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) hemorrhage_16/NN (l_appos) SAH_18/NNP
D015119_D013345 CID EACA_4/NNP (r_appos) acid_2/NN (r_nsubjpass) used_8/VBN (l_xcomp) prevent_10/VB (l_dobj) rebleeding_11/NN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) hemorrhage_16/NN
D015119_D013345 CID EACA_4/NNP (r_appos) acid_2/NN (r_nsubjpass) used_8/VBN (l_xcomp) prevent_10/VB (l_dobj) rebleeding_11/NN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) hemorrhage_16/NN (l_appos) SAH_18/NNP
D015119_D013345 CID EACA_27/NNP (r_pobj) with_26/IN (r_prep) treated_25/VBN (r_acl) patients_21/NNS (r_pobj) in_20/IN (r_prep) thrombi_19/NNP (r_pobj) with_12/IN (l_pobj) SAH_13/NNP
D015119_D013345 CID EACA_4/NNP (r_compound) therapy_5/NN (l_prep) in_6/IN (l_pobj) patient_8/NN (l_prep) with_9/IN (l_pobj) SAH_10/NNP
D015119_D013345 CID EACA_4/NNP (r_compound) therapy_5/NN (l_prep) in_6/IN (l_pobj) patient_8/NN (l_prep) with_9/IN (l_pobj) SAH_10/NNP (l_conj) documentation_13/NN (l_prep) of_14/IN (l_pobj) SAH_16/NNP
D015119_D013927 CID EACA_17/NNP (r_compound) therapy_18/NN (r_pobj) of_16/IN (r_prep) complications_15/NNS (l_amod) thrombotic_14/JJ
D015119_D013927 CID EACA_27/NNP (r_pobj) with_26/IN (r_prep) treated_25/VBN (r_acl) patients_21/NNS (r_pobj) in_20/IN (r_prep) thrombi_19/NNP
D015119_D013927 CID EACA_13/NNP (r_nsubjpass) implicated_17/VBN (l_advcl) observed_6/VBN (l_nsubjpass) thrombi_3/NNS
D015119_D013927 CID EACA_13/NNP (r_nsubjpass) implicated_17/VBN (l_prep) in_18/IN (l_pobj) pathogenesis_20/NN (l_prep) of_21/IN (l_pobj) thrombi_23/NNP
D015119_D020767 CID EACA_27/NNP (r_pobj) with_26/IN (r_prep) treated_25/VBN (r_acl) patients_21/NNS (r_pobj) in_20/IN (r_prep) thrombi_19/NNP (r_pobj) with_12/IN (r_prep) patients_11/NNS (r_pobj) in_10/IN (r_prep) deterioration_5/NN (l_conj) thrombosis_9/NN
D015119_D013923 NONE EACA_27/NNP (l_conj) phenomena_32/NNS
D015119_D004211 NONE EACA_13/NNP (r_nsubjpass) implicated_17/VBN (l_prep) in_18/IN (l_pobj) pathogenesis_20/NN (l_prep) of_21/IN (l_pobj) thrombi_23/NNP (l_prep) in_24/IN (l_pobj) patients_25/NNS (l_prep) with_26/IN (l_pobj) coagulation_29/NN
D015119_D004211 NONE EACA_13/NNP (r_nsubjpass) implicated_17/VBN (l_prep) in_18/IN (l_pobj) pathogenesis_20/NN (l_prep) of_21/IN (l_pobj) thrombi_23/NNP (l_prep) in_24/IN (l_pobj) patients_25/NNS (l_prep) with_26/IN (l_pobj) coagulation_29/NN (l_conj) coagulopathies_34/NNS
25006369
C061870_D005207 NONE rocuronium_4/NN (r_pobj) of_3/IN (r_prep) dose_2/NN (l_acl) decrease_6/VB (l_dobj) fasciculation_7/NN
C061870_D005207 NONE rocuronium_8/NN (r_pobj) of_7/IN (r_prep) dose_6/NN (r_dobj) identified_3/VBD (l_advcl) prevent_10/VB (l_dobj) fasciculation_14/NN
C061870_D005207 NONE rocuronium_22/NN (r_pobj) of_21/IN (r_prep) influence_20/NN (r_dobj) evaluated_18/VBD (r_conj) prevent_10/VB (l_dobj) fasciculation_14/NN
C061870_D005207 NONE rocuronium_19/NN (r_pobj) of_18/IN (r_prep) dose_17/NN (r_pobj) of_15/IN (r_prep) amount_14/NN (r_dobj) increasing_12/VBG (r_pcomp) with_11/IN (r_prep) less_10/JJR (r_acomp) was_8/VBD (l_nsubj) incidence_1/NN (l_prep) of_4/IN (l_pobj) fasciculation_7/NN
C061870_D005207 NONE rocuronium_4/NN (r_pobj) with_1/IN (r_prep) Precurarization_0/NN (r_nsubj) was_5/VBD (l_attr) dose_8/NN (l_acl) considering_9/VBG (l_dobj) reduction_11/NN (l_prep) in_12/IN (l_pobj) incidence_14/NN (l_prep) of_17/IN (l_pobj) fasciculation_18/NN
C061870_D063806 NONE rocuronium_4/NN (r_pobj) of_3/IN (r_prep) dose_2/NN (l_acl) decrease_6/VB (l_dobj) fasciculation_7/NN (l_conj) myalgia_9/NN
C061870_D063806 NONE rocuronium_8/NN (r_pobj) of_7/IN (r_prep) dose_6/NN (r_dobj) identified_3/VBD (l_advcl) prevent_10/VB (l_dobj) fasciculation_14/NN (l_conj) myalgia_16/NN
C061870_D063806 NONE rocuronium_22/NN (r_pobj) of_21/IN (r_prep) influence_20/NN (r_dobj) evaluated_18/VBD (r_conj) prevent_10/VB (l_dobj) fasciculation_14/NN (l_conj) myalgia_16/NN
C061870_D063806 NONE rocuronium_15/NN (r_pobj) of_14/IN (r_prep) dose_13/NN (r_pobj) of_11/IN (r_prep) amount_10/NN (r_dobj) increasing_8/VBG (r_pcomp) to_7/IN (r_prep) according_6/VBG (r_prep) decrease_5/VB (r_xcomp) tend_3/VBP (l_nsubj) Those_0/DT (l_prep) of_1/IN (l_pobj) myalgia_2/NN
C061870_D063806 NONE rocuronium_4/NN (r_pobj) with_1/IN (r_prep) Precurarization_0/NN (r_nsubj) was_5/VBD (l_attr) dose_8/NN (l_acl) considering_9/VBG (l_dobj) reduction_11/NN (l_prep) in_12/IN (l_pobj) incidence_14/NN (l_prep) of_17/IN (l_pobj) fasciculation_18/NN (l_conj) myalgia_20/NN
D013390_D005207 CID succinylcholine_11/NNP (r_compound) administration_12/NN (r_pobj) following_10/VBG (r_prep) decrease_6/VB (l_dobj) fasciculation_7/NN
D013390_D005207 CID Succinylcholine_0/NNP (r_nsubj) produces_2/VBZ (l_dobj) effects_5/NNS (l_prep) including_7/VBG (l_pobj) fasciculation_9/NN
D013390_D005207 CID succinylcholine_11/NN (r_npadvmod) induced_13/VBN (r_amod) fasciculation_14/NN
D013390_D005207 CID succinylcholine_30/NN (r_pobj) by_29/IN (r_agent) produced_28/VBN (r_acl) onset_27/NN (r_pobj) of_26/IN (r_prep) speed_25/NN (r_pobj) on_23/IN (r_prep) evaluated_18/VBD (r_conj) prevent_10/VB (l_dobj) fasciculation_14/NN
D013390_D005207 CID succinylcholine_3/NN (r_dobj) received_2/VBD (l_conj) assessed_15/VBN (l_dobj) incidence_17/NN (l_prep) of_20/IN (l_pobj) fasciculations_21/NNS
D013390_D063806 CID succinylcholine_11/NNP (r_compound) administration_12/NN (r_pobj) following_10/VBG (r_prep) decrease_6/VB (l_dobj) fasciculation_7/NN (l_conj) myalgia_9/NN
D013390_D063806 CID Succinylcholine_0/NNP (r_nsubj) produces_2/VBZ (l_dobj) effects_5/NNS (l_prep) including_7/VBG (l_pobj) fasciculation_9/NN (l_conj) myalgia_11/NN
D013390_D063806 CID succinylcholine_11/NN (r_npadvmod) induced_13/VBN (r_amod) fasciculation_14/NN (l_conj) myalgia_16/NN
D013390_D063806 CID succinylcholine_30/NN (r_pobj) by_29/IN (r_agent) produced_28/VBN (r_acl) onset_27/NN (r_pobj) of_26/IN (r_prep) speed_25/NN (r_pobj) on_23/IN (r_prep) evaluated_18/VBD (r_conj) prevent_10/VB (l_dobj) fasciculation_14/NN (l_conj) myalgia_16/NN
D013390_D063806 CID succinylcholine_3/NN (r_dobj) received_2/VBD (l_conj) assessed_15/VBN (l_advcl) assessed_26/VBN (l_nsubjpass) myalgia_24/NNP
7411769
D007213_D006947 CID Indomethacin_0/NN (r_npadvmod) induced_2/VBN (r_amod) hyperkalemia_3/NN
D007213_D006947 CID indomethacin_23/NN (r_pobj) with_22/IN (r_prep) developed_15/VBN (r_acl) hyperkalemia_11/NN
D007213_D015210 NONE Indomethacin_0/NN (r_npadvmod) induced_2/VBN (r_amod) hyperkalemia_3/NN (l_prep) in_4/IN (l_pobj) patients_6/NNS (l_prep) with_7/IN (l_pobj) arthritis_9/NN
D007213_D015210 NONE indomethacin_23/NN (r_pobj) with_22/IN (r_prep) developed_15/VBN (l_prep) after_16/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) arthritis_21/NN
D007213_D051437 CID indomethacin_23/NN (r_pobj) with_22/IN (r_prep) developed_15/VBN (r_acl) hyperkalemia_11/NN (l_conj) insufficiency_14/NN
D011453_D006994 NONE prostaglandin_8/JJ (r_amod) synthesis_9/NN (l_conj) hypoaidosteronism_13/NN
D011188_D003920 NONE potassium_6/NN (r_compound) balance_7/NN (r_conj) function_4/NN (r_pobj) to_2/IN (r_prep) attention_1/NN (l_prep) in_21/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) mellitus_26/NN
D011188_D007674 NONE potassium_6/NN (r_compound) balance_7/NN (r_conj) function_4/NN (r_pobj) to_2/IN (r_prep) attention_1/NN (l_prep) in_21/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) mellitus_26/NN (l_conj) disease_30/NN
D007213_D003920 NONE indomethacin_11/NN (r_dobj) receiving_10/VBG (r_acl) patients_9/NNS (r_pobj) in_8/IN (r_prep) function_4/NN (r_pobj) to_2/IN (r_prep) attention_1/NN (l_prep) in_21/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) mellitus_26/NN
D007213_D007674 NONE indomethacin_11/NN (r_dobj) receiving_10/VBG (r_acl) patients_9/NNS (r_pobj) in_8/IN (r_prep) function_4/NN (r_pobj) to_2/IN (r_prep) attention_1/NN (l_prep) in_21/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) mellitus_26/NN (l_conj) disease_30/NN
16801510
D008691_D008133 CID methadone_11/NN (r_dobj) receiving_10/VBG (r_acl) users_9/NNS (r_pobj) in_6/IN (r_prep) syndrome_5/NN
D008691_D008133 CID methadone_12/NN (r_compound) treatment_13/NN (r_pobj) with_11/IN (r_prep) prolongation_10/NN
D008691_D008133 CID methadone_3/NN (r_pobj) to_2/IN (r_prep) addition_1/NN (r_pobj) In_0/IN (r_prep) considered_15/VBN (l_prep) as_16/IN (l_pobj) factors_19/NNS (l_prep) for_20/IN (l_pobj) prolongation_22/NN
D008691_D008133 CID methadone_4/NN (r_compound) maintenance_5/NN (r_compound) patients_6/NNS (r_pobj) in_3/IN (r_prep) prolongation_2/NN
D008691_D008133 CID Methadone_0/NNP (r_npadvmod) dose_1/NN (l_advcl) contribute_16/VBP (l_prep) to_17/IN (l_pobj) prolongation_19/NN
D008691_D008133 CID methadone_9/NN (r_pobj) of_8/IN (r_prep) doses_7/NNS (r_pobj) with_5/IN (r_prep) occur_4/VB (l_nsubj) syndrome_2/NN
D008691_D016171 NONE methadone_8/NN (r_compound) group_9/NN (r_pobj) in_6/IN (r_prep) patients_1/NNS (r_nsubj) presented_10/VBD (l_dobj) pointes_13/FW
D008691_D007008 NONE methadone_12/NN (r_npadvmod) dose_13/NN (r_acl) attribution_4/NN (l_conj) interactions_21/NNS (l_conj) hypokalemia_23/NN
D011188_D008133 NONE potassium_10/NN (r_compound) level_11/NN (r_conj) inhibitors_8/NNS (r_pobj) of_4/IN (r_prep) presence_3/NN (r_nsubj) contribute_16/VBP (l_prep) to_17/IN (l_pobj) prolongation_19/NN
24812279
D018943_D066126 NONE anthracycline_6/JJ (r_compound) cardiotoxicity_7/NN
D004317_D009369 NONE Doxorubicin_0/NNP (r_nsubj) is_4/VBZ (l_attr) therapeutic_10/JJ (l_amod) cancer_9/JJ
D004317_D009369 NONE DOX_2/NNP (r_appos) Doxorubicin_0/NNP (r_nsubj) is_4/VBZ (l_attr) therapeutic_10/JJ (l_amod) cancer_9/JJ
D004317_D066126 NONE Doxorubicin_0/NNP (r_nsubj) is_4/VBZ (l_conj) associated_14/VBN (l_prep) with_15/IN (l_pobj) cardiotoxicity_22/NN
D004317_D066126 NONE DOX_2/NNP (r_appos) Doxorubicin_0/NNP (r_nsubj) is_4/VBZ (l_conj) associated_14/VBN (l_prep) with_15/IN (l_pobj) cardiotoxicity_22/NN
D004317_D066126 NONE DOX_13/NNP (r_compound) cardiotoxicity_14/NN
D004317_D006333 CID DOX_5/NNP (r_npadvmod) induced_7/VBN (r_amod) failure_9/NN
1756784
D010862_D001930 CID pilocarpine_7/NNP (r_npadvmod) induced_9/VBN (r_amod) status_10/NN (r_pobj) during_6/IN (r_prep) Damage_0/NN (l_prep) of_1/IN (l_pobj) reticulata_5/NN
D010862_D013226 CID pilocarpine_7/NNP (r_npadvmod) induced_9/VBN (r_amod) status_10/NN (r_pobj) during_6/IN (r_prep) Damage_0/NN (r_nsubj) epilepticus_11/NN
D010862_D013226 CID pilocarpine_12/NN (r_pobj) of_11/IN (r_prep) injection_10/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (l_nsubjpass) epilepticus_5/NN
D002118_D009422 NONE calcium_10/NN (r_npadvmod) binding_12/VBG (r_amod) protein_13/NN (r_pobj) against_5/IN (r_prep) antibodies_4/NNS (r_conj) staining_2/VBG (r_nsubj) served_17/VBD (l_xcomp) detect_19/VB (l_dobj) damage_21/NN
12912689
D016190_D012175 NONE carboplatin_5/NNP (r_compound) chemotherapy_6/NN (l_prep) for_7/IN (l_pobj) retinoblastoma_8/NN
D016190_D012175 NONE carboplatin_2/NNP (r_compound) injections_3/NNS (r_nsubjpass) used_7/VBN (l_prep) as_8/IN (l_pobj) adjunct_14/NN (l_prep) to_15/IN (l_pobj) chemotherapy_17/NN (l_prep) for_18/IN (l_pobj) retinoblastoma_20/NN
D016190_D012175 NONE carboplatin_15/NNP (r_dobj) received_13/VBN (r_relcl) retinoblastoma_10/NN
D016190_D012175 NONE carboplatin_24/NNP (r_pobj) of_22/IN (r_prep) injections_21/NNS (r_pobj) with_17/IN (r_prep) treated_13/VBN (l_prep) for_14/IN (l_pobj) retinoblastoma_16/NN
D016190_D064420 NONE carboplatin_2/NNP (r_compound) injections_3/NNS (r_nsubjpass) used_7/VBN (l_prep) as_8/IN (l_pobj) adjunct_14/NN (l_amod) free_13/JJ (l_npadvmod) toxicity_11/NN
D016190_D064420 NONE carboplatin_1/NNP (r_nsubj) is_2/VBZ (l_acomp) free_4/JJ (l_prep) of_5/IN (l_pobj) toxicity_6/NN
D016190_D015835 CID carboplatin_14/NNP (r_compound) chemotherapy_15/NNP (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_acl) patients_10/NNS (r_pobj) in_9/IN (r_prep) motility_8/NN
D016190_D015835 CID carboplatin_15/NNP (r_dobj) received_13/VBN (r_relcl) retinoblastoma_10/NN (r_pobj) with_9/IN (r_prep) patients_8/NNS (r_pobj) in_5/IN (r_prep) motility_4/NN
D016190_D005355 CID carboplatin_1/NNP (r_compound) chemotherapy_2/NN (r_nsubjpass) associated_4/VBN (l_prep) with_5/IN (l_pobj) fibrosis_7/NN
9061777
D016291_D012640 CID MK-801_0/NNP (r_dep) augments_1/VBZ (l_dobj) seizure_6/NN
D016291_D012640 CID MK-801_7/NNP (r_dep) on_8/IN (l_pobj) model_14/NN (l_compound) seizure_13/NN
D016291_D012640 CID MK-801_20/NNP (r_dep) (_21/-LRB- (r_punct) development_12/NN (l_prep) of_13/IN (l_pobj) seizure_18/NN
D016291_D012640 CID MK-801_11/NNP (r_punct) seizure_9/NN
D016291_D012640 CID MK-801_11/NNP (r_punct) seizure_9/NN (l_acl) augmented_13/VBD (l_dobj) seizure_16/NN
D016291_D001930 NONE MK-801_0/NNP (r_dep) augments_1/VBZ (l_conj) protects_8/VBZ (l_prep) against_9/IN (l_pobj) damage_11/NN
D016291_D001930 NONE MK-801_4/NNP (r_conj) scopolamine_2/NN (r_conj) Pentobarbital_0/NN (r_nsubj) protected_5/VBD (l_dobj) damage_8/NN
D016291_D001930 NONE MK-801-treated_15/NNP (r_nummod) group_16/NN (r_pobj) in_13/IN (r_prep) appeared_23/VBD (r_advcl) protected_5/VBD (l_dobj) damage_8/NN
D010862_D012640 CID pilocarpine_2/NN (r_npadvmod) induced_4/VBN (r_amod) seizure_6/NN
D010862_D012640 CID pilocarpine_10/NN (r_npadvmod) induced_12/VBN (r_amod) model_14/NN (l_compound) seizure_13/NN
D010862_D012640 CID pilocarpine_3/NNP (l_appos) tonic_9/JJ (l_conj) seizure_12/NN
D010862_D012640 CID pilocarpine_14/NN (r_npadvmod) induced_16/VBN (r_amod) seizure_18/NN
D010862_D012640 CID pilocarpine_10/NN (r_npadvmod) treated_12/VBN (r_amod) group_13/NN (r_pobj) in_8/IN (r_prep) appeared_7/VBD (l_nsubj) seizure_2/NN
D010862_D012640 CID pilocarpine_5/NN (r_npadvmod) induced_7/VBN (r_amod) seizure_9/NN
D010862_D012640 CID pilocarpine_5/NN (r_npadvmod) induced_7/VBN (r_amod) seizure_9/NN (l_acl) augmented_13/VBD (l_dobj) seizure_16/NN
D010862_D012640 CID pilocarpine_19/NNP (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) seizure_16/NN (r_dobj) augmented_13/VBD (r_acl) seizure_9/NN
D010862_D012640 CID pilocarpine_19/NNP (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) seizure_16/NN
D010862_D001930 NONE pilocarpine_2/NN (r_npadvmod) induced_4/VBN (r_amod) seizure_6/NN (r_dobj) augments_1/VBZ (l_conj) protects_8/VBZ (l_prep) against_9/IN (l_pobj) damage_11/NN
D010862_D001930 NONE pilocarpine_10/NNP (r_pobj) by_9/IN (r_prep) damage_8/NN
D010862_D001930 NONE pilocarpine_8/NNP (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) epilepticus_5/NN (r_nsubjpass) initiated_10/VBN (r_ccomp) indicate_2/VBP (l_ccomp) cause_25/VB (l_dobj) damage_27/NN
D012601_D012640 NONE Scopolamine_0/NN (r_nsubj) prevented_11/VBN (l_dobj) development_12/NN (l_prep) of_13/IN (l_pobj) seizure_18/NN
D012601_D012640 NONE Scopolamine_0/NN (r_nsubj) blocked_3/VBD (l_dobj) seizure_9/NN
D012601_D012640 NONE Scopolamine_0/NN (r_nsubj) blocked_3/VBD (l_dobj) seizure_9/NN (l_acl) augmented_13/VBD (l_dobj) seizure_16/NN
D010424_D012640 NONE pentobarbital_6/NN (r_appos) Scopolamine_0/NN (r_nsubj) prevented_11/VBN (l_dobj) development_12/NN (l_prep) of_13/IN (l_pobj) seizure_18/NN
D010424_D012640 NONE pentobarbital_2/NN (r_conj) Scopolamine_0/NN (r_nsubj) blocked_3/VBD (l_dobj) seizure_9/NN
D010424_D012640 NONE pentobarbital_2/NN (r_conj) Scopolamine_0/NN (r_nsubj) blocked_3/VBD (l_dobj) seizure_9/NN (l_acl) augmented_13/VBD (l_dobj) seizure_16/NN
D010862_D009410 CID Pilocarpine_0/NNP (r_nsubj) produced_1/VBD (l_dobj) death_3/NN
D010424_D001930 NONE Pentobarbital_0/NN (r_nsubj) protected_5/VBD (l_dobj) damage_8/NN
D012601_D001930 NONE scopolamine_2/NN (r_conj) Pentobarbital_0/NN (r_nsubj) protected_5/VBD (l_dobj) damage_8/NN
D010862_D013226 CID pilocarpine_8/NNP (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) epilepticus_5/NN
D016202_D013226 NONE NMDA_31/NNP (r_nmod) mechanism_35/NN (r_pobj) through_28/IN (r_prep) damage_27/NN (r_dobj) cause_25/VB (r_ccomp) indicate_2/VBP (l_ccomp) initiated_10/VBN (l_nsubjpass) epilepticus_5/NN
D016202_D001930 NONE NMDA_31/NNP (r_nmod) mechanism_35/NN (r_pobj) through_28/IN (r_prep) damage_27/NN
12051122
D014750_D007010 CID Vincristine_14/NN (r_pobj) of_13/IN (r_prep) use_12/NN (r_pobj) with_10/IN (r_prep) reported_9/VBN (l_nsubj) Hyponatremia_0/NN
D014750_D007010 CID vincristine_32/NN (r_npadvmod) treated_34/VBN (r_amod) patients_35/NNS (r_pobj) among_31/IN (r_prep) secretion_22/NN (r_pobj) of_20/IN (r_prep) hyponatremia_17/NN
D014750_D007010 CID vincristine_33/NN (r_pobj) of_32/IN (r_prep) use_31/NN (r_pobj) during_29/IN (r_prep) reported_28/VBN (r_relcl) Lilly_4/NNP (r_dobj) searched_1/VBD (l_prep) for_12/IN (l_pobj) cases_15/NNS (l_prep) of_16/IN (l_pobj) hyponatremia_17/NN
D014750_D007010 CID vincristine_11/NN (r_compound) use_12/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) SIADH_8/NNP (r_conj) cases_4/NNS (l_prep) of_5/IN (l_pobj) hyponatremia_6/NN
D014750_D007010 CID vincristine_17/NN (r_compound) use_18/NN (r_pobj) with_16/IN (r_prep) associated_15/VBN (r_acl) SIADH_14/NNP (r_conj) hyponatremia_12/NN
D014750_D007177 CID Vincristine_14/NN (r_pobj) of_13/IN (r_prep) use_12/NN (r_pobj) with_10/IN (r_prep) reported_9/VBN (l_nsubj) Hyponatremia_0/NN (l_prep) of_3/IN (l_pobj) hormone_8/NN
D014750_D007177 CID vincristine_32/NN (r_npadvmod) treated_34/VBN (r_amod) patients_35/NNS (r_pobj) among_31/IN (r_prep) secretion_22/NN (l_prep) of_23/IN (l_pobj) hormone_27/NN
D014750_D007177 CID vincristine_32/NN (r_npadvmod) treated_34/VBN (r_amod) patients_35/NNS (r_pobj) among_31/IN (r_prep) secretion_22/NN (l_prep) of_23/IN (l_pobj) hormone_27/NN (l_appos) SIADH_29/NNP
D014750_D007177 CID vincristine_33/NN (r_pobj) of_32/IN (r_prep) use_31/NN (r_pobj) during_29/IN (r_prep) reported_28/VBN (r_relcl) Lilly_4/NNP (r_dobj) searched_1/VBD (l_prep) for_12/IN (l_pobj) cases_15/NNS (l_prep) of_16/IN (l_pobj) hyponatremia_17/NN (l_conj) SIADH_19/NNP
D014750_D007177 CID vincristine_11/NN (r_compound) use_12/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) SIADH_8/NNP
D014750_D007177 CID vincristine_17/NN (r_compound) use_18/NN (r_pobj) with_16/IN (r_prep) associated_15/VBN (r_acl) SIADH_14/NNP
D014750_D007177 CID vincristine_9/NN (r_pobj) with_8/IN (r_prep) associated_7/VBN (r_acl) SIADH_6/NNP
24451297
C065180_D056486 CID Fluvastatin_10/NNP (r_compound) Therapy_11/NNP (r_pobj) After_9/IN (r_prep) Hours_8/NNS (r_pobj) Within_6/IN (r_prep) Injury_5/NN
C065180_D056486 CID fluvastatin_19/NNP (r_pobj) with_18/IN (r_prep) treatment_17/NN (r_dobj) beginning_16/VBG (r_pcomp) after_15/IN (r_prep) appeared_12/VBD (r_relcl) damage_9/NN
D019161_D056486 NONE statins_1/NNS (r_nsubj) are_2/VBP (r_advcl) reported_23/VBN (l_nsubjpass) cases_10/NNS (l_prep) of_11/IN (l_pobj) injury_16/NN
2131034
D013852_D011115 CID thiotepa_7/NNP (r_compound) combination_8/NN (r_compound) chemotherapy_9/NN (r_pobj) after_5/IN (r_prep) polyneuropathy_1/NNS
D013852_D020258 CID thiotepa_19/NN (r_pobj) including_18/VBG (r_prep) chemotherapy_17/NN (r_pobj) of_11/IN (r_prep) administration_10/NN (r_pobj) to_8/IN (r_prep) related_7/VBN (r_acl) toxicity_6/NN
D013852_D020258 CID TSPA_21/NNP (r_appos) thiotepa_19/NN (r_pobj) including_18/VBG (r_prep) chemotherapy_17/NN (r_pobj) of_11/IN (r_prep) administration_10/NN (r_pobj) to_8/IN (r_prep) related_7/VBN (r_acl) toxicity_6/NN
D013852_D020258 CID TSPA_17/NNP (r_conj) arabinoside_13/NN (r_conj) methotrexate_8/NNP (r_pobj) with_5/IN (r_prep) described_4/VBN (l_nsubjpass) toxicities_1/NNS
D013852_D020258 CID TSPA_6/NNP (r_nsubj) is_7/VBZ (r_acl) fact_4/NN (r_pobj) of_2/IN (r_prep) spite_1/NN (r_pobj) In_0/IN (r_prep) cause_24/VB (l_dobj) neurotoxicity_26/NN
D008727_D020258 CID methotrexate_8/NNP (r_pobj) with_5/IN (r_prep) described_4/VBN (l_nsubjpass) toxicities_1/NNS
D008727_D020258 CID MTX_16/NNP (r_pobj) with_15/IN (r_prep) combination_14/NN (r_nsubj) cause_24/VB (l_dobj) neurotoxicity_26/NN
D003561_D020258 CID arabinoside_13/NN (r_conj) methotrexate_8/NNP (r_pobj) with_5/IN (r_prep) described_4/VBN (l_nsubjpass) toxicities_1/NNS
D003561_D020258 CID C_20/NNP (r_conj) MTX_16/NNP (r_pobj) with_15/IN (r_prep) combination_14/NN (r_nsubj) cause_24/VB (l_dobj) neurotoxicity_26/NN
9782254
D007980_D010300 NONE DOPA_28/NNP (r_npadvmod) induced_30/VBN (r_amod) dyskinesias_31/NN (r_conj) rigidity_23/NN (r_conj) bradykinesia_21/NN (r_pobj) of_20/IN (r_prep) treatment_19/NN (r_pobj) for_18/IN (r_prep) underwent_8/VBD (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) disease_7/NN
D007980_D018476 NONE DOPA_28/NNP (r_npadvmod) induced_30/VBN (r_amod) dyskinesias_31/NN (r_conj) rigidity_23/NN (r_conj) bradykinesia_21/NN
D007980_D009127 NONE DOPA_28/NNP (r_npadvmod) induced_30/VBN (r_amod) dyskinesias_31/NN (r_conj) rigidity_23/NN
D007980_D004409 CID DOPA_28/NNP (r_npadvmod) induced_30/VBN (r_amod) dyskinesias_31/NN
11799346
D015662_D001714 CID Cotrimoxazole_0/NNP (r_nsubjpass) involved_7/VBN (l_dobj) episodes_12/NNS (l_amod) manic_11/JJ
D008795_D001714 CID metronidazole_2/NN (r_conj) Cotrimoxazole_0/NNP (r_nsubjpass) involved_7/VBN (l_dobj) episodes_12/NNS (l_amod) manic_11/JJ
D004917_D001714 CID erythromycin_5/NN (r_conj) metronidazole_2/NN (r_conj) Cotrimoxazole_0/NNP (r_nsubjpass) involved_7/VBN (l_dobj) episodes_12/NNS (l_amod) manic_11/JJ
D017291_D001714 CID clarithromycin_6/NNS (r_dobj) showed_5/VBD (l_advcl) be_10/VB (l_attr) associated_14/VBN (l_prep) with_15/IN (l_pobj) development_17/NN (l_prep) of_18/IN (l_pobj) mania_19/NN
D002939_D001714 CID ciprofloxacin_8/NN (r_conj) clarithromycin_6/NNS (r_dobj) showed_5/VBD (l_advcl) be_10/VB (l_attr) associated_14/VBN (l_prep) with_15/IN (l_pobj) development_17/NN (l_prep) of_18/IN (l_pobj) mania_19/NN
24727461
C005975_D028361 NONE Hydroxytyrosol_0/NNP (r_nsubj) ameliorates_1/VBZ (l_dobj) stress_3/NN (l_conj) dysfunction_6/NN
C005975_D066126 NONE Hydroxytyrosol_0/NNP (r_nsubj) ameliorates_1/VBZ (l_dobj) stress_3/NN (l_prep) in_7/IN (l_pobj) cardiotoxicity_11/NN
C005975_D066126 NONE hydroxytyrosol_17/NN (r_pobj) with_14/IN (r_prep) ameliorated_13/VBN (l_nsubjpass) toxicity_10/NN
C005975_D001943 NONE Hydroxytyrosol_0/NNP (r_nsubj) ameliorates_1/VBZ (l_dobj) stress_3/NN (l_prep) in_12/IN (l_pobj) rats_13/NNS (l_prep) with_14/IN (l_pobj) cancer_16/NN
C005975_D001943 NONE hydroxytyrosol_17/NN (l_prep) in_18/IN (l_pobj) rats_19/NNS (l_prep) with_20/IN (l_pobj) cancer_22/NN
C005975_D001943 NONE hydroxytyrosol_17/NNP (r_appos) control_15/NN (r_appos) groups_13/NNS (r_pobj) into_11/IN (r_prep) divided_10/VBN (l_nsubjpass) rats_3/NNS (l_acl) bearing_4/VBG (l_dobj) tumors_6/NNS
C005975_D001943 NONE hydroxytyrosol_40/NN (r_conj) doxorubicin_38/NN (r_conj) doxorubicin_28/NN (r_conj) divided_10/VBN (l_nsubjpass) rats_3/NNS (l_acl) bearing_4/VBG (l_dobj) tumors_6/NNS
D004317_D028361 NONE doxorubicin_8/NN (r_npadvmod) induced_10/VBN (r_amod) cardiotoxicity_11/NN (r_pobj) in_7/IN (r_prep) stress_3/NN (l_conj) dysfunction_6/NN
D004317_D028361 NONE Doxorubicin_0/NNS (r_nsubj) causes_1/VBZ (l_dobj) cardiotoxicity_3/NN (l_acl) characterized_4/VBN (l_agent) by_5/IN (l_pobj) increases_7/NNS (l_prep) in_8/IN (l_pobj) stress_10/NN (l_conj) dysfunction_13/NN
D004317_D066126 NONE doxorubicin_8/NN (r_npadvmod) induced_10/VBN (r_amod) cardiotoxicity_11/NN
D004317_D066126 NONE Doxorubicin_0/NNS (r_nsubj) causes_1/VBZ (l_dobj) cardiotoxicity_3/NN
D004317_D066126 NONE doxorubicin_5/NN (r_npadvmod) associated_7/VBN (r_amod) toxicity_10/NN
D004317_D001943 NONE doxorubicin_8/NN (r_npadvmod) induced_10/VBN (r_amod) cardiotoxicity_11/NN (r_pobj) in_7/IN (r_prep) stress_3/NN (l_prep) in_12/IN (l_pobj) rats_13/NNS (l_prep) with_14/IN (l_pobj) cancer_16/NN
D004317_D001943 NONE doxorubicin_5/NN (r_npadvmod) associated_7/VBN (r_amod) toxicity_10/NN (r_nsubjpass) ameliorated_13/VBN (l_prep) with_14/IN (l_pobj) hydroxytyrosol_17/NN (l_prep) in_18/IN (l_pobj) rats_19/NNS (l_prep) with_20/IN (l_pobj) cancer_22/NN
D004317_D001943 NONE doxorubicin_28/NN (r_conj) divided_10/VBN (l_nsubjpass) rats_3/NNS (l_acl) bearing_4/VBG (l_dobj) tumors_6/NNS
D004317_D001943 NONE doxorubicin_38/NN (r_conj) doxorubicin_28/NN (r_conj) divided_10/VBN (l_nsubjpass) rats_3/NNS (l_acl) bearing_4/VBG (l_dobj) tumors_6/NNS
D004317_D009369 NONE doxorubicin_28/NNS (r_pobj) as_27/IN (r_prep) drugs_25/NNS (r_pobj) of_24/IN (r_prep) effect_23/NN (r_dobj) potentiate_20/VB (r_xcomp) shown_18/VBN (r_conj) involved_3/VBN (l_prep) in_4/IN (l_pobj) processes_6/NNS (l_prep) including_7/VBG (l_pobj) cancer_8/NN
D004317_D002318 NONE doxorubicin_28/NNS (r_pobj) as_27/IN (r_prep) drugs_25/NNS (r_pobj) of_24/IN (r_prep) effect_23/NN (r_dobj) potentiate_20/VB (r_xcomp) shown_18/VBN (r_conj) involved_3/VBN (l_prep) in_4/IN (l_pobj) processes_6/NNS (l_prep) including_7/VBG (l_pobj) cancer_8/NN (l_conj) disease_13/NN
C005975_D006331 NONE Hydroxytyrosol_0/NNP (r_nsubj) improved_1/VBD (l_dobj) disturbances_4/NNS
C005975_D006331 NONE hydroxytyrosol_4/NNP (r_compound) protect_5/VB (r_preconj) that_3/IN (r_det) damage_8/NN
D004317_D006331 CID doxorubicin_7/NNS (r_pobj) by_6/IN (r_agent) enhanced_5/VBN (r_acl) disturbances_4/NNS
D004317_D006331 CID doxorubicin_11/NN (r_pobj) by_10/IN (r_agent) provoked_9/VBN (r_acl) damage_8/NN
12487093
D004837_D006973 CID Adrenaline_0/NN (r_npadvmod) induced_2/VBN (r_amod) hypertension_3/NN
D004837_D006973 CID adrenaline_27/NN (r_dobj) giving_26/VBG (r_pcomp) after_25/IN (r_prep) evaluated_13/VBN (r_relcl) BBB_9/NNP (r_dobj) destroy_7/VB (r_xcomp) used_5/VBN (l_nsubjpass) hypertension_3/NN
C009591_D006973 NONE triphenyltetrazolium_15/NN (r_dobj) using_14/VBG (r_advcl) evaluated_13/VBN (r_relcl) BBB_9/NNP (r_dobj) destroy_7/VB (r_xcomp) used_5/VBN (l_nsubjpass) hypertension_3/NN
C009591_D006973 NONE TTC_17/NNP (r_appos) triphenyltetrazolium_15/NN (r_dobj) using_14/VBG (r_advcl) evaluated_13/VBN (r_relcl) BBB_9/NNP (r_dobj) destroy_7/VB (r_xcomp) used_5/VBN (l_nsubjpass) hypertension_3/NN
10770468
D008094_D001714 NONE lithium_8/NN (r_compound) therapy_9/NN (r_dobj) receiving_6/VBG (r_acl) patient_5/NN (l_amod) bipolar_4/JJ
D008094_D001714 NONE lithium_8/NN (r_compound) therapy_9/NN (r_dobj) receiving_6/VBG (r_acl) patient_5/NN (r_pobj) in_2/IN (r_prep) findings_1/NNS (r_nsubj) prompted_16/VBD (l_xcomp) conduct_20/VB (l_dobj) study_23/NN (l_prep) of_24/IN (l_pobj) patients_26/NNS (l_amod) bipolar_25/JJ
D008094_D001714 NONE lithium_28/NN (r_npadvmod) associated_30/VBN (r_amod) hypercalcemia_31/NN (r_pobj) with_27/IN (r_prep) patients_26/NNS (r_pobj) of_24/IN (r_prep) study_23/NN (r_dobj) conduct_20/VB (r_xcomp) prompted_16/VBD (l_nsubj) findings_1/NNS (l_prep) in_2/IN (l_pobj) patient_5/NN (l_amod) bipolar_4/JJ
D008094_D001714 NONE lithium_28/NN (r_npadvmod) associated_30/VBN (r_amod) hypercalcemia_31/NN (r_pobj) with_27/IN (r_prep) patients_26/NNS (l_amod) bipolar_25/JJ
D008094_D001714 NONE lithium_18/NN (r_npadvmod) treated_20/VBN (r_amod) patients_23/NNS (l_compound) normocalcemic_22/JJ (l_amod) bipolar_21/JJ
D008094_D001714 NONE lithium_18/NN (r_npadvmod) treated_20/VBN (r_amod) patients_23/NNS (r_conj) age-_13/NN (r_dobj) included_12/VBD (r_relcl) C1_9/NNP (l_conj) C2_27/NNP (l_relcl) included_30/VBD (l_dobj) patients_33/NNS (l_amod) bipolar_31/JJ
D008094_D001714 NONE lithium_11/NN (r_npadvmod) associated_13/VBN (r_amod) hypercalcemia_14/NN (r_pobj) with_10/IN (r_prep) diseases_6/NNS (l_conj) patients_9/NNS (l_amod) bipolar_8/JJ
D008094_D006934 CID lithium_8/NN (r_compound) therapy_9/NN (r_dobj) receiving_6/VBG (r_acl) patient_5/NN (l_relcl) developed_11/VBD (l_dobj) hypercalcemia_12/NN
D008094_D006934 CID lithium_8/NN (r_compound) therapy_9/NN (r_dobj) receiving_6/VBG (r_acl) patient_5/NN (r_pobj) in_2/IN (r_prep) findings_1/NNS (r_nsubj) prompted_16/VBD (l_xcomp) conduct_20/VB (l_dobj) study_23/NN (l_prep) of_24/IN (l_pobj) patients_26/NNS (l_prep) with_27/IN (l_pobj) hypercalcemia_31/NN
D008094_D006934 CID lithium_28/NN (r_npadvmod) associated_30/VBN (r_amod) hypercalcemia_31/NN (r_pobj) with_27/IN (r_prep) patients_26/NNS (r_pobj) of_24/IN (r_prep) study_23/NN (r_dobj) conduct_20/VB (r_xcomp) prompted_16/VBD (l_nsubj) findings_1/NNS (l_prep) in_2/IN (l_pobj) patient_5/NN (l_relcl) developed_11/VBD (l_dobj) hypercalcemia_12/NN
D008094_D006934 CID lithium_28/NN (r_npadvmod) associated_30/VBN (r_amod) hypercalcemia_31/NN
D008094_D006934 CID lithium_17/NN (r_amod) treated_19/VBN (r_amod) patients_20/NNS (r_dobj) identified_13/VBD (l_prep) After_0/IN (l_pcomp) eliminating_1/VBG (l_dobj) hypercalcemias_3/NNS
D008094_D006934 CID lithium_17/NN (r_amod) treated_19/VBN (r_amod) patients_20/NNS (l_prep) with_21/IN (l_pobj) hypercalcemias_22/NNP
D008094_D006934 CID lithium_17/NN (r_amod) treated_19/VBN (r_amod) patients_20/NNS (l_conj) patients_36/NNS (l_prep) with_37/IN (l_pobj) hypercalcemia_41/NN
D008094_D006934 CID lithium_38/NN (r_npadvmod) associated_40/VBN (r_amod) hypercalcemia_41/NN (r_pobj) with_37/IN (r_prep) patients_36/NNS (r_conj) patients_20/NNS (r_dobj) identified_13/VBD (l_prep) After_0/IN (l_pcomp) eliminating_1/VBG (l_dobj) hypercalcemias_3/NNS
D008094_D006934 CID lithium_38/NN (r_npadvmod) associated_40/VBN (r_amod) hypercalcemia_41/NN (r_pobj) with_37/IN (r_prep) patients_36/NNS (r_conj) patients_20/NNS (l_prep) with_21/IN (l_pobj) hypercalcemias_22/NNP
D008094_D006934 CID lithium_38/NN (r_npadvmod) associated_40/VBN (r_amod) hypercalcemia_41/NN
D008094_D006934 CID lithium_11/NN (r_npadvmod) associated_13/VBN (r_amod) hypercalcemia_14/NN (r_pobj) with_10/IN (r_prep) diseases_6/NNS (r_pobj) from_4/IN (r_prep) resulting_3/VBG (r_acl) hypercalcemia_2/NN
D008094_D006934 CID lithium_11/NN (r_npadvmod) associated_13/VBN (r_amod) hypercalcemia_14/NN
D008094_D001919 NONE lithium_8/NN (r_compound) therapy_9/NN (r_dobj) receiving_6/VBG (r_acl) patient_5/NN (l_relcl) developed_11/VBD (l_dobj) hypercalcemia_12/NN (l_conj) bradyarrhythmia_15/NN
D008094_D001919 NONE lithium_28/NN (r_npadvmod) associated_30/VBN (r_amod) hypercalcemia_31/NN (r_pobj) with_27/IN (r_prep) patients_26/NNS (r_pobj) of_24/IN (r_prep) study_23/NN (r_dobj) conduct_20/VB (r_xcomp) prompted_16/VBD (l_nsubj) findings_1/NNS (l_prep) in_2/IN (l_pobj) patient_5/NN (l_relcl) developed_11/VBD (l_dobj) hypercalcemia_12/NN (l_conj) bradyarrhythmia_15/NN
D008094_D009369 NONE lithium_17/NN (r_amod) treated_19/VBN (r_amod) patients_20/NNS (l_prep) with_21/IN (l_pobj) hypercalcemias_22/NNP (l_acl) related_23/VBN (l_prep) to_24/IN (l_pobj) malignancies_25/NNS
D008094_D009369 NONE lithium_38/NN (r_npadvmod) associated_40/VBN (r_amod) hypercalcemia_41/NN (r_pobj) with_37/IN (r_prep) patients_36/NNS (r_conj) patients_20/NNS (l_prep) with_21/IN (l_pobj) hypercalcemias_22/NNP (l_acl) related_23/VBN (l_prep) to_24/IN (l_pobj) malignancies_25/NNS
1655018
D000728_D006528 CID androgen_8/NN (r_pobj) with_7/IN (r_prep) treated_6/VBN (r_acl) carcinoma_1/NN
D000728_D005199 NONE androgen_8/NN (r_pobj) with_7/IN (r_prep) treated_6/VBN (r_acl) carcinoma_1/NN (l_prep) in_2/IN (l_pobj) anemia_5/NN
D000728_D005199 NONE androgens_25/NNS (r_pobj) with_24/IN (r_prep) treated_23/VBN (r_conj) known_12/VBN (l_xcomp) have_14/VB (l_dobj) anemia_17/NN
D000728_D005199 NONE androgen-_20/JJ (r_dep) and_21/CC (r_cc) treated_24/VBN (r_amod) anemia_27/NN
D000305_D006528 CID corticosteroid_10/NN (r_conj) androgen_8/NN (r_pobj) with_7/IN (r_prep) treated_6/VBN (r_acl) carcinoma_1/NN
D000305_D005199 NONE corticosteroid_10/NN (r_conj) androgen_8/NN (r_pobj) with_7/IN (r_prep) treated_6/VBN (r_acl) carcinoma_1/NN (l_prep) in_2/IN (l_pobj) anemia_5/NN
D000305_D005199 NONE corticosteroids_27/NNS (r_conj) androgens_25/NNS (r_pobj) with_24/IN (r_prep) treated_23/VBN (r_conj) known_12/VBN (l_xcomp) have_14/VB (l_dobj) anemia_17/NN
D000305_D005199 NONE corticosteroid_22/NN (r_npadvmod) treated_24/VBN (r_amod) anemia_27/NN
D000728_D008113 NONE androgen-_20/JJ (r_dep) and_21/CC (r_cc) treated_24/VBN (r_amod) anemia_27/NN (r_appos) observations_6/NNS (l_relcl) develop_16/VB (l_nsubj) neoplasms_12/NNS
D000728_D010382 CID androgen-_20/JJ (r_dep) and_21/CC (r_cc) treated_24/VBN (r_amod) anemia_27/NN (r_appos) observations_6/NNS (l_relcl) develop_16/VB (l_nsubj) neoplasms_12/NNS (l_conj) peliosis_14/NNP
D000305_D008113 NONE corticosteroid_22/NN (r_npadvmod) treated_24/VBN (r_amod) anemia_27/NN (r_appos) observations_6/NNS (l_relcl) develop_16/VB (l_nsubj) neoplasms_12/NNS
D000305_D010382 CID corticosteroid_22/NN (r_npadvmod) treated_24/VBN (r_amod) anemia_27/NN (r_appos) observations_6/NNS (l_relcl) develop_16/VB (l_nsubj) neoplasms_12/NNS (l_conj) peliosis_14/NNP
17351238
D005996_D007022 CID GTN_8/NNP (r_compound) administration_9/NN (r_pobj) following_6/VBG (r_prep) drop_2/NN (l_prep) in_3/IN (l_pobj) pressure_5/NN
D005996_D007022 CID GTN_4/NNP (l_relcl) experienced_7/VBD (l_dobj) drop_10/NN (l_prep) in_11/IN (l_pobj) pressure_13/NN
D001285_D007022 NONE sulphate_23/NN (r_pobj) by_21/IN (r_agent) rectified_20/VBN (l_npadvmod) minutes_1/NNS (l_prep) after_2/IN (l_pobj) GTN_4/NNP (l_relcl) experienced_7/VBD (l_dobj) drop_10/NN (l_prep) in_11/IN (l_pobj) pressure_13/NN
12678199
D000638_D016171 CID Amiodarone_0/NNP (r_npadvmod) induced_2/VBN (r_amod) pointes_5/FW
D000638_D016171 CID amiodarone_23/NN (r_compound) therapy_24/NN (r_pobj) with_21/IN (r_prep) associated_20/VBN (r_acl) torsade_14/NNP (l_nummod) pointes_16/FW
D000638_D016171 CID amiodarone_23/NN (r_compound) therapy_24/NN (r_pobj) with_21/IN (r_prep) associated_20/VBN (r_acl) torsade_14/NNP (l_nummod) pointes_16/FW (l_appos) TdP_18/NNP
D000638_D016171 CID amiodarone_21/NN (r_compound) therapy_22/NN (r_pobj) of_20/IN (r_prep) context_19/NN (r_pobj) in_17/IN (r_prep) resulted_23/VBD (r_ccomp) speculate_3/VBP (l_punct) TdP._0/NNP
D000638_D016171 CID amiodarone_25/NN (r_npadvmod) induced_27/VBN (r_amod) proarrhythmia_28/NN (r_pobj) in_24/IN (r_prep) resulted_23/VBD (r_ccomp) speculate_3/VBP (l_punct) TdP._0/NNP
D000638_D016171 CID amiodarone_4/NN (r_compound) therapy_5/NN (r_pobj) of_3/IN (r_prep) absence_2/NN (r_pobj) In_0/IN (r_prep) induce_13/VB (l_dobj) TdP_14/NN
D004077_D016171 NONE digoxin_19/NN (r_conj) hypokalemia_17/NN (r_pobj) including_16/VBG (r_prep) factors_15/NNS (r_pobj) of_12/IN (r_prep) context_11/NN (r_pobj) in_9/IN (r_prep) occurred_8/VBD (l_nsubj) case_5/NN (l_prep) of_6/IN (l_pobj) TdP_7/NNP
D004077_D007008 NONE digoxin_19/NN (r_conj) hypokalemia_17/NN
D000638_-1 NONE amiodarone_21/NN (r_compound) therapy_22/NN (r_pobj) of_20/IN (r_prep) context_19/NN (r_pobj) in_17/IN (r_prep) resulted_23/VBD (l_prep) in_24/IN (l_pobj) proarrhythmia_28/NN
D000638_-1 NONE amiodarone_25/NN (r_npadvmod) induced_27/VBN (r_amod) proarrhythmia_28/NN
D000638_D007008 NONE amiodarone_4/NN (r_compound) therapy_5/NN (r_pobj) of_3/IN (r_prep) absence_2/NN (r_pobj) In_0/IN (r_prep) induce_13/VB (l_prep) despite_15/IN (l_pobj) hypokalemia_16/NN
D000638_C537153 NONE amiodarone_4/NN (r_compound) therapy_5/NN (r_pobj) of_3/IN (r_prep) absence_2/NN (r_pobj) In_0/IN (r_prep) induce_13/VB (l_prep) despite_15/IN (l_pobj) hypokalemia_16/NN (l_conj) hypomagnesemia_18/NN
2974281
D011433_D006332 NONE propranolol_3/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) on_7/IN (l_pobj) hypertrophy_13/NN
D007545_D006332 CID isoproterenol_8/NN (r_npadvmod) induced_10/VBN (r_amod) hypertrophy_13/NN
D007545_D006332 CID isoproterenol_9/NN (r_npadvmod) induced_11/VBN (r_amod) hypertrophy_13/NN
D007545_D006332 CID isoproterenol_7/NN (r_dobj) prevent_6/VB (l_prep) from_8/IN (l_pcomp) producing_9/VBG (l_dobj) hypertrophy_11/NN
D009952_D006332 NONE ornithine_7/NN (r_compound) decarboxylase_8/NN (r_compound) activity_9/NN (r_dobj) suppress_4/VB (l_prep) with_10/IN (l_pobj) blockers_14/NNS (l_prep) in_15/IN (l_pobj) hearts_17/NNS
D011433_D006984 NONE propranolol_1/NN (r_nsubj) stop_6/VB (l_dobj) changes_8/NNS (l_prep) in_9/IN (l_pobj) pattern_14/NN (l_prep) of_15/IN (l_pobj) heart_19/NN (l_amod) hypertrophied_17/JJ
10726030
D006493_D013921 CID heparin_3/NN (r_npadvmod) induced_5/VBN (r_amod) thrombocytopenia_6/NN
D006493_D013921 CID heparin_14/NN (r_compound) therapy_15/NN (r_pobj) of_13/IN (r_prep) effects_12/NNS (r_conj) thrombosis_8/NN (r_conj) thrombocytopenia_6/NN
D006493_D013921 CID heparin_7/NN (r_compound) therapy_8/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) include_9/VBP (l_dobj) thrombocytopenia_13/NN
D006493_D013921 CID heparin_7/NN (r_compound) therapy_8/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) include_9/VBP (l_dobj) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN
D006493_D013921 CID heparin_10/NN (r_npadvmod) induced_12/VBN (r_amod) thrombocytopenia_13/NN
D006493_D013921 CID heparin_10/NN (r_npadvmod) induced_12/VBN (r_amod) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN
D006493_D013921 CID heparin_15/NN (r_npadvmod) associated_17/VBN (r_amod) osteoporosis_18/NN (r_conj) thrombocytopenia_13/NN
D006493_D013921 CID heparin_15/NN (r_npadvmod) associated_17/VBN (r_amod) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN
D006493_D013921 NONE heparin_18/NN (r_pobj) of_17/IN (r_prep) use_16/NN (r_pobj) given_12/VBN (r_prep) are_21/VBP (l_acomp) common_23/JJ (l_appos) HITT_26/NNP
D006493_D013927 NONE heparin_3/NN (r_npadvmod) induced_5/VBN (r_amod) thrombocytopenia_6/NN (l_conj) thrombosis_8/NN
D006493_D013927 NONE heparin_14/NN (r_compound) therapy_15/NN (r_pobj) of_13/IN (r_prep) effects_12/NNS (r_conj) thrombosis_8/NN
D006493_D013927 NONE Heparin_0/NNP (r_nsubjpass) used_16/VBN (l_xcomp) treat_18/VB (l_dobj) thrombosis_19/NN
D006493_D013927 NONE heparin_9/NN (r_nsubj) remains_10/VBZ (l_advcl) treat_16/VB (l_dobj) episodes_19/NNS (l_amod) thrombotic_18/JJ
D006493_D013927 NONE heparin_18/NN (r_pobj) of_17/IN (r_prep) use_16/NN (r_pobj) given_12/VBN (r_prep) are_21/VBP (l_acomp) common_23/JJ (l_appos) HITT_26/NNP
D006493_D006470 NONE heparin_7/NN (r_pobj) of_6/IN (r_prep) effect_5/NN (r_attr) is_1/VBZ (l_nsubj) Bleeding_0/NN
D006493_D006470 NONE heparin_9/NN (r_compound) therapy_10/NN (r_dobj) receiving_8/VBG (r_acl) patients_7/NNS (r_pobj) in_6/IN (r_prep) concern_5/NN (r_pobj) of_3/IN (r_prep) is_2/VBZ (l_nsubj) bleeding_1/NN
D006493_D010024 CID heparin_7/NN (r_compound) therapy_8/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) include_9/VBP (l_dobj) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN
D006493_D010024 CID heparin_10/NN (r_npadvmod) induced_12/VBN (r_amod) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN
D006493_D010024 CID heparin_15/NN (r_npadvmod) associated_17/VBN (r_amod) osteoporosis_18/NN
D006493_D010024 CID heparin_18/NN (r_pobj) of_17/IN (r_prep) use_16/NN (r_pobj) given_12/VBN (r_prep) are_21/VBP (l_acomp) common_23/JJ (l_appos) HITT_26/NNP (l_conj) osteoporosis_28/NN
D006493_D004802 CID heparin_7/NN (r_compound) therapy_8/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) include_9/VBP (l_dobj) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN
D006493_D004802 CID heparin_10/NN (r_npadvmod) induced_12/VBN (r_amod) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN
D006493_D004802 CID heparin_15/NN (r_npadvmod) associated_17/VBN (r_amod) osteoporosis_18/NN (l_conj) eosinophilia_20/NN
D006493_D012871 CID heparin_7/NN (r_compound) therapy_8/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) include_9/VBP (l_dobj) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS
D006493_D012871 CID heparin_10/NN (r_npadvmod) induced_12/VBN (r_amod) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS
D006493_D012871 CID heparin_15/NN (r_npadvmod) associated_17/VBN (r_amod) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS
D006493_D004342 CID heparin_7/NN (r_compound) therapy_8/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) include_9/VBP (l_dobj) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS
D006493_D004342 CID heparin_10/NN (r_npadvmod) induced_12/VBN (r_amod) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS
D006493_D004342 CID heparin_15/NN (r_npadvmod) associated_17/VBN (r_amod) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS
D006493_D000505 CID heparin_7/NN (r_compound) therapy_8/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) include_9/VBP (l_dobj) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN (l_conj) alopecia_31/NNP
D006493_D000505 CID heparin_10/NN (r_npadvmod) induced_12/VBN (r_amod) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN (l_conj) alopecia_31/NNP
D006493_D000505 CID heparin_15/NN (r_npadvmod) associated_17/VBN (r_amod) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN (l_conj) alopecia_31/NNP
D006493_D006947 CID heparin_7/NN (r_compound) therapy_8/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) include_9/VBP (l_dobj) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN (l_conj) alopecia_31/NNP (l_conj) transaminasemia_33/NNP (l_conj) hyperkalemia_35/NN
D006493_D006947 CID heparin_10/NN (r_npadvmod) induced_12/VBN (r_amod) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN (l_conj) alopecia_31/NNP (l_conj) transaminasemia_33/NNP (l_conj) hyperkalemia_35/NN
D006493_D006947 CID heparin_15/NN (r_npadvmod) associated_17/VBN (r_amod) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN (l_conj) alopecia_31/NNP (l_conj) transaminasemia_33/NNP (l_conj) hyperkalemia_35/NN
D006493_D006994 CID heparin_7/NN (r_compound) therapy_8/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) include_9/VBP (l_dobj) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN (l_conj) alopecia_31/NNP (l_conj) transaminasemia_33/NNP (l_conj) hyperkalemia_35/NN (l_conj) hypoaldosteronism_37/NNP
D006493_D006994 CID heparin_10/NN (r_npadvmod) induced_12/VBN (r_amod) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN (l_conj) alopecia_31/NNP (l_conj) transaminasemia_33/NNP (l_conj) hyperkalemia_35/NN (l_conj) hypoaldosteronism_37/NNP
D006493_D006994 CID heparin_15/NN (r_npadvmod) associated_17/VBN (r_amod) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN (l_conj) alopecia_31/NNP (l_conj) transaminasemia_33/NNP (l_conj) hyperkalemia_35/NN (l_conj) hypoaldosteronism_37/NNP
D006493_D011317 CID heparin_7/NN (r_compound) therapy_8/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) include_9/VBP (l_dobj) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN (l_conj) alopecia_31/NNP (l_conj) transaminasemia_33/NNP (l_conj) hyperkalemia_35/NN (l_conj) hypoaldosteronism_37/NNP (l_conj) priapism_40/NN
D006493_D011317 CID heparin_10/NN (r_npadvmod) induced_12/VBN (r_amod) thrombocytopenia_13/NN (l_conj) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN (l_conj) alopecia_31/NNP (l_conj) transaminasemia_33/NNP (l_conj) hyperkalemia_35/NN (l_conj) hypoaldosteronism_37/NNP (l_conj) priapism_40/NN
D006493_D011317 CID heparin_15/NN (r_npadvmod) associated_17/VBN (r_amod) osteoporosis_18/NN (l_conj) eosinophilia_20/NN (l_conj) reactions_23/NNS (l_conj) reactions_26/NNS (l_amod) other_27/JJ (l_prep) than_28/IN (l_pobj) thrombocytopenia_29/NN (l_conj) alopecia_31/NNP (l_conj) transaminasemia_33/NNP (l_conj) hyperkalemia_35/NN (l_conj) hypoaldosteronism_37/NNP (l_conj) priapism_40/NN
24040781
C107135_D011507 CID everolimus_13/NNP (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_acl) proteinuria_10/NN
C107135_D011507 CID everolimus_33/NN (r_pobj) to_32/IN (r_prep) conversion_29/NN (r_pobj) after_28/IN (r_prep) developed_26/VBD (l_dobj) proteinuria_27/NN
C107135_D000686 CID everolimus_13/NNP (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_acl) proteinuria_10/NN (r_pobj) with_9/IN (r_prep) patient_8/NN (r_pobj) in_3/IN (r_prep) diagnosis_2/NN (l_appos) amyloidosis_16/NN (l_compound) AL_15/NNP
C107135_D000686 CID everolimus_13/NNP (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_acl) proteinuria_10/NN (r_pobj) with_9/IN (r_prep) patient_8/NN (r_pobj) in_3/IN (r_prep) diagnosis_2/NN (l_appos) amyloidosis_16/NN
C107135_D000686 CID everolimus_33/NN (r_pobj) to_32/IN (r_prep) conversion_29/NN (r_pobj) after_28/IN (r_prep) developed_26/VBD (r_relcl) significance_24/NN (r_pobj) of_22/IN (r_prep) gammapathy_21/NNS (r_pobj) with_16/IN (r_prep) patient_15/NN (r_pobj) in_10/IN (r_prep) report_4/VBP (l_dobj) diagnosis_7/NN (l_prep) of_8/IN (l_pobj) amyloidosis_9/NN
D020123_D011507 NONE rapamycin_13/NN (r_amod) inhibitors_14/NNS (r_pobj) of_12/IN (r_prep) target_11/NN (r_pobj) with_9/IN (r_prep) treated_8/VBN (r_acl) complication_4/NN (r_attr) is_1/VBZ (l_nsubj) Proteinuria_0/NNP
D016559_D000686 NONE tacrolimus_31/NN (r_pobj) from_30/IN (r_prep) conversion_29/NN (r_pobj) after_28/IN (r_prep) developed_26/VBD (r_relcl) significance_24/NN (r_pobj) of_22/IN (r_prep) gammapathy_21/NNS (r_pobj) with_16/IN (r_prep) patient_15/NN (r_pobj) in_10/IN (r_prep) report_4/VBP (l_dobj) diagnosis_7/NN (l_prep) of_8/IN (l_pobj) amyloidosis_9/NN
D016559_D011507 NONE tacrolimus_31/NN (r_pobj) from_30/IN (r_prep) conversion_29/NN (r_pobj) after_28/IN (r_prep) developed_26/VBD (l_dobj) proteinuria_27/NN
8312983
D005473_D003693 CID fluoxetine_2/NN (r_compound) treatment_3/NN (r_pobj) during_1/IN (r_prep) Delirium_0/NN
D005473_D003693 CID fluoxetine_18/NN (r_pobj) with_13/IN (r_prep) connected_12/VBN (r_acl) delirium_11/NN
D005473_D003693 CID fluoxetine_20/NNP (r_nmod) concentration_24/NN (r_appos) fluoxetine_18/NN (r_pobj) with_13/IN (r_prep) connected_12/VBN (r_acl) delirium_11/NN
D015283_D006970 NONE citalopram_9/NNP (r_pobj) of_8/IN (r_prep) concentration_7/NN (r_nsubjpass) associated_22/VBN (l_prep) with_23/IN (l_pobj) difficulties_28/NNS (l_nmod) somnolence_25/NN
D015283_D020820 NONE citalopram_9/NNP (r_pobj) of_8/IN (r_prep) concentration_7/NN (r_nsubjpass) associated_22/VBN (l_prep) with_23/IN (l_pobj) difficulties_28/NNS
D005473_D006948 CID fluoxetine_18/NN (r_pobj) with_13/IN (r_prep) connected_12/VBN (r_acl) delirium_11/NN (l_amod) hyperkinetic_10/JJ
D005473_D006948 CID fluoxetine_20/NNP (r_nmod) concentration_24/NN (r_appos) fluoxetine_18/NN (r_pobj) with_13/IN (r_prep) connected_12/VBN (r_acl) delirium_11/NN (l_amod) hyperkinetic_10/JJ
C036139_D006948 NONE desmethylfluoxetine_22/NNP (r_conj) fluoxetine_20/NNP (r_nmod) concentration_24/NN (r_appos) fluoxetine_18/NN (r_pobj) with_13/IN (r_prep) connected_12/VBN (r_acl) delirium_11/NN (l_amod) hyperkinetic_10/JJ
C036139_D003693 NONE desmethylfluoxetine_22/NNP (r_conj) fluoxetine_20/NNP (r_nmod) concentration_24/NN (r_appos) fluoxetine_18/NN (r_pobj) with_13/IN (r_prep) connected_12/VBN (r_acl) delirium_11/NN
1760851
D004317_D066126 CID doxorubicin_3/NN (r_pobj) of_2/IN (r_prep) cardiotoxicity_1/NN
D004317_D066126 CID doxorubicin_18/NNS (r_appos) toxicity_10/NN (l_conj) cardiotoxicity_14/NN
D004317_D066126 CID DOX_20/NNP (r_appos) doxorubicin_18/NNS (r_appos) toxicity_10/NN (l_conj) cardiotoxicity_14/NN
D004317_D066126 CID DOX_21/NNP (r_dobj) received_18/VBD (r_relcl) animals_16/NNS (r_pobj) in_15/IN (r_prep) observed_13/VBN (l_nsubjpass) deaths_8/NNS (l_acl) related_9/VBN (l_prep) to_10/IN (l_pobj) cardiotoxicity_11/NN
D004317_D066126 CID DOX_21/NNP (r_dobj) received_18/VBD (r_relcl) animals_16/NNS (r_pobj) in_15/IN (r_prep) observed_13/VBN (r_ccomp) revealed_38/VBD (l_xcomp) marked_39/JJ (l_dobj) changes_40/NNS (l_prep) in_41/IN (l_pobj) heart_43/NN (l_relcl) were_45/VBD (l_acomp) consistent_46/JJ (l_prep) with_47/IN (l_pobj) cardiotoxicity_51/NN
D004317_D066126 CID DOX_30/NNP (r_conj) copolymer_27/NN (r_pobj) of_25/IN (r_prep) mixture_24/NN (r_conj) DOX_21/NNP (r_dobj) received_18/VBD (r_relcl) animals_16/NNS (r_pobj) in_15/IN (r_prep) observed_13/VBN (l_nsubjpass) deaths_8/NNS (l_acl) related_9/VBN (l_prep) to_10/IN (l_pobj) cardiotoxicity_11/NN
D004317_D066126 CID DOX_30/NNP (r_conj) copolymer_27/NN (r_pobj) of_25/IN (r_prep) mixture_24/NN (r_conj) DOX_21/NNP (r_dobj) received_18/VBD (r_relcl) animals_16/NNS (r_pobj) in_15/IN (r_prep) observed_13/VBN (r_ccomp) revealed_38/VBD (l_xcomp) marked_39/JJ (l_dobj) changes_40/NNS (l_prep) in_41/IN (l_pobj) heart_43/NN (l_relcl) were_45/VBD (l_acomp) consistent_46/JJ (l_prep) with_47/IN (l_pobj) cardiotoxicity_51/NN
D004317_D066126 CID DOX_48/NNP (r_npadvmod) induced_50/VBN (r_amod) cardiotoxicity_51/NN (r_pobj) with_47/IN (r_prep) consistent_46/JJ (r_acomp) were_45/VBD (r_relcl) heart_43/NN (r_pobj) in_41/IN (r_prep) changes_40/NNS (r_dobj) marked_39/JJ (r_xcomp) revealed_38/VBD (l_ccomp) observed_13/VBN (l_nsubjpass) deaths_8/NNS (l_acl) related_9/VBN (l_prep) to_10/IN (l_pobj) cardiotoxicity_11/NN
D004317_D066126 CID DOX_48/NNP (r_npadvmod) induced_50/VBN (r_amod) cardiotoxicity_51/NN
C032976_D066126 NONE N-(2-hydroxypropyl)methacrylamide_9/NNP (r_compound) conjugates_10/NNS (r_pobj) of_8/IN (r_prep) form_7/NN (r_pobj) in_5/IN (r_prep) given_4/VBN (r_acl) cardiotoxicity_1/NN
C032976_D066126 NONE N-(2-hydroxypropyl)methacrylamide_33/NNP (r_pobj) of_31/IN (r_prep) form_30/NN (r_pobj) in_28/IN (r_conj) as_24/IN (r_prep) given_22/VBN (r_prep) evaluate_6/VB (l_dobj) toxicity_10/NN (l_conj) cardiotoxicity_14/NN
C032976_D066126 NONE HPMA_26/NNP (r_amod) copolymer_27/NN (r_pobj) of_25/IN (r_prep) mixture_24/NN (r_conj) DOX_21/NNP (r_dobj) received_18/VBD (r_relcl) animals_16/NNS (r_pobj) in_15/IN (r_prep) observed_13/VBN (l_nsubjpass) deaths_8/NNS (l_acl) related_9/VBN (l_prep) to_10/IN (l_pobj) cardiotoxicity_11/NN
C032976_D066126 NONE HPMA_26/NNP (r_amod) copolymer_27/NN (r_pobj) of_25/IN (r_prep) mixture_24/NN (r_conj) DOX_21/NNP (r_dobj) received_18/VBD (r_relcl) animals_16/NNS (r_pobj) in_15/IN (r_prep) observed_13/VBN (r_ccomp) revealed_38/VBD (l_xcomp) marked_39/JJ (l_dobj) changes_40/NNS (l_prep) in_41/IN (l_pobj) heart_43/NN (l_relcl) were_45/VBD (l_acomp) consistent_46/JJ (l_prep) with_47/IN (l_pobj) cardiotoxicity_51/NN
D004317_D064420 NONE doxorubicin_18/NNS (r_appos) toxicity_10/NN
D004317_D064420 NONE DOX_20/NNP (r_appos) doxorubicin_18/NNS (r_appos) toxicity_10/NN
C032976_D064420 NONE N-(2-hydroxypropyl)methacrylamide_33/NNP (r_pobj) of_31/IN (r_prep) form_30/NN (r_pobj) in_28/IN (r_conj) as_24/IN (r_prep) given_22/VBN (r_prep) evaluate_6/VB (l_dobj) toxicity_10/NN
24072398
D008694_D020258 NONE methamphetamine_5/NN (r_pobj) of_4/IN (r_prep) dose_3/NN (l_amod) neurotoxic_2/JJ
D008694_D003866 CID methamphetamine_5/NN (r_pobj) of_4/IN (r_prep) dose_3/NN (r_nsubj) induces_6/VBZ (l_dobj) behaviour_14/NN (l_amod) like_13/JJ (l_npadvmod) depressive_11/JJ
D008694_D003866 CID METH_12/NNS (r_pobj) of_11/IN (r_prep) dosage_10/NN (r_nsubj) causes_14/VBZ (l_dobj) phenotype_20/NN (l_amod) depressive_19/JJ
D008694_D003866 CID METH_23/NNS (r_compound) dose_24/NN (r_pobj) following_19/VBG (r_prep) assessed_4/VBD (l_dobj) behaviour_9/NN (l_amod) like_8/JJ (l_npadvmod) depressive_6/JJ
D008694_D003866 CID METH_7/NNS (r_pobj) by_6/IN (r_agent) induced_5/VBN (r_acl) profile_4/NN (l_amod) like_3/JJ (l_amod) depressive_1/JJ
D008694_D003866 CID METH_13/NNS (r_pobj) of_12/IN (r_prep) dose_11/NN (r_nsubj) induces_14/VBZ (l_dobj) behaviour_21/NN (l_amod) like_20/JJ (l_npadvmod) depressive_18/JJ
D004298_D003866 NONE dopamine_29/NN (r_pobj) of_28/IN (r_prep) levels_27/NNS (r_pobj) in_25/IN (r_prep) reduction_24/NN (r_pobj) by_22/IN (r_agent) indicated_21/VBN (r_advcl) accompanied_9/VBN (l_nsubjpass) profile_4/NN (l_amod) like_3/JJ (l_amod) depressive_1/JJ
D015102_D003866 NONE DOPAC_31/NNP (r_conj) dopamine_29/NN (r_pobj) of_28/IN (r_prep) levels_27/NNS (r_pobj) in_25/IN (r_prep) reduction_24/NN (r_pobj) by_22/IN (r_agent) indicated_21/VBN (r_advcl) accompanied_9/VBN (l_nsubjpass) profile_4/NN (l_amod) like_3/JJ (l_amod) depressive_1/JJ
D006719_D003866 NONE HVA_33/NNP (r_conj) DOPAC_31/NNP (r_conj) dopamine_29/NN (r_pobj) of_28/IN (r_prep) levels_27/NNS (r_pobj) in_25/IN (r_prep) reduction_24/NN (r_pobj) by_22/IN (r_agent) indicated_21/VBN (r_advcl) accompanied_9/VBN (l_nsubjpass) profile_4/NN (l_amod) like_3/JJ (l_amod) depressive_1/JJ
D014443_D003866 NONE tyrosine_35/NN (r_amod) hydroxylase_36/NN (r_appos) dopamine_29/NN (r_pobj) of_28/IN (r_prep) levels_27/NNS (r_pobj) in_25/IN (r_prep) reduction_24/NN (r_pobj) by_22/IN (r_agent) indicated_21/VBN (r_advcl) accompanied_9/VBN (l_nsubjpass) profile_4/NN (l_amod) like_3/JJ (l_amod) depressive_1/JJ
D012701_D003866 NONE serotonin_38/NNS (r_conj) hydroxylase_36/NN (r_appos) dopamine_29/NN (r_pobj) of_28/IN (r_prep) levels_27/NNS (r_pobj) in_25/IN (r_prep) reduction_24/NN (r_pobj) by_22/IN (r_agent) indicated_21/VBN (r_advcl) accompanied_9/VBN (l_nsubjpass) profile_4/NN (l_amod) like_3/JJ (l_amod) depressive_1/JJ
1289188
D003676_D058186 NONE desferrioxamine_6/NN (r_compound) therapy_7/NN (r_pobj) during_4/IN (r_prep) occurring_3/VBG (r_acl) failure_2/NN
D003676_D058186 NONE desferrioxamine_24/NN (r_pobj) by_23/IN (r_agent) caused_22/VBN (r_acl) failure_21/NN
D003676_D013789 NONE desferrioxamine_11/NN (r_nmod) treatment_15/NN (r_dobj) undergoing_8/VBG (l_nsubj) patient_1/NN (l_prep) with_2/IN (l_pobj) thalassemia_6/NN
D003676_D013789 NONE DFX_13/NNP (r_appos) desferrioxamine_11/NN (r_nmod) treatment_15/NN (r_dobj) undergoing_8/VBG (l_nsubj) patient_1/NN (l_prep) with_2/IN (l_pobj) thalassemia_6/NN
9132810
D008727_D056784 CID methotrexate_34/NN (r_pobj) with_30/IN (r_prep) treated_29/VBN (r_acl) patients_17/NNS (l_prep) with_18/IN (l_pobj) leukoencephalopathy_21/NNP
D008727_D054198 NONE methotrexate_34/NN (r_pobj) with_30/IN (r_prep) treated_29/VBN (r_acl) patients_17/NNS (l_prep) with_18/IN (l_pobj) leukoencephalopathy_21/NNP (l_relcl) developed_24/VBD (l_prep) from_25/IN (l_pobj) leukemia_28/NN
25006961
D008094_D018500 CID lithium_6/NN (r_npadvmod) induced_8/VBN (r_amod) diabetes_10/NN (r_compound) insipidus_11/XX
D008094_D018500 CID Lithium_0/NN (r_nsubj) induces_6/VBZ (l_dobj) insipidus_9/NN
D008094_D018500 CID Lithium_0/NN (r_nsubj) induces_6/VBZ (l_dobj) insipidus_9/NN (l_appos) NDI_11/NNP
D008094_D018500 CID lithium_18/NN (r_npadvmod) induced_20/VBN (r_amod) NDI_21/NNP
D008094_D018500 CID lithium_33/NN (r_compound) therapy_34/NN (r_pobj) with_32/IN (r_prep) associated_31/VBN (r_acl) polyuria_30/NN (r_pobj) of_27/IN (r_prep) development_26/NN (r_dobj) prevents_24/VBZ (r_conj) preserves_7/VBZ (l_dobj) expression_14/NN (l_prep) in_17/IN (l_pobj) NDI_21/NNP
D008094_D011141 CID lithium_20/NN (r_npadvmod) induced_22/VBN (r_amod) polyuria_23/NN
D008094_D011141 CID lithium_18/NN (r_npadvmod) induced_20/VBN (r_amod) NDI_21/NNP (r_pobj) in_17/IN (r_prep) expression_14/NN (r_dobj) preserves_7/VBZ (l_conj) prevents_24/VBZ (l_dobj) development_26/NN (l_prep) of_27/IN (l_pobj) polyuria_30/NN
D008094_D011141 CID lithium_33/NN (r_compound) therapy_34/NN (r_pobj) with_32/IN (r_prep) associated_31/VBN (r_acl) polyuria_30/NN
9538487
D008094_D006944 CID lithium_5/NN (r_npadvmod) induced_7/VBN (r_amod) diabetes_9/NN (r_compound) insipidus_10/XX (r_pobj) by_4/IN (r_agent) precipitated_3/VBN (r_acl) coma_2/NN
D008094_D006944 CID lithium_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) depression_12/NN (r_pobj) of_10/IN (r_prep) history_9/NN (r_pobj) with_6/IN (r_prep) man_4/NN (r_nsubjpass) admitted_18/VBN (l_prep) with_19/IN (l_pobj) coma_23/NN
D008094_D018500 CID lithium_5/NN (r_npadvmod) induced_7/VBN (r_amod) diabetes_9/NN (r_compound) insipidus_10/XX
D008094_D018500 CID lithium_25/NN (r_npadvmod) induced_27/VBN (r_acomp) be_24/VB (r_xcomp) likely_22/JJ (r_advmod) indicated_17/VBD (l_dobj) insipidus_20/NN
D008094_D001714 NONE lithium_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) depression_12/NN
D005947_D011141 NONE glucose_20/NN (r_pobj) for_19/IN (r_prep) negative_18/JJ (r_acomp) been_17/VBN (r_relcl) history_6/NN (l_prep) of_7/IN (l_pobj) polyuria_8/NN
D005947_D011141 NONE glucose_11/NN (r_compound) concentrations_12/NNS (r_pobj) despite_8/IN (r_prep) remained_6/VBD (l_attr) polyuric_7/NNS
D005947_D059606 NONE glucose_20/NN (r_pobj) for_19/IN (r_prep) negative_18/JJ (r_acomp) been_17/VBN (r_relcl) history_6/NN (l_prep) of_7/IN (l_pobj) polyuria_8/NN (l_conj) polydipsia_10/NN
D005947_-1 NONE glucose_11/NN (r_compound) concentrations_12/NNS (r_pobj) despite_8/IN (r_prep) remained_6/VBD (l_prep) After_0/IN (l_pobj) recovery_1/NN (l_prep) from_2/IN (l_pobj) hyperglycaemia_3/NN
D005947_D018500 NONE glucose_11/NN (r_compound) concentrations_12/NNS (r_pobj) despite_8/IN (r_prep) remained_6/VBD (l_conj) indicated_17/VBD (l_dobj) insipidus_20/NN
D008094_-1 NONE lithium_25/NN (r_npadvmod) induced_27/VBN (r_acomp) be_24/VB (r_xcomp) likely_22/JJ (r_advmod) indicated_17/VBD (r_conj) remained_6/VBD (l_prep) After_0/IN (l_pobj) recovery_1/NN (l_prep) from_2/IN (l_pobj) hyperglycaemia_3/NN
D008094_D011141 CID lithium_25/NN (r_npadvmod) induced_27/VBN (r_acomp) be_24/VB (r_xcomp) likely_22/JJ (r_advmod) indicated_17/VBD (r_conj) remained_6/VBD (l_attr) polyuric_7/NNS
25054547
D013390_D001049 CID suxamethonium_25/NNP (r_pobj) with_24/IN (r_prep) apnea_23/NN
D013390_D001049 CID suxamethonium_14/NNP (r_appos) relaxants_12/NNS (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) after_7/IN (r_prep) characterized_3/VBN (l_agent) by_4/IN (l_pobj) apnea_6/NN
D013390_C537417 CID suxamethonium_14/NNP (r_appos) relaxants_12/NNS (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) after_7/IN (r_prep) characterized_3/VBN (l_nsubjpass) deficiency_1/NN
C049430_C537417 CID mivacurium_16/NNP (r_conj) suxamethonium_14/NNP (r_appos) relaxants_12/NNS (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) after_7/IN (r_prep) characterized_3/VBN (l_nsubjpass) deficiency_1/NN
C049430_D001049 CID mivacurium_16/NNP (r_conj) suxamethonium_14/NNP (r_appos) relaxants_12/NNS (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) after_7/IN (r_prep) characterized_3/VBN (l_agent) by_4/IN (l_pobj) apnea_6/NN
12359538
D003042_D002637 NONE cocaine_7/NN (r_npadvmod) associated_9/VBN (r_amod) pain_11/NN
D003042_D002637 NONE cocaine_24/NN (r_npadvmod) associated_26/VBN (r_amod) pain_28/NN
D003042_D002637 NONE cocaine_10/NN (r_compound) chest_11/NN (r_compound) pain_12/NN
D003042_D002637 NONE cocaine_19/NN (r_npadvmod) associated_21/VBN (r_amod) pain_23/NN
D003042_D009202 NONE cocaine_24/NN (r_npadvmod) associated_26/VBN (r_amod) pain_28/NN (r_pobj) with_23/IN (r_prep) patients_22/NNS (r_pobj) in_21/IN (r_prep) difficult_20/JJ (r_ccomp) make_11/VBP (l_nsubj) abnormalities_2/NNS (l_acl) associated_7/VBN (l_prep) with_8/IN (l_pobj) necrosis_10/NN
D003042_D009203 CID cocaine_24/NN (r_npadvmod) associated_26/VBN (r_amod) pain_28/NN (r_pobj) with_23/IN (r_prep) patients_22/NNS (r_pobj) in_21/IN (r_prep) difficult_20/JJ (r_ccomp) make_11/VBP (l_dobj) diagnosis_13/NN (l_prep) of_14/IN (l_pobj) infarction_16/NN
D003042_D009203 CID cocaine_24/NN (r_npadvmod) associated_26/VBN (r_amod) pain_28/NN (r_pobj) with_23/IN (r_prep) patients_22/NNS (r_pobj) in_21/IN (r_prep) difficult_20/JJ (r_ccomp) make_11/VBP (l_dobj) diagnosis_13/NN (l_prep) of_14/IN (l_pobj) infarction_16/NN (l_appos) MI_18/NNP
D003042_D009203 CID cocaine_10/NN (r_compound) chest_11/NN (r_compound) pain_12/NN (r_pobj) with_9/IN (r_prep) patients_8/NNS (r_pobj) in_7/IN (r_prep) positivity_6/NN (l_acl) admitted_13/VBD (l_prep) for_14/IN (l_pobj) exclusion_15/NN (l_prep) of_16/IN (l_pobj) MI_17/NNP
D003042_D009203 CID cocaine_10/NN (r_compound) use_11/NN (r_pobj) after_9/IN (r_prep) admitted_5/VBN (l_prep) for_6/IN (l_pobj) MI_8/NN
D003042_D009203 CID cocaine_19/NN (r_npadvmod) associated_21/VBN (r_amod) pain_23/NN (l_conj) MI_26/NNP
D003042_D009336 NONE cocaine_19/NN (r_npadvmod) associated_21/VBN (r_amod) pain_23/NN (r_pobj) with_18/IN (r_prep) patients_17/NNS (r_pobj) in_16/IN (r_prep) necrosis_15/NN
2718706
D007741_D007022 CID labetalol_4/NNP (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) hypotension_1/NN
D007741_D007022 CID labetalol_4/NNP (r_dobj) using_3/VBG (r_pcomp) of_2/IN (r_prep) feasibility_1/NN (l_prep) as_15/IN (l_pobj) agent_18/NN (l_amod) hypotensive_17/JJ
D007741_D007022 CID labetalol_4/NNP (r_nsubj) induces_5/VBZ (l_dobj) hypotension_8/NN
D006221_D007022 CID halothane_6/NNP (r_pobj) with_5/IN (r_prep) induced_2/VBN (r_acl) hypotension_1/NN
D006221_D007022 CID halothane_25/NNP (r_appos) anaesthetics_23/NNS (r_pobj) with_21/IN (r_prep) combination_20/NN (r_pobj) in_19/IN (r_prep) agent_18/NN (l_amod) hypotensive_17/JJ
D006221_D007022 CID H_2/NN (r_compound) concentration_3/NN (l_prep) during_4/IN (l_pobj) hypotension_5/NN
D004737_D007022 CID enflurane_8/NNP (r_conj) halothane_6/NNP (r_pobj) with_5/IN (r_prep) induced_2/VBN (r_acl) hypotension_1/NN
D004737_D007022 CID enflurane_27/NNP (r_conj) halothane_25/NNP (r_appos) anaesthetics_23/NNS (r_pobj) with_21/IN (r_prep) combination_20/NN (r_pobj) in_19/IN (r_prep) agent_18/NN (l_amod) hypotensive_17/JJ
D007530_D007022 CID isoflurane_10/NN (r_conj) enflurane_8/NNP (r_conj) halothane_6/NNP (r_pobj) with_5/IN (r_prep) induced_2/VBN (r_acl) hypotension_1/NN
D007530_D007022 CID isoflurane_29/NNP (r_conj) enflurane_27/NNP (r_conj) halothane_25/NNP (r_appos) anaesthetics_23/NNS (r_pobj) with_21/IN (r_prep) combination_20/NN (r_pobj) in_19/IN (r_prep) agent_18/NN (l_amod) hypotensive_17/JJ
D007530_D007022 CID isoflurane_31/NNP (r_compound) group_32/NN (r_pobj) except_29/IN (r_prep) level_23/NN (r_pobj) to_20/IN (r_prep) returned_18/VBD (r_conj) rose_7/VBD (l_prep) During_0/IN (l_pobj) hypotension_1/NN
D007530_D007022 CID isoflurane_31/NNP (r_compound) group_32/NN (r_pobj) except_29/IN (r_prep) level_23/NN (r_pobj) to_20/IN (r_prep) returned_18/VBD (r_conj) rose_7/VBD (l_prep) before_15/IN (l_pobj) hypotension_16/NN
D003404_D007022 NONE creatinine_5/NN (r_compound) concentration_6/NN (r_nsubj) rose_7/VBD (l_prep) During_0/IN (l_pobj) hypotension_1/NN
D003404_D007022 NONE creatinine_5/NN (r_compound) concentration_6/NN (r_nsubj) rose_7/VBD (l_prep) before_15/IN (l_pobj) hypotension_16/NN
D007741_D013610 NONE labetalol_4/NNP (r_nsubj) induces_5/VBZ (l_prep) without_9/IN (l_pobj) tachycardia_11/NN
D007741_D006973 NONE labetalol_4/NNP (r_nsubj) induces_5/VBZ (l_conj) rebound_13/NN (l_dobj) hypertension_14/NN
24618873
D008614_D002526 NONE pethidine_9/NN (r_pobj) of_8/IN (r_prep) infusion_7/NN (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) dysfunction_3/NN
D008614_D005128 NONE pethidine_9/NN (r_pobj) of_8/IN (r_prep) infusion_7/NN (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) dysfunction_3/NN
D008614_D010146 NONE Pethidine_0/NNP (r_nsubj) is_1/VBZ (l_attr) opioid_3/NN (l_relcl) gains_5/VBZ (l_prep) for_8/IN (l_pobj) control_12/NN (l_compound) pain_11/NN
D008614_D010146 NONE pethidine_19/NNP (r_nsubj) cause_21/VB (l_prep) In_0/IN (l_pobj) those_10/DT (l_relcl) need_12/VBP (l_dobj) control_17/NN (l_compound) pain_16/NN
D008614_D051437 NONE pethidine_19/NNP (r_nsubj) cause_21/VB (l_prep) In_0/IN (l_pobj) patients_1/NNS (l_prep) with_2/IN (l_pobj) function_7/NN
D008614_D017093 NONE pethidine_19/NNP (r_nsubj) cause_21/VB (l_prep) In_0/IN (l_pobj) patients_1/NNS (l_prep) with_2/IN (l_pobj) function_7/NN
D008614_D020258 NONE pethidine_19/NNP (r_nsubj) cause_21/VB (l_dobj) effects_29/NNS (l_prep) through_30/IN (l_pobj) metabolite_33/NN (l_amod) neurotoxic_32/JJ
D008614_D001523 NONE pethidine_19/NNP (r_nsubj) cause_21/VB (l_dobj) effects_29/NNS (l_acl) resulting_37/VBG (l_prep) in_38/IN (l_pobj) irritability_39/NN
D008614_D012640 NONE pethidine_19/NNP (r_nsubj) cause_21/VB (l_dobj) effects_29/NNS (l_acl) resulting_37/VBG (l_prep) in_38/IN (l_pobj) irritability_39/NN (l_conj) attack_42/NN (l_compound) seizure_41/NN
C002752_D051437 NONE norpethidine_35/RB (r_appos) metabolite_33/NN (r_pobj) through_30/IN (r_prep) effects_29/NNS (r_dobj) cause_21/VB (l_prep) In_0/IN (l_pobj) patients_1/NNS (l_prep) with_2/IN (l_pobj) function_7/NN
C002752_D017093 NONE norpethidine_35/RB (r_appos) metabolite_33/NN (r_pobj) through_30/IN (r_prep) effects_29/NNS (r_dobj) cause_21/VB (l_prep) In_0/IN (l_pobj) patients_1/NNS (l_prep) with_2/IN (l_pobj) function_7/NN
C002752_D010146 NONE norpethidine_35/RB (r_appos) metabolite_33/NN (r_pobj) through_30/IN (r_prep) effects_29/NNS (r_dobj) cause_21/VB (l_prep) In_0/IN (l_pobj) those_10/DT (l_relcl) need_12/VBP (l_dobj) control_17/NN (l_compound) pain_16/NN
C002752_D020258 NONE norpethidine_35/RB (r_appos) metabolite_33/NN (l_amod) neurotoxic_32/JJ
C002752_D001523 NONE norpethidine_35/RB (r_appos) metabolite_33/NN (r_pobj) through_30/IN (r_prep) effects_29/NNS (l_acl) resulting_37/VBG (l_prep) in_38/IN (l_pobj) irritability_39/NN
C002752_D012640 CID norpethidine_35/RB (r_appos) metabolite_33/NN (r_pobj) through_30/IN (r_prep) effects_29/NNS (l_acl) resulting_37/VBG (l_prep) in_38/IN (l_pobj) irritability_39/NN (l_conj) attack_42/NN (l_compound) seizure_41/NN
17255138
D052246_D009203 CID inhibitors_11/NNS (r_pobj) with_9/IN (r_prep) risk_1/NN (l_prep) of_2/IN (l_pobj) infarction_5/NN
D052246_D009203 CID inhibitors_11/NNS (r_pobj) with_9/IN (r_prep) risk_1/NN (l_prep) of_2/IN (l_pobj) infarction_5/NN (l_appos) AMI_7/NNP
D052246_D009203 CID inhibitors_18/NNS (r_dobj) using_16/VBG (r_advcl) bleeding_12/VBG (l_nsubj) AMI_9/NNP
D000894_D009203 CID drugs_34/NNS (r_pobj) with_21/IN (r_prep) compared_20/VBN (r_prep) offset_13/VB (l_nsubj) risk_1/NN (l_prep) of_2/IN (l_pobj) infarction_5/NN
D000894_D009203 CID drugs_34/NNS (r_pobj) with_21/IN (r_prep) compared_20/VBN (r_prep) offset_13/VB (l_nsubj) risk_1/NN (l_prep) of_2/IN (l_pobj) infarction_5/NN (l_appos) AMI_7/NNP
D052246_D006471 NONE inhibitors_18/NNS (r_dobj) using_16/VBG (r_advcl) bleeding_12/VBG
D000082_D009203 NONE acetaminophen_24/NN (r_conj) NSAIDs_22/JJ (r_appos) inhibitors_18/NNS (r_dobj) using_16/VBG (r_advcl) bleeding_12/VBG (l_nsubj) AMI_9/NNP
D000082_D009203 NONE acetaminophen_25/NN (r_pobj) vs_23/IN (r_prep) GI_22/NNP (l_nmod) AMI_20/NNP
D000082_D009203 NONE acetaminophen_12/NNP (r_pobj) of_11/IN (r_prep) that_10/DT (r_pobj) to_9/IN (r_prep) similar_8/JJ (r_acomp) was_7/VBD (l_nsubj) toxicity_4/NN (l_compound) GI_3/NNP (l_nmod) AMI_1/NNP
D000082_D006471 NONE acetaminophen_24/NN (r_conj) NSAIDs_22/JJ (r_appos) inhibitors_18/NNS (r_dobj) using_16/VBG (r_advcl) bleeding_12/VBG
D001241_D009203 NONE aspirin_5/NN (r_pobj) of_4/IN (r_prep) users_3/NNS (r_pobj) Among_0/IN (r_prep) were_32/VBD (l_nsubj) ratios_10/NNS (l_prep) of_17/IN (l_pobj) hospitalization_18/NN (l_prep) for_19/IN (l_pobj) GI_22/NNP (l_nmod) AMI_20/NNP
D001241_D009203 NONE aspirin_29/NN (r_nmod) group_31/NN (r_pobj) with_27/IN (r_prep) ratios_10/NNS (l_prep) of_17/IN (l_pobj) hospitalization_18/NN (l_prep) for_19/IN (l_pobj) GI_22/NNP (l_nmod) AMI_20/NNP
D001241_D009203 NONE aspirin_5/NN (r_pobj) of_4/IN (r_prep) users_3/NNS (r_pobj) Among_0/IN (r_prep) seemed_8/VBD (l_xcomp) carry_10/VB (l_dobj) risk_13/NN (l_prep) for_14/IN (l_pobj) bleeding_18/NN (l_compound) GI_17/NNP (l_nmod) AMI_15/NNP
C116926_D009203 CID rofecoxib_34/NNP (r_attr) were_32/VBD (l_nsubj) ratios_10/NNS (l_prep) of_17/IN (l_pobj) hospitalization_18/NN (l_prep) for_19/IN (l_pobj) GI_22/NNP (l_nmod) AMI_20/NNP
C116926_D009203 CID rofecoxib_21/NNP (r_pobj) of_20/IN (r_prep) those_19/DT (r_pobj) than_18/IN (r_prep) better_17/JJR (r_acomp) be_16/VB (r_xcomp) seemed_14/VBD (r_conj) was_7/VBD (l_nsubj) toxicity_4/NN (l_compound) GI_3/NNP (l_nmod) AMI_1/NNP
C105934_D009203 NONE celecoxib_42/NNP (r_appos) rofecoxib_34/NNP (r_attr) were_32/VBD (l_nsubj) ratios_10/NNS (l_prep) of_17/IN (l_pobj) hospitalization_18/NN (l_prep) for_19/IN (l_pobj) GI_22/NNP (l_nmod) AMI_20/NNP
C105934_D009203 NONE celecoxib_6/NNP (r_pobj) of_5/IN (r_prep) toxicity_4/NN (l_compound) GI_3/NNP (l_nmod) AMI_1/NNP
D009288_D009203 CID naproxen_50/NN (r_npadvmod) celecoxib_42/NNP (r_appos) rofecoxib_34/NNP (r_attr) were_32/VBD (l_nsubj) ratios_10/NNS (l_prep) of_17/IN (l_pobj) hospitalization_18/NN (l_prep) for_19/IN (l_pobj) GI_22/NNP (l_nmod) AMI_20/NNP
D009288_D009203 CID naproxen_7/NNP (r_nsubj) seemed_8/VBD (l_xcomp) carry_10/VB (l_dobj) risk_13/NN (l_prep) for_14/IN (l_pobj) bleeding_18/NN (l_compound) GI_17/NNP (l_nmod) AMI_15/NNP
D004008_D009203 NONE diclofenac_58/NNP (r_appos) rofecoxib_34/NNP (r_attr) were_32/VBD (l_nsubj) ratios_10/NNS (l_prep) of_17/IN (l_pobj) hospitalization_18/NN (l_prep) for_19/IN (l_pobj) GI_22/NNP (l_nmod) AMI_20/NNP
D007052_D009203 NONE ibuprofen_66/NN (r_conj) diclofenac_58/NNP (r_appos) rofecoxib_34/NNP (r_attr) were_32/VBD (l_nsubj) ratios_10/NNS (l_prep) of_17/IN (l_pobj) hospitalization_18/NN (l_prep) for_19/IN (l_pobj) GI_22/NNP (l_nmod) AMI_20/NNP
D001241_D006471 NONE aspirin_5/NN (r_pobj) of_4/IN (r_prep) users_3/NNS (r_pobj) Among_0/IN (r_prep) seemed_8/VBD (l_xcomp) carry_10/VB (l_dobj) risk_13/NN (l_prep) for_14/IN (l_pobj) bleeding_18/NN
D009288_D006471 CID naproxen_7/NNP (r_nsubj) seemed_8/VBD (l_xcomp) carry_10/VB (l_dobj) risk_13/NN (l_prep) for_14/IN (l_pobj) bleeding_18/NN
C105934_D064420 NONE celecoxib_6/NNP (r_pobj) of_5/IN (r_prep) toxicity_4/NN
D000082_D064420 NONE acetaminophen_12/NNP (r_pobj) of_11/IN (r_prep) that_10/DT (r_pobj) to_9/IN (r_prep) similar_8/JJ (r_acomp) was_7/VBD (l_nsubj) toxicity_4/NN
C116926_D064420 NONE rofecoxib_21/NNP (r_pobj) of_20/IN (r_prep) those_19/DT (r_pobj) than_18/IN (r_prep) better_17/JJR (r_acomp) be_16/VB (r_xcomp) seemed_14/VBD (r_conj) was_7/VBD (l_nsubj) toxicity_4/NN
24234943
C086816_D007177 CID desvenlafaxine_8/NNP (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) secretion_5/NN (l_compound) hormone_4/NN
C086816_D007177 CID desvenlafaxine_18/NNP (r_pobj) with_17/IN (r_prep) associated_16/VBN (r_acl) secretion_15/NN (l_nmod) hormone_11/NN
C086816_D007177 CID desvenlafaxine_18/NNP (r_pobj) with_17/IN (r_prep) associated_16/VBN (r_acl) secretion_15/NN (l_nmod) SIADH_13/NNP
C086816_D009325 CID desvenlafaxine_3/NN (r_dobj) included_2/VBD (l_conj) included_7/VBD (l_dobj) nausea_8/NN
C086816_D001008 CID desvenlafaxine_3/NN (r_dobj) included_2/VBD (l_conj) included_7/VBD (l_dobj) nausea_8/NN (l_conj) anxiety_10/NN
C086816_D003221 CID desvenlafaxine_3/NN (r_dobj) included_2/VBD (l_conj) included_7/VBD (l_dobj) nausea_8/NN (l_conj) anxiety_10/NN (l_conj) confusion_12/NN
D012964_D007177 NONE sodium_6/NN (r_nmod) L_10/NN (l_amod) consistent_12/JJ (l_prep) with_13/IN (l_pobj) diagnosis_15/NN (l_prep) of_16/IN (l_pobj) SIADH_17/NNP
C086816_D007010 CID desvenlafaxine_5/NNP (r_nsubj) cause_7/VB (l_dobj) hyponatremia_10/NN
12498738
C043211_D009202 NONE Carvedilol_0/NNP (r_nsubj) protects_1/VBZ (l_prep) against_2/IN (l_pobj) cardiomyopathy_7/NN
C043211_D009202 NONE carvedilol_7/NNS (r_pobj) by_6/IN (r_prep) protection_5/NN (r_nsubj) afford_18/VB (l_prep) in_22/IN (l_pcomp) minimizing_23/VBG (l_dobj) dysfunction_29/NN (l_conj) cardiomyopathy_31/NN
D004317_D009202 CID doxorubicin_3/NN (r_npadvmod) induced_5/VBN (r_amod) cardiomyopathy_7/NN
D004317_D009202 CID doxorubicin_18/NNS (r_pobj) by_17/IN (r_agent) caused_16/VBN (r_acl) cardiomyopathy_15/NN
D004317_D009202 CID doxorubicin_37/NN (r_compound) therapy_38/NN (r_dobj) accompanies_33/VBZ (r_relcl) dysfunction_29/NN (l_conj) cardiomyopathy_31/NN
C043211_D064420 NONE carvedilol_11/NNP (r_nsubj) protects_25/VBZ (l_prep) against_26/IN (l_pobj) dysfunction_33/NN (l_acl) associated_34/VBN (l_prep) with_35/IN (l_pobj) toxicity_38/NN
D004317_D064420 NONE doxorubicin_37/NN (r_compound) toxicity_38/NN
C043211_D028361 NONE carvedilol_7/NNS (r_pobj) by_6/IN (r_prep) protection_5/NN (r_nsubj) afford_18/VB (l_prep) in_22/IN (l_pcomp) minimizing_23/VBG (l_dobj) dysfunction_29/NN
C043211_D009369 NONE carvedilol_7/NNS (r_pobj) by_6/IN (r_prep) protection_5/NN (r_nsubj) afford_18/VB (l_prep) in_22/IN (l_pcomp) minimizing_23/VBG (l_dobj) dysfunction_29/NN (l_relcl) accompanies_33/VBZ (l_dobj) therapy_38/NN (l_prep) in_39/IN (l_pobj) patients_41/NNS (l_compound) cancer_40/NN
D004317_D028361 NONE doxorubicin_37/NN (r_compound) therapy_38/NN (r_dobj) accompanies_33/VBZ (r_relcl) dysfunction_29/NN
D004317_D009369 NONE doxorubicin_37/NN (r_compound) therapy_38/NN (l_prep) in_39/IN (l_pobj) patients_41/NNS (l_compound) cancer_40/NN
1158089
D013752_D005234 CID tetracycline_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) liver_1/NN
D013752_D005234 CID tetracycline_18/NNP (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) liver_15/NN
D013752_D005234 CID tetracycline_37/NN (r_pobj) to_36/IN (r_prep) response_35/NN (r_pobj) in_34/IN (r_prep) involved_23/VBN (l_prep) in_24/IN (l_pobj) production_26/NN (l_prep) of_27/IN (l_pobj) liver_33/NN
D019301_D003866 NONE acid_5/NN (r_pobj) of_2/IN (r_prep) provision_1/NN (r_pobj) With_0/IN (r_prep) observed_19/VBN (l_prep) between_20/IN (l_pobj) dose_21/NN (l_conj) accumulation_26/NN (l_prep) of_27/IN (l_pobj) triglyceride_28/NN (l_prep) in_29/IN (l_pobj) liver_31/NN (l_conj) depression_33/NN
D013752_D003866 NONE tetracycline_23/NN (r_pobj) of_22/IN (r_prep) dose_21/NN (l_conj) accumulation_26/NN (l_prep) of_27/IN (l_pobj) triglyceride_28/NN (l_prep) in_29/IN (l_pobj) liver_31/NN (l_conj) depression_33/NN
D013752_D003866 NONE tetracycline_19/NN (r_pobj) of_18/IN (r_prep) effects_17/NNS (l_prep) on_20/IN (l_pobj) depression_21/NN
D014280_D003866 NONE triglyceride_28/NN (l_prep) in_29/IN (l_pobj) liver_31/NN (l_conj) depression_33/NN
D014280_D003866 NONE triglyceride_37/NN (r_pobj) of_36/IN (r_prep) output_35/NN (r_pobj) of_34/IN (r_prep) liver_31/NN (l_conj) depression_33/NN
D014280_D003866 NONE triglyceride_25/NN (r_pobj) of_24/IN (r_prep) output_23/NN (r_pobj) of_22/IN (r_prep) depression_21/NN
D014280_D005234 NONE triglyceride_4/NN (r_pobj) of_3/IN (r_prep) secretion_2/NN (r_nsubj) accounted_5/VBD (l_advcl) indicating_17/VBG (l_ccomp) involved_23/VBN (l_prep) in_24/IN (l_pobj) production_26/NN (l_prep) of_27/IN (l_pobj) liver_33/NN
D014280_D005234 NONE triglyceride_15/NN (r_pobj) of_12/IN (r_prep) %_11/NN (r_pobj) for_7/IN (r_prep) accounted_5/VBD (l_advcl) indicating_17/VBG (l_ccomp) involved_23/VBN (l_prep) in_24/IN (l_pobj) production_26/NN (l_prep) of_27/IN (l_pobj) liver_33/NN
D014280_D005234 NONE triglyceride_29/NN (r_npadvmod) rich_31/JJ (r_amod) liver_33/NN
19815465
D020888_D014786 CID vigabatrin_8/NNP (r_pobj) to_7/IN (r_prep) specific_6/JJ (r_acomp) are_4/VBP (l_nsubj) defects_3/NNS
D020888_D014786 CID vigabatrin_11/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) defects_5/NNS
D020888_D014786 CID VGB_13/NNP (r_appos) vigabatrin_11/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) defects_5/NNS
D020888_D004827 NONE VGB_24/NNP (r_pobj) to_23/IN (r_prep) exposure_22/NN (r_conj) previous_18/JJ (r_conj) current_16/JJ (r_appos) therapy_14/NN (r_pobj) of_11/IN (r_prep) basis_10/NN (r_pobj) on_8/IN (r_prep) grouped_7/VBN (l_nsubjpass) people_3/NNS (l_prep) with_4/IN (l_pobj) epilepsy_5/NN
D020888_D012164 CID VGB_19/NNP (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) toxicity_16/NN
8829135
C058876_D000647 NONE Nefiracetam_0/NNP (r_nsubj) reverses_4/VBZ (l_dobj) amnesia_8/NN
C058876_D000647 NONE DM-9384_2/NNP (r_appos) Nefiracetam_0/NNP (r_nsubj) reverses_4/VBZ (l_dobj) amnesia_8/NN
C058876_D000647 NONE nefiracetam_28/NNS (r_pobj) of_27/IN (r_prep) ability_26/NN (r_dobj) evaluated_24/VBD (l_advcl) attenuate_30/VB (l_dobj) amnesia_31/NN
C058876_D000647 NONE nefiracetam_4/NNP (r_pobj) of_3/IN (r_prep) administration_2/NN (r_nsubj) reversed_8/VBD (l_dobj) amnesia_10/NN
D001058_D000647 CID apomorphine_5/NN (r_npadvmod) induced_7/VBN (r_amod) amnesia_8/NN
D001058_D000647 CID apomorphine_2/NNP (r_nsubj) inhibits_3/VBZ (r_advcl) evaluated_24/VBD (l_advcl) attenuate_30/VB (l_dobj) amnesia_31/NN
D001058_D000647 CID apomorphine_13/NNP (r_pobj) by_12/IN (r_agent) induced_11/VBN (r_acl) amnesia_10/NN
C058876_D007859 NONE Nefiracetam_0/NNP (r_nsubj) is_1/VBZ (l_attr) derivative_5/NN (l_relcl) attenuates_7/VBZ (l_dobj) deficits_17/NNS
D011760_D007859 NONE pyrrolidone_4/NN (r_compound) derivative_5/NN (l_relcl) attenuates_7/VBZ (l_dobj) deficits_17/NNS
D012601_D007859 CID scopolamine_8/NN (r_npadvmod) induced_10/VBN (r_amod) learning_11/NN (r_nmod) deficits_17/NNS
17572393
D008550_D054220 NONE melatonin_3/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) upon_4/IN (l_pobj) cortex_8/NN (l_prep) in_9/IN (l_pobj) model_12/NN (l_prep) of_13/IN (l_pobj) dysplasia_18/NN
D008550_D054220 NONE melatonin_31/NN (r_pobj) of_29/IN (r_prep) effects_28/NNS (l_prep) upon_32/IN (l_pobj) dysplasia_38/NN
D002330_D054220 CID BCNU_14/NNP (r_npadvmod) induced_16/VBN (r_amod) dysplasia_18/NN
D002330_D054220 CID carmustine-[1,3-bis_17/NNP (r_pobj) to_16/IN (r_prep) exposure_15/NN (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) cerebellum_11/NN (r_pobj) in_8/IN (r_prep) alterations_7/NNS (r_dobj) evaluate_5/VB (l_conj) investigate_26/VB (l_dobj) effects_28/NNS (l_prep) upon_32/IN (l_pobj) dysplasia_38/NN
D002330_D054220 CID 2-chloroethyl)-1-nitrosoure_19/CD (r_appos) carmustine-[1,3-bis_17/NNP (r_pobj) to_16/IN (r_prep) exposure_15/NN (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) cerebellum_11/NN (r_pobj) in_8/IN (r_prep) alterations_7/NNS (r_dobj) evaluate_5/VB (l_conj) investigate_26/VB (l_dobj) effects_28/NNS (l_prep) upon_32/IN (l_pobj) dysplasia_38/NN
D002330_D054220 CID BCNU_22/NNP (r_appos) alterations_7/NNS (r_dobj) evaluate_5/VB (l_conj) investigate_26/VB (l_dobj) effects_28/NNS (l_prep) upon_32/IN (l_pobj) dysplasia_38/NN
D002330_D054220 CID BCNU_34/NNP (r_npadvmod) induced_36/VBN (r_amod) dysplasia_38/NN
D002330_D054220 CID BCNU_25/NNP (r_npadvmod) exposed_27/VBN (r_amod) group_30/NN (l_compound) dysplasia_29/NN
10672628
D009569_D002375 NONE oxide_7/NN (r_compound) synthesis_8/NN (r_pobj) of_4/IN (r_prep) inhibition_3/NN (r_nsubj) modifies_9/VBZ (l_dobj) catalepsy_13/NN
D009569_D002375 NONE oxide_18/NN (r_compound) synthase_19/NN (r_pobj) of_15/IN (r_prep) inhibitor_14/NN (r_appos) arginine_6/NNP (r_nsubj) induces_24/VBZ (l_dobj) catalepsy_25/NN
D006220_D002375 CID haloperidol_10/NN (r_npadvmod) induced_12/VBN (r_amod) catalepsy_13/NN
D006220_D002375 CID haloperidol_4/NNP (r_pobj) as_3/IN (r_prep) drugs_1/NNS (r_nsubj) cause_12/VBP (l_dobj) catalepsy_13/NN
D006220_D002375 CID haloperidol_11/NN (r_npadvmod) induced_13/VBN (r_amod) catalepsy_14/NN
D006220_D002375 CID haloperidol_15/NN (r_npadvmod) induced_17/VBN (r_amod) catalepsy_18/NN
D009249_D002375 NONE NADPH_18/NNP (r_compound) diaphorase_20/NNP (r_compound) neurons_21/NNS (r_pobj) of_17/IN (r_prep) number_16/NN (r_conj) catalepsy_13/NN
D019335_D002375 NONE arginine_6/NNP (r_nsubj) induces_24/VBZ (l_dobj) catalepsy_25/NN
D019335_D002375 NONE NOARG_10/NNP (r_appos) arginine_6/NNP (r_nsubj) induces_24/VBZ (l_dobj) catalepsy_25/NN
D019335_D002375 NONE NOARG_8/NNP (r_compound) treatment_9/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (l_prep) in_10/IN (l_pobj) catalepsy_14/NN
D019335_D002375 NONE NOARG_2/NNP (r_nmod) administration_6/NN (r_nsubj) produced_7/VBD (l_dobj) tolerance_8/NN (l_prep) of_9/IN (l_conj) of_14/IN (l_pobj) catalepsy_18/NN
D019335_D002375 NONE NOARG_12/NNP (r_pobj) of_9/IN (l_conj) of_14/IN (l_pobj) catalepsy_18/NN
D004298_D002375 NONE dopamine_8/NN (r_compound) receptors_9/NNS (r_dobj) block_7/VBP (r_relcl) haloperidol_4/NNP (r_pobj) as_3/IN (r_prep) drugs_1/NNS (r_nsubj) cause_12/VBP (l_dobj) catalepsy_13/NN
24902786
D013739_D008569 NONE Testosterone_0/NN (r_nsubj) ameliorates_1/VBZ (l_dobj) impairment_6/NN
D013739_D008569 NONE testosterone_7/NN (r_pobj) of_6/IN (r_prep) effects_5/NNS (l_prep) on_8/IN (l_pobj) streptozotocin_9/NNS (l_appos) impairment_13/NN
D013739_D008569 NONE testosterone_19/NN (r_compound) replacement_20/NN (r_dobj) attenuated_17/VBD (r_conj) impaired_8/VBD (l_dobj) memory_10/NN
D013739_D008569 NONE testosterone_19/NN (r_compound) replacement_20/NN (l_conj) impairment_29/NN
D013739_D008569 NONE Testosterone_0/NN (r_compound) administration_1/NN (r_nsubj) ameliorates_2/VBZ (l_dobj) impairment_9/NN
D013311_D008569 CID streptozotocin_2/NN (r_npadvmod) induced_4/VBN (r_amod) impairment_6/NN
D013311_D008569 CID streptozotocin_9/NNS (l_appos) impairment_13/NN
D013311_D008569 CID STZ)-induced_11/VBN (r_nummod) impairment_13/NN
D013311_D008569 CID STZ-_23/NNP (r_dobj) improving_22/VBG (r_pcomp) in_21/IN (r_prep) replacement_20/NN (r_dobj) attenuated_17/VBD (r_conj) impaired_8/VBD (l_dobj) memory_10/NN
D013311_D008569 CID STZ-_23/NNP (r_dobj) improving_22/VBG (r_pcomp) in_21/IN (r_prep) replacement_20/NN (l_conj) impairment_29/NN
D013311_D008569 CID STZ-_3/NNP (r_nmod) impairment_9/NN
D005485_D008569 CID flutamide_2/NNP (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) impaired_8/VBD (l_dobj) memory_10/NN
D005485_D008569 CID flutamide_2/NNP (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) impaired_8/VBD (l_conj) attenuated_17/VBD (l_dobj) replacement_20/NN (l_conj) impairment_29/NN
C067431_D008569 CID letrozole_4/NNP (r_conj) flutamide_2/NNP (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) impaired_8/VBD (l_dobj) memory_10/NN
C067431_D008569 CID letrozole_4/NNP (r_conj) flutamide_2/NNP (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) impaired_8/VBD (l_conj) attenuated_17/VBD (l_dobj) replacement_20/NN (l_conj) impairment_29/NN
D013629_D008569 CID tamoxifen_6/NNP (r_conj) letrozole_4/NNP (r_conj) flutamide_2/NNP (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) impaired_8/VBD (l_dobj) memory_10/NN
D013629_D008569 CID tamoxifen_6/NNP (r_conj) letrozole_4/NNP (r_conj) flutamide_2/NNP (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) impaired_8/VBD (l_conj) attenuated_17/VBD (l_dobj) replacement_20/NN (l_conj) impairment_29/NN
6615679
D013999_D001919 CID timolol_6/NNS (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) bradycardia_1/NNS
D013999_D001919 CID maleate_16/NN (r_compound) drops_18/NNS (r_pobj) with_11/IN (r_prep) treated_10/VBN (r_relcl) man_4/NN (r_nsubj) developed_20/VBD (l_dobj) bradycardia_22/NN
D013999_D007022 CID timolol_6/NNS (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) bradycardia_1/NNS (l_conj) hypotension_3/NN
D013999_D007022 CID maleate_16/NN (r_compound) drops_18/NNS (r_pobj) with_11/IN (r_prep) treated_10/VBN (r_relcl) man_4/NN (r_nsubj) developed_20/VBD (l_conj) became_24/VBD (l_acomp) hypotensive_25/JJ
D010862_D001919 CID pilocarpine_8/NNP (r_compound) drops_10/VBZ (r_conj) timolol_6/NNS (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) bradycardia_1/NNS
D010862_D001919 CID nitrate_13/NN (r_nmod) drops_18/NNS (r_pobj) with_11/IN (r_prep) treated_10/VBN (r_relcl) man_4/NN (r_nsubj) developed_20/VBD (l_dobj) bradycardia_22/NN
D010862_D007022 CID pilocarpine_8/NNP (r_compound) drops_10/VBZ (r_conj) timolol_6/NNS (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) bradycardia_1/NNS (l_conj) hypotension_3/NN
D010862_D007022 CID nitrate_13/NN (r_nmod) drops_18/NNS (r_pobj) with_11/IN (r_prep) treated_10/VBN (r_relcl) man_4/NN (r_nsubj) developed_20/VBD (l_conj) became_24/VBD (l_acomp) hypotensive_25/JJ
D006221_D001919 NONE halothane_27/NNP (r_compound) anaesthesia_28/NN (r_pobj) during_26/IN (r_prep) became_24/VBD (r_conj) developed_20/VBD (l_dobj) bradycardia_22/NN
D006221_D001919 NONE halothane_11/NNP (r_compound) anaesthesia_12/NN (l_prep) with_13/IN (l_pobj) bradycardia_15/NNS
D006221_D007022 NONE halothane_27/NNP (r_compound) anaesthesia_28/NN (r_pobj) during_26/IN (r_prep) became_24/VBD (l_acomp) hypotensive_25/JJ
D006221_D007022 NONE halothane_11/NNP (r_compound) anaesthesia_12/NN (l_prep) with_13/IN (l_pobj) bradycardia_15/NNS (l_conj) hypotension_17/NN
9869655
D004997_D002780 CID ethinylestradiol_6/NNP (r_nsubjpass) associated_14/VBN (l_nsubjpass) cholestasis_10/NN
D004997_D002780 CID EE)-induced_8/JJ (r_nummod) cholestasis_10/NN
D001647_D002780 NONE salt_24/NN (r_nmod) synthesis_28/NN (r_pobj) of_22/IN (r_prep) pathway_21/NN (r_pobj) of_18/IN (r_prep) inhibition_17/NN (r_pobj) with_15/IN (r_prep) associated_14/VBN (l_nsubjpass) cholestasis_10/NN
D001647_D002780 NONE BS_26/NNP (r_nmod) synthesis_28/NN (r_pobj) of_22/IN (r_prep) pathway_21/NN (r_pobj) of_18/IN (r_prep) inhibition_17/NN (r_pobj) with_15/IN (r_prep) associated_14/VBN (l_nsubjpass) cholestasis_10/NN
24459006
D015725_D000380 CID Fluconazole_0/NNP (r_compound) agranulocytosis_2/NN
D015725_D000380 CID fluconazole_6/NNP (r_nmod) agranulocytosis_8/NN
D015725_D000380 CID fluconazole_21/NNP (r_pobj) with_20/IN (r_prep) therapy_19/NN (r_pobj) of_18/IN (r_prep) result_17/NN (r_pobj) as_15/IN (r_prep) occurred_14/VBD (l_nsubj) agranulocytosis_11/NN
D015725_D013921 CID Fluconazole_0/NNP (r_compound) agranulocytosis_2/NN (l_conj) thrombocytopenia_4/NN
D015725_D013921 CID fluconazole_6/NNP (r_nmod) agranulocytosis_8/NN (l_prep) with_9/IN (l_pobj) thrombocytopenia_10/NN
D015725_D013921 CID fluconazole_21/NNP (r_pobj) with_20/IN (r_prep) therapy_19/NN (r_pobj) of_18/IN (r_prep) result_17/NN (r_pobj) as_15/IN (r_prep) occurred_14/VBD (l_nsubj) agranulocytosis_11/NN (l_conj) thrombocytopenia_13/NN
D015725_D001855 NONE fluconazole_13/NN (r_pobj) of_12/IN (r_prep) initiation_11/NN (r_pobj) to_9/IN (r_prep) relationship_4/NN (l_prep) of_5/IN (l_pobj) suppression_8/NN
3409843
D002220_D000741 CID carbamazepine_8/NN (r_pobj) with_7/IN (r_prep) treated_6/VBN (r_acl) patient_5/NN (r_pobj) in_3/IN (r_prep) anemia_2/NN
D002220_D000741 CID carbamazepine_8/NN (r_compound) treatment_9/NN (r_pobj) due_6/IN (r_amod) case_1/NN (l_prep) of_2/IN (l_pobj) anemia_5/NN
D002220_D004827 NONE carbamazepine_8/NN (r_compound) treatment_9/NN (l_prep) in_10/IN (l_pobj) woman_13/NN (l_amod) epileptic_12/JJ
D002220_D001855 NONE carbamazepine_9/NN (r_pobj) to_8/IN (r_pcomp) due_7/IN (r_prep) concerns_1/NNS (l_prep) of_2/IN (l_pobj) toxicity_6/NN
11395263
D000431_D009203 NONE ethanol_5/NN (r_compound) extract_6/NN (l_prep) of_7/IN (l_pobj) rhizomes_10/NNS (l_prep) on_16/IN (l_pobj) infarction_21/NN
D007545_D009203 CID isoproterenol_17/NN (r_npadvmod) induced_19/VBN (r_amod) infarction_21/NN
D007545_D009203 CID isoproterenol_3/NN (r_npadvmod) induced_5/VBN (r_amod) infarction_7/NN
18025637
D005473_D012170 CID fluoxetine_5/NN (r_conj) occlusion_3/NN
D005473_D012170 CID fluoxetine_9/NN (r_npadvmod) induced_11/VBN (r_amod) hypertension_13/NN (r_pobj) with_8/IN (r_prep) associated_7/VBN (r_acl) occlusion_6/NN
D005473_D006973 CID fluoxetine_9/NN (r_npadvmod) induced_11/VBN (r_amod) hypertension_13/NN
D012701_D006973 NONE serotonin_6/NN (r_compound) therapy_9/NN (r_pobj) of_4/IN (r_prep) complication_3/NN (r_pobj) Although_0/IN (r_prep) is_12/VBZ (l_ccomp) are_16/VBP (l_acomp) aware_17/JJ (l_ccomp) cause_22/VB (l_dobj) hypertension_23/NN
24733133
C031942_D055499 NONE argatroban_2/JJ (r_nmod) thrombolysis_7/NNP
C031942_D055499 NONE argatroban_21/NNP (r_nmod) thrombolysis_26/NN
C031942_D013921 NONE argatroban_2/JJ (r_nmod) thrombolysis_7/NNP (r_pobj) of_1/IN (r_prep) Use_0/NNP (l_prep) in_10/IN (l_pobj) patient_13/NN (l_prep) with_14/IN (l_pobj) thrombocytopenia_18/NN
C031942_D013921 NONE argatroban_21/NNP (r_nmod) thrombolysis_26/NN (r_pobj) with_20/IN (r_prep) treated_19/VBN (r_conj) developed_7/VBD (l_dobj) thrombocytopenia_11/NN
C031942_D013921 NONE argatroban_21/NNP (r_nmod) thrombolysis_26/NN (r_pobj) with_20/IN (r_prep) treated_19/VBN (r_conj) developed_7/VBD (l_prep) with_12/IN (l_pobj) thrombosis_13/NN (l_appos) HITT_15/NNP
C031942_D013921 NONE argatroban_18/NNP (r_pobj) with_17/IN (r_prep) treated_16/VBN (l_nsubjpass) man_4/NN (l_amod) secondary_11/JJ (l_prep) to_12/IN (l_pobj) HITT_13/NNP
C031942_D013927 NONE argatroban_2/JJ (r_nmod) thrombolysis_7/NNP (r_pobj) of_1/IN (r_prep) Use_0/NNP (l_prep) with_19/IN (l_pobj) thrombosis_20/NN
C031942_D013927 NONE argatroban_21/NNP (r_nmod) thrombolysis_26/NN (r_pobj) with_20/IN (r_prep) treated_19/VBN (r_conj) developed_7/VBD (l_prep) with_12/IN (l_pobj) thrombosis_13/NN
C031942_D013927 NONE argatroban_21/NNP (r_nmod) thrombolysis_26/NN (r_pobj) with_20/IN (r_prep) treated_19/VBN (r_conj) developed_7/VBD (l_prep) with_12/IN (l_pobj) thrombosis_13/NN (l_appos) HITT_15/NNP
C031942_D013927 NONE argatroban_18/NNP (r_pobj) with_17/IN (r_prep) treated_16/VBN (l_nsubjpass) man_4/NN (l_amod) secondary_11/JJ (l_prep) to_12/IN (l_pobj) HITT_13/NNP
D006493_D055499 NONE heparin_15/NN (r_npadvmod) induced_17/VBN (r_amod) thrombocytopenia_18/NN (r_pobj) with_14/IN (r_prep) patient_13/NN (r_pobj) in_10/IN (r_prep) Use_0/NNP (l_prep) of_1/IN (l_pobj) thrombolysis_7/NNP
D006493_D055499 NONE heparin_8/NN (r_npadvmod) induced_10/VBN (r_amod) thrombocytopenia_11/NN (r_dobj) developed_7/VBD (l_conj) treated_19/VBN (l_prep) with_20/IN (l_pobj) thrombolysis_26/NN
D006493_D013921 CID heparin_15/NN (r_npadvmod) induced_17/VBN (r_amod) thrombocytopenia_18/NN
D006493_D013921 CID heparin_8/NN (r_npadvmod) induced_10/VBN (r_amod) thrombocytopenia_11/NN
D006493_D013921 CID heparin_2/NN (r_npadvmod) induced_4/VBN (r_amod) thrombocytopenia_5/NN
D006493_D013921 NONE heparin_8/NN (r_npadvmod) induced_10/VBN (r_amod) thrombocytopenia_11/NN (r_dobj) developed_7/VBD (l_prep) with_12/IN (l_pobj) thrombosis_13/NN (l_appos) HITT_15/NNP
D006493_D013927 NONE heparin_15/NN (r_npadvmod) induced_17/VBN (r_amod) thrombocytopenia_18/NN (r_pobj) with_14/IN (r_prep) patient_13/NN (r_pobj) in_10/IN (r_prep) Use_0/NNP (l_prep) with_19/IN (l_pobj) thrombosis_20/NN
D006493_D013927 NONE heparin_8/NN (r_npadvmod) induced_10/VBN (r_amod) thrombocytopenia_11/NN (r_dobj) developed_7/VBD (l_prep) with_12/IN (l_pobj) thrombosis_13/NN
D006493_D013927 NONE heparin_8/NN (r_npadvmod) induced_10/VBN (r_amod) thrombocytopenia_11/NN (r_dobj) developed_7/VBD (l_prep) with_12/IN (l_pobj) thrombosis_13/NN (l_appos) HITT_15/NNP
C031942_D004844 NONE argatroban_13/NNP (r_pobj) on_12/IN (r_prep) restarted_11/VBN (r_conj) resolved_2/VBD (l_nsubj) epistaxis_1/NN
C031942_D000686 NONE argatroban_18/NNP (r_pobj) with_17/IN (r_prep) treated_16/VBN (l_nsubjpass) man_4/NN (l_prep) with_5/IN (l_pobj) amyloidosis_7/NN
C031942_D013479 NONE argatroban_18/NNP (r_pobj) with_17/IN (r_prep) treated_16/VBN (l_nsubjpass) man_4/NN (l_prep) with_5/IN (l_pobj) amyloidosis_7/NN (l_conj) syndrome_10/NN
6517710
D011796_D003328 CID hydrochloride_10/NN (r_dobj) ingesting_8/VBG (r_acl) heart_4/NN (r_dobj) involving_2/VBG (r_acl) thrombosis_1/NN
D011796_D003328 CID hydrochloride_3/NN (r_nsubj) had_13/VBD (l_advcl) have_31/VB (l_dobj) thrombosis_33/NN
D011796_D013927 NONE hydrochloride_3/NN (r_nsubj) had_13/VBD (l_dobj) thrombosis_14/NN
D012977_D013927 NONE nitrite_8/NN (r_conj) hydrochloride_3/NN (r_nsubj) had_13/VBD (l_dobj) thrombosis_14/NN
D012977_D003328 NONE nitrite_8/NN (r_conj) hydrochloride_3/NN (r_nsubj) had_13/VBD (l_advcl) have_31/VB (l_dobj) thrombosis_33/NN
20046642
D008668_D003072 NONE MT_9/NNP (r_compound) induction_10/NN (l_prep) on_11/IN (l_pobj) carmustine_12/NNP (l_appos) dysfunction_17/NN
D002330_D003072 CID carmustine_12/NNP (l_appos) dysfunction_17/NN
D002330_D003072 CID BCNU)-induced_14/NNP (r_punct) carmustine_12/NNP (l_appos) dysfunction_17/NN
D002330_D007859 CID BCNU_5/NNP (r_compound) administration_6/NN (r_nsubj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) deterioration_9/NN (l_prep) of_10/IN (l_pobj) learning_11/NN (l_conj) memory_16/NN
D002330_D008569 CID BCNU_5/NNP (r_compound) administration_6/NN (r_nsubj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) deterioration_9/NN (l_prep) of_10/IN (l_pobj) learning_11/NN (l_conj) memory_16/NN
D005978_D007859 NONE glutathione_34/NN (r_nmod) GR_37/NNP (r_nmod) activity_39/NN (r_pobj) with_31/IN (r_prep) accompanied_30/VBN (r_conj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) deterioration_9/NN (l_prep) of_10/IN (l_pobj) learning_11/NN (l_conj) memory_16/NN
D005978_D007859 NONE glutathione_42/NN (r_nmod) content_46/NN (r_conj) activity_39/NN (r_pobj) with_31/IN (r_prep) accompanied_30/VBN (r_conj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) deterioration_9/NN (l_prep) of_10/IN (l_pobj) learning_11/NN (l_conj) memory_16/NN
D005978_D007859 NONE GSH_44/NNP (r_nmod) content_46/NN (r_conj) activity_39/NN (r_pobj) with_31/IN (r_prep) accompanied_30/VBN (r_conj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) deterioration_9/NN (l_prep) of_10/IN (l_pobj) learning_11/NN (l_conj) memory_16/NN
D005978_D008569 NONE glutathione_34/NN (r_nmod) GR_37/NNP (r_nmod) activity_39/NN (r_pobj) with_31/IN (r_prep) accompanied_30/VBN (r_conj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) deterioration_9/NN (l_prep) of_10/IN (l_pobj) learning_11/NN (l_conj) memory_16/NN
D005978_D008569 NONE glutathione_42/NN (r_nmod) content_46/NN (r_conj) activity_39/NN (r_pobj) with_31/IN (r_prep) accompanied_30/VBN (r_conj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) deterioration_9/NN (l_prep) of_10/IN (l_pobj) learning_11/NN (l_conj) memory_16/NN
D005978_D008569 NONE GSH_44/NNP (r_nmod) content_46/NN (r_conj) activity_39/NN (r_pobj) with_31/IN (r_prep) accompanied_30/VBN (r_conj) resulted_7/VBD (l_prep) in_8/IN (l_pobj) deterioration_9/NN (l_prep) of_10/IN (l_pobj) learning_11/NN (l_conj) memory_16/NN
D002330_D009369 NONE BCNU_2/NNP (r_compound) administration_3/NN (r_nsubj) increased_4/VBD (l_dobj) contents_22/NNS (l_nmod) factor_8/NN (l_compound) necrosis_7/NN (l_compound) tumor_6/NN
D002330_D009336 NONE BCNU_2/NNP (r_compound) administration_3/NN (r_nsubj) increased_4/VBD (l_dobj) contents_22/NNS (l_nmod) factor_8/NN (l_compound) necrosis_7/NN
D008668_D009369 NONE MT_16/NNP (r_appos) factor_8/NN (l_compound) necrosis_7/NN (l_compound) tumor_6/NN
D008668_D009336 NONE MT_16/NNP (r_appos) factor_8/NN (l_compound) necrosis_7/NN
D008315_D009369 NONE malondialdehyde_18/NNP (r_conj) MT_16/NNP (r_appos) factor_8/NN (l_compound) necrosis_7/NN (l_compound) tumor_6/NN
D008315_D009369 NONE MDA_20/NNP (r_nmod) contents_22/NNS (l_nmod) factor_8/NN (l_compound) necrosis_7/NN (l_compound) tumor_6/NN
D008315_D009336 NONE malondialdehyde_18/NNP (r_conj) MT_16/NNP (r_appos) factor_8/NN (l_compound) necrosis_7/NN
D008315_D009336 NONE MDA_20/NNP (r_nmod) contents_22/NNS (l_nmod) factor_8/NN (l_compound) necrosis_7/NN
D008668_D064420 NONE MT_3/NNP (r_compound) induction_4/NN (r_nsubj) halts_5/VBZ (l_dobj) toxicity_10/NN
D002330_D064420 NONE BCNU_6/NNP (r_npadvmod) induced_8/VBN (r_amod) toxicity_10/NN
D005978_D064420 NONE GSH_17/NNP (r_compound) depletion_18/NN (r_conj) inhibition_15/NN (r_dobj) prevented_13/VBD (r_advcl) halts_5/VBZ (l_dobj) toxicity_10/NN
D008315_D064420 NONE MDA_27/NNP (r_conj) TNFalpha_25/NNP (r_pobj) of_24/IN (r_prep) levels_23/NNS (r_dobj) counteracted_20/VBD (r_conj) prevented_13/VBD (r_advcl) halts_5/VBZ (l_dobj) toxicity_10/NN
17954033
D019259_D019694 NONE lamivudine_6/NN (r_npadvmod) untreated_8/JJ (r_amod) patients_10/NNS (l_prep) with_11/IN (l_pobj) infection_16/NN
D019259_D019694 NONE Lamivudine_0/NNP (r_nsubjpass) used_2/VBN (l_prep) for_3/IN (l_pobj) treatment_5/NN (l_prep) of_6/IN (l_pobj) patients_10/NNS (l_compound) B_9/NNP
D019259_D019694 NONE lamivudine_20/NN (r_npadvmod) untreated_22/JJ (r_amod) patients_26/NNS (l_compound) B_25/NN
D019259_D019694 NONE lamivudine_14/NN (r_npadvmod) untreated_16/JJ (r_amod) patients_20/NNS (l_compound) B_19/NN
D019259_D019694 NONE lamivudine_14/NNP (r_pobj) with_13/IN (r_prep) treated_12/VBN (r_relcl) patients_7/NNS (l_compound) B_6/NN
D019259_D019694 NONE lamivudine_9/NN (r_npadvmod) untreated_11/JJ (r_amod) patients_12/NNS (l_prep) with_13/IN (l_pobj) B_16/NNP
D019259_D019694 NONE lamivudine_9/NN (r_npadvmod) untreated_11/JJ (r_amod) patients_12/NNS (r_pobj) in_8/IN (r_prep) mutants_7/NNS (r_pobj) of_4/IN (r_prep) occurrence_3/NN (r_nsubjpass) reported_19/VBN (r_advcl) detected_25/VBN (l_prep) in_26/IN (l_pobj) patients_34/NNS (l_compound) B_33/NN
D019259_D019694 NONE lamivudine_28/NN (r_npadvmod) untreated_30/JJ (r_amod) patients_34/NNS (r_pobj) in_26/IN (r_prep) detected_25/VBN (l_advcl) reported_19/VBN (l_nsubjpass) occurrence_3/NN (l_prep) of_4/IN (l_pobj) mutants_7/NNS (l_prep) in_8/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) B_16/NNP
D019259_D019694 NONE lamivudine_28/NN (r_npadvmod) untreated_30/JJ (r_amod) patients_34/NNS (l_compound) B_33/NN
D019259_D006509 NONE lamivudine_20/NN (r_npadvmod) untreated_22/JJ (r_amod) patients_26/NNS (r_pobj) in_19/IN (r_prep) variability_18/NN (r_pobj) as_15/IN (r_prep) occur_14/VBP (l_nsubj) mutants_7/NNS (l_appos) virus_12/NN (l_compound) B_11/NNP
19338378
C031942_D013921 NONE argatroban_9/NNP (r_compound) therapy_10/NN (l_prep) in_11/IN (l_pobj) thrombocytopenia_15/NN
C031942_D013921 NONE Argatroban_0/NNP (r_nsubj) is_1/VBZ (l_amod) direct_6/JJ (l_prep) thrombin_7/NN (l_pobj) inhibitor_8/NN (l_acl) used_9/VBN (l_prep) in_16/IN (l_pobj) thrombocytopenia_20/NN
C031942_D013921 NONE Argatroban_0/NNP (r_nsubj) is_1/VBZ (l_amod) direct_6/JJ (l_prep) thrombin_7/NN (l_pobj) inhibitor_8/NN (l_acl) used_9/VBN (l_prep) in_16/IN (l_pobj) thrombocytopenia_20/NN (l_appos) HIT_22/NN
C031942_D013921 NONE Argatroban_0/NNP (r_nsubj) is_1/VBZ (l_amod) direct_6/JJ (l_prep) thrombin_7/NN (l_pobj) inhibitor_8/NN (l_acl) used_9/VBN (l_prep) for_25/IN (l_pobj) patients_26/NNS (l_prep) with_27/IN (l_conj) at_29/IN (l_pobj) risk_30/NN (l_prep) of_31/IN (l_pobj) HIT_32/NN
C031942_D013921 NONE argatroban_11/NNP (r_compound) therapy_12/NN (l_prep) in_13/IN (l_pobj) HIT_14/NNP
C031942_D013921 NONE argatroban_5/NNP (l_amod) dose_6/NN (l_prep) in_7/IN (l_pobj) HIT_8/NN
C031942_D013921 NONE argatroban_6/NNP (r_compound) therapy_7/NN (l_prep) in_8/IN (l_pobj) HIT_9/NNP
C031942_D013921 NONE argatroban_6/NNP (r_compound) therapy_7/NN (r_pobj) with_5/IN (r_prep) familiarity_1/NN (r_nsubj) facilitate_20/VB (l_dobj) reduction_21/NN (l_prep) of_22/IN (l_pobj) harm_23/NN (l_acl) associated_24/VBN (l_prep) with_25/IN (l_pobj) thromboses_30/NNS (l_nmod) HIT_26/NNP
C031942_D013921 NONE argatroban_38/NNP (r_compound) errors_40/NNS (r_appos) treatment_34/NN (r_conj) reduction_21/NN (r_dobj) facilitate_20/VB (l_nsubj) familiarity_1/NN (l_prep) with_5/IN (l_pobj) therapy_7/NN (l_prep) in_8/IN (l_pobj) HIT_9/NNP
C031942_D013921 NONE argatroban_38/NNP (r_compound) errors_40/NNS (r_appos) treatment_34/NN (r_conj) reduction_21/NN (l_prep) of_22/IN (l_pobj) harm_23/NN (l_acl) associated_24/VBN (l_prep) with_25/IN (l_pobj) thromboses_30/NNS (l_nmod) HIT_26/NNP
D006493_D013921 NONE heparin_12/NN (r_npadvmod) induced_14/VBN (r_amod) thrombocytopenia_15/NN
D006493_D013921 NONE heparin_17/NN (r_npadvmod) induced_19/VBN (r_amod) thrombocytopenia_20/NN
D006493_D013921 NONE heparin_17/NN (r_npadvmod) induced_19/VBN (r_amod) thrombocytopenia_20/NN (l_appos) HIT_22/NN
D006493_D013921 NONE heparin_17/NN (r_npadvmod) induced_19/VBN (r_amod) thrombocytopenia_20/NN (r_pobj) in_16/IN (r_prep) used_9/VBN (l_prep) for_25/IN (l_pobj) patients_26/NNS (l_prep) with_27/IN (l_conj) at_29/IN (l_pobj) risk_30/NN (l_prep) of_31/IN (l_pobj) HIT_32/NN
C031942_D013927 NONE Argatroban_0/NNP (r_nsubj) is_1/VBZ (l_amod) direct_6/JJ (l_prep) thrombin_7/NN (l_pobj) inhibitor_8/NN (l_acl) used_9/VBN (l_prep) for_10/IN (l_pobj) prophylaxis_11/NN (l_prep) of_14/IN (l_pobj) thrombosis_15/NN
D006493_D013927 NONE heparin_17/NN (r_npadvmod) induced_19/VBN (r_amod) thrombocytopenia_20/NN (r_pobj) in_16/IN (r_prep) used_9/VBN (l_prep) for_10/IN (l_pobj) prophylaxis_11/NN (l_prep) of_14/IN (l_pobj) thrombosis_15/NN
C031942_D009765 NONE argatroban_3/NNP (r_nsubjpass) investigated_7/VBN (r_ccomp) is_15/VBZ (l_advcl) be_33/VB (l_nsubj) age_19/NN (l_conj) sex_21/NN (l_conj) ethnicity_25/NN (l_conj) obesity_27/NN
C031942_D006470 CID argatroban_3/NNP (r_pobj) with_2/IN (r_prep) bleeding_1/VBG
7315949
D009638_D013035 CID norepinephrine_9/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (r_acl) spasm_4/NN
D009638_D006547 NONE norepinephrine_17/NNP (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) vasoconstriction_12/NN (r_nsubj) produced_18/VBD (l_dobj) hernias_25/NNS
12865514
D007980_D010300 NONE levodopa_29/NN (r_npadvmod) induced_31/VBN (r_amod) dyskinesias_32/NNP (r_conj) rigidity_26/NN (r_conj) bradykinesia_24/JJ (r_appos) Stages_11/NNP (r_appos) patients_3/NNS (l_acl) suffering_4/VBG (l_prep) from_5/IN (l_pobj) disease_9/NN
D007980_D018476 NONE levodopa_29/NN (r_npadvmod) induced_31/VBN (r_amod) dyskinesias_32/NNP (r_conj) rigidity_26/NN (r_conj) bradykinesia_24/JJ
D007980_D009127 NONE levodopa_29/NN (r_npadvmod) induced_31/VBN (r_amod) dyskinesias_32/NNP (r_conj) rigidity_26/NN
D007980_D004409 CID levodopa_29/NN (r_npadvmod) induced_31/VBN (r_amod) dyskinesias_32/NNP
D007980_D004409 CID levodopa_4/NNP (r_compound) dose_5/NN (r_pobj) in_2/IN (r_prep) reduction_1/NN (r_nsubj) is_6/VBZ (l_acomp) useful_7/JJ (l_prep) in_8/IN (l_pcomp) controlling_9/VBG (l_dobj) dyskinesias_13/NN
2320485
D008750_D000743 CID Methyldopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) anemia_4/NN
D008750_D000743 CID methyldopa_5/NN (r_npadvmod) induced_7/VBN (r_amod) anemia_9/NN
D008750_D013575 NONE Methyldopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) anemia_4/NN (r_nsubj) presenting_10/VBG (l_prep) as_11/IN (l_pobj) syncope_14/NN
D008750_D013575 NONE methyldopa_5/NN (r_npadvmod) induced_7/VBN (r_amod) anemia_9/NN (r_pobj) of_4/IN (r_prep) case_3/NN (l_prep) in_10/IN (l_pobj) boy_15/NN (l_relcl) presented_17/VBD (l_prep) with_22/IN (l_pobj) syncope_25/NN
D008750_D000744 NONE Methyldopa_0/NNP (r_nsubj) causes_1/VBZ (l_dobj) anemia_5/NN
D008750_D004630 NONE methyldopa_5/NN (r_npadvmod) induced_7/VBN (r_amod) anemia_9/NN (r_pobj) of_4/IN (r_prep) case_3/NN (l_prep) in_10/IN (l_pobj) boy_15/NN (l_relcl) presented_17/VBD (l_prep) to_18/IN (l_pobj) department_21/NN
D008750_D014947 NONE methyldopa_7/NN (r_pobj) with_5/IN (r_prep) treated_4/VBN (l_prep) during_8/IN (l_pobj) admission_11/NN (l_compound) trauma_10/NN
20192893
D003287_D007674 CID medium_1/JJ (r_amod) nephrotoxicity_2/NN
D003287_D007674 CID medium_6/NN (r_amod) administration_10/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) dysfunction_1/NN
D003287_D007674 CID CM_8/NNP (r_nmod) administration_10/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) dysfunction_1/NN
D003287_D007674 CID CM_8/NN (r_pobj) of_7/IN (r_prep) effect_6/NN (l_compound) nephrotoxic_5/JJ
D003287_D007674 CID CM_17/NNP (r_compound) administration_18/NN (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) damage_14/NN
D003287_D064420 NONE CM_13/NN (r_compound) toxicity_14/NN
16309808
D004294_D012148 NONE domperidone_1/NN (r_nsubj) potentiate_2/VB (l_dobj) syndrome_8/NN
D004294_D012148 NONE domperidone_11/NNP (r_nsubj) induce_22/VB (l_conj) aggravate_24/VB (l_dobj) symptoms_25/NNS (l_prep) of_26/IN (l_pobj) RLS_27/NNP
D004294_D012148 NONE domperidone_21/NN (r_compound) therapy_22/NN (r_pobj) to_19/IN (r_prep) added_18/VBN (r_conj) report_2/VBP (l_dobj) comorbid_7/NN (l_prep) with_8/IN (l_pobj) dyspepsia_10/NN (l_relcl) developed_12/VBD (l_dobj) RLS_13/NNP
D004294_D012148 NONE domperione_24/NN (r_pobj) of_23/IN (r_prep) effect_22/NN (r_dobj) support_19/VB (l_nsubj) relationship_3/NN (l_prep) between_4/IN (l_pobj) use_6/NN (l_prep) of_7/IN (l_pobj) mirtazapine_8/NN (l_conj) symptoms_11/NNS (l_prep) of_12/IN (l_pobj) RLS_13/NNP
D004294_D012148 NONE domperione_24/NN (l_prep) on_25/IN (l_pobj) RLS_29/NNP
C035133_D012148 CID mirtazapine_3/NN (r_npadvmod) associated_5/VBN (r_amod) syndrome_8/NN
C035133_D012148 CID Mirtazapine_0/NNP (r_nsubjpass) associated_15/VBN (l_prep) with_16/IN (l_pobj) RLS_17/NNP
C035133_D012148 CID mirtazapine_15/NNP (r_pobj) after_14/IN (r_prep) developed_12/VBD (l_dobj) RLS_13/NNP
C035133_D012148 CID mirtazapine_15/NNP (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_advcl) have_4/VB (l_dobj) symptoms_5/NNS (l_prep) of_6/IN (l_pobj) RLS_7/NNP
C035133_D012148 CID mirtazapine_15/NNP (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_advcl) have_4/VB (r_xcomp) started_2/VBD (l_conj) resolved_21/VBD (l_nsubj) symptoms_20/NNS (l_compound) RLS_19/NNP
C035133_D012148 CID mirtazapine_27/NN (r_pobj) of_25/IN (r_prep) discontinuation_24/NN (r_pobj) upon_23/IN (r_prep) resolved_21/VBD (r_conj) started_2/VBD (l_xcomp) have_4/VB (l_dobj) symptoms_5/NNS (l_prep) of_6/IN (l_pobj) RLS_7/NNP
C035133_D012148 CID mirtazapine_27/NN (r_pobj) of_25/IN (r_prep) discontinuation_24/NN (r_pobj) upon_23/IN (r_prep) resolved_21/VBD (l_nsubj) symptoms_20/NNS (l_compound) RLS_19/NNP
C035133_D012148 CID mirtazapine_8/NN (l_conj) symptoms_11/NNS (l_prep) of_12/IN (l_pobj) RLS_13/NNP
C035133_D012148 CID mirtazapine_8/NN (r_pobj) of_7/IN (r_prep) use_6/NN (r_pobj) between_4/IN (r_prep) relationship_3/NN (r_nsubj) support_19/VB (l_dobj) effect_22/NN (l_prep) of_23/IN (l_pobj) domperione_24/NN (l_prep) on_25/IN (l_pobj) RLS_29/NNP
C035133_D012148 CID mirtazapine_26/NNP (r_npadvmod) associated_28/VBN (r_amod) RLS_29/NNP (r_pobj) on_25/IN (r_prep) domperione_24/NN (r_pobj) of_23/IN (r_prep) effect_22/NN (r_dobj) support_19/VB (l_nsubj) relationship_3/NN (l_prep) between_4/IN (l_pobj) use_6/NN (l_prep) of_7/IN (l_pobj) mirtazapine_8/NN (l_conj) symptoms_11/NNS (l_prep) of_12/IN (l_pobj) RLS_13/NNP
C035133_D012148 CID mirtazapine_26/NNP (r_npadvmod) associated_28/VBN (r_amod) RLS_29/NNP
C035133_D012148 CID mirtazapine_10/NNP (r_nsubjpass) associated_13/VBN (l_prep) with_14/IN (l_pobj) RLS_15/NNP
D007980_D012148 NONE levodopa_12/NN (r_nmod) agonists_15/NNS (r_pobj) by_11/IN (r_agent) improved_10/VBN (l_nsubjpass) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) RLS_6/NNP
D007980_D012148 NONE levodopa_12/NN (r_nmod) agonists_15/NNS (r_pobj) by_11/IN (r_agent) improved_10/VBN (l_advcl) induce_24/VB (l_conj) aggravate_26/VB (l_dobj) symptoms_28/NNS (l_compound) RLS_27/NNP
D004298_D012148 NONE dopamine_14/NN (r_conj) levodopa_12/NN (r_nmod) agonists_15/NNS (r_pobj) by_11/IN (r_agent) improved_10/VBN (l_nsubjpass) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) RLS_6/NNP
D004298_D012148 NONE dopamine_14/NN (r_conj) levodopa_12/NN (r_nmod) agonists_15/NNS (r_pobj) by_11/IN (r_agent) improved_10/VBN (l_advcl) induce_24/VB (l_conj) aggravate_26/VB (l_dobj) symptoms_28/NNS (l_compound) RLS_27/NNP
D004298_D012148 NONE dopamine_19/NN (r_compound) D2_20/NN (r_compound) antagonists_22/NNS (r_nsubj) induce_24/VB (r_advcl) improved_10/VBN (l_nsubjpass) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) RLS_6/NNP
D004298_D012148 NONE dopamine_19/NN (r_compound) D2_20/NN (r_compound) antagonists_22/NNS (r_nsubj) induce_24/VB (l_conj) aggravate_26/VB (l_dobj) symptoms_28/NNS (l_compound) RLS_27/NNP
D004298_D012148 NONE dopamine_15/NN (r_compound) D2_16/NN (r_compound) antagonist_18/NN (r_appos) domperidone_11/NNP (r_nsubj) induce_22/VB (l_conj) aggravate_24/VB (l_dobj) symptoms_25/NNS (l_prep) of_26/IN (l_pobj) RLS_27/NNP
D004298_D012148 NONE dopamine_24/NN (r_compound) D2_25/NN (r_compound) antagonists_27/NNS (r_dobj) receiving_22/VBG (r_acl) those_21/DT (r_appos) individuals_18/NNS (r_pobj) in_16/IN (r_prep) associated_13/VBN (l_prep) with_14/IN (l_pobj) RLS_15/NNP
C035133_D004415 NONE mirtazapine_15/NNP (r_pobj) after_14/IN (r_prep) developed_12/VBD (r_relcl) dyspepsia_10/NN
D004294_D004415 NONE domperidone_21/NN (r_compound) therapy_22/NN (r_pobj) to_19/IN (r_prep) added_18/VBN (r_conj) report_2/VBP (l_dobj) comorbid_7/NN (l_prep) with_8/IN (l_pobj) dyspepsia_10/NN
18189308
D003520_D003556 CID cyclophosphamide_12/NN (r_npadvmod) induced_14/VBN (r_amod) cystitis_15/NN
D003520_D003556 CID cyclophosphamide_27/NN (r_pobj) by_26/IN (r_agent) induced_25/VBN (r_acl) inflammation_24/NN
D003520_D003556 CID CYP_29/NNP (r_appos) cyclophosphamide_27/NN (r_pobj) by_26/IN (r_agent) induced_25/VBN (r_acl) inflammation_24/NN
D003520_D003556 CID CYP_0/NNP (r_npadvmod) induced_2/VBN (r_amod) cystitis_3/NN
D003520_D003556 CID CYP_27/NNP (r_npadvmod) induced_29/VBN (r_amod) cystitis_30/NN
D003520_D003556 CID CYP_7/NNP (r_npadvmod) induced_9/VBN (r_amod) cystitis_10/NN
D014443_D003556 NONE tyrosine_9/NN (r_compound) receptors_11/NNS (r_pobj) of_8/IN (r_prep) expression_5/NN (l_prep) in_15/IN (l_pobj) reflexes_17/NNS (l_prep) with_18/IN (l_pobj) inflammation_21/NN
16323982
D017373_D003327 NONE CPA_7/NN (r_compound) treatment_8/NN (r_pobj) on_6/IN (r_prep) period_2/NN (r_pobj) After_0/IN (r_prep) found_18/VBN (l_xcomp) affected_21/VBN (l_agent) by_22/IN (l_pobj) disease_25/NN
D017373_D003324 CID CPA_14/NN (r_compound) therapy_15/NN (r_pobj) by_12/IN (r_agent) caused_11/VBN (r_advcl) arteriosclerosis_2/NN
D017373_D050171 CID CPA_14/NN (r_compound) therapy_15/NN (r_pobj) by_12/IN (r_agent) caused_11/VBN (r_advcl) arteriosclerosis_2/NN (r_nsubjpass) mediated_17/VBN (l_prep) through_18/IN (l_pobj) changes_19/NNS (l_prep) in_20/IN (l_pobj) cholesterol_22/NN (l_conj) I_27/NNP (l_conj) les_35/FW (l_amod) other_37/JJ (l_prep) than_38/IN (l_pobj) effect_44/NN
D002784_D003324 NONE cholesterol_22/NN (r_pobj) in_20/IN (r_prep) changes_19/NNS (r_pobj) through_18/IN (r_prep) mediated_17/VBN (l_nsubjpass) arteriosclerosis_2/NN
D002784_D050171 NONE cholesterol_22/NN (l_conj) I_27/NNP (l_conj) les_35/FW (l_amod) other_37/JJ (l_prep) than_38/IN (l_pobj) effect_44/NN
D004967_D003324 NONE estrogen_47/NN (r_pobj) by_46/IN (r_agent) caused_45/VBN (r_acl) effect_44/NN (r_pobj) than_38/IN (r_prep) other_37/JJ (r_amod) les_35/FW (r_conj) I_27/NNP (r_conj) cholesterol_22/NN (r_pobj) in_20/IN (r_prep) changes_19/NNS (r_pobj) through_18/IN (r_prep) mediated_17/VBN (l_nsubjpass) arteriosclerosis_2/NN
D004967_D050171 NONE estrogen_47/NN (r_pobj) by_46/IN (r_agent) caused_45/VBN (r_acl) effect_44/NN
24840785
D000157_D001145 CID Aconitine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) causes_6/VBZ (l_dobj) arrhythmia_7/NN
D000157_D001145 CID aconitine_6/NNP (r_nsubj) aggravates_8/VBZ (l_dobj) overload_12/NN (l_conj) causes_14/VBZ (l_dobj) arrhythmia_15/NN
D002118_D001145 NONE Ca2_3/CD (r_nmod) causes_6/VBZ (l_dobj) arrhythmia_7/NN
D002118_D001145 NONE Ca(2_3/NNP (r_nmod) overload_6/NN (r_nsubj) lead_7/VBP (l_conj) caused_18/VBD (l_dobj) arrhythmia_19/NN
D002118_D001145 NONE Ca(2_9/NNP (r_nmod) overload_12/NN (l_conj) causes_14/VBZ (l_dobj) arrhythmia_15/NN
D012964_D066126 NONE Na(+_7/NN (r_dep) )_8/-RRB- (r_punct) channels_9/NNS (r_nsubj) have_10/VBP (l_prep) in_13/IN (l_pobj) cardiotoxicity_15/NN
D000157_D066126 CID aconitine_17/NN (r_pobj) of_16/IN (r_prep) cardiotoxicity_15/NN
D002118_D011041 NONE Ca(2_10/NNP (r_pobj) of_9/IN (r_prep) role_8/NN (r_pobj) on_6/IN (r_prep) available_5/JJ (r_acomp) are_4/VBP (l_prep) in_13/IN (l_pobj) poisoning_15/NN
D002118_D011041 NONE Ca(2_10/NNP (r_pobj) of_8/IN (r_prep) importance_7/NN (r_dobj) explored_5/VBD (l_advcl) signaling_13/NN (l_prep) in_14/IN (l_pobj) poisoning_16/NN
D000157_D011041 CID aconitine_14/JJ (r_compound) poisoning_15/NN
D000157_D011041 CID aconitine_15/JJ (r_compound) poisoning_16/NN
D000157_D009202 NONE aconitine_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) on_5/IN (l_pobj) injury_7/NN
D000157_D009202 NONE aconitine_4/NN (r_nsubj) resulted_5/VBD (l_prep) in_6/IN (l_pobj) injury_8/NN
D000157_D064420 NONE aconitine_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_dobj) investigate_1/VB (r_advcl) performed_10/VBD (l_dobj) assay_12/NN (l_compound) cytotoxicity_11/NN
D019344_D009202 NONE lactate_26/NN (r_compound) level_28/NN (r_conj) performed_10/VBD (l_advcl) investigate_1/VB (l_dobj) effects_2/NNS (l_prep) on_5/IN (l_pobj) injury_7/NN
D019344_D064420 NONE lactate_26/NN (r_compound) level_28/NN (r_conj) performed_10/VBD (l_dobj) assay_12/NN (l_compound) cytotoxicity_11/NN
15276093
C451780_D006937 NONE lovastatin_5/NN (r_nsubj) is_6/VBZ (l_attr) product_10/NN (l_acl) approved_11/VBN (l_prep) for_12/IN (l_pobj) treatment_13/NN (l_prep) of_14/IN (l_pobj) hypercholesterolemia_16/NN
C451780_D050171 NONE lovastatin_5/NN (r_nsubj) is_6/VBZ (l_attr) product_10/NN (l_acl) approved_11/VBN (l_prep) for_12/IN (l_pobj) treatment_13/NN (l_prep) of_14/IN (l_pobj) hypercholesterolemia_16/NN (l_conj) dyslipidemia_19/NN
C451780_D050171 NONE lovastatin_30/NN (r_conj) dyslipidemia_23/NN
D003401_D009135 NONE creatine_3/NN (r_compound) phosphokinase_4/NN (r_pobj) of_2/IN (r_prep) increase_1/NN (r_nsubj) occurred_14/VBD (l_conj) observed_30/VBN (l_nsubjpass) cases_23/NNS (l_prep) of_24/IN (l_pobj) myopathy_28/NN
11299446
C027429_D010302 CID veralipride_7/NN (r_pobj) of_6/IN (r_prep) use_5/NN (r_pobj) after_3/IN (r_prep) Worsening_0/VBG (l_prep) of_1/IN (l_pobj) Parkinsonism_2/NNP
C027429_D010302 CID veralipride_27/NNP (r_pobj) with_26/IN (r_prep) symptoms_25/NNS (r_pobj) of_22/IN (r_prep) therapy_21/NN (r_pobj) following_20/VBG (r_prep) worsening_15/NN (r_dobj) shown_12/VBN (r_relcl) disease_9/NN
24588023
D014148_D012640 CID acid_4/NN (l_conj) seizures_7/NNS (l_amod) convulsive_6/JJ
D014148_D012640 CID acid_4/NN (l_conj) seizures_7/NNS
D014148_D012640 CID acid_37/NN (r_conj) clamp_34/NN (r_pobj) of_30/IN (r_prep) duration_29/NN (r_conj) arrest_27/NN (r_appos) failure_22/NN (r_dobj) ascending_17/VBG (r_pcomp) of_16/IN (r_prep) calcification_15/NN (r_dobj) redo_11/VB (r_conj) included_5/VBD (l_nsubj) predictors_1/NNS (l_prep) of_2/IN (l_pobj) seizures_4/NNS
D014148_D012640 CID acid_9/NN (r_nsubj) was_10/VBD (l_attr) predictor_14/NN (l_prep) of_15/IN (l_pobj) seizures_16/NNS
D014148_D012640 CID acid_2/NN (r_nsubj) is_3/VBZ (r_advcl) weighed_22/VBN (l_prep) against_23/IN (l_pobj) risk_25/NN (l_prep) of_26/IN (l_pobj) seizures_28/NNS
D014148_D006333 NONE acid_37/NN (r_conj) clamp_34/NN (r_pobj) of_30/IN (r_prep) duration_29/NN (r_conj) arrest_27/NN (r_appos) failure_22/NN
D014148_D007035 NONE acid_37/NN (r_conj) clamp_34/NN (r_pobj) of_30/IN (r_prep) duration_29/NN (r_conj) arrest_27/NN (l_amod) hypothermic_25/JJ
12372954
D009530_D009395 CID nicergoline_5/NN (r_pobj) due_3/IN (r_amod) nephritis_2/NN
D009530_D009395 CID Sermion_7/NNP (r_appos) nicergoline_5/NN (r_pobj) due_3/IN (r_amod) nephritis_2/NN
D009530_D009395 CID nicergoline_13/NN (r_pobj) due_11/IN (r_prep) case_3/NN (l_prep) of_4/IN (l_pobj) nephritis_7/NN
D009530_D009395 CID nicergoline_13/NN (r_pobj) due_11/IN (r_prep) case_3/NN (l_prep) of_4/IN (l_pobj) nephritis_7/NN (l_appos) AIN_9/NNP
D009530_D009395 CID Sermion_15/NNP (r_appos) nicergoline_13/NN (r_pobj) due_11/IN (r_prep) case_3/NN (l_prep) of_4/IN (l_pobj) nephritis_7/NN
D009530_D009395 CID Sermion_15/NNP (r_appos) nicergoline_13/NN (r_pobj) due_11/IN (r_prep) case_3/NN (l_prep) of_4/IN (l_pobj) nephritis_7/NN (l_appos) AIN_9/NNP
D009530_D009395 CID nicergoline_10/NNP (r_npadvmod) associated_12/VBN (r_amod) AIN_13/NNP
D009530_D012170 NONE nicergoline_7/NN (r_dobj) taking_6/VBG (l_prep) due_11/JJ (l_pobj) occlusion_15/NN
C036067_D012170 NONE lysine_10/NNP (r_dobj) bendazac_9/NNP (r_conj) taking_6/VBG (l_prep) due_11/JJ (l_pobj) occlusion_15/NN
8318674
D003561_D011654 CID C_10/NNP (r_pobj) after_4/IN (r_prep) edema_1/NN
D003561_D012769 CID C_10/NNP (r_pobj) after_4/IN (r_prep) edema_1/NN (l_conj) shock_3/NN
D003561_D012769 CID C_29/NNP (r_nsubjpass) associated_32/VBN (r_ccomp) hypothesize_22/VBP (l_advcl) thought_5/VBN (l_xcomp) involved_8/VBN (l_prep) in_9/IN (l_pobj) development_11/NN (l_prep) of_12/IN (l_pobj) shock_14/NN
D003561_D008223 NONE C_10/NNP (l_prep) for_11/IN (l_pobj) lymphoma_12/NN
D003561_D008223 NONE C_13/NNP (r_pobj) with_7/IN (r_prep) treated_6/VBN (l_prep) for_14/IN (l_pobj) lymphomas_15/NNS
D003561_D012128 NONE C_29/NNP (r_nsubjpass) associated_32/VBN (r_ccomp) hypothesize_22/VBP (l_advcl) thought_5/VBN (l_xcomp) involved_8/VBN (l_prep) in_9/IN (l_pobj) development_11/NN (l_prep) of_12/IN (l_pobj) shock_14/NN (l_conj) syndrome_19/NN
24438483
D002045_D002318 NONE bupivacaine_4/NN (r_npadvmod) induced_6/VBN (r_amod) depression_8/NN
D015742_D002318 NONE propofol_14/NN (r_pobj) of_13/IN (r_prep) formulations_12/NNS (r_dobj) using_9/VBG (r_acl) treatment_2/NN (l_prep) of_3/IN (l_pobj) depression_8/NN
D002045_D066126 CID bupivacaine_14/NN (r_pobj) of_13/IN (r_prep) doses_12/NNS (r_dobj) increase_10/VB (r_xcomp) shown_8/VBN (l_conj) alleviate_23/VB (l_dobj) cardiotoxicity_27/NN
D002045_D066126 CID bupivacaine_24/NN (r_npadvmod) induced_26/VBN (r_amod) cardiotoxicity_27/NN
D002045_D066126 CID bupivacaine_18/NN (r_npadvmod) induced_20/VBN (r_amod) cardiotoxicity_21/NN
D002045_D066126 CID bupivacaine_3/NN (r_compound) levels_4/NNS (r_nsubj) were_5/VBD (r_ccomp) conclude_38/VBP (l_ccomp) delayed_56/VBD (l_dobj) onset_58/NN (l_prep) of_59/IN (l_pobj) effects_64/NNS (l_amod) cardiotoxic_63/JJ
D002045_D066126 CID Bupivacaine_15/NNP (r_compound) levels_16/NNS (r_pobj) in_12/IN (r_prep) than_11/IN (r_prep) lower_7/JJR (r_acomp) were_5/VBD (r_ccomp) conclude_38/VBP (l_ccomp) delayed_56/VBD (l_dobj) onset_58/NN (l_prep) of_59/IN (l_pobj) effects_64/NNS (l_amod) cardiotoxic_63/JJ
D002045_D066126 CID bupivacaine_60/NN (r_npadvmod) induced_62/VBN (r_amod) effects_64/NNS (l_amod) cardiotoxic_63/JJ
D002045_D066126 CID bupivacaine_70/NN (r_compound) levels_71/NNS (r_conj) effects_64/NNS (l_amod) cardiotoxic_63/JJ
D015742_D066126 NONE propofol_21/NN (r_pobj) of_20/IN (r_prep) content_19/NN (r_nsubj) alleviate_23/VB (l_dobj) cardiotoxicity_27/NN
D015742_D066126 NONE propofol_11/NN (r_pobj) of_10/IN (r_prep) effects_9/NNS (l_prep) in_12/IN (l_pobj) emulsions_16/NNS (l_prep) on_17/IN (l_pobj) cardiotoxicity_21/NN
D015742_D066126 NONE propofol_44/NN (r_pobj) with_43/IN (r_prep) treatment_42/NN (r_nsubj) delayed_56/VBD (l_dobj) onset_58/NN (l_prep) of_59/IN (l_pobj) effects_64/NNS (l_amod) cardiotoxic_63/JJ
D015742_D066126 NONE propofol_50/NN (r_pobj) with_49/IN (r_prep) compared_48/VBN (r_prep) delayed_56/VBD (l_dobj) onset_58/NN (l_prep) of_59/IN (l_pobj) effects_64/NNS (l_amod) cardiotoxic_63/JJ
D002045_D001145 NONE bupivacaine_37/NN (r_compound) consumption_38/NN (r_pobj) of_36/IN (r_prep) amount_35/NN (r_dobj) recorded_1/VBD (l_prep) to_3/IN (l_pobj) occurrence_6/NN (l_compound) dysrhythmia_5/NN
D002045_D006323 CID bupivacaine_37/NN (r_compound) consumption_38/NN (r_pobj) of_36/IN (r_prep) amount_35/NN (l_nmod) mean_25/VBP (l_dobj) pressure_27/NN (l_conj) time_30/NN (l_conj) asystole_32/NN
10390729
D011188_D009069 NONE K(+)-channel_15/CD (r_nummod) blockers_16/NNS (r_pobj) of_13/IN (r_prep) neither_12/DT (r_nsubj) affected_17/VBD (l_dobj) hypoactivity_21/NN
D011188_D009069 NONE K(+)-channel_25/ADD (r_compound) blockers_26/NNS (r_nsubj) prevented_27/VBD (r_conj) affected_17/VBD (l_dobj) hypoactivity_21/NN
D011188_D009069 NONE K(+)-channels_8/NNS (r_pobj) of_7/IN (r_prep) blockade_6/NN (r_nsubj) is_13/VBZ (l_acomp) sufficient_15/JJ (l_xcomp) prevent_17/VB (l_dobj) hypoactivity_21/NN
D011188_D006948 NONE K(+)-channel_15/CD (r_nummod) blockers_16/NNS (r_pobj) of_13/IN (r_prep) neither_12/DT (r_nsubj) affected_17/VBD (l_conj) prevented_27/VBD (l_dobj) hyperactivity_32/NN
D011188_D006948 NONE K(+)-channel_25/ADD (r_compound) blockers_26/NNS (r_nsubj) prevented_27/VBD (l_dobj) hyperactivity_32/NN
D011188_D006948 NONE K(+)-channels_8/NNS (r_pobj) of_7/IN (r_prep) blockade_6/NN (r_nsubj) is_13/VBZ (l_advcl) seems_27/VBZ (l_nsubj) hyperactivity_26/NN
D009020_D009069 NONE morphine_18/NN (r_npadvmod) induced_20/VBN (r_amod) hypoactivity_21/NN
D009020_D009069 NONE morphine_28/NN (r_npadvmod) induced_30/VBN (r_amod) hyperactivity_32/NN (r_dobj) prevented_27/VBD (r_conj) affected_17/VBD (l_dobj) hypoactivity_21/NN
D009020_D009069 NONE morphine_18/NN (r_amod) induced_20/VBN (r_amod) hypoactivity_21/NN
D009020_D009069 NONE morphine_23/NN (r_npadvmod) induced_25/VBN (r_amod) hyperactivity_26/NN (r_nsubj) seems_27/VBZ (r_advcl) is_13/VBZ (l_acomp) sufficient_15/JJ (l_xcomp) prevent_17/VB (l_dobj) hypoactivity_21/NN
D009020_D006948 CID morphine_18/NN (r_npadvmod) induced_20/VBN (r_amod) hypoactivity_21/NN (r_dobj) affected_17/VBD (l_conj) prevented_27/VBD (l_dobj) hyperactivity_32/NN
D009020_D006948 CID morphine_28/NN (r_npadvmod) induced_30/VBN (r_amod) hyperactivity_32/NN
D009020_D006948 CID morphine_18/NN (r_amod) induced_20/VBN (r_amod) hypoactivity_21/NN (r_dobj) prevent_17/VB (r_xcomp) sufficient_15/JJ (r_acomp) is_13/VBZ (l_advcl) seems_27/VBZ (l_nsubj) hyperactivity_26/NN
D009020_D006948 CID morphine_23/NN (r_npadvmod) induced_25/VBN (r_amod) hyperactivity_26/NN
D011803_D009069 NONE quinine-_33/XX (r_pobj) to_31/IN (r_prep) connected_30/VBN (r_xcomp) seems_27/VBZ (r_advcl) is_13/VBZ (l_acomp) sufficient_15/JJ (l_xcomp) prevent_17/VB (l_dobj) hypoactivity_21/NN
D011803_D006948 NONE quinine-_33/XX (r_pobj) to_31/IN (r_prep) connected_30/VBN (r_xcomp) seems_27/VBZ (l_nsubj) hyperactivity_26/NN
9725303
D019469_D014517 NONE indinavir_11/NNS (r_compound) therapy_12/NN (r_dobj) undergoing_10/VBG (l_nsubj) obstruction_5/NN
D019469_D014517 NONE indinavir_5/JJ (r_compound) crystals_6/NNS (r_pobj) by_3/IN (r_agent) caused_2/VBN (r_acl) obstruction_1/NN
D019469_D014517 NONE indinavir_25/NNP (r_compound) therapy_26/NN (r_dobj) receive_24/VBP (r_relcl) infection_22/NN (r_pobj) with_20/IN (r_prep) patients_19/NNS (r_pobj) in_18/IN (r_prep) stones_15/NNS (l_conj) obstruction_17/NN
D019469_D014514 CID indinavir_16/NNS (r_dobj) receiving_15/VBG (r_acl) patients_14/NNS (r_pobj) in_9/IN (r_prep) calculi_8/NNS
D019469_D014514 NONE indinavir_25/NNP (r_compound) therapy_26/NN (r_dobj) receive_24/VBP (r_relcl) infection_22/NN (r_pobj) with_20/IN (r_prep) patients_19/NNS (r_pobj) in_18/IN (r_prep) stones_15/NNS (l_conj) obstruction_17/NN
D019469_D015658 NONE indinavir_16/NNS (r_dobj) receiving_15/VBG (r_acl) patients_14/NNS (l_amod) infected_13/VBN
D019469_D015658 NONE indinavir_25/NNP (r_compound) therapy_26/NN (r_dobj) receive_24/VBP (r_relcl) infection_22/NN
D019469_D052878 NONE indinavir_16/NNS (l_appos) inhibitor_24/NN (l_relcl) associated_28/VBN (l_prep) with_29/IN (l_pobj) incidence_32/NN (l_prep) of_33/IN (l_pobj) urolithiasis_34/NN
9570197
D003042_D018487 CID cocaine_8/NN (r_pobj) of_6/IN (r_prep) amount_5/NN (r_nsubj) causes_9/VBZ (l_dobj) deterioration_12/NN (l_prep) of_13/IN (l_pobj) function_20/NN
D003042_D018487 CID cocaine_7/NN (r_pobj) of_6/IN (r_prep) infusion_5/NN (r_nsubj) causes_21/VBZ (l_dobj) deterioration_23/NN (l_prep) of_24/IN (l_pobj) performance_29/NN
D003042_D002637 NONE hydrochloride_77/NN (r_appos) saline_68/NN (r_pobj) of_67/IN (r_prep) infusion_66/NN (r_pobj) of_62/IN (r_prep) minutes_61/NNS (r_pobj) during_55/IN (r_conj) before_53/IN (r_prep) pressure_36/NN (r_conj) rate_29/NN (r_dobj) measured_27/VBD (l_ccomp) referred_15/VBN (l_prep) for_16/IN (l_pobj) catheterization_18/NN (l_prep) for_19/IN (l_pobj) evaluation_21/NN (l_prep) of_22/IN (l_pobj) pain_24/NN
3798047
D008775_D001919 CID methylprednisolone_6/NN (r_compound) therapy_7/NN (r_pobj) after_1/IN (r_prep) Bradycardia_0/NN
D008775_D001172 NONE methylprednisolone_13/NN (r_nmod) therapy_17/NN (r_dobj) received_8/VBD (r_relcl) patients_3/NNS (l_prep) with_4/IN (l_pobj) arthritis_6/NN
D008775_D001172 NONE MP_15/NNP (r_nmod) therapy_17/NN (r_dobj) received_8/VBD (r_relcl) patients_3/NNS (l_prep) with_4/IN (l_pobj) arthritis_6/NN
D008775_D006331 NONE MP_3/NNP (r_nsubjpass) contraindicated_6/VBN (l_prep) in_7/IN (l_pobj) patients_8/NNS (l_prep) with_9/IN (l_pobj) disease_12/NN
25031906
D017311_D004408 CID Amlodipine_14/NNP (r_pobj) of_13/IN (r_prep) effect_12/NN (r_attr) be_4/VB (r_xcomp) Going_2/VBG (l_nsubj) Dysguesia_1/NNP
D017311_D004408 CID amlodipine_7/NNP (r_pobj) of_6/IN (r_prep) effect_5/NN (r_nsubj) is_8/VBZ (l_attr) dysguesia_9/NNP
D017311_D004408 CID amlodipine_3/NNP (r_nsubj) cause_5/VB (l_dobj) dysguesia_6/NNP
D017311_D004408 CID amlodipine_13/NNP (l_conj) dysguesia_15/NNP
D017311_D006973 NONE amlodipine_14/NNP (r_nmod) loss_16/NN (r_pobj) with_13/IN (r_prep) hypertension_9/NN
D017311_D012678 NONE amlodipine_14/NNP (r_nmod) loss_16/NN (l_prep) of_17/IN (l_pobj) sensation_19/NN
15817013
D014859_D001281 NONE warfarin_8/NN (r_pobj) on_7/IN (r_prep) aged_1/VBN (l_prep) over_2/IN (l_pobj) 75_3/CD (l_prep) in_4/IN (l_pobj) fibrillation_6/NN
D014859_D001281 NONE warfarin_22/NN (r_pobj) on_18/IN (r_prep) fibrillation_17/NN
D014859_D001281 NONE warfarin_32/NN (r_pobj) on_31/IN (r_prep) fibrillation_30/NN
D014859_D006470 CID warfarin_8/NN (r_pobj) on_7/IN (r_prep) aged_1/VBN (r_acl) People_0/NNS (l_appos) rate_11/NN (l_prep) of_12/IN (l_pobj) hemorrhage_14/NN
D014859_D006470 CID warfarin_22/NN (r_pobj) on_18/IN (r_prep) fibrillation_17/NN (r_pobj) with_15/IN (r_prep) aged_11/VBN (r_acl) people_10/NNS (r_pobj) in_9/IN (r_prep) incidence_3/NN (l_prep) of_4/IN (l_pobj) hemorrhage_6/NN
D014859_D006470 CID warfarin_9/NN (r_amod) use_10/NN (r_conj) strokes_6/NNS (r_conj) episodes_4/NNS (l_amod) bleeding_3/VBG
D014859_D006470 CID warfarin_31/NN (r_pobj) on_30/IN (r_prep) rate_29/NN (r_nsubj) was_32/VBD (r_conj) resulted_18/VBD (r_conj) was_5/VBD (l_nsubj) rate_1/NN (l_prep) of_2/IN (l_pobj) hemorrhage_4/NN
D014859_D006470 CID warfarin_38/NN (r_amod) treatment_39/NN (r_nsubj) is_40/VBZ (r_ccomp) demonstrating_35/VBG (r_advcl) was_32/VBD (r_conj) resulted_18/VBD (r_conj) was_5/VBD (l_nsubj) rate_1/NN (l_prep) of_2/IN (l_pobj) hemorrhage_4/NN
D014859_D020521 NONE warfarin_8/NN (r_pobj) on_7/IN (r_prep) aged_1/VBN (r_acl) People_0/NNS (l_appos) rate_11/NN (l_conj) stroke_16/NN
D014859_D020521 NONE warfarin_22/NN (r_pobj) on_18/IN (r_prep) fibrillation_17/NN (r_pobj) with_15/IN (r_prep) aged_11/VBN (r_acl) people_10/NNS (r_pobj) in_9/IN (r_prep) incidence_3/NN (l_prep) of_4/IN (l_pobj) hemorrhage_6/NN (l_conj) stroke_8/NN
D014859_D020521 NONE warfarin_9/NN (r_amod) use_10/NN (r_conj) strokes_6/NNS
D014859_D020521 NONE warfarin_7/NN (r_pobj) of_6/IN (r_prep) initiation_5/NN (r_pobj) after_4/IN (r_prep) rate_3/NN (l_compound) stroke_2/NN
D014859_D020521 NONE warfarin_31/NN (r_pobj) on_30/IN (r_prep) rate_29/NN (l_compound) stroke_28/NN
D014859_D020521 NONE warfarin_38/NN (r_amod) treatment_39/NN (r_nsubj) is_40/VBZ (r_ccomp) demonstrating_35/VBG (r_advcl) was_32/VBD (l_nsubj) rate_29/NN (l_compound) stroke_28/NN
3925479
D006220_D002375 CID haloperidol_6/NN (r_npadvmod) induced_8/VBN (r_amod) catalepsy_9/NN
D006220_D002375 CID haloperidol_19/NNP (r_appos) blocker_17/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_relcl) catalepsy_10/NN
D006220_D002375 CID haloperidol_8/NN (r_npadvmod) induced_10/VBN (r_amod) catalepsy_11/NN
D006220_D002375 CID haloperidol_19/NNP (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_relcl) catalepsy_13/NN
D006220_D002375 CID haloperidol_15/NNP (r_pobj) as_14/IN (r_prep) neuroleptics_12/NNS (r_pobj) by_11/IN (r_agent) produced_10/VBN (r_relcl) catalepsy_7/NN
D014150_D002375 NONE neuroleptic_25/NN (r_amod) induced_27/VBN (r_amod) catalepsy_28/NN (r_pobj) of_24/IN (r_prep) expression_23/NN (r_pobj) for_21/IN (r_prep) be_19/VB (r_xcomp) need_17/VBP (r_conj) promotes_11/VBZ (l_dobj) catalepsy_12/NN
D014150_D002375 NONE neuroleptic_25/NN (r_amod) induced_27/VBN (r_amod) catalepsy_28/NN
D014150_D002375 NONE neuroleptics_12/NNS (r_pobj) by_11/IN (r_agent) produced_10/VBN (r_relcl) catalepsy_7/NN
D010862_D002375 CID pilocarpine_6/NNP (r_appos) doses_1/NNS (r_nsubj) induce_9/VB (l_dobj) catalepsy_10/NN
D010862_D002375 CID pilocarpine_3/NNP (r_pobj) of_2/IN (r_prep) doses_1/NNS (r_nsubj) caused_4/VBD (l_dobj) enhancement_7/NN (l_prep) of_8/IN (l_pobj) catalepsy_10/NN
D001285_D002375 NONE atropine_5/NN (r_appos) blocker_3/NN (r_nsubj) disrupted_7/VBD (l_dobj) catalepsy_11/NN
D000109_D002375 NONE acetylcholine_4/NN (r_compound) synthesis_6/NN (r_compound) inhibitor_7/NN (r_pobj) of_2/IN (r_prep) injection_1/NN (r_nsubj) prevented_11/VBD (l_dobj) catalepsy_13/NN
D006426_D002375 NONE hemicholinium_9/NNP (r_appos) inhibitor_7/NN (r_pobj) of_2/IN (r_prep) injection_1/NN (r_nsubj) prevented_11/VBD (l_dobj) catalepsy_13/NN
20513036
C542870_D010243 NONE botox_3/NNP (r_compound) injection_4/NN (r_pobj) after_2/IN (r_prep) paralysis_1/NN
C542870_D010243 NONE Botox_10/NNP (r_compound) injections_11/NNS (r_pobj) following_9/VBG (r_prep) report_2/VBP (l_dobj) cases_4/NNS (l_prep) of_5/IN (l_pobj) paralysis_8/NN
C542870_D010243 NONE Botox_12/NNP (r_compound) dose_13/NN (r_conj) sex_9/NN (r_conj) age_7/NN (r_conj) paralysis_5/NN
C542870_D010243 NONE Botox_12/NNP (r_compound) dose_13/NN (r_conj) sex_9/NN (r_conj) age_7/NN (r_conj) paralysis_5/NN (r_pobj) with_2/IN (r_prep) patients_1/NNS (r_pobj) For_0/IN (r_prep) noted_24/VBN (l_advmod) course_20/NN (l_prep) following_21/VBG (l_pobj) paralysis_22/NN
C542870_D010243 NONE Botox_16/NNP (r_compound) dose_17/NN (r_conj) dose_13/NN (r_conj) sex_9/NN (r_conj) age_7/NN (r_conj) paralysis_5/NN
C542870_D010243 NONE Botox_16/NNP (r_compound) dose_17/NN (r_conj) dose_13/NN (r_conj) sex_9/NN (r_conj) age_7/NN (r_conj) paralysis_5/NN (r_pobj) with_2/IN (r_prep) patients_1/NNS (r_pobj) For_0/IN (r_prep) noted_24/VBN (l_advmod) course_20/NN (l_prep) following_21/VBG (l_pobj) paralysis_22/NN
C542870_D010243 NONE Botox_6/NNP (r_compound) injection_7/NN (r_nsubj) was_10/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) paralysis_4/NN
C542870_D010243 NONE Botox_8/NNP (r_compound) injections_9/NNS (r_pobj) of_7/IN (r_prep) complication_6/NN (r_attr) is_3/VBZ (l_nsubj) paralysis_2/NN
C542870_D010243 NONE Botox_8/NNP (r_pobj) of_7/IN (r_prep) diffusion_6/NN (r_attr) is_5/VBZ (l_nsubj) mechanism_2/NN (l_prep) of_3/IN (l_pobj) paralysis_4/NN
C542870_D014826 CID botox_3/NNP (r_compound) injection_4/NN (l_prep) for_5/IN (l_pobj) dysphonia_8/NN
C542870_D014826 CID Botox_3/NNP (r_nmod) injections_5/NNS (r_appos) toxin_1/NN (r_nsubj) are_10/VBP (l_attr) standard_13/NN (l_prep) for_16/IN (l_pobj) dysphonia_19/NN
C542870_D014826 CID Botox_3/NNP (r_nmod) injections_5/NNS (r_appos) toxin_1/NN (r_nsubj) are_10/VBP (l_attr) standard_13/NN (l_prep) for_16/IN (l_pobj) dysphonia_19/NN (l_appos) ADSD_21/NNP
C542870_D014826 CID Botox_10/NNP (r_compound) injections_11/NNS (l_prep) for_12/IN (l_pobj) ADSD_13/NNP
C542870_D014826 CID Botox_7/NNP (r_dobj) receiving_6/VBG (r_acl) patients_5/NNS (r_pobj) of_3/IN (r_prep) database_2/NN (r_pobj) From_0/IN (r_prep) diagnosed_13/VBN (l_prep) with_14/IN (l_pobj) ADSD_15/NNP
C542870_D014826 CID Botox_6/NNP (r_compound) injection_7/NN (l_prep) for_8/IN (l_pobj) ADSD_9/NNP
C542870_D014826 CID Botox_8/NNP (r_compound) injections_9/NNS (r_pobj) of_7/IN (r_prep) complication_6/NN (l_prep) for_10/IN (l_pobj) ADSD_11/NNP
C542870_D055154 NONE Botox_3/NNP (r_compound) injections_4/NNS (r_dobj) received_2/VBD (l_prep) for_5/IN (l_pobj) dysphonia_7/NN
24554916
D010758_D002779 CID phosphorus_4/NN (r_compound) poisoning_5/NN (r_pobj) of_2/IN (r_prep) presentation_1/NN (l_compound) Cholestatic_0/JJ
D010758_D002779 CID phosphorus_6/NN (r_compound) poisoning_7/NN (r_pobj) of_4/IN (r_prep) case_3/NN (l_relcl) patient_11/NN (l_acl) presented_12/VBN (l_prep) with_13/IN (l_pobj) features_16/NNS (l_prep) of_17/IN (l_pobj) cholestasis_18/NN
D010758_D002779 CID phosphorus_6/NN (r_compound) poisoning_7/NN (r_pobj) of_4/IN (r_prep) case_3/NN (l_relcl) patient_11/NN (l_acl) highlighting_19/VBG (l_dobj) fact_21/NN (l_acl) be_26/VB (l_nsubj) cholestasis_23/NN
D010758_D002779 CID phosphorus_32/NN (r_compound) hepatotoxicity_33/NN (r_pobj) of_30/IN (r_prep) feature_29/NN (r_attr) be_26/VB (r_acl) fact_21/NN (r_dobj) highlighting_19/VBG (r_acl) patient_11/NN (l_acl) presented_12/VBN (l_prep) with_13/IN (l_pobj) features_16/NNS (l_prep) of_17/IN (l_pobj) cholestasis_18/NN
D010758_D002779 CID phosphorus_32/NN (r_compound) hepatotoxicity_33/NN (r_pobj) of_30/IN (r_prep) feature_29/NN (r_attr) be_26/VB (l_nsubj) cholestasis_23/NN
D010758_D011041 NONE phosphorus_4/NN (r_compound) poisoning_5/NN
D010758_D011041 NONE phosphorus_3/NN (r_pobj) with_1/IN (r_prep) Poisoning_0/NN
D010758_D011041 NONE phosphorus_6/NN (r_compound) poisoning_7/NN
D010758_D011041 NONE phosphorus_32/NN (r_compound) hepatotoxicity_33/NN (r_pobj) of_30/IN (r_prep) feature_29/NN (r_attr) be_26/VB (r_acl) fact_21/NN (r_dobj) highlighting_19/VBG (r_acl) patient_11/NN (r_relcl) case_3/NN (l_prep) of_4/IN (l_pobj) poisoning_7/NN
D010758_D056486 NONE phosphorus_1/NN (r_nsubj) is_12/VBZ (l_acomp) known_14/JJ (l_xcomp) cause_16/VB (l_dobj) hepatotoxicity_17/NN
D010758_D056486 NONE phosphorus_6/NN (r_compound) poisoning_7/NN (r_pobj) of_4/IN (r_prep) case_3/NN (l_relcl) patient_11/NN (l_acl) highlighting_19/VBG (l_dobj) fact_21/NN (l_acl) be_26/VB (l_attr) feature_29/NN (l_prep) of_30/IN (l_pobj) hepatotoxicity_33/NN
D010758_D056486 NONE phosphorus_32/NN (r_compound) hepatotoxicity_33/NN
D010758_D006505 CID phosphorus_3/NN (r_pobj) with_1/IN (r_prep) Poisoning_0/NN (r_nsubj) manifests_5/VBZ (l_prep) with_6/IN (l_pobj) hepatitis_8/NN
D010758_D017114 CID phosphorus_3/NN (r_pobj) with_1/IN (r_prep) Poisoning_0/NN (r_nsubj) manifests_5/VBZ (l_prep) with_6/IN (l_pobj) hepatitis_8/NN (l_acl) leading_9/VBG (l_prep) to_10/IN (l_pobj) failure_13/NN
17543491
6687006
D003913_D006948 CID amphetamine_6/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) hyperactivity_1/NN
C012102_D006948 NONE DSP4_17/NNP (r_compound) pretreatment_18/NN (r_pobj) by_16/IN (r_agent) reduced_15/VBN (l_nsubjpass) hyperactivity_1/NN
C012102_D006948 NONE DSP4_7/NNP (r_pobj) by_6/IN (r_agent) induced_5/VBN (r_acl) hyperactivity_4/NN
C012102_D006948 NONE DSP4_28/NNP (r_pobj) of_27/IN (r_prep) action_26/NN (r_dobj) prevents_23/VBZ (r_relcl) agent_18/NN (r_pobj) with_12/IN (r_prep) pretreatment_11/NN (r_pobj) by_10/IN (r_agent) blocked_9/VBN (l_nsubjpass) reduction_1/NN (l_prep) of_2/IN (l_pobj) hyperactivity_4/NN
D000661_D019956 NONE amphetamine_7/NN (r_npadvmod) induced_9/VBN (r_amod) stereotypies_10/NNS
C012102_D019956 NONE DSP4_17/NNP (r_pobj) with_16/IN (r_prep) pretreatment_15/NN (r_pobj) by_14/IN (r_agent) blocked_13/VBN (l_nsubjpass) rearings_4/NNS (l_conj) stereotypies_10/NNS
D000661_D006948 NONE amphetamine_3/NN (r_compound) hyperactivity_4/NN
D000661_D020258 NONE amphetamine_3/NN (r_compound) hyperactivity_4/NN (r_pobj) of_2/IN (r_prep) reduction_1/NN (r_nsubjpass) blocked_9/VBN (l_agent) by_10/IN (l_pobj) pretreatment_11/NN (l_prep) with_12/IN (l_pobj) agent_18/NN (l_relcl) prevents_23/VBZ (l_dobj) action_26/NN (l_amod) neurotoxic_25/JJ
C012102_D020258 NONE DSP4_7/NNP (r_pobj) by_6/IN (r_agent) induced_5/VBN (r_acl) hyperactivity_4/NN (r_pobj) of_2/IN (r_prep) reduction_1/NN (r_nsubjpass) blocked_9/VBN (l_agent) by_10/IN (l_pobj) pretreatment_11/NN (l_prep) with_12/IN (l_pobj) agent_18/NN (l_relcl) prevents_23/VBZ (l_dobj) action_26/NN (l_amod) neurotoxic_25/JJ
C012102_D020258 NONE DSP4_28/NNP (r_pobj) of_27/IN (r_prep) action_26/NN (l_amod) neurotoxic_25/JJ
D009638_D006948 NONE noradrenaline_14/NN (r_compound) uptake_16/NN (r_compound) agent_18/NN (r_pobj) with_12/IN (r_prep) pretreatment_11/NN (r_pobj) by_10/IN (r_agent) blocked_9/VBN (l_nsubjpass) reduction_1/NN (l_prep) of_2/IN (l_pobj) hyperactivity_4/NN
D009638_D020258 NONE noradrenaline_14/NN (r_compound) uptake_16/NN (r_compound) agent_18/NN (l_relcl) prevents_23/VBZ (l_dobj) action_26/NN (l_amod) neurotoxic_25/JJ
D003891_D006948 NONE desipramine_20/NNP (r_appos) agent_18/NN (r_pobj) with_12/IN (r_prep) pretreatment_11/NN (r_pobj) by_10/IN (r_agent) blocked_9/VBN (l_nsubjpass) reduction_1/NN (l_prep) of_2/IN (l_pobj) hyperactivity_4/NN
D003891_D020258 NONE desipramine_20/NNP (r_appos) agent_18/NN (l_relcl) prevents_23/VBZ (l_dobj) action_26/NN (l_amod) neurotoxic_25/JJ
20129423
D002220_D004802 CID carbamazepine_1/NN (r_nsubj) induced_2/VBD (l_oprd) eosinophilic_4/JJ
D002220_D004342 CID carbamazepine_1/NN (r_nsubj) induced_2/VBD (l_oprd) eosinophilic_4/JJ (l_appos) hypersensitivity_6/NN
D002220_D004342 CID carbamazepine_1/NN (r_nsubj) induced_2/VBD (l_prep) myocarditis_8/JJ (l_appos) emphasis_10/NN (l_prep) on_11/IN (l_pobj) characteristics_15/NNS (l_conj) mechanisms_17/NNS (l_prep) of_20/IN (l_pobj) hypersensitivity_22/NN
D002220_D004342 CID carbamazepine_10/NN (r_pobj) of_9/IN (r_prep) effect_8/NN (r_nsubj) necrotizing_12/VBG (r_advcl) fatal_2/JJ (r_amod) eosinophilic_13/JJ (r_amod) myocarditis_17/JJ (l_npadvmod) hypersensitivity_15/NN
D002220_D004342 CID carbamazepine_11/NN (r_pobj) of_10/IN (r_prep) administration_9/NN (r_pobj) to_8/IN (r_prep) secondary_7/JJ (r_amod) hypersensitivity_5/NN
D002220_D009205 CID carbamazepine_1/NN (r_nsubj) induced_2/VBD (l_prep) myocarditis_8/JJ
D002220_D009205 CID carbamazepine_10/NN (r_pobj) of_9/IN (r_prep) effect_8/NN (r_nsubj) necrotizing_12/VBG (r_advcl) fatal_2/JJ (r_amod) eosinophilic_13/JJ (r_amod) myocarditis_17/JJ
D002220_D009205 CID carbamazepine_11/NN (r_pobj) of_10/IN (r_prep) administration_9/NN (r_pobj) to_8/IN (r_prep) secondary_7/JJ (l_amod) myocarditis_6/JJ
D002220_D009205 CID carbamazepine_12/NN (r_pobj) of_10/IN (r_prep) case_9/NN (l_acl) induced_13/VBN (l_dobj) myocarditis_14/NN
12119460
D005472_D013274 NONE 5-fluorouracil_3/CD (r_dep) /_4/SYM (r_punct) dose_2/NN (r_amod) acid_6/NN (l_prep) in_7/IN (l_pobj) combination_8/NN (l_prep) in_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) cancer_21/NN
D005472_D013274 NONE 5-fluorouracil_5/CD (r_pobj) of_4/IN (r_prep) infusion_3/NN (l_prep) as_15/IN (l_pobj) part_16/NN (l_prep) of_17/IN (l_pobj) regimens_22/NNS (l_prep) in_23/IN (l_pobj) cancer_26/NN
D005472_D013274 NONE 5-fluorouracil_5/CD (r_pobj) of_4/IN (r_prep) infusion_3/NN (l_prep) as_15/IN (l_pobj) part_16/NN (l_prep) of_17/IN (l_pobj) regimens_22/NNS (l_prep) in_23/IN (l_pobj) cancer_26/NN (l_appos) AGC_28/NNP
D005472_D013274 NONE 5-FU_7/CD (r_pobj) of_4/IN (r_prep) infusion_3/NN (l_prep) as_15/IN (l_pobj) part_16/NN (l_prep) of_17/IN (l_pobj) regimens_22/NNS (l_prep) in_23/IN (l_pobj) cancer_26/NN
D005472_D013274 NONE 5-FU_7/CD (r_pobj) of_4/IN (r_prep) infusion_3/NN (l_prep) as_15/IN (l_pobj) part_16/NN (l_prep) of_17/IN (l_pobj) regimens_22/NNS (l_prep) in_23/IN (l_pobj) cancer_26/NN (l_appos) AGC_28/NNP
D005472_D013274 NONE 5-FU_18/CD (r_pobj) 24-hour_17/NN (r_dobj) receive_15/VB (r_advcl) recruited_9/VBD (l_dobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) AGC_13/NNP
D005472_D013274 NONE 5-FU_3/CD (r_nmod) FA_5/NNP (r_nmod) MMC_7/NNP (r_nsubj) is_8/VBZ (l_attr) regimen_16/NN (l_prep) for_17/IN (l_pobj) AGC_18/NNP
D002955_D013274 NONE acid_6/NN (l_prep) in_7/IN (l_pobj) combination_8/NN (l_prep) in_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) cancer_21/NN
D002955_D013274 NONE acid_11/NN (r_conj) infusion_3/NN (l_prep) as_15/IN (l_pobj) part_16/NN (l_prep) of_17/IN (l_pobj) regimens_22/NNS (l_prep) in_23/IN (l_pobj) cancer_26/NN
D002955_D013274 NONE acid_11/NN (r_conj) infusion_3/NN (l_prep) as_15/IN (l_pobj) part_16/NN (l_prep) of_17/IN (l_pobj) regimens_22/NNS (l_prep) in_23/IN (l_pobj) cancer_26/NN (l_appos) AGC_28/NNP
D002955_D013274 NONE FA_13/NNP (r_appos) acid_11/NN (r_conj) infusion_3/NN (l_prep) as_15/IN (l_pobj) part_16/NN (l_prep) of_17/IN (l_pobj) regimens_22/NNS (l_prep) in_23/IN (l_pobj) cancer_26/NN
D002955_D013274 NONE FA_13/NNP (r_appos) acid_11/NN (r_conj) infusion_3/NN (l_prep) as_15/IN (l_pobj) part_16/NN (l_prep) of_17/IN (l_pobj) regimens_22/NNS (l_prep) in_23/IN (l_pobj) cancer_26/NN (l_appos) AGC_28/NNP
D002955_D013274 NONE FA_27/NNP (r_nmod) mg_29/NN (r_pobj) by_25/IN (r_agent) preceded_24/VBN (r_advcl) recruited_9/VBD (l_dobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) AGC_13/NNP
D002955_D013274 NONE FA_5/NNP (r_nmod) MMC_7/NNP (r_nsubj) is_8/VBZ (l_attr) regimen_16/NN (l_prep) for_17/IN (l_pobj) AGC_18/NNP
D016685_D013274 NONE C_14/NN (r_pobj) with_9/IN (r_prep) combination_8/NN (l_prep) in_15/IN (l_pobj) treatment_17/NN (l_prep) of_18/IN (l_pobj) cancer_21/NN
D016685_D013274 NONE MMC_7/NNP (r_nsubj) is_8/VBZ (l_attr) regimen_16/NN (l_prep) for_17/IN (l_pobj) AGC_18/NNP
D005472_D064420 NONE 5-fluorouracil_5/CD (r_pobj) of_4/IN (r_prep) infusion_3/NN (r_nsubj) shown_31/VBN (l_xcomp) be_33/VB (l_prep) with_36/IN (l_pobj) toxicity_38/NN
D005472_D064420 NONE 5-FU_7/CD (r_pobj) of_4/IN (r_prep) infusion_3/NN (r_nsubj) shown_31/VBN (l_xcomp) be_33/VB (l_prep) with_36/IN (l_pobj) toxicity_38/NN
D002955_D064420 NONE acid_11/NN (r_conj) infusion_3/NN (r_nsubj) shown_31/VBN (l_xcomp) be_33/VB (l_prep) with_36/IN (l_pobj) toxicity_38/NN
D002955_D064420 NONE FA_13/NNP (r_appos) acid_11/NN (r_conj) infusion_3/NN (r_nsubj) shown_31/VBN (l_xcomp) be_33/VB (l_prep) with_36/IN (l_pobj) toxicity_38/NN
D002945_D006463 NONE cisplatin_7/NN (r_npadvmod) containing_9/VBG (r_amod) regimens_10/NNS (r_pobj) to_6/IN (r_prep) alternative_5/NN (r_pobj) as_3/IN (r_prep) serve_2/VB (r_ccomp) has_15/VBZ (l_xcomp) considered_18/VBN (l_ccomp) occur_23/VB (l_nsubj) HUS_21/NNP
3895875
D008012_D009203 NONE lidocaine_1/NN (l_prep) in_2/IN (l_pobj) phase_5/NN (l_prep) of_6/IN (l_pobj) infarction_9/NN
D008012_D009203 NONE lidocaine_25/NN (r_pobj) of_24/IN (r_prep) trial_23/NN (r_dobj) entered_17/VBD (l_nsubj) patients_3/NNS (l_prep) with_4/IN (l_pobj) infarction_7/NN
D008012_D009203 NONE lidocaine_3/NN (r_compound) level_4/NN (r_appos) plasma_2/NN (l_prep) without_11/IN (l_pobj) infarction_14/NN
D008012_D009203 NONE lidocaine_7/NNP (r_pobj) of_6/IN (r_prep) administration_5/NN (r_dobj) advocate_3/VB (l_prep) in_9/IN (l_pobj) hours_12/NNS (l_prep) of_13/IN (l_pobj) infarction_16/NN
D008012_D017180 NONE Lidocaine_0/NNP (r_nsubj) followed_9/VBN (r_ccomp) prevent_17/VB (l_dobj) tachycardia_20/NN
D008012_D017180 NONE lidocaine_45/NNP (r_pobj) of_44/IN (r_prep) administration_43/NN (r_pobj) after_41/IN (r_prep) minutes_40/NNS (r_pobj) between_36/IN (r_prep) warning_34/NN (r_pcomp) with_33/IN (r_prep) patients_32/NNS (r_pobj) of_31/IN (r_prep) number_30/NN (r_pobj) in_28/IN (r_prep) reduction_27/NN (r_attr) was_24/VBD (r_advcl) prevent_17/VB (l_dobj) tachycardia_20/NN
D008012_D001145 NONE Lidocaine_0/NNP (r_nsubj) followed_9/VBN (r_ccomp) prevent_17/VB (l_advcl) was_24/VBD (l_attr) reduction_27/NN (l_prep) in_28/IN (l_pobj) number_30/NN (l_prep) of_31/IN (l_pobj) patients_32/NNS (l_prep) with_33/IN (l_pcomp) warning_34/NN (l_dobj) arrhythmias_35/NNS
D008012_D001145 NONE lidocaine_45/NNP (r_pobj) of_44/IN (r_prep) administration_43/NN (r_pobj) after_41/IN (r_prep) minutes_40/NNS (r_pobj) between_36/IN (r_prep) warning_34/NN (l_dobj) arrhythmias_35/NNS
D008012_D007238 NONE lidocaine_3/NN (r_compound) level_4/NN (r_appos) plasma_2/NN (r_nsubj) was_15/VBD (l_prep) for_20/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) infarction_25/NN
D008012_D007022 CID lidocaine_19/NN (r_compound) group_20/NN (r_pobj) in_17/IN (r_prep) was_14/VBD (r_ccomp) occurred_23/VBD (l_nsubj) hypotension_22/NN
D008012_D007022 CID lidocaine_33/NN (r_dobj) received_32/VBN (r_relcl) patients_26/NNS (r_pobj) in_24/IN (r_prep) occurred_23/VBD (l_nsubj) hypotension_22/NN
D008012_D007022 CID lidocaine_47/NN (r_dobj) had_46/VBN (r_relcl) asystole_40/NN (r_pobj) from_39/IN (r_prep) died_38/VBD (r_conj) occurred_23/VBD (l_nsubj) hypotension_22/NN
D008012_D006323 NONE lidocaine_19/NN (r_compound) group_20/NN (r_pobj) in_17/IN (r_prep) was_14/VBD (r_ccomp) occurred_23/VBD (l_conj) died_38/VBD (l_prep) from_39/IN (l_pobj) asystole_40/NN
D008012_D006323 NONE lidocaine_33/NN (r_dobj) received_32/VBN (r_relcl) patients_26/NNS (r_pobj) in_24/IN (r_prep) occurred_23/VBD (l_conj) died_38/VBD (l_prep) from_39/IN (l_pobj) asystole_40/NN
D008012_D006323 NONE lidocaine_47/NN (r_dobj) had_46/VBN (r_relcl) asystole_40/NN
11474137
D003300_D034381 NONE copper_2/NN (r_nmod) dismutase_7/NN (r_pobj) of_1/IN (r_prep) Overexpression_0/NN (r_nsubj) protects_8/VBZ (l_prep) from_9/IN (l_pobj) loss_14/NN
D015032_D034381 NONE zinc_4/NN (r_compound) superoxide_6/NN (r_compound) dismutase_7/NN (r_pobj) of_1/IN (r_prep) Overexpression_0/NN (r_nsubj) protects_8/VBZ (l_prep) from_9/IN (l_pobj) loss_14/NN
D013481_D034381 NONE superoxide_6/NN (r_compound) dismutase_7/NN (r_pobj) of_1/IN (r_prep) Overexpression_0/NN (r_nsubj) protects_8/VBZ (l_prep) from_9/IN (l_pobj) loss_14/NN
D007612_D034381 CID kanamycin_10/NNP (r_npadvmod) induced_12/VBN (r_amod) loss_14/NN
D010100_D006311 NONE oxygen_4/NN (r_compound) species_5/NNS (l_prep) in_6/IN (l_pobj) ototoxicity_10/NN
D010100_D006311 NONE oxygen_4/NN (r_compound) species_5/NNS (r_pobj) of_2/IN (r_prep) participation_1/NN (r_nsubjpass) deduced_13/VBN (l_prep) from_14/IN (l_pobj) observations_15/NNS (l_acl) catalyze_21/VBP (l_conj) attenuate_32/VBP (l_dobj) ototoxicity_33/NN
D000617_D006311 NONE aminoglycoside_7/RB (r_npadvmod) induced_9/VBN (r_amod) ototoxicity_10/NN
D000617_D006311 NONE aminoglycoside_7/RB (r_npadvmod) induced_9/VBN (r_amod) ototoxicity_10/NN (r_pobj) in_6/IN (r_prep) species_5/NNS (r_pobj) of_2/IN (r_prep) participation_1/NN (r_nsubjpass) deduced_13/VBN (l_prep) from_14/IN (l_pobj) observations_15/NNS (l_acl) catalyze_21/VBP (l_conj) attenuate_32/VBP (l_dobj) ototoxicity_33/NN
D000617_D006311 NONE aminoglycoside_17/JJ (r_compound) iron_19/NN (r_compound) complexes_20/NNS (r_nsubj) catalyze_21/VBP (r_acl) observations_15/NNS (r_pobj) from_14/IN (r_prep) deduced_13/VBN (l_nsubjpass) participation_1/NN (l_prep) of_2/IN (l_pobj) species_5/NNS (l_prep) in_6/IN (l_pobj) ototoxicity_10/NN
D000617_D006311 NONE aminoglycoside_17/JJ (r_compound) iron_19/NN (r_compound) complexes_20/NNS (r_nsubj) catalyze_21/VBP (l_conj) attenuate_32/VBP (l_dobj) ototoxicity_33/NN
D000617_D006311 NONE aminoglycoside_18/RB (r_npadvmod) induced_20/VBN (r_amod) ototoxicity_21/NN
D007501_D006311 NONE iron_19/NN (r_compound) complexes_20/NNS (r_nsubj) catalyze_21/VBP (r_acl) observations_15/NNS (r_pobj) from_14/IN (r_prep) deduced_13/VBN (l_nsubjpass) participation_1/NN (l_prep) of_2/IN (l_pobj) species_5/NNS (l_prep) in_6/IN (l_pobj) ototoxicity_10/NN
D007501_D006311 NONE iron_19/NN (r_compound) complexes_20/NNS (r_nsubj) catalyze_21/VBP (l_conj) attenuate_32/VBP (l_dobj) ototoxicity_33/NN
D013481_D006311 NONE superoxide_25/NN (r_amod) radicals_26/NNS (r_pobj) of_24/IN (r_prep) formation_23/NN (r_dobj) catalyze_21/VBP (r_acl) observations_15/NNS (r_pobj) from_14/IN (r_prep) deduced_13/VBN (l_nsubjpass) participation_1/NN (l_prep) of_2/IN (l_pobj) species_5/NNS (l_prep) in_6/IN (l_pobj) ototoxicity_10/NN
D013481_D006311 NONE superoxide_25/NN (r_amod) radicals_26/NNS (r_pobj) of_24/IN (r_prep) formation_23/NN (r_dobj) catalyze_21/VBP (l_conj) attenuate_32/VBP (l_dobj) ototoxicity_33/NN
D013481_D006311 NONE superoxide_10/NN (r_compound) dismutase_11/NN (r_pobj) of_5/IN (r_prep) overexpression_4/NN (r_nsubj) protect_18/VB (l_prep) from_21/IN (l_pobj) ototoxicity_22/NN
D013481_D006311 NONE superoxide_5/NN (r_compound) dismutase_6/NN (r_pobj) of_4/IN (r_prep) overexpression_3/NN (r_pobj) by_2/IN (r_prep) protection_1/NN (r_nsubj) supports_7/VBZ (l_dobj) hypothesis_9/NN (l_acl) plays_13/VBZ (l_prep) in_17/IN (l_pobj) ototoxicity_21/NN
D003300_D006311 NONE Cu_6/JJ (r_nmod) superoxide_10/NN (r_compound) dismutase_11/NN (r_pobj) of_5/IN (r_prep) overexpression_4/NN (r_nsubj) protect_18/VB (l_prep) from_21/IN (l_pobj) ototoxicity_22/NN
D015032_D006311 NONE Zn_8/JJ (r_compound) superoxide_10/NN (r_compound) dismutase_11/NN (r_pobj) of_5/IN (r_prep) overexpression_4/NN (r_nsubj) protect_18/VB (l_prep) from_21/IN (l_pobj) ototoxicity_22/NN
19728177
D000082_D017114 CID acetaminophen_27/NN (r_nmod) edema_31/NN (r_pobj) from_26/IN (r_prep) facility_17/NN (l_prep) in_18/IN (l_pobj) female_23/NN (l_prep) with_24/IN (l_pobj) FHF_25/NNP
D000082_D017114 CID acetaminophen_5/NN (r_pobj) from_4/IN (r_prep) confirmed_2/VBD (l_dobj) FHF_3/NNP
D000082_D017114 CID acetaminophen_8/NN (r_compound) overdose_9/NN (r_pobj) from_7/IN (r_prep) patients_1/NNS (l_prep) with_2/IN (l_pobj) FHF_3/NNP
D000082_D001929 CID acetaminophen_27/NN (r_nmod) edema_31/NN
D000082_D001929 CID acetaminophen_5/NN (l_conj) edema_8/NN
D000082_D001929 CID acetaminophen_8/NN (r_compound) overdose_9/NN (r_pobj) from_7/IN (r_prep) patients_1/NNS (l_prep) with_2/IN (l_pobj) FHF_3/NNP (l_conj) edema_6/NN
D000082_D064420 NONE acetaminophen_15/NN (r_pobj) from_14/IN (r_prep) toxicity_13/NN
D000082_D062787 NONE acetaminophen_8/NN (r_compound) overdose_9/NN
D000082_D007035 NONE acetaminophen_8/NN (r_compound) overdose_9/NN (r_pobj) from_7/IN (r_prep) patients_1/NNS (r_pobj) In_0/IN (r_prep) used_17/VBN (l_nsubjpass) hypothermia_13/NN
10510854
D006220_D002375 CID haloperidol_9/NNP (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) catalepsy_6/NN
16906379
D008911_D014657 NONE Minocycline_0/NNP (r_npadvmod) induced_2/VBN (r_amod) vasculitis_3/NN
D008911_D014657 NONE minocycline_10/NN (r_npadvmod) induced_12/VBN (r_amod) vasculitis_13/NN
D008911_D010488 CID Minocycline_0/NNP (r_npadvmod) induced_2/VBN (r_amod) vasculitis_3/NN (l_acl) fulfilling_4/VBG (l_dobj) criteria_6/NNS (l_prep) of_7/IN (l_pobj) nodosa_9/NNP
D008911_D011565 NONE minocycline_9/NNP (r_dobj) taking_8/VBG (l_prep) for_10/IN (l_pobj) fever_14/NN (l_nmod) pustulosis_12/NNP
D008911_D005334 NONE minocycline_9/NNP (r_dobj) taking_8/VBG (l_prep) for_10/IN (l_pobj) fever_14/NN
D008911_D063806 NONE minocycline_9/NNP (r_dobj) taking_8/VBG (r_relcl) man_4/NN (l_appos) myalgias_16/NNP
D008911_D011115 NONE minocycline_9/NNP (r_dobj) taking_8/VBG (r_relcl) man_4/NN (l_appos) myalgias_16/NNP (l_conj) polyneuropathy_18/NNS
D008911_D013733 NONE minocycline_9/NNP (r_dobj) taking_8/VBG (r_relcl) man_4/NN (l_appos) myalgias_16/NNP (l_conj) polyneuropathy_18/NNS (l_conj) pain_22/NN
12535818
D000638_D001919 CID Amiodarone_0/NNP (l_conj) risk_3/NN (l_prep) of_4/IN (l_pobj) bradyarrhythmia_5/NN
D000638_D001919 CID amiodarone_12/NN (r_pobj) of_11/IN (r_prep) use_10/NN (r_nsubj) increases_21/VBZ (l_dobj) risk_23/NN (l_prep) of_24/IN (l_pobj) bradyarrhythmia_25/NN
D000638_D001919 CID amiodarone_5/NN (r_compound) therapy_6/NN (r_pobj) during_4/IN (r_prep) Reports_0/NNS (l_prep) of_1/IN (l_pobj) bradyarrhythmia_3/NN
D000638_D001919 CID amiodarone_7/NN (r_pobj) of_6/IN (r_prep) use_5/NN (r_nsubj) increases_17/VBZ (l_dobj) risk_19/NN (l_prep) of_20/IN (l_pobj) bradyarrhythmia_21/NN
D000638_D001281 NONE Amiodarone_0/NNP (l_conj) risk_3/NN (l_prep) of_4/IN (l_pobj) bradyarrhythmia_5/NN (l_acl) requiring_6/VBG (l_prep) in_9/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) fibrillation_14/NN
D000638_D001281 NONE amiodarone_12/NN (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) fibrillation_17/NN
D000638_D001281 NONE amiodarone_12/NN (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) fibrillation_17/NN (l_appos) AF_19/NNP
D000638_D001281 NONE amiodarone_7/NN (r_pobj) of_6/IN (r_prep) use_5/NN (l_prep) with_11/IN (l_pobj) AF_12/NNP
D000638_D009203 NONE Amiodarone_0/NNP (l_conj) risk_3/NN (l_prep) of_4/IN (l_pobj) bradyarrhythmia_5/NN (l_acl) requiring_6/VBG (l_prep) in_9/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) fibrillation_14/NN (l_conj) infarction_18/NN
D000638_D009203 NONE amiodarone_7/NN (r_pobj) of_6/IN (r_prep) use_5/NN (l_conj) MI_16/NN
D000638_D001145 NONE amiodarone_5/NN (r_compound) therapy_6/NN (r_pobj) during_4/IN (r_prep) Reports_0/NNS (r_nsubj) are_7/VBP (l_acomp) infrequent_8/JJ (l_conj) limited_10/JJ (l_prep) to_11/IN (l_pobj) studies_12/NNS (l_acl) assessing_13/VBG (l_dobj) use_17/NN (l_prep) in_18/IN (l_pobj) management_20/NN (l_prep) of_21/IN (l_pobj) patients_22/NNS (l_prep) with_23/IN (l_pobj) arrhythmias_25/NNS
24068571
D013874_D003693 CID thiopentone_3/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubjpass) associated_6/VBN (l_prep) with_7/IN (l_pobj) risk_14/NN (l_prep) for_15/IN (l_pobj) delirium_16/NN
D015742_D003693 NONE propofol_19/NN (r_pobj) to_18/IN (r_prep) compared_17/VBN (r_prep) risk_14/NN (l_prep) for_15/IN (l_pobj) delirium_16/NN
26033014
C051786_D009369 NONE metolachlor_3/NN (r_compound) use_4/NN (r_conj) incidence_1/NN (l_compound) Cancer_0/NN
C051786_D009369 NONE metolachlor_22/NNP (r_dobj) using_21/VBG (r_xcomp) reported_19/VBD (r_relcl) applicators_13/NNS (r_pobj) for_11/IN (r_prep) evaluated_1/VBD (l_dobj) incidence_3/NN (l_compound) cancer_2/NN
C051786_D009369 NONE metolachlor_11/NN (r_compound) use_12/NN (r_pobj) of_10/IN (r_prep) metrics_9/NNS (l_appos) days_15/NNS (l_conj) incidence_25/NN (l_compound) cancer_24/NN
C051786_D009369 NONE metolachlor_5/NNP (r_compound) use_6/NN (l_prep) of_9/IN (l_pobj) cancers_11/NNS
C051786_D009369 NONE metolachlor_5/NNP (r_compound) use_6/NN (l_prep) of_9/IN (l_pobj) cancers_11/NNS (l_acl) combined_12/VBN (l_prep) with_17/IN (l_pobj) lag_20/NN (l_conj) cancers_27/NNS
C051786_D008113 CID Metolachlor_0/NNP (r_nsubjpass) classified_8/VBN (l_agent) by_14/IN (l_pobj) Agency_19/NNP (l_acl) based_20/VBN (l_prep) on_21/IN (l_pobj) neoplasms_24/NNS
C051786_D008113 CID metolachlor_6/NNP (r_nmod) cancer_9/NN
C051786_D008113 CID metolachlor_6/NNP (r_nmod) cancer_9/NN (r_pobj) between_5/IN (r_prep) association_4/NN (r_pobj) of_2/IN (r_prep) suggestion_1/NN (r_nsubj) is_13/VBZ (l_conj) echoes_18/VBZ (l_dobj) observation_19/NN (l_prep) of_20/IN (l_pobj) neoplasms_23/NNS
C051786_D008113 CID metolachlor_21/NN (r_compound) use_22/NN (r_pobj) of_20/IN (r_prep) effects_19/NNS (r_dobj) differentiate_18/VB (l_nsubj) findings_3/NNS (l_prep) for_4/IN (l_pobj) cancer_7/NN
C051786_D008175 NONE metolachlor_12/NN (r_compound) use_13/NN (r_pobj) of_11/IN (r_prep) levels_10/NNS (r_pobj) at_8/IN (r_prep) suggestion_2/NN (l_prep) of_3/IN (l_pobj) risk_7/NN (l_compound) cancer_6/NN
C051786_D008223 NONE metolachlor_21/NN (r_compound) use_22/NN (r_pobj) of_20/IN (r_prep) effects_19/NNS (r_dobj) differentiate_18/VB (l_nsubj) findings_3/NNS (l_prep) for_4/IN (l_pobj) cancer_7/NN (l_conj) up_15/NN (l_compound) warrant_12/NN (l_compound) lymphoma_11/NN
24709919
D036145_D006930 NONE ginsenosides_2/NNS (l_prep) on_3/IN (l_pobj) hyperalgesia_7/NN
C049864_D006930 NONE ginsenosides_15/NNS (r_conj) Rg1_11/NN (r_pobj) of_8/IN (r_prep) effects_7/NNS (l_prep) on_23/IN (l_pobj) OIH_24/NNP
C049864_D006930 NONE Re_0/IN (r_prep) inhibited_5/VBD (l_dobj) OIH_6/NNP
C049864_D006930 NONE Re_6/NN (r_intj) ginsenoside_5/NN (r_nsubj) contribute_15/VB (l_prep) toward_16/IN (l_pobj) reversal_17/NN (l_prep) of_18/IN (l_pobj) OIH_19/NNP
C035054_D006930 NONE ginsenosides_15/NNS (r_conj) Rg1_11/NN (r_pobj) of_8/IN (r_prep) effects_7/NNS (l_prep) on_23/IN (l_pobj) OIH_24/NNP
C035054_D006930 NONE ginsenosides_6/NNS (r_nsubj) failed_7/VBD (l_xcomp) prevent_9/VB (l_dobj) OIH_10/NNP
C035054_D006930 NONE Rg1_2/NN (r_nsubj) showed_3/VBD (l_dobj) tendency_5/NN (l_acl) aggravate_7/VB (l_dobj) OIH_8/NNP
C035054_D006930 NONE Rg1_10/NN (r_nsubj) contribute_15/VB (l_prep) toward_16/IN (l_pobj) reversal_17/NN (l_prep) of_18/IN (l_pobj) OIH_19/NNP
C442759_D006930 NONE ginsenosides_15/NNS (r_conj) Rg1_11/NN (r_pobj) of_8/IN (r_prep) effects_7/NNS (l_prep) on_23/IN (l_pobj) OIH_24/NNP
C442759_D006930 NONE ginsenosides_6/NNS (r_nsubj) failed_7/VBD (l_xcomp) prevent_9/VB (l_dobj) OIH_10/NNP
C442759_D006930 NONE Rb1_12/CD (r_conj) Rg1_10/NN (r_nsubj) contribute_15/VB (l_prep) toward_16/IN (l_pobj) reversal_17/NN (l_prep) of_18/IN (l_pobj) OIH_19/NNP
D009020_D006930 CID morphine_9/NNP (r_pobj) of_8/IN (r_prep) administration_7/NN (r_pobj) after_5/IN (r_prep) achieved_2/VBN (l_nsubjpass) OIH_0/NNP
D019342_D006930 NONE acid_16/NN (r_npadvmod) induced_18/VBN (r_amod) test_20/NN (r_conj) test_12/NN (r_pobj) in_7/IN (r_prep) inhibited_5/VBD (l_dobj) OIH_6/NNP
D019342_D006930 NONE acid_12/NN (r_npadvmod) induced_14/VBN (r_amod) test_16/NN (r_pobj) in_9/IN (r_prep) aggravate_7/VB (l_dobj) OIH_8/NNP
1360900
D004976_D012640 CID acid_1/NN (r_npadvmod) induced_3/VBN (r_amod) convulsions_4/NNS
D004976_D012640 CID acid_4/NN (r_pobj) of_2/IN (r_prep) injection_1/NN (l_appos) dose_9/NN (l_amod) convulsive_8/JJ
D004976_D012640 CID acid_2/NN (r_npadvmod) induced_4/VBN (r_amod) convulsions_5/NNS
D012701_D012640 NONE 5-hydroxytryptamine_22/CD (r_pobj) of_21/IN (r_prep) turnover_20/NN (r_dobj) accelerated_16/VBD (l_nsubj) injection_1/NN (l_appos) dose_9/NN (l_amod) convulsive_8/JJ
D012701_D012640 NONE 5-HT_24/CD (r_appos) turnover_20/NN (r_dobj) accelerated_16/VBD (l_nsubj) injection_1/NN (l_appos) dose_9/NN (l_amod) convulsive_8/JJ
D005680_D012640 NONE acid_34/NN (r_pobj) of_30/IN (r_prep) synthesis_29/NN (r_dobj) suppressed_27/VBD (r_conj) accelerated_16/VBD (l_nsubj) injection_1/NN (l_appos) dose_9/NN (l_amod) convulsive_8/JJ
D000109_D012640 NONE acetylcholine_36/NN (r_conj) acid_34/NN (r_pobj) of_30/IN (r_prep) synthesis_29/NN (r_dobj) suppressed_27/VBD (r_conj) accelerated_16/VBD (l_nsubj) injection_1/NN (l_appos) dose_9/NN (l_amod) convulsive_8/JJ
7661171
D016595_D007674 NONE misoprostol_6/NNP (r_pobj) of_5/IN (r_prep) effect_4/NN (l_prep) on_7/IN (l_pobj) dysfunction_12/NN
D016595_D007674 NONE Misoprostol_0/NNP (r_nsubjpass) shown_7/VBN (l_xcomp) counteract_10/VB (l_dobj) dysfunction_16/NN
D016595_D005355 NONE misoprostol_6/NNP (r_pobj) of_5/IN (r_prep) effect_4/NN (l_prep) on_7/IN (l_pobj) dysfunction_12/NN (l_prep) in_13/IN (l_pobj) cirrhosis_16/NN
D016595_D005355 NONE Misoprostol_0/NNP (r_nsubjpass) shown_7/VBN (l_xcomp) counteract_10/VB (l_dobj) dysfunction_16/NN (l_prep) in_17/IN (l_pobj) patients_21/NNS (l_amod) cirrhotic_20/JJ
D016595_D005355 NONE misoprostol_36/NN (r_pobj) of_35/IN (r_prep) doses_34/NNS (r_conj) indomethacin_31/NN (r_pobj) of_30/IN (r_prep) mg_29/NNS (r_pobj) of_27/IN (r_prep) combination_26/NN (r_pobj) after_23/IN (r_conj) before_21/IN (r_prep) assessed_11/VBN (l_prep) in_15/IN (l_pobj) patients_20/NNS (l_amod) cirrhotic_19/JJ
D016595_D005355 NONE misoprostol_10/NN (r_pobj) of_9/IN (r_prep) micrograms_8/NNS (r_pobj) of_6/IN (r_prep) ability_5/NN (r_nsubjpass) confirmed_22/VBN (r_advcl) be_30/VB (l_xcomp) avoid_33/VB (l_dobj) therapy_38/NN (l_prep) in_39/IN (l_pobj) patients_40/NNS (l_prep) with_41/IN (l_pobj) cirrhosis_42/NN
D007213_D007674 CID indomethacin_8/NN (r_npadvmod) induced_10/VBN (r_amod) dysfunction_12/NN
D007213_D007674 CID indomethacin_12/NN (r_npadvmod) induced_14/VBN (r_amod) dysfunction_16/NN
D007213_D005355 NONE indomethacin_8/NN (r_npadvmod) induced_10/VBN (r_amod) dysfunction_12/NN (l_prep) in_13/IN (l_pobj) cirrhosis_16/NN
D007213_D005355 NONE indomethacin_12/NN (r_npadvmod) induced_14/VBN (r_amod) dysfunction_16/NN (l_prep) in_17/IN (l_pobj) patients_21/NNS (l_amod) cirrhotic_20/JJ
D007213_D005355 NONE indomethacin_31/NN (r_pobj) of_30/IN (r_prep) mg_29/NNS (r_pobj) of_27/IN (r_prep) combination_26/NN (r_pobj) after_23/IN (r_conj) before_21/IN (r_prep) assessed_11/VBN (l_prep) in_15/IN (l_pobj) patients_20/NNS (l_amod) cirrhotic_19/JJ
D007213_D005355 NONE indomethacin_17/NN (r_pobj) of_16/IN (r_prep) effects_15/NNS (r_dobj) prevent_12/VB (r_acl) ability_5/NN (r_nsubjpass) confirmed_22/VBN (r_advcl) be_30/VB (l_xcomp) avoid_33/VB (l_dobj) therapy_38/NN (l_prep) in_39/IN (l_pobj) patients_40/NNS (l_prep) with_41/IN (l_pobj) cirrhosis_42/NN
D012964_D005355 NONE sodium_6/NN (r_conj) hemodynamics_3/NNS (r_pobj) of_1/IN (r_prep) Parameters_0/NNS (r_nsubjpass) assessed_11/VBN (l_prep) in_15/IN (l_pobj) patients_20/NNS (l_amod) cirrhotic_19/JJ
6985498
D008733_D056486 CID methoxyflurane_8/NNP (r_pobj) with_7/IN (r_prep) anesthesia_6/NN (r_pobj) after_5/IN (r_prep) Hepatitis_0/NN
D008733_D000141 CID methoxyflurane_8/NNP (r_pobj) with_7/IN (r_prep) anesthesia_6/NN (r_pobj) after_5/IN (r_prep) Hepatitis_0/NN (l_conj) acidosis_4/NN
D008733_D000141 CID methoxyflurane_10/NNP (r_compound) anesthesia_11/NN (r_pobj) under_9/IN (r_prep) operated_5/VBN (r_acl) man_4/NN (r_nsubj) developed_12/VBD (l_dobj) syndrome_17/NN (l_conj) acidosis_21/NN
D008733_D041881 NONE methoxyflurane_10/NNP (r_compound) anesthesia_11/NN (r_pobj) under_9/IN (r_prep) operated_5/VBN (l_prep) for_6/IN (l_pobj) cholecystitis_8/NN
D008733_D048550 NONE methoxyflurane_10/NNP (r_compound) anesthesia_11/NN (r_pobj) under_9/IN (r_prep) operated_5/VBN (r_acl) man_4/NN (r_nsubj) developed_12/VBD (l_dobj) syndrome_17/NN
23952588
D007980_D004409 CID levodopa_5/NN (r_npadvmod) induced_7/VBN (r_amod) dyskinesia_8/NN
D007980_D004409 CID levodopa_2/NN (r_compound) therapy_3/NN (r_nsubj) leads_11/VBZ (l_prep) to_12/IN (l_pobj) development_14/NN (l_prep) of_15/IN (l_pobj) fluctuations_17/NNS (l_conj) dyskinesia_19/NN
D007980_D004409 CID levodopa_7/NN (r_npadvmod) induced_9/VBN (r_amod) dyskinesia_10/NN
D007980_D004409 CID levodopa_13/NN (r_compound) therapy_14/NN (r_pobj) with_11/IN (r_prep) was_1/VBD (l_nsubj) Dyskinesia_0/NNP
D007980_D004409 CID levodopa_16/NN (r_compound) therapy_17/NN (r_pobj) of_15/IN (r_prep) duration_14/NN (r_appos) age_6/NN (r_dobj) had_3/VBD (l_nsubj) Patients_0/NNS (l_prep) with_1/IN (l_pobj) dyskinesia_2/NN
D007980_D004409 CID levodopa_16/NN (r_compound) therapy_17/NN (r_pobj) of_15/IN (r_prep) duration_14/NN (r_appos) age_6/NN (l_appos) duration_26/NN (l_appos) dose_37/NN (l_conj) scores_48/NNS (l_prep) than_54/IN (l_pobj) patients_55/NNS (l_prep) without_56/IN (l_pobj) dyskinesia_57/NN
D007980_D004409 CID levodopa_36/NN (r_compound) dose_37/NN (r_appos) duration_26/NN (r_appos) age_6/NN (r_dobj) had_3/VBD (l_nsubj) Patients_0/NNS (l_prep) with_1/IN (l_pobj) dyskinesia_2/NN
D007980_D004409 CID levodopa_36/NN (r_compound) dose_37/NN (l_conj) scores_48/NNS (l_prep) than_54/IN (l_pobj) patients_55/NNS (l_prep) without_56/IN (l_pobj) dyskinesia_57/NN
D007980_D004409 CID levodopa_9/NN (r_compound) therapy_10/NN (r_pobj) of_8/IN (r_prep) duration_7/NN (r_attr) were_6/VBD (l_nsubj) predictors_3/NNS (l_prep) of_4/IN (l_pobj) dyskinesia_5/NN
D007980_D004409 CID levodopa_18/NN (r_compound) dose_19/NN (r_conj) age_13/NN (r_conj) therapy_10/NN (r_pobj) of_8/IN (r_prep) duration_7/NN (r_attr) were_6/VBD (l_nsubj) predictors_3/NNS (l_prep) of_4/IN (l_pobj) dyskinesia_5/NN
D007980_D004409 CID levodopa_3/NN (r_npadvmod) induced_5/VBN (r_amod) dyskinesia_6/NN
D007980_D010300 NONE levodopa_5/NN (r_npadvmod) induced_7/VBN (r_amod) dyskinesia_8/NN (r_pobj) of_4/IN (r_prep) predictors_3/NNS (r_conj) factors_1/NNS (l_prep) among_9/IN (l_pobj) Malaysians_11/NNPS (l_prep) with_12/IN (l_pobj) disease_15/NN
D007980_D010300 NONE levodopa_2/NN (r_compound) therapy_3/NN (l_prep) for_4/IN (l_pobj) disease_7/NN
D007980_D010300 NONE levodopa_2/NN (r_compound) therapy_3/NN (l_prep) for_4/IN (l_pobj) disease_7/NN (l_appos) PD_9/NNP
D007980_D010300 NONE levodopa_7/NN (r_npadvmod) induced_9/VBN (r_amod) dyskinesia_10/NN (r_pobj) of_6/IN (r_prep) prevalence_3/NN (r_dobj) studied_1/VBD (l_prep) with_15/IN (l_pobj) PD_16/NNP
D007980_D010300 NONE levodopa_14/NN (r_compound) therapy_15/NN (r_pobj) on_12/IN (r_prep) involving_7/VBG (l_dobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) PD_11/NNP
24345882
D008727_D054198 NONE methotrexate_9/NNP (r_compound) consequence_10/NN (r_appos) protocols_3/NNS (l_compound) leukemia_2/NN
D008727_D054198 NONE methotrexate_5/NN (r_nmod) neurotoxicity_9/NN (r_pobj) about_1/IN (r_prep) Concerns_0/NNS (r_nsubj) led_13/VBN (l_prep) to_14/IN (l_pobj) modifications_15/NNS (l_prep) in_16/IN (l_pobj) therapy_21/NN (l_conj) rescue_24/NN (l_conj) frequency_27/NN (l_prep) of_28/IN (l_pobj) administration_31/NN (l_prep) in_32/IN (l_pobj) children_33/NNS (l_prep) with_34/IN (l_pobj) leukemia_37/NN
D008727_D054198 NONE MTX_7/NNP (r_nmod) neurotoxicity_9/NN (r_pobj) about_1/IN (r_prep) Concerns_0/NNS (r_nsubj) led_13/VBN (l_prep) to_14/IN (l_pobj) modifications_15/NNS (l_prep) in_16/IN (l_pobj) therapy_21/NN (l_conj) rescue_24/NN (l_conj) frequency_27/NN (l_prep) of_28/IN (l_pobj) administration_31/NN (l_prep) in_32/IN (l_pobj) children_33/NNS (l_prep) with_34/IN (l_pobj) leukemia_37/NN
D008727_D054198 NONE MTX_30/NNP (r_compound) administration_31/NN (l_prep) in_32/IN (l_pobj) children_33/NNS (l_prep) with_34/IN (l_pobj) leukemia_37/NN
D008727_D020258 NONE methotrexate_5/NN (r_nmod) neurotoxicity_9/NN
D008727_D020258 NONE MTX_7/NNP (r_nmod) neurotoxicity_9/NN
D008727_D020258 NONE MTX_30/NNP (r_compound) administration_31/NN (r_pobj) of_28/IN (r_prep) frequency_27/NN (r_conj) rescue_24/NN (r_conj) therapy_21/NN (r_pobj) in_16/IN (r_prep) modifications_15/NNS (r_pobj) to_14/IN (r_prep) led_13/VBN (l_nsubj) Concerns_0/NNS (l_prep) about_1/IN (l_pobj) neurotoxicity_9/NN
611664
D011433_C544351 NONE propranolol_2/NNS (r_pobj) of_1/IN (r_prep) Use_0/NN (l_prep) in_3/IN (l_pobj) treatment_5/NN (l_prep) of_6/IN (l_pobj) hypotension_9/NN
D011433_C544351 NONE propranolol_4/NN (r_nsubj) is_5/VBZ (l_attr) drug_8/NN (l_prep) in_9/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) hypotension_16/NN
D002395_D004342 NONE catecholamines_6/NNS (r_dobj) exhibited_2/VBD (l_conj) marked_19/VBN (l_dobj) hypersensitivity_20/NN
D009638_D004342 NONE norepinephrine_27/NN (r_pobj) of_25/IN (r_prep) effects_24/NNS (r_pobj) to_21/IN (r_prep) marked_19/VBN (l_dobj) hypersensitivity_20/NN
D011433_D006973 CID propranolol_9/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (l_nsubjpass) hypertension_5/NN
3423103
D003000_D007022 CID clonidine_11/NN (r_npadvmod) induced_13/VBN (r_amod) hypotension_14/NN
D003000_D007022 CID clonidine_1/NN (r_npadvmod) induced_3/VBN (r_amod) hypotension_4/NN
D003000_D007022 CID clonidine_13/NN (r_npadvmod) induced_15/VBN (r_amod) hypotension_16/NN
D003000_D001919 CID clonidine_11/NN (r_npadvmod) induced_13/VBN (r_amod) hypotension_14/NN (l_conj) bradycardia_16/NN
D003000_D001919 CID clonidine_6/NN (r_npadvmod) induced_8/VBN (r_amod) bradycardia_9/NNS
D003000_D001919 CID clonidine_29/NN (r_advcl) reduced_18/VBD (l_dobj) magnitude_20/NN (l_prep) of_21/IN (l_pobj) vasodepressor_23/NNP (l_conj) responses_27/NNS (l_compound) bradycardiac_26/NNP
D003000_D001919 CID clonidine_13/NN (r_npadvmod) induced_15/VBN (r_amod) hypotension_16/NN (l_conj) bradycardia_18/NN
D012701_D001919 NONE 5-HT_7/CD (r_compound) nerves_8/NNS (r_pobj) of_4/IN (r_prep) destruction_3/NN (r_nsubj) reduced_18/VBD (l_dobj) magnitude_20/NN (l_prep) of_21/IN (l_pobj) vasodepressor_23/NNP (l_conj) responses_27/NNS (l_compound) bradycardiac_26/NNP
D015116_D001919 NONE 5,7-dihydroxytryptamine_16/CD (r_pobj) of_15/IN (r_prep) injection_14/NN (r_pobj) by_11/IN (r_agent) produced_10/VBN (r_acl) destruction_3/NN (r_nsubj) reduced_18/VBD (l_dobj) magnitude_20/NN (l_prep) of_21/IN (l_pobj) vasodepressor_23/NNP (l_conj) responses_27/NNS (l_compound) bradycardiac_26/NNP
1858969
D004049_D004660 CID diethylcarbamazine_9/NNP (r_pobj) with_8/IN (r_prep) treatment_5/NN (r_pobj) during_4/IN (r_prep) cases_1/NNS (l_prep) of_2/IN (l_pobj) encephalitis_3/NN
D004049_D004660 CID diethylcarbamazine_7/NNP (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) following_4/VBG (r_acl) cases_1/NNS (l_prep) of_2/IN (l_pobj) encephalitis_3/NN
D004049_D004660 CID DEC_9/NNP (r_appos) diethylcarbamazine_7/NNP (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) following_4/VBG (r_acl) cases_1/NNS (l_prep) of_2/IN (l_pobj) encephalitis_3/NN
D004049_D008118 NONE diethylcarbamazine_9/NNP (r_pobj) with_8/IN (r_prep) treatment_5/NN (l_prep) of_6/IN (l_pobj) loiasis_7/NNP
D004049_D005368 NONE diethylcarbamazine_7/NNP (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) following_4/VBG (r_acl) cases_1/NNS (r_nsubjpass) observed_12/VBN (l_prep) in_13/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) filariasis_19/NN
D004049_D005368 NONE DEC_9/NNP (r_appos) diethylcarbamazine_7/NNP (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) following_4/VBG (r_acl) cases_1/NNS (r_nsubjpass) observed_12/VBN (l_prep) in_13/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) filariasis_19/NN
7931490
D017829_D009325 NONE granisetron_4/NNP (r_pobj) of_3/IN (r_prep) Efficacy_0/NN (l_prep) in_12/IN (l_pobj) prevention_14/NN (l_prep) of_15/IN (l_pobj) nausea_16/NN
D017829_D009325 NONE granisetron_13/NNP (r_pobj) of_12/IN (r_prep) doses_11/NNS (r_pobj) of_8/IN (r_prep) effects_4/NNS (r_dobj) assess_1/VB (l_advcl) administered_26/VBN (l_dobj) dose_34/NN (l_prep) for_35/IN (l_pobj) prophylaxis_36/NN (l_prep) of_37/IN (l_pobj) nausea_41/NN
D017829_D009325 NONE Kytril_15/NNP (r_appos) granisetron_13/NNP (r_pobj) of_12/IN (r_prep) doses_11/NNS (r_pobj) of_8/IN (r_prep) effects_4/NNS (r_dobj) assess_1/VB (l_advcl) administered_26/VBN (l_dobj) dose_34/NN (l_prep) for_35/IN (l_pobj) prophylaxis_36/NN (l_prep) of_37/IN (l_pobj) nausea_41/NN
D017829_D014839 NONE granisetron_4/NNP (r_pobj) of_3/IN (r_prep) Efficacy_0/NN (l_prep) in_12/IN (l_pobj) prevention_14/NN (l_prep) of_15/IN (l_pobj) nausea_16/NN (l_conj) vomiting_18/NN
D017829_D014839 NONE granisetron_13/NNP (r_pobj) of_12/IN (r_prep) doses_11/NNS (r_pobj) of_8/IN (r_prep) effects_4/NNS (r_dobj) assess_1/VB (l_advcl) administered_26/VBN (l_dobj) dose_34/NN (l_prep) for_35/IN (l_pobj) prophylaxis_36/NN (l_prep) of_37/IN (l_pobj) nausea_41/NN (l_conj) vomiting_43/NN
D017829_D014839 NONE Kytril_15/NNP (r_appos) granisetron_13/NNP (r_pobj) of_12/IN (r_prep) doses_11/NNS (r_pobj) of_8/IN (r_prep) effects_4/NNS (r_dobj) assess_1/VB (l_advcl) administered_26/VBN (l_dobj) dose_34/NN (l_prep) for_35/IN (l_pobj) prophylaxis_36/NN (l_prep) of_37/IN (l_pobj) nausea_41/NN (l_conj) vomiting_43/NN
D017829_D014839 NONE granisetron_1/NNP (r_compound) doses_2/NNS (r_nsubj) vomiting_24/VBG
D017829_D014839 NONE granisetron_1/NNP (r_compound) doses_2/NNS (r_nsubj) vomiting_24/VBG (r_nsubjpass) recorded_35/VBN (l_conj) %_48/NN (l_conj) response_57/NN (l_appos) vomiting_60/NN
D017829_D014839 NONE granisetron_8/NNP (r_pobj) of_7/IN (r_prep) dose_6/NN (r_nsubj) was_9/VBD (l_acomp) effective_10/JJ (l_prep) in_11/IN (l_pcomp) controlling_12/VBG (l_dobj) vomiting_13/NN
D017829_D014839 NONE granisetron_8/NNP (r_pobj) of_7/IN (r_prep) dose_6/NN (r_nsubj) was_9/VBD (l_acomp) effective_10/JJ (l_prep) in_11/IN (l_pcomp) controlling_12/VBG (l_prep) in_14/IN (l_pobj) %_19/NN (l_prep) of_20/IN (l_pobj) patients_21/NNS (l_relcl) received_23/VBD (l_conj) prevented_35/VBD (l_dobj) vomiting_36/NN
D012701_D009325 NONE 5-hydroxytryptamine-3_8/CD (r_nummod) antagonist_10/NN (r_appos) Efficacy_0/NN (l_prep) in_12/IN (l_pobj) prevention_14/NN (l_prep) of_15/IN (l_pobj) nausea_16/NN
D012701_D014839 NONE 5-hydroxytryptamine-3_8/CD (r_nummod) antagonist_10/NN (r_appos) Efficacy_0/NN (l_prep) in_12/IN (l_pobj) prevention_14/NN (l_prep) of_15/IN (l_pobj) nausea_16/NN (l_conj) vomiting_18/NN
D002945_D009325 CID cisplatin_24/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) nausea_16/NN
D002945_D009325 CID cisplatin_38/NN (r_npadvmod) induced_40/VBN (r_amod) nausea_41/NN
D002945_D014839 CID cisplatin_24/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) nausea_16/NN (l_conj) vomiting_18/NN
D002945_D014839 CID cisplatin_38/NN (r_npadvmod) induced_40/VBN (r_amod) nausea_41/NN (l_conj) vomiting_43/NN
D002945_D014839 CID cisplatin_24/NN (r_dobj) received_23/VBD (r_relcl) patients_21/NNS (r_pobj) of_20/IN (r_prep) %_19/NN (r_pobj) in_14/IN (r_prep) controlling_12/VBG (l_dobj) vomiting_13/NN
D002945_D014839 CID cisplatin_24/NN (r_dobj) received_23/VBD (l_conj) prevented_35/VBD (l_dobj) vomiting_36/NN
8603459
D004317_D066126 CID Doxorubicin_0/NNS (r_npadvmod) induced_2/VBN (r_amod) cardiotoxicity_3/NN
D004317_D066126 CID doxorubicin_11/NN (r_npadvmod) induced_13/VBN (r_amod) cardiotoxicity_14/NN
D004317_D066126 CID doxorubicin_13/NN (r_npadvmod) induced_15/VBN (r_amod) cardiotoxicity_16/NN
D004317_D006984 NONE doxorubicin_5/NN (r_npadvmod) treated_7/VBN (r_amod) animals_8/NNS (r_pobj) of_4/IN (r_prep) hearts_3/NNS (r_nsubjpass) enlarged_10/VBN (l_conj) were_14/VBD (l_acomp) hypertrophic_15/JJ
D064730_D064420 NONE ICRF-187_16/NNP (r_pobj) of_15/IN (r_prep) protection_14/NN (r_nsubjpass) determined_18/VBN (l_advcl) exerted_3/VBD (l_dobj) toxicity_5/NN
D064730_D064420 NONE ICRF-187_16/NNP (r_pobj) of_15/IN (r_prep) protection_14/NN (r_nsubjpass) determined_18/VBN (l_xcomp) using_19/VBG (l_prep) with_23/IN (l_pobj) toxicity_26/NN
D004317_D064420 NONE doxorubicin_34/NNS (r_appos) doses_30/NNS (r_appos) toxicity_26/NN (r_pobj) with_23/IN (r_prep) using_19/VBG (r_xcomp) determined_18/VBN (l_advcl) exerted_3/VBD (l_dobj) toxicity_5/NN
D004317_D064420 NONE doxorubicin_34/NNS (r_appos) doses_30/NNS (r_appos) toxicity_26/NN
D064730_D066126 NONE ICRF-187_24/NNP (r_pobj) by_23/IN (r_agent) provided_22/VBN (r_acl) protection_21/NN (r_pobj) by_19/IN (r_agent) demonstrated_18/VBN (r_advcl) testing_9/NN (l_prep) against_12/IN (l_pobj) cardiotoxicity_16/NN
24971338
D020123_D007674 NONE sirolimus_2/NNP (r_pobj) to_1/TO (r_prep) Conversion_0/NN (r_nsubj) ameliorates_3/VBZ (l_dobj) nephropathy_7/NN
D020123_D007674 NONE sirolimus_10/VB (r_pobj) to_9/TO (r_prep) from_3/IN (r_prep) conversion_2/NN (r_pobj) of_1/IN (r_prep) Protocols_0/NNS (r_nsubjpass) used_17/VBN (l_xcomp) prevent_23/VB (l_dobj) nephropathy_27/NN
D020123_D007674 NONE SRL_12/NNP (r_appos) sirolimus_10/VB (r_pobj) to_9/TO (r_prep) from_3/IN (r_prep) conversion_2/NN (r_pobj) of_1/IN (r_prep) Protocols_0/NNS (r_nsubjpass) used_17/VBN (l_xcomp) prevent_23/VB (l_dobj) nephropathy_27/NN
D020123_D007674 NONE SRL_0/NNP (r_npadvmod) treated_2/VBN (r_amod) rats_3/NNS (r_nsubj) presented_4/VBD (l_prep) as_13/IN (l_pobj) markers_16/NNS (l_prep) of_17/IN (l_pobj) impairment_19/NN
D020123_D007674 NONE SRL_2/NNP (r_pobj) to_1/IN (r_prep) Conversion_0/NN (r_nsubj) prevented_3/VBD (l_dobj) evolution_9/NN (l_compound) damage_8/NN
D020123_D007674 NONE SRL_35/NNP (r_pobj) to_34/IN (r_prep) replacement_33/NN (r_pobj) of_31/IN (r_prep) biomarker_30/NN (r_attr) be_27/VB (r_xcomp) seems_25/VBZ (r_advcl) prevented_3/VBD (l_dobj) evolution_9/NN (l_compound) damage_8/NN
D016572_D007674 CID cyclosporine_4/NN (r_npadvmod) induced_6/VBN (r_amod) nephropathy_7/NN
D016572_D007674 CID A_5/DT (r_pobj) from_3/IN (r_prep) conversion_2/NN (r_pobj) of_1/IN (r_prep) Protocols_0/NNS (r_nsubjpass) used_17/VBN (l_xcomp) prevent_23/VB (l_dobj) nephropathy_27/NN
D016572_D007674 CID CsA_7/NN (r_appos) A_5/DT (r_pobj) from_3/IN (r_prep) conversion_2/NN (r_pobj) of_1/IN (r_prep) Protocols_0/NNS (r_nsubjpass) used_17/VBN (l_xcomp) prevent_23/VB (l_dobj) nephropathy_27/NN
D016572_D007674 CID CsA_24/NN (r_npadvmod) induced_26/VBN (r_amod) nephropathy_27/NN
D016572_D007674 CID CsA_1/NN (r_compound) treatment_2/NN (r_nsubj) presented_3/VBD (l_dobj) lesions_9/NNS
D016572_D007674 CID CsA_1/NN (r_compound) exposure_2/NN (r_nsubj) aggravated_3/VBD (l_dobj) damage_5/NN
D016572_D007674 CID CsA_4/NN (r_npadvmod) induced_6/VBN (r_amod) evolution_9/NN (l_compound) damage_8/NN
D016572_D007674 CID CsA_32/JJ (r_compound) replacement_33/NN (r_pobj) of_31/IN (r_prep) biomarker_30/NN (r_attr) be_27/VB (r_xcomp) seems_25/VBZ (r_advcl) prevented_3/VBD (l_dobj) evolution_9/NN (l_compound) damage_8/NN
D006416_D007674 NONE hematoxylin_5/NNP (r_pobj) in_4/IN (r_prep) analyzed_3/VBN (l_nsubjpass) lesions_1/NNS
D004801_D007674 NONE eosin_7/NNP (r_conj) hematoxylin_5/NNP (r_pobj) in_4/IN (r_prep) analyzed_3/VBN (l_nsubjpass) lesions_1/NNS
D020123_D011507 CID SRL_0/NNP (r_npadvmod) treated_2/VBN (r_amod) rats_3/NNS (r_nsubj) presented_4/VBD (l_dobj) proteinuria_5/NN
3323259
D002118_D002318 NONE calcium_6/NN (r_pobj) of_5/IN (r_prep) importance_4/NN (l_prep) in_7/IN (l_pobj) pathogenesis_9/NN (l_prep) of_10/IN (l_pobj) disease_12/NN
D002118_D002318 NONE calcium_6/NN (r_pobj) of_5/IN (r_prep) importance_4/NN (r_pobj) of_2/IN (r_prep) recognition_1/NN (r_dobj) Increasing_0/VBG (r_csubj) stimulated_14/VBN (l_prep) into_16/IN (l_pobj) use_18/NN (l_prep) of_19/IN (l_pcomp) blocking_22/VBG (l_prep) for_24/IN (l_pobj) treatment_25/NN (l_prep) of_26/IN (l_pobj) variety_28/NN (l_prep) of_29/IN (l_pobj) diseases_31/NNS
D002121_D002318 NONE agents_23/NNS (r_dobj) blocking_22/VBG (r_pcomp) of_19/IN (r_prep) use_18/NN (r_pobj) into_16/IN (r_prep) stimulated_14/VBN (l_csubj) Increasing_0/VBG (l_dobj) recognition_1/NN (l_prep) of_2/IN (l_pobj) importance_4/NN (l_prep) in_7/IN (l_pobj) pathogenesis_9/NN (l_prep) of_10/IN (l_pobj) disease_12/NN
D002121_D002318 NONE agents_23/NNS (r_dobj) blocking_22/VBG (l_prep) for_24/IN (l_pobj) treatment_25/NN (l_prep) of_26/IN (l_pobj) variety_28/NN (l_prep) of_29/IN (l_pobj) diseases_31/NNS
C038806_D000787 NONE dihydropyridine_3/NN (l_appos) angina_14/NN
C038806_D006973 NONE dihydropyridine_3/NN (l_appos) angina_14/NN (l_conj) hypertension_16/NN
D009543_D000787 NONE nifedipine_12/NN (r_compound) angina_14/NN
D009543_D006973 NONE nifedipine_12/NN (r_compound) angina_14/NN (l_conj) hypertension_16/NN
D009568_D006973 NONE nitrendipine_7/NNP (r_nsubj) offers_10/VBZ (l_dobj) schedule_14/NN (l_relcl) encourages_17/VBZ (l_dobj) compliance_19/NN (l_prep) in_20/IN (l_pobj) therapy_24/NN (l_prep) of_25/IN (l_pobj) hypertension_26/NN
D015737_D006973 NONE nisoldipine_9/NNP (r_conj) nitrendipine_7/NNP (r_nsubj) offers_10/VBZ (l_dobj) schedule_14/NN (l_relcl) encourages_17/VBZ (l_dobj) compliance_19/NN (l_prep) in_20/IN (l_pobj) therapy_24/NN (l_prep) of_25/IN (l_pobj) hypertension_26/NN
D015737_D000787 NONE nisoldipine_5/NNP (r_pobj) of_4/IN (r_prep) properties_3/NNS (r_nsubj) led_7/VBN (l_prep) to_8/IN (l_pobj) investigation_10/NN (l_prep) for_14/IN (l_pobj) use_15/NN (l_prep) in_16/IN (l_pobj) angina_17/NN
D009553_D013345 NONE nimodipine_6/NN (r_nsubj) useful_8/JJ (l_prep) in_9/IN (l_pobj) treatment_11/NN (l_prep) of_12/IN (l_pobj) hemorrhage_14/NN
D009553_D008881 NONE nimodipine_6/NN (r_nsubj) useful_8/JJ (l_prep) in_9/IN (l_pobj) treatment_11/NN (l_prep) of_12/IN (l_pobj) hemorrhage_14/NN (l_appos) headache_17/NN
D009553_D003704 NONE nimodipine_6/NN (r_nsubj) useful_8/JJ (l_prep) in_9/IN (l_pobj) treatment_11/NN (l_prep) of_12/IN (l_pobj) hemorrhage_14/NN (l_appos) headache_17/NN (l_conj) dementia_19/NN
D009553_D020521 NONE nimodipine_6/NN (r_nsubj) useful_8/JJ (l_prep) in_9/IN (l_pobj) treatment_11/NN (l_prep) of_12/IN (l_pobj) hemorrhage_14/NN (l_appos) headache_17/NN (l_conj) dementia_19/NN (l_conj) stroke_22/NN
C038806_D006261 NONE dihydropyridine_4/NNP (r_compound) calcium_5/NN (r_compound) channel_6/NN (r_compound) blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN
C038806_D005483 NONE dihydropyridine_4/NNP (r_compound) calcium_5/NN (r_compound) channel_6/NN (r_compound) blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN (l_conj) flushing_17/NN
C038806_-1 NONE dihydropyridine_4/NNP (r_compound) calcium_5/NN (r_compound) channel_6/NN (r_compound) blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN (l_conj) flushing_17/NN (l_conj) palpitations_19/NNS
C038806_D004487 NONE dihydropyridine_4/NNP (r_compound) calcium_5/NN (r_compound) channel_6/NN (r_compound) blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN (l_conj) flushing_17/NN (l_conj) palpitations_19/NNS (l_conj) edema_21/NN
C038806_D009325 NONE dihydropyridine_4/NNP (r_compound) calcium_5/NN (r_compound) channel_6/NN (r_compound) blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN (l_conj) flushing_17/NN (l_conj) palpitations_19/NNS (l_conj) edema_21/NN (l_conj) nausea_23/NN
C038806_D000855 NONE dihydropyridine_4/NNP (r_compound) calcium_5/NN (r_compound) channel_6/NN (r_compound) blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN (l_conj) flushing_17/NN (l_conj) palpitations_19/NNS (l_conj) edema_21/NN (l_conj) nausea_23/NN (l_conj) anorexia_25/NN
C038806_D004244 NONE dihydropyridine_4/NNP (r_compound) calcium_5/NN (r_compound) channel_6/NN (r_compound) blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN (l_conj) flushing_17/NN (l_conj) palpitations_19/NNS (l_conj) edema_21/NN (l_conj) nausea_23/NN (l_conj) anorexia_25/NN (l_conj) dizziness_28/NN
D002121_D006261 CID blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN
D002121_D005483 CID blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN (l_conj) flushing_17/NN
D002121_-1 NONE blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN (l_conj) flushing_17/NN (l_conj) palpitations_19/NNS
D002121_D004487 CID blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN (l_conj) flushing_17/NN (l_conj) palpitations_19/NNS (l_conj) edema_21/NN
D002121_D009325 CID blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN (l_conj) flushing_17/NN (l_conj) palpitations_19/NNS (l_conj) edema_21/NN (l_conj) nausea_23/NN
D002121_D000855 CID blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN (l_conj) flushing_17/NN (l_conj) palpitations_19/NNS (l_conj) edema_21/NN (l_conj) nausea_23/NN (l_conj) anorexia_25/NN
D002121_D004244 CID blockers_7/NNS (r_nsubj) are_8/VBP (l_prep) with_13/IN (l_pobj) headache_14/NN (l_conj) flushing_17/NN (l_conj) palpitations_19/NNS (l_conj) edema_21/NN (l_conj) nausea_23/NN (l_conj) anorexia_25/NN (l_conj) dizziness_28/NN
25084821
C069541_D009503 CID Quetiapine_0/LS (r_npadvmod) induced_2/VBN (r_amod) neutropenia_3/NN
C069541_D009503 CID Quetiapine_0/NNP (r_nsubj) is_1/VBZ (l_attr) derivative_4/JJ (l_amod) similar_6/JJ (l_prep) to_7/IN (l_pobj) clozapine_8/NNP (l_relcl) has_11/VBZ (l_dobj) risk_14/NN (l_prep) of_15/IN (l_pcomp) causing_16/VBG (l_dobj) dyscrasias_18/NNS (l_appos) neutropenia_21/NN
C069541_D009503 CID quetiapine_14/NNP (r_pobj) with_13/IN (r_prep) treatment_12/NN (r_pobj) after_11/IN (r_prep) developed_9/VBD (l_dobj) neutropenia_10/NN
C069541_D009503 CID quetiapine_9/NNP (r_pobj) of_8/IN (r_prep) effect_7/NN (r_attr) is_2/VBZ (l_nsubj) neutropenia_1/NN
C069541_D001714 NONE Quetiapine_0/LS (r_npadvmod) induced_2/VBN (r_amod) neutropenia_3/NN (l_prep) in_4/IN (l_pobj) patient_7/NN (l_amod) bipolar_6/JJ
C069541_D006528 NONE Quetiapine_0/LS (r_npadvmod) induced_2/VBN (r_amod) neutropenia_3/NN (l_prep) in_4/IN (l_pobj) patient_7/NN (l_prep) with_8/IN (l_pobj) carcinoma_10/NN
C069541_D006528 NONE quetiapine_14/NNP (r_pobj) with_13/IN (r_prep) treatment_12/NN (r_pobj) after_11/IN (r_prep) developed_9/VBD (r_relcl) carcinoma_7/NN
C069541_D006402 NONE Quetiapine_0/NNP (r_nsubj) is_1/VBZ (l_attr) derivative_4/JJ (l_amod) similar_6/JJ (l_prep) to_7/IN (l_pobj) clozapine_8/NNP (l_relcl) has_11/VBZ (l_dobj) risk_14/NN (l_prep) of_15/IN (l_pcomp) causing_16/VBG (l_dobj) dyscrasias_18/NNS
D003024_D006402 NONE clozapine_8/NNP (l_relcl) has_11/VBZ (l_dobj) risk_14/NN (l_prep) of_15/IN (l_pcomp) causing_16/VBG (l_dobj) dyscrasias_18/NNS
D003024_D009503 NONE clozapine_8/NNP (l_relcl) has_11/VBZ (l_dobj) risk_14/NN (l_prep) of_15/IN (l_pcomp) causing_16/VBG (l_dobj) dyscrasias_18/NNS (l_appos) neutropenia_21/NN
C069541_D007970 CID quetiapine_7/NNP (r_pobj) with_6/IN (r_prep) treated_5/VBN (r_pcomp) after_3/IN (r_prep) developed_1/VBD (l_dobj) leucopenia_2/NNP
C069541_D008107 NONE quetiapine_23/NNP (r_pobj) to_22/IN (r_prep) reaction_21/NN (r_pobj) for_19/IN (r_prep) marker_18/NN (r_attr) be_15/VB (r_conj) be_3/VB (l_nsubj) dysfunction_1/NN
C069541_D005334 CID quetiapine_23/NNP (r_pobj) to_22/IN (r_prep) reaction_21/NN (r_pobj) for_19/IN (r_prep) marker_18/NN (r_attr) be_15/VB (l_nsubj) fever_13/NN
11105626
D015474_D065817 CID isotretinoin_21/NN (r_pobj) to_20/IN (r_prep) exposure_19/NN (r_pobj) due_17/IN (r_prep) report_1/VBP (l_prep) with_5/IN (l_pobj) anomalies_8/NNS (l_appos) anotia_10/NNP
D015474_D004310 CID isotretinoin_21/NN (r_pobj) to_20/IN (r_prep) exposure_19/NN (r_pobj) due_17/IN (r_prep) report_1/VBP (l_prep) with_5/IN (l_pobj) anomalies_8/NNS (l_appos) anotia_10/NNP (l_conj) malformation_15/NN
26115410
D001152_D009369 CID iAs_14/JJ (r_compound) exposure_15/NN (r_dobj) relate_10/VBP (l_prep) in_25/IN (l_pobj) relationship_26/NN (l_prep) to_27/IN (l_pobj) cancer_28/NN
D001152_D009369 CID iAs_25/JJ (r_compound) exposure_26/NN (r_pobj) with_21/IN (r_prep) associated_20/VBN (r_relcl) risk_12/NN (l_prep) of_13/IN (l_pobj) development_15/NN (l_compound) cancer_14/NN
D001152_D009369 CID iAs_28/JJ (r_compound) exposure_29/NN (r_nsubj) elicits_30/VBZ (r_relcl) mechanisms_22/NNS (r_attr) are_19/VBP (l_nsubj) reprogramming_1/NN (l_relcl) imparts_3/VBZ (l_dobj) changes_5/NNS (l_prep) in_6/IN (l_pobj) expression_8/NN (l_appos) development_11/NN (l_prep) of_12/IN (l_pobj) cells_15/NNS (l_compound) cancer_13/NN
D001152_D009369 CID iAs_8/JJ (r_compound) exposure_9/NN (l_conj) development_12/NN (l_compound) cancer_11/NN
17379047
C081489_D006973 NONE valsartan_2/NN (r_nmod) hydrochlorothiazide_4/NNP (r_compound) therapy_6/NN (r_pobj) of_1/IN (r_prep) Comparison_0/NN (l_appos) study_24/NN (l_acl) followed_25/VBN (l_agent) by_26/IN (l_pobj) therapy_31/NN (l_prep) in_32/IN (l_pobj) adults_34/NNS (l_amod) hypertensive_33/JJ
D006852_D006973 NONE hydrochlorothiazide_4/NNP (r_compound) therapy_6/NN (r_pobj) of_1/IN (r_prep) Comparison_0/NN (l_appos) study_24/NN (l_acl) followed_25/VBN (l_agent) by_26/IN (l_pobj) therapy_31/NN (l_prep) in_32/IN (l_pobj) adults_34/NNS (l_amod) hypertensive_33/JJ
C081489_C562386 NONE valsartan_8/NN (l_appos) VAL_10/NNP (l_conj) hydrochlorothiazide_13/NN (l_appos) combinations_20/NNS (l_prep) in_21/IN (l_pobj) patients_22/NNS (l_prep) with_23/IN (l_pobj) hypertension_25/NN
C081489_C562386 NONE VAL_10/NNP (l_conj) hydrochlorothiazide_13/NN (l_appos) combinations_20/NNS (l_prep) in_21/IN (l_pobj) patients_22/NNS (l_prep) with_23/IN (l_pobj) hypertension_25/NN
D006852_C562386 NONE hydrochlorothiazide_13/NN (l_appos) combinations_20/NNS (l_prep) in_21/IN (l_pobj) patients_22/NNS (l_prep) with_23/IN (l_pobj) hypertension_25/NN
D006852_C562386 NONE HCTZ)-monotherapy_15/NN (r_nummod) combinations_20/NNS (l_prep) in_21/IN (l_pobj) patients_22/NNS (l_prep) with_23/IN (l_pobj) hypertension_25/NN
C081489_D007008 NONE VAL_7/NNP (r_nmod) HCTZ_9/NNP (r_compound) combinations_10/NNS (r_pobj) with_6/IN (r_prep) lower_5/JJR (r_acomp) was_4/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) hypokalemia_3/NN
C081489_D007008 NONE VAL_8/NNP (r_nmod) HCTZ_10/NNP (r_pobj) with_7/IN (r_prep) therapies_6/NNS (r_nsubjpass) associated_12/VBN (l_conj) were_23/VBD (l_conj) associated_29/VBN (l_prep) with_30/IN (l_pobj) hypokalemia_32/NN
D006852_D007008 CID HCTZ_9/NNP (r_compound) combinations_10/NNS (r_pobj) with_6/IN (r_prep) lower_5/JJR (r_acomp) was_4/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) hypokalemia_3/NN
D006852_D007008 CID HCTZ_17/NNP (r_compound) monotherapies_18/NNS (r_pobj) with_16/IN (r_prep) than_15/IN (r_prep) lower_5/JJR (r_acomp) was_4/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_pobj) hypokalemia_3/NN
D006852_D007008 CID HCTZ_10/NNP (r_pobj) with_7/IN (r_prep) therapies_6/NNS (r_nsubjpass) associated_12/VBN (l_conj) were_23/VBD (l_conj) associated_29/VBN (l_prep) with_30/IN (l_pobj) hypokalemia_32/NN
D006852_D007008 CID HCTZ_34/NNP (r_pobj) than_33/IN (r_prep) hypokalemia_32/NN
3439580
D007099_D006973 CID imipramine_5/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (r_acl) neuroblastoma_2/NN (r_pobj) in_1/IN (r_prep) Hypertension_0/NN
D007099_D006973 CID Imipramine_16/NNP (r_pobj) of_14/IN (r_prep) discontinuation_13/NN (r_dobj) following_12/VBG (r_acl) none_11/NN (r_conj) had_2/VBD (r_advcl) believe_27/VBP (l_ccomp) caused_37/VBD (l_dobj) hypertension_39/NN
D007099_D009447 NONE imipramine_5/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (r_acl) neuroblastoma_2/NN
D007099_D009447 NONE Imipramine_16/NNP (r_dobj) given_15/VBN (r_relcl) neuroblastoma_12/NN
D007099_D002653 NONE Imipramine_16/NNP (r_dobj) given_15/VBN (l_advcl) control_18/VB (l_dobj) disorder_21/NN
7671401
D000806_D000799 CID inhibitor_19/NN (r_pobj) with_14/IN (r_prep) therapy_13/NN (r_pobj) to_9/IN (r_prep) related_8/VBN (r_acl) frequency_1/NN (l_conj) severity_3/NN (l_prep) of_4/IN (l_pobj) oedema_7/NN
D000806_D000799 CID inhibitors_6/NNS (r_pobj) of_4/IN (r_prep) introduction_3/NN (r_pobj) after_1/IN (r_prep) reported_15/VBN (l_nsubjpass) bouts_9/NNS (l_prep) of_10/IN (l_pobj) oedema_13/NN
D000806_D000799 CID inhibitors_13/NNS (r_pobj) to_11/IN (r_prep) reactions_10/NNS (l_prep) after_14/IN (l_conj) in_20/IN (l_pobj) patients_21/NNS (l_prep) with_22/IN (l_pobj) oedema_28/NN
D000806_D006973 NONE inhibitors_7/NNS (r_appos) enzyme_3/NNS (l_acl) used_9/VBD (l_xcomp) treat_11/VB (l_dobj) hypertension_12/NN
D000806_D006333 NONE inhibitors_7/NNS (r_appos) enzyme_3/NNS (l_acl) used_9/VBD (l_xcomp) treat_11/VB (l_dobj) hypertension_12/NN (l_conj) failure_16/NN
15859361
C105934_D003875 NONE celecoxib_2/NNP (r_pobj) of_1/IN (r_prep) Safety_0/NN (l_prep) in_3/IN (l_pobj) patients_4/NNS (l_prep) with_5/IN (l_pobj) reactions_8/NNS
C105934_D003875 NONE CE_5/NNP (r_pobj) of_4/IN (r_prep) tolerability_3/NN (r_dobj) evaluated_1/VBD (l_prep) in_6/IN (l_pobj) group_8/NN (l_prep) of_9/IN (l_pobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) history_13/NN (l_prep) of_14/IN (l_pobj) reactions_17/NNS
D000082_D003875 CID acetaminophen_10/NN (r_pobj) to_9/IN (r_prep) reactions_8/NNS
D000082_D003875 CID paracetamol_12/NN (r_appos) acetaminophen_10/NN (r_pobj) to_9/IN (r_prep) reactions_8/NNS
D000082_D003875 CID P_19/NN (r_pobj) to_18/IN (r_prep) reactions_17/NNS
D000082_D003875 CID P_3/NN (l_conj) reactions_9/NNS
C012655_D003875 CID nimesulide_15/NNP (r_conj) paracetamol_12/NN (r_appos) acetaminophen_10/NN (r_pobj) to_9/IN (r_prep) reactions_8/NNS
C012655_D003875 CID N_21/NN (r_conj) P_19/NN (r_pobj) to_18/IN (r_prep) reactions_17/NNS
C012655_D003875 CID N_5/NN (r_dep) -_6/HYPH (r_dep) induced_7/VBN (r_amod) reactions_9/NNS
D000082_D004342 NONE P_7/NN (r_pobj) to_6/IN (r_prep) hypersensitivity_5/NN
D000082_D004342 NONE P_10/NN (r_nmod) patients_17/NNS (r_pobj) among_8/IN (r_prep) documented_7/VBN (l_nsubjpass) reaction_3/NN (l_compound) hypersensitivity_2/NN
C012655_D004342 NONE N_9/NN (r_conj) P_7/NN (r_pobj) to_6/IN (r_prep) hypersensitivity_5/NN
C012655_D004342 NONE N_12/NN (r_dep) -_13/HYPH (r_punct) P_10/NN (r_nmod) patients_17/NNS (r_pobj) among_8/IN (r_prep) documented_7/VBN (l_nsubjpass) reaction_3/NN (l_compound) hypersensitivity_2/NN
C105934_D004342 NONE CE_5/NNP (r_pobj) to_4/IN (r_prep) reaction_3/NN (l_compound) hypersensitivity_2/NN
6585590
D004317_D066126 NONE doxorubicin_8/NNS (r_pobj) of_7/IN (r_prep) nephrotoxicity_6/NN (r_conj) cardiotoxicity_3/NN
D004317_D066126 NONE doxorubicin_9/NNS (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) nephrotoxicity_6/NN (r_conj) cardiotoxicity_3/NN
D004317_D066126 NONE doxorubicin_17/NNS (r_nmod) kg_19/NN (r_pobj) of_14/IN (r_prep) dose_13/NN (r_pobj) at_11/IN (r_prep) observed_10/VBN (r_conj) scored_4/VBD (l_nsubj) evidence_1/NN (l_prep) of_2/IN (l_pobj) cardiotoxicity_3/NN
D004317_D007674 NONE doxorubicin_8/NNS (r_pobj) of_7/IN (r_prep) nephrotoxicity_6/NN
D004317_D007674 NONE doxorubicin_9/NNS (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) nephrotoxicity_6/NN
D004317_D007674 NONE doxorubicin_14/NNS (r_nmod) kg_16/NNS (r_pobj) of_11/IN (r_prep) dose_10/NN (r_pobj) above_8/IN (r_prep) seen_7/VBN (l_nsubjpass) evidence_2/NN (l_prep) of_3/IN (l_pobj) damage_5/NN
D004317_-1 NONE doxorubicin_8/NNS (r_pobj) of_7/IN (r_prep) nephrotoxicity_6/NN (r_conj) cardiotoxicity_3/NN (r_conj) effect_1/NN (l_prep) in_9/IN (l_pobj) rat_21/NN (l_amod) bearing_15/VBG (l_npadvmod) immunocytoma_13/NNP
D004317_-1 NONE doxorubicin_9/NNS (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) nephrotoxicity_6/NN (r_conj) cardiotoxicity_3/NN (r_conj) activity_1/NN (r_nsubjpass) studied_11/VBN (l_advcl) bearing_21/VBG (l_dobj) immunocytoma_26/NNP
D004317_D009369 NONE doxorubicin_18/NNS (r_pobj) of_17/IN (r_prep) injections_16/NNS (r_pobj) with_14/IN (r_prep) treated_13/VBN (l_nsubjpass) Animals_0/NNS (l_prep) with_1/IN (l_pobj) tumor_3/NN
D004317_D009369 NONE doxorubicin_7/NNS (r_nmod) kg_9/NN (r_pobj) with_4/IN (r_prep) observed_3/VBN (l_nsubjpass) regression_1/NN (l_compound) Tumor_0/NN
D004317_D009369 NONE doxorubicin_10/NNS (r_nmod) kg_12/NN (r_pobj) with_7/IN (r_prep) induced_6/VBN (l_nsubjpass) disappearance_1/NN (l_prep) of_2/IN (l_pobj) tumor_4/NN
D004317_D000419 CID doxorubicin_14/NNS (r_nmod) kg_16/NNS (l_relcl) resulted_19/VBD (l_prep) in_20/IN (l_pobj) albuminuria_21/NNP
11385188
D003042_D006331 NONE cocaine_7/NN (r_compound) users_8/NNS (r_pobj) in_4/IN (r_prep) disease_3/NN
D003042_D006331 NONE cocaine_12/NN (r_compound) users_13/NNS (r_pobj) in_7/IN (r_prep) disease_6/NN
D003042_D006331 NONE cocaine_16/NN (r_compound) users_17/NNS (r_nsubj) underwent_24/VBD (l_advcl) determine_1/VB (l_dobj) prevalence_3/NN (l_prep) of_4/IN (l_pobj) disease_6/NN
D003042_D003324 CID cocaine_18/NN (r_compound) users_19/NNS (r_pobj) in_14/IN (r_prep) is_8/VBZ (l_nsubj) disease_7/NN
D003042_D009202 CID cocaine_18/NN (r_compound) users_19/NNS (r_pobj) in_14/IN (r_prep) is_8/VBZ (l_nsubj) disease_7/NN
11229942
D003042_D066126 NONE Cocaine_0/NN (l_conj) ethanol_2/NN (l_conj) cardiotoxity_6/NN
D003042_D066126 NONE cocaine_28/NN (r_compound) metabolite_29/NN (r_appos) cocaethylene_22/NN (r_pobj) to_21/IN (r_prep) due_20/JJ (r_acomp) be_19/VB (l_ccomp) be_5/VB (l_nsubj) toxicity_3/NN
D003042_D066126 NONE cocaine_17/NN (r_pobj) of_16/IN (r_prep) cardiotoxicity_15/NN
D003042_D019970 NONE Cocaine_0/NN (l_prep) in_7/IN (l_pobj) model_10/NN (l_prep) of_11/IN (l_pobj) cocaine_12/NN (l_conj) abuse_15/NN
D003042_D000437 NONE Cocaine_0/NN (l_prep) in_7/IN (l_pobj) model_10/NN (l_prep) of_11/IN (l_pobj) cocaine_12/NN (l_conj) abuse_15/NN
D000431_D066126 NONE ethanol_2/NN (l_conj) cardiotoxity_6/NN
D000431_D066126 NONE ethanol_36/NN (r_pobj) of_35/IN (r_prep) presence_34/NN (r_pobj) in_32/IN (r_prep) formed_30/VBN (r_acl) metabolite_29/NN (r_appos) cocaethylene_22/NN (r_pobj) to_21/IN (r_prep) due_20/JJ (r_acomp) be_19/VB (l_ccomp) be_5/VB (l_nsubj) toxicity_3/NN
D000431_D066126 NONE ethanol_19/NN (r_conj) cocaine_17/NN (r_pobj) of_16/IN (r_prep) cardiotoxicity_15/NN
D000431_D019970 NONE ethanol_2/NN (r_conj) Cocaine_0/NN (l_prep) in_7/IN (l_pobj) model_10/NN (l_prep) of_11/IN (l_pobj) cocaine_12/NN (l_conj) abuse_15/NN
D000431_D000437 NONE ethanol_2/NN (r_conj) Cocaine_0/NN (l_prep) in_7/IN (l_pobj) model_10/NN (l_prep) of_11/IN (l_pobj) cocaine_12/NN (l_conj) abuse_15/NN
C066444_D066126 NONE cocaethylene_5/NN (r_conj) ethanol_2/NN (l_conj) cardiotoxity_6/NN
C066444_D066126 NONE cocaethylene_22/NN (r_pobj) to_21/IN (r_prep) due_20/JJ (r_acomp) be_19/VB (l_ccomp) be_5/VB (l_nsubj) toxicity_3/NN
C066444_D066126 NONE CE_24/NNP (r_appos) cocaethylene_22/NN (r_pobj) to_21/IN (r_prep) due_20/JJ (r_acomp) be_19/VB (l_ccomp) be_5/VB (l_nsubj) toxicity_3/NN
C066444_D066126 NONE CE_11/NNP (r_pobj) of_10/IN (r_prep) role_9/NN (l_prep) in_12/IN (l_pobj) cardiotoxicity_15/NN
C066444_D019970 NONE cocaethylene_5/NN (r_conj) ethanol_2/NN (r_conj) Cocaine_0/NN (l_prep) in_7/IN (l_pobj) model_10/NN (l_prep) of_11/IN (l_pobj) cocaine_12/NN (l_conj) abuse_15/NN
C066444_D000437 NONE cocaethylene_5/NN (r_conj) ethanol_2/NN (r_conj) Cocaine_0/NN (l_prep) in_7/IN (l_pobj) model_10/NN (l_prep) of_11/IN (l_pobj) cocaine_12/NN (l_conj) abuse_15/NN
C066444_D009202 NONE cocaethylene_2/NN (r_compound) concentrations_3/NNS (r_nsubjpass) associated_5/VBN (l_prep) with_6/IN (l_pobj) depression_9/NN
2614930
D009543_D001919 CID Nifedipine_0/NN (r_nsubj) induced_1/VBN (l_dobj) bradycardia_2/NNS
D009543_D009422 NONE Nifedipine_0/NN (r_nsubj) induced_1/VBN (l_prep) in_3/IN (l_pobj) patient_5/NN (l_prep) with_6/IN (l_pobj) neuropathy_8/NN
D009543_D001282 NONE nifedipine_25/NN (r_advcl) slowed_16/VBD (r_relcl) rate_10/NN (r_pobj) at_7/IN (r_prep) have_4/VB (l_dobj) flutter_6/NN
D009543_D013610 CID nifedipine_10/NN (r_nsubj) induces_11/VBZ (l_dobj) tachycardia_12/NN
2650911
D004967_D002292 NONE estrogen_3/NN (r_compound) sites_5/NNS (l_prep) in_6/IN (l_pobj) nuclei_7/NNS (l_prep) of_8/IN (l_pobj) diethylstilbesterol_9/NNP (l_appos) carcinomas_13/NNS
D004967_D002292 NONE Estrogen_0/NN (r_compound) sites_2/NNS (r_nsubjpass) demonstrated_4/VBN (l_conj) induced_14/VBN (l_dobj) carcinomas_16/NNS
D004967_D002292 NONE estrogen_13/NN (r_pobj) of_12/IN (r_prep) binding_11/NN (r_pobj) in_9/IN (r_prep) preferential_8/JJ (r_dobj) documenting_6/VBG (r_acl) report_5/NN (r_attr) is_1/VBZ (l_conj) induced_20/VBN (l_dobj) carcinomas_23/NNS
D004967_D002292 NONE estrogen_19/NN (r_pobj) in_18/IN (r_prep) cells_17/NNS (r_pobj) of_16/IN (r_prep) nuclei_15/NNS (r_pobj) to_14/IN (r_prep) documenting_6/VBG (r_acl) report_5/NN (r_attr) is_1/VBZ (l_conj) induced_20/VBN (l_dobj) carcinomas_23/NNS
D004054_D002292 CID diethylstilbesterol_9/NNP (l_appos) carcinomas_13/NNS
D004054_D002292 CID diethylstilbesterol_13/NN (r_nsubj) induced_14/VBN (l_dobj) carcinomas_16/NNS
D004958_D009369 NONE estradiol_10/NNP (r_pobj) of_7/IN (r_prep) injection_6/NN (r_pobj) in_4/IN (r_prep) following_2/VBG (r_prep) Radiolabelling_0/VBG (r_advcl) increased_13/VBN (l_prep) over_15/IN (l_pobj) nuclei_17/NNS (l_prep) of_18/IN (l_pobj) cells_20/NNS (l_compound) tumor_19/NN
D012834_D009369 NONE silver_33/NN (r_amod) grains_34/NNS (r_pobj) of_31/IN (r_prep) concentration_30/NN (r_dobj) revealed_24/VBD (l_ccomp) increased_13/VBN (l_prep) over_15/IN (l_pobj) nuclei_17/NNS (l_prep) of_18/IN (l_pobj) cells_20/NNS (l_compound) tumor_19/NN
25096313
D013256_D009422 NONE steroid_5/NN (r_compound) injection_6/NN (r_pobj) after_4/IN (r_prep) neuropathy_3/NN
D013256_D009422 NONE steroid_19/NN (r_compound) injection_20/NN (r_pobj) after_17/IN (r_prep) occurred_16/VBD (r_relcl) neuropathy_11/NN
D013256_D013716 NONE steroid_19/NN (r_compound) injection_20/NN (r_pobj) after_17/IN (r_prep) occurred_16/VBD (l_advcl) treat_26/VB (l_dobj) epicondylitis_28/NN
D013256_D013716 NONE steroid_14/NN (r_compound) injection_15/NN (l_prep) for_16/IN (l_pobj) treatment_18/NN (l_prep) of_19/IN (l_pobj) epicondylitis_21/NN
D013256_D010292 CID steroid_23/NN (r_compound) injection_24/NN (r_pobj) after_21/IN (r_prep) occurred_20/VBN (l_nsubj) woman_4/NN (l_acl) presented_5/VBN (l_prep) with_6/IN (l_pobj) sensation_8/NN (l_conj) paresthesia_10/NN
D013256_D010292 CID steroid_23/NN (r_compound) injection_24/NN (r_pobj) after_21/IN (r_prep) occurred_20/VBN (l_nsubj) paresthesia_18/NN
1735570
D014294_D007022 CID trimethaphan_1/NNP (r_npadvmod) induced_3/VBN (r_amod) hypotension_4/NN
D014294_D001919 NONE trimethaphan_1/NNP (r_npadvmod) induced_3/VBN (r_amod) hypotension_4/NN (r_nsubjpass) accompanied_6/VBN (l_agent) by_7/IN (l_pobj) bradycardia_10/NN
16092435
D012266_D066126 NONE ribose_8/NN (l_prep) on_9/IN (l_pobj) cardiotoxicity_13/NN
D012266_D066126 NONE ribose_2/NN (r_nsubj) influence_12/VB (l_dobj) cardiotoxicity_14/NN
D004317_D066126 NONE adriamycin_10/NN (r_npadvmod) evoked_12/VBN (r_amod) cardiotoxicity_13/NN
D004317_D066126 NONE Adriamycin_0/NN (r_nsubj) evoked_8/VBN (l_dobj) toxicity_12/NN
D004317_D066126 NONE ADR_13/NNP (r_compound) cardiotoxicity_14/NN
D012266_D009202 NONE ribose_5/NN (l_prep) on_6/IN (l_pobj) myocardiopathy_10/NNP
D004317_D009202 CID adriamycin_7/NN (r_npadvmod) induced_9/VBN (r_amod) myocardiopathy_10/NNP
19154241
D008094_D006961 CID lithium_3/NN (r_compound) therapy_4/NN (l_acl) leading_5/VBG (l_prep) to_6/IN (l_pobj) hyperparathyroidism_7/NN
D008094_D006934 CID lithium_6/NN (r_npadvmod) treated_8/VBN (r_amod) patient_9/NN (l_relcl) had_11/VBD (l_dobj) hypercalcemia_13/NN
D008094_D006934 CID lithium_6/NN (r_npadvmod) treated_8/VBN (r_amod) patients_9/NNS (r_pobj) of_5/IN (r_prep) %_4/NN (r_nsubj) become_10/VBP (l_attr) hypercalcemic_11/JJ
D008094_D049950 NONE lithium_16/NN (r_compound) therapy_17/NN (r_pobj) of_12/IN (r_prep) effect_11/NN (r_attr) is_2/VBZ (l_nsubj) hyperparathyroidism_1/NN
7457821
23949582
D015080_D030342 NONE Mesna_0/NNS (r_nsubj) reduces_2/VBZ (l_dobj) genotoxicity_5/NN
D007069_D030342 NONE IFO_3/NNP (r_poss) genotoxicity_5/NN
3475563
D001507_D002180 CID dipropionate_11/NNP (r_pobj) with_9/IN (r_prep) developed_4/VBD (l_dobj) candidiasis_6/NN
D001507_D002180 CID beclomethasone_9/NN (r_pobj) on_7/IN (r_prep) placed_6/VBN (r_relcl) patients_3/NNS (r_pobj) Of_0/IN (r_prep) developed_16/VBN (l_dobj) hoarseness_18/NN (l_appos) thrush_23/NN
D001507_D006685 CID dipropionate_11/NNP (r_pobj) with_9/IN (r_prep) developed_4/VBD (l_dobj) candidiasis_6/NN (l_conj) hoarseness_8/NN
D001507_D006685 CID beclomethasone_9/NN (r_pobj) on_7/IN (r_prep) placed_6/VBN (r_relcl) patients_3/NNS (r_pobj) Of_0/IN (r_prep) developed_16/VBN (l_dobj) hoarseness_18/NN
D001507_D006685 CID beclomethasone_9/NN (r_pobj) on_7/IN (r_prep) restarted_6/VBN (r_ccomp) conclude_1/VBP (r_ccomp) challenged_32/VBN (l_nsubjpass) patients_23/NNS (l_relcl) develop_25/VBP (l_dobj) hoarseness_26/NN
D001507_D006685 CID beclomethasone_7/NN (r_conj) prednisone_4/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubj) increase_9/VB (l_dobj) risk_11/NN (l_prep) of_12/IN (l_pcomp) developing_13/VBG (l_dobj) hoarseness_14/NN
D001507_D001249 NONE beclomethasone_9/NN (r_pobj) on_7/IN (r_prep) placed_6/VBN (r_relcl) patients_3/NNS (l_amod) asthmatic_2/JJ
D011241_D006685 NONE prednisone_4/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubj) increase_9/VB (l_dobj) risk_11/NN (l_prep) of_12/IN (l_pcomp) developing_13/VBG (l_dobj) hoarseness_14/NN
D011241_D002177 NONE prednisone_4/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubj) increase_9/VB (l_dobj) risk_11/NN (l_prep) of_12/IN (l_pcomp) developing_13/VBG (l_dobj) hoarseness_14/NN (l_conj) candidiasis_16/NN
D001507_D002177 NONE beclomethasone_7/NN (r_conj) prednisone_4/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubj) increase_9/VB (l_dobj) risk_11/NN (l_prep) of_12/IN (l_pcomp) developing_13/VBG (l_dobj) hoarseness_14/NN (l_conj) candidiasis_16/NN
25119790
D003474_D007674 NONE Curcumin_0/NN (r_nsubj) prevents_1/VBZ (l_dobj) nephrotoxicity_5/NN
D003474_D007674 NONE curcumin_8/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (l_prep) against_20/IN (l_pobj) injury_23/NN
D003474_D007674 NONE curcumin_4/NN (r_nsubj) is_5/VBZ (l_acomp) able_6/JJ (l_xcomp) attenuate_8/VB (l_prep) in_9/IN (l_pobj) nephropathy_14/NN
C030272_D007674 CID maleate_2/NN (r_npadvmod) induced_4/VBN (r_amod) nephrotoxicity_5/NN
C030272_D007674 CID maleate_26/NNP (r_pobj) by_25/IN (r_agent) induced_24/VBN (r_acl) injury_23/NN
C030272_D007674 CID Maleate_0/NN (r_npadvmod) induced_2/VBN (r_amod) injury_4/NN
C030272_D007674 CID Maleate_0/NN (r_npadvmod) induced_2/VBN (r_amod) injury_4/NN (r_nsubj) included_5/VBN (l_dobj) increase_6/NN (l_prep) in_7/IN (l_conj) in_12/IN (l_pobj) excretion_15/NN (l_prep) of_16/IN (l_pobj) protein_18/NN (l_conj) glucose_20/NN (l_conj) sodium_22/NN (l_conj) lipocalin_28/NNP (l_conj) upregulation_45/NN (l_prep) of_46/IN (l_pobj) molecule_49/NN (l_compound) injury_48/NN
C030272_D007674 CID maleate_11/FW (r_npadvmod) induced_13/VBN (r_amod) nephropathy_14/NN
D010100_D007674 NONE oxygen_16/NN (r_compound) consumption_17/NN (r_conj) stress_13/NN (r_conj) alterations_10/NNS (r_pobj) to_8/IN (r_prep) relation_7/NN (r_appos) nephrotoxicity_5/NN
C030272_D011507 CID maleate_12/NN (r_pobj) of_11/IN (r_prep) injection_10/NN (r_pobj) by_7/IN (r_agent) induced_6/VBN (l_nsubjpass) proteinuria_1/NN
C030272_D009336 CID Maleate_0/NN (r_npadvmod) induced_2/VBN (r_amod) injury_4/NN (r_nsubj) included_5/VBN (l_dobj) increase_6/NN (l_appos) decrease_53/NN (l_conj) determined_75/VBN (l_nsubjpass) expression_60/NN (l_prep) besides_61/IN (l_prep) of_62/IN (l_pobj) necrosis_63/NN
D005947_D007674 NONE glucose_20/NN (r_conj) protein_18/NN (r_pobj) of_16/IN (r_prep) excretion_15/NN (r_pobj) in_12/IN (r_conj) in_7/IN (r_prep) increase_6/NN (r_dobj) included_5/VBN (l_nsubj) injury_4/NN
D005947_D007674 NONE glucose_20/NN (l_conj) sodium_22/NN (l_conj) lipocalin_28/NNP (l_conj) upregulation_45/NN (l_prep) of_46/IN (l_pobj) molecule_49/NN (l_compound) injury_48/NN
D005947_D009336 NONE glucose_20/NN (r_conj) protein_18/NN (r_pobj) of_16/IN (r_prep) excretion_15/NN (r_pobj) in_12/IN (r_conj) in_7/IN (r_prep) increase_6/NN (l_appos) decrease_53/NN (l_conj) determined_75/VBN (l_nsubjpass) expression_60/NN (l_prep) besides_61/IN (l_prep) of_62/IN (l_pobj) necrosis_63/NN
D012964_D007674 NONE sodium_22/NN (r_conj) glucose_20/NN (r_conj) protein_18/NN (r_pobj) of_16/IN (r_prep) excretion_15/NN (r_pobj) in_12/IN (r_conj) in_7/IN (r_prep) increase_6/NN (r_dobj) included_5/VBN (l_nsubj) injury_4/NN
D012964_D007674 NONE sodium_22/NN (l_conj) lipocalin_28/NNP (l_conj) upregulation_45/NN (l_prep) of_46/IN (l_pobj) molecule_49/NN (l_compound) injury_48/NN
D012964_D009336 NONE sodium_22/NN (r_conj) glucose_20/NN (r_conj) protein_18/NN (r_pobj) of_16/IN (r_prep) excretion_15/NN (r_pobj) in_12/IN (r_conj) in_7/IN (r_prep) increase_6/NN (l_appos) decrease_53/NN (l_conj) determined_75/VBN (l_nsubjpass) expression_60/NN (l_prep) besides_61/IN (l_prep) of_62/IN (l_pobj) necrosis_63/NN
9158667
D014212_D013927 CID acid_12/NN (r_compound) therapy_13/NN (r_pobj) during_6/IN (r_prep) complications_1/NNS (l_amod) Thrombotic_0/JJ
D014212_D015473 NONE acid_12/NN (r_compound) therapy_13/NN (r_pobj) during_6/IN (r_prep) complications_1/NNS (l_prep) in_2/IN (l_pobj) leukemia_5/NN
D014212_D015473 NONE acid_30/NN (r_pobj) with_24/IN (r_prep) treated_23/VBN (l_prep) due_7/IN (l_pobj) occlusion_9/NN (l_prep) of_10/IN (l_pobj) vessels_12/NNS (l_prep) in_13/IN (l_pobj) patient_15/NN (l_prep) with_16/IN (l_pobj) leukemia_19/NN
D014212_D015473 NONE acid_30/NN (r_pobj) with_24/IN (r_prep) treated_23/VBN (l_prep) due_7/IN (l_pobj) occlusion_9/NN (l_prep) of_10/IN (l_pobj) vessels_12/NNS (l_prep) in_13/IN (l_pobj) patient_15/NN (l_prep) with_16/IN (l_pobj) leukemia_19/NN (l_appos) APL_21/NNP
D014212_D015473 NONE ATRA_32/NNP (r_appos) acid_30/NN (r_pobj) with_24/IN (r_prep) treated_23/VBN (l_prep) due_7/IN (l_pobj) occlusion_9/NN (l_prep) of_10/IN (l_pobj) vessels_12/NNS (l_prep) in_13/IN (l_pobj) patient_15/NN (l_prep) with_16/IN (l_pobj) leukemia_19/NN
D014212_D015473 NONE ATRA_32/NNP (r_appos) acid_30/NN (r_pobj) with_24/IN (r_prep) treated_23/VBN (l_prep) due_7/IN (l_pobj) occlusion_9/NN (l_prep) of_10/IN (l_pobj) vessels_12/NNS (l_prep) in_13/IN (l_pobj) patient_15/NN (l_prep) with_16/IN (l_pobj) leukemia_19/NN (l_appos) APL_21/NNP
D014212_D015473 NONE ATRA_14/NNP (r_pobj) with_13/IN (r_prep) treated_12/VBN (r_acl) patient_11/NN (l_compound) APL_10/NNP
D014212_D015473 NONE ATRA_11/NNP (r_compound) therapy_12/NN (l_prep) in_13/IN (l_pobj) patients_15/NNS (l_compound) APL_14/NNP
D014212_D015473 NONE ATRA_25/NNP (r_pobj) with_24/IN (r_prep) protocol_23/NN (r_pobj) in_20/IN (r_prep) included_19/VBN (r_conj) presented_9/VBD (l_dobj) signs_12/NNS (l_prep) of_15/IN (l_pobj) APL_16/NNP
D014212_D015473 NONE ATRA_3/NNP (r_nsubj) is_4/VBZ (l_attr) choice_8/NN (l_prep) for_9/IN (l_pobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) APL_12/NNP
D014212_D058186 CID acid_30/NN (r_pobj) with_24/IN (r_prep) treated_23/VBN (r_acl) case_1/NN (l_prep) of_2/IN (l_pobj) failure_5/NN
D014212_D058186 CID ATRA_32/NNP (r_appos) acid_30/NN (r_pobj) with_24/IN (r_prep) treated_23/VBN (r_acl) case_1/NN (l_prep) of_2/IN (l_pobj) failure_5/NN
D014212_D058186 CID ATRA_14/NNP (r_pobj) with_13/IN (r_prep) treated_12/VBN (r_acl) patient_11/NN (r_pobj) in_8/IN (r_prep) failure_7/NN
D014212_-1 NONE acid_30/NN (r_pobj) with_24/IN (r_prep) treated_23/VBN (l_prep) due_7/IN (l_pobj) occlusion_9/NN (l_prep) of_10/IN (l_pobj) vessels_12/NNS
D014212_-1 NONE ATRA_32/NNP (r_appos) acid_30/NN (r_pobj) with_24/IN (r_prep) treated_23/VBN (l_prep) due_7/IN (l_pobj) occlusion_9/NN (l_prep) of_10/IN (l_pobj) vessels_12/NNS
D014148_D058186 NONE acid_36/NN (r_nsubjpass) described_39/VBN (l_nsubjpass) case_1/NN (l_prep) of_2/IN (l_pobj) failure_5/NN
D014148_-1 NONE acid_36/NN (r_nsubjpass) described_39/VBN (l_nsubjpass) case_1/NN (l_acl) treated_23/VBN (l_prep) due_7/IN (l_pobj) occlusion_9/NN (l_prep) of_10/IN (l_pobj) vessels_12/NNS
D014148_D015473 NONE acid_36/NN (r_nsubjpass) described_39/VBN (l_nsubjpass) case_1/NN (l_acl) treated_23/VBN (l_prep) due_7/IN (l_pobj) occlusion_9/NN (l_prep) of_10/IN (l_pobj) vessels_12/NNS (l_prep) in_13/IN (l_pobj) patient_15/NN (l_prep) with_16/IN (l_pobj) leukemia_19/NN
D014148_D015473 NONE acid_36/NN (r_nsubjpass) described_39/VBN (l_nsubjpass) case_1/NN (l_acl) treated_23/VBN (l_prep) due_7/IN (l_pobj) occlusion_9/NN (l_prep) of_10/IN (l_pobj) vessels_12/NNS (l_prep) in_13/IN (l_pobj) patient_15/NN (l_prep) with_16/IN (l_pobj) leukemia_19/NN (l_appos) APL_21/NNP
D014212_D013923 NONE ATRA_11/NNP (r_compound) therapy_12/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) complications_8/NNS (l_compound) thromboembolic_7/JJ
D006493_D013927 NONE heparin_13/NN (r_dobj) using_9/VBG (r_pcomp) by_8/IN (r_prep) avoided_7/VBN (l_nsubjpass) events_1/NNS (l_amod) Thrombotic_0/JJ
24535067
D005045_D009207 CID etomidate_2/NN (r_npadvmod) induced_4/VBN (r_amod) myoclonus_5/NN
D005045_D009207 CID etomidate_26/NN (r_npadvmod) induced_28/VBN (r_amod) myoclonus_29/NN
D005045_D009207 CID etomidate_16/NN (r_npadvmod) induced_18/VBN (r_amod) myoclonus_19/NN
D005283_D009207 NONE Fentanyl_11/NN (r_appos) Prevention_0/NN (l_prep) of_1/IN (l_pobj) myoclonus_5/NN
D005283_D009207 NONE fentanyl_13/NN (r_nmod) midazolam_15/NNP (l_conj) combination_19/NN (l_relcl) prevent_25/VB (l_dobj) myoclonus_29/NN
D005283_D009207 NONE fentanyl_21/NN (r_pobj) of_20/IN (r_prep) combination_19/NN (l_relcl) prevent_25/VB (l_dobj) myoclonus_29/NN
D005283_D009207 NONE fentanyl_5/NN (r_pobj) with_4/IN (r_prep) pretreatment_3/NN (r_nsubj) was_12/VBD (l_acomp) effective_13/JJ (l_prep) in_14/IN (l_pcomp) preventing_15/VBG (l_dobj) myoclonus_19/NN
D005283_D009207 NONE fentanyl_9/NN (r_pobj) of_8/IN (r_prep) fentanyl_5/NN (r_pobj) with_4/IN (r_prep) pretreatment_3/NN (r_nsubj) was_12/VBD (l_acomp) effective_13/JJ (l_prep) in_14/IN (l_pcomp) preventing_15/VBG (l_dobj) myoclonus_19/NN
D008874_D009207 NONE midazolam_13/NN (r_conj) Fentanyl_11/NN (r_appos) Prevention_0/NN (l_prep) of_1/IN (l_pobj) myoclonus_5/NN
D008874_D009207 NONE midazolam_15/NNP (l_conj) combination_19/NN (l_relcl) prevent_25/VB (l_dobj) myoclonus_29/NN
D008874_D009207 NONE midazolam_23/NNP (r_conj) fentanyl_21/NN (r_pobj) of_20/IN (r_prep) combination_19/NN (l_relcl) prevent_25/VB (l_dobj) myoclonus_29/NN
D008874_D009207 NONE midazolam_11/NNP (r_conj) pretreatment_3/NN (r_nsubj) was_12/VBD (l_acomp) effective_13/JJ (l_prep) in_14/IN (l_pcomp) preventing_15/VBG (l_dobj) myoclonus_19/NN
D005045_D009069 NONE etomidate_19/NNP (r_compound) injection_20/NN (r_pobj) after_18/IN (r_prep) minutes_17/NNS (r_pobj) during_14/IN (r_prep) severity_13/NN (r_pobj) to_11/IN (r_prep) according_10/VBG (r_prep) graded_9/VBN (r_conj) observed_7/VBN (r_relcl) movements_1/NNS
D005045_D010146 NONE etomidate_6/NN (r_pcomp) due_4/IN (r_amod) severity_1/NN (l_prep) of_2/IN (l_pobj) pain_3/NN
11835460
D007980_D015835 CID Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_4/NN
D007980_D015835 CID Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_4/NNS
D007980_D015835 CID levodopa_17/NN (r_pobj) of_16/IN (r_prep) effect_15/NN (r_pobj) during_12/IN (r_prep) deviations_9/NNS (r_pobj) with_5/IN (r_prep) patient_4/NN (r_pobj) on_2/IN (r_prep) report_1/VBP (l_conj) hypothesize_20/VB (l_ccomp) needed_31/VBN (l_prep) for_32/IN (l_pobj) appearance_34/NN (l_prep) of_35/IN (l_pobj) dyskinesias_41/NN
D007980_D015835 CID levodopa_37/NN (r_npadvmod) induce_39/VB (r_amod) dyskinesias_41/NN
D007980_D010300 NONE Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_4/NN (l_prep) in_5/IN (l_pobj) disease_8/NN
2818777
D010672_D056486 NONE Phenytoin_0/NNP (r_nsubj) induced_1/VBD (l_dobj) injury_4/NN
D010672_D017093 CID phenytoin_10/NNP (r_compound) administration_11/NN (r_pobj) after_9/IN (r_prep) failure_8/NN
89511
D004967_D014591 NONE oestrogen_10/NN (r_compound) therapy_11/NN (r_dobj) receiving_9/VBG (r_acl) women_8/NNS (r_pobj) in_6/IN (r_prep) disease_5/NN
D004967_D014591 NONE oestrogen_16/NN (r_compound) therapy_17/NN (r_dobj) receiving_15/VBG (r_acl) women_14/NNS (r_pobj) among_11/IN (r_prep) disease_10/NN
D004967_D006965 CID oestrogen_6/NN (r_compound) therapy_7/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (l_nsubjpass) hyperplasia_1/NN
D004967_D006965 CID oestrogen_16/NN (r_compound) therapy_17/NN (l_conj) difficulty_20/NN (l_prep) in_21/IN (l_pcomp) distinguishing_22/VBG (l_dobj) hyperplasia_24/NN
D011372_D006965 NONE progestagen_9/NNP (r_pobj) without_8/IN (r_prep) therapy_7/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (l_nsubjpass) hyperplasia_1/NN
D009640_D006965 NONE norethisterone_8/NN (r_compound) daily_9/RB (r_pobj) of_5/IN (r_prep) days_4/NNS (r_pobj) of_2/IN (r_prep) courses_1/NNS (r_nsubj) caused_10/VBD (l_prep) in_14/IN (l_pobj) cases_17/NNS (l_prep) of_18/IN (l_pobj) hyperplasia_20/NN
D009640_D006965 NONE norethisterone_8/NN (r_compound) daily_9/RB (r_pobj) of_5/IN (r_prep) days_4/NNS (r_pobj) of_2/IN (r_prep) courses_1/NNS (r_nsubj) caused_10/VBD (l_prep) in_14/IN (l_pobj) cases_17/NNS (l_conj) 6_22/CD (l_prep) of_23/IN (l_pobj) cases_26/NNS (l_prep) of_27/IN (l_pobj) hyperplasia_29/NN
D004967_D016889 NONE oestrogen_16/NN (r_compound) therapy_17/NN (r_pobj) of_11/IN (r_prep) problems_10/NNS (r_dobj) demonstrated_8/VBN (l_nsubj) cases_1/NNS (l_prep) of_2/IN (l_pobj) carcinoma_4/NN
D004967_D009369 NONE oestrogen_16/NN (r_compound) therapy_17/NN (l_conj) difficulty_20/NN (l_prep) in_21/IN (l_pcomp) distinguishing_22/VBG (l_dobj) hyperplasia_24/NN (l_prep) from_25/IN (l_pobj) malignancy_26/NN
D004967_D004714 NONE oestrogen_4/NN (r_compound) therapy_5/NN (r_nsubj) seem_15/VB (l_xcomp) increase_17/VB (l_dobj) risk_19/NN (l_prep) of_20/IN (l_pobj) hyperplasia_22/NN
D004967_D002277 NONE oestrogen_4/NN (r_compound) therapy_5/NN (r_nsubj) seem_15/VB (l_xcomp) increase_17/VB (l_dobj) risk_19/NN (l_prep) of_20/IN (l_pobj) hyperplasia_22/NN (l_conj) carcinoma_24/NN
D011372_D004714 NONE progestagen_12/NNP (r_pobj) of_11/IN (r_prep) days_10/NNS (r_pobj) with_6/IN (r_prep) therapy_5/NN (r_nsubj) seem_15/VB (l_xcomp) increase_17/VB (l_dobj) risk_19/NN (l_prep) of_20/IN (l_pobj) hyperplasia_22/NN
D011372_D002277 NONE progestagen_12/NNP (r_pobj) of_11/IN (r_prep) days_10/NNS (r_pobj) with_6/IN (r_prep) therapy_5/NN (r_nsubj) seem_15/VB (l_xcomp) increase_17/VB (l_dobj) risk_19/NN (l_prep) of_20/IN (l_pobj) hyperplasia_22/NN (l_conj) carcinoma_24/NN
7248895
D003520_D010386 NONE cyclophosphamide_7/RB (r_compound) therapy_8/NN (r_pobj) following_6/VBG (r_prep) pelvis_5/NNS
D003520_D010386 NONE cyclophosphamide_15/JJ (r_compound) treatment_16/NN (r_pobj) with_14/IN (r_prep) association_13/NN (r_pobj) in_12/IN (r_prep) reported_11/VBD (r_acl) carcinoma_6/NN (l_prep) of_7/IN (l_pobj) pelvis_10/NNS
D003520_D006869 NONE cyclophosphamide_23/RB (r_dobj) wtih_22/IN (r_prep) treated_18/VBN (r_pcomp) after_16/IN (r_prep) had_13/VBD (l_nsubj) woman_4/NN (l_prep) with_5/IN (l_pobj) hydroureteronephrosis_7/NN
D003520_D006869 NONE cyclophosphamide_21/NN (r_pobj) to_20/IN (r_prep) exposure_14/NN (r_pobj) that_9/IN (r_dobj) suggests_8/VBZ (l_nsubj) association_1/NN (l_prep) with_5/IN (l_pobj) hydroureteronephrosis_7/NN
D003520_D006417 CID cyclophosphamide_23/RB (r_dobj) wtih_22/IN (r_prep) treated_18/VBN (r_pcomp) after_16/IN (r_prep) had_13/VBD (l_dobj) hematuria_15/NN
D003520_D020293 NONE cyclophosphamide_23/RB (r_dobj) wtih_22/IN (l_prep) for_24/IN (l_pobj) vasculitis_26/NN
D003520_D006470 NONE cyclophosphamide_4/NN (r_pobj) of_3/IN (r_prep) ability_2/NN (l_acl) cause_6/VB (l_dobj) cystitis_8/NN
D003520_D003556 NONE cyclophosphamide_4/NN (r_pobj) of_3/IN (r_prep) ability_2/NN (l_acl) cause_6/VB (l_dobj) cystitis_8/NN
D003520_D002277 CID cyclophosphamide_4/NN (r_pobj) of_3/IN (r_prep) ability_2/NN (l_amod) indistinguishable_13/JJ (l_prep) from_14/IN (l_pobj) carcinoma_17/NN
D003520_D014571 NONE cyclophosphamide_4/NN (r_pobj) of_3/IN (r_prep) ability_2/NN (r_nsubj) is_18/VBZ (r_advcl) appreciated_26/VBN (l_ccomp) associated_31/VBN (l_prep) with_32/IN (l_pobj) carcinoma_33/NN (l_prep) of_34/IN (l_pobj) tract_37/NN
D003520_D014571 NONE cyclophosphamide_11/JJ (r_compound) treatment_12/NN (r_pobj) with_10/IN (r_prep) association_9/NN (r_pobj) in_8/IN (r_prep) reported_7/VBN (r_acl) cancer_6/NN
D003520_D009369 NONE cyclophosphamide_21/NN (r_pobj) to_20/IN (r_prep) exposure_14/NN (r_pobj) that_9/IN (r_dobj) suggests_8/VBZ (l_nsubj) association_1/NN (l_prep) of_2/IN (l_pobj) tumor_4/NN
D003520_-1 NONE cyclophosphamide_8/IN (r_compound) treatment_9/NN (r_pobj) for_4/IN (r_prep) candidates_3/NNS (r_attr) are_2/VBP (r_relcl) Patients_0/NNS (r_nsubjpass) evaluated_13/VBN (l_prep) for_14/IN (l_pobj) uropathy_16/NNP
10939760
D013411_D058186 CID sulfadiazine_2/NN (r_compound) nephrotoxicity_4/NN
D013411_D058186 CID Sulfadiazine_0/JJ (r_nmod) nephrotoxicity_2/NN
D013411_D014123 NONE Sulfadiazine_0/JJ (r_nmod) nephrotoxicity_2/NN (r_nsubj) reviving_4/VBG (l_prep) because_6/IN (l_pobj) use_9/NN (l_prep) in_10/IN (l_pobj) toxoplasmosis_11/NN
D013411_D009846 NONE sulfadiazine_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_pobj) Under_0/IN (r_prep) developed_5/VBD (l_dobj) oliguria_6/NNP
D013411_D015746 NONE sulfadiazine_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_pobj) Under_0/IN (r_prep) developed_5/VBD (l_dobj) oliguria_6/NNP (l_conj) pain_9/NN
D013411_D051437 NONE sulfadiazine_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_pobj) Under_0/IN (r_prep) developed_5/VBD (l_dobj) oliguria_6/NNP (l_conj) pain_9/NN (l_conj) failure_12/NN
D013411_D007669 CID sulfadiazine_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_pobj) Under_0/IN (r_prep) developed_5/VBD (l_conj) showed_14/VBD (l_dobj) calculi_18/NNS
10764869
D016559_D009901 CID tacrolimus_10/NN (r_nmod) therapy_14/NN (r_pobj) on_9/IN (r_prep) patient_8/NN (r_pobj) in_6/IN (r_prep) case_1/NN (l_prep) of_2/IN (l_pobj) neuropathy_5/NN
D016559_D009901 CID FK506_12/NNP (r_nmod) therapy_14/NN (r_pobj) on_9/IN (r_prep) patient_8/NN (r_pobj) in_6/IN (r_prep) case_1/NN (l_prep) of_2/IN (l_pobj) neuropathy_5/NN
D016559_D009901 CID tacrolimus_12/NN (r_dobj) receiving_11/VBG (r_acl) patient_10/NN (r_pobj) in_8/IN (r_prep) case_3/NN (l_prep) of_4/IN (l_pobj) neuropathy_7/NN
D016559_D009901 CID 506_15/CD (r_nummod) FK_14/NNP (r_appos) tacrolimus_12/NN (r_dobj) receiving_11/VBG (r_acl) patient_10/NN (r_pobj) in_8/IN (r_prep) case_3/NN (l_prep) of_4/IN (l_pobj) neuropathy_7/NN
D016559_D009901 CID Tacrolimus_0/NNP (r_nsubjpass) associated_7/VBN (l_prep) with_8/IN (l_pobj) toxicity_11/NN
D016559_D015354 NONE tacrolimus_8/NN (r_pobj) of_6/IN (r_prep) discontinuation_5/NN (r_pobj) despite_4/IN (r_prep) occurred_3/VBD (l_nsubj) Deterioration_0/NN (l_prep) of_1/IN (l_pobj) vision_2/NN
8985298
D019259_D006509 NONE Lamivudine_0/NNP (r_nsubj) is_1/VBZ (l_acomp) effective_2/JJ (l_prep) in_3/IN (l_pcomp) suppressing_4/VBG (l_dobj) DNA_8/NN (l_compound) virus_7/NN (l_compound) B_6/NNP
D019259_D006509 NONE Lamivudine_0/NNP (r_nsubj) is_1/VBZ (l_attr) analogue_6/NN (l_relcl) has_8/VBZ (l_dobj) effects_11/NNS (l_prep) on_12/IN (l_pobj) replication_16/NN (l_compound) virus_15/NN (l_compound) B_14/NNP
D019259_D006509 NONE cytosine_5/NN (r_compound) analogue_6/NN (l_relcl) has_8/VBZ (l_dobj) effects_11/NNS (l_prep) on_12/IN (l_pobj) replication_16/NN (l_compound) virus_15/NN (l_compound) B_14/NNP
D019259_D006509 NONE lamivudine_4/NNP (r_dobj) receiving_3/VBG (r_acl) patients_2/NNS (r_nsubj) had_5/VBD (l_dobj) decrease_7/NN (l_prep) in_8/IN (l_pobj) virus_11/NN (l_compound) B_10/NNP
D006514_D006509 CID antigen_14/NN (r_compound) carriers_15/NNS (r_pobj) in_9/IN (r_prep) DNA_8/NN (l_compound) virus_7/NN (l_compound) B_6/NNP
24928523
C400082_D009101 NONE bortezomib_2/NNP (r_pobj) of_1/IN (r_prep) Combination_0/NN (l_prep) as_11/IN (l_pobj) therapy_14/NN (l_prep) after_15/IN (l_pobj) transplantation_19/NN (l_prep) for_20/IN (l_pobj) myeloma_23/NN
C400082_D009101 NONE bortezomib_15/NNP (r_pobj) of_14/IN (r_prep) regimen_13/NN (r_pobj) of_11/IN (r_prep) safety_8/NN (r_dobj) analyzed_6/VBD (l_prep) as_24/IN (l_pobj) therapy_26/NN (l_prep) in_27/IN (l_pobj) patients_30/NNS (l_prep) with_31/IN (l_pobj) MM_34/NNP
D013792_D009101 NONE thalidomide_4/NN (r_conj) bortezomib_2/NNP (r_pobj) of_1/IN (r_prep) Combination_0/NN (l_prep) as_11/IN (l_pobj) therapy_14/NN (l_prep) after_15/IN (l_pobj) transplantation_19/NN (l_prep) for_20/IN (l_pobj) myeloma_23/NN
D013792_D009101 NONE thalidomide_17/NN (r_conj) bortezomib_15/NNP (r_pobj) of_14/IN (r_prep) regimen_13/NN (r_pobj) of_11/IN (r_prep) safety_8/NN (r_dobj) analyzed_6/VBD (l_prep) as_24/IN (l_pobj) therapy_26/NN (l_prep) in_27/IN (l_pobj) patients_30/NNS (l_prep) with_31/IN (l_pobj) MM_34/NNP
D003907_D009101 NONE dexamethasone_7/NN (r_conj) thalidomide_4/NN (r_conj) bortezomib_2/NNP (r_pobj) of_1/IN (r_prep) Combination_0/NN (l_prep) as_11/IN (l_pobj) therapy_14/NN (l_prep) after_15/IN (l_pobj) transplantation_19/NN (l_prep) for_20/IN (l_pobj) myeloma_23/NN
D003907_D009101 NONE dexamethasone_20/NN (r_conj) thalidomide_17/NN (r_conj) bortezomib_15/NNP (r_pobj) of_14/IN (r_prep) regimen_13/NN (r_pobj) of_11/IN (r_prep) safety_8/NN (r_dobj) analyzed_6/VBD (l_prep) as_24/IN (l_pobj) therapy_26/NN (l_prep) in_27/IN (l_pobj) patients_30/NNS (l_prep) with_31/IN (l_pobj) MM_34/NNP
15605432
D004317_D028361 CID adriamycin_6/NN (r_npadvmod) induced_8/VBN (r_amod) injury_11/NN
D004317_D028361 CID ADR_3/NNP (r_nsubj) induced_4/VBN (r_ccomp) showed_2/VBD (l_prep) at_11/IN (l_pobj) point_15/NN (l_prep) as_16/IN (l_pcomp) appeared_21/VBD (l_nsubj) injury_19/NN
D010100_D066126 NONE oxygen_12/NN (r_nsubj) resulted_29/VBD (l_nsubj) cardiotoxicity_27/NN
D009584_D066126 NONE ROS)/nitrogen_14/NNP (r_compound) species_15/NNS (r_nsubj) reported_19/VBN (r_parataxis) oxygen_12/NN (r_nsubj) resulted_29/VBD (l_nsubj) cardiotoxicity_27/NN
D004317_D066126 NONE adriamycin_24/NN (r_pobj) in_23/IN (r_prep) present_22/JJ (r_acomp) be_21/VB (r_xcomp) reported_19/VBN (r_parataxis) oxygen_12/NN (r_nsubj) resulted_29/VBD (l_nsubj) cardiotoxicity_27/NN
D004317_D066126 NONE ADR)-induced_26/NNP (r_compound) cardiotoxicity_27/NN
C027576_D028361 NONE 4HNE_5/CD (r_compound) protein_7/NN (r_compound) adducts_8/NNS (r_dobj) induced_4/VBN (r_ccomp) showed_2/VBD (l_prep) at_11/IN (l_pobj) point_15/NN (l_prep) as_16/IN (l_pcomp) appeared_21/VBD (l_nsubj) injury_19/NN
24742750
D016593_D016171 CID Terfenadine_6/NNP (r_conj) blockers_4/NNS (l_relcl) reported_12/VBN (l_xcomp) cause_14/VB (l_dobj) TdP_19/NNP (l_nmod) Pointes_17/NNP
D016593_D016171 CID Terfenadine_6/NNP (r_conj) blockers_4/NNS (l_relcl) reported_12/VBN (l_xcomp) cause_14/VB (l_dobj) TdP_19/NNP
D015283_D016171 CID Citalopram_8/NNP (r_conj) Terfenadine_6/NNP (r_conj) blockers_4/NNS (l_relcl) reported_12/VBN (l_xcomp) cause_14/VB (l_dobj) TdP_19/NNP (l_nmod) Pointes_17/NNP
D015283_D016171 CID Citalopram_8/NNP (r_conj) Terfenadine_6/NNP (r_conj) blockers_4/NNS (l_relcl) reported_12/VBN (l_xcomp) cause_14/VB (l_dobj) TdP_19/NNP
6106951
D005479_D064420 NONE FZP_2/NNP (r_compound) toxocity_3/NN
D005479_D012798 NONE FZP_2/NNP (r_compound) toxocity_3/NN (r_pobj) of_1/IN (r_prep) Signs_0/NNS (r_nsubj) included_6/VBD (l_dobj) salivation_8/NN
D005479_D014202 NONE FZP_2/NNP (r_compound) toxocity_3/NN (r_pobj) of_1/IN (r_prep) Signs_0/NNS (r_nsubj) included_6/VBD (l_dobj) salivation_8/NN (l_conj) behavior_12/NN (l_conj) retching_14/VBG (l_conj) tremors_17/NNS
D005479_D012640 CID FZP_2/NNP (r_compound) toxocity_3/NN (r_pobj) of_1/IN (r_prep) Signs_0/NNS (r_nsubj) included_6/VBD (l_dobj) salivation_8/NN (l_conj) behavior_12/NN (l_conj) retching_14/VBG (l_conj) tremors_17/NNS (l_conj) convulsions_19/NNS
D005479_D012640 CID FZP_6/NNP (r_nsubj) protected_8/VBD (l_prep) against_9/IN (l_pobj) convulsions_10/NNS
D005479_D012640 CID FZP_3/NNP (r_pobj) of_2/IN (r_prep) doses_1/NNS (r_nsubj) were_4/VBD (l_acomp) lower_5/JJR (l_prep) than_6/IN (l_pobj) those_7/DT (l_relcl) cause_11/VB (l_dobj) convulsions_12/NNS
D005479_D004827 NONE FZP_9/NNP (r_pobj) of_8/IN (r_prep) use_7/NN (l_prep) in_10/IN (l_pobj) situations_12/NNS (l_relcl) is_16/VBZ (l_attr) excitability_19/NN (l_prep) as_22/IN (l_pobj) epilepsy_23/NN
19184102
D014635_D065626 CID valproate_5/NN (r_amod) therapy_6/NN (r_pobj) during_4/IN (r_prep) disease_3/NN
D014635_D065626 CID VPA_20/NNP (r_compound) treatment_21/NN (r_pobj) during_19/IN (r_prep) developed_17/VBD (r_relcl) child_15/NN (r_pobj) in_13/IN (r_prep) arising_12/VBG (r_acl) case_3/NN (l_prep) of_4/IN (l_pobj) disease_8/NN
D014635_D065626 CID VPA_20/NNP (r_compound) treatment_21/NN (r_pobj) during_19/IN (r_prep) developed_17/VBD (r_relcl) child_15/NN (r_pobj) in_13/IN (r_prep) arising_12/VBG (r_acl) case_3/NN (l_prep) of_4/IN (l_pobj) disease_8/NN (l_appos) NAFLD_10/NNP
D014635_D065626 CID VPA_18/NNP (r_pobj) with_17/IN (r_prep) treatment_16/NN (r_conj) resistance_10/NN (r_conj) hyperinsulinemia_7/NN (r_appos) obesity_5/NN (r_nsubjpass) associated_22/VBN (l_prep) with_23/IN (l_pobj) development_25/NN (l_prep) of_26/IN (l_pobj) NAFLD_27/NNP
D014635_D065626 CID VPA_35/NNP (r_compound) withdrawal_36/NN (r_pobj) after_34/IN (r_prep) is_32/VBZ (l_ccomp) suggests_3/VBZ (l_ccomp) associated_22/VBN (l_prep) with_23/IN (l_pobj) development_25/NN (l_prep) of_26/IN (l_pobj) NAFLD_27/NNP
D014635_D004827 NONE acid_1/NN (r_nsubj) is_5/VBZ (l_acomp) effective_6/JJ (l_prep) for_7/IN (l_pobj) treatment_9/NN (l_prep) of_10/IN (l_pobj) types_12/NNS (l_prep) of_13/IN (l_pobj) epilepsy_14/NN
D014635_D004827 NONE VPA_3/NNP (r_appos) acid_1/NN (r_nsubj) is_5/VBZ (l_acomp) effective_6/JJ (l_prep) for_7/IN (l_pobj) treatment_9/NN (l_prep) of_10/IN (l_pobj) types_12/NNS (l_prep) of_13/IN (l_pobj) epilepsy_14/NN
D014635_D009765 CID VPA_20/NNP (r_compound) treatment_21/NN (r_pobj) during_19/IN (r_prep) developed_17/VBD (l_dobj) obesity_18/NN
D014635_D009765 CID VPA_18/NNP (r_pobj) with_17/IN (r_prep) treatment_16/NN (r_conj) resistance_10/NN (r_conj) hyperinsulinemia_7/NN (r_appos) obesity_5/NN
D014635_D009765 CID VPA_35/NNP (r_compound) withdrawal_36/NN (r_pobj) after_34/IN (r_prep) is_32/VBZ (l_ccomp) suggests_3/VBZ (l_ccomp) associated_22/VBN (l_nsubjpass) obesity_5/NN
D014635_D015431 NONE VPA_4/NNP (r_compound) therapy_5/NN (r_pobj) of_3/IN (r_prep) withdrawal_2/NN (r_pobj) After_0/IN (r_prep) showed_9/VBD (l_dobj) loss_13/NN
D014635_D006946 CID VPA_18/NNP (r_pobj) with_17/IN (r_prep) treatment_16/NN (r_conj) resistance_10/NN (r_conj) hyperinsulinemia_7/NN
D014635_D006946 CID VPA_35/NNP (r_compound) withdrawal_36/NN (r_pobj) after_34/IN (r_prep) is_32/VBZ (l_ccomp) suggests_3/VBZ (l_ccomp) associated_22/VBN (l_nsubjpass) obesity_5/NN (l_appos) hyperinsulinemia_7/NN
D014635_D007333 CID VPA_18/NNP (r_pobj) with_17/IN (r_prep) treatment_16/NN (r_conj) resistance_10/NN
D014635_D007333 CID VPA_35/NNP (r_compound) withdrawal_36/NN (r_pobj) after_34/IN (r_prep) is_32/VBZ (l_ccomp) suggests_3/VBZ (l_ccomp) associated_22/VBN (l_nsubjpass) obesity_5/NN (l_appos) hyperinsulinemia_7/NN (l_conj) resistance_10/NN
2625524
D006220_D012640 NONE Haloperidol_0/NNP (r_nsubj) failed_1/VBD (l_xcomp) prevent_3/VB (l_dobj) seizures_7/NNS
D006220_D012640 NONE Haloperidol_0/NNP (r_nsubj) decreased_1/VBD (l_dobj) incidence_3/NN (l_prep) of_4/IN (l_pobj) seizures_8/NNS
D006220_D012640 NONE haloperidol_11/NNP (r_appos) blocker_10/NNP (r_pobj) for_6/IN (r_prep) role_5/NN (l_prep) without_20/IN (l_pcomp) reducing_21/VBG (l_dobj) incidence_23/NN (l_prep) of_24/IN (l_pobj) seizures_25/NNS
D006220_D012640 NONE haloperidol_3/NNP (r_nsubj) demonstrated_4/VBD (l_dobj) ability_6/NN (l_acl) reduce_8/VB (l_dobj) seizures_12/NNS
D000661_D012640 CID amphetamine_4/NN (r_npadvmod) induced_6/VBN (r_amod) seizures_7/NNS
D000661_D012640 CID amphetamine_18/NN (r_compound) exposure_19/NN (r_pobj) from_14/IN (r_prep) death_13/NN (r_pobj) against_12/IN (r_prep) role_5/NN (l_prep) without_20/IN (l_pcomp) reducing_21/VBG (l_dobj) incidence_23/NN (l_prep) of_24/IN (l_pobj) seizures_25/NNS
D003042_D012640 CID cocaine_5/NN (r_npadvmod) induced_7/VBN (r_amod) seizures_8/NNS
D003042_D012640 CID cocaine_9/NN (r_npadvmod) induced_11/VBN (r_amod) seizures_12/NNS
D004298_D012640 NONE dopamine_9/NN (r_compound) blocker_10/NNP (r_pobj) for_6/IN (r_prep) role_5/NN (l_prep) without_20/IN (l_pcomp) reducing_21/VBG (l_dobj) incidence_23/NN (l_prep) of_24/IN (l_pobj) seizures_25/NNS
24333387
D013311_D020258 NONE Streptozotocin_12/NNP (r_pobj) in_11/IN (r_prep) events_10/NNS (r_appos) activation_1/NN (l_conj) neurotoxicity_6/NN
D013311_D020258 NONE STZ_0/NN (r_compound) treatment_1/NN (r_nsubj) showed_2/VBD (l_advcl) remains_25/VBZ (l_advcl) indicating_27/VBG (l_dobj) neurotoxicity_31/NN
D013311_D020258 NONE STZ_20/NN (r_nmod) activation_23/NN (l_conj) death_27/NN (l_conj) post_29/NN (l_dobj) neurotoxicity_31/NN
D013311_D020258 NONE STZ_16/NN (r_nmod) impairment_19/NN (r_pobj) in_15/IN (r_prep) factors_14/NNS (r_attr) are_11/VBP (l_nsubj) activation_6/NN (l_conj) post_8/NN (l_dobj) neurotoxicity_10/NN
D013311_D008569 CID Streptozotocin_12/NNP (r_pobj) in_11/IN (r_prep) events_10/NNS (r_appos) activation_1/NN (l_appos) impairment_18/NN
D013311_D008569 CID Streptozotocin_15/NNP (r_pobj) in_13/IN (r_prep) toxicity_12/NN (r_nsubj) induced_19/VBN (r_amod) rats_22/NNS (l_amod) impaired_21/VBN
D013311_D008569 CID STZ_17/NNP (r_appos) Streptozotocin_15/NNP (r_pobj) in_13/IN (r_prep) toxicity_12/NN (r_nsubj) induced_19/VBN (r_amod) rats_22/NNS (l_amod) impaired_21/VBN
D013311_D008569 CID STZ_21/NNP (r_pobj) after_20/IN (r_prep) days_19/NNS (r_pobj) on_15/IN (r_prep) test_14/NN (r_pobj) in_10/IN (r_prep) found_9/VBN (l_nsubjpass) deficit_7/NN
D013311_D008569 CID STZ_16/NN (r_nmod) impairment_19/NN
D013311_D064420 NONE Streptozotocin_15/NNP (r_pobj) in_13/IN (r_prep) toxicity_12/NN
D013311_D064420 NONE STZ_17/NNP (r_appos) Streptozotocin_15/NNP (r_pobj) in_13/IN (r_prep) toxicity_12/NN
D013311_D064420 NONE STZ_0/NNP (r_nsubj) increased_3/VBD (l_conj) reduced_15/VBD (l_prep) in_19/IN (l_pobj) preparation_21/NN (l_acl) illustrating_22/VBG (l_dobj) generation_25/NN (l_conj) excitotoxicity_27/NN
D013311_D007249 CID STZ_0/NN (r_nsubj) causes_1/VBZ (l_dobj) expression_3/NN (l_prep) of_4/IN (l_pobj) GFAP_5/NNP (l_appos) activation_14/NN (l_conj) neuroinflammation_16/NN
D009573_D064420 NONE nitrite_9/NN (r_conj) ROS_7/NNP (r_pobj) of_6/IN (r_prep) level_5/NN (r_dobj) increased_3/VBD (l_conj) reduced_15/VBD (l_prep) in_19/IN (l_pobj) preparation_21/NN (l_acl) illustrating_22/VBG (l_dobj) generation_25/NN (l_conj) excitotoxicity_27/NN
D002118_D064420 NONE Ca(2_11/NNP (r_conj) nitrite_9/NN (r_conj) ROS_7/NNP (r_pobj) of_6/IN (r_prep) level_5/NN (r_dobj) increased_3/VBD (l_conj) reduced_15/VBD (l_prep) in_19/IN (l_pobj) preparation_21/NN (l_acl) illustrating_22/VBG (l_dobj) generation_25/NN (l_conj) excitotoxicity_27/NN
D008559_D020258 NONE Memantine_3/NNP (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_nsubj) attenuated_19/VBN (l_dobj) activation_23/NN (l_conj) death_27/NN (l_conj) post_29/NN (l_dobj) neurotoxicity_31/NN
D007052_D020258 NONE Ibuprofen_10/NNP (r_conj) Memantine_3/NNP (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_nsubj) attenuated_19/VBN (l_dobj) activation_23/NN (l_conj) death_27/NN (l_conj) post_29/NN (l_dobj) neurotoxicity_31/NN
3711722
D003035_D009202 CID cobalt_4/NN (r_compound) cardiomyopathy_5/NN
D004317_D006333 CID doxorubicin_4/NN (r_npadvmod) induced_6/VBN (r_amod) failure_8/NN
733189
D000305_D015356 NONE corticosteroid_13/NN (r_compound) suspensions_14/NNS (r_pobj) of_9/IN (r_prep) injection_8/NN (r_pobj) following_6/VBG (r_prep) artery_2/NN (l_conj) occlusion_5/NN
C000873_D015356 CID acetate_24/NN (r_pobj) with_22/IN (r_prep) injection_21/NN (r_pobj) following_14/VBG (r_prep) blindness_13/NN (r_pobj) with_12/IN (r_prep) occlusions_11/NNS
C000873_D001766 NONE acetate_24/NN (r_pobj) with_22/IN (r_prep) injection_21/NN (r_pobj) following_14/VBG (r_prep) blindness_13/NN
D008012_D015356 NONE lidocaine_28/NN (r_pobj) with_27/IN (r_prep) combination_26/NN (r_pobj) in_25/IN (r_prep) acetate_24/NN (r_pobj) with_22/IN (r_prep) injection_21/NN (r_pobj) following_14/VBG (r_prep) blindness_13/NN (r_pobj) with_12/IN (r_prep) occlusions_11/NNS
D008012_D001766 NONE lidocaine_28/NN (r_pobj) with_27/IN (r_prep) combination_26/NN (r_pobj) in_25/IN (r_prep) acetate_24/NN (r_pobj) with_22/IN (r_prep) injection_21/NN (r_pobj) following_14/VBG (r_prep) blindness_13/NN
D004837_D015356 NONE epinephrine_30/NN (r_conj) lidocaine_28/NN (r_pobj) with_27/IN (r_prep) combination_26/NN (r_pobj) in_25/IN (r_prep) acetate_24/NN (r_pobj) with_22/IN (r_prep) injection_21/NN (r_pobj) following_14/VBG (r_prep) blindness_13/NN (r_pobj) with_12/IN (r_prep) occlusions_11/NNS
D004837_D001766 NONE epinephrine_30/NN (r_conj) lidocaine_28/NN (r_pobj) with_27/IN (r_prep) combination_26/NN (r_pobj) in_25/IN (r_prep) acetate_24/NN (r_pobj) with_22/IN (r_prep) injection_21/NN (r_pobj) following_14/VBG (r_prep) blindness_13/NN
D010406_D015356 NONE penicillin_33/NN (r_conj) epinephrine_30/NN (r_conj) lidocaine_28/NN (r_pobj) with_27/IN (r_prep) combination_26/NN (r_pobj) in_25/IN (r_prep) acetate_24/NN (r_pobj) with_22/IN (r_prep) injection_21/NN (r_pobj) following_14/VBG (r_prep) blindness_13/NN (r_pobj) with_12/IN (r_prep) occlusions_11/NNS
D010406_D001766 NONE penicillin_33/NN (r_conj) epinephrine_30/NN (r_conj) lidocaine_28/NN (r_pobj) with_27/IN (r_prep) combination_26/NN (r_pobj) in_25/IN (r_prep) acetate_24/NN (r_pobj) with_22/IN (r_prep) injection_21/NN (r_pobj) following_14/VBG (r_prep) blindness_13/NN
12452552
D018967_D007676 NONE risperidone_19/NNP (r_pobj) of_18/IN (r_prep) administration_17/NN (r_pobj) after_16/IN (r_prep) developed_9/VBD (l_nsubj) patient_1/NN (l_prep) with_2/IN (l_pobj) failure_5/NN
D018967_D007676 NONE risperidone_19/NNP (r_pobj) of_18/IN (r_prep) administration_17/NN (r_pobj) after_16/IN (r_prep) developed_9/VBD (l_nsubj) CRF_7/NNP
D018967_D009459 CID risperidone_19/NNP (r_pobj) of_18/IN (r_prep) administration_17/NN (r_pobj) after_16/IN (r_prep) developed_9/VBD (l_dobj) syndrome_12/NN
D018967_D009459 CID risperidone_19/NNP (r_pobj) of_18/IN (r_prep) administration_17/NN (r_pobj) after_16/IN (r_prep) developed_9/VBD (l_dobj) syndrome_12/NN (l_appos) NMS_14/NNP
D008728_D007676 NONE levomepromazine_21/NNP (r_conj) risperidone_19/NNP (r_pobj) of_18/IN (r_prep) administration_17/NN (r_pobj) after_16/IN (r_prep) developed_9/VBD (l_nsubj) patient_1/NN (l_prep) with_2/IN (l_pobj) failure_5/NN
D008728_D007676 NONE levomepromazine_21/NNP (r_conj) risperidone_19/NNP (r_pobj) of_18/IN (r_prep) administration_17/NN (r_pobj) after_16/IN (r_prep) developed_9/VBD (l_nsubj) CRF_7/NNP
D008728_D009459 CID levomepromazine_21/NNP (r_conj) risperidone_19/NNP (r_pobj) of_18/IN (r_prep) administration_17/NN (r_pobj) after_16/IN (r_prep) developed_9/VBD (l_dobj) syndrome_12/NN
D008728_D009459 CID levomepromazine_21/NNP (r_conj) risperidone_19/NNP (r_pobj) of_18/IN (r_prep) administration_17/NN (r_pobj) after_16/IN (r_prep) developed_9/VBD (l_dobj) syndrome_12/NN (l_appos) NMS_14/NNP
8819482
D002118_D017202 NONE calcium_4/NN (r_compound) antagonist_5/NN (l_prep) on_9/IN (l_pobj) ischemia_14/NN
D002118_D023921 NONE calcium_4/NN (r_compound) antagonist_5/NN (l_prep) on_9/IN (l_pobj) ischemia_14/NN (l_prep) in_15/IN (l_pobj) dogs_16/NNS (l_prep) with_17/IN (l_pobj) stenosis_20/NN
C082828_D017202 NONE CD-832_7/NNP (r_appos) antagonist_5/NN (l_prep) on_9/IN (l_pobj) ischemia_14/NN
C082828_D017202 NONE CD-832_2/NNP (r_dep) on_3/IN (r_prep) Effects_0/NNS (l_parataxis) studied_10/VBN (l_nsubjpass) ischemia_8/NN
C082828_D017202 NONE CD-832_4/NNP (r_nsubj) improves_5/VBZ (l_dobj) ischemia_7/NN
C082828_D017202 NONE CD-832_21/NNP (r_pobj) of_20/IN (r_prep) property_19/NN (r_nsubj) plays_22/VBZ (r_ccomp) suggest_14/VBP (r_conj) improves_5/VBZ (l_dobj) ischemia_7/NN
C082828_D017202 NONE CD-832_31/NNP (r_pobj) of_30/IN (r_prep) effects_29/NNS (r_pobj) in_26/IN (r_prep) plays_22/VBZ (r_ccomp) suggest_14/VBP (r_conj) improves_5/VBZ (l_dobj) ischemia_7/NN
C082828_D023921 NONE CD-832_7/NNP (r_appos) antagonist_5/NN (l_prep) on_9/IN (l_pobj) ischemia_14/NN (l_prep) in_15/IN (l_pobj) dogs_16/NNS (l_prep) with_17/IN (l_pobj) stenosis_20/NN
C082828_D023921 NONE CD-832_2/NNP (r_dep) on_3/IN (r_prep) Effects_0/NNS (l_parataxis) studied_10/VBN (l_prep) in_11/IN (l_pobj) dogs_12/NNS (l_prep) with_13/IN (l_pobj) stenosis_16/NN
D007545_D017202 CID isoproterenol_10/NN (r_npadvmod) induced_12/VBN (r_amod) ischemia_14/NN
D007545_D017202 CID isoproterenol_4/NNP (r_pobj) on_3/IN (r_prep) Effects_0/NNS (l_parataxis) studied_10/VBN (l_nsubjpass) ischemia_8/NN
D007545_D017202 CID ISO)-induced_6/JJ (r_det) ischemia_8/NN
D007545_D017202 CID ISO_9/NN (r_compound) infusion_10/NN (r_pobj) during_8/IN (r_prep) ischemia_7/NN
D007545_D023921 NONE isoproterenol_10/NN (r_npadvmod) induced_12/VBN (r_amod) ischemia_14/NN (l_prep) in_15/IN (l_pobj) dogs_16/NNS (l_prep) with_17/IN (l_pobj) stenosis_20/NN
D007545_D023921 NONE isoproterenol_4/NNP (r_pobj) on_3/IN (r_prep) Effects_0/NNS (l_parataxis) studied_10/VBN (l_prep) in_11/IN (l_pobj) dogs_12/NNS (l_prep) with_13/IN (l_pobj) stenosis_16/NN
D007545_D023921 NONE ISO)-induced_6/JJ (r_det) ischemia_8/NN (r_nsubjpass) studied_10/VBN (l_prep) in_11/IN (l_pobj) dogs_12/NNS (l_prep) with_13/IN (l_pobj) stenosis_16/NN
D007545_D023921 NONE ISO_12/NN (r_compound) infusion_13/NN (r_pobj) of_10/IN (r_prep) periods_9/NNS (r_nsubj) increased_22/VBD (l_prep) In_0/IN (l_pobj) presence_2/NN (l_prep) of_3/IN (l_pobj) stenosis_6/NN
D009543_D017202 NONE nifedipine_30/NN (r_pobj) for_29/IN (r_prep) those_28/DT (r_pobj) with_27/IN (r_prep) compared_26/VBN (l_nsubjpass) Effects_0/NNS (l_parataxis) studied_10/VBN (l_nsubjpass) ischemia_8/NN
D009543_D023921 NONE nifedipine_30/NN (r_pobj) for_29/IN (r_prep) those_28/DT (r_pobj) with_27/IN (r_prep) compared_26/VBN (l_nsubjpass) Effects_0/NNS (l_parataxis) studied_10/VBN (l_prep) in_11/IN (l_pobj) dogs_12/NNS (l_prep) with_13/IN (l_pobj) stenosis_16/NN
D004110_D017202 NONE diltiazem_32/NN (r_conj) nifedipine_30/NN (r_pobj) for_29/IN (r_prep) those_28/DT (r_pobj) with_27/IN (r_prep) compared_26/VBN (l_nsubjpass) Effects_0/NNS (l_parataxis) studied_10/VBN (l_nsubjpass) ischemia_8/NN
D004110_D023921 NONE diltiazem_32/NN (r_conj) nifedipine_30/NN (r_pobj) for_29/IN (r_prep) those_28/DT (r_pobj) with_27/IN (r_prep) compared_26/VBN (l_nsubjpass) Effects_0/NNS (l_parataxis) studied_10/VBN (l_prep) in_11/IN (l_pobj) dogs_12/NNS (l_prep) with_13/IN (l_pobj) stenosis_16/NN
D007545_D003251 NONE ISO_3/NN (r_compound) infusion_4/NN (l_prep) with_5/IN (l_pobj) stenosis_6/NN
D007545_D003251 NONE ISO_4/NN (r_compound) infusion_5/NN (l_prep) with_6/IN (l_pobj) stenosis_7/NN
D007545_D003251 NONE ISO_36/NN (r_compound) infusion_37/NN (l_prep) with_38/IN (l_pobj) stenosis_39/NN
D007545_D003251 NONE ISO_9/NN (r_compound) infusion_10/NN (l_prep) with_11/IN (l_pobj) stenosis_12/NN
C082828_D003251 NONE CD-832_13/NNP (r_dep) (_14/-LRB- (r_punct) micrograms_18/NNS (r_pobj) of_12/IN (r_prep) doses_11/NNS (r_dobj) performed_8/VBN (l_nsubjpass) infusion_4/NN (l_prep) with_5/IN (l_pobj) stenosis_6/NN
C082828_D003251 NONE CD-832_4/NNP (r_nsubj) improves_5/VBZ (l_dobj) ischemia_7/NN (l_prep) during_8/IN (l_pobj) infusion_10/NN (l_prep) with_11/IN (l_pobj) stenosis_12/NN
C082828_D003251 NONE CD-832_21/NNP (r_pobj) of_20/IN (r_prep) property_19/NN (r_nsubj) plays_22/VBZ (r_ccomp) suggest_14/VBP (r_conj) improves_5/VBZ (l_dobj) ischemia_7/NN (l_prep) during_8/IN (l_pobj) infusion_10/NN (l_prep) with_11/IN (l_pobj) stenosis_12/NN
C082828_D003251 NONE CD-832_31/NNP (r_pobj) of_30/IN (r_prep) effects_29/NNS (r_pobj) in_26/IN (r_prep) plays_22/VBZ (r_ccomp) suggest_14/VBP (r_conj) improves_5/VBZ (l_dobj) ischemia_7/NN (l_prep) during_8/IN (l_pobj) infusion_10/NN (l_prep) with_11/IN (l_pobj) stenosis_12/NN
4082466
D009020_D012640 CID Morphine_0/NN (r_npadvmod) induced_2/VBN (r_amod) seizures_3/NNS
D009020_D012640 CID sulfate_12/NN (r_pobj) of_9/IN (r_prep) course_8/NN (r_pobj) during_6/IN (r_prep) suffered_2/VBD (l_prep) from_3/IN (l_pobj) seizures_5/NNS
D009020_D012640 CID morphine_2/NN (r_dobj) received_1/VBD (l_prep) in_3/IN (l_pobj) doses_4/NNS (l_amod) larger_19/JJR (l_prep) than_20/IN (l_pobj) group_22/NN (l_prep) of_23/IN (l_pobj) neonates_25/NNS (l_relcl) received_27/VBD (l_conj) had_37/VBD (l_dobj) seizures_39/NNS
D009020_D012640 CID morphine_18/NN (r_pobj) of_17/IN (r_prep) cessation_16/NN (r_pobj) after_15/IN (r_prep) stopped_11/VBD (r_conj) ruled_6/VBN (l_nsubjpass) reasons_2/NNS (l_prep) for_3/IN (l_pobj) seizures_4/NNS
D009020_D012640 CID morphine_18/NN (r_pobj) of_17/IN (r_prep) cessation_16/NN (r_pobj) after_15/IN (r_prep) stopped_11/VBD (l_nsubj) convulsions_10/NNS
20566328
D003042_D028361 NONE cocaine_4/NN (r_npadvmod) induced_6/VBN (r_amod) dysfunction_8/NN (r_pobj) to_3/IN (r_prep) contributes_2/VBZ (l_nsubj) impairment_1/NN
D003042_D028361 NONE cocaine_15/NN (r_pobj) to_14/IN (r_prep) exposure_13/NN (r_pobj) after_9/IN (r_prep) was_6/VBD (l_advcl) suggesting_17/VBG (l_ccomp) were_22/VBD (l_nsubj) abnormalities_21/NNS
D003042_D028361 NONE cocaine_35/NN (r_pobj) to_34/IN (r_prep) response_33/NN (r_pobj) in_30/IN (r_prep) event_29/NN (r_conj) late_24/JJ (r_attr) were_22/VBD (l_nsubj) abnormalities_21/NNS
D003042_D028361 NONE cocaine_11/NN (r_npadvmod) induced_13/VBN (r_amod) dysfunction_15/NN (r_nsubj) be_17/VB (l_acomp) due_18/IN (l_prep) to_19/IN (l_pobj) defect_22/NN
D003042_D006331 CID cocaine_4/NN (r_npadvmod) induced_6/VBN (r_amod) dysfunction_8/NN
D003042_D006331 CID cocaine_18/NN (r_npadvmod) induced_20/VBN (r_amod) dysfunction_22/NN
D003042_D006331 CID cocaine_11/NN (r_npadvmod) induced_13/VBN (r_amod) dysfunction_15/NN
C476756_D028361 NONE MitoQ._15/NN (r_pobj) by_11/IN (r_prep) Prevention_10/NN (r_dep) contributes_2/VBZ (l_nsubj) impairment_1/NN
C476756_D028361 NONE MitoQ_0/NNS (r_nsubjpass) shown_9/VBN (l_xcomp) prevent_12/VB (l_dobj) abnormalities_15/NNS
C476756_D006331 NONE MitoQ._15/NN (r_pobj) by_11/IN (r_prep) Prevention_10/NN (r_dep) contributes_2/VBZ (l_prep) to_3/IN (l_pobj) dysfunction_8/NN
C476756_D006331 NONE MitoQ_0/NNS (r_nsubjpass) shown_9/VBN (l_xcomp) prevent_12/VB (l_dobj) abnormalities_15/NNS (l_conj) dysfunction_20/NN
C476756_-1 NONE MitoQ_0/NNS (r_nsubjpass) shown_9/VBN (l_xcomp) prevent_12/VB (l_dobj) abnormalities_15/NNS (l_conj) dysfunction_20/NN (l_acl) characterized_21/VBN (l_agent) by_23/IN (l_pobj) dysfunction_26/NN
19139825
D019772_D005909 NONE Topotecan_0/JJ (l_prep) in_1/IN (l_pobj) combination_2/NN (l_prep) in_5/IN (l_pobj) glioblastoma_7/NN
D019772_D005909 NONE topotecan_15/NNP (l_prep) in_34/IN (l_pobj) adults_36/NNS (l_prep) with_37/IN (l_pobj) GBM_42/NNP
D019772_D005910 NONE Topotecan_0/NNP (r_nsubj) is_1/VBZ (l_advcl) exhibits_7/VBZ (l_dobj) inhibition_9/NN (l_prep) of_10/IN (l_pobj) glioma_12/NN
10986547
C076029_D001714 NONE olanzapine_2/NN (r_pobj) of_1/IN (r_prep) Efficacy_0/NN (l_prep) in_3/IN (l_pobj) mania_6/NN
C076029_D001714 NONE olanzapine_7/NN (r_pobj) of_6/IN (r_prep) efficacy_3/NN (l_prep) for_10/IN (l_pobj) treatment_12/NN (l_prep) of_13/IN (l_pobj) mania_16/NN
C076029_D001714 NONE olanzapine_22/NN (r_pobj) to_21/IN (r_prep) randomized_20/VBN (l_nsubjpass) total_1/NN (l_prep) of_2/IN (l_pobj) patients_4/NNS (l_prep) with_5/IN (l_pobj) diagnosis_10/NN (l_prep) of_11/IN (l_pobj) disorder_13/NN
C076029_D001714 NONE olanzapine_22/NN (r_pobj) to_21/IN (r_prep) randomized_20/VBN (l_nsubjpass) total_1/NN (l_prep) of_2/IN (l_pobj) patients_4/NNS (l_prep) with_5/IN (l_pobj) diagnosis_10/NN (l_amod) manic_15/JJ
C076029_D001714 NONE Olanzapine_0/NNP (r_nsubj) demonstrated_1/VBD (l_dobj) efficacy_3/NN (l_prep) than_4/IN (l_pobj) placebo_5/NN (l_prep) in_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) mania_12/NN
C076029_D015430 CID olanzapine_2/NN (r_npadvmod) treated_4/VBN (r_amod) patients_5/NNS (r_nsubj) had_6/VBD (l_dobj) gain_17/NN
C076029_D006970 CID olanzapine_2/NN (r_npadvmod) treated_4/VBN (r_amod) patients_5/NNS (r_nsubj) had_6/VBD (l_conj) experienced_37/VBD (l_dobj) somnolence_42/NN
1449452
D004077_D001281 NONE digoxin_5/NN (l_compound) fibrillation_4/NN
D004077_D001145 CID digoxin_2/NN (r_nsubj) has_3/VBZ (l_dobj) effects_5/NNS (l_prep) as_7/IN (l_pcomp) increasing_8/VBG (l_conj) causing_16/VBG (l_dobj) arrhythmias_17/NNS
D004077_D009203 NONE digoxin_19/NN (r_nsubj) increase_21/VB (l_prep) after_23/IN (l_pobj) infarction_25/NN
D004077_D009203 NONE digoxin_19/NN (r_nsubj) increase_21/VB (l_prep) after_23/IN (l_pobj) infarction_25/NN (l_appos) MI_27/NNP
24923469
7378868
D013390_D014313 CID Suxamethonium_0/NN (r_npadvmod) induced_2/VBN (r_amod) stiffness_4/NN
D013390_D014313 CID suxamethonium_12/NN (r_pobj) after_11/IN (r_prep) occur_10/VB (l_nsubj) rigidity_6/NN
D013390_D063806 CID Suxamethonium_0/NN (r_npadvmod) induced_2/VBN (r_amod) stiffness_4/NN (l_conj) myalgia_6/NN
D013390_D063806 CID suxamethonium_12/NN (r_pobj) after_11/IN (r_prep) occur_10/VB (l_nsubj) rigidity_6/NN (l_conj) myalgia_8/NN
D010197_D014313 NONE pancuronium_21/NN (r_pobj) with_20/IN (r_prep) pretreatment_19/NN (r_pobj) despite_18/IN (r_prep) occur_10/VB (l_nsubj) rigidity_6/NN
D010197_D063806 NONE pancuronium_21/NN (r_pobj) with_20/IN (r_prep) pretreatment_19/NN (r_pobj) despite_18/IN (r_prep) occur_10/VB (l_nsubj) rigidity_6/NN (l_conj) myalgia_8/NN
2553470
D016291_D013226 NONE MK-801_3/NNP (r_dep) on_4/IN (r_prep) actions_1/NNS (r_nsubj) epilepticus_12/NN
D016291_D013226 NONE MK-801_2/NNP (r_dep) 30_3/CD (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) reduced_17/VBN (l_prep) during_12/IN (l_pobj) epilepticus_14/NN
D008094_D013226 CID lithium_6/NN (r_compound) pilocarpine_8/NN (r_compound) model_9/NN (r_pobj) on_4/IN (r_prep) actions_1/NNS (r_nsubj) epilepticus_12/NN
D008094_D013226 CID lithium_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) seizures_9/NNS (r_dobj) block_8/VB (r_xcomp) easy_6/JJ (r_acomp) is_4/VBZ (r_advcl) is_24/VBZ (l_xcomp) terminate_28/VB (l_dobj) epilepticus_31/NN
D008094_D013226 CID lithium_20/NN (r_compound) pilocarpine_22/NN (r_compound) model_23/NN (r_pobj) in_18/IN (r_prep) damage_17/NN (r_conj) epilepticus_14/NN
D010862_D013226 CID pilocarpine_8/NN (r_compound) model_9/NN (r_pobj) on_4/IN (r_prep) actions_1/NNS (r_nsubj) epilepticus_12/NN
D010862_D013226 CID pilocarpine_14/NN (r_conj) lithium_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) seizures_9/NNS (r_dobj) block_8/VB (r_xcomp) easy_6/JJ (r_acomp) is_4/VBZ (r_advcl) is_24/VBZ (l_xcomp) terminate_28/VB (l_dobj) epilepticus_31/NN
D010862_D013226 CID pilocarpine_21/NNP (r_pobj) to_20/IN (r_prep) prior_19/RB (r_advmod) induced_10/VBN (r_acl) seizures_9/NNS (r_dobj) block_8/VB (r_xcomp) easy_6/JJ (r_acomp) is_4/VBZ (r_advcl) is_24/VBZ (l_xcomp) terminate_28/VB (l_dobj) epilepticus_31/NN
D010862_D013226 CID pilocarpine_8/NNP (r_pobj) after_7/IN (r_prep) min_6/NN (r_amod) Administration_0/NN (r_nsubj) reduced_17/VBN (l_prep) during_12/IN (l_pobj) epilepticus_14/NN
D010862_D013226 CID pilocarpine_22/NN (r_compound) model_23/NN (r_pobj) in_18/IN (r_prep) damage_17/NN (r_conj) epilepticus_14/NN
D010862_D013226 CID pilocarpine_13/NNP (r_conj) NMDA_11/NNP (r_pobj) of_10/IN (r_prep) doses_9/NNS (r_nsubj) were_14/VBD (l_advcl) resulting_17/VBG (l_prep) in_18/IN (l_pobj) epilepticus_20/NN
D016291_D012640 NONE MK-801_0/NNP (r_dep) ,_1/, (r_punct) tested_18/VBN (l_advcl) using_24/VBG (l_dobj) models_27/NNS (l_compound) seizure_26/NN
D016291_D012640 NONE MK-801_4/NNP (r_punct) produced_5/VBD (l_advcl) suggesting_29/VBG (l_dobj) seizures_35/NNS
D016291_D012640 NONE MK-801_6/NNP (r_dep) in_7/IN (r_prep) effect_4/NN (r_nsubj) occurred_14/VBD (l_prep) after_15/IN (l_pobj) periods_17/NNS (l_prep) of_18/IN (l_pobj) activity_20/NN (l_compound) seizure_19/NN
D016291_D012640 NONE MK-801_2/NNP (r_dep) 30_3/CD (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) reduced_17/VBN (l_dobj) activity_22/NN (l_compound) seizure_21/NN
D016202_D012640 NONE aspartate_10/NN (r_nsubjpass) tested_18/VBN (l_advcl) using_24/VBG (l_dobj) models_27/NNS (l_compound) seizure_26/NN
D016202_D012640 NONE NMDA_12/NNP (r_appos) aspartate_10/NN (r_nsubjpass) tested_18/VBN (l_advcl) using_24/VBG (l_dobj) models_27/NNS (l_compound) seizure_26/NN
D008094_D012640 NONE lithium_31/NN (r_pobj) of_30/IN (r_prep) coadministration_29/NN (r_appos) models_27/NNS (l_compound) seizure_26/NN
D008094_D012640 NONE lithium_16/NN (r_compound) pilocarpine_18/NN (r_compound) model_19/NN (r_pobj) with_14/IN (r_prep) action_13/NN (r_dobj) produced_5/VBD (l_advcl) suggesting_29/VBG (l_dobj) seizures_35/NNS
D008094_D012640 NONE lithium_9/NN (r_compound) pilocarpine_11/NN (r_compound) model_12/NN (r_pobj) in_7/IN (r_prep) effect_4/NN (r_nsubj) occurred_14/VBD (l_prep) after_15/IN (l_pobj) periods_17/NNS (l_prep) of_18/IN (l_pobj) activity_20/NN (l_compound) seizure_19/NN
D008094_D012640 NONE lithium_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) seizures_9/NNS
D008094_D012640 NONE lithium_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) seizures_9/NNS (r_dobj) block_8/VB (r_xcomp) easy_6/JJ (r_acomp) is_4/VBZ (r_advcl) is_24/VBZ (l_xcomp) terminate_28/VB (l_conj) block_33/VB (l_dobj) lethality_35/NN (l_prep) of_36/IN (l_pobj) seizures_38/NNS
D010862_D012640 NONE pilocarpine_33/NN (r_conj) lithium_31/NN (r_pobj) of_30/IN (r_prep) coadministration_29/NN (r_appos) models_27/NNS (l_compound) seizure_26/NN
D010862_D012640 NONE pilocarpine_41/NN (r_pobj) of_40/IN (r_prep) dose_39/NN (r_pobj) of_36/IN (r_prep) coadministration_29/NN (r_appos) models_27/NNS (l_compound) seizure_26/NN
D010862_D012640 NONE pilocarpine_18/NN (r_compound) model_19/NN (r_pobj) with_14/IN (r_prep) action_13/NN (r_dobj) produced_5/VBD (l_advcl) suggesting_29/VBG (l_dobj) seizures_35/NNS
D010862_D012640 NONE pilocarpine_26/NNP (r_pobj) with_25/IN (r_prep) treated_24/VBN (r_acl) rats_23/NNS (r_pobj) with_22/IN (r_prep) produced_5/VBD (l_advcl) suggesting_29/VBG (l_dobj) seizures_35/NNS
D010862_D012640 NONE pilocarpine_11/NN (r_compound) model_12/NN (r_pobj) in_7/IN (r_prep) effect_4/NN (r_nsubj) occurred_14/VBD (l_prep) after_15/IN (l_pobj) periods_17/NNS (l_prep) of_18/IN (l_pobj) activity_20/NN (l_compound) seizure_19/NN
D010862_D012640 NONE pilocarpine_14/NN (r_conj) lithium_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) seizures_9/NNS
D010862_D012640 NONE pilocarpine_14/NN (r_conj) lithium_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) seizures_9/NNS (r_dobj) block_8/VB (r_xcomp) easy_6/JJ (r_acomp) is_4/VBZ (r_advcl) is_24/VBZ (l_xcomp) terminate_28/VB (l_conj) block_33/VB (l_dobj) lethality_35/NN (l_prep) of_36/IN (l_pobj) seizures_38/NNS
D010862_D012640 NONE pilocarpine_21/NNP (r_pobj) to_20/IN (r_prep) prior_19/RB (r_advmod) induced_10/VBN (r_acl) seizures_9/NNS
D010862_D012640 NONE pilocarpine_21/NNP (r_pobj) to_20/IN (r_prep) prior_19/RB (r_advmod) induced_10/VBN (r_acl) seizures_9/NNS (r_dobj) block_8/VB (r_xcomp) easy_6/JJ (r_acomp) is_4/VBZ (r_advcl) is_24/VBZ (l_xcomp) terminate_28/VB (l_conj) block_33/VB (l_dobj) lethality_35/NN (l_prep) of_36/IN (l_pobj) seizures_38/NNS
D010862_D012640 NONE pilocarpine_8/NNP (r_pobj) after_7/IN (r_prep) min_6/NN (r_amod) Administration_0/NN (r_nsubj) reduced_17/VBN (l_dobj) activity_22/NN (l_compound) seizure_21/NN
D016202_D013226 NONE NMDA_6/NNP (r_compound) receptors_7/NNS (r_pobj) of_5/IN (r_prep) activation_4/NN (r_nsubj) plays_8/VBZ (l_dobj) role_11/NN (l_prep) in_12/IN (l_pobj) epilepticus_14/NN
D016202_D013226 NONE NMDA_11/NNP (r_pobj) of_10/IN (r_prep) doses_9/NNS (r_nsubj) were_14/VBD (l_advcl) resulting_17/VBG (l_prep) in_18/IN (l_pobj) epilepticus_20/NN
D016202_D001930 NONE NMDA_6/NNP (r_compound) receptors_7/NNS (r_pobj) of_5/IN (r_prep) activation_4/NN (r_nsubj) plays_8/VBZ (l_dobj) role_11/NN (l_prep) in_12/IN (l_pobj) epilepticus_14/NN (l_conj) damage_17/NN
D008094_D001930 NONE lithium_20/NN (r_compound) pilocarpine_22/NN (r_compound) model_23/NN (r_pobj) in_18/IN (r_prep) damage_17/NN
D010862_D001930 NONE pilocarpine_22/NN (r_compound) model_23/NN (r_pobj) in_18/IN (r_prep) damage_17/NN
1564030
D005473_D001714 CID fluoxetine_3/NN (r_compound) treatment_4/NN (r_pobj) with_2/IN (r_prep) associated_1/VBN (r_acl) Mania_0/NNP
D005473_D001714 CID fluoxetine_8/NNP (r_nsubjpass) reported_11/VBN (l_xcomp) induce_13/VB (l_dobj) mania_14/NN
D005473_D001714 CID fluoxetine_20/NNP (r_pobj) with_19/IN (r_prep) pharmacotherapy_18/NN (r_pobj) during_17/IN (r_prep) developed_15/VBD (l_dobj) mania_16/NN
D005473_D001714 CID fluoxetine_11/NN (r_compound) pharmacotherapy_12/NN (r_pobj) during_10/IN (r_prep) factors_2/NNS (l_prep) for_3/IN (l_pobj) development_5/NN (l_prep) of_6/IN (l_pobj) mania_7/NN
D005473_D001714 CID fluoxetine_11/NN (r_compound) pharmacotherapy_12/NN (r_pobj) during_10/IN (r_prep) factors_2/NNS (l_prep) for_3/IN (l_pobj) development_5/NN (l_prep) of_6/IN (l_pobj) mania_7/NN (l_conj) hypomania_9/NN
D005473_D001714 CID fluoxetine_11/NN (r_compound) pharmacotherapy_12/NN (r_pobj) during_10/IN (r_prep) factors_2/NNS (r_nsubj) were_16/VBD (l_conj) depression_30/NN (l_conj) history_37/NN (l_prep) of_38/IN (l_pobj) disorder_40/NN (l_appos) disorder_44/NN
D005473_D001714 CID fluoxetine_11/NN (r_compound) pharmacotherapy_12/NN (r_pobj) during_10/IN (r_prep) factors_2/NNS (r_nsubj) were_16/VBD (l_conj) depression_30/NN (l_conj) history_37/NN (l_conj) diagnosis_48/NN (l_prep) of_49/IN (l_pobj) disorder_51/NN
D005473_D001714 CID fluoxetine_19/NN (r_nmod) mania_21/NN
D005473_D003866 NONE Fluoxetine_0/NNP (r_nsubj) gaining_9/VBG (l_dobj) acceptance_11/NN (l_prep) in_12/IN (l_pobj) treatment_14/NN (l_prep) of_15/IN (l_pobj) depression_17/NN
D005473_D003866 NONE fluoxetine_20/NNP (r_pobj) with_19/IN (r_prep) pharmacotherapy_18/NN (r_pobj) during_17/IN (r_prep) developed_15/VBD (r_relcl) years_10/NNS (r_appos) cases_1/NNS (l_prep) of_2/IN (l_pobj) adolescents_5/NNS (l_amod) depressed_4/JJ
D005473_D003866 NONE fluoxetine_11/NN (r_compound) pharmacotherapy_12/NN (r_pobj) during_10/IN (r_prep) factors_2/NNS (r_nsubj) were_16/VBD (l_conj) depression_30/NN
D012701_D003866 NONE serotonin_4/NN (r_appos) Fluoxetine_0/NNP (r_nsubj) gaining_9/VBG (l_dobj) acceptance_11/NN (l_prep) in_12/IN (l_pobj) treatment_14/NN (l_prep) of_15/IN (l_pobj) depression_17/NN
D005473_D001289 NONE fluoxetine_11/NN (r_compound) pharmacotherapy_12/NN (r_pobj) during_10/IN (r_prep) factors_2/NNS (r_nsubj) were_16/VBD (l_attr) combination_18/NN (l_prep) of_19/IN (l_pobj) disorder_24/NN
D005473_D011618 NONE fluoxetine_11/NN (r_compound) pharmacotherapy_12/NN (r_pobj) during_10/IN (r_prep) factors_2/NNS (r_nsubj) were_16/VBD (l_conj) depression_30/NN (l_prep) with_31/IN (l_pobj) features_33/NNS (l_amod) psychotic_32/JJ
D005473_D019964 NONE fluoxetine_11/NN (r_compound) pharmacotherapy_12/NN (r_pobj) during_10/IN (r_prep) factors_2/NNS (r_nsubj) were_16/VBD (l_conj) depression_30/NN (l_conj) history_37/NN (l_prep) of_38/IN (l_pobj) disorder_40/NN
1556529
D015215_D056486 CID Zidovudine_0/RB (r_npadvmod) induced_2/VBN (r_amod) hepatitis_3/NN
D015215_D056486 CID zidovudine_7/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (r_acl) hepatitis_4/NN
D015215_D000163 NONE zidovudine_7/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (l_prep) in_8/IN (l_pobj) patient_13/NN (l_prep) with_14/IN (l_pobj) AIDS_15/NNP
17042797
D010862_D013226 CID pilocarpine_14/NNP (r_npadvmod) induced_16/VBN (r_amod) status_17/NN (r_nsubj) epilepticus_18/NN
D010862_D013226 CID pilocarpine_22/NN (r_npadvmod) induced_24/VBN (r_amod) status_25/NN (r_nsubj) epilepticus_26/NN
D010862_D004833 CID pilocarpine_16/NNP (r_compound) model_17/NN (l_prep) of_18/IN (l_pobj) epilepsy_21/NN
12059909
D003520_D064420 NONE cyclophosphamide_3/NN (r_pobj) of_2/IN (r_prep) toxicity_1/NN
D003520_D064420 NONE CY_1/NNP (r_compound) toxicity_2/NN
D003520_D064420 NONE CY_7/NNP (r_pobj) of_6/IN (r_prep) toxicity_5/NN
D003520_D006470 CID CY_1/NNP (r_compound) toxicity_2/NN (r_nsubj) caused_3/VBD (l_dobj) cystitis_7/NN (l_amod) haemorrhagic_6/JJ
D003520_D003556 CID CY_1/NNP (r_compound) toxicity_2/NN (r_nsubj) caused_3/VBD (l_dobj) cystitis_7/NN
D003520_D003556 CID CY_4/NNP (r_compound) ulcerous_6/JJ (l_conj) forms_11/NNS (l_prep) of_12/IN (l_pobj) cystitis_14/NN
20682692
D013311_D003928 CID streptozotocin_15/NN (r_npadvmod) induced_17/VBN (r_amod) nephropathy_19/NN
D013311_D003928 CID STZ_22/NN (r_npadvmod) induced_24/VBN (r_amod) nephropathy_26/NN
D013311_D003928 CID STZ_20/NN (r_npadvmod) induced_22/VBN (r_amod) nephropathy_24/NN
D000804_D003922 NONE angiotensin_13/NN (r_compound) system_14/NN (r_pobj) of_9/IN (r_prep) blockade_8/NN (l_prep) in_15/IN (l_pobj) patients_16/NNS (l_prep) with_17/IN (l_pobj) diabetes_20/NN
D000804_D007674 NONE angiotensin_13/NN (r_compound) system_14/NN (r_pobj) of_9/IN (r_prep) blockade_8/NN (r_nsubj) retard_25/VB (l_dobj) progression_27/NN (l_prep) of_28/IN (l_pobj) nephropathy_29/NN
D000804_D003928 NONE angiotensin_13/NN (r_compound) system_14/NN (r_pobj) of_9/IN (r_prep) blockade_8/NN (r_nsubj) retard_25/VB (l_advcl) suggesting_31/VBG (l_ccomp) involved_37/VBN (l_prep) in_38/IN (l_pobj) pathogenesis_40/NN (l_prep) of_41/IN (l_pobj) nephropathy_44/NN
D000804_D003928 NONE angiotensin_13/NN (r_compound) system_14/NN (r_pobj) of_9/IN (r_prep) blockade_8/NN (r_nsubj) retard_25/VB (l_advcl) suggesting_31/VBG (l_ccomp) involved_37/VBN (l_prep) in_38/IN (l_pobj) pathogenesis_40/NN (l_prep) of_41/IN (l_pobj) nephropathy_44/NN (l_appos) nephropathy_47/NN
D013311_D005355 NONE streptozotocin_28/NNS (r_pobj) with_27/IN (r_prep) microalbuminuria_24/NNP (r_pobj) of_23/IN (r_prep) independently_22/RB (r_advmod) development_17/NN (l_prep) of_18/IN (l_pobj) fibrosis_21/NN
D013311_D005355 NONE STZ)-induced_30/NNP (r_nummod) diabetes_31/NN (r_appos) streptozotocin_28/NNS (r_pobj) with_27/IN (r_prep) microalbuminuria_24/NNP (r_pobj) of_23/IN (r_prep) independently_22/RB (r_advmod) development_17/NN (l_prep) of_18/IN (l_pobj) fibrosis_21/NN
D013311_D003920 NONE streptozotocin_28/NNS (l_appos) diabetes_31/NN
D013311_D003920 NONE STZ)-induced_30/NNP (r_nummod) diabetes_31/NN
16867246
D002746_D001480 CID chlorpromazine_5/NN (r_npadvmod) induced_7/VBN (r_amod) syndrome_9/NN
D002746_D001480 CID chlorpromazine_11/NN (r_npadvmod) induced_13/VBN (r_amod) EPS_14/NNP
D002746_D001480 CID chlorpromazine_40/NN (r_pobj) with_39/IN (r_prep) treated_38/VBN (l_nsubj) Ser311Cys_6/NNP (l_prep) in_14/IN (l_pobj) gene_17/NN (l_prep) in_18/IN (l_pobj) inpatients_21/NNS (l_appos) 59_23/CD (l_prep) with_24/IN (l_pobj) EPS_25/NNP
D002746_D001480 CID chlorpromazine_40/NN (r_pobj) with_39/IN (r_prep) treated_38/VBN (l_nsubj) Ser311Cys_6/NNP (l_prep) without_28/IN (l_pobj) EPS_29/NNP
D002746_D012559 NONE chlorpromazine_5/NN (r_npadvmod) induced_7/VBN (r_amod) syndrome_9/NN (l_prep) in_10/IN (l_pobj) patients_13/NNS (l_amod) schizophrenic_12/JJ
D002746_D012559 NONE chlorpromazine_11/NN (r_npadvmod) induced_13/VBN (r_amod) EPS_14/NNP (r_pobj) in_10/IN (r_prep) plays_9/VBZ (l_prep) in_15/IN (l_pobj) patients_17/NNS (l_amod) schizophrenic_16/JJ
D002746_D012559 NONE chlorpromazine_40/NN (r_pobj) with_39/IN (r_prep) treated_38/VBN (l_nsubj) Ser311Cys_6/NNP (l_prep) in_14/IN (l_pobj) gene_17/NN (l_prep) in_18/IN (l_pobj) inpatients_21/NNS (l_amod) schizophrenic_20/JJ
D002746_D012559 NONE chlorpromazine_30/NNP (r_pobj) by_29/IN (r_agent) induced_28/VBN (r_acl) effect_27/NN (l_prep) in_34/IN (l_pobj) patients_36/NNS (l_prep) with_37/IN (l_pobj) schizophrenia_38/NN
8659767
D002045_D001145 NONE bupivacaine_1/NN (r_nsubj) precipitate_6/VB (l_dobj) dysrhythmias_7/NNS
D002045_D001145 NONE bupivacaine_10/NN (r_dobj) circulating_9/VBG (r_csubj) potentiate_15/VB (l_advcl) precipitate_6/VB (l_dobj) dysrhythmias_7/NNS
D002045_D001145 NONE Bupivacaine_0/NNP (r_nsubj) antagonizes_1/VBZ (l_prep) in_4/IN (l_conj) in_11/IN (l_pobj) dogs_13/NNS (l_prep) with_14/IN (l_pobj) dysrhythmias_17/NNS
D004837_D001145 NONE epinephrine_3/NN (r_conj) bupivacaine_1/NN (r_nsubj) precipitate_6/VB (l_dobj) dysrhythmias_7/NNS
D004837_D001145 NONE epinephrine_19/NN (r_pobj) of_18/IN (r_prep) effects_17/NNS (r_dobj) potentiate_15/VB (l_advcl) precipitate_6/VB (l_dobj) dysrhythmias_7/NNS
D004837_D001145 NONE epinephrine_2/NN (r_compound) dysrhythmogenicity_3/NN (r_dobj) antagonizes_1/VBZ (l_prep) in_4/IN (l_conj) in_11/IN (l_pobj) dogs_13/NNS (l_prep) with_14/IN (l_pobj) dysrhythmias_17/NNS
D002045_D009203 NONE bupivacaine_4/NN (r_nsubj) alters_5/VBZ (l_prep) in_13/IN (l_conj) in_19/IN (l_pobj) dogs_21/NNS (l_prep) with_22/IN (l_pobj) infarction_24/NN
D004837_D009203 NONE epinephrine_12/NN (r_pobj) of_11/IN (r_prep) administration_10/NN (r_pobj) of_8/IN (r_prep) dysrhythmogenicity_7/NN (r_dobj) alters_5/VBZ (l_prep) in_13/IN (l_conj) in_19/IN (l_pobj) dogs_21/NNS (l_prep) with_22/IN (l_pobj) infarction_24/NN
D004837_D009203 NONE epinephrine_16/NN (r_dobj) received_13/VBD (l_prep) after_2/IN (l_pobj) infarction_5/NN
D006221_D009203 NONE halothane_9/NN (r_npadvmod) anesthetized_11/VBN (r_amod) dogs_12/NNS (r_nsubj) received_13/VBD (l_prep) after_2/IN (l_pobj) infarction_5/NN
D006221_D017180 NONE halothane_9/NN (r_npadvmod) anesthetized_11/VBN (r_amod) dogs_12/NNS (r_nsubj) received_13/VBD (l_advcl) appeared_19/VBD (l_nsubj) VT_18/NNP
D004837_D017180 CID epinephrine_16/NN (r_dobj) received_13/VBD (l_advcl) appeared_19/VBD (l_nsubj) VT_18/NNP
D004837_D017180 CID epinephrine_2/NN (r_compound) dysrhythmogenicity_3/NN (r_dobj) antagonizes_1/VBZ (l_prep) in_4/IN (l_pobj) dogs_6/NNS (l_amod) susceptible_7/JJ (l_prep) to_8/IN (l_pobj) VT_9/NNP
D002045_D017180 NONE Bupivacaine_0/NNP (r_nsubj) antagonizes_1/VBZ (l_prep) in_4/IN (l_pobj) dogs_6/NNS (l_amod) susceptible_7/JJ (l_prep) to_8/IN (l_pobj) VT_9/NNP
24675088
D004317_D066126 NONE doxorubicin_12/NN (r_npadvmod) induced_14/VBN (r_amod) cardiotoxicity_15/NN
D004317_D009202 CID doxorubicin_12/NNS (l_appos) cardiomyopathy_15/NN
D004317_D009202 CID DOX)-induced_14/VBN (r_amod) cardiomyopathy_15/NN
D004317_D064420 NONE doxorubicin_12/NNS (r_pobj) of_10/IN (r_prep) model_9/NN (r_dobj) utilized_6/VBN (l_advcl) applying_17/VBG (l_conj) provide_31/VB (l_dobj) characterization_35/NN (l_prep) to_36/IN (l_pobj) date_37/NN (l_prep) of_38/IN (l_pobj) timecourse_40/NN (l_prep) of_41/IN (l_pobj) events_48/NNS (l_acl) underlying_49/VBG (l_dobj) toxicity_51/NN
D004317_D064420 NONE DOX)-induced_14/VBN (r_amod) cardiomyopathy_15/NN (r_appos) doxorubicin_12/NNS (r_pobj) of_10/IN (r_prep) model_9/NN (r_dobj) utilized_6/VBN (l_advcl) applying_17/VBG (l_conj) provide_31/VB (l_dobj) characterization_35/NN (l_prep) to_36/IN (l_pobj) date_37/NN (l_prep) of_38/IN (l_pobj) timecourse_40/NN (l_prep) of_41/IN (l_pobj) events_48/NNS (l_acl) underlying_49/VBG (l_dobj) toxicity_51/NN
D005682_D018754 NONE gadolinium_8/NN (r_conj) delayed_5/JJ (r_amod) enhancement_10/NN (l_conj) grading_13/NN (l_conj) dysfunction_17/NN
19914299
D005473_D008569 NONE Fluoxetine_0/NNP (r_nsubj) improves_1/VBZ (l_dobj) deficits_4/NNS
D005472_D008569 CID 5-fluorouracil_10/CD (r_punct) improves_1/VBZ (l_dobj) deficits_4/NNS
25071004
C039726_D000740 NONE artesunate_6/NN (r_pobj) with_4/IN (r_prep) treatment_3/NN (r_pobj) after_2/IN (r_prep) anemia_1/NN
C039726_D000743 CID artesunate_12/NN (r_pobj) with_10/IN (r_prep) treatment_9/NN (r_pobj) after_8/IN (r_prep) described_7/VBN (l_nsubjpass) Cases_0/NNS (l_prep) of_1/IN (l_pobj) anemia_4/NN
C039726_D008288 NONE artesunate_12/NN (r_pobj) with_10/IN (r_prep) treatment_9/NN (r_pobj) after_8/IN (r_prep) described_7/VBN (l_dobj) Organization_18/NNP (l_appos) drug_24/NN (l_prep) for_25/IN (l_pobj) treatment_27/NN (l_prep) of_28/IN (l_pobj) malaria_30/NN
C039726_D008288 NONE artesunate_14/NN (l_prep) for_15/IN (l_pobj) malaria_17/NN
24717468
D020927_D007022 CID dexmedetomidine_14/NN (r_dobj) receive_13/VBP (r_relcl) patients_11/NNS (r_pobj) in_8/IN (r_prep) prevalence_7/NN (r_pobj) at_5/IN (r_prep) occur_4/VBP (l_nsubj) hypotension_1/NN
D020927_D001919 CID dexmedetomidine_14/NN (r_dobj) receive_13/VBP (r_relcl) patients_11/NNS (r_pobj) in_8/IN (r_prep) prevalence_7/NN (r_pobj) at_5/IN (r_prep) occur_4/VBP (l_nsubj) hypotension_1/NN (l_conj) bradycardia_3/NN
D015742_D007022 CID propofol_16/NN (r_conj) dexmedetomidine_14/NN (r_dobj) receive_13/VBP (r_relcl) patients_11/NNS (r_pobj) in_8/IN (r_prep) prevalence_7/NN (r_pobj) at_5/IN (r_prep) occur_4/VBP (l_nsubj) hypotension_1/NN
D015742_D001919 CID propofol_16/NN (r_conj) dexmedetomidine_14/NN (r_dobj) receive_13/VBP (r_relcl) patients_11/NNS (r_pobj) in_8/IN (r_prep) prevalence_7/NN (r_pobj) at_5/IN (r_prep) occur_4/VBP (l_nsubj) hypotension_1/NN (l_conj) bradycardia_3/NN
3109094
D003520_D001745 CID cyclophosphamide_5/RB (r_npadvmod) induced_7/VBN (r_amod) lesions_8/NNS (l_prep) of_9/IN (l_pobj) bladder_12/NN
D015080_D001745 NONE mesna_20/NNS (r_pobj) by_19/IN (r_prep) prevention_18/NN (r_conj) investigations_2/NNS (l_prep) of_3/IN (l_pobj) lesions_8/NNS (l_prep) of_9/IN (l_pobj) bladder_12/NN
D003520_D003556 NONE cyclophosphamide_2/RB (r_npadvmod) induced_4/VBN (r_amod) cystitis_5/NN
D003520_D004487 NONE cyclophosphamide_2/RB (r_npadvmod) induced_4/VBN (r_amod) cystitis_5/NN (r_nsubjpass) characterized_7/VBN (l_agent) by_8/IN (l_pobj) detachment_11/NN (l_conj) edema_18/NN
D003520_D009336 NONE cyclophosphamide_2/RB (r_npadvmod) induced_4/VBN (r_amod) cystitis_5/NN (r_nsubjpass) characterized_7/VBN (l_prep) owing_19/VBG (l_prep) to_20/IN (l_pobj) damage_21/NN (l_prep) to_22/IN (l_pobj) bed_25/NN (l_conj) necroses_29/NNS
20447294
D009020_D009437 NONE morphine_4/NN (r_pobj) between_3/IN (r_prep) synergy_2/NN (l_prep) in_14/IN (l_pobj) models_16/NNS (l_prep) of_17/IN (l_pobj) pain_21/NN
D009020_D009437 NONE morphine_22/NN (r_pobj) with_21/IN (r_prep) combinations_20/NNS (l_prep) in_23/IN (l_pobj) models_25/NNS (l_prep) of_26/IN (l_pobj) pain_30/NN
D012964_D009437 NONE sodium_8/NN (r_compound) channel_9/NN (r_compound) blocker_10/NN (r_conj) morphine_4/NN (r_pobj) between_3/IN (r_prep) synergy_2/NN (l_prep) in_14/IN (l_pobj) models_16/NNS (l_prep) of_17/IN (l_pobj) pain_21/NN
D012964_D009437 NONE sodium_10/NN (r_compound) channel_11/NN (r_compound) blocker_12/NN (l_prep) with_13/IN (l_conj) in_19/IN (l_pobj) combinations_20/NNS (l_prep) in_23/IN (l_pobj) models_25/NNS (l_prep) of_26/IN (l_pobj) pain_30/NN
C401121_D009437 NONE CNSB002_12/NNP (r_appos) blocker_10/NN (r_conj) morphine_4/NN (r_pobj) between_3/IN (r_prep) synergy_2/NN (l_prep) in_14/IN (l_pobj) models_16/NNS (l_prep) of_17/IN (l_pobj) pain_21/NN
C401121_D009437 NONE CNSB002_7/NNP (l_appos) blocker_12/NN (l_prep) with_13/IN (l_conj) in_19/IN (l_pobj) combinations_20/NNS (l_prep) in_23/IN (l_pobj) models_25/NNS (l_prep) of_26/IN (l_pobj) pain_30/NN
D002351_D010146 NONE carrageenan_24/NN (r_npadvmod) induced_26/VBN (r_amod) inflammation_28/NN (r_appos) constructed_8/VBN (l_advcl) using_12/VBG (l_dobj) withdrawal_14/NN (l_prep) in_18/IN (l_pobj) models_22/NNS (l_compound) pain_21/NN
D002351_D007249 CID carrageenan_24/NN (r_npadvmod) induced_26/VBN (r_amod) inflammation_28/NN
D002351_D003929 NONE carrageenan_24/NN (r_npadvmod) induced_26/VBN (r_amod) inflammation_28/NN (l_conj) streptozotocin_30/NNS (l_appos) neuropathy_34/NN
D013311_D010146 NONE streptozotocin_30/NNS (r_conj) inflammation_28/NN (r_appos) constructed_8/VBN (l_advcl) using_12/VBG (l_dobj) withdrawal_14/NN (l_prep) in_18/IN (l_pobj) models_22/NNS (l_compound) pain_21/NN
D013311_D010146 NONE STZ)-induced_32/VBN (r_nummod) neuropathy_34/NN (r_appos) streptozotocin_30/NNS (r_conj) inflammation_28/NN (r_appos) constructed_8/VBN (l_advcl) using_12/VBG (l_dobj) withdrawal_14/NN (l_prep) in_18/IN (l_pobj) models_22/NNS (l_compound) pain_21/NN
D013311_D007249 NONE streptozotocin_30/NNS (r_conj) inflammation_28/NN
D013311_D007249 NONE STZ)-induced_32/VBN (r_nummod) neuropathy_34/NN (r_appos) streptozotocin_30/NNS (r_conj) inflammation_28/NN
D013311_D003929 CID streptozotocin_30/NNS (l_appos) neuropathy_34/NN
D013311_D003929 CID STZ)-induced_32/VBN (r_nummod) neuropathy_34/NN
D002351_D009422 NONE carrageenan_15/NN (r_compound) model_16/NN (l_conj) 44.18_18/CD (l_conj) 9.14_23/CD (l_prep) in_27/IN (l_pobj) model_33/NN (l_compound) neuropathy_32/NN
D002351_D009422 NONE carrageenan_29/NN (r_compound) model_30/NN (r_pobj) in_27/IN (r_prep) 0.56_23/CD (l_prep) in_36/IN (l_pobj) model_39/NN (l_compound) neuropathy_38/NN
D013311_D009422 NONE STZ_29/NN (r_npadvmod) induced_31/VBN (r_amod) model_33/NN (l_compound) neuropathy_32/NN
C401121_D009422 NONE CNSB002_35/NNP (r_pobj) for_34/IN (r_prep) model_33/NN (l_compound) neuropathy_32/NN
C401121_D009422 NONE CNSB002_10/NNP (r_pobj) with_9/IN (r_prep) combination_8/NN (r_pobj) in_7/IN (r_prep) given_6/VBN (r_advcl) values_2/NNS (r_nsubj) were_15/VBD (l_npadvmod) mg/kg_41/CD (l_nummod) 0.56_23/CD (l_prep) in_36/IN (l_pobj) model_39/NN (l_compound) neuropathy_38/NN
C401121_D009422 NONE CNSB002_15/NNP (r_pobj) with_14/IN (r_prep) increased_9/VBN (l_prep) from_16/IN (l_prep) to_21/IN (l_pobj) reversal_26/NN (l_prep) in_29/IN (l_pobj) models_34/NNS (l_amod) inflammatory_31/JJ (l_conj) neuropathic_33/JJ
D009020_D009422 NONE morphine_37/NN (r_conj) CNSB002_35/NNP (r_pobj) for_34/IN (r_prep) model_33/NN (l_compound) neuropathy_32/NN
D009020_D009422 NONE morphine_4/NN (r_pobj) for_3/IN (r_prep) values_2/NNS (r_nsubj) were_15/VBD (l_npadvmod) mg/kg_41/CD (l_nummod) 0.56_23/CD (l_prep) in_36/IN (l_pobj) model_39/NN (l_compound) neuropathy_38/NN
D009020_D009422 NONE morphine_3/NN (r_pobj) after_2/IN (r_prep) antinociception_1/NN (r_nsubjpass) increased_9/VBN (l_prep) from_16/IN (l_prep) to_21/IN (l_pobj) reversal_26/NN (l_prep) in_29/IN (l_pobj) models_34/NNS (l_amod) inflammatory_31/JJ (l_conj) neuropathic_33/JJ
D009020_D006930 NONE morphine_3/NN (r_pobj) after_2/IN (r_prep) antinociception_1/NN (r_nsubjpass) increased_9/VBN (l_prep) from_16/IN (l_prep) to_21/IN (l_pobj) reversal_26/NN (l_prep) of_27/IN (l_pobj) hyperalgesia_28/NN
C401121_D006930 NONE CNSB002_15/NNP (r_pobj) with_14/IN (r_prep) increased_9/VBN (l_prep) from_16/IN (l_prep) to_21/IN (l_pobj) reversal_26/NN (l_prep) of_27/IN (l_pobj) hyperalgesia_28/NN
9881641
D005905_D007022 NONE Glibenclamide_0/NNP (r_npadvmod) sensitive_2/JJ (r_amod) hypotension_3/NN
D005905_D007022 NONE glibenclamide_9/NNP (r_pobj) by_8/IN (r_agent) attenuated_7/VBN (l_nsubjpass) Hypotension_0/NN
D005905_D007022 NONE glibenclamide_15/NN (r_npadvmod) sensitive_17/JJ (r_amod) channels_19/NNS (r_pobj) of_14/IN (r_prep) activation_13/NN (r_pobj) to_11/IN (r_prep) attributable_10/JJ (r_acomp) is_8/VBZ (l_nsubj) hypotension_7/NN
C040442_D007022 CID helodermin_6/NNP (r_pobj) by_5/IN (r_agent) produced_4/VBN (r_acl) hypotension_3/NN
C040442_D007022 CID Helodermin_0/NNP (r_nsubj) produced_1/VBD (l_dobj) hypotension_2/NN
C040442_D007022 CID helodermin_4/NNP (r_npadvmod) induced_6/VBN (r_amod) hypotension_7/NN
C040442_D007022 CID helodermin_4/NNP (r_npadvmod) induced_6/VBN (r_amod) hypotension_7/NN (r_dobj) affect_3/VB (l_advcl) shortened_11/VBD (l_dobj) duration_13/NN (l_prep) of_14/IN (l_pobj) acetylcholine_15/NN (l_appos) hypotension_18/NN
C040442_D007022 CID helodermin_4/NNP (r_npadvmod) produced_6/VBN (r_amod) hypotension_7/NN
D019806_D007022 CID levcromakalim_14/NN (r_npadvmod) produced_16/VBN (r_amod) decrease_17/NN (r_dobj) abolished_12/VBD (r_relcl) glibenclamide_9/NNP (r_pobj) by_8/IN (r_agent) attenuated_7/VBN (l_nsubjpass) Hypotension_0/NN
D000109_D007022 CID acetylcholine_15/NN (r_pobj) of_14/IN (r_prep) duration_13/NN (r_dobj) shortened_11/VBD (r_advcl) affect_3/VB (l_dobj) hypotension_7/NN
D000109_D007022 CID acetylcholine_15/NN (l_appos) hypotension_18/NN
D000109_D007022 CID ACh)-produced_17/VBN (r_compound) hypotension_18/NN (r_appos) acetylcholine_15/NN (r_pobj) of_14/IN (r_prep) duration_13/NN (r_dobj) shortened_11/VBD (r_advcl) affect_3/VB (l_dobj) hypotension_7/NN
D000109_D007022 CID ACh)-produced_17/VBN (r_compound) hypotension_18/NN
D011188_D007022 NONE K+_18/NNP (r_nummod) channels_19/NNS (r_pobj) of_14/IN (r_prep) activation_13/NN (r_pobj) to_11/IN (r_prep) attributable_10/JJ (r_acomp) is_8/VBZ (l_nsubj) hypotension_7/NN
D011188_D007022 NONE K(ATP_21/CD (r_nmod) channels_23/NNS (r_appos) channels_19/NNS (r_pobj) of_14/IN (r_prep) activation_13/NN (r_pobj) to_11/IN (r_prep) attributable_10/JJ (r_acomp) is_8/VBZ (l_nsubj) hypotension_7/NN
D000255_D007022 NONE K(ATP_21/CD (r_nmod) channels_23/NNS (r_appos) channels_19/NNS (r_pobj) of_14/IN (r_prep) activation_13/NN (r_pobj) to_11/IN (r_prep) attributable_10/JJ (r_acomp) is_8/VBZ (l_nsubj) hypotension_7/NN
895432
D007545_D009203 CID isoproterenol_7/NN (r_npadvmod) induced_9/VBN (r_amod) infarction_11/NN
D007545_D009203 CID isoproterenol_8/NN (r_npadvmod) induced_10/VBN (r_amod) infarction_12/NN
D007545_D007238 NONE isoproterenol_16/NN (r_pobj) of_15/IN (r_prep) dosages_14/NNS (r_pobj) of_12/IN (r_prep) effects_11/NNS (r_pobj) with_9/IN (r_prep) associated_8/VBN (r_acl) mortality_7/NN (r_dobj) reduced_5/VBD (l_conj) had_18/VBD (l_prep) on_20/IN (l_pobj) severity_22/NN (l_prep) of_23/IN (l_pobj) infarction_25/NN
24571687
D020927_D019462 CID dexmedetomidine_7/NN (r_pobj) following_5/VBG (r_prep) syncope_1/NN
D020927_D001919 CID dexmedetomidine_7/NN (r_pobj) following_5/VBG (r_prep) syncope_1/NN (l_conj) bradycardia_4/NNS
D020927_D001919 CID dexmedetomidine_15/NNP (r_pobj) of_13/IN (r_prep) administration_12/NN (r_pobj) following_11/VBG (r_prep) girl_10/NN (r_pobj) in_5/IN (r_prep) report_1/VBP (l_dobj) syncope_2/NN (l_conj) bradycardia_4/NNS
D020927_D013575 NONE dexmedetomidine_15/NNP (r_pobj) of_13/IN (r_prep) administration_12/NN (r_pobj) following_11/VBG (r_prep) girl_10/NN (r_pobj) in_5/IN (r_prep) report_1/VBP (l_dobj) syncope_2/NN
17151160
C076029_D012559 NONE olanzapine_3/NN (r_pobj) of_2/IN (r_prep) comparison_1/NN (l_prep) versus_4/IN (l_pobj) risperidone_5/NNP (l_prep) for_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) schizophrenia_13/NN
C076029_D012559 NONE olanzapine_7/NN (r_pobj) for_6/IN (r_prep) outcomes_5/NNS (l_prep) versus_8/IN (l_pobj) risperidone_9/NNP (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) disorders_18/NNS (l_compound) schizophrenia_16/NN
C076029_D012559 NONE olanzapine_30/NN (r_pobj) with_29/IN (r_prep) treatment_28/NN (r_pobj) to_27/IN (r_prep) assigned_26/VBN (l_prep) with_0/IN (l_pobj) schizophrenia_4/NN
D018967_D012559 NONE risperidone_5/NNP (l_prep) for_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) schizophrenia_13/NN
D018967_D012559 NONE risperidone_9/NNP (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) disorders_18/NNS (l_compound) schizophrenia_16/NN
D018967_D012559 NONE risperidone_40/NNP (r_conj) olanzapine_30/NN (r_pobj) with_29/IN (r_prep) treatment_28/NN (r_pobj) to_27/IN (r_prep) assigned_26/VBN (l_prep) with_0/IN (l_pobj) schizophrenia_4/NN
C076029_D011618 NONE olanzapine_30/NN (r_pobj) with_29/IN (r_prep) treatment_28/NN (r_pobj) to_27/IN (r_prep) assigned_26/VBN (l_prep) with_0/IN (l_pobj) schizophrenia_4/NN (l_appos) disorder_11/NN
C076029_D011618 NONE olanzapine_30/NN (r_pobj) with_29/IN (r_prep) treatment_28/NN (r_pobj) to_27/IN (r_prep) assigned_26/VBN (l_prep) with_0/IN (l_pobj) schizophrenia_4/NN (l_appos) disorder_11/NN (l_conj) disorder_19/NN
D018967_D011618 NONE risperidone_40/NNP (r_conj) olanzapine_30/NN (r_pobj) with_29/IN (r_prep) treatment_28/NN (r_pobj) to_27/IN (r_prep) assigned_26/VBN (l_prep) with_0/IN (l_pobj) schizophrenia_4/NN (l_appos) disorder_11/NN
D018967_D011618 NONE risperidone_40/NNP (r_conj) olanzapine_30/NN (r_pobj) with_29/IN (r_prep) treatment_28/NN (r_pobj) to_27/IN (r_prep) assigned_26/VBN (l_prep) with_0/IN (l_pobj) schizophrenia_4/NN (l_appos) disorder_11/NN (l_conj) disorder_19/NN
D018967_D010302 NONE risperidone_28/NNP (r_pobj) with_27/IN (r_prep) were_18/VBD (l_ccomp) differ_11/VB (l_nsubj) outcomes_2/NNS (l_conj) measures_4/NNS (l_prep) of_5/IN (l_pobj) parkinsonism_6/NN
D018967_D017109 NONE risperidone_28/NNP (r_pobj) with_27/IN (r_prep) were_18/VBD (l_ccomp) differ_11/VB (l_nsubj) outcomes_2/NNS (l_conj) measures_4/NNS (l_prep) of_5/IN (l_pobj) parkinsonism_6/NN (l_conj) akathisia_8/NN
D018967_D001480 CID risperidone_28/NNP (r_pobj) with_27/IN (r_prep) were_18/VBD (l_ccomp) differ_11/VB (l_prep) between_12/IN (l_pobj) scores_17/NNS (l_compound) severity_16/NN (l_compound) symptom_15/NN
C076029_D015430 CID olanzapine_6/NN (r_pobj) with_5/IN (r_prep) occurred_4/VBD (l_nsubj) gain_3/NN
C076029_D015430 CID olanzapine_14/NN (r_pobj) with_13/IN (r_prep) greater_12/JJR (r_acomp) was_11/VBD (r_conj) caused_2/VBD (l_dobj) gain_6/NN
C076029_D015430 CID olanzapine_14/NN (r_pobj) with_13/IN (r_prep) greater_12/JJR (r_acomp) was_11/VBD (l_nsubj) gain_10/NN
D018967_D015430 CID risperidone_9/NN (r_pobj) with_8/IN (r_prep) than_7/IN (r_prep) Significantly_0/RB (r_advmod) more_1/JJR (r_amod) gain_3/NN
23892921
C467567_D009101 NONE lenalidomide_12/NN (r_pobj) of_11/IN (r_prep) efficacy_8/NN (l_prep) in_15/IN (l_pobj) patients_16/NNS (l_prep) with_17/IN (l_pobj) myeloma_22/NN
C467567_D009101 NONE lenalidomide_12/NN (r_pobj) of_11/IN (r_prep) efficacy_8/NN (r_pobj) on_6/IN (r_prep) data_5/NNS (l_appos) study_34/NN (l_prep) of_35/IN (l_pobj) Group_40/NNP (l_compound) Myeloma_38/NNP
C467567_D009101 NONE Lenalidomide_0/JJ (r_nsubj) is_6/VBZ (l_attr) standard_8/NN (l_prep) for_11/IN (l_pobj) myeloma_16/NN
C467567_D009101 NONE Lenalidomide_0/JJ (r_nsubj) is_6/VBZ (l_attr) standard_8/NN (l_prep) for_11/IN (l_pobj) myeloma_16/NN (l_appos) RRMM_18/NN
C467567_D009101 NONE RD_4/NNP (r_appos) dexamethasone_2/NN (r_conj) Lenalidomide_0/JJ (r_nsubj) is_6/VBZ (l_attr) standard_8/NN (l_prep) for_11/IN (l_pobj) myeloma_16/NN
C467567_D009101 NONE RD_4/NNP (r_appos) dexamethasone_2/NN (r_conj) Lenalidomide_0/JJ (r_nsubj) is_6/VBZ (l_attr) standard_8/NN (l_prep) for_11/IN (l_pobj) myeloma_16/NN (l_appos) RRMM_18/NN
C467567_D009101 NONE RD_7/NNP (r_dobj) received_6/VBD (r_relcl) patients_4/NNS (l_compound) RRMM_3/NN
C467567_D009101 NONE RD_4/NNP (r_nsubj) is_5/VBZ (l_prep) in_9/IN (l_pobj) RRMM_10/NNS
D003907_D009101 NONE dexamethasone_14/NN (r_conj) lenalidomide_12/NN (r_pobj) of_11/IN (r_prep) efficacy_8/NN (l_prep) in_15/IN (l_pobj) patients_16/NNS (l_prep) with_17/IN (l_pobj) myeloma_22/NN
D003907_D009101 NONE dexamethasone_14/NN (r_conj) lenalidomide_12/NN (r_pobj) of_11/IN (r_prep) efficacy_8/NN (r_pobj) on_6/IN (r_prep) data_5/NNS (l_appos) study_34/NN (l_prep) of_35/IN (l_pobj) Group_40/NNP (l_compound) Myeloma_38/NNP
D003907_D009101 NONE dexamethasone_2/NN (r_conj) Lenalidomide_0/JJ (r_nsubj) is_6/VBZ (l_attr) standard_8/NN (l_prep) for_11/IN (l_pobj) myeloma_16/NN
D003907_D009101 NONE dexamethasone_2/NN (r_conj) Lenalidomide_0/JJ (r_nsubj) is_6/VBZ (l_attr) standard_8/NN (l_prep) for_11/IN (l_pobj) myeloma_16/NN (l_appos) RRMM_18/NN
D003907_D009101 NONE RD_4/NNP (r_appos) dexamethasone_2/NN (r_conj) Lenalidomide_0/JJ (r_nsubj) is_6/VBZ (l_attr) standard_8/NN (l_prep) for_11/IN (l_pobj) myeloma_16/NN
D003907_D009101 NONE RD_4/NNP (r_appos) dexamethasone_2/NN (r_conj) Lenalidomide_0/JJ (r_nsubj) is_6/VBZ (l_attr) standard_8/NN (l_prep) for_11/IN (l_pobj) myeloma_16/NN (l_appos) RRMM_18/NN
D003907_D009101 NONE RD_7/NNP (r_dobj) received_6/VBD (r_relcl) patients_4/NNS (l_compound) RRMM_3/NN
D003907_D009101 NONE RD_4/NNP (r_nsubj) is_5/VBZ (l_prep) in_9/IN (l_pobj) RRMM_10/NNS
25986755
D002110_D005921 NONE caffeine_18/NN (r_compound) exposure_19/NN (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) offspring_14/NN (r_pobj) in_12/IN (r_prep) glomerulosclerosis_11/NNP
D002110_D005317 CID caffeine_7/NN (r_compound) exposure_8/NN (r_nsubj) induce_13/VB (l_dobj) retardation_16/NN
D002110_D005317 CID caffeine_7/NN (r_compound) exposure_8/NN (r_nsubj) induce_13/VB (l_dobj) retardation_16/NN (l_appos) IUGR_18/NNP
D003404_D005921 NONE creatinine_26/NN (r_pobj) of_24/IN (r_prep) levels_23/NNS (r_pobj) by_21/IN (r_agent) accompanied_20/VBN (r_acl) glomerulosclerosis_13/NNP
D003404_D005355 NONE creatinine_26/NN (r_pobj) of_24/IN (r_prep) levels_23/NNS (r_pobj) by_21/IN (r_agent) accompanied_20/VBN (r_acl) glomerulosclerosis_13/NNP (l_conj) fibrosis_18/NN
8957205
D000324_D006935 NONE corticotropin_1/NN (r_npadvmod) releasing_3/VBG (r_amod) hormone_9/NN (r_nsubj) modulate_10/VBP (l_dobj) response_14/NN (l_compound) hypercapnic_12/NNP
D013972_D006935 NONE thyrotropin_6/NN (r_npadvmod) releasing_8/VBG (r_amod) hormone_9/NN (r_nsubj) modulate_10/VBP (l_dobj) response_14/NN (l_compound) hypercapnic_12/NNP
19841052
D016578_D015658 NONE cocaine_3/NN (r_pobj) of_1/IN (r_prep) Smoking_0/VBG (l_prep) as_4/IN (l_pobj) factor_7/NN (l_prep) for_8/IN (l_pobj) infection_10/NN
D016578_D015658 NONE cocaine_10/NN (r_nsubj) has_11/VBZ (l_prep) on_12/IN (l_pobj) incidence_14/NN (l_prep) of_15/IN (l_pobj) infection_17/NN
D016578_D015658 NONE cocaine_6/NN (r_pobj) of_4/IN (r_prep) use_3/NN (r_pobj) Given_0/VBN (r_prep) sought_9/VBD (l_xcomp) examine_11/VB (l_ccomp) become_19/VBN (l_attr) factor_22/NN (l_prep) for_23/IN (l_pobj) infection_25/NN
D016578_D006679 CID cocaine_13/NN (r_pobj) of_11/IN (r_prep) smokers_10/NNS (r_pobj) among_8/IN (r_prep) seroconversion_7/NN
D016578_D006679 CID cocaine_22/NN (r_pobj) of_20/IN (r_prep) smokers_19/NNS (r_attr) were_17/VBD (r_relcl) participants_15/NNS (r_pobj) among_14/IN (r_prep) seroconversion_13/NN
D016578_D006679 CID cocaine_3/NN (r_pobj) of_1/IN (r_prep) Smoking_0/VBG (r_nsubjpass) found_5/VBN (l_xcomp) be_7/VB (l_attr) factor_11/NN (l_prep) for_12/IN (l_pobj) seroconversion_14/NN
12752472
D010862_D004827 CID pilocarpine_15/NN (r_npadvmod) induced_17/VBN (r_amod) epilepsy_18/NN
D010862_D006985 NONE pilocarpine_10/NNP (r_npadvmod) treated_12/VBN (r_amod) rats_15/NNS (r_pobj) in_9/IN (r_prep) decrease_5/NN (r_dobj) caused_3/VBD (l_nsubj) maneuver_2/NN (l_compound) hyperventilation_1/NN
8808730
D009569_D001745 NONE oxide_5/NN (r_compound) synthase_6/NN (r_pobj) of_2/IN (r_prep) expression_1/NN (l_prep) following_11/VBG (l_pobj) irritation_14/NN
D009569_D014570 NONE oxide_13/NN (r_compound) synthase_14/NN (r_pobj) of_10/IN (r_prep) expression_9/NN (r_pobj) in_7/IN (r_prep) alterations_6/NNS (r_dobj) examine_5/VB (l_prep) following_21/VBG (l_pobj) irritation_25/NN (l_prep) of_26/IN (l_pobj) tract_29/NN
D003520_D003556 CID cyclophosphamide_5/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_nsubjpass) cystitis_1/NN
D003520_D003556 CID CYP_7/NNP (r_appos) cyclophosphamide_5/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_nsubjpass) cystitis_1/NN
D000171_D003556 NONE acrolein_13/NN (r_pobj) to_12/IN (r_prep) metabolized_11/VBN (r_relcl) cyclophosphamide_5/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_nsubjpass) cystitis_1/NN
16112787
D014640_D007674 CID vancomycin_12/NN (r_npadvmod) induced_14/VBN (r_amod) nephrotoxicity_15/NN
D014640_D007674 CID vancomycin_8/NNP (r_dobj) examine_7/VB (l_conj) investigate_25/VB (l_dobj) role_27/NN (l_prep) of_28/IN (l_pobj) erdosteine_29/NN (l_appos) agent_33/NN (l_relcl) has_36/VBZ (l_attr) properties_39/NNS (l_prep) on_41/IN (l_pobj) tissue_43/NN (l_prep) against_44/IN (l_pobj) impairment_51/NN
D014640_D007674 CID VCM)-induced_10/VBN (r_amod) stress_12/NN (r_appos) vancomycin_8/NNP (r_dobj) examine_7/VB (l_conj) investigate_25/VB (l_dobj) role_27/NN (l_prep) of_28/IN (l_pobj) erdosteine_29/NN (l_appos) agent_33/NN (l_relcl) has_36/VBZ (l_attr) properties_39/NNS (l_prep) on_41/IN (l_pobj) tissue_43/NN (l_prep) against_44/IN (l_pobj) impairment_51/NN
D014640_D007674 CID VCM_47/NN (r_npadvmod) induced_49/VBN (r_amod) impairment_51/NN
D014640_D007674 CID VCM_0/NNP (r_compound) administration_1/NN (r_nsubj) increased_6/VBD (l_dobj) malondialdehyde_8/NNP (l_appos) MDA_10/NNP (l_conj) excretion_33/NN (l_nmod) glucosaminidase_22/NNP (l_appos) NAG_24/NNP (l_appos) marker_27/NN (l_prep) of_28/IN (l_pobj) injury_31/NN
D014640_D007674 CID VCM_5/NN (r_npadvmod) induced_7/VBN (r_amod) nephrotoxicity_8/NN
D014640_D007674 CID VCM_13/NN (r_npadvmod) induced_15/VBN (r_amod) nephrotoxicity_16/NN
D014640_D007674 CID VCM_13/NN (r_npadvmod) induced_15/VBN (r_amod) nephrotoxicity_16/NN (r_pobj) in_11/IN (r_prep) role_10/NN (r_dobj) plays_7/VBZ (l_conj) reduces_25/VBZ (l_dobj) damage_31/NN
D014640_D007674 CID VCM_27/NN (r_npadvmod) induced_29/VBN (r_amod) kidney_30/NN (r_compound) damage_31/NN (r_dobj) reduces_25/VBZ (r_conj) plays_7/VBZ (l_dobj) role_10/NN (l_prep) in_11/IN (l_pobj) nephrotoxicity_16/NN
D014640_D007674 CID VCM_27/NN (r_npadvmod) induced_29/VBN (r_amod) kidney_30/NN (r_compound) damage_31/NN
C048498_D007674 NONE erdosteine_19/NN (r_pobj) by_18/IN (r_prep) protection_17/NN (r_appos) role_5/NN (l_prep) of_6/IN (l_pobj) stress_8/NN (l_prep) in_9/IN (l_pobj) pathogenesis_10/NN (l_prep) of_11/IN (l_pobj) nephrotoxicity_15/NN
C048498_D007674 NONE erdosteine_29/NN (l_appos) agent_33/NN (l_relcl) has_36/VBZ (l_attr) properties_39/NNS (l_prep) on_41/IN (l_pobj) tissue_43/NN (l_prep) against_44/IN (l_pobj) impairment_51/NN
C048498_D007674 NONE Erdosteine_0/NNP (r_nsubj) showed_1/VBD (l_dobj) protection_3/NN (l_prep) against_4/IN (l_pobj) nephrotoxicity_8/NN
C048498_D007674 NONE erdosteine_24/NN (r_pobj) with_23/IN (r_prep) stress_22/NN (r_pobj) of_20/IN (r_prep) modulation_19/NN (r_nsubj) reduces_25/VBZ (r_conj) plays_7/VBZ (l_dobj) role_10/NN (l_prep) in_11/IN (l_pobj) nephrotoxicity_16/NN
C048498_D007674 NONE erdosteine_24/NN (r_pobj) with_23/IN (r_prep) stress_22/NN (r_pobj) of_20/IN (r_prep) modulation_19/NN (r_nsubj) reduces_25/VBZ (l_dobj) damage_31/NN
D010100_D007674 NONE oxygen_18/NN (r_compound) species_19/NNS (r_pobj) of_16/IN (r_prep) production_15/NN (r_dobj) promotes_14/VBZ (r_relcl) stress_12/NN (r_appos) vancomycin_8/NNP (r_dobj) examine_7/VB (l_conj) investigate_25/VB (l_dobj) role_27/NN (l_prep) of_28/IN (l_pobj) erdosteine_29/NN (l_appos) agent_33/NN (l_relcl) has_36/VBZ (l_attr) properties_39/NNS (l_prep) on_41/IN (l_pobj) tissue_43/NN (l_prep) against_44/IN (l_pobj) impairment_51/NN
D008315_D007674 NONE malondialdehyde_8/NNP (l_appos) MDA_10/NNP (l_conj) excretion_33/NN (l_nmod) glucosaminidase_22/NNP (l_appos) NAG_24/NNP (l_appos) marker_27/NN (l_prep) of_28/IN (l_pobj) injury_31/NN
D008315_D007674 NONE MDA_10/NNP (l_conj) excretion_33/NN (l_nmod) glucosaminidase_22/NNP (l_appos) NAG_24/NNP (l_appos) marker_27/NN (l_prep) of_28/IN (l_pobj) injury_31/NN
D013481_D007674 NONE superoxide_36/NN (r_compound) dismutase_37/NN (r_conj) excretion_33/NN (l_nmod) glucosaminidase_22/NNP (l_appos) NAG_24/NNP (l_appos) marker_27/NN (l_prep) of_28/IN (l_pobj) injury_31/NN
D014640_D001284 NONE VCM_21/NN (r_npadvmod) treated_23/VBN (r_amod) rats_24/NNS (r_pobj) in_20/IN (r_prep) vacuolization_12/NN (l_conj) atrophy_14/NN
D014640_-1 NONE VCM_21/NN (r_npadvmod) treated_23/VBN (r_amod) rats_24/NNS (r_pobj) in_20/IN (r_prep) vacuolization_12/NN (l_conj) atrophy_14/NN (l_conj) desquamation_16/NN
D014640_D009336 NONE VCM_21/NN (r_npadvmod) treated_23/VBN (r_amod) rats_24/NNS (r_pobj) in_20/IN (r_prep) vacuolization_12/NN (l_conj) atrophy_14/NN (l_conj) desquamation_16/NN (l_conj) necrosis_19/NN
C048498_D001284 NONE erdosteine_33/JJ (r_compound) groups_34/NNS (r_conj) control_30/NN (r_pobj) of_28/IN (r_prep) those_27/DT (r_pobj) than_26/IN (r_prep) more_25/JJR (r_amod) dilatation_4/NN (l_prep) of_5/IN (l_pobj) lumens_7/NNS (l_conj) vacuolization_12/NN (l_conj) atrophy_14/NN
C048498_-1 NONE erdosteine_33/JJ (r_compound) groups_34/NNS (r_conj) control_30/NN (r_pobj) of_28/IN (r_prep) those_27/DT (r_pobj) than_26/IN (r_prep) more_25/JJR (r_amod) dilatation_4/NN (l_prep) of_5/IN (l_pobj) lumens_7/NNS (l_conj) vacuolization_12/NN (l_conj) atrophy_14/NN (l_conj) desquamation_16/NN
C048498_D009336 NONE erdosteine_33/JJ (r_compound) groups_34/NNS (r_conj) control_30/NN (r_pobj) of_28/IN (r_prep) those_27/DT (r_pobj) than_26/IN (r_prep) more_25/JJR (r_amod) dilatation_4/NN (l_prep) of_5/IN (l_pobj) lumens_7/NNS (l_conj) vacuolization_12/NN (l_conj) atrophy_14/NN (l_conj) desquamation_16/NN (l_conj) necrosis_19/NN
15018178
D015662_D000743 CID sulfomethoxazole_24/NNP (r_pobj) by_21/IN (r_agent) induced_20/VBN (r_acl) crisis_19/NN (l_compound) anemia_18/NN
D015662_D002534 NONE sulfomethoxazole_24/NNP (r_pobj) by_21/IN (r_agent) induced_20/VBN (r_acl) crisis_19/NN (r_dobj) had_13/VBD (l_advcl) resulting_26/VBG (l_prep) in_27/IN (l_pobj) anoxia_29/NN
19020118
15265979
D000638_D056486 CID Amiodarone_0/NNP (r_nsubjpass) reported_12/VBN (l_xcomp) cause_14/VB (l_dobj) hepatotoxicity_15/NN
D000638_D056486 CID amiodarone_12/NN (r_pobj) of_11/IN (r_prep) effects_10/NNS (l_amod) hepatotoxic_9/JJ
D000638_D056486 CID amiodarone_12/NN (r_pobj) of_11/IN (r_prep) effects_10/NNS (r_pobj) regarding_7/VBG (r_prep) information_6/NN (r_dobj) provide_2/VBP (l_conj) indicate_14/VBP (l_ccomp) protects_17/VBZ (l_prep) against_18/IN (l_pobj) hepatotoxicity_22/NN
D000638_D056486 CID amiodarone_19/NN (r_npadvmod) induced_21/VBN (r_amod) hepatotoxicity_22/NN (r_pobj) against_18/IN (r_prep) protects_17/VBZ (r_ccomp) indicate_14/VBP (r_conj) provide_2/VBP (l_dobj) information_6/NN (l_prep) regarding_7/VBG (l_pobj) effects_10/NNS (l_amod) hepatotoxic_9/JJ
D000638_D056486 CID amiodarone_19/NN (r_npadvmod) induced_21/VBN (r_amod) hepatotoxicity_22/NN
D000638_D006529 CID Amiodarone_0/NNP (r_nsubj) induced_1/VBD (l_dobj) hepatomegaly_2/NNP
D014280_D006529 NONE triglycerides_15/NNS (r_pobj) in_13/IN (r_prep) decrease_12/NN (r_conj) accumulation_7/NN (r_dobj) hepatocyte_4/JJ (r_conj) induced_1/VBD (l_dobj) hepatomegaly_2/NNP
D005947_D006529 NONE glucose_17/NN (r_conj) triglycerides_15/NNS (r_pobj) in_13/IN (r_prep) decrease_12/NN (r_conj) accumulation_7/NN (r_dobj) hepatocyte_4/JJ (r_conj) induced_1/VBD (l_dobj) hepatomegaly_2/NNP
D000638_D015431 NONE amiodarone_12/NN (r_pobj) with_11/IN (r_prep) treatment_7/NN (r_nsubj) resulted_13/VBD (l_prep) in_14/IN (l_pobj) rate_17/NN (l_conj) extent_19/NN (l_prep) of_20/IN (l_pobj) loss_24/NN
D000638_D006528 NONE amiodarone_3/NN (r_pobj) of_2/IN (r_prep) inability_1/NN (r_nsubj) activate_6/VB (l_ccomp) expressed_13/VBN (l_prep) in_14/IN (l_pobj) cells_18/NNS (l_compound) hepatoma_17/NNP
D000638_D006528 NONE amiodarone_24/NN (r_pobj) of_23/IN (r_prep) effects_22/NNS (r_nsubj) were_31/VBD (r_ccomp) indicates_19/VBZ (l_csubj) activate_6/VB (l_ccomp) expressed_13/VBN (l_prep) in_14/IN (l_pobj) cells_18/NNS (l_compound) hepatoma_17/NNP
11439380
D013792_D009422 NONE Thalidomide_0/NN (r_compound) neuropathy_1/NN
D013792_D009422 NONE thalidomide_3/NN (r_npadvmod) induced_5/VBN (r_amod) neuropathy_6/NN
D013792_D009422 NONE thalidomide_8/NN (r_pobj) of_7/IN (r_prep) complication_6/NN (r_attr) be_3/VB (l_nsubj) Neuropathy_0/NN
D013792_D011471 NONE Thalidomide_0/NN (r_compound) neuropathy_1/NN (r_nsubj) treated_4/VBN (l_prep) for_5/IN (l_pobj) cancer_8/NN
D013792_D011471 NONE thalidomide_19/NN (r_pobj) of_17/IN (r_prep) trial_16/NN (r_pobj) in_11/IN (r_prep) men_3/NNS (l_prep) with_4/IN (l_pobj) cancer_10/NN
D000728_D011471 NONE androgen_6/NN (r_npadvmod) independent_8/JJ (r_amod) cancer_10/NN
8308951
D014859_D002543 CID warfarin_3/NN (r_npadvmod) like_5/JJ (r_amod) anticoagulant_6/NN (r_pobj) to_2/IN (r_prep) exposure_1/NN (l_acl) causing_7/VBG (l_dobj) hemorrhage_10/NN
D014859_D006406 NONE warfarin_7/NN (r_advmod) induced_9/VBN (r_amod) coagulopathy_10/NN (r_pobj) due_5/IN (r_amod) case_1/NN (l_prep) of_2/IN (l_pobj) hematoma_4/NN
D014859_D001778 NONE warfarin_7/NN (r_advmod) induced_9/VBN (r_amod) coagulopathy_10/NN
D014859_D001778 NONE warfarin_3/NN (r_pobj) of_2/IN (r_prep) absorption_1/NN (l_acl) causing_4/VBG (l_dobj) coagulopathy_5/NN
D010894_D001778 NONE piroxicam_5/NNP (r_pobj) with_4/IN (r_prep) interaction_3/NN (r_nsubj) exacerbated_14/VBN (l_dobj) coagulopathy_16/NN
6627074
D013390_D001049 CID Succinylcholine_0/JJ (r_compound) apnoea_1/NN
D013390_D001049 CID succinylcholine_14/NN (r_compound) apnoea_15/NN
D013390_D020879 NONE succinylcholine_15/NNP (r_pobj) of_14/IN (r_prep) administration_13/NN (r_pobj) following_11/VBG (r_prep) antagonize_7/VB (l_dobj) blockade_10/NN
6529939
D011433_D001146 CID propranolol_9/NNS (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) block_6/NN (r_conj) rhythm_2/NN
D011433_D001146 CID propranolol_28/JJ (r_compound) daily_29/RB (r_pobj) with_25/IN (r_prep) angina_24/NN (r_pobj) for_23/IN (r_prep) treatment_22/NN (r_pobj) under_21/IN (r_prep) observed_13/VBN (l_csubjpass) Alternating_0/VBG (l_dobj) block_11/NN (l_nmod) rhythm_2/NN
D011433_D012848 CID propranolol_9/NNS (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) block_6/NN
D011433_D012848 CID propranolol_28/JJ (r_compound) daily_29/RB (r_pobj) with_25/IN (r_prep) angina_24/NN (r_pobj) for_23/IN (r_prep) treatment_22/NN (r_pobj) under_21/IN (r_prep) observed_13/VBN (l_csubjpass) Alternating_0/VBG (l_dobj) block_11/NN
D011433_D000787 NONE propranolol_28/JJ (r_compound) daily_29/RB (r_pobj) with_25/IN (r_prep) angina_24/NN
D011433_D019955 NONE propranolol_6/NN (r_nsubj) being_7/VBG (l_attr) cause_9/NN (l_prep) of_10/IN (l_pobj) disorder_13/NN
8160791
D005839_D007674 CID gentamicin_9/NN (r_npadvmod) mediated_11/VBN (r_amod) nephropathy_12/NN
D005839_D007674 CID gentamicin_16/NNS (l_appos) nephropathy_19/NN
D005839_D007674 CID GM)-mediated_18/VBN (r_nummod) nephropathy_19/NN
D005839_D007674 CID GM_2/NNP (r_pobj) of_1/IN (r_prep) Administration_0/NNP (r_nsubj) induced_12/VBD (l_dobj) reduction_15/NN (l_prep) in_16/IN (l_pobj) flow_19/NN (l_conj) clearance_25/NN (l_appos) CIn_27/NNP (l_conj) damage_34/NN
D005839_D007674 CID GM_27/NNP (r_npadvmod) mediated_29/VBN (r_amod) nephropathy_30/NN
D005839_D007674 CID GM_14/NNP (r_npadvmod) mediated_16/VBN (r_amod) nephropathy_17/NN
D006152_D007674 NONE monophosphate_7/NN (r_nmod) excretion_11/NN (r_pobj) in_3/IN (r_prep) reduction_2/NN (r_nsubjpass) observed_25/VBN (l_prep) in_26/IN (l_pobj) nephropathy_30/NN
D006152_D007674 NONE cGMP_9/NNP (r_dep) )_10/-RRB- (r_punct) excretion_11/NN (r_pobj) in_3/IN (r_prep) reduction_2/NN (r_nsubjpass) observed_25/VBN (l_prep) in_26/IN (l_pobj) nephropathy_30/NN
C038983_D007674 NONE DMTU_3/NNP (r_nsubj) reduced_5/VBD (l_dobj) damage_8/NN
C038983_D007674 NONE DMTU_9/NNP (r_conj) SOD_7/NNP (r_nsubj) have_10/VBP (l_dobj) effects_12/NNS (l_prep) on_13/IN (l_pobj) nephropathy_17/NN
3074291
C017590_D001249 NONE bromide_6/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (l_prep) on_13/IN (l_pobj) asthma_15/NN
C017590_D001249 NONE bromide_10/NN (r_appos) drug_7/NN (r_pobj) of_2/IN (l_conj) of_13/IN (l_pobj) preparation_19/NN (l_prep) upon_20/IN (l_pobj) asthma_22/NN
C017590_D001249 NONE Oxitropium_0/NN (r_nsubj) proves_1/VBZ (l_xcomp) be_3/VB (l_attr) alternative_6/NN (l_prep) in_9/IN (l_pobj) asthma_11/NN
D013806_D001249 NONE theophylline_12/NN (r_pobj) of_8/IN (r_conj) of_4/IN (r_prep) effect_3/NN (l_prep) on_13/IN (l_pobj) asthma_15/NN
D013806_D001249 NONE theophylline_18/NN (r_compound) preparation_19/NN (l_prep) upon_20/IN (l_pobj) asthma_22/NN
D013806_D001249 NONE theophylline_8/NN (r_pobj) to_7/IN (r_prep) alternative_6/NN (l_prep) in_9/IN (l_pobj) asthma_11/NN
C017590_D009325 NONE oxitropium_6/NN (r_pobj) of_5/IN (r_prep) effects_4/NNS (r_dobj) reported_2/VBD (l_prep) compared_9/VBN (l_prep) to_10/IN (l_pobj) subjects_12/NNS (l_acl) reporting_13/VBG (l_dobj) nausea_14/NN
C017590_D014839 NONE oxitropium_6/NN (r_pobj) of_5/IN (r_prep) effects_4/NNS (r_dobj) reported_2/VBD (l_prep) compared_9/VBN (l_prep) to_10/IN (l_pobj) subjects_12/NNS (l_acl) reporting_13/VBG (l_dobj) nausea_14/NN (l_conj) vomiting_16/NN
C017590_D014202 NONE oxitropium_6/NN (r_pobj) of_5/IN (r_prep) effects_4/NNS (r_dobj) reported_2/VBD (l_prep) compared_9/VBN (l_prep) to_10/IN (l_pobj) subjects_12/NNS (l_acl) reporting_13/VBG (l_dobj) nausea_14/NN (l_conj) vomiting_16/NN (l_conj) tremors_18/NNS
D013806_D009325 CID theophylline_20/NN (r_pobj) after_19/IN (r_prep) reporting_13/VBG (l_dobj) nausea_14/NN
D013806_D014839 CID theophylline_20/NN (r_pobj) after_19/IN (r_prep) reporting_13/VBG (l_dobj) nausea_14/NN (l_conj) vomiting_16/NN
D013806_D014202 CID theophylline_20/NN (r_pobj) after_19/IN (r_prep) reporting_13/VBG (l_dobj) nausea_14/NN (l_conj) vomiting_16/NN (l_conj) tremors_18/NNS
11401944
D013015_D016171 CID sotalol_32/NNP (r_pobj) by_29/IN (r_agent) induced_28/VBN (r_acl) prolongation_27/NN (r_pobj) with_25/IN (r_prep) producing_14/VBG (l_dobj) trigger_16/NN (l_acl) initiate_18/VB (l_dobj) torsade_19/NN (l_pobj) pointes_21/FW
D013015_D016171 CID sotalol_32/NNP (r_pobj) by_29/IN (r_agent) induced_28/VBN (r_acl) prolongation_27/NN (r_pobj) with_25/IN (r_prep) producing_14/VBG (l_dobj) trigger_16/NN (l_acl) initiate_18/VB (l_dobj) torsade_19/NN (l_pobj) pointes_21/FW (l_appos) TdP_23/NNP
D013015_D016171 CID sotalol_7/NNP (r_pobj) by_4/IN (r_prep) increase_1/NN (r_nsubj) facilitated_8/VBD (l_dobj) propagation_10/NN (l_relcl) initiated_14/VBD (l_dobj) episodes_16/NNS (l_prep) of_17/IN (l_pobj) TdP_19/NN
D013015_D008133 CID sotalol_32/NNP (r_pobj) by_29/IN (r_agent) induced_28/VBN (r_acl) prolongation_27/NN
D013015_D008133 CID Sotalol_2/NNP (r_nsubj) prolonged_4/VBD (l_advcl) leading_26/VBG (l_prep) to_27/IN (l_pobj) prolongation_29/NN
D013015_D008133 CID sotalol_4/NNP (r_nsubj) induced_8/VBD (r_advcl) produced_16/VBD (l_dobj) EADs_18/NNS (l_relcl) seen_29/VBN (l_nsubjpass) prolongation_27/NN
C086123_D016171 NONE azimilide_34/JJ (r_conj) sotalol_32/NNP (r_pobj) by_29/IN (r_agent) induced_28/VBN (r_acl) prolongation_27/NN (r_pobj) with_25/IN (r_prep) producing_14/VBG (l_dobj) trigger_16/NN (l_acl) initiate_18/VB (l_dobj) torsade_19/NN (l_pobj) pointes_21/FW
C086123_D016171 NONE azimilide_34/JJ (r_conj) sotalol_32/NNP (r_pobj) by_29/IN (r_agent) induced_28/VBN (r_acl) prolongation_27/NN (r_pobj) with_25/IN (r_prep) producing_14/VBG (l_dobj) trigger_16/NN (l_acl) initiate_18/VB (l_dobj) torsade_19/NN (l_pobj) pointes_21/FW (l_appos) TdP_23/NNP
C086123_D008133 NONE azimilide_34/JJ (r_conj) sotalol_32/NNP (r_pobj) by_29/IN (r_agent) induced_28/VBN (r_acl) prolongation_27/NN
C086123_D008133 NONE azimilide_6/NNP (r_conj) sotalol_4/NNP (r_nsubj) induced_8/VBD (r_advcl) produced_16/VBD (l_dobj) EADs_18/NNS (l_relcl) seen_29/VBN (l_nsubjpass) prolongation_27/NN
3833372
D013999_D006973 NONE maleate_23/NNP (r_pobj) of_21/IN (r_prep) mg_20/NNS (r_dobj) containing_18/VBG (r_acl) combination_17/NN (r_pobj) of_12/IN (r_prep) safety_9/NN (r_dobj) determine_7/VB (l_advcl) administered_30/VBN (l_prep) to_36/IN (l_pobj) patients_38/NNS (l_amod) hypertensive_37/JJ
D006852_D006973 NONE hydrochlorothiazide_28/NN (r_pobj) of_27/IN (r_prep) mg_26/NNS (r_conj) mg_20/NNS (r_dobj) containing_18/VBG (r_acl) combination_17/NN (r_pobj) of_12/IN (r_prep) safety_9/NN (r_dobj) determine_7/VB (l_advcl) administered_30/VBN (l_prep) to_36/IN (l_pobj) patients_38/NNS (l_amod) hypertensive_37/JJ
35781
D003000_D002375 CID clonidine_3/NN (l_prep) on_8/IN (l_conj) on_21/IN (l_pobj) effect_23/NN (l_amod) cataleptic_22/JJ
D003000_D002375 CID clonidine_5/NN (r_pobj) by_4/IN (r_agent) increased_3/VBN (l_nsubjpass) catalepsy_1/NN
D009278_D002375 CID naphazoline_5/NNP (r_conj) clonidine_3/NN (l_prep) on_8/IN (l_conj) on_21/IN (l_pobj) effect_23/NN (l_amod) cataleptic_22/JJ
D009278_D002375 CID naphazoline_9/NNP (r_pobj) by_8/IN (r_agent) decreased_7/VBN (r_conj) increased_3/VBN (l_nsubjpass) catalepsy_1/NN
C009695_D002375 CID xylometazoline_7/NNP (r_conj) naphazoline_5/NNP (r_conj) clonidine_3/NN (l_prep) on_8/IN (l_conj) on_21/IN (l_pobj) effect_23/NN (l_amod) cataleptic_22/JJ
C009695_D002375 CID xylometazoline_11/NNP (r_conj) naphazoline_9/NNP (r_pobj) by_8/IN (r_agent) decreased_7/VBN (r_conj) increased_3/VBN (l_nsubjpass) catalepsy_1/NN
D009020_D002375 CID morphine_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) analgesia_9/NN (r_pobj) on_8/IN (l_conj) on_21/IN (l_pobj) effect_23/NN (l_amod) cataleptic_22/JJ
D009020_D002375 CID morphine_25/NN (r_pobj) of_24/IN (r_prep) effect_23/NN (l_amod) cataleptic_22/JJ
D009020_D002375 CID morphine_26/NN (r_pobj) by_25/IN (r_agent) induced_24/VBN (r_acl) catalepsy_23/NN
D003061_D002375 CID codeine_14/NN (r_appos) morphine_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) analgesia_9/NN (r_pobj) on_8/IN (l_conj) on_21/IN (l_pobj) effect_23/NN (l_amod) cataleptic_22/JJ
D003061_D002375 CID codine_27/NNP (r_conj) morphine_25/NN (r_pobj) of_24/IN (r_prep) effect_23/NN (l_amod) cataleptic_22/JJ
D003061_D002375 CID Codeine_0/NNP (r_compound) catalepsy_1/NN
D005283_D002375 CID fentanyl_16/NN (r_conj) codeine_14/NN (r_appos) morphine_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) analgesia_9/NN (r_pobj) on_8/IN (l_conj) on_21/IN (l_pobj) effect_23/NN (l_amod) cataleptic_22/JJ
D005283_D002375 CID fentanyl_29/NN (r_conj) codine_27/NNP (r_conj) morphine_25/NN (r_pobj) of_24/IN (r_prep) effect_23/NN (l_amod) cataleptic_22/JJ
D005283_D002375 CID fentanyl_28/NN (r_conj) morphine_26/NN (r_pobj) by_25/IN (r_agent) induced_24/VBN (r_acl) catalepsy_23/NN
D010423_D002375 NONE pentazocine_18/NN (r_conj) fentanyl_16/NN (r_conj) codeine_14/NN (r_appos) morphine_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) analgesia_9/NN (r_pobj) on_8/IN (l_conj) on_21/IN (l_pobj) effect_23/NN (l_amod) cataleptic_22/JJ
D009638_D002375 NONE NA_8/NNP (r_compound) receptors_9/NNS (r_dobj) stimulating_6/VBG (r_acl) drugs_5/NNS (r_nsubj) failed_10/VBD (r_ccomp) found_2/VBN (l_conj) enhanced_22/VBD (l_dobj) catalepsy_23/NN
7479194
D015662_D064420 NONE sulfamethoxazole_12/NNP (r_pobj) of_9/IN (r_prep) study_8/NN (l_prep) for_18/IN (l_pobj) toxicity_22/NN
D014295_D064420 NONE trimethoprim_14/NN (r_appos) sulfamethoxazole_12/NNP (r_pobj) of_9/IN (r_prep) study_8/NN (l_prep) for_18/IN (l_pobj) toxicity_22/NN
D002506_D064420 NONE cephalexin_17/NNP (r_conj) trimethoprim_14/NN (r_appos) sulfamethoxazole_12/NNP (r_pobj) of_9/IN (r_prep) study_8/NN (l_prep) for_18/IN (l_pobj) toxicity_22/NN
D015662_D008107 CID SMZ_15/NNP (r_dobj) prescribed_12/VBN (r_acl) persons_11/NNS (r_pobj) for_10/IN (r_prep) similar_9/JJ (r_acomp) was_8/VBD (l_nsubj) risk_1/NN (l_prep) of_2/IN (l_pobj) disease_7/NN
D015662_D008107 NONE sulfamethoxazole_19/NN (r_dobj) prescribed_16/VBN (r_relcl) people_13/NNS (r_pobj) of_11/IN (r_prep) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D015662_D008107 NONE SMZ_23/NNP (r_appos) sulfamethoxazole_19/NN (r_dobj) prescribed_16/VBN (r_relcl) people_13/NNS (r_pobj) of_11/IN (r_prep) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D015662_D006402 NONE sulfamethoxazole_19/NN (r_dobj) prescribed_16/VBN (r_relcl) people_13/NNS (r_pobj) of_11/IN (r_prep) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D015662_D006402 NONE SMZ_23/NNP (r_appos) sulfamethoxazole_19/NN (r_dobj) prescribed_16/VBN (r_relcl) people_13/NNS (r_pobj) of_11/IN (r_prep) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D015662_D012871 NONE sulfamethoxazole_19/NN (r_dobj) prescribed_16/VBN (r_relcl) people_13/NNS (r_pobj) of_11/IN (r_prep) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D015662_D012871 NONE SMZ_23/NNP (r_appos) sulfamethoxazole_19/NN (r_dobj) prescribed_16/VBN (r_relcl) people_13/NNS (r_pobj) of_11/IN (r_prep) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D015662_D007674 NONE sulfamethoxazole_19/NN (r_dobj) prescribed_16/VBN (r_relcl) people_13/NNS (r_pobj) of_11/IN (r_prep) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D015662_D007674 NONE SMZ_23/NNP (r_appos) sulfamethoxazole_19/NN (r_dobj) prescribed_16/VBN (r_relcl) people_13/NNS (r_pobj) of_11/IN (r_prep) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D014295_D008107 CID trimethoprim_22/NN (r_conj) was_8/VBD (l_nsubj) risk_1/NN (l_prep) of_2/IN (l_pobj) disease_7/NN
D014295_D008107 NONE trimethoprim_28/NN (r_appos) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D014295_D006402 NONE trimethoprim_28/NN (r_appos) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D014295_D012871 NONE trimethoprim_28/NN (r_appos) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D014295_D007674 NONE trimethoprim_28/NN (r_appos) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D002506_D008107 NONE cephalexin_34/NNP (r_conj) trimethoprim_28/NN (r_appos) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D002506_D006402 NONE cephalexin_34/NNP (r_conj) trimethoprim_28/NN (r_appos) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D002506_D012871 NONE cephalexin_34/NNP (r_conj) trimethoprim_28/NN (r_appos) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D002506_D007674 NONE cephalexin_34/NNP (r_conj) trimethoprim_28/NN (r_appos) study_10/NN (r_dobj) conducted_1/VBD (l_advcl) estimate_37/VB (l_dobj) risk_39/NN (l_prep) of_40/IN (l_pobj) liver_42/NN (l_conj) blood_44/NN (l_conj) skin_46/NN (l_conj) disorders_50/NNS
D015662_D004892 NONE SMZ_15/NNP (r_pobj) to_12/IN (r_prep) exposed_11/VBN (r_relcl) disorders_5/NNS (l_prep) of_17/IN (l_pobj) seven_18/CD (l_prep) with_19/IN (l_pobj) multiforme_21/NN
D015662_D004892 NONE SMZ_34/NNP (r_pobj) to_31/IN (r_prep) exposed_30/VBN (r_conj) experienced_3/VBD (l_dobj) disorders_5/NNS (l_prep) of_17/IN (l_pobj) seven_18/CD (l_prep) with_19/IN (l_pobj) multiforme_21/NN
D015662_D013262 CID SMZ_15/NNP (r_pobj) to_12/IN (r_prep) exposed_11/VBN (r_relcl) disorders_5/NNS (l_prep) of_17/IN (l_pobj) seven_18/CD (l_prep) with_19/IN (l_pobj) multiforme_21/NN (l_conj) syndrome_26/NN
D015662_D013262 CID SMZ_34/NNP (r_pobj) to_31/IN (r_prep) exposed_30/VBN (r_conj) experienced_3/VBD (l_dobj) disorders_5/NNS (l_prep) of_17/IN (l_pobj) seven_18/CD (l_prep) with_19/IN (l_pobj) multiforme_21/NN (l_conj) syndrome_26/NN
D002506_D013262 CID cephalexin_13/NN (r_dobj) took_12/VBD (r_relcl) patient_10/NN (r_pobj) in_8/IN (r_prep) occurred_7/VBD (l_nsubj) case_2/NN (l_prep) of_3/IN (l_pobj) necrolysis_6/NN
7477981
D007980_D004409 NONE Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_3/NNP
D007980_D004409 NONE levodopa_11/NN (r_npadvmod) responsive_13/JJ (r_amod) patients_14/NNS (r_pobj) in_9/IN (r_prep) evaluated_1/VBD (l_dobj) severity_3/NN (l_prep) of_4/IN (l_pobj) disability_6/NN (l_conj) dyskinesias_8/NNP
D007980_D004409 NONE levodopa-_12/NN (r_dobj) reduce_11/VB (l_conj) dyskinesias_18/NNP
D005473_D004409 CID fluoxetine_7/NN (r_pobj) by_6/IN (r_agent) improved_5/VBN (l_nsubjpass) dyskinesias_3/NNP
D005473_D004409 CID fluoxetine_37/NNP (r_pobj) of_36/IN (r_prep) administration_35/NN (r_pobj) after_33/IN (r_conj) before_31/RB (r_prep) challenge_22/NN (r_pobj) after_19/IN (r_prep) evaluated_1/VBD (l_dobj) severity_3/NN (l_prep) of_4/IN (l_pobj) disability_6/NN (l_conj) dyskinesias_8/NNP
D005473_D004409 CID fluoxetine_1/NN (r_compound) treatment_2/NN (r_pobj) After_0/IN (r_prep) was_5/VBD (l_attr) improvement_10/NN (l_appos) 0.05_14/CD (l_prep) of_16/IN (l_pobj) dyskinesias_20/NNP
D005473_D004409 CID fluoxetine_9/NNP (r_pobj) with_8/IN (r_prep) transmission_7/NN (r_nsubj) reduce_11/VB (l_conj) dyskinesias_18/NNP
D007980_D009069 NONE levodopa_11/NN (r_npadvmod) responsive_13/JJ (r_amod) patients_14/NNS (r_pobj) in_9/IN (r_prep) evaluated_1/VBD (l_dobj) severity_3/NN (l_prep) of_4/IN (l_pobj) disability_6/NN
D007980_D009069 NONE levodopa-_12/NN (r_dobj) reduce_11/VB (l_prep) without_19/IN (l_pobj) disability_23/NN
D007980_D010300 NONE levodopa_11/NN (r_npadvmod) responsive_13/JJ (r_amod) patients_14/NNS (l_prep) with_15/IN (l_pobj) disease_18/NN
D007980_D010300 NONE levodopa-_12/NN (r_dobj) reduce_11/VB (l_prep) without_19/IN (l_pobj) disability_23/NN (l_amod) parkinsonian_21/NNP
D004298_D009069 NONE dopamine_26/NN (r_compound) agonist_27/NN (r_pobj) with_23/IN (r_prep) challenge_22/NN (r_pobj) after_19/IN (r_prep) evaluated_1/VBD (l_dobj) severity_3/NN (l_prep) of_4/IN (l_pobj) disability_6/NN
D004298_D009069 NONE dopamine_14/NN (r_amod) dyskinesias_18/NNP (r_conj) reduce_11/VB (l_prep) without_19/IN (l_pobj) disability_23/NN
D004298_D004409 NONE dopamine_26/NN (r_compound) agonist_27/NN (r_pobj) with_23/IN (r_prep) challenge_22/NN (r_pobj) after_19/IN (r_prep) evaluated_1/VBD (l_dobj) severity_3/NN (l_prep) of_4/IN (l_pobj) disability_6/NN (l_conj) dyskinesias_8/NNP
D004298_D004409 NONE dopamine_14/NN (r_amod) dyskinesias_18/NNP
D004298_D010300 NONE dopamine_26/NN (r_compound) agonist_27/NN (r_pobj) with_23/IN (r_prep) challenge_22/NN (r_pobj) after_19/IN (r_prep) evaluated_1/VBD (l_prep) in_9/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) disease_18/NN
D004298_D010300 NONE dopamine_14/NN (r_amod) dyskinesias_18/NNP (r_conj) reduce_11/VB (l_prep) without_19/IN (l_pobj) disability_23/NN (l_amod) parkinsonian_21/NNP
D001058_D009069 NONE apomorphine_29/NNP (r_appos) agonist_27/NN (r_pobj) with_23/IN (r_prep) challenge_22/NN (r_pobj) after_19/IN (r_prep) evaluated_1/VBD (l_dobj) severity_3/NN (l_prep) of_4/IN (l_pobj) disability_6/NN
D001058_D009069 NONE apomorphine_17/NNP (r_npadvmod) induced_19/VBN (r_amod) dyskinesias_20/NNP (r_pobj) of_16/IN (r_prep) 0.05_14/CD (r_appos) improvement_10/NN (l_prep) without_21/IN (l_pobj) modification_22/NN (l_prep) of_23/IN (l_pobj) disability_26/NNP
D001058_D004409 CID apomorphine_29/NNP (r_appos) agonist_27/NN (r_pobj) with_23/IN (r_prep) challenge_22/NN (r_pobj) after_19/IN (r_prep) evaluated_1/VBD (l_dobj) severity_3/NN (l_prep) of_4/IN (l_pobj) disability_6/NN (l_conj) dyskinesias_8/NNP
D001058_D004409 CID apomorphine_17/NNP (r_npadvmod) induced_19/VBN (r_amod) dyskinesias_20/NNP
D001058_D010300 NONE apomorphine_29/NNP (r_appos) agonist_27/NN (r_pobj) with_23/IN (r_prep) challenge_22/NN (r_pobj) after_19/IN (r_prep) evaluated_1/VBD (l_prep) in_9/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) disease_18/NN
D001058_D010300 NONE apomorphine_17/NNP (r_npadvmod) induced_19/VBN (r_amod) dyskinesias_20/NNP (r_pobj) of_16/IN (r_prep) 0.05_14/CD (r_appos) improvement_10/NN (l_prep) without_21/IN (l_pobj) modification_22/NN (l_prep) of_23/IN (l_pobj) disability_26/NNP (l_amod) parkinsonian_24/NNP
D005473_D009069 NONE fluoxetine_37/NNP (r_pobj) of_36/IN (r_prep) administration_35/NN (r_pobj) after_33/IN (r_conj) before_31/RB (r_prep) challenge_22/NN (r_pobj) after_19/IN (r_prep) evaluated_1/VBD (l_dobj) severity_3/NN (l_prep) of_4/IN (l_pobj) disability_6/NN
D005473_D009069 NONE fluoxetine_1/NN (r_compound) treatment_2/NN (r_pobj) After_0/IN (r_prep) was_5/VBD (l_attr) improvement_10/NN (l_prep) without_21/IN (l_pobj) modification_22/NN (l_prep) of_23/IN (l_pobj) disability_26/NNP
D005473_D009069 NONE fluoxetine_9/NNP (r_pobj) with_8/IN (r_prep) transmission_7/NN (r_nsubj) reduce_11/VB (l_prep) without_19/IN (l_pobj) disability_23/NN
D005473_D010300 NONE fluoxetine_37/NNP (r_pobj) of_36/IN (r_prep) administration_35/NN (r_pobj) after_33/IN (r_conj) before_31/RB (r_prep) challenge_22/NN (r_pobj) after_19/IN (r_prep) evaluated_1/VBD (l_prep) in_9/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) disease_18/NN
D005473_D010300 NONE fluoxetine_1/NN (r_compound) treatment_2/NN (r_pobj) After_0/IN (r_prep) was_5/VBD (l_attr) improvement_10/NN (l_prep) without_21/IN (l_pobj) modification_22/NN (l_prep) of_23/IN (l_pobj) disability_26/NNP (l_amod) parkinsonian_24/NNP
D005473_D010300 NONE fluoxetine_9/NNP (r_pobj) with_8/IN (r_prep) transmission_7/NN (r_nsubj) reduce_11/VB (l_prep) without_19/IN (l_pobj) disability_23/NN (l_amod) parkinsonian_21/NNP
9889429
D009543_D006973 NONE nifedipine_8/NN (r_amod) tablets_12/NNS (l_prep) for_13/IN (l_pobj) hypertension_18/NN
D009543_D006973 NONE nifedipine_26/NN (r_appos) blocker_21/NN (r_pobj) with_17/IN (r_prep) treated_13/VBN (l_nsubjpass) patients_2/NNS (l_prep) with_3/IN (l_pobj) hypertension_4/NN
D009543_D006973 NONE nifedipine_7/NN (r_nsubj) is_8/VBZ (l_acomp) useful_9/JJ (l_prep) for_10/IN (l_pobj) patients_13/NNS (l_amod) hypertensive_11/JJ
D009543_D011565 NONE nifedipine_8/NN (r_amod) tablets_12/NNS (l_prep) for_13/IN (l_pobj) hypertension_18/NN (l_prep) in_19/IN (l_pobj) patients_20/NNS (l_prep) with_21/IN (l_pobj) psoriasis_22/NN
D009543_D011565 NONE nifedipine_26/NN (r_appos) blocker_21/NN (r_pobj) with_17/IN (r_prep) treated_13/VBN (l_nsubjpass) patients_2/NNS (l_amod) psoriatic_1/JJ
D009543_D011565 NONE nifedipine_7/NN (r_nsubj) is_8/VBZ (l_acomp) useful_9/JJ (l_prep) for_10/IN (l_pobj) patients_13/NNS (l_amod) psoriatic_12/JJ
D016572_D006973 CID A_15/NN (r_npadvmod) induced_17/VBN (r_amod) hypertension_18/NN
D016572_D006973 CID A_10/DT (r_det) therapy_11/NN (r_pobj) of_8/IN (r_prep) course_7/NN (r_pobj) during_5/IN (r_prep) patients_2/NNS (l_prep) with_3/IN (l_pobj) hypertension_4/NN
D016572_D006973 CID A_13/DT (r_det) therapy_14/NN (r_pobj) before_11/IN (r_prep) exhibited_6/VBN (l_dobj) state_10/NN (l_amod) hypertensive_9/JJ
D016572_D006973 CID A_21/NN (r_pobj) with_19/IN (r_prep) treatment_18/NN (r_pobj) under_14/IN (r_prep) patients_13/NNS (l_amod) hypertensive_11/JJ
D016572_D011565 NONE A_15/NN (r_npadvmod) induced_17/VBN (r_amod) hypertension_18/NN (l_prep) in_19/IN (l_pobj) patients_20/NNS (l_prep) with_21/IN (l_pobj) psoriasis_22/NN
D016572_D011565 NONE A_10/DT (r_det) therapy_11/NN (r_pobj) of_8/IN (r_prep) course_7/NN (r_pobj) during_5/IN (r_prep) patients_2/NNS (l_amod) psoriatic_1/JJ
D016572_D011565 NONE A_21/NN (r_pobj) with_19/IN (r_prep) treatment_18/NN (r_pobj) under_14/IN (r_prep) patients_13/NNS (l_amod) psoriatic_12/JJ
D002118_D011565 NONE calcium_19/NN (r_compound) channel_20/NN (r_compound) blocker_21/NN (r_pobj) with_17/IN (r_prep) treated_13/VBN (l_nsubjpass) patients_2/NNS (l_amod) psoriatic_1/JJ
D002118_D006973 NONE calcium_19/NN (r_compound) channel_20/NN (r_compound) blocker_21/NN (r_pobj) with_17/IN (r_prep) treated_13/VBN (l_nsubjpass) patients_2/NNS (l_prep) with_3/IN (l_pobj) hypertension_4/NN
D016572_D005885 CID A_8/NN (r_pobj) with_6/IN (r_prep) therapy_5/NN (r_pobj) during_3/IN (r_prep) events_2/NNS (r_nsubj) included_11/VBD (l_dobj) increase_13/NN (l_prep) in_19/IN (l_pobj) 9_20/CD (l_prep) of_21/IN (l_pobj) patients_24/NNS (l_prep) of_27/IN (l_pobj) hyperplasia_29/NN
D016572_D005885 CID A_21/NN (r_pobj) with_19/IN (r_prep) treatment_18/NN (r_pobj) under_14/IN (r_prep) patients_13/NNS (r_pobj) for_10/IN (r_prep) useful_9/JJ (r_acomp) is_8/VBZ (l_conj) monitored_29/VBN (l_prep) for_30/IN (l_pobj) hyperplasia_32/NN
D009543_D005885 CID nifedipine_10/NN (r_conj) A_8/NN (r_pobj) with_6/IN (r_prep) therapy_5/NN (r_pobj) during_3/IN (r_prep) events_2/NNS (r_nsubj) included_11/VBD (l_dobj) increase_13/NN (l_prep) in_19/IN (l_pobj) 9_20/CD (l_prep) of_21/IN (l_pobj) patients_24/NNS (l_prep) of_27/IN (l_pobj) hyperplasia_29/NN
D009543_D005885 CID nifedipine_7/NN (r_nsubj) is_8/VBZ (l_conj) monitored_29/VBN (l_prep) for_30/IN (l_pobj) hyperplasia_32/NN
D001806_D005885 NONE nitrogen_17/NN (r_compound) levels_18/NNS (r_pobj) in_14/IN (r_prep) increase_13/NN (l_prep) in_19/IN (l_pobj) 9_20/CD (l_prep) of_21/IN (l_pobj) patients_24/NNS (l_prep) of_27/IN (l_pobj) hyperplasia_29/NN
2217015
D008528_D009503 CID acid_1/NN (r_npadvmod) induced_3/VBN (r_amod) neutropenia_4/NN
D008528_D009503 CID acid_3/NN (r_npadvmod) induced_5/VBN (r_amod) failure_10/NN (l_conj) neutropenia_13/NN
D008528_D051437 CID acid_1/NN (r_npadvmod) induced_3/VBN (r_amod) neutropenia_4/NN (l_conj) failure_7/NN
D008528_D051437 CID acid_3/NN (r_npadvmod) induced_5/VBN (r_amod) failure_10/NN
D008528_D007037 NONE acid_1/NN (r_npadvmod) induced_3/VBN (r_amod) neutropenia_4/NN (l_prep) with_11/IN (l_pobj) hypothyroidism_12/NN
D008528_D007037 NONE acid_10/NN (r_dobj) use_8/VB (l_prep) in_11/IN (l_pobj) patients_13/NNS (l_amod) hypothyroid_12/JJ
D008528_D007037 NONE acid_10/NN (r_dobj) use_8/VB (l_advcl) corrected_19/VBN (l_nsubjpass) hypothyroidism_16/NN
8096565
D018170_D009203 CID sumatriptan_4/NNP (r_pobj) with_3/IN (r_prep) infarction_2/NN
D018170_D009203 CID sumatriptan_15/NNP (r_pobj) of_14/IN (r_prep) administration_13/NN (r_pobj) after_12/IN (r_prep) infarction_11/NN
D018170_D003027 NONE sumatriptan_15/NNP (r_pobj) of_14/IN (r_prep) administration_13/NN (r_pobj) after_12/IN (r_prep) infarction_11/NN (r_pobj) with_7/IN (r_prep) describe_1/VBP (l_prep) for_19/IN (l_pobj) headache_21/NN
22836123
D016559_D007674 NONE tacrolimus_8/NN (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) crisis_5/NN
D016559_D007674 NONE tacrolimus_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) SRC_9/NNP
D011239_D007674 NONE prednisolone_10/NN (r_conj) tacrolimus_8/NN (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) crisis_5/NN
D000305_D007674 NONE corticosteroid_4/NN (r_compound) use_5/NN (r_pobj) to_1/IN (r_prep) Moderate_0/JJ (r_nsubjpass) recognized_7/VBN (l_prep) as_8/IN (l_pobj) factor_12/NN (l_prep) for_13/IN (l_pobj) SRC_14/NNP
D000305_D007674 NONE corticosteroids_14/NNS (r_conj) tacrolimus_12/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) SRC_9/NNP
D016572_D057049 CID cyclosporine_11/NN (r_pobj) by_10/IN (r_agent) precipitated_9/VBN (r_acl) microangiopathy_8/NN
D016572_D012595 NONE cyclosporine_11/NN (r_pobj) by_10/IN (r_agent) precipitated_9/VBN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) SSc_15/NNP
D016559_D012595 CID tacrolimus_13/NN (r_compound) use_14/NN (l_prep) in_15/IN (l_pobj) patients_16/NNS (l_prep) with_17/IN (l_pobj) SSc_18/NNP
15614572
D014196_D009062 NONE trazodone_5/NN (r_pobj) with_4/IN (r_prep) pretreatment_3/NN (l_prep) on_6/IN (l_pobj) stereotypies_13/NNS
D014196_D002375 NONE trazodone_5/NN (r_pobj) with_4/IN (r_prep) pretreatment_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (l_prep) on_15/IN (l_pobj) catalepsy_16/NN
D014196_D002375 NONE trazodone_4/NN (r_nsubj) induces_5/VBZ (l_dobj) catalepsy_6/NN
D014196_D002375 NONE Trazodone_0/NN (r_nsubj) induce_9/VB (l_dobj) catalepsy_10/NN
D014196_D002375 NONE Trazodone_0/NN (r_nsubj) induce_9/VB (l_conj) antagonize_15/VB (l_dobj) apomorphine_16/NNP (l_appos) catalepsy_31/NNP
D014196_D002375 NONE trazodone_11/NNP (r_nmod) stereotypy_14/NN (r_appos) pretreatment_2/NN (l_conj) antagonized_17/VBD (l_dobj) catalepsy_19/NN
D014196_D002375 NONE Trazodone_0/NN (l_prep) at_1/IN (l_pobj) catalepsy_10/NN
D014196_D002375 NONE trazodone_3/NN (r_pobj) that_2/IN (r_dobj) suggest_1/VBP (l_conj) releases_20/VBZ (l_conj) potentiates_34/VBZ (l_conj) antagonizes_38/VBZ (l_dobj) catalepsy_40/NN
D003913_D009062 NONE dexamphetamine-_7/NNP (r_amod) on_6/IN (l_pobj) stereotypies_13/NNS
D003913_D002375 NONE dexamphetamine-_7/NNP (r_amod) on_6/IN (r_prep) pretreatment_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (l_prep) on_15/IN (l_pobj) catalepsy_16/NN
D003913_D002375 NONE dexamphetamine_13/NN (r_compound) stereotypy_14/NN (r_appos) pretreatment_2/NN (l_conj) antagonized_17/VBD (l_dobj) catalepsy_19/NN
D003913_D002375 NONE dexamphetamine_15/NNP (r_conj) apomorphine_13/NN (r_nmod) stereotypies_16/NNS (r_dobj) antagonized_12/VBD (r_conj) Trazodone_0/NN (l_prep) at_1/IN (l_pobj) catalepsy_10/NN
D003913_D002375 NONE dexamphetamine_35/NN (r_compound) stereotypy_36/NN (r_dobj) potentiates_34/VBZ (l_conj) antagonizes_38/VBZ (l_dobj) catalepsy_40/NN
D001058_D009062 NONE apomorphine_9/NNP (r_npadvmod) induced_11/VBN (r_amod) stereotypies_13/NNS
D001058_D009062 NONE apomorphine_21/NNP (r_conj) haloperidol_19/NNP (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) catalepsy_16/NN (r_pobj) on_15/IN (r_prep) effect_1/NN (l_prep) of_2/IN (l_pobj) pretreatment_3/NN (l_prep) on_6/IN (l_pobj) stereotypies_13/NNS
D001058_D002375 CID apomorphine_9/NNP (r_npadvmod) induced_11/VBN (r_amod) stereotypies_13/NNS (r_pobj) on_6/IN (r_prep) pretreatment_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (l_prep) on_15/IN (l_pobj) catalepsy_16/NN
D001058_D002375 CID apomorphine_21/NNP (r_conj) haloperidol_19/NNP (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) catalepsy_16/NN
D001058_D002375 CID apomorphine_16/NNP (r_dobj) antagonize_15/VB (r_conj) induce_9/VB (l_dobj) catalepsy_10/NN
D001058_D002375 CID apomorphine_16/NNP (l_appos) catalepsy_31/NNP
D001058_D002375 CID apomorphine_25/NNP (r_conj) stereotypy_23/NNP (r_appos) apomorphine_16/NNP (r_dobj) antagonize_15/VB (r_conj) induce_9/VB (l_dobj) catalepsy_10/NN
D001058_D002375 CID apomorphine_25/NNP (r_conj) stereotypy_23/NNP (r_appos) apomorphine_16/NNP (l_appos) catalepsy_31/NNP
D001058_D002375 CID apomorphine_13/NN (r_nmod) stereotypies_16/NNS (r_dobj) antagonized_12/VBD (r_conj) Trazodone_0/NN (l_prep) at_1/IN (l_pobj) catalepsy_10/NN
D006220_D009062 NONE haloperidol_19/NNP (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) catalepsy_16/NN (r_pobj) on_15/IN (r_prep) effect_1/NN (l_prep) of_2/IN (l_pobj) pretreatment_3/NN (l_prep) on_6/IN (l_pobj) stereotypies_13/NNS
D006220_D002375 CID haloperidol_19/NNP (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) catalepsy_16/NN
D006220_D002375 CID haloperidol_18/NN (r_compound) catalepsy_19/NN
D006220_D002375 CID haloperidol_39/NNP (r_compound) catalepsy_40/NN
D004874_D009062 NONE ergometrine_30/NNP (r_npadvmod) induced_32/VBN (r_amod) shake_35/NN (r_pobj) on_29/IN (r_prep) studied_47/VBN (l_nsubjpass) effect_1/NN (l_prep) of_2/IN (l_pobj) pretreatment_3/NN (l_prep) on_6/IN (l_pobj) stereotypies_13/NNS
D004874_D002375 NONE ergometrine_30/NNP (r_npadvmod) induced_32/VBN (r_amod) shake_35/NN (r_pobj) on_29/IN (r_prep) studied_47/VBN (l_nsubjpass) effect_1/NN (l_prep) on_15/IN (l_pobj) catalepsy_16/NN
D004874_D002375 NONE ergometrine_21/NN (r_npadvmod) induced_23/VBN (r_amod) behavior_25/NN (r_conj) catalepsy_19/NN
D005473_D009062 NONE fluoxetine_41/NN (r_npadvmod) induced_43/VBN (r_amod) erections_45/NNS (r_conj) behavior_39/NN (r_pobj) on_29/IN (r_prep) studied_47/VBN (l_nsubjpass) effect_1/NN (l_prep) of_2/IN (l_pobj) pretreatment_3/NN (l_prep) on_6/IN (l_pobj) stereotypies_13/NNS
D005473_D002375 NONE fluoxetine_41/NN (r_npadvmod) induced_43/VBN (r_amod) erections_45/NNS (r_conj) behavior_39/NN (r_pobj) on_29/IN (r_prep) studied_47/VBN (l_nsubjpass) effect_1/NN (l_prep) on_15/IN (l_pobj) catalepsy_16/NN
D005473_D002375 NONE fluoxetine_27/NN (r_npadvmod) induced_29/VBN (r_amod) erections_31/NNS (r_conj) behavior_25/NN (r_conj) catalepsy_19/NN
D012701_D002375 NONE 5-HT_16/CD (r_nummod) receptors_18/NNS (r_dobj) blocking_14/VBG (r_pcomp) by_13/IN (r_prep) releases_20/VBZ (l_conj) potentiates_34/VBZ (l_conj) antagonizes_38/VBZ (l_dobj) catalepsy_40/NN
D012701_D002375 NONE 5-HT_30/CD (r_pobj) by_29/IN (r_agent) caused_28/VBN (r_acl) inhibition_27/NN (r_pobj) from_25/IN (r_prep) neurons_24/NNS (r_dobj) releases_20/VBZ (l_conj) potentiates_34/VBZ (l_conj) antagonizes_38/VBZ (l_dobj) catalepsy_40/NN
7727612
D008140_D009207 CID lorazepam_3/NN (r_compound) therapy_4/NN (r_pobj) with_2/IN (r_prep) associated_1/VBN (r_acl) Myoclonus_0/NNP
D008140_D009207 CID lorazepam_19/NNP (r_pobj) of_18/IN (r_prep) administration_17/NN (r_pobj) following_14/VBG (r_prep) experienced_12/VBD (l_dobj) myoclonus_13/NN
3832950
D002998_D004827 NONE Clonazepam_0/XX (l_prep) for_2/IN (l_pobj) epilepsy_3/NN
D002998_D004827 NONE clonazepam_23/NN (r_pobj) with_22/IN (r_prep) treated_21/VBN (l_nsubjpass) patients_1/NNS (l_prep) with_12/IN (l_pobj) types_14/NNS (l_prep) of_15/IN (l_pobj) epilepsy_16/NN
D002998_D013036 NONE clonazepam_23/NN (r_pobj) with_22/IN (r_prep) treated_21/VBN (l_nsubjpass) patients_1/NNS (l_prep) with_12/IN (l_pobj) types_14/NNS (l_prep) than_17/IN (l_pobj) spasms_19/NNS
6299641
D007545_D013610 CID isoproterenol_1/NN (r_npadvmod) induced_3/VBN (r_amod) tachycardia_4/NN
D007545_D013610 CID isoproterenol_3/NN (r_compound) tachycardia_4/NN
D007545_D013610 CID isoproterenol_29/NNP (r_nsubj) activates_30/VBZ (r_advcl) are_2/VBP (l_acomp) consistent_3/JJ (l_prep) with_4/IN (l_pobj) hypothesis_6/NN (l_acl) results_12/NNS (l_nsubj) tachycardia_11/NN
D001285_D013610 NONE atropine_10/NN (r_pobj) after_9/IN (r_conj) before_7/IN (r_prep) determined_6/VBN (l_nsubjpass) effects_1/NNS (l_prep) on_2/IN (l_pobj) tachycardia_4/NN
3323599
D011692_D009401 NONE aminonucleoside_3/JJ (r_compound) nephrosis_4/NN
D011692_D005923 CID aminonucleoside_22/NNP (r_pobj) of_19/IN (r_prep) administration_18/NN (r_pobj) by_15/IN (r_agent) developed_12/VBN (l_nsubjpass) model_2/NN (l_prep) of_3/IN (l_pobj) sclerosis_7/NN
D011692_D005923 CID aminonucleoside_22/NNP (r_pobj) of_19/IN (r_prep) administration_18/NN (r_pobj) by_15/IN (r_agent) developed_12/VBN (l_nsubjpass) model_2/NN (l_prep) of_3/IN (l_pobj) sclerosis_7/NN (l_appos) FSGS_9/NNP
D011692_D005923 CID AMNS_24/NNP (r_appos) aminonucleoside_22/NNP (r_pobj) of_19/IN (r_prep) administration_18/NN (r_pobj) by_15/IN (r_agent) developed_12/VBN (l_nsubjpass) model_2/NN (l_prep) of_3/IN (l_pobj) sclerosis_7/NN
D011692_D005923 CID AMNS_24/NNP (r_appos) aminonucleoside_22/NNP (r_pobj) of_19/IN (r_prep) administration_18/NN (r_pobj) by_15/IN (r_agent) developed_12/VBN (l_nsubjpass) model_2/NN (l_prep) of_3/IN (l_pobj) sclerosis_7/NN (l_appos) FSGS_9/NNP
D011692_D005923 CID AMNS_14/NNP (r_pobj) of_13/IN (r_prep) toxicity_12/NN (r_dobj) enhances_10/VBZ (l_conj) produces_20/VBZ (l_dobj) FSGS_22/NN
D011479_D005923 NONE sulfate_28/NN (r_pobj) of_19/IN (r_prep) administration_18/NN (r_pobj) by_15/IN (r_agent) developed_12/VBN (l_nsubjpass) model_2/NN (l_prep) of_3/IN (l_pobj) sclerosis_7/NN
D011479_D005923 NONE sulfate_28/NN (r_pobj) of_19/IN (r_prep) administration_18/NN (r_pobj) by_15/IN (r_agent) developed_12/VBN (l_nsubjpass) model_2/NN (l_prep) of_3/IN (l_pobj) sclerosis_7/NN (l_appos) FSGS_9/NNP
D011479_D005923 NONE PS_30/NNP (r_appos) sulfate_28/NN (r_pobj) of_19/IN (r_prep) administration_18/NN (r_pobj) by_15/IN (r_agent) developed_12/VBN (l_nsubjpass) model_2/NN (l_prep) of_3/IN (l_pobj) sclerosis_7/NN
D011479_D005923 NONE PS_30/NNP (r_appos) sulfate_28/NN (r_pobj) of_19/IN (r_prep) administration_18/NN (r_pobj) by_15/IN (r_agent) developed_12/VBN (l_nsubjpass) model_2/NN (l_prep) of_3/IN (l_pobj) sclerosis_7/NN (l_appos) FSGS_9/NNP
D011479_D005923 NONE PS_9/NNP (r_pobj) of_8/IN (r_prep) administration_7/NN (r_nsubj) enhances_10/VBZ (l_conj) produces_20/VBZ (l_dobj) FSGS_22/NN
D011479_D064420 NONE PS_9/NNP (r_pobj) of_8/IN (r_prep) administration_7/NN (r_nsubj) enhances_10/VBZ (l_dobj) toxicity_12/NN
D011479_D007676 NONE PS_9/NNP (r_pobj) of_8/IN (r_prep) administration_7/NN (r_nsubj) enhances_10/VBZ (l_conj) produces_20/VBZ (l_prep) in_23/IN (l_pobj) rats_24/NNS (l_acl) resulting_25/VBG (l_prep) in_26/IN (l_pobj) disease_32/NN
D011692_D064420 NONE AMNS_14/NNP (r_pobj) of_13/IN (r_prep) toxicity_12/NN
D011692_D007676 CID AMNS_14/NNP (r_pobj) of_13/IN (r_prep) toxicity_12/NN (r_dobj) enhances_10/VBZ (l_conj) produces_20/VBZ (l_prep) in_23/IN (l_pobj) rats_24/NNS (l_acl) resulting_25/VBG (l_prep) in_26/IN (l_pobj) disease_32/NN
17297207
D011803_D001145 NONE Quinine_0/NN (r_npadvmod) induced_2/VBN (r_amod) arrhythmia_3/NN
D011803_D001145 NONE quinine_25/NN (r_compound) infusion_26/NN (r_nsubjpass) reported_28/VBN (r_ccomp) getting_24/VBG (r_advcl) presented_15/VBD (l_prep) with_16/IN (l_pobj) arrhythmia_17/NN
D011803_D001145 NONE Quinine_0/NNP (r_nsubj) is_5/VBZ (l_attr) alkaloid_8/NN (l_relcl) has_10/VBZ (l_dobj) property_14/NN (l_amod) arrhythmic_13/JJ
D011803_D001145 NONE Quinine_0/NNP (r_nsubj) is_5/VBZ (l_advcl) cause_24/VB (l_nsubj) it_17/PRP (l_amod) arrhythmic_21/JJ
D011803_D001145 NONE Quinine_0/NNP (r_nsubj) is_5/VBZ (l_advcl) cause_24/VB (l_dobj) arrhythmias_26/NNS
D011803_D001145 NONE Quinine_0/NNP (r_nsubj) is_5/VBZ (l_advcl) cause_24/VB (l_dobj) arrhythmias_26/NNS (l_prep) including_28/VBG (l_pobj) arrhythmia_30/NN
D011803_D001145 NONE quinine_3/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubjpass) done_6/VBN (l_prep) because_12/IN (l_pobj) effect_18/NN (l_amod) arrhythmic_17/JJ
D011803_D016778 NONE Quinine_0/NN (r_npadvmod) induced_2/VBN (r_amod) arrhythmia_3/NN (l_prep) in_4/IN (l_pobj) patient_6/NN (l_prep) with_7/IN (l_pobj) malaria_9/NN
D011803_D016778 NONE quinine_25/NN (r_compound) infusion_26/NN (r_nsubjpass) reported_28/VBN (r_ccomp) getting_24/VBG (r_advcl) presented_15/VBD (r_relcl) jaundice_13/NN (r_pobj) with_12/IN (r_prep) patient_11/NN (l_compound) malaria_10/NN
D011803_D016778 NONE quinine_11/NN (r_compound) infusion_12/NN (r_dobj) got_10/VBD (r_conj) diagnosed_3/VBN (l_prep) as_4/IN (l_pobj) malaria_6/NN
D011803_D007565 NONE quinine_25/NN (r_compound) infusion_26/NN (r_nsubjpass) reported_28/VBN (r_ccomp) getting_24/VBG (r_advcl) presented_15/VBD (r_relcl) jaundice_13/NN
D011803_D007565 NONE quinine_11/NN (r_compound) infusion_12/NN (r_dobj) got_10/VBD (r_conj) diagnosed_3/VBN (l_prep) as_4/IN (l_pobj) malaria_6/NN (l_prep) with_7/IN (l_pobj) jaundice_8/NN
D011803_D018879 CID quinine_25/NN (r_compound) infusion_26/NN (r_nsubjpass) reported_28/VBN (r_ccomp) getting_24/VBG (r_advcl) presented_15/VBD (l_prep) with_16/IN (l_pobj) arrhythmia_17/NN (l_appos) contraction_21/NN
D011803_D018879 CID Quinine_0/NNP (r_nsubj) is_5/VBZ (l_advcl) cause_24/VB (l_dobj) arrhythmias_26/NNS (l_prep) including_28/VBG (l_pobj) arrhythmia_30/NN (l_prep) as_32/IN (l_pobj) PVC_34/NN
D005947_D016778 NONE dextrose_14/NN (r_pobj) in_13/IN (r_prep) infusion_12/NN (r_dobj) got_10/VBD (r_conj) diagnosed_3/VBN (l_prep) as_4/IN (l_pobj) malaria_6/NN
D005947_D007565 NONE dextrose_14/NN (r_pobj) in_13/IN (r_prep) infusion_12/NN (r_dobj) got_10/VBD (r_conj) diagnosed_3/VBN (l_prep) as_4/IN (l_pobj) malaria_6/NN (l_prep) with_7/IN (l_pobj) jaundice_8/NN
D011803_-1 NONE quinine_4/NN (r_compound) infusion_5/NN (r_pobj) of_3/IN (r_prep) hours_2/NNS (r_pobj) After_0/IN (r_prep) felt_8/VBD (l_dobj) palpitation_9/NN
D011802_D001145 NONE quinidine_3/NN (r_pobj) like_2/IN (r_prep) Quinine_0/NNP (r_nsubj) is_5/VBZ (l_attr) alkaloid_8/NN (l_relcl) has_10/VBZ (l_dobj) property_14/NN (l_amod) arrhythmic_13/JJ
D011802_D001145 NONE quinidine_3/NN (r_pobj) like_2/IN (r_prep) Quinine_0/NNP (r_nsubj) is_5/VBZ (l_advcl) cause_24/VB (l_nsubj) it_17/PRP (l_amod) arrhythmic_21/JJ
D011802_D001145 NONE quinidine_3/NN (r_pobj) like_2/IN (r_prep) Quinine_0/NNP (r_nsubj) is_5/VBZ (l_advcl) cause_24/VB (l_dobj) arrhythmias_26/NNS
D011802_D001145 NONE quinidine_3/NN (r_pobj) like_2/IN (r_prep) Quinine_0/NNP (r_nsubj) is_5/VBZ (l_advcl) cause_24/VB (l_dobj) arrhythmias_26/NNS (l_prep) including_28/VBG (l_pobj) arrhythmia_30/NN
D011802_D018879 NONE quinidine_3/NN (r_pobj) like_2/IN (r_prep) Quinine_0/NNP (r_nsubj) is_5/VBZ (l_advcl) cause_24/VB (l_dobj) arrhythmias_26/NNS (l_prep) including_28/VBG (l_pobj) arrhythmia_30/NN (l_prep) as_32/IN (l_pobj) PVC_34/NN
D011803_D006331 NONE quinine_3/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubjpass) done_6/VBN (l_prep) in_21/IN (l_pobj) patients_23/NNS (l_relcl) have_25/VBP (l_dobj) diseases_27/NNS
D011803_D014883 NONE quinine_3/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubjpass) done_6/VBN (l_prep) in_21/IN (l_pobj) patients_23/NNS (l_relcl) have_25/VBP (l_dobj) diseases_27/NNS (l_conj) patients_29/NNS (l_prep) with_30/IN (l_pobj) disorder_32/NN
D011803_D007008 NONE quinine_3/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubjpass) done_6/VBN (l_prep) in_21/IN (l_pobj) patients_23/NNS (l_relcl) have_25/VBP (l_dobj) diseases_27/NNS (l_conj) patients_29/NNS (l_prep) with_30/IN (l_pobj) disorder_32/NN (l_appos) hypokalemia_34/NN
D011803_D014839 NONE quinine_3/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubjpass) done_6/VBN (l_prep) in_21/IN (l_pobj) patients_23/NNS (l_relcl) have_25/VBP (l_dobj) diseases_27/NNS (l_conj) patients_29/NNS (l_prep) with_30/IN (l_pobj) disorder_32/NN (l_appos) hypokalemia_34/NN (l_relcl) occurs_38/VBZ (l_prep) due_39/IN (l_pobj) vomiting_41/NN
D011803_D003967 NONE quinine_3/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubjpass) done_6/VBN (l_prep) in_21/IN (l_pobj) patients_23/NNS (l_relcl) have_25/VBP (l_dobj) diseases_27/NNS (l_conj) patients_29/NNS (l_prep) with_30/IN (l_pobj) disorder_32/NN (l_appos) hypokalemia_34/NN (l_relcl) occurs_38/VBZ (l_prep) due_39/IN (l_pobj) vomiting_41/NN (l_conj) diarrhea_44/NN
D011803_D008288 NONE quinine_3/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubjpass) done_6/VBN (l_prep) in_21/IN (l_pobj) patients_23/NNS (l_relcl) have_25/VBP (l_dobj) diseases_27/NNS (l_conj) patients_29/NNS (l_prep) with_30/IN (l_pobj) disorder_32/NN (l_appos) hypokalemia_34/NN (l_relcl) occurs_38/VBZ (l_prep) due_39/IN (l_pobj) vomiting_41/NN (l_prep) in_45/IN (l_pobj) cases_47/NNS (l_compound) malaria_46/NN
18801087
D000638_D055370 CID Amiodarone_0/NN (r_npadvmod) related_2/VBN (r_amod) mass_4/NN
D000638_D055370 CID amiodarone_36/NN (r_pobj) with_35/IN (r_prep) treatment_34/NN (r_pobj) after_33/IN (r_prep) developed_15/VBD (l_dobj) mass_18/NN
D000638_D055370 CID amiodarone_47/NN (r_npadvmod) related_49/VBN (r_amod) lesion_50/NN (r_attr) was_45/VBD (r_ccomp) indicating_42/VBG (r_advcl) infiltrates_25/VBZ (r_conj) suspected_5/VBN (l_nsubjpass) mass_2/NN
D000638_D055370 CID amiodarone_11/NN (r_npadvmod) related_13/VBN (r_amod) lesion_15/NN
D000638_D055370 CID amiodarone_36/NN (r_compound) treatment_37/NN (r_pobj) of_35/IN (r_prep) complication_34/NN (r_attr) be_31/VB (r_ccomp) suggests_26/VBZ (r_conj) highlights_3/VBZ (l_dobj) possibility_5/NN (l_acl) be_20/VB (l_nsubj) diagnosis_8/NN (l_prep) between_9/IN (l_pobj) lesion_15/NN
D000638_D015433 CID Amiodarone_0/NN (r_npadvmod) related_2/VBN (r_amod) mass_4/NN (l_conj) glomerulonephritis_8/NN
D000638_D015433 CID amiodarone_11/NN (r_npadvmod) related_13/VBN (r_amod) lesion_15/NN (r_pobj) between_9/IN (r_prep) diagnosis_8/NN (r_nsubj) be_20/VB (r_acl) possibility_5/NN (r_dobj) highlights_3/VBZ (l_conj) suggests_26/VBZ (l_ccomp) be_31/VB (l_nsubj) glomerulonephritis_29/NN
D000638_D015433 CID amiodarone_36/NN (r_compound) treatment_37/NN (r_pobj) of_35/IN (r_prep) complication_34/NN (r_attr) be_31/VB (l_nsubj) glomerulonephritis_29/NN
D000638_D006349 NONE Amiodarone_0/NN (r_npadvmod) related_2/VBN (r_amod) mass_4/NN (l_prep) in_9/IN (l_pobj) patient_11/NN (l_prep) with_12/IN (l_pobj) disease_15/NN
D000638_D006349 NONE amiodarone_36/NN (r_pobj) with_35/IN (r_prep) treatment_34/NN (r_pobj) after_33/IN (r_prep) developed_15/VBD (r_relcl) patient_13/NN (r_pobj) in_11/IN (r_prep) is_2/VBZ (l_attr) case_5/NN (l_prep) of_6/IN (l_pobj) disease_9/NN
D000638_D001145 NONE Amiodarone_0/NNP (r_nsubj) is_1/VBZ (l_attr) drug_6/NN (l_amod) arrhythmic_5/JJ
D000638_D013610 NONE Amiodarone_0/NNP (r_nsubj) is_1/VBZ (l_attr) drug_6/NN (l_prep) for_7/IN (l_pobj) tachycardia_11/NN
D000638_D011507 NONE amiodarone_36/NN (r_pobj) with_35/IN (r_prep) treatment_34/NN (r_pobj) after_33/IN (r_prep) developed_15/VBD (l_dobj) mass_18/NN (l_appos) cm_21/NNS (l_conj) proteinuria_26/NN
D000638_D008175 NONE amiodarone_47/NN (r_npadvmod) related_49/VBN (r_amod) lesion_50/NN (r_attr) was_45/VBD (r_ccomp) indicating_42/VBG (r_advcl) infiltrates_25/VBZ (r_conj) suspected_5/VBN (l_xcomp) be_7/VB (l_attr) cancer_9/NN
D000638_D009369 NONE amiodarone_11/NN (r_npadvmod) related_13/VBN (r_amod) lesion_15/NN (l_conj) neoplasm_18/NN
D000638_D009369 NONE amiodarone_36/NN (r_compound) treatment_37/NN (r_pobj) of_35/IN (r_prep) complication_34/NN (r_attr) be_31/VB (r_ccomp) suggests_26/VBZ (r_conj) highlights_3/VBZ (l_dobj) possibility_5/NN (l_acl) be_20/VB (l_nsubj) diagnosis_8/NN (l_prep) between_9/IN (l_pobj) lesion_15/NN (l_conj) neoplasm_18/NN
3538855
D000617_D007674 CID aminoglycoside_5/RB (r_compound) nephrotoxicity_6/NN
D000617_D007674 CID aminoglycoside_3/RB (r_npadvmod) induced_5/VBN (r_amod) nephrotoxicity_6/NN
D000617_D007674 CID aminoglycosides_7/NNS (r_nsubj) cause_8/VBP (r_nmod) damage_11/NN (r_dobj) indicate_6/VBP (l_conj) cause_22/VB (l_dobj) dysfunction_26/NN
D000617_D007674 CID aminoglycoside_13/NN (r_compound) levels_14/NNS (r_conj) duration_8/NN (r_nsubj) increase_34/VBP (l_dobj) risk_36/NN (l_prep) for_37/IN (l_pobj) nephrotoxicity_38/NN
D000617_D007674 CID aminoglycoside_13/NN (r_npadvmod) induced_15/VBN (r_amod) nephrotoxicity_16/NN
D000617_D058186 NONE aminoglycosides_3/NNS (r_pobj) of_2/IN (r_prep) trials_1/NNS (r_nsubj) indicate_8/VBP (l_ccomp) ranges_20/NNS (l_nsubj) risk_12/NN (l_prep) for_13/IN (l_pcomp) developing_14/VBG (l_dobj) failure_17/NN
D000617_D008107 NONE aminoglycoside_13/NN (r_compound) levels_14/NNS (l_conj) disease_17/NN
D003404_D008107 NONE creatinine_25/NN (r_compound) clearance_26/NN (r_conj) age_20/NN (r_conj) disease_17/NN
D003404_D007674 NONE creatinine_25/NN (r_compound) clearance_26/NN (r_conj) age_20/NN (r_conj) disease_17/NN (r_conj) levels_14/NNS (r_conj) duration_8/NN (r_nsubj) increase_34/VBP (l_dobj) risk_36/NN (l_prep) for_37/IN (l_pobj) nephrotoxicity_38/NN
6695685
D014700_D001145 CID verapamil_5/NN (r_compound) therapy_6/NN (r_pobj) during_3/IN (r_prep) rhythms_2/NNS
D014700_D001145 CID verapamil_20/NN (r_dobj) receiving_18/VBG (r_acl) patients_17/NNS (r_pobj) in_15/IN (r_prep) rhythms_14/NNS
D014700_D002637 NONE verapamil_8/NN (r_nsubj) increased_10/VBD (l_prep) In_0/IN (l_pobj) patients_1/NNS (l_prep) with_2/IN (l_pobj) syndromes_6/NNS (l_compound) pain_5/NN
3084231
D014635_D003704 CID acid_2/NN (r_npadvmod) induced_4/VBN (r_amod) dementia_5/NN
D014635_D003704 CID acid_2/NN (r_npadvmod) induced_4/VBN (r_amod) dementia_5/NN
D014635_D004827 NONE acid_2/NN (r_npadvmod) induced_4/VBN (r_amod) dementia_5/NN (r_nsubjpass) documented_7/VBN (l_prep) in_8/IN (l_pobj) man_13/NN (l_prep) with_14/IN (l_pobj) epilepsy_15/NN
D014635_D022124 CID acid_25/NN (r_pobj) of_23/IN (r_prep) effect_22/NN (r_appos) system_17/NN (l_conj) effect_30/NN (l_conj) effect_41/NN (l_acl) mediated_42/VBN (l_prep) through_43/IN (l_pobj) hyperammonemia_48/NN
D014635_D022124 CID acid_45/NN (r_npadvmod) induced_47/VBN (r_amod) hyperammonemia_48/NN
24665854
D014635_D022124 CID Valproate_0/RB (r_advmod) induced_2/VBN (r_amod) encephalopathy_4/NN (l_compound) hyperammonemic_3/JJ
D014635_D022124 CID Valproate_0/RB (r_advmod) induced_2/VBN (r_amod) encephalopathy_4/NN (l_compound) hyperammonemic_3/JJ
D014635_D022124 CID valproate_12/JJ (r_amod) treatment_13/NN (r_pobj) of_11/IN (r_prep) effect_10/NN (r_attr) is_5/VBZ (l_nsubj) encephalopathy_4/NN (l_compound) hyperammonemic_3/JJ
D014635_D022124 CID valproate_21/NN (r_pobj) with_20/IN (r_prep) therapy_19/NN (r_pobj) on_14/IN (r_prep) was_13/VBD (l_conj) revealed_26/VBD (l_prep) with_29/IN (l_pobj) hyperammonemia_30/NNP
D014635_D001927 NONE Valproate_0/RB (r_advmod) induced_2/VBN (r_amod) encephalopathy_4/NN
D014635_D001927 NONE Valproate_0/RB (r_advmod) induced_2/VBN (r_amod) encephalopathy_4/NN
D014635_D001927 NONE valproate_12/JJ (r_amod) treatment_13/NN (r_pobj) of_11/IN (r_prep) effect_10/NN (r_attr) is_5/VBZ (l_nsubj) encephalopathy_4/NN
D014635_D004827 NONE valproate_21/NN (r_pobj) with_20/IN (r_prep) therapy_19/NN (r_pobj) on_14/IN (r_prep) was_13/VBD (l_acomp) due_22/IN (l_pobj) epilepsy_24/NN
D014635_D003244 CID valproate_21/NN (r_pobj) with_20/IN (r_prep) therapy_19/NN (r_pobj) on_14/IN (r_prep) was_13/VBD (l_conj) revealed_26/VBD (l_dobj) consciousness_28/NN
6310832
D016572_D007239 CID cyclosporine_12/NN (r_pobj) on_11/IN (r_prep) infections_1/NNS
D016572_D007239 CID cyclosporine_27/NN (r_compound) patients_28/NNS (r_pobj) than_24/IN (r_prep) infections_17/NNS (r_conj) infections_7/NNS
D016572_D007239 CID cyclosporine_27/NN (r_compound) patients_28/NNS (r_pobj) than_24/IN (r_prep) infections_17/NNS
D016572_D007239 CID cyclosporine_8/JJ (r_nmod) patients_10/NNS (r_pobj) than_7/IN (r_prep) infections_6/NNS
D016572_D007239 CID cyclosporine_8/JJ (r_nmod) patients_10/NNS (l_conj) infections_13/NNS
D016572_D007239 CID cyclosporine_10/NN (r_pobj) on_9/IN (r_prep) deaths_4/NNS (r_attr) were_1/VBD (l_conj) played_16/VBD (l_nsubj) infection_15/NN
D016572_D007239 CID cyclosporine_6/NN (r_npadvmod) treated_8/VBN (r_amod) patients_10/NNS (r_pobj) in_5/IN (r_prep) common_4/JJ (r_acomp) were_2/VBD (l_nsubj) infections_1/NNS
D001379_D007239 CID Aza_2/NNP (r_compound) patients_3/NNS (r_nsubj) had_4/VBD (l_dobj) infections_7/NNS
D001379_D007239 CID Aza_2/NNP (r_compound) patients_3/NNS (r_nsubj) had_4/VBD (l_dobj) infections_7/NNS (l_conj) infections_17/NNS
D001379_D007239 CID Aza_16/NNP (r_nmod) patients_18/NNS (r_pobj) than_14/IN (r_prep) infections_13/NNS (r_conj) patients_10/NNS (r_pobj) than_7/IN (r_prep) infections_6/NNS
D001379_D007239 CID Aza_16/NNP (r_nmod) patients_18/NNS (r_pobj) than_14/IN (r_prep) infections_13/NNS
D001379_D007239 CID Aza_12/NNP (r_conj) cyclosporine_10/NN (r_pobj) on_9/IN (r_prep) deaths_4/NNS (r_attr) were_1/VBD (l_conj) played_16/VBD (l_nsubj) infection_15/NN
D001379_D007239 CID Aza_13/NNP (r_npadvmod) treated_15/VBN (r_amod) patients_16/NNS (r_pobj) in_12/IN (r_prep) than_11/IN (r_prep) were_2/VBD (l_nsubj) infections_1/NNS
D016572_D016470 NONE cyclosporine_3/NN (r_pobj) on_2/IN (r_prep) patients_1/NNS (r_nsubj) had_4/VBD (l_dobj) bacteremias_7/NNS
D001379_D013203 NONE Aza_0/NNP (r_compound) patients_1/NNS (r_nsubj) had_2/VBD (l_dobj) infections_6/NNS
D001379_D009181 NONE Aza_0/NNP (r_compound) patients_1/NNS (r_nsubj) had_2/VBD (l_conj) occurred_23/VBD (l_nsubj) infections_22/NNS
D016572_D003586 NONE cyclosporine_2/NN (r_compound) patients_3/NNS (r_pobj) Of_0/IN (r_prep) had_7/VBD (l_dobj) symptoms_8/NNS (l_acl) related_9/VBN (l_prep) to_10/IN (l_pobj) infection_12/NN
D016572_D020031 NONE cyclosporine_14/NN (r_compound) patients_15/NNS (r_pobj) of_12/IN (r_prep) %_11/NN (r_pobj) in_9/IN (r_prep) found_8/VBN (l_nsubjpass) evidence_1/NN (l_prep) for_2/IN (l_pobj) infection_6/NN
753803
D014810_D009135 NONE E_6/NNS (r_pobj) of_4/IN (r_prep) lack_3/NN (r_pobj) due_1/IN (r_amod) Myopathy_0/NNP
D014810_D009135 NONE E_6/NNS (l_conj) myopathy_8/NN
D014810_D009135 NONE E._46/NN (r_pobj) in_44/IN (r_prep) deficient_43/JJ (r_amod) diet_42/NN (r_pobj) by_40/IN (r_agent) rendered_38/VBN (r_acl) rats_37/NNS (r_pobj) in_36/IN (r_prep) doses_35/NNS (r_pobj) at_33/IN (r_prep) effects_23/NNS (r_dobj) investigate_20/VB (r_xcomp) encouraged_16/VBN (l_nsubj) results_2/NNS (l_acl) obtained_3/VBN (l_prep) in_4/IN (l_pobj) departments_7/NNS (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_compound) myopathic_9/JJ
D014810_D009135 NONE E._46/NN (r_pobj) in_44/IN (r_prep) deficient_43/JJ (r_amod) diet_42/NN (r_pobj) by_40/IN (r_agent) rendered_38/VBN (l_oprd) myopathic_39/NNP
D014810_D009135 NONE E_91/NN (r_pobj) of_89/IN (r_prep) lack_88/NN (r_attr) is_84/VBZ (r_conj) occurs_58/VBZ (r_advcl) have_19/VBP (r_conj) conclude_2/VBP (l_prep) by_3/IN (l_pcomp) affirming_4/VBG (l_dobj) efficacy_7/NN (l_prep) of_8/IN (l_pobj) steroids_11/NNS (l_prep) in_12/IN (l_pobj) disease_15/NN
D014810_D009136 CID E._15/NN (r_pobj) in_13/IN (r_prep) lacking_12/VBG (r_acl) diet_11/NN (r_dobj) giving_8/VBG (r_pcomp) by_7/IN (r_prep) induced_2/VBD (l_dobj) myodystrophy_3/NN
D013256_D009135 NONE steroids_14/NNS (r_dobj) anabolizing_13/VBG (r_xcomp) using_12/VBG (r_pcomp) by_11/IN (r_prep) obtained_3/VBN (l_prep) in_4/IN (l_pobj) departments_7/NNS (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_compound) myopathic_9/JJ
D013256_D009135 NONE steroids_14/NNS (r_dobj) anabolizing_13/VBG (r_xcomp) using_12/VBG (r_pcomp) by_11/IN (r_prep) obtained_3/VBN (r_acl) results_2/NNS (r_nsubj) encouraged_16/VBN (l_xcomp) investigate_20/VB (l_dobj) effects_23/NNS (l_prep) at_33/IN (l_pobj) doses_35/NNS (l_prep) in_36/IN (l_pobj) rats_37/NNS (l_acl) rendered_38/VBN (l_oprd) myopathic_39/NNP
D013256_D009135 NONE steroids_11/NNS (l_prep) in_12/IN (l_pobj) disease_15/NN
D008696_D009135 NONE Dianabol_29/NNP (r_appos) agent_27/NN (r_pobj) of_24/IN (r_prep) effects_23/NNS (r_dobj) investigate_20/VB (r_xcomp) encouraged_16/VBN (l_nsubj) results_2/NNS (l_acl) obtained_3/VBN (l_prep) in_4/IN (l_pobj) departments_7/NNS (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_compound) myopathic_9/JJ
D008696_D009135 NONE Dianabol_29/NNP (r_appos) agent_27/NN (r_pobj) of_24/IN (r_prep) effects_23/NNS (l_prep) at_33/IN (l_pobj) doses_35/NNS (l_prep) in_36/IN (l_pobj) rats_37/NNS (l_acl) rendered_38/VBN (l_oprd) myopathic_39/NNP
-1_D009135 NONE CIBA_31/NNP (r_appos) Dianabol_29/NNP (r_appos) agent_27/NN (r_pobj) of_24/IN (r_prep) effects_23/NNS (r_dobj) investigate_20/VB (r_xcomp) encouraged_16/VBN (l_nsubj) results_2/NNS (l_acl) obtained_3/VBN (l_prep) in_4/IN (l_pobj) departments_7/NNS (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_compound) myopathic_9/JJ
-1_D009135 NONE CIBA_31/NNP (r_appos) Dianabol_29/NNP (r_appos) agent_27/NN (r_pobj) of_24/IN (r_prep) effects_23/NNS (l_prep) at_33/IN (l_pobj) doses_35/NNS (l_prep) in_36/IN (l_pobj) rats_37/NNS (l_acl) rendered_38/VBN (l_oprd) myopathic_39/NNP
24927617
C486464_D012206 CID telaprevir_10/NNP (r_pobj) with_9/IN (r_prep) treated_8/VBN (r_acl) patient_7/NN (r_conj) Rhabdomyolysis_0/NN
C486464_D006526 NONE telaprevir_10/NNP (r_pobj) with_9/IN (r_prep) treated_8/VBN (r_acl) patient_7/NN (l_amod) infected_6/VBD
C486464_D006526 NONE telaprevir_20/NNP (r_conj) interferon_18/NNP (r_dobj) received_11/VBD (l_nsubj) man_3/NN (l_prep) with_4/IN (l_pobj) infection_10/NN
D019821_D012206 CID simvastatin_12/NN (r_conj) telaprevir_10/NNP (r_pobj) with_9/IN (r_prep) treated_8/VBN (r_acl) patient_7/NN (r_conj) Rhabdomyolysis_0/NN
D019821_D006526 NONE simvastatin_12/NN (r_conj) telaprevir_10/NNP (r_pobj) with_9/IN (r_prep) treated_8/VBN (r_acl) patient_7/NN (l_amod) infected_6/VBD
D012254_D006526 NONE ribavirin_15/NNP (r_pobj) with_14/IN (r_prep) received_11/VBD (l_nsubj) man_3/NN (l_prep) with_4/IN (l_pobj) infection_10/NN
C417083_D006526 NONE interferon_18/NNP (r_dobj) received_11/VBD (l_nsubj) man_3/NN (l_prep) with_4/IN (l_pobj) infection_10/NN
D019821_D064420 NONE simvastatin_2/RB (r_pobj) At_0/IN (r_prep) discontinued_8/VBN (l_advcl) due_11/IN (l_nsubj) toxicity_10/NN
D019821_D009135 CID Simvastatin_0/NNP (r_compound) plasma_1/NN (r_compound) concentration_2/NN (r_nsubj) increased_3/VBD (l_conj) related_15/VBN (l_nsubjpass) toxicity_13/NN
D019821_D009135 CID statin_10/NN (r_npadvmod) induced_11/VBN (r_amod) toxicity_13/NN
D019821_D009135 CID statin_21/NN (r_pobj) of_19/IN (r_prep) concentration_18/NN (r_pobj) to_16/IN (r_prep) related_15/VBN (l_nsubjpass) toxicity_13/NN
24659727
D008130_D008223 NONE lomustine_2/NNP (r_pobj) of_1/IN (r_prep) Tolerability_0/NN (l_prep) in_3/IN (l_pobj) combination_4/NN (l_prep) in_7/IN (l_pobj) dogs_8/NNS (l_prep) with_9/IN (l_pobj) lymphoma_10/NN
D008130_D008223 NONE lomustine_10/NNP (r_pobj) of_9/IN (r_prep) protocol_8/NN (l_prep) in_19/IN (l_pobj) dogs_20/NNS (l_prep) with_21/IN (l_pobj) lymphoma_22/NN
D008130_D008223 NONE CCNU_12/NNP (r_appos) lomustine_10/NNP (r_pobj) of_9/IN (r_prep) protocol_8/NN (l_prep) in_19/IN (l_pobj) dogs_20/NNS (l_prep) with_21/IN (l_pobj) lymphoma_22/NN
D003520_D008223 NONE cyclophosphamide_6/NN (r_pobj) with_5/IN (r_prep) combination_4/NN (l_prep) in_7/IN (l_pobj) dogs_8/NNS (l_prep) with_9/IN (l_pobj) lymphoma_10/NN
D003520_D008223 NONE cyclophosphamide_15/NN (r_conj) lomustine_10/NNP (r_pobj) of_9/IN (r_prep) protocol_8/NN (l_prep) in_19/IN (l_pobj) dogs_20/NNS (l_prep) with_21/IN (l_pobj) lymphoma_22/NN
D003520_D008223 NONE CTX_17/NNP (r_appos) cyclophosphamide_15/NN (r_conj) lomustine_10/NNP (r_pobj) of_9/IN (r_prep) protocol_8/NN (l_prep) in_19/IN (l_pobj) dogs_20/NNS (l_prep) with_21/IN (l_pobj) lymphoma_22/NN
D008130_D064420 NONE lomustine_10/NNP (r_pobj) of_9/IN (r_prep) protocol_8/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) toxicity_4/NN
D008130_D064420 NONE CCNU_12/NNP (r_appos) lomustine_10/NNP (r_pobj) of_9/IN (r_prep) protocol_8/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) toxicity_4/NN
D003520_D064420 NONE cyclophosphamide_15/NN (r_conj) lomustine_10/NNP (r_pobj) of_9/IN (r_prep) protocol_8/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) toxicity_4/NN
D003520_D064420 NONE CTX_17/NNP (r_appos) cyclophosphamide_15/NN (r_conj) lomustine_10/NNP (r_pobj) of_9/IN (r_prep) protocol_8/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) toxicity_4/NN
D008130_D009503 CID CCNU_20/NNP (r_nmod) CTX_22/NNP (r_pobj) of_19/IN (r_prep) treatment_18/NN (r_pobj) after_15/IN (r_prep) frequency_10/NN (r_nsubj) was_23/VBD (r_conj) was_1/VBD (l_nsubj) Neutropenia_0/NNP
D008130_D009503 CID CCNU_20/NNP (r_nmod) CTX_22/NNP (r_pobj) of_19/IN (r_prep) treatment_18/NN (r_pobj) after_15/IN (r_prep) frequency_10/NN (l_prep) of_11/IN (l_pobj) neutropenia_14/NN
D003520_D009503 CID CTX_22/NNP (r_pobj) of_19/IN (r_prep) treatment_18/NN (r_pobj) after_15/IN (r_prep) frequency_10/NN (r_nsubj) was_23/VBD (r_conj) was_1/VBD (l_nsubj) Neutropenia_0/NNP
D003520_D009503 CID CTX_22/NNP (r_pobj) of_19/IN (r_prep) treatment_18/NN (r_pobj) after_15/IN (r_prep) frequency_10/NN (l_prep) of_11/IN (l_pobj) neutropenia_14/NN
10985896
D004317_D010051 NONE doxorubicin_5/NNS (r_pobj) of_3/IN (r_prep) trial_2/NN (l_prep) in_13/IN (l_pobj) cancers_23/NNS
D004317_D010051 NONE doxorubicin_5/NNS (r_dobj) demonstrated_3/VBN (l_xcomp) be_10/VB (l_attr) agent_14/NN (l_prep) in_15/IN (l_pobj) cancer_20/NN
D004317_D010051 NONE Doxil_7/NNP (r_appos) doxorubicin_5/NNS (r_dobj) demonstrated_3/VBN (l_xcomp) be_10/VB (l_attr) agent_14/NN (l_prep) in_15/IN (l_pobj) cancer_20/NN
D004317_D010051 NONE doxorubicin_41/NNS (r_pobj) with_39/IN (r_prep) treated_38/VBN (l_nsubjpass) Patients_0/NNS (l_prep) with_1/IN (l_pobj) cancers_6/NNS
D004317_D005185 NONE doxorubicin_5/NNS (r_pobj) of_3/IN (r_prep) trial_2/NN (l_prep) in_13/IN (l_pobj) cancers_23/NNS
D004317_D005185 NONE doxorubicin_41/NNS (r_pobj) with_39/IN (r_prep) treated_38/VBN (l_nsubjpass) Patients_0/NNS (l_prep) with_1/IN (l_pobj) cancers_6/NNS
D004317_D010534 NONE doxorubicin_5/NNS (r_pobj) of_3/IN (r_prep) trial_2/NN (l_prep) in_13/IN (l_pobj) cancers_23/NNS (l_conj) carcinoma_26/NN (l_prep) of_27/IN (l_pobj) peritoneum_29/NN
D004317_D010534 NONE doxorubicin_41/NNS (r_pobj) with_39/IN (r_prep) treated_38/VBN (l_nsubjpass) Patients_0/NNS (l_prep) with_1/IN (l_pobj) cancers_6/NNS (l_conj) carcinoma_10/NN
D010984_D010051 NONE platinum_14/NN (r_nmod) ovarian_19/NN (r_nmod) cancers_23/NNS
D010984_D010051 NONE platinum_16/NN (r_npadvmod) resistant_18/JJ (r_amod) cancer_20/NN
D010984_D010051 NONE platinum_12/NN (r_npadvmod) refractory_16/JJ (r_amod) disease_17/NN (r_pobj) with_11/IN (r_prep) Patients_0/NNS (l_prep) with_1/IN (l_pobj) cancers_6/NNS
D010984_D010051 NONE platinum-_15/NN (r_nmod) cancer_21/NN
D010984_D005185 NONE platinum_14/NN (r_nmod) ovarian_19/NN (r_nmod) cancers_23/NNS
D010984_D005185 NONE platinum_12/NN (r_npadvmod) refractory_16/JJ (r_amod) disease_17/NN (r_pobj) with_11/IN (r_prep) Patients_0/NNS (l_prep) with_1/IN (l_pobj) cancers_6/NNS
D010984_D010534 NONE platinum_14/NN (r_nmod) ovarian_19/NN (r_nmod) cancers_23/NNS (l_conj) carcinoma_26/NN (l_prep) of_27/IN (l_pobj) peritoneum_29/NN
D010984_D010534 NONE platinum_12/NN (r_npadvmod) refractory_16/JJ (r_amod) disease_17/NN (r_pobj) with_11/IN (r_prep) Patients_0/NNS (l_prep) with_1/IN (l_pobj) cancers_6/NNS (l_conj) carcinoma_10/NN
D017239_D010051 NONE paclitaxel_16/NN (r_npadvmod) refractory_18/JJ (r_amod) ovarian_19/NN (r_nmod) cancers_23/NNS
D017239_D010051 NONE paclitaxel_14/NN (r_npadvmod) refractory_16/JJ (r_amod) disease_17/NN (r_pobj) with_11/IN (r_prep) Patients_0/NNS (l_prep) with_1/IN (l_pobj) cancers_6/NNS
D017239_D010051 NONE paclitaxel_17/NN (r_npadvmod) refractory_19/JJ (r_amod) cancer_21/NN
D017239_D005185 NONE paclitaxel_16/NN (r_npadvmod) refractory_18/JJ (r_amod) ovarian_19/NN (r_nmod) cancers_23/NNS
D017239_D005185 NONE paclitaxel_14/NN (r_npadvmod) refractory_16/JJ (r_amod) disease_17/NN (r_pobj) with_11/IN (r_prep) Patients_0/NNS (l_prep) with_1/IN (l_pobj) cancers_6/NNS
D017239_D010534 NONE paclitaxel_16/NN (r_npadvmod) refractory_18/JJ (r_amod) ovarian_19/NN (r_nmod) cancers_23/NNS (l_conj) carcinoma_26/NN (l_prep) of_27/IN (l_pobj) peritoneum_29/NN
D017239_D010534 NONE paclitaxel_14/NN (r_npadvmod) refractory_16/JJ (r_amod) disease_17/NN (r_pobj) with_11/IN (r_prep) Patients_0/NNS (l_prep) with_1/IN (l_pobj) cancers_6/NNS (l_conj) carcinoma_10/NN
D004317_D064420 NONE doxorubicin_5/NNS (r_dobj) demonstrated_3/VBN (l_xcomp) be_10/VB (l_prep) with_22/IN (l_pobj) toxicity_25/NN
D004317_D064420 NONE Doxil_7/NNP (r_appos) doxorubicin_5/NNS (r_dobj) demonstrated_3/VBN (l_xcomp) be_10/VB (l_prep) with_22/IN (l_pobj) toxicity_25/NN
D004317_D064420 NONE doxorubicin_3/FW (r_appos) liposomal_2/NN (r_nsubj) results_5/NNS (l_prep) in_6/IN (l_pobj) toxicity_8/NN
D004317_D060831 CID doxorubicin_5/NNS (r_dobj) demonstrated_3/VBN (l_xcomp) be_10/VB (l_prep) with_22/IN (l_pobj) toxicity_25/NN (l_acl) being_41/VBG (l_attr) erythrodysesthesia_43/NN
D004317_D060831 CID doxorubicin_5/NNS (r_dobj) demonstrated_3/VBN (l_xcomp) be_10/VB (l_prep) with_22/IN (l_pobj) toxicity_25/NN (l_acl) being_41/VBG (l_attr) erythrodysesthesia_43/NN (l_appos) syndrome_49/NN
D004317_D060831 CID Doxil_7/NNP (r_appos) doxorubicin_5/NNS (r_dobj) demonstrated_3/VBN (l_xcomp) be_10/VB (l_prep) with_22/IN (l_pobj) toxicity_25/NN (l_acl) being_41/VBG (l_attr) erythrodysesthesia_43/NN
D004317_D060831 CID Doxil_7/NNP (r_appos) doxorubicin_5/NNS (r_dobj) demonstrated_3/VBN (l_xcomp) be_10/VB (l_prep) with_22/IN (l_pobj) toxicity_25/NN (l_acl) being_41/VBG (l_attr) erythrodysesthesia_43/NN (l_appos) syndrome_49/NN
D004317_D060831 CID doxorubicin_3/FW (r_appos) liposomal_2/NN (r_nsubj) results_5/NNS (l_prep) in_6/IN (l_pobj) toxicity_8/NN (l_appos) stomatitis_10/NN (l_conj) syndrome_15/NN
D004317_D013280 CID doxorubicin_5/NNS (r_dobj) demonstrated_3/VBN (l_xcomp) be_10/VB (l_prep) with_22/IN (l_pobj) toxicity_25/NN (l_acl) being_41/VBG (l_attr) erythrodysesthesia_43/NN (l_appos) syndrome_49/NN (l_conj) stomatitis_53/NN
D004317_D013280 CID Doxil_7/NNP (r_appos) doxorubicin_5/NNS (r_dobj) demonstrated_3/VBN (l_xcomp) be_10/VB (l_prep) with_22/IN (l_pobj) toxicity_25/NN (l_acl) being_41/VBG (l_attr) erythrodysesthesia_43/NN (l_appos) syndrome_49/NN (l_conj) stomatitis_53/NN
D004317_D013280 CID doxorubicin_3/FW (r_appos) liposomal_2/NN (r_nsubj) results_5/NNS (l_prep) in_6/IN (l_pobj) toxicity_8/NN (l_appos) stomatitis_10/NN
D010984_D064420 NONE platinum_16/NN (r_npadvmod) resistant_18/JJ (r_amod) cancer_20/NN (r_pobj) in_15/IN (r_prep) agent_14/NN (r_attr) be_10/VB (l_prep) with_22/IN (l_pobj) toxicity_25/NN
D010984_D060831 NONE platinum_16/NN (r_npadvmod) resistant_18/JJ (r_amod) cancer_20/NN (r_pobj) in_15/IN (r_prep) agent_14/NN (r_attr) be_10/VB (l_prep) with_22/IN (l_pobj) toxicity_25/NN (l_acl) being_41/VBG (l_attr) erythrodysesthesia_43/NN
D010984_D060831 NONE platinum_16/NN (r_npadvmod) resistant_18/JJ (r_amod) cancer_20/NN (r_pobj) in_15/IN (r_prep) agent_14/NN (r_attr) be_10/VB (l_prep) with_22/IN (l_pobj) toxicity_25/NN (l_acl) being_41/VBG (l_attr) erythrodysesthesia_43/NN (l_appos) syndrome_49/NN
D010984_D013280 NONE platinum_16/NN (r_npadvmod) resistant_18/JJ (r_amod) cancer_20/NN (r_pobj) in_15/IN (r_prep) agent_14/NN (r_attr) be_10/VB (l_prep) with_22/IN (l_pobj) toxicity_25/NN (l_acl) being_41/VBG (l_attr) erythrodysesthesia_43/NN (l_appos) syndrome_49/NN (l_conj) stomatitis_53/NN
891494
D010672_D001927 CID Phenytoin_0/NNP (r_compound) encephalopathy_1/NN
D010672_D001927 CID phenytoin_3/NN (r_nmod) encephalopathy_7/NN
D010672_D001927 CID DPH_5/NNP (r_nmod) encephalopathy_7/NN
D010672_D012640 NONE phenytoin_3/NN (r_nmod) encephalopathy_7/NN (l_prep) with_8/IN (l_pobj) seizures_10/NNS
D010672_D012640 NONE DPH_5/NNP (r_nmod) encephalopathy_7/NN (l_prep) with_8/IN (l_pobj) seizures_10/NNS
D010672_D012640 NONE DPH_8/NN (r_compound) treatment_9/NN (r_pobj) starting_7/VBG (r_acl) patient_6/NN (r_pobj) in_4/IN (l_pobj) increase_12/NN (l_prep) in_13/IN (l_pobj) seizures_14/NNS
D010672_D012640 NONE DPH_34/NNP (r_dobj) eliminating_33/VBG (r_pcomp) for_32/IN (r_prep) need_31/NN (r_pobj) to_28/IN (r_prep) alert_25/VB (l_prep) in_4/IN (l_pobj) increase_12/NN (l_prep) in_13/IN (l_pobj) seizures_14/NNS
D010672_D005076 NONE DPH_6/NNP (r_pobj) of_4/IN (r_prep) concentration_3/NN (r_nsubj) was_7/VBD (r_ccomp) presented_12/VBD (l_dobj) rash_16/NN
D010672_D005076 NONE DPH_18/NNP (r_compound) treatment_19/NN (r_pobj) during_17/IN (r_prep) presented_12/VBD (l_dobj) rash_16/NN
D010672_D005076 NONE DPH_29/NNP (r_compound) injection_30/NN (r_nsubj) had_31/VBD (r_conj) was_23/VBD (r_conj) presented_12/VBD (l_dobj) rash_16/NN
24816962
D008795_D001927 CID Metronidazole_0/NN (r_npadvmod) induced_2/VBN (r_amod) encephalopathy_3/NN
D008795_D001927 CID metronidazole_13/NN (r_compound) intake_14/NN (r_pobj) following_11/VBG (r_prep) features_8/NNS (l_prep) of_9/IN (l_pobj) encephalopathy_10/NN
D008795_D064420 NONE metronidazole_3/NN (r_compound) toxicity_4/NN
23872883
D007545_D066126 CID isoproterenol_18/NN (r_npadvmod) induced_20/VBN (r_amod) cardiotoxicity_21/NN
24587916
D003907_D006973 CID dexamethasone_6/NN (r_npadvmod) induced_8/VBN (r_amod) hypertension_9/NN
D003907_D006973 CID Dex-_1/NNP (r_dep) )_2/-RRB- (r_punct) hypertension_4/NN
D003907_D006973 CID Dex_19/NNP (r_compound) administration_20/NN (r_pobj) upon_18/IN (r_prep) effect_7/NN (l_prep) on_13/IN (l_pobj) stress_15/NN (l_conj) hypertension_17/NN
D003907_D006973 CID Dex_0/NNP (r_npadvmod) induced_2/VBN (r_amod) hypertension_3/NN
D003907_D006973 CID Dex_18/NNP (r_npadvmod) induced_20/VBN (r_amod) hypertension_21/NN
D006861_D015431 NONE H2O2_11/NNP (r_dobj) reduced_7/VBD (r_conj) prevented_1/VBD (l_dobj) loss_4/NN
17159032
D006886_D014786 CID hydroxychloroquine_8/NN (r_dobj) taking_7/VBG (r_acl) patients_6/NNS (r_pobj) in_5/IN (r_prep) loss_4/NN
D006886_D014786 CID hydroxychloroquine_17/NN (r_compound) treatment_18/NN (r_pobj) to_16/IN (r_prep) attributed_15/VBN (r_relcl) abnormalities_11/NNS
24684312
D018698_D010146 NONE glutamate_3/NN (r_pobj) of_2/IN (r_prep) injections_1/NNS (r_nsubj) are_6/VBP (l_acomp) attractive_7/JJ (l_xcomp) use_9/VB (l_prep) in_10/IN (l_pobj) models_14/NNS (l_compound) pain_13/NN
D018698_D006930 NONE glutamate_3/NN (r_pobj) of_2/IN (r_prep) injections_1/NNS (r_nsubj) are_6/VBP (l_advcl) mimic_19/VBP (l_nsubj) hyperalgesia_16/NN
D018698_D006930 NONE glutamate_3/NN (r_pobj) of_2/IN (r_prep) injections_1/NNS (r_nsubj) are_6/VBP (l_advcl) mimic_19/VBP (l_nsubj) hyperalgesia_16/NN (l_conj) allodynia_18/NN
D018698_D006930 NONE glutamate_3/NN (r_nsubj) yield_6/VBP (l_dobj) responses_11/NNS (l_nmod) hyperalgesic_8/NNP
D018698_D006930 NONE glutamate_3/NN (r_nsubj) yield_6/VBP (l_dobj) responses_11/NNS (l_nmod) hyperalgesic_8/NNP (l_conj) allodynic_10/NNP
D018698_D013001 NONE glutamate_3/NN (r_pobj) of_2/IN (r_prep) injections_1/NNS (r_nsubj) are_6/VBP (l_advcl) mimic_19/VBP (l_dobj) aspects_21/NNS (l_prep) of_22/IN (l_pobj) disorders_25/NNS
D002211_D010146 NONE capsaicin_5/NN (r_conj) glutamate_3/NN (r_pobj) of_2/IN (r_prep) injections_1/NNS (r_nsubj) are_6/VBP (l_acomp) attractive_7/JJ (l_xcomp) use_9/VB (l_prep) in_10/IN (l_pobj) models_14/NNS (l_compound) pain_13/NN
D002211_D006930 CID capsaicin_5/NN (r_conj) glutamate_3/NN (r_pobj) of_2/IN (r_prep) injections_1/NNS (r_nsubj) are_6/VBP (l_advcl) mimic_19/VBP (l_nsubj) hyperalgesia_16/NN
D002211_D006930 CID capsaicin_5/NN (r_conj) glutamate_3/NN (r_pobj) of_2/IN (r_prep) injections_1/NNS (r_nsubj) are_6/VBP (l_advcl) mimic_19/VBP (l_nsubj) hyperalgesia_16/NN (l_conj) allodynia_18/NN
D002211_D006930 CID capsaicin_1/NN (r_pobj) For_0/IN (r_prep) detected_7/VBN (l_nsubjpass) hyperalgesia_5/NN
D002211_D006930 CID Capsaicin_0/NN (r_compound) injection_1/NN (r_nsubj) was_2/VBD (l_acomp) reproducible_3/JJ (l_prep) for_4/IN (l_pobj) hyperalgesia_6/NN
D002211_D006930 CID Capsaicin_0/NN (r_compound) injection_1/NN (r_nsubj) was_2/VBD (l_acomp) reproducible_3/JJ (l_prep) for_4/IN (l_pobj) hyperalgesia_6/NN (l_conj) allodynia_13/NNP
D002211_D006930 CID capsaicin_5/NN (r_conj) glutamate_3/NN (r_nsubj) yield_6/VBP (l_dobj) responses_11/NNS (l_nmod) hyperalgesic_8/NNP
D002211_D006930 CID capsaicin_5/NN (r_conj) glutamate_3/NN (r_nsubj) yield_6/VBP (l_dobj) responses_11/NNS (l_nmod) hyperalgesic_8/NNP (l_conj) allodynic_10/NNP
D002211_D013001 NONE capsaicin_5/NN (r_conj) glutamate_3/NN (r_pobj) of_2/IN (r_prep) injections_1/NNS (r_nsubj) are_6/VBP (l_advcl) mimic_19/VBP (l_dobj) aspects_21/NNS (l_prep) of_22/IN (l_pobj) disorders_25/NNS
23535177
D007980_D010300 NONE levodopa_19/NN (r_npadvmod) induced_21/VBN (r_amod) dyskinesias_22/NNP (r_conj) disease_14/NN
D007980_D010300 NONE levodopa_19/NN (r_npadvmod) induced_21/VBN (r_amod) dyskinesias_22/NNP (r_conj) disease_14/NN (l_appos) PD_16/NNP
D007980_D004409 CID levodopa_19/NN (r_npadvmod) induced_21/VBN (r_amod) dyskinesias_22/NNP
D007980_D004409 CID levodopa_19/NN (r_npadvmod) induced_21/VBN (r_amod) dyskinesias_22/NNP (l_appos) LIDs_24/NNP
19715529
18450790
D013792_D010523 CID Thalidomide_0/NN (l_conj) neurotoxicity_3/NN
D013792_D010523 CID thalidomide_17/NN (r_pobj) of_16/IN (r_prep) doses_15/NNS (r_pobj) with_13/IN (r_prep) treated_12/VBN (r_acl) patients_11/NNS (r_pobj) in_10/IN (r_prep) incidence_5/NN (l_prep) of_6/IN (l_pobj) neuropathy_9/NN
D013792_D008178 NONE thalidomide_30/NN (r_pobj) with_29/IN (r_prep) treated_28/VBN (r_acl) amplitude_17/NN (l_prep) in_18/IN (l_pobj) patients_19/NNS (l_prep) with_20/IN (l_pobj) erythematosus_24/NN
D013792_D008178 NONE thalidomide_30/NN (r_pobj) with_29/IN (r_prep) treated_28/VBN (r_acl) amplitude_17/NN (l_prep) in_18/IN (l_pobj) patients_19/NNS (l_prep) with_20/IN (l_pobj) erythematosus_24/NN (l_appos) CLE_26/NNP
D013792_D008178 NONE thalidomide_41/NN (r_pobj) of_40/IN (r_prep) potential_39/NN (r_dobj) identify_36/VB (r_xcomp) use_32/VB (r_conj) treated_28/VBN (r_acl) amplitude_17/NN (l_prep) in_18/IN (l_pobj) patients_19/NNS (l_prep) with_20/IN (l_pobj) erythematosus_24/NN
D013792_D008178 NONE thalidomide_41/NN (r_pobj) of_40/IN (r_prep) potential_39/NN (r_dobj) identify_36/VB (r_xcomp) use_32/VB (r_conj) treated_28/VBN (r_acl) amplitude_17/NN (l_prep) in_18/IN (l_pobj) patients_19/NNS (l_prep) with_20/IN (l_pobj) erythematosus_24/NN (l_appos) CLE_26/NNP
D013792_D008178 NONE thalidomide_13/NN (r_pobj) with_12/IN (r_prep) treatment_11/NN (r_pobj) during_10/IN (r_prep) data_3/NNS (l_prep) in_4/IN (l_pobj) patients_7/NNS (l_prep) with_8/IN (l_pobj) CLE_9/NNP
D013792_D020258 NONE thalidomide_30/NN (r_pobj) with_29/IN (r_prep) treated_28/VBN (l_conj) use_32/VB (l_xcomp) identify_36/VB (l_dobj) potential_39/NN (l_amod) neurotoxic_38/JJ
D013792_D020258 NONE thalidomide_41/NN (r_pobj) of_40/IN (r_prep) potential_39/NN (l_amod) neurotoxic_38/JJ
D013792_D020258 NONE thalidomide_10/NN (r_pobj) of_9/IN (r_prep) potential_8/NN (l_amod) neurotoxic_7/JJ
17721298
D016578_D003320 CID cocaine_6/NN (r_compound) use_7/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) ulcers_1/NNS
D016578_D003320 CID cocaine_8/NN (r_compound) use_9/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) ulcers_4/NNS
D016578_D003320 CID cocaine_2/NN (r_compound) use_3/NN (r_nsubjpass) associated_6/VBN (l_prep) with_7/IN (l_pobj) development_9/NN (l_prep) of_10/IN (l_pobj) ulcers_12/NNS
24100055
D006493_D013921 CID heparin_2/NN (r_npadvmod) induced_4/VBN (r_amod) II_7/NNP
D006493_D013921 CID heparin_6/NN (r_npadvmod) induced_8/VBN (r_amod) II_11/NNP
D006493_D013921 CID heparin_6/NN (r_npadvmod) induced_8/VBN (r_amod) II_11/NNP (r_pobj) of_2/IN (r_prep) impact_1/NN (l_appos) II_15/NNP
D006493_D013921 CID heparin_6/NN (r_npadvmod) induced_8/VBN (r_amod) II_11/NNP (r_pobj) of_2/IN (r_prep) impact_1/NN (l_prep) as_17/IN (l_pobj) cause_19/NN (l_prep) of_20/IN (l_pobj) thrombocytopenia_21/NN
D006493_D013921 CID heparin_12/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_nsubjpass) avoided_15/VBN (l_prep) For_0/IN (l_pobj) reduction_2/NN (l_prep) of_3/IN (l_pobj) II_6/NNP
D006493_D013921 CID heparin_29/NN (r_pobj) with_23/IN (r_prep) performed_22/VBN (r_conj) avoided_15/VBN (l_prep) For_0/IN (l_pobj) reduction_2/NN (l_prep) of_3/IN (l_pobj) II_6/NNP
16876986
D010862_D012640 CID pilocarpine_6/NN (r_npadvmod) induced_8/VBN (r_amod) seizures_9/NNS
D010862_D012640 CID pilocarpine_6/NN (r_compound) injections_7/NNS (r_pobj) by_5/IN (r_agent) induced_4/VBN (l_nsubjpass) seizures_2/NNS
8667442
D002117_D006934 CID 1,25(OH)2D_6/CD (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) syndrome_3/NN
D002117_D006934 CID calcitriol_14/NN (r_conj) carbonate_12/NN (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_advcl) resulting_15/VBG (l_prep) in_16/IN (l_pobj) admissions_18/NNS (l_prep) to_19/IN (l_pobj) hospital_21/NN (l_prep) for_22/IN (l_pobj) syndrome_26/NN
D002117_D007011 NONE 1,25(OH)2D_6/CD (r_pobj) by_5/IN (r_agent) induced_4/VBN (l_prep) in_7/IN (l_pobj) patient_9/NN (l_prep) with_10/IN (l_pobj) hypoparathyroidism_11/NNP
D002117_D007011 NONE calcitriol_14/NN (r_conj) carbonate_12/NN (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_relcl) patient_4/NN (l_prep) with_5/IN (l_pobj) hypoparathyroidism_6/NNP
D002118_D006934 CID calcium_24/NN (r_pobj) of_23/IN (r_prep) amounts_22/NNS (r_pobj) with_20/IN (r_prep) treatment_15/NN (r_pobj) of_13/IN (r_prep) context_12/NN (r_pobj) in_10/IN (r_prep) described_6/VBN (l_nsubjpass) syndrome_3/NN
D002118_D010437 NONE calcium_24/NN (r_pobj) of_23/IN (r_prep) amounts_22/NNS (r_pobj) with_20/IN (r_prep) treatment_15/NN (l_prep) of_16/IN (l_pobj) disease_19/NN
D000468_D006934 CID alkali_26/JJ (r_conj) calcium_24/NN (r_pobj) of_23/IN (r_prep) amounts_22/NNS (r_pobj) with_20/IN (r_prep) treatment_15/NN (r_pobj) of_13/IN (r_prep) context_12/NN (r_pobj) in_10/IN (r_prep) described_6/VBN (l_nsubjpass) syndrome_3/NN
D000468_D010437 NONE alkali_26/JJ (r_conj) calcium_24/NN (r_pobj) of_23/IN (r_prep) amounts_22/NNS (r_pobj) with_20/IN (r_prep) treatment_15/NN (l_prep) of_16/IN (l_pobj) disease_19/NN
D009853_D014456 NONE omeprazole_9/NN (r_conj) blockers_7/NNS (r_appos) therapy_4/NN (l_compound) ulcer_3/NN
D009853_D006934 NONE omeprazole_9/NN (r_conj) blockers_7/NNS (r_appos) therapy_4/NN (r_pobj) with_1/IN (r_prep) decreased_23/VBN (l_nsubj) frequency_16/NN (l_prep) of_17/IN (l_pobj) syndrome_21/NN
D009853_D006934 NONE omeprazole_9/NN (r_conj) blockers_7/NNS (r_appos) therapy_4/NN (r_pobj) with_1/IN (r_prep) decreased_23/VBN (r_advcl) remains_37/VBZ (l_nsubj) triad_28/NN (l_prep) of_29/IN (l_pobj) hypercalcemia_30/NN
D009853_D000471 NONE omeprazole_9/NN (r_conj) blockers_7/NNS (r_appos) therapy_4/NN (r_pobj) with_1/IN (r_prep) decreased_23/VBN (r_advcl) remains_37/VBZ (l_nsubj) triad_28/NN (l_prep) of_29/IN (l_pobj) hypercalcemia_30/NN (l_conj) alkalosis_32/NN
D009853_D051437 NONE omeprazole_9/NN (r_conj) blockers_7/NNS (r_appos) therapy_4/NN (r_pobj) with_1/IN (r_prep) decreased_23/VBN (r_advcl) remains_37/VBZ (l_nsubj) triad_28/NN (l_prep) of_29/IN (l_pobj) hypercalcemia_30/NN (l_conj) alkalosis_32/NN (l_conj) impairment_36/NN
D013392_D014456 NONE sucralfate_12/NNP (r_conj) omeprazole_9/NN (r_conj) blockers_7/NNS (r_appos) therapy_4/NN (l_compound) ulcer_3/NN
D013392_D006934 NONE sucralfate_12/NNP (r_conj) omeprazole_9/NN (r_conj) blockers_7/NNS (r_appos) therapy_4/NN (r_pobj) with_1/IN (r_prep) decreased_23/VBN (l_nsubj) frequency_16/NN (l_prep) of_17/IN (l_pobj) syndrome_21/NN
D013392_D006934 NONE sucralfate_12/NNP (r_conj) omeprazole_9/NN (r_conj) blockers_7/NNS (r_appos) therapy_4/NN (r_pobj) with_1/IN (r_prep) decreased_23/VBN (r_advcl) remains_37/VBZ (l_nsubj) triad_28/NN (l_prep) of_29/IN (l_pobj) hypercalcemia_30/NN
D013392_D000471 NONE sucralfate_12/NNP (r_conj) omeprazole_9/NN (r_conj) blockers_7/NNS (r_appos) therapy_4/NN (r_pobj) with_1/IN (r_prep) decreased_23/VBN (r_advcl) remains_37/VBZ (l_nsubj) triad_28/NN (l_prep) of_29/IN (l_pobj) hypercalcemia_30/NN (l_conj) alkalosis_32/NN
D013392_D051437 NONE sucralfate_12/NNP (r_conj) omeprazole_9/NN (r_conj) blockers_7/NNS (r_appos) therapy_4/NN (r_pobj) with_1/IN (r_prep) decreased_23/VBN (r_advcl) remains_37/VBZ (l_nsubj) triad_28/NN (l_prep) of_29/IN (l_pobj) hypercalcemia_30/NN (l_conj) alkalosis_32/NN (l_conj) impairment_36/NN
D002119_D007011 NONE carbonate_12/NN (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_relcl) patient_4/NN (l_prep) with_5/IN (l_pobj) hypoparathyroidism_6/NNP
D002119_D006934 CID carbonate_12/NN (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_advcl) resulting_15/VBG (l_prep) in_16/IN (l_pobj) admissions_18/NNS (l_prep) to_19/IN (l_pobj) hospital_21/NN (l_prep) for_22/IN (l_pobj) syndrome_26/NN
C019248_D006934 NONE pamidronate_3/NN (r_dobj) illustrates_1/VBZ (l_advcl) presents_14/VBZ (l_nsubj) syndrome_13/NN
C019248_D006934 NONE pamidronate_3/NN (r_dobj) illustrates_1/VBZ (l_advcl) presents_14/VBZ (l_prep) as_15/IN (l_pobj) emergency_17/NN
14616590
D015742_D010146 CID Disoprivan_32/NNP (r_pobj) with_31/IN (r_prep) than_30/IN (r_prep) frequently_27/RB (r_advmod) occurred_25/VBD (l_nsubj) Pain_0/NN
D015742_D013924 CID Disoprivan_32/NNP (r_pobj) with_31/IN (r_prep) than_30/IN (r_prep) frequently_27/RB (r_advmod) occurred_25/VBD (l_nsubj) Pain_0/NN (l_npadvmod) 0.01_11/CD (l_conj) thrombophlebitis_14/NNP
24209900
D007069_D001927 NONE Ifosfamide_0/NNP (r_nmod) encephalopathy_2/NN
D007069_D001927 NONE ifosfamide_16/JJ (r_dobj) receiving_11/VBG (r_acl) patients_10/NNS (r_pobj) of_9/IN (r_prep) %_8/NN (r_pobj) in_4/IN (r_prep) reported_3/VBN (l_nsubjpass) Encephalopathy_0/NN
D007069_D001927 NONE ifosfamide_16/NNP (r_nmod) encephalopathy_18/NN
D007069_D001927 NONE ifosfamide_29/NNP (r_amod) encephalopathy_32/NN
D007069_D001927 NONE ifosfamide_16/NNP (r_dobj) receiving_15/VBG (r_advcl) experienced_3/VBD (l_dobj) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) encephalopathy_6/NN
D007069_D001927 NONE ifosfamide_2/JJ (r_nmod) encephalopathy_4/NN
D007069_D001927 NONE ifosfamide_9/NNP (r_dobj) receiving_8/VBG (l_ccomp) develop_11/VBP (l_dobj) features_12/NNS (l_prep) of_13/IN (l_pobj) encephalopathy_14/NN
D007069_D009369 NONE Ifosfamide_0/NNP (r_nsubj) is_1/VBZ (l_attr) agent_4/NN (l_amod) useful_5/JJ (l_prep) in_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) range_12/NN (l_prep) of_13/IN (l_pobj) cancers_14/NNS
D007069_D009369 NONE Ifosfamide_0/NNP (r_nsubj) is_1/VBZ (l_attr) agent_4/NN (l_amod) useful_5/JJ (l_prep) in_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) range_12/NN (l_prep) of_13/IN (l_pobj) cancers_14/NNS (l_prep) including_15/VBG (l_pobj) sarcomas_16/NNS (l_conj) lymphoma_18/NN (l_conj) cancers_23/NNS
D007069_D009369 NONE ifosfamide_29/NNP (r_amod) encephalopathy_32/NN (r_dobj) developed_28/VBD (r_advcl) done_10/VBN (l_conj) admitted_15/VBD (l_prep) to_16/IN (l_pobj) Center_20/NNP (l_compound) Cancer_19/NNP
D007069_D012509 NONE Ifosfamide_0/NNP (r_nsubj) is_1/VBZ (l_attr) agent_4/NN (l_amod) useful_5/JJ (l_prep) in_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) range_12/NN (l_prep) of_13/IN (l_pobj) cancers_14/NNS (l_prep) including_15/VBG (l_pobj) sarcomas_16/NNS
D007069_D008223 NONE Ifosfamide_0/NNP (r_nsubj) is_1/VBZ (l_attr) agent_4/NN (l_amod) useful_5/JJ (l_prep) in_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) range_12/NN (l_prep) of_13/IN (l_pobj) cancers_14/NNS (l_prep) including_15/VBG (l_pobj) sarcomas_16/NNS (l_conj) lymphoma_18/NN
3975902
D010424_D002318 NONE pentobarbital_6/NN (r_pobj) to_4/IN (r_prep) dysfunction_1/NN
D010424_D004342 NONE pentobarbital_6/NN (r_pobj) to_4/IN (r_prep) dysfunction_1/NN (l_conj) hypersensitivity_3/NN
D010424_D004342 NONE pentobarbital_18/JJ (r_pobj) to_16/IN (r_prep) was_8/VBD (l_attr) hypersensitivity_11/NN
D010424_D004342 NONE pentobarbital_24/NN (r_pobj) to_22/IN (r_prep) characteristics_8/NNS (l_conj) disturbances_13/NNS (l_conj) hypersensitivity_17/NN
C024986_D002318 NONE chloride_11/NN (r_compound) ingestion_12/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) pentobarbital_6/NN (r_pobj) to_4/IN (r_prep) dysfunction_1/NN
C024986_D004342 NONE chloride_11/NN (r_compound) ingestion_12/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) pentobarbital_6/NN (r_pobj) to_4/IN (r_prep) dysfunction_1/NN (l_conj) hypersensitivity_3/NN
D001464_D006973 NONE Barium_0/NN (r_npadvmod) supplemented_2/VBN (r_amod) rats_7/NNS (r_nsubjpass) characterized_9/VBN (l_agent) by_10/IN (l_pobj) hypertension_13/NN
D001464_D006973 NONE barium_21/NN (r_pobj) of_20/IN (r_prep) month_19/NN (r_nmod) treatment_31/NN (r_pobj) after_17/IN (r_prep) was_15/VBD (r_relcl) hypertension_13/NN
D001464_D002318 NONE barium_18/NN (r_npadvmod) induced_20/VBN (r_amod) disturbances_21/NNS (l_prep) within_22/IN (l_pobj) system_25/NN
D001464_D004342 NONE barium_6/NN (r_compound) effect_7/NN (r_pobj) of_4/IN (r_prep) aspect_3/NN (r_nsubj) was_8/VBD (l_attr) hypersensitivity_11/NN
D001464_D004342 NONE barium_37/NN (r_compound) exposure_38/NN (r_pobj) by_35/IN (r_agent) induced_34/VBN (r_acl) disorder_33/NN (r_pobj) of_28/IN (r_prep) existence_27/NN (r_dobj) suggest_25/VBP (l_nsubj) characteristics_8/NNS (l_conj) disturbances_13/NNS (l_conj) hypersensitivity_17/NN
D010424_D008659 NONE pentobarbital_24/NN (r_pobj) to_22/IN (r_prep) characteristics_8/NNS (l_conj) disturbances_13/NNS
D010424_D009202 NONE pentobarbital_24/NN (r_pobj) to_22/IN (r_prep) characteristics_8/NNS (r_nsubj) suggest_25/VBP (l_dobj) existence_27/NN (l_prep) of_28/IN (l_pobj) disorder_33/NN
D001464_D008659 NONE barium_37/NN (r_compound) exposure_38/NN (r_pobj) by_35/IN (r_agent) induced_34/VBN (r_acl) disorder_33/NN (r_pobj) of_28/IN (r_prep) existence_27/NN (r_dobj) suggest_25/VBP (l_nsubj) characteristics_8/NNS (l_conj) disturbances_13/NNS
D001464_D009202 NONE barium_37/NN (r_compound) exposure_38/NN (r_pobj) by_35/IN (r_agent) induced_34/VBN (r_acl) disorder_33/NN
24055495
D005690_D003072 CID galactose_4/NN (r_compound) treatment_5/NN (r_nsubj) prevents_6/VBZ (l_dobj) deficits_8/NNS
D005690_D003072 CID galactose_9/NN (r_pobj) of_5/IN (r_prep) effects_4/NNS (l_conj) treatment_18/NN (l_prep) on_19/IN (l_pobj) deficits_21/NNS
D005690_D003072 CID galactose_4/NN (r_compound) treatment_5/NN (r_pobj) of_2/IN (r_prep) month_1/NN (r_nsubj) initiated_6/VBN (l_conj) prevented_16/VBD (l_dobj) development_17/NN (l_prep) of_18/IN (l_pobj) deficits_26/NNS
D005690_D003072 CID galactose_1/NN (r_compound) exposure_2/NN (r_nsubj) have_4/VB (l_conj) be_14/VB (l_acomp) worth_15/JJ (l_xcomp) investigating_16/VBG (l_prep) for_17/IN (l_pobj) improvement_18/NN (l_prep) of_19/IN (l_pobj) deficits_21/NNS
D013311_D003072 CID streptozotocin_16/NNS (r_pobj) with_15/IN (r_prep) treated_13/VBD (r_ccomp) prevents_6/VBZ (l_dobj) deficits_8/NNS
D013311_D003072 CID streptozotocin_23/NN (r_npadvmod) induced_25/VBN (r_amod) model_32/NN (r_pobj) in_22/IN (r_prep) deficits_21/NNS
D013311_D003072 CID STZ_27/NNP (r_nmod) icv_29/NNP (r_nmod) model_32/NN (r_pobj) in_22/IN (r_prep) deficits_21/NNS
D013311_D003072 CID STZ_10/NNP (r_compound) icv_12/NNP (r_compound) administration_13/NN (r_pobj) after_8/IN (r_prep) initiated_6/VBN (l_conj) prevented_16/VBD (l_dobj) development_17/NN (l_prep) of_18/IN (l_pobj) deficits_26/NNS
D013311_D003072 CID STZ_20/NNP (r_compound) icv_22/NNP (r_npadvmod) induced_24/VBN (r_amod) deficits_26/NNS
D005947_D003704 NONE glucose_33/NN (r_compound) transport_34/NN (r_pobj) by_31/IN (r_agent) followed_30/VBN (r_acl) system_29/NN (r_pobj) of_21/IN (r_prep) dysfunction_20/NN (r_pobj) with_19/IN (r_prep) associated_18/VBN (l_nsubjpass) dementia_7/NN
D005947_D003704 NONE glucose_36/NN (r_compound) transporter_37/NN (r_compound) GLUT4_38/NNP (r_pobj) via_35/IN (r_prep) transport_34/NN (r_pobj) by_31/IN (r_agent) followed_30/VBN (r_acl) system_29/NN (r_pobj) of_21/IN (r_prep) dysfunction_20/NN (r_pobj) with_19/IN (r_prep) associated_18/VBN (l_nsubjpass) dementia_7/NN
D005947_D003704 NONE glucose_41/NN (r_compound) metabolism_42/NN (r_dobj) decreased_40/VBD (r_conj) associated_18/VBN (l_nsubjpass) dementia_7/NN
D005947_D000544 CID glucose_33/NN (r_compound) transport_34/NN (r_pobj) by_31/IN (r_agent) followed_30/VBN (r_acl) system_29/NN (r_pobj) of_21/IN (r_prep) dysfunction_20/NN (r_pobj) with_19/IN (r_prep) associated_18/VBN (l_nsubjpass) dementia_7/NN (l_prep) of_8/IN (l_pobj) type_16/NN (l_nmod) disease_12/NN
D005947_D000544 CID glucose_36/NN (r_compound) transporter_37/NN (r_compound) GLUT4_38/NNP (r_pobj) via_35/IN (r_prep) transport_34/NN (r_pobj) by_31/IN (r_agent) followed_30/VBN (r_acl) system_29/NN (r_pobj) of_21/IN (r_prep) dysfunction_20/NN (r_pobj) with_19/IN (r_prep) associated_18/VBN (l_nsubjpass) dementia_7/NN (l_prep) of_8/IN (l_pobj) type_16/NN (l_nmod) disease_12/NN
D005947_D000544 CID glucose_41/NN (r_compound) metabolism_42/NN (r_dobj) decreased_40/VBD (r_conj) associated_18/VBN (l_nsubjpass) dementia_7/NN (l_prep) of_8/IN (l_pobj) type_16/NN (l_nmod) disease_12/NN
D005690_D008569 NONE galactose_5/NN (r_pobj) of_4/IN (r_prep) injections_3/NNS (r_nsubj) induce_6/VBP (l_dobj) deterioration_8/NN
D005690_D008569 NONE galactose_25/NN (r_compound) treatment_26/NN (r_pobj) of_23/IN (r_prep) effects_22/NNS (r_nsubjpass) tested_33/VBN (r_conj) induce_6/VBP (l_dobj) deterioration_8/NN
D005690_D018149 NONE galactose_1/NN (r_compound) exposure_2/NN (r_nsubj) have_4/VB (l_conj) be_14/VB (l_acomp) worth_15/JJ (l_xcomp) investigating_16/VBG (l_prep) for_17/IN (l_pobj) improvement_18/NN (l_prep) of_19/IN (l_pobj) deficits_21/NNS (l_acl) associated_22/VBN (l_prep) with_23/IN (l_pobj) hypometabolism_25/NN
D005690_D000544 NONE galactose_1/NN (r_compound) exposure_2/NN (r_nsubj) have_4/VB (l_conj) be_14/VB (l_acomp) worth_15/JJ (l_xcomp) investigating_16/VBG (l_prep) for_17/IN (l_pobj) improvement_18/NN (l_prep) of_19/IN (l_pobj) deficits_21/NNS (l_acl) associated_22/VBN (l_prep) with_23/IN (l_pobj) hypometabolism_25/NN (l_prep) in_26/IN (l_pobj) AD_27/NN
23871786
C006780_D001008 CID A_4/NNP (r_poss) behavior_9/NN (l_amod) like_8/JJ (l_npadvmod) anxiety_6/NN
C006780_D001008 CID BPA_17/NNP (r_pobj) to_16/IN (r_prep) exposed_15/VBN (r_acl) mice_14/NNS (r_pobj) in_13/IN (r_prep) increased_12/VBN (l_nsubjpass) behavior_10/NN (l_amod) like_9/JJ (l_npadvmod) anxiety_7/NN
C006780_D001008 CID BPA_5/NNP (r_compound) exposure_6/NN (r_nsubj) increased_7/VBD (l_dobj) behavior_11/NN (l_amod) like_10/JJ (l_npadvmod) anxiety_8/NN
3125850
D013390_D005207 CID suxamethonium_5/NN (r_npadvmod) induced_7/VBN (r_amod) fasciculations_9/NNS
D013390_D005207 CID suxamethonium_9/NNP (r_pobj) by_8/IN (r_agent) caused_7/VBN (r_acl) fasciculations_6/NNS
D013390_D005207 CID suxamethonium_13/NN (r_pobj) by_12/IN (r_agent) caused_11/VBN (r_acl) fasciculations_10/NNS
D013390_D005207 CID suxamethonium_7/NN (r_npadvmod) induced_9/VBN (r_amod) fasciculations_11/NNS
D015760_D005207 NONE alfentanil_15/NNP (r_pobj) by_14/IN (r_prep) inhibition_13/NN (r_npadvmod) Increase_0/VB (l_prep) during_4/IN (l_pobj) fasciculations_9/NNS
D015760_D005207 NONE alfentanil_19/NN (r_compound) group_20/NN (r_pobj) in_17/IN (r_prep) than_16/IN (r_prep) were_10/VBD (l_nsubj) incidence_1/NN (l_prep) of_4/IN (l_pobj) fasciculations_6/NNS
D015760_D005207 NONE alfentanil_26/NN (r_compound) group_27/NN (r_pobj) in_24/IN (r_prep) than_23/IN (r_prep) was_6/VBD (l_nsubj) pressure_2/NN (l_prep) during_3/IN (l_pobj) fasciculations_5/NNS
D014867_D005207 NONE H2O_21/NN (r_appos) group_12/NN (r_pobj) in_9/IN (r_prep) was_6/VBD (l_nsubj) pressure_2/NN (l_prep) during_3/IN (l_pobj) fasciculations_5/NNS
48835
D011433_D007003 NONE propranolol_2/NNS (l_prep) of_3/IN (l_pobj) effects_5/NNS (l_prep) of_6/IN (l_pobj) hypoglycaemia_8/NN
16034922
D004967_D020521 CID oestrogen_3/NN (r_nmod) HT_6/NNP (r_nsubj) increased_9/VBD (l_dobj) risk_11/NN (l_prep) of_12/IN (l_pobj) stroke_13/NN
D004967_D005705 CID oestrogen_3/NN (r_nmod) HT_6/NNP (r_nsubj) increased_9/VBD (l_dobj) risk_11/NN (l_prep) of_12/IN (l_pobj) stroke_13/NN (l_conj) disease_16/NN
18340638
D001379_D000740 CID azathioprine_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubj) include_5/VBP (l_dobj) anemia_6/NN
D001379_D000740 CID Azathioprine_0/JJ (r_nsubj) triggers_1/VBZ (l_appos) effect_7/NN (l_acl) contributing_9/VBG (l_prep) to_10/IN (l_pobj) anemia_14/NN
D001379_D000740 CID azathioprine_11/NN (r_advmod) induced_13/VBN (r_amod) anemia_14/NN
D010718_D000740 NONE phosphatidylserine_19/NN (r_pobj) of_18/IN (r_prep) exposure_17/NN (r_pobj) by_16/IN (r_agent) characterized_15/VBN (r_relcl) death_9/NN (r_pobj) from_5/IN (r_prep) result_4/VB (l_nsubj) anemia_2/NN
D010718_D000740 NONE PS_21/NNP (r_appos) phosphatidylserine_19/NN (r_pobj) of_18/IN (r_prep) exposure_17/NN (r_pobj) by_16/IN (r_agent) characterized_15/VBN (r_relcl) death_9/NN (r_pobj) from_5/IN (r_prep) result_4/VB (l_nsubj) anemia_2/NN
15229250
D008694_D001930 CID methamphetamine_20/NN (r_nmod) abuse_24/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) brain_16/NN
D008694_D001930 CID MA_22/NNP (r_nmod) abuse_24/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) brain_16/NN
D008694_D001930 CID MA_34/NNP (r_dobj) used_33/VBD (r_relcl) subjects_31/NNS (r_pobj) in_28/IN (r_prep) ventricles_27/VBZ
D008694_D001930 CID MA_10/NNP (r_compound) abuse_11/NN (r_pobj) of_9/IN (r_prep) symptoms_8/NNS (r_pobj) for_6/IN (r_prep) account_5/VB (r_xcomp) help_4/VB (l_xcomp) providing_13/VBG (l_dobj) targets_15/NNS (l_prep) for_16/IN (l_pobj) injury_21/NN
D008694_D008659 NONE MA_7/NNP (r_dobj) used_6/VBN (r_relcl) subjects_3/NNS (r_pobj) of_1/IN (r_prep) Studies_0/NNS (r_nsubj) revealed_10/VBN (l_dobj) deficits_11/NNS (l_prep) in_12/IN (l_pobj) systems_16/NNS (l_conj) abnormalities_20/NNS
D008694_D003072 NONE MA_26/NNP (r_compound) abuse_27/NN (r_pobj) with_24/IN (r_prep) associated_23/VBN (r_acl) alterations_22/NNS (r_pobj) of_19/IN (r_prep) pattern_18/NN (r_dobj) determined_16/VBD (l_conj) related_32/VBD (l_prep) to_35/IN (l_pobj) impairment_37/NN
D008694_D006984 NONE MA_3/NNP (r_compound) abusers_4/NNS (r_nsubj) had_5/VBD (l_npadvmod) 0.05_29/CD (l_conj) hypertrophy_36/NN
D008694_D008569 CID methamphetamine_7/NN (r_compound) abuse_8/NN (r_nsubj) causes_9/VBZ (l_dobj) pattern_12/NN (l_relcl) contributes_17/VBZ (l_prep) to_18/IN (l_pobj) performance_21/NN
15882284
D001241_D007676 CID aspirin_11/NN (l_conj) disease_29/NN
D001241_D007676 CID aspirin_11/NN (l_conj) disease_29/NN (l_appos) ESRD_31/NNP
D001241_D007676 CID aspirin_6/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) ESRD_3/NNP
D001241_D007676 CID aspirin_6/NN (r_pobj) of_5/IN (r_prep) use_4/NN (r_nsubj) increase_8/VB (l_dobj) risk_10/NN (l_prep) of_11/IN (l_pobj) ESRD_12/NNP
D001241_D007674 NONE aspirin_6/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) ESRD_3/NNP (r_pobj) of_2/IN (r_prep) risk_1/NN (r_nsubjpass) related_8/VBN (l_conj) was_20/VBD (l_prep) among_23/IN (l_pobj) subset_25/NN (l_prep) of_26/IN (l_pobj) patients_27/NNS (l_prep) with_28/IN (l_pobj) nephropathy_30/NN
9128918
D004298_D006966 NONE dopamine_5/NN (r_compound) neurons_6/NNS (r_pobj) in_4/IN (r_prep) changes_3/NNS (r_conj) hyperprolactinemia_1/NN
D004298_D006966 NONE dopamine_9/NN (r_compound) antagonist_11/NN (r_appos) haloperidol_6/NNP (r_pobj) with_5/IN (r_prep) treatment_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (l_nsubjpass) Hyperprolactinemia_0/NNP
D004298_D006966 NONE dopamine_6/NN (r_nmod) concentrations_10/NNS (l_prep) After_0/IN (l_pobj) months_2/NNS (l_prep) of_3/IN (l_pobj) hyperprolactinemia_4/NN
D004298_D006966 NONE DA_8/NNP (r_nmod) concentrations_10/NNS (l_prep) After_0/IN (l_pobj) months_2/NNS (l_prep) of_3/IN (l_pobj) hyperprolactinemia_4/NN
D004298_D006966 NONE DA_10/NNP (r_compound) concentrations_11/NNS (r_pobj) in_9/IN (r_prep) increase_8/NN (r_dobj) produced_4/VBD (l_nsubj) months_1/NNS (l_prep) of_2/IN (l_pobj) hyperprolactinemia_3/NN
D004298_D006966 NONE DA_2/NNP (r_compound) response_3/NN (r_nsubjpass) lost_5/VBN (l_advcl) followed_15/VBN (l_nsubjpass) hyperprolactinemia_13/NN
D004298_D006966 NONE DA_8/NNP (r_pobj) of_7/IN (r_prep) levels_6/NNS (r_pobj) in_4/IN (r_prep) change_3/NN (r_attr) was_1/VBD (l_prep) after_70/IN (l_pobj) 6-months_71/CD (l_prep) of_72/IN (l_pobj) hyperprolactinemia_73/NN
D004298_D006966 NONE DA_8/NNP (r_pobj) of_7/IN (r_prep) levels_6/NNS (r_pobj) in_4/IN (r_prep) change_3/NN (r_attr) was_1/VBD (l_attr) increase_76/NN (l_prep) after_83/IN (l_pobj) 9-months_84/CD (l_prep) of_85/IN (l_pobj) hyperprolactinemia_86/NN
D004298_D006966 NONE DA_78/NNP (r_compound) concentrations_79/NNS (r_pobj) in_77/IN (r_prep) increase_76/NN (r_attr) was_1/VBD (l_prep) after_70/IN (l_pobj) 6-months_71/CD (l_prep) of_72/IN (l_pobj) hyperprolactinemia_73/NN
D004298_D006966 NONE DA_78/NNP (r_compound) concentrations_79/NNS (r_pobj) in_77/IN (r_prep) increase_76/NN (l_prep) after_83/IN (l_pobj) 9-months_84/CD (l_prep) of_85/IN (l_pobj) hyperprolactinemia_86/NN
D006220_D006966 CID haloperidol_6/NNP (r_pobj) with_5/IN (r_prep) treatment_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (l_nsubjpass) Hyperprolactinemia_0/NNP
D006220_D006966 CID haloperidol_10/NN (r_npadvmod) induced_12/VBN (r_amod) hyperprolactinemia_13/NN
D009638_D006966 NONE norepinephrine_10/NN (r_conj) DA_8/NNP (r_pobj) of_7/IN (r_prep) levels_6/NNS (r_pobj) in_4/IN (r_prep) change_3/NN (r_attr) was_1/VBD (l_prep) after_70/IN (l_pobj) 6-months_71/CD (l_prep) of_72/IN (l_pobj) hyperprolactinemia_73/NN
D009638_D006966 NONE norepinephrine_10/NN (r_conj) DA_8/NNP (r_pobj) of_7/IN (r_prep) levels_6/NNS (r_pobj) in_4/IN (r_prep) change_3/NN (r_attr) was_1/VBD (l_attr) increase_76/NN (l_prep) after_83/IN (l_pobj) 9-months_84/CD (l_prep) of_85/IN (l_pobj) hyperprolactinemia_86/NN
D009638_D006966 NONE NE_12/NNP (r_parataxis) norepinephrine_10/NN (r_conj) DA_8/NNP (r_pobj) of_7/IN (r_prep) levels_6/NNS (r_pobj) in_4/IN (r_prep) change_3/NN (r_attr) was_1/VBD (l_prep) after_70/IN (l_pobj) 6-months_71/CD (l_prep) of_72/IN (l_pobj) hyperprolactinemia_73/NN
D009638_D006966 NONE NE_12/NNP (r_parataxis) norepinephrine_10/NN (r_conj) DA_8/NNP (r_pobj) of_7/IN (r_prep) levels_6/NNS (r_pobj) in_4/IN (r_prep) change_3/NN (r_attr) was_1/VBD (l_attr) increase_76/NN (l_prep) after_83/IN (l_pobj) 9-months_84/CD (l_prep) of_85/IN (l_pobj) hyperprolactinemia_86/NN
D012701_D006966 NONE serotonin_15/NNS (r_dep) was_1/VBD (l_prep) after_70/IN (l_pobj) 6-months_71/CD (l_prep) of_72/IN (l_pobj) hyperprolactinemia_73/NN
D012701_D006966 NONE serotonin_15/NNS (r_dep) was_1/VBD (l_attr) increase_76/NN (l_prep) after_83/IN (l_pobj) 9-months_84/CD (l_prep) of_85/IN (l_pobj) hyperprolactinemia_86/NN
D012701_D006966 NONE 5-HT_17/CD (r_appos) serotonin_15/NNS (r_dep) was_1/VBD (l_prep) after_70/IN (l_pobj) 6-months_71/CD (l_prep) of_72/IN (l_pobj) hyperprolactinemia_73/NN
D012701_D006966 NONE 5-HT_17/CD (r_appos) serotonin_15/NNS (r_dep) was_1/VBD (l_attr) increase_76/NN (l_prep) after_83/IN (l_pobj) 9-months_84/CD (l_prep) of_85/IN (l_pobj) hyperprolactinemia_86/NN
D006897_D006966 NONE acid_63/NN (r_pobj) in_61/IN (r_prep) decrease_60/NN (r_pobj) for_58/IN (r_prep) except_57/IN (r_prep) serotonin_15/NNS (r_dep) was_1/VBD (l_prep) after_70/IN (l_pobj) 6-months_71/CD (l_prep) of_72/IN (l_pobj) hyperprolactinemia_73/NN
D006897_D006966 NONE acid_63/NN (r_pobj) in_61/IN (r_prep) decrease_60/NN (r_pobj) for_58/IN (r_prep) except_57/IN (r_prep) serotonin_15/NNS (r_dep) was_1/VBD (l_attr) increase_76/NN (l_prep) after_83/IN (l_pobj) 9-months_84/CD (l_prep) of_85/IN (l_pobj) hyperprolactinemia_86/NN
D006897_D006966 NONE 5-HIAA_65/CD (r_appos) acid_63/NN (r_pobj) in_61/IN (r_prep) decrease_60/NN (r_pobj) for_58/IN (r_prep) except_57/IN (r_prep) serotonin_15/NNS (r_dep) was_1/VBD (l_prep) after_70/IN (l_pobj) 6-months_71/CD (l_prep) of_72/IN (l_pobj) hyperprolactinemia_73/NN
D006897_D006966 NONE 5-HIAA_65/CD (r_appos) acid_63/NN (r_pobj) in_61/IN (r_prep) decrease_60/NN (r_pobj) for_58/IN (r_prep) except_57/IN (r_prep) serotonin_15/NNS (r_dep) was_1/VBD (l_attr) increase_76/NN (l_prep) after_83/IN (l_pobj) 9-months_84/CD (l_prep) of_85/IN (l_pobj) hyperprolactinemia_86/NN
24434397
D014148_D012640 NONE acid_1/NN (r_nmod) seizure_6/NN
D014148_D012640 NONE TNA_14/NNP (r_pobj) of_13/IN (r_prep) overdose_12/NN (r_attr) be_10/VB (r_xcomp) believed_8/VBN (l_nsubjpass) cause_4/NN (l_prep) of_5/IN (l_pobj) convulsions_6/NNS
D014148_D051437 NONE acid_1/NN (r_nmod) seizure_6/NN (l_prep) in_7/IN (l_pobj) failure_9/NN
D014148_D004830 CID TNA_7/NNP (r_pobj) of_6/IN (r_prep) dose_5/NN (r_pobj) after_2/IN (r_prep) had_10/VBD (l_dobj) episode_12/NN (l_prep) of_13/IN (l_pobj) convulsions_17/NNS
D014148_D062787 NONE TNA_14/NNP (r_pobj) of_13/IN (r_prep) overdose_12/NN
6673474
D009599_D007022 CID nitroprusside_14/NNP (r_pobj) under_12/IN (r_prep) dogs_11/NNS (r_pobj) in_10/IN (r_prep) studied_9/VBN (l_conj) hypotension_24/NN
D009599_D007022 CID SNP_16/NNP (r_appos) nitroprusside_14/NNP (r_pobj) under_12/IN (r_prep) dogs_11/NNS (r_pobj) in_10/IN (r_prep) studied_9/VBN (l_conj) hypotension_24/NN
D009599_D007022 CID nitroprusside_30/JJ (r_amod) hypotension_31/NN (r_nsubjpass) used_35/VBN (r_ccomp) confirm_28/VB (l_prep) Regarding_0/VBG (l_pobj) effects_2/NNS (l_prep) of_3/IN (l_pobj) hypotension_7/NN
D009599_D007022 CID nitroprusside_30/JJ (r_amod) hypotension_31/NN
D009599_D007022 CID nitroprusside_30/JJ (r_amod) hypotension_31/NN (r_nsubjpass) used_35/VBN (l_prep) to_36/IN (l_pobj) decrease_42/NN (l_conj) hypotension_47/NN
D009599_D007022 CID SNP_6/NNP (r_compound) hypotension_7/NN
D014294_D007022 CID trimetaphan_19/NNP (r_nmod) hypotension_24/NN
D014294_D007022 CID TMP_21/NNP (r_nmod) hypotension_24/NN
D014294_D007022 CID trimetaphan_46/NNP (r_compound) hypotension_47/NN (r_conj) decrease_42/NN (r_pobj) to_36/IN (r_prep) used_35/VBN (r_ccomp) confirm_28/VB (l_prep) Regarding_0/VBG (l_pobj) effects_2/NNS (l_prep) of_3/IN (l_pobj) hypotension_7/NN
D014294_D007022 CID trimetaphan_46/NNP (r_compound) hypotension_47/NN (r_conj) decrease_42/NN (r_pobj) to_36/IN (r_prep) used_35/VBN (l_nsubjpass) hypotension_31/NN
D014294_D007022 CID trimetaphan_46/NNP (r_compound) hypotension_47/NN
20595935
D014700_D006966 NONE Verapamil_0/NN (r_compound) stimulation_1/NN (r_compound) test_2/NN (l_prep) in_3/IN (l_pobj) hyperprolactinemia_4/NNP
D014700_D006966 NONE Verapamil_2/NN (r_compound) stimulation_3/NN (r_compound) test_4/NN (r_nsubjpass) investigated_7/VBN (l_prep) as_8/IN (l_pobj) tool_10/NN (l_prep) for_11/IN (l_pobj) diagnosis_13/NN (l_prep) of_14/IN (l_pobj) hyperprolactinemia_15/NNP
D014700_D006966 NONE Verapamil_0/NNP (r_nsubj) increased_2/VBD (l_dep) PRL_12/NN (l_appos) PRL_59/NN (l_conj) hyperprolactinemia_69/NNP
D014700_D006966 NONE verapamil_7/NN (r_pobj) to_6/IN (r_aux) defined_8/VBN (r_acl) unresponsiveness_5/NN (r_nsubj) discriminated_15/VBN (r_ccomp) revealed_3/VBD (l_npadvmod) sensitivity_22/NN (l_appos) specificity_27/NN (l_appos) %_30/NN (l_acl) associated_46/VBN (l_prep) with_47/IN (l_pobj) pseudoprolactinoma_48/NNP (l_conj) hyperprolactinemia_53/NN
D014700_D006966 NONE Verapamil_0/NN (r_compound) responsiveness_1/NN (r_nsubj) is_2/VBZ (l_attr) finding_6/NN (l_prep) for_7/IN (l_pobj) diagnosis_10/NN (l_prep) of_11/IN (l_pobj) hyperprolactinemia_12/NNP
D014700_D006966 NONE verapamil_2/NN (r_compound) unresponsiveness_3/NN (r_nsubj) discriminates_4/VBZ (l_prep) from_17/IN (l_pobj) causes_19/NNS (l_prep) of_20/IN (l_pobj) hyperprolactinemia_21/NN
D014700_D015175 NONE verapamil_12/NN (r_pobj) of_11/IN (r_prep) value_10/NN (r_dobj) investigate_7/VB (l_prep) in_13/IN (l_pobj) population_15/NN (l_relcl) screened_19/VBN (l_prep) for_20/IN (l_pobj) macroprolactinemia_21/NNP
D014700_D015175 NONE Verapamil_0/NNP (r_nsubj) increased_2/VBD (l_dep) PRL_12/NN (l_appos) PRL_59/NN (l_dep) macroprolactinoma_18/NNP
D014700_D015175 NONE Verapamil_0/NNP (r_nsubj) increased_2/VBD (l_dep) PRL_12/NN (l_appos) PRL_59/NN (l_dep) macroprolactinoma_18/NNP (l_conj) microprolactinoma_29/NNP
D014700_D015175 NONE Verapamil_0/NNP (r_nsubj) increased_2/VBD (l_dep) PRL_12/NN (l_appos) PRL_59/NN (l_dep) macroprolactinoma_18/NNP (l_conj) macroprolactinemia_40/NNP
D014700_-1 NONE Verapamil_0/NNP (r_nsubj) increased_2/VBD (l_dep) PRL_12/NN (l_appos) PRL_59/NN (l_dep) macroprolactinoma_18/NNP (l_conj) in_53/IN (l_pobj) pseudoprolactinoma_54/NNP
D014700_-1 NONE verapamil_7/NN (r_pobj) to_6/IN (r_aux) defined_8/VBN (r_acl) unresponsiveness_5/NN (r_nsubj) discriminated_15/VBN (r_ccomp) revealed_3/VBD (l_npadvmod) sensitivity_22/NN (l_appos) specificity_27/NN (l_appos) %_30/NN (l_acl) associated_46/VBN (l_prep) with_47/IN (l_pobj) pseudoprolactinoma_48/NNP
D018967_D015175 NONE risperidone_66/NNP (r_npadvmod) induced_68/VBN (r_amod) hyperprolactinemia_69/NNP (r_conj) PRL_59/NN (l_dep) macroprolactinoma_18/NNP
D018967_D015175 NONE risperidone_66/NNP (r_npadvmod) induced_68/VBN (r_amod) hyperprolactinemia_69/NNP (r_conj) PRL_59/NN (l_dep) macroprolactinoma_18/NNP (l_conj) microprolactinoma_29/NNP
D018967_D015175 NONE risperidone_66/NNP (r_npadvmod) induced_68/VBN (r_amod) hyperprolactinemia_69/NNP (r_conj) PRL_59/NN (l_dep) macroprolactinoma_18/NNP (l_conj) macroprolactinemia_40/NNP
D018967_-1 NONE risperidone_66/NNP (r_npadvmod) induced_68/VBN (r_amod) hyperprolactinemia_69/NNP (r_conj) PRL_59/NN (l_dep) macroprolactinoma_18/NNP (l_conj) in_53/IN (l_pobj) pseudoprolactinoma_54/NNP
D018967_-1 NONE risperidone_50/NNP (r_npadvmod) induced_52/VBN (r_amod) hyperprolactinemia_53/NN (r_conj) pseudoprolactinoma_48/NNP
D018967_D006966 CID risperidone_66/NNP (r_npadvmod) induced_68/VBN (r_amod) hyperprolactinemia_69/NNP
D018967_D006966 CID risperidone_50/NNP (r_npadvmod) induced_52/VBN (r_amod) hyperprolactinemia_53/NN
2767010
C043114_D012640 NONE ACC-9653_0/NNP (r_nmod) sodium_3/NN (r_nsubj) have_4/VBP (l_dobj) activity_7/NN (l_prep) against_8/IN (l_pobj) seizures_9/NNS
C043114_D012640 NONE sodium_3/NN (r_nsubj) have_4/VBP (l_dobj) activity_7/NN (l_prep) against_8/IN (l_pobj) seizures_9/NNS
C043114_D017180 NONE ACC-9653_0/NNP (r_nmod) sodium_3/NN (r_nsubj) have_4/VBP (l_dobj) activity_7/NN (l_prep) against_8/IN (l_pobj) tachycardia_13/NN
C043114_D017180 NONE sodium_3/NN (r_nsubj) have_4/VBP (l_dobj) activity_7/NN (l_prep) against_8/IN (l_pobj) tachycardia_13/NN
D010042_D017180 CID ouabain_9/NN (r_npadvmod) induced_11/VBN (r_amod) tachycardia_13/NN
C043114_D001145 NONE ACC-9653_4/NN (r_nmod) sodium_7/NN (l_amod) necessary_8/JJ (l_xcomp) convert_10/VB (l_dobj) arrhythmia_12/NN
C043114_D001145 NONE sodium_7/NN (l_amod) necessary_8/JJ (l_xcomp) convert_10/VB (l_dobj) arrhythmia_12/NN
C043114_D001145 NONE sodium_2/NN (r_nsubj) displayed_3/VBN (l_prep) in_4/IN (l_pobj) activity_7/NN (l_prep) against_8/IN (l_pobj) arrhythmias_12/NNS
D013327_D001145 CID strophanthidin_9/NNP (r_npadvmod) induced_11/VBN (r_amod) arrhythmias_12/NNS
C043114_D064420 NONE ACC-9653_4/NNP (r_nmod) sodium_7/NN (r_pobj) of_3/IN (r_prep) studies_2/NNS (l_compound) toxicity_1/NN
C043114_D064420 NONE sodium_7/NN (r_pobj) of_3/IN (r_prep) studies_2/NNS (l_compound) toxicity_1/NN
15482540
D012254_D000740 NONE ribavirin_3/NN (r_advmod) induced_5/VBN (r_amod) anemia_6/NN
D012254_D000740 NONE ribavirin_10/NN (r_advmod) induced_12/VBN (r_amod) anemia_13/NN
D012254_D000740 NONE ribavirin_12/RB (r_advmod) induced_14/VBN (r_amod) anemia_15/NN
D012254_D000740 NONE Ribavirin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) anemia_3/NN
D016898_D019698 NONE Interferon_0/NNP (l_conj) therapy_4/NN (l_prep) for_5/IN (l_pobj) C_8/NNP
D016898_D019698 NONE alpha-2b_12/NN (r_dobj) received_9/VBD (r_relcl) patients_3/NNS (l_prep) with_4/IN (l_pobj) C_7/NNP
D016898_D000743 CID Interferon_0/NNP (r_nsubj) produces_9/VBZ (l_dobj) anemia_11/NN
D012254_D019698 NONE ribavirin_2/NNP (r_conj) Interferon_0/NNP (l_conj) therapy_4/NN (l_prep) for_5/IN (l_pobj) C_8/NNP
D012254_D019698 NONE ribavirin_27/NNP (r_pobj) with_26/IN (r_prep) combination_25/NN (r_pobj) in_24/IN (r_prep) weeks_23/NNS (r_pobj) for_21/IN (r_prep) administered_19/VBD (r_acl) MU_18/NNP (r_pobj) of_16/IN (r_prep) dose_15/NN (r_pobj) at_13/IN (r_prep) received_9/VBD (r_relcl) patients_3/NNS (l_prep) with_4/IN (l_pobj) C_7/NNP
D012254_D000743 CID ribavirin_2/NNP (r_conj) Interferon_0/NNP (r_nsubj) produces_9/VBZ (l_dobj) anemia_11/NN
23433219
D008694_D011605 CID methamphetamine_6/NN (r_compound) psychosis_7/NN
D008694_D011605 CID methamphetamine_9/NN (r_npadvmod) dependent_11/JJ (r_amod) patients_12/NNS (r_pobj) in_8/IN (r_prep) factors_4/NNS (l_prep) of_5/IN (l_pobj) psychosis_7/NN
D008694_D011605 CID methamphetamine_14/NN (r_npadvmod) induced_16/VBN (r_amod) psychosis_17/NN
D008694_D011605 CID methamphetamine_21/NN (r_compound) dependence_22/NN (r_pobj) with_20/IN (r_prep) patients_19/NNS (r_pobj) in_18/IN (r_prep) risk_9/NN (l_prep) of_10/IN (l_pobj) lifetime_11/NN (l_conj) psychosis_17/NN
D008694_D011605 CID methamphetamine_8/NN (r_npadvmod) induced_10/VBN (r_amod) psychosis_11/NN
D008694_D011605 CID methamphetamine_5/NN (r_pobj) of_4/IN (r_prep) diagnosis_3/NN (r_pobj) with_1/IN (r_prep) Patients_0/NNS (r_nsubjpass) interviewed_12/VBN (l_advcl) using_13/VBG (l_prep) for_22/IN (l_pobj) psychosis_26/NN
D008694_D011605 CID methamphetamine_23/NN (r_npadvmod) induced_25/VBN (r_amod) psychosis_26/NN
D008694_D011605 CID methamphetamine_32/NN (r_compound) uses_33/NNS (r_conj) disorder_21/NN (r_conj) disorder_9/NN (r_nsubjpass) associated_36/VBN (l_prep) with_37/IN (l_pobj) psychosis_42/NN
D008694_D011605 CID methamphetamine_39/NN (r_npadvmod) induced_41/VBN (r_amod) psychosis_42/NN
D008694_D011605 CID methamphetamine_10/NN (r_compound) dependence_11/NN (r_pobj) with_9/IN (r_prep) patients_8/NNS (r_pobj) in_7/IN (r_prep) risk_4/NN (l_prep) of_5/IN (l_pobj) psychosis_6/NN
D008694_D011605 CID methamphetamine_7/NN (r_compound) dependence_8/NN (r_pobj) of_6/IN (r_prep) cases_5/NNS (r_nsubjpass) screened_11/VBN (l_prep) for_12/IN (l_pobj) symptoms_14/NNS
D008694_D001714 CID methamphetamine_32/NN (r_compound) uses_33/NNS (r_conj) disorder_21/NN (r_conj) disorder_9/NN
D008694_D001714 CID methamphetamine_39/NN (r_npadvmod) induced_41/VBN (r_amod) psychosis_42/NN (r_pobj) with_37/IN (r_prep) associated_36/VBN (l_nsubjpass) disorder_9/NN
D008694_D000987 CID methamphetamine_32/NN (r_compound) uses_33/NNS (r_conj) disorder_21/NN
D008694_D000987 CID methamphetamine_39/NN (r_npadvmod) induced_41/VBN (r_amod) psychosis_42/NN (r_pobj) with_37/IN (r_prep) associated_36/VBN (l_nsubjpass) disorder_9/NN (l_conj) disorder_21/NN
D008694_D000987 CID methamphetamine_15/NN (r_compound) use_16/NN (r_conj) personality_11/NN
D008694_D019964 NONE methamphetamine_15/NN (r_compound) use_16/NN (r_conj) personality_11/NN (r_conj) disorder_8/NN
17445520
D002110_D016584 CID Caffeine_0/NN (r_compound) test_2/NN (l_prep) in_3/IN (l_pobj) disorder_5/NN
D002110_D016584 CID Caffeine_0/NN (r_compound) test_2/NN (l_prep) with_8/IN (l_pobj) attacks_10/NNS
D002110_D016584 CID caffeine_51/NN (r_compound) challenge_52/NN (r_compound) test_53/NN (r_pobj) by_48/IN (r_prep) induction_44/NN (r_pobj) to_42/IN (r_prep) way_41/NN (r_pobj) in_38/IN (r_prep) respond_37/VBP (l_nsubj) patients_6/NNS (l_prep) with_7/IN (l_pobj) disorder_9/NN
D002110_D016584 CID caffeine_51/NN (r_compound) challenge_52/NN (r_compound) test_53/NN (r_pobj) by_48/IN (r_prep) induction_44/NN (r_pobj) to_42/IN (r_prep) way_41/NN (r_pobj) in_38/IN (r_prep) respond_37/VBP (l_nsubj) patients_6/NNS (l_prep) with_7/IN (l_pobj) disorder_9/NN (l_appos) PD_11/NNP
D002110_D016584 CID caffeine_51/NN (r_compound) challenge_52/NN (r_compound) test_53/NN (r_pobj) by_48/IN (r_prep) induction_44/NN (r_pobj) to_42/IN (r_prep) way_41/NN (r_pobj) in_38/IN (r_prep) respond_37/VBP (l_nsubj) patients_6/NNS (l_conj) patients_14/NNS (l_prep) with_15/IN (l_pobj) depression_17/NN (l_prep) with_18/IN (l_pobj) attacks_20/NNS
D002110_D016584 CID caffeine_51/NN (r_compound) challenge_52/NN (r_compound) test_53/NN (r_pobj) by_48/IN (r_prep) induction_44/NN (l_prep) of_45/IN (l_pobj) attacks_47/NNS
D002110_D016584 CID caffeine_56/NN (r_compound) challenge_57/NN (r_compound) test_58/NN (r_pobj) after_53/IN (r_prep) had_49/VBD (l_nsubj) total_1/NN (l_prep) of_2/IN (l_pobj) %_4/NN (l_prep) of_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) PD_13/NNP
D002110_D016584 CID caffeine_56/NN (r_compound) challenge_57/NN (r_compound) test_58/NN (r_pobj) after_53/IN (r_prep) had_49/VBD (l_dobj) attack_52/NN
D002110_D016584 CID caffeine_10/NN (r_pobj) to_9/IN (r_prep) sensitive_8/JJ (r_acomp) were_6/VBD (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) PD_3/NNP
D002110_D016584 CID caffeine_7/NN (r_npadvmod) free_9/JJ (r_amod) intake_11/NN (r_pobj) after_5/IN (r_prep) observed_4/VBN (l_nsubjpass) attack_2/NN
D002110_D016584 CID caffeine_26/NN (r_compound) challenge_27/NN (r_compound) test_28/NN (r_pobj) to_23/IN (r_prep) hyperreactivity_22/NN (r_conj) matter_13/RB (r_advmod) is_5/VBZ (l_attr) association_7/NN (l_prep) between_8/IN (l_pobj) attacks_10/NNS
D002110_D016584 CID caffeine_26/NN (r_compound) challenge_27/NN (r_compound) test_28/NN (r_pobj) to_23/IN (r_prep) hyperreactivity_22/NN (r_conj) matter_13/RB (l_advcl) associated_15/VBN (l_prep) with_16/IN (l_pobj) PD_17/NNP
D002110_D016584 NONE caffeine_51/NN (r_compound) challenge_52/NN (r_compound) test_53/NN (r_pobj) by_48/IN (r_prep) induction_44/NN (r_pobj) to_42/IN (r_prep) way_41/NN (r_pobj) in_38/IN (r_prep) respond_37/VBP (l_nsubj) patients_6/NNS (l_conj) patients_14/NNS (l_prep) with_15/IN (l_pobj) depression_17/NN (l_prep) with_18/IN (l_pobj) attacks_20/NNS (l_appos) MDP_22/NNP
D002110_D016584 NONE caffeine_56/NN (r_compound) challenge_57/NN (r_compound) test_58/NN (r_pobj) after_53/IN (r_prep) had_49/VBD (l_nsubj) total_1/NN (l_appos) %_16/NN (l_prep) of_22/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) MDP_25/NNP
D002110_D016584 NONE caffeine_10/NN (r_pobj) to_9/IN (r_prep) sensitive_8/JJ (r_acomp) were_6/VBD (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) PD_3/NNP (l_conj) MDP_5/NNP
D002110_D016584 NONE caffeine_26/NN (r_compound) challenge_27/NN (r_compound) test_28/NN (r_pobj) to_23/IN (r_prep) hyperreactivity_22/NN (r_conj) matter_13/RB (l_advcl) associated_15/VBN (l_prep) with_16/IN (l_pobj) PD_17/NNP (l_conj) MDP_19/NNP
D002110_D003866 NONE Caffeine_0/NN (r_compound) test_2/NN (l_prep) in_3/IN (l_pobj) disorder_5/NN (l_conj) depression_7/NN
D002110_D003865 NONE caffeine_51/NN (r_compound) challenge_52/NN (r_compound) test_53/NN (r_pobj) by_48/IN (r_prep) induction_44/NN (r_pobj) to_42/IN (r_prep) way_41/NN (r_pobj) in_38/IN (r_prep) respond_37/VBP (l_nsubj) patients_6/NNS (l_conj) patients_14/NNS (l_prep) with_15/IN (l_pobj) depression_17/NN
D002110_D003865 NONE caffeine_51/NN (r_compound) challenge_52/NN (r_compound) test_53/NN (r_pobj) by_48/IN (r_prep) induction_44/NN (r_pobj) to_42/IN (r_prep) way_41/NN (r_pobj) in_38/IN (r_prep) respond_37/VBP (l_nsubj) patients_6/NNS (l_conj) patients_14/NNS (l_prep) with_15/IN (l_pobj) depression_17/NN (l_prep) with_18/IN (l_pobj) attacks_20/NNS (l_appos) MDP_22/NNP
D002110_D003865 NONE caffeine_56/NN (r_compound) challenge_57/NN (r_compound) test_58/NN (r_pobj) after_53/IN (r_prep) had_49/VBD (l_nsubj) total_1/NN (l_appos) %_16/NN (l_prep) of_22/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) MDP_25/NNP
D002110_D003865 NONE caffeine_56/NN (r_compound) challenge_57/NN (r_compound) test_58/NN (r_pobj) after_53/IN (r_prep) had_49/VBD (l_nsubj) total_1/NN (l_appos) %_16/NN (l_prep) of_22/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) MDP_25/NNP (l_appos) %_28/NN (l_prep) of_34/IN (l_pobj) patients_35/NNS (l_prep) with_36/IN (l_pobj) MD_37/NNP
D002110_D003865 NONE caffeine_10/NN (r_pobj) to_9/IN (r_prep) sensitive_8/JJ (r_acomp) were_6/VBD (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) PD_3/NNP (l_conj) MDP_5/NNP
D002110_D003865 NONE caffeine_10/NN (r_pobj) to_9/IN (r_prep) sensitive_8/JJ (l_advcl) were_12/VBD (l_nsubj) patients_13/NNS (l_prep) with_14/IN (l_pobj) MD_15/NNP
D002110_D003865 NONE caffeine_26/NN (r_compound) challenge_27/NN (r_compound) test_28/NN (r_pobj) to_23/IN (r_prep) hyperreactivity_22/NN (r_conj) matter_13/RB (l_advcl) associated_15/VBN (l_prep) with_16/IN (l_pobj) PD_17/NNP (l_conj) MDP_19/NNP
D002110_D001523 NONE caffeine_51/NN (r_compound) challenge_52/NN (r_compound) test_53/NN (r_pobj) by_48/IN (r_prep) induction_44/NN (r_pobj) to_42/IN (r_prep) way_41/NN (r_pobj) in_38/IN (r_prep) respond_37/VBP (l_nsubj) patients_6/NNS (l_conj) patients_14/NNS (l_prep) with_15/IN (l_pobj) depression_17/NN (l_prep) with_18/IN (l_pobj) attacks_20/NNS (l_appos) Manual_28/NNP (l_prep) of_29/IN (l_pobj) Disorders_31/NNPS
D002110_D001008 NONE caffeine_17/NN (r_nsubjpass) administered_28/VBN (l_prep) in_29/IN (l_pobj) form_32/NN (l_conj) scales_35/NNS (l_compound) anxiety_34/NN
D002110_D001008 NONE caffeine_20/NN (r_npadvmod) free_22/JJ (r_amod) solution_26/NN (r_conj) caffeine_17/NN (r_nsubjpass) administered_28/VBN (l_prep) in_29/IN (l_pobj) form_32/NN (l_conj) scales_35/NNS (l_compound) anxiety_34/NN
8825380
D011692_D007674 CID aminonucleoside_15/RB (r_compound) nephropathy_16/NN
D011692_D007674 CID aminonucleoside_15/RB (r_nmod) nephropathy_19/NN
D011692_D007674 CID aminonucleoside_15/RB (r_nmod) nephropathy_19/NN (l_appos) model_23/NN (l_prep) of_24/IN (l_pobj) disease_26/NN
D011692_D007674 CID PAN_17/NNP (r_nmod) nephropathy_19/NN
D011692_D007674 CID PAN_17/NNP (r_nmod) nephropathy_19/NN (l_appos) model_23/NN (l_prep) of_24/IN (l_pobj) disease_26/NN
D011692_D007674 CID PAN_27/NNP (r_compound) nephropathy_28/NN
D011692_D007674 CID PAN_9/NNP (r_pobj) of_8/IN (r_prep) injections_7/NNS (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_nsubjpass) glomerulopathy_1/NN
D011692_D007674 CID PAN_6/NNP (r_compound) nephropathy_7/NN
D011692_D007674 CID PAN_33/NNP (r_compound) animals_35/NNS (l_compound) nephropathy_34/NN
D011692_D007674 CID PAN_3/NNP (r_compound) nephropathy_4/NN
D011692_D007674 CID PAN_19/NNP (r_compound) nephropathy_20/NN
D011692_D006130 NONE PAN_27/NNP (r_compound) nephropathy_28/NN (r_pobj) with_25/IN (r_prep) rats_24/NNS (r_pobj) in_23/IN (r_prep) failure_22/NN
D008315_D007674 NONE malondialdehyde_22/NNP (r_compound) content_23/NN (r_conj) injury_17/NN (r_conj) glomerulosclerosis_14/NN (r_dobj) increased_12/VBN (r_conj) associated_6/VBN (l_prep) with_7/IN (l_pobj) hypertrophy_10/NN
D008315_D007674 NONE malondialdehyde_26/NNP (r_compound) content_27/NN (l_conj) damage_33/NN
D008315_D005921 NONE malondialdehyde_22/NNP (r_compound) content_23/NN (r_conj) injury_17/NN (r_conj) glomerulosclerosis_14/NN
D008315_-1 NONE malondialdehyde_22/NNP (r_compound) content_23/NN (r_conj) injury_17/NN
D008315_D011507 NONE malondialdehyde_26/NNP (r_compound) content_27/NN (r_conj) area_22/NN (r_conj) GFR_18/NNP (r_conj) proteinuria_16/NN
1943082
D005978_D007511 NONE glutathione_8/NN (r_pobj) in_4/IN (r_prep) change_3/NN (l_prep) following_9/VBG (l_pobj) injury_14/NN (l_compound) reperfusion_13/NN (l_compound) ischemia_11/NN
D005978_D015427 NONE glutathione_8/NN (r_pobj) in_4/IN (r_prep) change_3/NN (l_prep) following_9/VBG (l_pobj) injury_14/NN
8701013
D015738_D003693 CID Famotidine_0/NNP (r_npadvmod) associated_2/VBN (r_amod) delirium_3/NN
D015738_D003693 CID famotidine_25/NNP (r_pobj) with_24/IN (r_prep) associated_23/VBN (l_advcl) shown_9/VBN (l_dobj) propensity_11/NN (l_acl) cause_13/VB (l_dobj) delirium_14/NN
D015738_D003693 CID famotidine_7/NN (r_npadvmod) associated_9/VBN (r_amod) delirium_10/NN
D015738_D003693 CID famotidine_20/NNP (r_pobj) of_19/IN (r_prep) removal_18/NN (r_pobj) upon_17/IN (r_prep) cleared_15/VBD (r_relcl) patients_13/NNS (r_pobj) in_11/IN (r_prep) cases_5/NNS (l_prep) of_6/IN (l_pobj) delirium_10/NN
D015738_D014456 NONE Famotidine_0/NNP (r_nsubj) is_1/VBZ (l_attr) antagonist_5/NN (l_acl) used_6/VBN (l_prep) in_7/IN (l_pobj) settings_9/NNS (l_prep) for_10/IN (l_pobj) prevention_11/NN (l_prep) of_12/IN (l_pobj) ulcers_14/NNS
2021990
D002927_D007022 CID cimetidine_15/RB (r_pobj) by_13/IN (r_agent) caused_12/VBN (r_acl) hypotension_11/NN
D002927_D007022 CID cimetidine_22/NN (r_pobj) of_21/IN (r_prep) activity_20/NN (r_nsubjpass) mediated_24/VBN (r_advcl) preventing_10/VBG (l_dobj) hypotension_11/NN
1424076
D014750_D007177 CID vincristine_9/NN (r_pobj) after_7/IN (r_prep) secretion_3/NN (l_prep) of_4/IN (l_pobj) hormone_6/NN
D014750_D007177 CID vincristine_16/NN (r_compound) infusion_17/NN (r_pobj) to_14/IN (r_prep) attributed_13/VBN (r_relcl) hormone_9/NN
D014750_D009101 NONE vincristine_18/NN (r_pobj) of_17/IN (r_prep) infusion_16/NN (r_pobj) with_11/IN (r_prep) treated_10/VBN (l_nsubjpass) woman_4/NN (l_prep) with_5/IN (l_pobj) myeloma_8/NN
D004317_D009101 NONE doxorubicin_20/NN (r_conj) vincristine_18/NN (r_pobj) of_17/IN (r_prep) infusion_16/NN (r_pobj) with_11/IN (r_prep) treated_10/VBN (l_nsubjpass) woman_4/NN (l_prep) with_5/IN (l_pobj) myeloma_8/NN
D003907_D009101 NONE dexamethasone_26/NN (r_pobj) of_24/IN (r_prep) days_23/NNS (r_conj) infusion_16/NN (r_pobj) with_11/IN (r_prep) treated_10/VBN (l_nsubjpass) woman_4/NN (l_prep) with_5/IN (l_pobj) myeloma_8/NN
24802403
D008687_D012640 NONE Metformin_0/NN (r_nsubj) protects_1/VBZ (l_prep) against_2/IN (l_pobj) seizures_3/NNS
D008687_D012640 NONE metformin_10/NN (r_pobj) of_9/IN (r_prep) effects_8/NNS (l_prep) on_11/IN (l_pobj) seizures_12/NNS
D008687_D012640 NONE metformin_6/NNP (r_nsubj) be_8/VB (l_attr) agent_11/NN (l_prep) for_12/IN (l_pobj) treatment_14/NN (l_conj) medicine_22/NN (l_prep) against_23/IN (l_pobj) impairment_25/NN (l_acl) induced_26/VBN (l_agent) by_27/IN (l_pobj) seizures_28/NNS
D008687_D007859 NONE Metformin_0/NN (r_nsubj) protects_1/VBZ (l_prep) against_2/IN (l_pobj) seizures_3/NNS (l_conj) impairments_8/NNS
D008687_D008569 NONE Metformin_0/NN (r_nsubj) protects_1/VBZ (l_prep) against_2/IN (l_pobj) seizures_3/NNS (l_conj) impairments_8/NNS
D010433_D012640 CID pentylenetetrazole_14/NN (r_npadvmod) induced_16/VBN (r_amod) kindling_17/NN (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) damage_11/NN (r_conj) impairments_8/NNS (r_conj) seizures_3/NNS
D010433_D012640 CID pentylenetetrazole_23/NN (r_npadvmod) induced_25/VBN (r_amod) animals_27/NNS (r_pobj) in_22/IN (r_prep) observed_21/VBN (r_acl) markers_20/NNS (r_conj) impairment_15/NN (r_conj) seizures_12/NNS
D010433_D007859 CID pentylenetetrazole_14/NN (r_npadvmod) induced_16/VBN (r_amod) kindling_17/NN (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) damage_11/NN (r_conj) impairments_8/NNS
D010433_D008569 CID pentylenetetrazole_14/NN (r_npadvmod) induced_16/VBN (r_amod) kindling_17/NN (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) damage_11/NN (r_conj) impairments_8/NNS
D008687_D003072 NONE metformin_10/NN (r_pobj) of_9/IN (r_prep) effects_8/NNS (l_prep) on_11/IN (l_pobj) seizures_12/NNS (l_conj) impairment_15/NN
D008687_D003072 NONE metformin_3/NNP (r_nsubj) suppressed_4/VBD (l_conj) ameliorated_10/VBD (l_dobj) impairment_13/NN
D008687_D003072 NONE metformin_6/NNP (r_nsubj) be_8/VB (l_attr) agent_11/NN (l_prep) for_12/IN (l_pobj) treatment_14/NN (l_conj) medicine_22/NN (l_prep) against_23/IN (l_pobj) impairment_25/NN
D010433_D003072 CID pentylenetetrazole_23/NN (r_npadvmod) induced_25/VBN (r_amod) animals_27/NNS (r_pobj) in_22/IN (r_prep) observed_21/VBN (r_acl) markers_20/NNS (r_conj) impairment_15/NN
D008687_D004827 NONE metformin_6/NNP (r_nsubj) be_8/VB (l_attr) agent_11/NN (l_prep) for_12/IN (l_pobj) treatment_14/NN (l_prep) of_15/IN (l_pobj) epilepsy_16/NN
14748761
C030852_D009369 NONE VNR_21/NNP (r_dobj) comparing_20/VBG (l_prep) with_22/IN (l_pobj) agents_25/NNS (l_prep) in_26/IN (l_pobj) treatment_28/NN (l_prep) of_29/IN (l_pobj) malignancies_31/NNS
C030852_D009369 NONE VNR_4/NNP (r_dobj) comparing_3/VBG (l_prep) in_8/IN (l_pobj) treatment_10/NN (l_prep) of_11/IN (l_pobj) cancer_12/NN
C030852_D066126 CID VNR_3/NNP (r_nmod) events_5/NNS (r_pobj) of_2/IN (r_prep) risk_1/NN (r_nsubj) was_6/VBD (l_acomp) similar_7/JJ (l_prep) to_8/IN (l_pobj) vindesine_9/NNP (l_conj) drugs_16/NNS (l_amod) cardiotoxic_15/JJ
D014751_D066126 NONE vindesine_9/NNP (l_conj) drugs_16/NNS (l_amod) cardiotoxic_15/JJ
D014751_D066126 NONE VDS_11/NNP (r_appos) vindesine_9/NNP (l_conj) drugs_16/NNS (l_amod) cardiotoxic_15/JJ
D005472_D066126 NONE fluorouracil_18/NN (r_appos) drugs_16/NNS (l_amod) cardiotoxic_15/JJ
D018943_D066126 NONE anthracyclines_20/NNP (r_nmod) leader_27/NN (r_appos) drugs_16/NNS (l_amod) cardiotoxic_15/JJ
C056507_D066126 NONE gemcitabine_22/NNP (r_nmod) leader_27/NN (r_appos) drugs_16/NNS (l_amod) cardiotoxic_15/JJ
C056507_D066126 NONE GEM_24/NNP (r_nmod) leader_27/NN (r_appos) drugs_16/NNS (l_amod) cardiotoxic_15/JJ
25041770
D019821_D012206 CID simvastatin_4/NNP (r_nmod) increment_7/NN (r_pobj) with_3/IN (r_prep) association_2/NN (r_pobj) in_1/IN (r_prep) Rhabdomyolysis_0/NN
D019821_D012206 CID statin_10/NN (r_nmod) rhabdomyolysis_12/NN
D017291_D012206 CID clarithromycin_9/NNS (r_pobj) in_8/IN (r_prep) increment_7/NN (r_pobj) with_3/IN (r_prep) association_2/NN (r_pobj) in_1/IN (r_prep) Rhabdomyolysis_0/NN
D017291_D012206 CID clarithromycin_17/NNS (r_pobj) of_16/IN (r_prep) dose_15/NN (r_pobj) in_13/IN (r_prep) increase_12/NN (r_pobj) after_10/IN (r_prep) occurred_9/VBD (l_nsubj) rhabdomyolysis_7/NN
2931989
D015474_D000152 NONE isotretinoin_13/NNP (l_appos) drug_18/NN (l_prep) in_19/IN (l_pobj) treatment_21/NN (l_prep) of_22/IN (l_pobj) acne_25/NN
D015474_D000013 NONE Isotretinoin_0/NNP (r_nsubjpass) contraindicated_2/VBN (l_prep) because_5/IN (l_pobj) abnormalities_11/NNS
D015474_D008850 NONE Isotretinoin_0/NNP (r_nsubjpass) contraindicated_2/VBN (l_prep) because_5/IN (l_pobj) abnormalities_11/NNS (l_prep) after_12/IN (l_pobj) use_14/NN (l_prep) including_16/VBG (l_pobj) microphthalmos_17/NNP
D015474_D006972 NONE Isotretinoin_0/NNP (r_nsubjpass) contraindicated_2/VBN (l_prep) because_5/IN (l_pobj) abnormalities_11/NNS (l_prep) after_12/IN (l_pobj) use_14/NN (l_prep) including_16/VBG (l_pobj) microphthalmos_17/NNP (l_conj) hypertelorism_20/NN
D015474_C563492 NONE Isotretinoin_0/NNP (r_nsubjpass) contraindicated_2/VBN (l_prep) because_5/IN (l_pobj) abnormalities_11/NNS (l_prep) after_12/IN (l_pobj) use_14/NN (l_prep) including_16/VBG (l_pobj) microphthalmos_17/NNP (l_conj) hypertelorism_20/NN (l_conj) hypoplasia_25/NN
19419794
D016627_D004409 NONE 6-hydroxydopamine_3/CD (r_nummod) lesion_4/NN (l_conj) development_7/NN (l_prep) of_8/IN (l_pobj) dyskinesias_9/NNP
C005177_D004409 NONE DOPA+benserazide_4/NNP (r_pobj) with_1/IN (r_prep) Treatment_0/NN (r_nsubj) resulted_9/VBD (l_prep) in_10/IN (l_pobj) dyskinesias_13/NN
D004298_D004409 NONE DA_17/NNP (r_compound) lesion_18/NN (r_conj) impairment_15/NN (r_pobj) of_13/IN (r_prep) severity_12/NN (r_dobj) increased_10/VBD (l_conj) reduced_21/VBD (l_dobj) dyskinesias_27/NN
D007980_D004409 CID DOPA_24/NNP (r_npadvmod) induced_26/VBN (r_amod) dyskinesias_27/NN
D007980_D004409 CID DOPA_19/NNP (r_npadvmod) induced_21/VBN (r_amod) dyskinesias_22/NN
24582773
C069541_D011595 CID quetiapine_11/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (r_acl) agitation_2/NN
C069541_D011595 CID quetiapine_9/NNP (r_pobj) of_8/IN (r_prep) introduction_7/NN (r_pobj) following_4/VBG (r_prep) h_3/NN (r_pobj) Within_0/IN (r_prep) presented_21/VBD (l_dobj) agitation_23/NN
C069541_D011595 CID quetiapine_7/NNP (r_pobj) of_6/IN (r_prep) reintroduction_5/NN (l_relcl) led_13/VBD (l_prep) to_14/IN (l_pobj) agitation_17/NN
C069541_D011595 CID quetiapine_7/NNP (r_pobj) of_6/IN (r_prep) reintroduction_5/NN (r_conj) withdrawal_1/NN (r_nsubj) enabled_19/VBD (l_xcomp) attribute_22/VB (l_dobj) agitation_24/NN
C069541_D011595 CID quetiapine_27/NNP (r_pobj) to_26/IN (r_prep) attribute_22/VB (r_xcomp) enabled_19/VBD (l_nsubj) withdrawal_1/NN (l_conj) reintroduction_5/NN (l_relcl) led_13/VBD (l_prep) to_14/IN (l_pobj) agitation_17/NN
C069541_D011595 CID quetiapine_27/NNP (r_pobj) to_26/IN (r_prep) attribute_22/VB (l_dobj) agitation_24/NN
C069541_D011618 NONE quetiapine_11/NN (l_prep) in_12/IN (l_pobj) disorder_16/NN
D003006_D011618 NONE zuclopenthixol_33/NNP (r_appos) antipsychotics_31/NNS (r_pobj) of_27/IN (r_prep) combination_26/NN (r_pobj) by_24/IN (r_agent) treated_23/VBN (r_advcl) report_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) suffering_10/NN (l_prep) from_11/IN (l_pobj) disorder_15/NN
D008094_D011618 NONE lithium_41/NN (r_nmod) day_46/NN (r_conj) zuclopenthixol_33/NNP (r_appos) antipsychotics_31/NNS (r_pobj) of_27/IN (r_prep) combination_26/NN (r_pobj) by_24/IN (r_agent) treated_23/VBN (r_advcl) report_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) suffering_10/NN (l_prep) from_11/IN (l_pobj) disorder_15/NN
C069541_D010554 NONE quetiapine_9/NNP (r_pobj) of_8/IN (r_prep) introduction_7/NN (r_pobj) following_4/VBG (r_prep) h_3/NN (r_pobj) Within_0/IN (r_prep) presented_21/VBD (l_advcl) contrasting_29/VBG (l_prep) with_30/IN (l_pobj) absence_32/NN (l_prep) of_33/IN (l_pobj) history_35/NN (l_prep) of_36/IN (l_pobj) aggressiveness_37/NN
C069541_D010554 NONE quetiapine_9/NNP (r_pobj) of_8/IN (r_prep) introduction_7/NN (r_pobj) following_4/VBG (r_prep) h_3/NN (r_pobj) Within_0/IN (r_prep) presented_21/VBD (l_advcl) contrasting_29/VBG (l_prep) with_30/IN (l_pobj) absence_32/NN (l_prep) of_33/IN (l_pobj) history_35/NN (l_prep) of_36/IN (l_pobj) aggressiveness_37/NN (l_conj) disorder_40/NN
1451544
D017275_D006973 NONE Isradipine_0/JJ (r_compound) treatment_1/NN (l_prep) for_2/IN (l_pobj) hypertension_3/NN
10327032
D005472_D022124 CID 5-fluorouracil_13/CD (r_pobj) of_12/IN (r_prep) infusion_11/NN (r_dobj) received_9/VBD (r_relcl) patients_7/NNS (r_pobj) in_5/IN (r_prep) encephalopathy_4/NN
D005472_D022124 CID 5-fluorouracil_21/CD (r_pobj) of_20/IN (r_prep) infusion_19/NN (r_pobj) to_17/IN (r_prep) related_16/VBN (r_acl) episodes_11/NNS (l_prep) of_12/IN (l_pobj) encephalopathy_15/NNS
D005472_D022124 CID 5-FU_23/CD (r_pobj) of_20/IN (r_prep) infusion_19/NN (r_pobj) to_17/IN (r_prep) related_16/VBN (r_acl) episodes_11/NNS (l_prep) of_12/IN (l_pobj) encephalopathy_15/NNS
D005472_D022124 CID 5-FU_42/CD (r_pobj) of_41/IN (r_prep) doses_32/NNS (r_dobj) receiving_29/VBG (r_acl) patients_28/NNS (r_pobj) in_26/IN (r_conj) seen_11/VBN (l_nsubjpass) levels_3/NNS (l_conj) onset_7/NN (l_prep) of_8/IN (l_pobj) hyperammonemia_9/NNP
D005472_D022124 CID 5-FU_13/CD (r_pobj) of_12/IN (r_prep) infusion_11/NN (r_dobj) receiving_9/VBG (r_acl) patients_8/NNS (r_pobj) in_7/IN (r_prep) occur_6/VB (l_nsubj) encephalopathy_4/NN
D005472_D001927 CID 5-fluorouracil_13/CD (r_pobj) of_12/IN (r_prep) infusion_11/NN (r_dobj) received_9/VBD (r_relcl) patients_7/NNS (r_pobj) in_5/IN (r_prep) encephalopathy_4/NN
D005472_D001927 CID 5-fluorouracil_21/CD (r_pobj) of_20/IN (r_prep) infusion_19/NN (r_pobj) to_17/IN (r_prep) related_16/VBN (r_acl) episodes_11/NNS (l_prep) of_12/IN (l_pobj) encephalopathy_15/NNS
D005472_D001927 CID 5-FU_23/CD (r_pobj) of_20/IN (r_prep) infusion_19/NN (r_pobj) to_17/IN (r_prep) related_16/VBN (r_acl) episodes_11/NNS (l_prep) of_12/IN (l_pobj) encephalopathy_15/NNS
D005472_D001927 CID 5-FU_13/CD (r_pobj) of_12/IN (r_prep) infusion_11/NN (r_dobj) receiving_9/VBG (r_acl) patients_8/NNS (r_pobj) in_7/IN (r_prep) occur_6/VB (l_nsubj) encephalopathy_4/NN
D005472_D009369 NONE 5-fluorouracil_13/CD (r_pobj) of_12/IN (r_prep) infusion_11/NN (r_dobj) received_9/VBD (r_relcl) patients_7/NNS (l_compound) cancer_6/NN
D005472_D009369 NONE 5-fluorouracil_21/CD (r_pobj) of_20/IN (r_prep) infusion_19/NN (r_pobj) to_17/IN (r_prep) related_16/VBN (r_acl) episodes_11/NNS (r_dobj) had_9/VBD (r_relcl) patients_7/NNS (l_compound) cancer_6/NN
D005472_D009369 NONE 5-FU_23/CD (r_pobj) of_20/IN (r_prep) infusion_19/NN (r_pobj) to_17/IN (r_prep) related_16/VBN (r_acl) episodes_11/NNS (r_dobj) had_9/VBD (r_relcl) patients_7/NNS (l_compound) cancer_6/NN
D005472_D003681 NONE 5-fluorouracil_13/CD (r_pobj) of_12/IN (r_prep) infusion_11/NN (r_dobj) received_9/VBD (l_prep) with_14/IN (l_pobj) complication_16/NN (l_prep) of_17/IN (l_pobj) dehydration_18/NN
D005472_D007239 NONE 5-fluorouracil_13/CD (r_pobj) of_12/IN (r_prep) infusion_11/NN (r_dobj) received_9/VBD (l_prep) with_14/IN (l_pobj) complication_16/NN (l_prep) of_17/IN (l_pobj) dehydration_18/NN (l_conj) infection_20/NN
D000644_D022124 NONE ammonium_2/NN (r_compound) levels_3/NNS (l_conj) onset_7/NN (l_prep) of_8/IN (l_pobj) hyperammonemia_9/NNP
D000644_D001424 NONE ammonium_2/NN (r_compound) levels_3/NNS (r_nsubjpass) seen_11/VBN (l_prep) in_12/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) infections_17/NNS
D005472_D001424 NONE 5-FU_42/CD (r_pobj) of_41/IN (r_prep) doses_32/NNS (r_dobj) receiving_29/VBG (r_acl) patients_28/NNS (r_pobj) in_26/IN (r_conj) seen_11/VBN (l_prep) in_12/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) infections_17/NNS
1522360
D012293_D006461 CID rifampin_8/NN (r_compound) therapy_9/NN (r_pobj) following_6/VBG (r_prep) hemolysis_1/NN
D012293_D006461 CID rifampin_8/NN (r_compound) therapy_9/NN (r_pobj) following_7/VBG (r_prep) failure_6/NN (r_pobj) to_3/IN (r_prep) leading_2/VBG (r_acl) hemolysis_1/NN
D012293_D006461 CID rifampin_12/NN (r_pobj) following_11/VBG (r_prep) developed_5/VBD (l_dobj) hemolysis_6/NN
D012293_D058186 CID rifampin_8/NN (r_compound) therapy_9/NN (r_pobj) following_6/VBG (r_prep) hemolysis_1/NN (l_conj) failure_5/NN
D012293_D058186 CID rifampin_8/NN (r_compound) therapy_9/NN (r_pobj) following_7/VBG (r_prep) failure_6/NN
D012293_D058186 CID rifampin_12/NN (r_pobj) following_11/VBG (r_prep) developed_5/VBD (l_dobj) hemolysis_6/NN (l_conj) failure_10/NN
D012293_D051437 NONE rifampin_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) complication_5/NN (r_attr) is_2/VBZ (l_nsubj) failure_1/NN
D012293_D007918 NONE rifampin_12/NN (r_pobj) following_11/VBG (r_prep) developed_5/VBD (r_relcl) patients_1/NNS (l_prep) with_2/IN (l_pobj) leprosy_3/NN
24464946
D015251_D066126 CID epirubicine_22/NNP (r_npadvmod) based_24/VBN (r_amod) chemotherapy_25/NN (r_pobj) during_21/IN (r_prep) detection_16/NN (l_prep) of_19/IN (l_pobj) cardiotoxicity_20/NN
D015251_D009202 NONE epirubicin_25/NN (r_compound) exposure_26/NN (r_pobj) after_24/IN (r_prep) predict_18/VB (l_nsubj) alterations_3/NNS (l_prep) of_4/IN (l_pobj) strain_6/NN
D015251_D006331 NONE epirubicin_25/NN (r_compound) exposure_26/NN (r_pobj) after_24/IN (r_prep) predict_18/VB (l_dobj) dysfunction_21/NN
D015251_D008228 NONE epirubicin_11/NNS (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_acl) patients_3/NNS (l_prep) with_4/IN (l_pobj) lymphoma_8/NN
D018943_D006331 NONE anthracycline_20/NN (r_npadvmod) based_22/VBN (r_amod) chemotherapy_23/NN (r_dobj) receiving_19/VBG (r_acl) patients_18/NNS (r_pobj) in_17/IN (r_prep) dysfunction_16/NN
18422462
D000409_D000740 NONE alanine_32/NN (r_compound) aminotransferase_33/NN (r_pobj) with_31/IN (r_prep) jaundice_30/NN (r_parataxis) hepatitis_27/NN (r_conj) CD4_19/NNP (r_nsubj) limits_38/NNS (r_appos) %_15/NN (r_pobj) in_13/IN (r_prep) observed_12/VBN (l_nsubjpass) anemia_2/NN
D000409_D056486 NONE alanine_32/NN (r_compound) aminotransferase_33/NN (r_pobj) with_31/IN (r_prep) jaundice_30/NN (r_parataxis) hepatitis_27/NN
D000409_D007565 NONE alanine_32/NN (r_compound) aminotransferase_33/NN (r_pobj) with_31/IN (r_prep) jaundice_30/NN
D019829_D005076 CID NVP_11/NNP (r_compound) therapy_12/NN (r_nsubjpass) associated_15/VBN (l_prep) with_16/IN (l_pobj) rash_18/NN
D019829_D010523 NONE NVP_11/NNP (r_compound) therapy_12/NN (r_nsubjpass) associated_15/VBN (l_prep) with_16/IN (l_pobj) rash_18/NN (l_prep) with_23/IN (l_pcomp) developing_24/VBG (l_dobj) neuropathy_26/NN
D018119_D005076 NONE T_21/NN (r_compound) therapy_22/NN (r_conj) rash_18/NN
D018119_D010523 CID T_21/NN (r_compound) therapy_22/NN (r_conj) rash_18/NN (l_prep) with_23/IN (l_pcomp) developing_24/VBG (l_dobj) neuropathy_26/NN
18945509
-1_D003324 NONE sulphonylurea_8/NNP (r_compound) treatment_9/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) disease_4/NN
-1_D003324 NONE sulphonylureas_25/NNS (r_pobj) with_23/IN (r_prep) treatment_18/NN (r_pobj) with_16/IN (r_prep) associated_15/VBN (r_acl) CAD_13/NNP (r_appos) disease_11/NN
-1_D003324 NONE sulphonylureas_25/NNS (r_pobj) with_23/IN (r_prep) treatment_18/NN (r_pobj) with_16/IN (r_prep) associated_15/VBN (r_acl) CAD_13/NNP
-1_D003924 NONE sulphonylurea_8/NNP (r_compound) treatment_9/NN (l_prep) of_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) diabetes_15/NN
-1_D003924 NONE sulphonylureas_25/NNS (r_pobj) with_23/IN (r_prep) treatment_18/NN (l_prep) of_19/IN (l_pobj) diabetes_22/NN
D005905_D003324 CID glibenclamide_25/NNP (r_pobj) with_24/IN (r_prep) increased_14/VBN (l_nsubj) hazard_1/NN (l_prep) of_2/IN (l_pobj) CAD_4/NNP
D005905_D003324 CID glibenclamide_7/NNP (r_pobj) with_6/IN (r_prep) diabetes_5/NN (r_pobj) of_2/IN (r_prep) treatment_1/NN (r_dobj) Initiating_0/VBG (r_csubjpass) associated_11/VBN (l_prep) with_12/IN (l_pobj) risk_14/NN (l_prep) of_15/IN (l_pobj) CAD_16/NNP
D005913_D003324 NONE glipizide_36/NNP (r_pobj) with_35/IN (r_prep) increased_14/VBN (l_nsubj) hazard_1/NN (l_prep) of_2/IN (l_pobj) CAD_4/NNP
D005913_D003324 NONE glipizide_9/NNP (r_conj) glibenclamide_7/NNP (r_pobj) with_6/IN (r_prep) diabetes_5/NN (r_pobj) of_2/IN (r_prep) treatment_1/NN (r_dobj) Initiating_0/VBG (r_csubjpass) associated_11/VBN (l_prep) with_12/IN (l_pobj) risk_14/NN (l_prep) of_15/IN (l_pobj) CAD_16/NNP
D008687_D003324 NONE metformin_53/NN (r_pobj) with_52/IN (r_prep) unchanged_51/JJ (r_acomp) was_50/VBD (r_conj) increased_14/VBN (l_nsubj) hazard_1/NN (l_prep) of_2/IN (l_pobj) CAD_4/NNP
D005905_D003924 NONE glibenclamide_7/NNP (r_pobj) with_6/IN (r_prep) diabetes_5/NN
D005913_D003924 NONE glipizide_9/NNP (r_conj) glibenclamide_7/NNP (r_pobj) with_6/IN (r_prep) diabetes_5/NN
D005907_D003924 NONE gliclazide_20/NNP (r_pobj) to_19/IN (r_prep) comparison_18/NN (r_pobj) in_17/IN (r_prep) associated_11/VBN (l_csubjpass) Initiating_0/VBG (l_dobj) treatment_1/NN (l_prep) of_2/IN (l_pobj) diabetes_5/NN
D005907_D003324 NONE gliclazide_20/NNP (r_pobj) to_19/IN (r_prep) comparison_18/NN (r_pobj) in_17/IN (r_prep) associated_11/VBN (l_prep) with_12/IN (l_pobj) risk_14/NN (l_prep) of_15/IN (l_pobj) CAD_16/NNP
C057619_D003924 NONE glimepiride_22/NNP (r_conj) gliclazide_20/NNP (r_pobj) to_19/IN (r_prep) comparison_18/NN (r_pobj) in_17/IN (r_prep) associated_11/VBN (l_csubjpass) Initiating_0/VBG (l_dobj) treatment_1/NN (l_prep) of_2/IN (l_pobj) diabetes_5/NN
C057619_D003324 NONE glimepiride_22/NNP (r_conj) gliclazide_20/NNP (r_pobj) to_19/IN (r_prep) comparison_18/NN (r_pobj) in_17/IN (r_prep) associated_11/VBN (l_prep) with_12/IN (l_pobj) risk_14/NN (l_prep) of_15/IN (l_pobj) CAD_16/NNP
24729111
D000638_D007037 CID Amiodarone_0/NNP (r_npadvmod) induced_2/VBN (r_amod) coma_4/NN
D000638_D007037 CID amiodarone_5/NN (r_npadvmod) induced_7/VBN (r_amod) coma_9/NN
D000638_D007037 CID amiodarone_9/NN (r_npadvmod) induced_11/VBN (r_amod) coma_13/NN
D000638_D003128 CID Amiodarone_0/NNP (r_npadvmod) induced_2/VBN (r_amod) coma_4/NN
D000638_D003128 CID amiodarone_5/NN (r_npadvmod) induced_7/VBN (r_amod) coma_9/NN
D000638_D003128 CID amiodarone_9/NN (r_npadvmod) induced_11/VBN (r_amod) coma_13/NN
D000638_D001919 CID amiodarone_20/NN (r_compound) therapy_21/NN (r_pobj) of_19/IN (r_prep) initiation_18/NN (r_pobj) after_17/IN (r_prep) have_8/VB (l_dobj) bradycardia_9/NNS
D000638_D007035 CID amiodarone_20/NN (r_compound) therapy_21/NN (r_pobj) of_19/IN (r_prep) initiation_18/NN (r_pobj) after_17/IN (r_prep) have_8/VB (l_dobj) bradycardia_9/NNS (l_conj) hypothermia_11/NN
D000638_D012131 CID amiodarone_20/NN (r_compound) therapy_21/NN (r_pobj) of_19/IN (r_prep) initiation_18/NN (r_pobj) after_17/IN (r_prep) have_8/VB (l_dobj) bradycardia_9/NNS (l_conj) hypothermia_11/NN (l_conj) failure_14/NN
D000638_D001281 NONE amiodarone_20/NN (r_compound) therapy_21/NN (r_pobj) of_19/IN (r_prep) initiation_18/NN (l_prep) for_22/IN (l_pobj) fibrillation_24/NN
D000638_D013959 NONE amiodarone_9/NN (r_npadvmod) induced_11/VBN (r_amod) coma_13/NN (l_prep) with_14/IN (l_pobj) history_16/NN (l_amod) significant_17/JJ (l_prep) for_18/IN (l_pobj) disease_21/NN
7739955
D002220_D009205 CID carbamazepine_10/NN (r_npadvmod) induced_12/VBN (r_amod) myocarditis_15/NN (r_dobj) had_8/VBD (l_ccomp) had_2/VBD (l_dobj) myocarditis_5/NN
D002220_D009205 CID carbamazepine_10/NN (r_npadvmod) induced_12/VBN (r_amod) myocarditis_15/NN
D002220_D004802 CID carbamazepine_10/NN (r_npadvmod) induced_12/VBN (r_amod) myocarditis_15/NN
D002220_D012770 NONE carbamazepine_10/NN (r_npadvmod) induced_12/VBN (r_amod) myocarditis_15/NN (r_dobj) had_8/VBD (l_conj) had_19/VBD (l_ccomp) resulting_22/VBG (l_prep) in_23/IN (l_pobj) shock_26/NN
10462057
D017330_D000741 CID remoxipride_4/JJ (r_compound) metabolites_5/NNS (r_pobj) by_3/IN (r_prep) apoptosis_2/NN (l_conj) cells_14/NNS (l_appos) relevance_17/NN (l_prep) to_18/IN (l_pobj) anemia_23/NN
D017330_D000741 CID remoxipride_19/NN (r_npadvmod) induced_21/VBN (r_amod) anemia_23/NN
D017330_D000741 CID remoxipride_4/JJ (r_appos) agent_2/NN (r_nsubjpass) associated_14/VBN (l_prep) with_15/IN (l_pobj) anemia_18/NN
D017330_D000741 CID amide_10/NN (r_appos) remoxipride_4/JJ (r_appos) agent_2/NN (r_nsubjpass) associated_14/VBN (l_prep) with_15/IN (l_pobj) anemia_18/NN
D017330_D000741 CID remoxipride_3/NN (r_nsubj) induce_7/VB (l_dobj) anemia_9/NN
D017330_D000741 CID remoxipride_3/NN (r_nsubj) induce_7/VB (l_conj) contribute_31/VB (l_prep) to_32/IN (l_pobj) mechanism_34/NN (l_appos) anemia_38/NN
D017330_D000741 CID remoxipride_44/NNP (r_pobj) with_43/IN (r_prep) associated_42/VBN (r_relcl) anemia_38/NN (r_appos) mechanism_34/NN (r_pobj) to_32/IN (r_prep) contribute_31/VB (r_conj) induce_7/VB (l_dobj) anemia_9/NN
D017330_D000741 CID remoxipride_44/NNP (r_pobj) with_43/IN (r_prep) associated_42/VBN (r_relcl) anemia_38/NN
C084325_D009336 NONE NCQ436_8/NNP (r_pobj) with_7/IN (r_prep) treated_6/VBN (r_acl) cells_5/NNS (r_pobj) in_4/IN (r_prep) observed_3/VBN (l_nsubjpass) necrosis_1/NN
C112341_D009336 NONE NCQ344_1/NNP (r_nsubj) had_2/VBD (l_advcl) inducing_11/VBG (l_prep) at_13/IN (l_pobj) concentrations_15/NNS (l_conj) necrosis_17/NN
D001554_D000741 CID benzene_5/NN (r_conj) remoxipride_3/NN (r_nsubj) induce_7/VB (l_dobj) anemia_9/NN
D001554_D000741 CID benzene_5/NN (r_conj) remoxipride_3/NN (r_nsubj) induce_7/VB (l_conj) contribute_31/VB (l_prep) to_32/IN (l_pobj) mechanism_34/NN (l_appos) anemia_38/NN
C084325_D000741 NONE NCQ436_21/NNP (r_pobj) of_20/IN (r_prep) ability_19/NN (r_nsubj) contribute_31/VB (r_conj) induce_7/VB (l_dobj) anemia_9/NN
C084325_D000741 NONE NCQ436_21/NNP (r_pobj) of_20/IN (r_prep) ability_19/NN (r_nsubj) contribute_31/VB (l_prep) to_32/IN (l_pobj) mechanism_34/NN (l_appos) anemia_38/NN
C112341_D000741 NONE NCQ344_23/NNP (r_conj) NCQ436_21/NNP (r_pobj) of_20/IN (r_prep) ability_19/NN (r_nsubj) contribute_31/VB (r_conj) induce_7/VB (l_dobj) anemia_9/NN
C112341_D000741 NONE NCQ344_23/NNP (r_conj) NCQ436_21/NNP (r_pobj) of_20/IN (r_prep) ability_19/NN (r_nsubj) contribute_31/VB (l_prep) to_32/IN (l_pobj) mechanism_34/NN (l_appos) anemia_38/NN
8511251
D003042_D017202 CID Cocaine_0/NN (r_nsubj) induced_1/VBD (l_dobj) ischemia_3/NN
D003042_D017202 CID cocaine_9/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) ischemia_6/NN
D005996_D007511 NONE nitroglycerin_11/NN (r_nmod) agents_15/NNS (r_pobj) by_10/IN (r_agent) reversed_9/VBN (l_nsubjpass) ischemia_1/NN
D005996_D003329 NONE nitroglycerin_11/NN (r_nmod) agents_15/NNS (r_pobj) by_10/IN (r_agent) reversed_9/VBN (l_nsubjpass) ischemia_1/NN (l_acl) induced_3/VBN (l_agent) by_4/IN (l_pobj) spasm_7/NN
D002118_D007511 NONE calcium_13/NN (r_conj) nitroglycerin_11/NN (r_nmod) agents_15/NNS (r_pobj) by_10/IN (r_agent) reversed_9/VBN (l_nsubjpass) ischemia_1/NN
D002118_D003329 NONE calcium_13/NN (r_conj) nitroglycerin_11/NN (r_nmod) agents_15/NNS (r_pobj) by_10/IN (r_agent) reversed_9/VBN (l_nsubjpass) ischemia_1/NN (l_acl) induced_3/VBN (l_agent) by_4/IN (l_pobj) spasm_7/NN
19108278
D011433_D001145 NONE propranolol_8/NNS (r_pobj) of_7/IN (r_prep) isomers_6/NNS (r_pobj) of_3/IN (r_prep) properties_2/NNS (l_conj) effects_11/NNS (l_prep) on_12/IN (l_pobj) arrhythmias_14/NNS
D011433_D001145 NONE propranolol_3/NNS (r_pobj) of_2/IN (r_prep) isomers_1/NNS (r_nsubj) were_4/VBD (l_acomp) capable_5/JJ (l_prep) of_6/IN (l_pcomp) preventing_7/VBG (l_dobj) arrhythmias_12/NNS
D011433_D001145 NONE -)-propranolol_25/, (r_intj) of_23/IN (r_prep) dose_22/NN (r_nsubj) was_26/VBD (r_conj) were_4/VBD (l_acomp) capable_5/JJ (l_prep) of_6/IN (l_pcomp) preventing_7/VBG (l_dobj) arrhythmias_12/NNS
D011433_D001145 NONE -propranolol_35/NNS (r_pobj) of_31/IN (r_prep) that_30/DT (r_pobj) whereas_29/IN (r_punct) was_26/VBD (r_conj) were_4/VBD (l_acomp) capable_5/JJ (l_prep) of_6/IN (l_pcomp) preventing_7/VBG (l_dobj) arrhythmias_12/NNS
D004837_D001145 CID adrenaline_8/NN (r_npadvmod) induced_10/VBN (r_amod) arrhythmias_12/NNS
D004837_D001145 CID adrenaline.7_13/NNP (r_pobj) of_12/IN (r_prep) dose_11/NN (r_dobj) increasing_9/VBG (r_pcomp) by_8/IN (r_prep) was_6/VBD (l_nsubj) Blockade_0/NN (l_prep) of_1/IN (l_pobj) arrhythmias_2/NNS
D006221_D001145 CID halothane_17/NNP (r_pobj) with_16/IN (r_prep) anaesthetized_15/VBN (r_acl) cats_14/NNS (r_pobj) in_13/IN (r_prep) arrhythmias_12/NNS
D011433_D017180 NONE propranolol_3/NNS (r_pobj) of_2/IN (r_prep) isomers_1/NNS (r_nsubj) were_4/VBD (l_acomp) capable_6/JJ (l_prep) of_7/IN (l_pcomp) reversing_8/VBG (l_dobj) tachycardia_10/NN
D010042_D017180 CID ouabain_13/NN (r_pobj) by_12/IN (r_agent) caused_11/VBN (r_acl) tachycardia_10/NN
9125676
D013015_-1 NONE sotalol_11/NNP (r_appos) d_7/NNP (r_pobj) of_6/IN (r_prep) use_5/NN (r_pobj) with_3/IN (r_prep) Efficacy_0/NN (l_conj) proarrhythmia_2/NNP
D013015_D017180 NONE sotalol_11/NNP (r_appos) d_7/NNP (r_pobj) of_6/IN (r_prep) use_5/NN (l_prep) for_12/IN (l_pobj) tachyarrhythmias_15/NNS
D013015_D017180 NONE sotalol_32/NNP (l_prep) for_33/IN (l_pobj) tachyarrhythmias_36/NNS
D013015_D017180 NONE sotalol_32/NNP (r_appos) d_28/NN (r_dobj) received_26/VBD (l_nsubj) patients_4/NNS (l_prep) with_18/IN (l_pobj) tachycardia_22/NN
D013015_D017180 NONE sotalol_32/NNP (r_appos) d_28/NN (r_dobj) received_26/VBD (l_advcl) prevent_34/VB (l_dobj) induction_35/NN (l_prep) of_36/IN (l_pobj) tachyarrhythmia_39/NN
D013015_D017180 NONE sotalol_8/NNP (r_nsubj) prevented_9/VBD (l_dobj) induction_10/NN (l_prep) of_11/IN (l_pobj) tachycardia_13/NN
D013015_D017180 NONE sotalol_13/NNP (r_appos) d_9/NN (r_pobj) by_7/IN (r_agent) prevented_6/VBN (l_nsubjpass) Induction_0/NN (l_prep) of_1/IN (l_pobj) tachyarrhythmia_4/NN
D013015_D017180 NONE sotalol_13/NNP (r_appos) d_9/NN (r_pobj) by_7/IN (r_agent) prevented_6/VBN (r_ccomp) remained_25/VBD (l_nsubj) tachyarrhythmia_24/NN
D013015_D017180 NONE sotalol_53/NNP (r_appos) d_49/NNP (r_pobj) of_48/IN (r_prep) mg_47/NNS (r_dobj) tolerate_44/VB (r_conj) remained_25/VBD (l_ccomp) prevented_6/VBN (l_nsubjpass) Induction_0/NN (l_prep) of_1/IN (l_pobj) tachyarrhythmia_4/NN
D013015_D017180 NONE sotalol_53/NNP (r_appos) d_49/NNP (r_pobj) of_48/IN (r_prep) mg_47/NNS (r_dobj) tolerate_44/VB (r_conj) remained_25/VBD (l_nsubj) tachyarrhythmia_24/NN
D013015_D016171 CID sotalol_32/NNP (r_appos) factors_19/NNS (r_conj) incidence_9/NN (l_prep) of_10/IN (l_pobj) pointes_13/FW
D013015_D016171 CID sotalol_32/NNP (r_appos) factors_19/NNS (l_prep) for_20/IN (l_pobj) pointes_23/FW
D013015_D016171 CID sotalol_21/NNP (r_dobj) had_6/VBD (l_prep) from_7/IN (l_pobj) pointes_10/FW
D013015_D016171 CID sotalol_10/NNP (r_nsubj) was_11/VBD (l_prep) in_14/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) pointes_19/FW
D013015_D016171 CID sotalol_23/NNP (r_appos) pointes_11/FW
D013015_D016171 CID sotalol_17/NNP (r_npadvmod) occurred_3/VBD (l_nsubj) pointes_2/FW
D013015_D016171 CID sotalol_26/NNP (r_nsubj) identify_28/VB (l_prep) with_33/IN (l_pobj) risk_36/NN (l_prep) for_37/IN (l_pobj) pointes_40/FW
D013015_D016171 CID sotalol_11/NNP (r_appos) d_7/NNP (r_pobj) of_6/IN (r_prep) application_5/NN (r_pobj) before_3/IN (r_prep) parameters_2/NNS (r_nsubj) identify_14/VB (l_prep) at_16/IN (l_pobj) risk_18/NN (l_prep) for_19/IN (l_pobj) pointes_22/FW
D013015_D003324 NONE sotalol_32/NNP (r_appos) d_28/NN (r_dobj) received_26/VBD (l_nsubj) patients_4/NNS (l_prep) with_7/IN (l_pobj) disease_10/NN
D013015_D002311 NONE sotalol_32/NNP (r_appos) d_28/NN (r_dobj) received_26/VBD (l_nsubj) patients_4/NNS (l_conj) 20_13/CD (l_prep) with_14/IN (l_pobj) cardiomyopathy_16/NN
D013015_D014693 NONE sotalol_32/NNP (r_appos) d_28/NN (r_dobj) received_26/VBD (l_nsubj) patients_4/NNS (l_prep) with_18/IN (l_pobj) tachycardia_22/NN (l_conj) fibrillation_25/NN
D013015_D014693 NONE sotalol_8/NNP (r_nsubj) prevented_9/VBD (l_dobj) induction_10/NN (l_prep) of_11/IN (l_pobj) tachycardia_13/NN (l_conj) fibrillation_16/NN
D013015_D006331 NONE sotalol_23/NNP (r_appos) pointes_11/FW (r_dobj) had_7/VBD (l_nsubj) patient_2/NN (l_prep) with_3/IN (l_pobj) disease_6/NN
256433
D014031_D007239 NONE tobramycin_2/NNS (l_acl) combined_3/VBN (l_prep) with_4/IN (l_pobj) carbenicillin_5/NNP (l_prep) for_6/IN (l_pobj) infections_7/NNS
D014031_D009369 NONE tobramycin_2/NNS (l_acl) combined_3/VBN (l_prep) with_4/IN (l_pobj) carbenicillin_5/NNP (l_prep) for_6/IN (l_pobj) infections_7/NNS (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_compound) cancer_9/NN
D002228_D007239 NONE carbenicillin_5/NNP (l_prep) for_6/IN (l_pobj) infections_7/NNS
D002228_D009369 NONE carbenicillin_5/NNP (l_prep) for_6/IN (l_pobj) infections_7/NNS (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_compound) cancer_9/NN
D014031_D009503 NONE tobramycin_8/NNS (r_nsubjpass) given_10/VBN (l_advcl) overcome_1/VB (l_dobj) effects_4/NNS (l_prep) of_5/IN (l_pobj) neutropenia_6/NN
D002228_D009503 NONE carbenicillin_18/NN (r_pobj) with_16/IN (r_prep) combined_15/VBN (r_conj) infusion_13/NN (r_pobj) by_11/IN (r_agent) given_10/VBN (l_advcl) overcome_1/VB (l_dobj) effects_4/NNS (l_prep) of_5/IN (l_pobj) neutropenia_6/NN
D003404_D053099 NONE creatinine_4/NN (r_appos) azotemia_1/NN
D014031_D053099 CID tobramycin_10/NNS (r_compound) concentration_11/NN (r_conj) therapy_7/NN (r_pobj) of_6/IN (r_prep) duration_5/NN (r_pobj) to_4/IN (r_prep) related_3/VBN (l_nsubjpass) Azotemia_0/NNP
16565833
C522803_D066126 NONE monoHER_7/NNP (r_nmod) administration_10/NN (r_pobj) between_6/IN (r_prep) interval_5/NN (l_prep) on_11/IN (l_pobj) protection_13/NN (l_prep) against_14/IN (l_pobj) cardiotoxicity_18/NN
C522803_D066126 NONE monohydroxyethylrutoside_3/NN (r_nsubj) showed_7/VBD (l_prep) against_9/IN (l_pobj) cardiotoxicity_13/NN
C522803_D066126 NONE monoHER_5/NNP (r_appos) monohydroxyethylrutoside_3/NN (r_nsubj) showed_7/VBD (l_prep) against_9/IN (l_pobj) cardiotoxicity_13/NN
D004317_D066126 NONE doxorubicin_9/NNP (r_conj) monoHER_7/NNP (r_nmod) administration_10/NN (r_pobj) between_6/IN (r_prep) interval_5/NN (l_prep) on_11/IN (l_pobj) protection_13/NN (l_prep) against_14/IN (l_pobj) cardiotoxicity_18/NN
D004317_D066126 NONE doxorubicin_15/NN (r_npadvmod) induced_17/VBN (r_amod) cardiotoxicity_18/NN
D004317_D066126 NONE doxorubicin_10/NNP (r_nsubj) continues_14/VBZ (l_prep) Despite_1/IN (l_pobj) cardiotoxicity_6/NN
D004317_D066126 NONE DOX_12/NNP (r_appos) doxorubicin_10/NNP (r_nsubj) continues_14/VBZ (l_prep) Despite_1/IN (l_pobj) cardiotoxicity_6/NN
D004317_D066126 NONE DOX_10/NNP (r_npadvmod) induced_12/VBN (r_amod) cardiotoxicity_13/NN
D004317_D006331 NONE DOX_0/NNP (r_npadvmod) induced_2/VBN (r_amod) damage_4/NN
D004317_D006331 NONE DOX_14/NNP (r_pobj) by_13/IN (r_prep) formation_9/NN (r_pobj) from_7/IN (r_prep) results_6/VBZ (l_nsubj) damage_4/NN
D004317_D006331 NONE DOX_6/NNP (r_pobj) with_5/IN (r_prep) treatment_4/NN (r_nsubj) induced_8/VBD (l_dobj) damage_11/NN
D005419_D066126 NONE flavonoid_2/NN (r_compound) monohydroxyethylrutoside_3/NN (r_nsubj) showed_7/VBD (l_prep) against_9/IN (l_pobj) cardiotoxicity_13/NN
D007501_D066126 NONE iron_19/NN (r_compound) properties_21/NNS (r_conj) scavenging_17/NN (r_pobj) through_14/IN (r_prep) showed_7/VBD (l_prep) against_9/IN (l_pobj) cardiotoxicity_13/NN
20169779
D015632_D010302 NONE MPTP_4/NNP (r_compound) model_6/NN (l_prep) of_7/IN (l_pobj) disease_10/NN
D015632_D010302 NONE MPTP_4/NNP (r_npadvmod) lesioned_6/VBN (r_amod) marmoset_7/NNP (r_nsubjpass) used_9/VBN (l_prep) as_10/IN (l_pobj) model_12/NN (l_prep) in_16/IN (l_pobj) patients_18/NNS (l_compound) PD_17/NNP
D015632_D010302 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_3/CD (r_dobj) administered_2/VBN (l_advcl) resulting_13/VBG (l_prep) in_14/IN (l_pobj) parkinsonism_16/NN
D007980_D001523 NONE levodopa_1/NN (r_npadvmod) treated_3/VBN (r_amod) marmoset_7/NNP (r_nsubjpass) used_9/VBN (l_prep) as_10/IN (l_pobj) model_12/NN (l_prep) of_13/IN (l_pobj) symptoms_15/NNS
D007980_D001523 NONE levodopa_7/NN (r_npadvmod) induced_9/VBN (r_amod) fluctuations_11/NNS (l_conj) behaviors_16/NNS
D007980_D001523 NONE levodopa_27/NN (r_pobj) to_26/IN (r_prep) prior_25/RB (r_advmod) evaluated_2/VBN (l_prep) for_3/IN (l_pobj) disability_5/NN (l_conj) dyskinesia_7/NN (l_conj) fluctuations_14/NNS (l_conj) behaviors_20/NNS
D007980_D001523 NONE levodopa_3/NN (r_npadvmod) induced_5/VBN (r_amod) behaviors_9/NNS
D007980_D001523 NONE levodopa_16/NNP (r_compound) treatment_17/NN (r_pobj) of_15/IN (r_prep) Day_13/NN (r_pobj) on_12/IN (r_prep) present_11/JJ (r_acomp) were_10/VBD (l_nsubj) behaviors_9/NNS
D007980_D001523 NONE levodopa_14/NNP (r_pobj) between_13/IN (r_prep) interaction_12/NN (r_attr) are_8/VBP (l_nsubj) disorders_5/NNS
D007980_D010302 NONE levodopa_1/NN (r_npadvmod) treated_3/VBN (r_amod) marmoset_7/NNP (r_nsubjpass) used_9/VBN (l_prep) as_10/IN (l_pobj) model_12/NN (l_prep) in_16/IN (l_pobj) patients_18/NNS (l_compound) PD_17/NNP
D007980_D010302 NONE levodopa_14/NNP (r_pobj) between_13/IN (r_prep) interaction_12/NN (r_attr) are_8/VBP (l_nsubj) disorders_5/NNS (l_prep) in_6/IN (l_pobj) PD_7/NNP
D015632_D001523 NONE MPTP_4/NNP (r_npadvmod) lesioned_6/VBN (r_amod) marmoset_7/NNP (r_nsubjpass) used_9/VBN (l_prep) as_10/IN (l_pobj) model_12/NN (l_prep) of_13/IN (l_pobj) symptoms_15/NNS
D007980_D020734 NONE levodopa_27/NN (r_pobj) to_26/IN (r_prep) prior_25/RB (r_advmod) evaluated_2/VBN (l_prep) for_3/IN (l_pobj) disability_5/NN
D007980_D004409 CID levodopa_27/NN (r_pobj) to_26/IN (r_prep) prior_25/RB (r_advmod) evaluated_2/VBN (l_prep) for_3/IN (l_pobj) disability_5/NN (l_conj) dyskinesia_7/NN
D007980_D004409 CID levodopa_9/NN (r_npadvmod) induced_11/VBN (r_amod) fluctuations_13/NNS (l_conj) dyskinesia_15/NN
D007980_D004409 CID levodopa_27/NN (r_compound) therapy_28/NN (r_pobj) of_26/IN (r_prep) duration_25/NN (r_pobj) with_23/IN (r_prep) correlated_22/VBN (r_relcl) increase_7/NN (l_prep) in_8/IN (l_pobj) fluctuations_13/NNS (l_conj) dyskinesia_15/NN
19515070
D019343_D064420 NONE citrate_6/NN (r_compound) anticoagulation_7/NN (r_attr) is_2/VBZ (l_conj) carries_15/VBZ (l_dobj) risk_17/NN (l_prep) of_18/IN (l_pobj) toxicity_20/NN
D019343_D064420 NONE citrate_19/NN (r_compound) toxicity_20/NN
D019343_D064420 NONE citrate_10/NN (r_compound) toxicity_11/NN
D000082_D017114 CID acetaminophen_11/NN (r_npadvmod) induced_13/VBN (r_amod) failure_16/NN
D000082_D058186 CID acetaminophen_11/NN (r_npadvmod) induced_13/VBN (r_amod) failure_16/NN (l_prep) with_17/IN (l_pobj) AKI_19/NNP
D019343_D017114 NONE citrate_30/NNP (r_compound) dialysate_31/NNP (r_pobj) with_29/IN (r_prep) anticoagulated_28/VBN (r_acl) transplantation_27/NN (r_pobj) during_25/IN (r_prep) underwent_21/VBD (r_relcl) failure_16/NN
D019343_D017114 NONE Citrate_0/NNP (r_compound) dialysate_1/NNP (r_nsubj) is_2/VBZ (l_attr) alternative_5/NN (l_prep) for_6/IN (l_pobj) support_8/NN (l_prep) in_12/IN (l_pobj) failure_15/NN
D019343_D058186 NONE citrate_30/NNP (r_compound) dialysate_31/NNP (r_pobj) with_29/IN (r_prep) anticoagulated_28/VBN (r_acl) transplantation_27/NN (r_pobj) during_25/IN (r_prep) underwent_21/VBD (r_relcl) failure_16/NN (l_prep) with_17/IN (l_pobj) AKI_19/NNP
3375885
D007213_D006947 CID indomethacin_3/NN (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Hyperkalemia_0/NN
D007213_D006947 CID indomethacin_26/NN (r_pobj) by_24/IN (r_agent) caused_23/VBN (l_nsubjpass) hyperkalemia_18/NN
D007213_D006947 CID indomethacin_22/NN (r_compound) therapy_23/NN (r_nsubjpass) continued_26/VBN (r_ccomp) allowing_21/VBG (r_conj) correcting_17/VBG (l_dobj) hyperkalemia_19/NN
D009288_D006947 CID naproxen_5/NN (r_conj) indomethacin_3/NN (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Hyperkalemia_0/NN
D009288_D006947 CID naproxen_28/NN (r_conj) indomethacin_26/NN (r_pobj) by_24/IN (r_agent) caused_23/VBN (l_nsubjpass) hyperkalemia_18/NN
D005438_D006947 NONE fludrocortisone_9/NN (r_pobj) by_8/IN (r_agent) reversed_7/VBN (r_conj) induced_1/VBN (r_acl) Hyperkalemia_0/NN
D005438_D006947 NONE fludrocortisone_13/NNP (r_nsubjpass) added_15/VBN (l_advcl) correcting_17/VBG (l_dobj) hyperkalemia_19/NN
D008528_D001172 NONE acid_14/NN (r_compound) nephropathy_15/NN (r_pobj) of_12/IN (r_prep) history_11/NN (r_conj) patient_4/NN (l_prep) with_5/IN (l_pobj) arthritis_8/NN
D008528_D007674 CID acid_14/NN (r_compound) nephropathy_15/NN
D008528_D006947 NONE acid_14/NN (r_compound) nephropathy_15/NN (l_relcl) caused_23/VBN (l_nsubjpass) hyperkalemia_18/NN
D008528_D006994 NONE acid_14/NN (r_compound) nephropathy_15/NN (l_relcl) caused_23/VBN (l_nsubjpass) hyperkalemia_18/NN (l_conj) hypoaldosteronism_21/NN
D007213_D001172 NONE indomethacin_26/NN (r_pobj) by_24/IN (r_agent) caused_23/VBN (r_relcl) nephropathy_15/NN (r_pobj) of_12/IN (r_prep) history_11/NN (r_conj) patient_4/NN (l_prep) with_5/IN (l_pobj) arthritis_8/NN
D007213_D007674 NONE indomethacin_26/NN (r_pobj) by_24/IN (r_agent) caused_23/VBN (r_relcl) nephropathy_15/NN
D007213_D006994 CID indomethacin_26/NN (r_pobj) by_24/IN (r_agent) caused_23/VBN (l_nsubjpass) hyperkalemia_18/NN (l_conj) hypoaldosteronism_21/NN
D009288_D001172 NONE naproxen_28/NN (r_conj) indomethacin_26/NN (r_pobj) by_24/IN (r_agent) caused_23/VBN (r_relcl) nephropathy_15/NN (r_pobj) of_12/IN (r_prep) history_11/NN (r_conj) patient_4/NN (l_prep) with_5/IN (l_pobj) arthritis_8/NN
D009288_D007674 NONE naproxen_28/NN (r_conj) indomethacin_26/NN (r_pobj) by_24/IN (r_agent) caused_23/VBN (r_relcl) nephropathy_15/NN
D009288_D006994 CID naproxen_28/NN (r_conj) indomethacin_26/NN (r_pobj) by_24/IN (r_agent) caused_23/VBN (l_nsubjpass) hyperkalemia_18/NN (l_conj) hypoaldosteronism_21/NN
D011453_D007674 NONE prostaglandin_17/NN (r_amod) inhibitors_19/NNS (r_pobj) with_16/IN (r_prep) type_11/VB (r_xcomp) predisposed_7/VBD (l_nsubj) disease_6/NN
D011453_D006994 NONE prostaglandin_17/NN (r_amod) inhibitors_19/NNS (r_pobj) with_16/IN (r_prep) type_11/VB (l_dobj) acidosis_15/NN
24999722
D005446_C537630 NONE acetonide_5/NNP (r_compound) implant_7/NNP (r_pobj) of_3/IN (r_prep) Safety_0/NN (l_prep) in_12/IN (l_pobj) retinochoroidopathy_14/NNP
D005446_C537630 NONE acetonide_8/NNP (r_compound) implant_10/NNP (r_pobj) of_5/IN (r_prep) outcomes_4/NNS (r_dobj) report_1/VB (l_prep) in_15/IN (l_pobj) patients_16/NNS (l_prep) with_17/IN (l_pobj) retinochoroidopathy_19/NNP
D005446_C537630 NONE acetonide_5/NNP (r_compound) implant_6/NNP (r_nsubj) helps_11/VBZ (l_xcomp) control_13/VB (l_prep) in_15/IN (l_pobj) cases_20/NNS (l_prep) of_21/IN (l_pobj) retinochoroidopathy_23/NNP
D005446_D007249 NONE acetonide_5/NNP (r_compound) implant_6/NNP (r_nsubj) helps_11/VBZ (l_xcomp) control_13/VB (l_dobj) inflammation_14/NN
2484903
D011441_D056486 CID propylthiouracil_3/NN (r_npadvmod) associated_5/VBN (r_amod) hepatitis_7/NN
D011441_D056486 CID propylthiouracil_22/NN (r_npadvmod) associated_24/VBN (r_amod) syndrome_28/NN (r_pobj) of_21/IN (r_prep) case_20/NN (r_conj) case_10/NN (r_nsubjpass) described_30/VBN (l_nsubjpass) cases_1/NNS (l_prep) of_2/IN (l_pobj) hepatitis_7/NN
D011441_D047508 NONE propylthiouracil_3/NN (r_npadvmod) associated_5/VBN (r_amod) hepatitis_7/NN (r_pobj) of_2/IN (r_prep) cases_1/NNS (r_nsubjpass) described_30/VBN (l_nsubjpass) case_10/NN (l_prep) of_11/IN (l_pobj) necrosis_17/NN
D011441_D047508 NONE propylthiouracil_22/NN (r_npadvmod) associated_24/VBN (r_amod) syndrome_28/NN (r_pobj) of_21/IN (r_prep) case_20/NN (r_conj) case_10/NN (l_prep) of_11/IN (l_pobj) necrosis_17/NN
D011441_D008180 CID propylthiouracil_3/NN (r_npadvmod) associated_5/VBN (r_amod) hepatitis_7/NN (r_pobj) of_2/IN (r_prep) cases_1/NNS (r_nsubjpass) described_30/VBN (l_nsubjpass) case_10/NN (l_conj) case_20/NN (l_prep) of_21/IN (l_pobj) syndrome_28/NN
D011441_D008180 CID propylthiouracil_22/NN (r_npadvmod) associated_24/VBN (r_amod) syndrome_28/NN
D008713_D056486 NONE methimazole_13/NN (r_npadvmod) associated_15/VBN (r_amod) necrosis_17/NN (r_pobj) of_11/IN (r_prep) case_10/NN (r_nsubjpass) described_30/VBN (l_nsubjpass) cases_1/NNS (l_prep) of_2/IN (l_pobj) hepatitis_7/NN
D008713_D047508 CID methimazole_13/NN (r_npadvmod) associated_15/VBN (r_amod) necrosis_17/NN
D008713_D008180 NONE methimazole_13/NN (r_npadvmod) associated_15/VBN (r_amod) necrosis_17/NN (r_pobj) of_11/IN (r_prep) case_10/NN (l_conj) case_20/NN (l_prep) of_21/IN (l_pobj) syndrome_28/NN
1779253
D002211_D051474 NONE capsaicin_3/NN (l_prep) in_4/IN (l_pobj) neuralgia_9/NN
D002211_D051474 NONE capsaicin_18/NN (r_pobj) to_16/IN (r_prep) response_15/NN (r_pobj) of_14/IN (r_prep) action_11/NN (r_pobj) of_10/IN (r_prep) course_9/NN (r_npadvmod) treated_38/VBN (l_nsubjpass) patients_21/NNS (l_prep) with_22/IN (l_pobj) neuralgia_27/NN
D002211_D051474 NONE capsaicin_18/NN (r_pobj) to_16/IN (r_prep) response_15/NN (r_pobj) of_14/IN (r_prep) action_11/NN (r_pobj) of_10/IN (r_prep) course_9/NN (r_npadvmod) treated_38/VBN (l_nsubjpass) patients_21/NNS (l_prep) with_22/IN (l_pobj) neuralgia_27/NN (l_appos) PHN_29/NNP
D002211_D051474 NONE capsaicin_42/NN (r_amod) cream_43/NN (r_pobj) with_39/IN (r_prep) treated_38/VBN (l_nsubjpass) patients_21/NNS (l_prep) with_22/IN (l_pobj) neuralgia_27/NN
D002211_D051474 NONE capsaicin_42/NN (r_amod) cream_43/NN (r_pobj) with_39/IN (r_prep) treated_38/VBN (l_nsubjpass) patients_21/NNS (l_prep) with_22/IN (l_pobj) neuralgia_27/NN (l_appos) PHN_29/NNP
D002211_D051474 NONE capsaicin_26/NN (l_prep) in_27/IN (l_pobj) PHN_28/NNP
D002211_D008413 CID capsaicin_28/NN (r_npadvmod) induced_30/VBN (r_amod) sensations_32/NNS (l_appos) 4_34/CD (l_conj) mastitis_37/NN
19447152
D010042_D001714 CID ouabain_6/NNP (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) model_1/NN (l_prep) of_2/IN (l_pobj) mania_3/NN
D010042_D001714 CID ouabain_7/NNP (r_pobj) of_6/IN (r_prep) administration_5/NN (r_appos) intracerebroventricular_1/NN (r_nsubjpass) suggested_17/VBN (l_xcomp) mimic_19/VB (l_dobj) symptoms_21/NNS (l_prep) of_22/IN (l_pobj) mania_25/NN
D010042_D001714 CID ouabain_3/NN (r_npadvmod) induced_5/VBN (r_amod) behavior_9/NN (l_amod) like_8/JJ (l_npadvmod) mania_6/NN
D010042_D001714 CID ouabain_3/NN (r_npadvmod) induced_5/VBN (r_amod) behavior_9/NN (r_nsubj) provide_11/VB (l_dobj) model_15/NN (l_relcl) test_17/VB (l_dobj) hypothesis_19/NN (l_prep) of_20/IN (l_pobj) involvement_22/NN (l_prep) of_23/IN (l_pobj) stress_25/NN (l_prep) in_26/IN (l_pobj) disorder_28/NN
D012964_D001714 NONE Na(+)/K(+)-ATPase_10/NNP (r_compound) inhibitor_11/NN (r_appos) ouabain_7/NNP (r_pobj) of_6/IN (r_prep) administration_5/NN (r_appos) intracerebroventricular_1/NN (r_nsubjpass) suggested_17/VBN (l_xcomp) mimic_19/VB (l_dobj) symptoms_21/NNS (l_prep) of_22/IN (l_pobj) mania_25/NN
D011188_D001714 NONE Na(+)/K(+)-ATPase_10/NNP (r_compound) inhibitor_11/NN (r_appos) ouabain_7/NNP (r_pobj) of_6/IN (r_prep) administration_5/NN (r_appos) intracerebroventricular_1/NN (r_nsubjpass) suggested_17/VBN (l_xcomp) mimic_19/VB (l_dobj) symptoms_21/NNS (l_prep) of_22/IN (l_pobj) mania_25/NN
D010042_D009069 NONE ouabain_4/NN (l_conj) induced_10/VBN (l_dobj) hyperlocomotion_11/NN
7369302
D011803_D000550 CID quinine_10/NN (r_compound) amblyopia_11/NN
D011803_D001766 CID sulfate_30/NN (r_pobj) of_28/IN (r_prep) use_27/NN (r_pobj) after_25/IN (r_prep) developed_18/VBN (r_acl) potentials_17/NNS (r_conj) supersensitivity_10/NNP (r_conj) response_7/NN (r_pobj) with_2/IN (r_prep) blindness_1/NN
D011803_D015845 CID sulfate_30/NN (r_pobj) of_28/IN (r_prep) use_27/NN (r_pobj) after_25/IN (r_prep) developed_18/VBN (r_acl) potentials_17/NNS (r_conj) supersensitivity_10/NNP (r_conj) response_7/NN (l_amod) pupillary_6/JJ
D011803_D015845 CID quinine_16/NN (r_compound) toxicity_17/NN (r_pobj) in_15/IN (r_prep) potentials_14/NNS (r_conj) supersensitivity_7/NNP (r_conj) response_4/NN (l_amod) pupillary_3/JJ
D011803_D009120 NONE sulfate_30/NN (r_pobj) of_28/IN (r_prep) use_27/NN (l_prep) for_31/IN (l_pobj) cramps_33/NNS
D011803_D064420 NONE quinine_16/NN (r_compound) toxicity_17/NN
3987172
D011433_D006973 NONE Propranolol_0/JJ (l_dobj) antagonism_1/NN (l_prep) of_2/IN (l_pobj) hypertension_6/NN
D011433_D006973 NONE propranolol_7/NNS (r_pobj) of_6/IN (r_prep) efficacy_3/NN (r_dobj) studied_1/VBD (l_prep) in_8/IN (l_pobj) treatment_10/NN (l_prep) of_11/IN (l_pobj) hypertension_15/NN
D010665_D006973 CID phenylpropanolamine_3/NN (r_npadvmod) induced_5/VBN (r_amod) hypertension_6/NN
D010665_D006973 CID Phenylpropanolamine_0/NNP (r_nmod) overdose_4/NN (r_nsubj) cause_6/VB (l_dobj) hypertension_8/NN
D010665_D006973 CID PPA_2/NNP (r_appos) Phenylpropanolamine_0/NNP (r_nmod) overdose_4/NN (r_nsubj) cause_6/VB (l_dobj) hypertension_8/NN
D010665_D006973 CID PPA_12/NNP (r_npadvmod) induced_14/VBN (r_amod) hypertension_15/NN
D010665_D062787 NONE Phenylpropanolamine_0/NNP (r_nmod) overdose_4/NN
D010665_D062787 NONE PPA_2/NNP (r_appos) Phenylpropanolamine_0/NNP (r_nmod) overdose_4/NN
D010665_D002543 NONE Phenylpropanolamine_0/NNP (r_nmod) overdose_4/NN (r_nsubj) cause_6/VB (l_dobj) hypertension_8/NN (l_conj) hemorrhage_11/NN
D010665_D002543 NONE PPA_2/NNP (r_appos) Phenylpropanolamine_0/NNP (r_nmod) overdose_4/NN (r_nsubj) cause_6/VB (l_dobj) hypertension_8/NN (l_conj) hemorrhage_11/NN
D010665_D020521 NONE PPA_10/NNP (r_nsubj) increased_11/VBD (l_dobj) volume_14/NN (l_compound) stroke_13/NN
17879217
D012293_D005921 CID Rifampicin_0/NNP (r_npadvmod) associated_2/VBN (r_amod) glomerulonephritis_5/NN
D012293_D005921 CID rifampicin_9/NNS (r_amod) therapy_10/NN (r_pobj) of_8/IN (r_prep) complication_7/NN (r_pobj) as_6/IN (r_prep) reported_5/VBN (l_nsubjpass) glomerulonephritis_2/NN
D012293_D005921 CID rifampicin_25/NNS (r_pobj) with_24/IN (r_prep) treated_23/VBN (r_advcl) developed_11/VBD (l_advmod) secondary_15/JJ (l_prep) to_16/IN (l_pobj) glomerulonephritis_20/NN
D012293_D005921 CID rifampicin_35/NNS (r_amod) therapy_36/NN (r_pobj) of_34/IN (r_prep) complication_33/NN (r_pobj) regarding_31/VBG (r_prep) review_28/VB (r_conj) developed_11/VBD (l_advmod) secondary_15/JJ (l_prep) to_16/IN (l_pobj) glomerulonephritis_20/NN
D012293_D013203 NONE Rifampicin_0/NNP (r_npadvmod) associated_2/VBN (r_amod) glomerulonephritis_5/NN (l_prep) in_6/IN (l_pobj) endocarditis_8/NN
D012293_D013203 NONE rifampicin_20/NNS (l_prep) for_21/IN (l_pobj) infections_23/NNS
D012293_D013203 NONE rifampicin_25/NNS (r_pobj) with_24/IN (r_prep) treated_23/VBN (r_advcl) developed_11/VBD (r_relcl) patient_6/NN (l_prep) with_7/IN (l_pobj) IE_9/NNP
D012293_D013203 NONE rifampicin_35/NNS (r_amod) therapy_36/NN (r_pobj) of_34/IN (r_prep) complication_33/NN (r_pobj) regarding_31/VBG (r_prep) review_28/VB (r_conj) developed_11/VBD (r_relcl) patient_6/NN (l_prep) with_7/IN (l_pobj) IE_9/NNP
D012293_D004696 NONE Rifampicin_0/NNP (r_npadvmod) associated_2/VBN (r_amod) glomerulonephritis_5/NN (l_prep) in_6/IN (l_pobj) endocarditis_8/NN
D012293_D004696 NONE rifampicin_20/NNS (r_pobj) of_19/IN (r_prep) use_18/NN (r_pobj) in_16/IN (r_prep) increase_15/NN (r_pobj) to_13/IN (r_prep) led_12/VBN (l_csubj) Changing_0/VBG (l_dobj) epidemiology_1/NN (l_prep) of_2/IN (l_pobj) infections_3/NNS (l_prep) as_5/IN (l_pobj) endocarditis_7/NNS
D012293_D004696 NONE rifampicin_20/NNS (r_pobj) of_19/IN (r_prep) use_18/NN (r_pobj) in_16/IN (r_prep) increase_15/NN (r_pobj) to_13/IN (r_prep) led_12/VBN (l_csubj) Changing_0/VBG (l_dobj) epidemiology_1/NN (l_prep) of_2/IN (l_pobj) infections_3/NNS (l_prep) as_5/IN (l_pobj) endocarditis_7/NNS (l_appos) IE_9/NNP
D012293_D004696 NONE rifampicin_25/NNS (r_pobj) with_24/IN (r_prep) treated_23/VBN (r_advcl) developed_11/VBD (r_relcl) patient_6/NN (l_prep) with_7/IN (l_pobj) IE_9/NNP
D012293_D004696 NONE rifampicin_35/NNS (r_amod) therapy_36/NN (r_pobj) of_34/IN (r_prep) complication_33/NN (r_pobj) regarding_31/VBG (r_prep) review_28/VB (r_conj) developed_11/VBD (r_relcl) patient_6/NN (l_prep) with_7/IN (l_pobj) IE_9/NNP
D012293_D014376 NONE rifampicin_9/NNS (r_amod) therapy_10/NN (l_prep) in_11/IN (l_pobj) patients_12/NNS (l_acl) receiving_13/VBG (l_dobj) treatment_14/NN (l_prep) for_15/IN (l_pobj) tuberculosis_16/NN
D012293_D007239 NONE rifampicin_20/NNS (r_pobj) of_19/IN (r_prep) use_18/NN (r_pobj) in_16/IN (r_prep) increase_15/NN (r_pobj) to_13/IN (r_prep) led_12/VBN (l_csubj) Changing_0/VBG (l_dobj) epidemiology_1/NN (l_prep) of_2/IN (l_pobj) infections_3/NNS
D012293_D058186 CID rifampicin_25/NNS (r_pobj) with_24/IN (r_prep) treated_23/VBN (r_advcl) developed_11/VBD (l_dobj) failure_14/NN
D012293_D058186 CID rifampicin_35/NNS (r_amod) therapy_36/NN (r_pobj) of_34/IN (r_prep) complication_33/NN (r_pobj) regarding_31/VBG (r_prep) review_28/VB (r_conj) developed_11/VBD (l_dobj) failure_14/NN
9831002
D008774_D009459 CID methylphenidate_4/NN (r_conj) syndrome_2/NN
D008774_D009459 CID methylphenidate_13/NN (r_pobj) by_12/IN (r_agent) caused_11/VBN (r_acl) female_4/NN (l_acl) presented_5/VBN (l_prep) with_6/IN (l_pobj) syndrome_9/NN
D008774_D009459 CID methylphenidate_13/NN (r_pobj) by_12/IN (r_agent) caused_11/VBN (r_acl) patient_5/NN (l_prep) with_6/IN (l_pobj) syndrome_9/NN
689020
D005280_D014202 CID hydrobromide_6/NN (r_compound) infusion_7/NN (r_pobj) of_3/IN (r_prep) end_2/NN (r_pobj) After_0/IN (r_prep) decreased_11/VBD (l_nsubj) amplitudes_10/NNS (l_compound) tremor_9/NN
D012312_D014202 CID HCl_19/NNP (r_compound) infusion_20/NN (r_pobj) following_16/VBG (r_acl) those_15/DT (r_pobj) than_14/IN (r_prep) faster_13/RBR (r_advmod) decreased_11/VBD (l_nsubj) amplitudes_10/NNS (l_compound) tremor_9/NN
24658375
D014212_D009220 CID acid_4/NN (r_npadvmod) induced_6/VBN (r_amod) myositis_8/NN
D014212_D009220 CID ATRA_6/NN (r_npadvmod) induced_8/VBN (r_amod) myositis_9/NN
D014212_D015473 NONE acid_4/NN (r_npadvmod) induced_6/VBN (r_amod) myositis_8/NN (l_prep) in_9/IN (l_pobj) patient_11/NN (l_prep) with_12/IN (l_pobj) leukemia_15/NN
D014212_D015473 NONE acid_4/NN (l_appos) component_10/NN (l_prep) for_14/IN (l_pobj) leukemia_17/NN
D014212_D015473 NONE acid_4/NN (l_appos) component_10/NN (l_prep) for_14/IN (l_pobj) leukemia_17/NN (l_appos) APL_19/NNP
D014212_D015473 NONE ATRA_6/NNP (r_appos) acid_4/NN (l_appos) component_10/NN (l_prep) for_14/IN (l_pobj) leukemia_17/NN
D014212_D015473 NONE ATRA_6/NNP (r_appos) acid_4/NN (l_appos) component_10/NN (l_prep) for_14/IN (l_pobj) leukemia_17/NN (l_appos) APL_19/NNP
10960401
D009020_D009759 CID morphine_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) nystagmus_1/NN
D009020_D009759 CID morphine_23/NN (r_pobj) of_17/IN (r_prep) dose_16/NN (r_dobj) receiving_12/VBG (r_advcl) developed_6/VBD (l_prep) with_8/IN (l_pobj) nystagmus_10/NN
D009020_D004244 CID morphine_23/NN (r_pobj) of_17/IN (r_prep) dose_16/NN (r_dobj) receiving_12/VBG (r_advcl) developed_6/VBD (l_dobj) dizziness_7/NN
612112
D005045_D009207 CID etomidate_5/NNP (r_nsubj) prove_7/VB (l_prep) because_22/IN (l_pobj) incidence_26/NN (l_prep) of_27/IN (l_pobj) myoclonia_28/NNP
24911645
C573355_D012640 NONE FC_9/NNP (r_pobj) with_7/IN (r_prep) pretreated_6/VBN (l_prep) in_10/IN (l_pobj) seizures_14/NNS
C573355_D012640 NONE GFC_7/NNP (r_compound) effects_8/NNS (r_dobj) evaluate_5/VB (l_prep) at_9/IN (l_pobj) doses_10/NNS (l_prep) of_11/IN (l_pobj) mg/kg_17/CD (l_prep) on_18/IN (l_pobj) parameters_20/NNS (l_compound) seizure_19/NN
C573355_D012640 NONE GFC_7/NNP (r_compound) effects_8/NNS (r_dobj) evaluate_5/VB (l_advcl) determine_22/VB (l_prep) after_60/IN (l_pobj) seizures_61/NNS
C573355_D012640 NONE GFC_0/NNP (r_nsubj) produced_1/VBD (l_dobj) latency_4/NN (l_prep) to_5/IN (l_pobj) seizure_7/NN
C573355_D012640 NONE GFC_4/NNP (r_nsubj) exert_6/VB (l_conj) reduce_10/VB (l_advcl) demonstrated_23/VBN (l_agent) by_24/IN (l_pobj) increase_25/NN (l_prep) in_26/IN (l_pobj) latency_27/NN (l_prep) to_28/IN (l_pobj) seizure_30/NN
D010862_D012640 CID pilocarpine_11/NNP (r_npadvmod) induced_13/VBN (r_amod) seizures_14/NNS
D010862_D012640 CID pilocarpine_16/NN (r_npadvmod) induced_18/VBN (r_amod) status_19/NN (r_compound) epilepticus_20/NN (r_pobj) of_15/IN (r_prep) installation_14/NN (r_pobj) of_13/IN (r_prep) frequency_12/NN (r_dobj) reduce_10/VB (l_advcl) demonstrated_23/VBN (l_agent) by_24/IN (l_pobj) increase_25/NN (l_prep) in_26/IN (l_pobj) latency_27/NN (l_prep) to_28/IN (l_pobj) seizure_30/NN
D000596_D012640 NONE acid_31/NN (r_nmod) levels_47/NNS (r_pobj) on_29/IN (r_prep) effects_28/NNS (r_conj) activity_25/NN (r_dobj) determine_22/VB (r_advcl) evaluate_5/VB (l_prep) at_9/IN (l_pobj) doses_10/NNS (l_prep) of_11/IN (l_pobj) mg/kg_17/CD (l_prep) on_18/IN (l_pobj) parameters_20/NNS (l_compound) seizure_19/NN
D000596_D012640 NONE acid_31/NN (r_nmod) levels_47/NNS (r_pobj) on_29/IN (r_prep) effects_28/NNS (r_conj) activity_25/NN (r_dobj) determine_22/VB (l_prep) after_60/IN (l_pobj) seizures_61/NNS
D005680_D012640 NONE acid_36/NN (r_nmod) levels_47/NNS (r_pobj) on_29/IN (r_prep) effects_28/NNS (r_conj) activity_25/NN (r_dobj) determine_22/VB (r_advcl) evaluate_5/VB (l_prep) at_9/IN (l_pobj) doses_10/NNS (l_prep) of_11/IN (l_pobj) mg/kg_17/CD (l_prep) on_18/IN (l_pobj) parameters_20/NNS (l_compound) seizure_19/NN
D005680_D012640 NONE acid_36/NN (r_nmod) levels_47/NNS (r_pobj) on_29/IN (r_prep) effects_28/NNS (r_conj) activity_25/NN (r_dobj) determine_22/VB (l_prep) after_60/IN (l_pobj) seizures_61/NNS
D005680_D012640 NONE GABA_38/NNP (r_appos) acid_36/NN (r_nmod) levels_47/NNS (r_pobj) on_29/IN (r_prep) effects_28/NNS (r_conj) activity_25/NN (r_dobj) determine_22/VB (r_advcl) evaluate_5/VB (l_prep) at_9/IN (l_pobj) doses_10/NNS (l_prep) of_11/IN (l_pobj) mg/kg_17/CD (l_prep) on_18/IN (l_pobj) parameters_20/NNS (l_compound) seizure_19/NN
D005680_D012640 NONE GABA_38/NNP (r_appos) acid_36/NN (r_nmod) levels_47/NNS (r_pobj) on_29/IN (r_prep) effects_28/NNS (r_conj) activity_25/NN (r_dobj) determine_22/VB (l_prep) after_60/IN (l_pobj) seizures_61/NNS
D018698_D012640 NONE glutamine_41/NN (r_conj) acid_36/NN (r_nmod) levels_47/NNS (r_pobj) on_29/IN (r_prep) effects_28/NNS (r_conj) activity_25/NN (r_dobj) determine_22/VB (r_advcl) evaluate_5/VB (l_prep) at_9/IN (l_pobj) doses_10/NNS (l_prep) of_11/IN (l_pobj) mg/kg_17/CD (l_prep) on_18/IN (l_pobj) parameters_20/NNS (l_compound) seizure_19/NN
D018698_D012640 NONE glutamine_41/NN (r_conj) acid_36/NN (r_nmod) levels_47/NNS (r_pobj) on_29/IN (r_prep) effects_28/NNS (r_conj) activity_25/NN (r_dobj) determine_22/VB (l_prep) after_60/IN (l_pobj) seizures_61/NNS
D001224_D012640 NONE aspartate_43/NN (r_conj) glutamine_41/NN (r_conj) acid_36/NN (r_nmod) levels_47/NNS (r_pobj) on_29/IN (r_prep) effects_28/NNS (r_conj) activity_25/NN (r_dobj) determine_22/VB (r_advcl) evaluate_5/VB (l_prep) at_9/IN (l_pobj) doses_10/NNS (l_prep) of_11/IN (l_pobj) mg/kg_17/CD (l_prep) on_18/IN (l_pobj) parameters_20/NNS (l_compound) seizure_19/NN
D001224_D012640 NONE aspartate_43/NN (r_conj) glutamine_41/NN (r_conj) acid_36/NN (r_nmod) levels_47/NNS (r_pobj) on_29/IN (r_prep) effects_28/NNS (r_conj) activity_25/NN (r_dobj) determine_22/VB (l_prep) after_60/IN (l_pobj) seizures_61/NNS
D005978_D012640 NONE glutathione_45/NN (r_conj) aspartate_43/NN (r_conj) glutamine_41/NN (r_conj) acid_36/NN (r_nmod) levels_47/NNS (r_pobj) on_29/IN (r_prep) effects_28/NNS (r_conj) activity_25/NN (r_dobj) determine_22/VB (r_advcl) evaluate_5/VB (l_prep) at_9/IN (l_pobj) doses_10/NNS (l_prep) of_11/IN (l_pobj) mg/kg_17/CD (l_prep) on_18/IN (l_pobj) parameters_20/NNS (l_compound) seizure_19/NN
D005978_D012640 NONE glutathione_45/NN (r_conj) aspartate_43/NN (r_conj) glutamine_41/NN (r_conj) acid_36/NN (r_nmod) levels_47/NNS (r_pobj) on_29/IN (r_prep) effects_28/NNS (r_conj) activity_25/NN (r_dobj) determine_22/VB (l_prep) after_60/IN (l_pobj) seizures_61/NNS
C573355_D013226 NONE GFC_4/NNP (r_nsubj) exert_6/VB (l_conj) reduce_10/VB (l_dobj) frequency_12/NN (l_prep) of_13/IN (l_pobj) installation_14/NN (l_prep) of_15/IN (l_pobj) epilepticus_20/NN
D010862_D013226 CID pilocarpine_16/NN (r_npadvmod) induced_18/VBN (r_amod) status_19/NN (r_compound) epilepticus_20/NN
3339945
D013806_D020258 NONE Theophylline_0/NN (r_compound) neurotoxicity_1/NN
D013806_D020258 NONE theophylline_12/NN (r_pobj) of_11/IN (r_prep) neurotoxicity_10/NN
D013806_D020258 NONE theophylline_15/NN (r_pobj) to_14/IN (r_prep) response_13/NN (l_amod) neurotoxic_12/JJ
D000628_D012640 CID aminophylline_21/NN (r_pobj) of_20/IN (r_prep) infusions_19/NNS (r_dobj) received_18/VBN (l_prep) until_22/IN (l_pobj) onset_23/NN (l_prep) of_24/IN (l_pobj) seizures_26/NNS
2383364
C048279_D002056 NONE diphosphanilate_6/NNP (r_pobj) of_3/IN (r_prep) study_2/NN (l_appos) agent_11/NN (l_prep) for_12/IN (l_pobj) burns_13/NNS
C048279_D002056 NONE phosphanilate_1/NN (r_nsubjpass) evaluated_16/VBN (l_prep) as_17/IN (l_pobj) burn_20/NN
C048279_D002056 NONE CHP_3/NNP (r_appos) phosphanilate_1/NN (r_nsubjpass) evaluated_16/VBN (l_prep) as_17/IN (l_pobj) burn_20/NN
C048279_D002056 NONE CHP_10/NNP (r_compound) concentrations_11/NNS (r_pobj) of_7/IN (r_prep) each_6/DT (r_pobj) with_5/IN (r_prep) treated_4/VBN (l_nsubjpass) site_2/NN (l_compound) burn_1/NN
C048279_D002056 NONE CHP_10/NNP (r_compound) concentrations_11/NNS (r_pobj) of_7/IN (r_prep) each_6/DT (r_pobj) with_5/IN (r_prep) treated_4/VBN (l_prep) from_13/IN (l_pobj) vehicle_23/NN (l_conj) cream_34/NN (l_appos) agent_38/NN (l_acl) used_40/VBN (l_prep) for_41/IN (l_pobj) treatment_43/NN (l_prep) of_44/IN (l_pobj) wounds_46/NNS (l_compound) burn_45/NN
D012837_D002056 NONE sulphadiazine_30/NN (r_nmod) AgSD_32/NNP (r_npadvmod) 1_26/CD (r_nummod) cream_34/NN (r_conj) vehicle_23/NN (r_pobj) from_13/IN (r_prep) treated_4/VBN (l_nsubjpass) site_2/NN (l_compound) burn_1/NN
D012837_D002056 NONE sulphadiazine_30/NN (r_nmod) AgSD_32/NNP (r_npadvmod) 1_26/CD (r_nummod) cream_34/NN (l_appos) agent_38/NN (l_acl) used_40/VBN (l_prep) for_41/IN (l_pobj) treatment_43/NN (l_prep) of_44/IN (l_pobj) wounds_46/NNS (l_compound) burn_45/NN
D012837_D002056 NONE AgSD_32/NNP (r_npadvmod) 1_26/CD (r_nummod) cream_34/NN (r_conj) vehicle_23/NN (r_pobj) from_13/IN (r_prep) treated_4/VBN (l_nsubjpass) site_2/NN (l_compound) burn_1/NN
D012837_D002056 NONE AgSD_32/NNP (r_npadvmod) 1_26/CD (r_nummod) cream_34/NN (l_appos) agent_38/NN (l_acl) used_40/VBN (l_prep) for_41/IN (l_pobj) treatment_43/NN (l_prep) of_44/IN (l_pobj) wounds_46/NNS (l_compound) burn_45/NN
C048279_D010146 CID CHP_6/NNP (r_compound) concentration_7/NN (l_conj) ratings_11/NNS (l_prep) of_12/IN (l_pobj) pain_13/NN
C048279_D010146 CID CHP_4/NNP (r_compound) cream_5/NN (r_nsubj) was_6/VBD (l_acomp) closest_7/JJS (l_prep) in_10/IN (l_pobj) tolerance_12/NN (l_compound) pain_11/NN
D012837_D010146 NONE AgSD_9/NNP (r_pobj) to_8/IN (r_prep) closest_7/JJS (l_prep) in_10/IN (l_pobj) tolerance_12/NN (l_compound) pain_11/NN
D012837_D010146 NONE AgSD_23/NNP (r_pobj) from_22/IN (r_prep) differed_20/VBD (l_ccomp) was_6/VBD (l_acomp) closest_7/JJS (l_prep) in_10/IN (l_pobj) tolerance_12/NN (l_compound) pain_11/NN
12828076
D000082_D017114 CID paracetamol_12/JJ (r_pobj) to_11/IN (r_prep) due_10/IN (r_prep) serum_1/NN (l_prep) in_4/IN (l_pobj) patients_5/NNS (l_prep) with_6/IN (l_pobj) failure_9/NN
D000082_D017114 CID paracetamol_12/JJ (r_pobj) to_11/IN (r_pcomp) due_10/IN (r_prep) were_1/VBD (l_prep) in_4/IN (l_pobj) patients_5/NNS (l_prep) with_6/IN (l_pobj) failure_9/NN
D000082_D062787 NONE paracetamol_12/JJ (r_pobj) to_11/IN (r_prep) due_10/IN (r_prep) serum_1/NN (r_nsubj) overdose_13/NN
D000082_D062787 NONE paracetamol_12/JJ (r_pobj) to_11/IN (r_pcomp) due_10/IN (l_pobj) overdose_13/NN
D000082_D056486 NONE paracetamol_12/JJ (r_pobj) to_11/IN (r_pcomp) due_10/IN (l_pobj) overdose_13/NN (l_prep) than_35/IN (l_pobj) those_36/DT (l_prep) to_42/TO (l_pobj) hepatitis_44/NN
19392810
D003932_D012206 CID heroin_7/NN (r_npadvmod) dependent_9/JJ (r_amod) male_10/NN (r_pobj) in_5/IN (r_prep) stroke_4/NN (l_nmod) Rhabdomyolysis_0/NN
D003932_D012206 CID heroin_14/NN (r_pobj) after_12/IN (r_prep) presented_5/VBN (l_prep) with_6/IN (l_pobj) rhabdomyolysis_7/NN
D003932_D012206 CID heroin_4/NN (r_conj) methadone_2/NN (r_dobj) using_1/VBG (r_acl) Those_0/DT (r_nsubj) increase_7/VB (l_dobj) risk_8/NN (l_prep) of_9/IN (l_pobj) rhabdomyolysis_10/NN
D003932_D012206 CID heroin_2/NN (r_npadvmod) related_4/VBN (r_amod) rhabdomyolysis_5/NN
D003932_D012206 CID heroin_9/NN (r_compound) abusers_10/NNS (r_pobj) in_8/IN (r_prep) stroke_7/NN (r_conj) rhabdomyolysis_5/NN
D003932_D002544 NONE heroin_7/NN (r_npadvmod) dependent_9/JJ (r_amod) male_10/NN (r_pobj) in_5/IN (r_prep) stroke_4/NN
D003932_D002544 NONE heroin_14/NN (r_pobj) after_12/IN (r_prep) presented_5/VBN (l_prep) with_6/IN (l_pobj) rhabdomyolysis_7/NN (l_conj) stroke_11/NN
D003932_D002544 NONE heroin_4/NN (r_conj) methadone_2/NN (r_dobj) using_1/VBG (r_acl) Those_0/DT (r_nsubj) increase_7/VB (l_dobj) risk_8/NN (l_prep) of_9/IN (l_pobj) rhabdomyolysis_10/NN (l_conj) stroke_13/NN
D008691_D012206 CID methadone_12/NN (r_compound) therapy_14/NN (r_pobj) under_11/IN (r_prep) stroke_4/NN (l_nmod) Rhabdomyolysis_0/NN
D008691_D012206 CID methadone_2/NN (r_dobj) using_1/VBG (r_acl) Those_0/DT (r_nsubj) increase_7/VB (l_dobj) risk_8/NN (l_prep) of_9/IN (l_pobj) rhabdomyolysis_10/NN
D008691_D002544 NONE methadone_12/NN (r_compound) therapy_14/NN (r_pobj) under_11/IN (r_prep) stroke_4/NN
D008691_D002544 NONE methadone_2/NN (r_dobj) using_1/VBG (r_acl) Those_0/DT (r_nsubj) increase_7/VB (l_dobj) risk_8/NN (l_prep) of_9/IN (l_pobj) rhabdomyolysis_10/NN (l_conj) stroke_13/NN
D003932_D020521 CID heroin_2/NN (r_npadvmod) related_4/VBN (r_amod) rhabdomyolysis_5/NN (l_conj) stroke_7/NN
D003932_D020521 CID heroin_9/NN (r_compound) abusers_10/NNS (r_pobj) in_8/IN (r_prep) stroke_7/NN
11176729
D000806_D006333 NONE inhibitors_9/NNS (r_pobj) of_4/IN (r_prep) doses_3/NNS (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) failure_15/NN
D000806_D006333 NONE inhibitors_9/NNS (r_appos) enzyme_5/NNS (r_pobj) with_1/IN (r_prep) Treatment_0/NN (r_nsubj) reduces_10/VBZ (l_prep) in_14/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) failure_19/NN
D000806_D006333 NONE inhibitors_9/NNS (r_appos) enzyme_5/NNS (r_pobj) with_1/IN (r_prep) Treatment_0/NN (r_nsubj) reduces_10/VBZ (l_prep) in_14/IN (l_pobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) failure_19/NN (l_appos) CHF_21/NNP
D000806_D006333 NONE inhibitor_5/NN (r_compound) therapy_6/NN (l_prep) in_7/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) CHF_11/NNP
D017706_D006333 NONE lisinopril_15/NN (l_prep) in_16/IN (l_pobj) CHF_17/NNP
D000806_D007022 NONE inhibitor_8/NN (r_dobj) receiving_5/VBG (r_pcomp) Of_0/IN (r_prep) titrated_18/VBN (l_prep) because_26/IN (l_pobj) symptoms_28/NNS (l_acl) related_30/VBN (l_prep) to_31/IN (l_pobj) hypotension_32/NN
D000806_D007674 NONE inhibitor_8/NN (r_dobj) receiving_5/VBG (r_pcomp) Of_0/IN (r_prep) titrated_18/VBN (l_prep) because_26/IN (l_conj) because_38/IN (l_pobj) dysfunction_41/NN
D000806_D006947 NONE inhibitor_8/NN (r_dobj) receiving_5/VBG (r_pcomp) Of_0/IN (r_prep) titrated_18/VBN (l_prep) because_26/IN (l_conj) because_38/IN (l_pobj) dysfunction_41/NN (l_conj) hyperkalemia_43/NN
16880771
D004298_D020521 NONE dopamine_3/NN (r_compound) precursor_4/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) enhances_6/VBZ (l_xcomp) learning_7/VBG (l_prep) in_8/IN (l_pobj) subjects_10/NNS (l_conj) patients_13/NNS (l_compound) stroke_12/NN
D004298_D020521 NONE dopamine_12/NN (r_nsubj) enhances_13/VBZ (l_dobj) learning_15/NN (l_prep) in_16/IN (l_pobj) subjects_18/NNS (l_conj) patients_21/NNS (l_compound) stroke_20/NN
D007980_D020521 NONE levodopa_5/NN (r_appos) precursor_4/NN (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) enhances_6/VBZ (l_xcomp) learning_7/VBG (l_prep) in_8/IN (l_pobj) subjects_10/NNS (l_conj) patients_13/NNS (l_compound) stroke_12/NN
D004298_D007859 NONE dopamine_1/NN (r_compound) agonist_2/NN (l_appos) learning_7/NN
920167
D014859_D005315 NONE warfarin_3/NN (r_advmod) induced_5/VBN (r_amod) embryopathy_6/NNS
D014859_-1 NONE warfarin_3/NN (r_advmod) induced_5/VBN (r_amod) embryopathy_6/NNS (r_dobj) showed_2/VBD (l_prep) with_7/IN (l_pobj) hypoplasia_9/NN
D014859_-1 NONE warfarin_19/NN (r_pobj) with_18/IN (r_prep) treated_17/VBN (r_acl) mothers_16/NNS (r_pobj) to_15/IN (r_prep) born_14/VBN (r_acl) infants_13/NNS (r_pobj) in_11/IN (r_prep) reported_10/VBN (l_nsubjpass) hypoplasia_1/NN
D014859_D002806 CID warfarin_3/NN (r_advmod) induced_5/VBN (r_amod) embryopathy_6/NNS (r_dobj) showed_2/VBD (l_prep) with_7/IN (l_pobj) hypoplasia_9/NN (l_conj) epiphyses_12/NNS
D014859_D002806 CID warfarin_3/NN (r_advmod) induced_5/VBN (r_amod) embryopathy_6/NNS (r_dobj) showed_2/VBD (l_prep) with_7/IN (l_pobj) hypoplasia_9/NN (l_conj) epiphyses_12/NNS (l_appos) punctata_15/NNP
D014859_D002806 CID warfarin_19/NN (r_pobj) with_18/IN (r_prep) treated_17/VBN (r_acl) mothers_16/NNS (r_pobj) to_15/IN (r_prep) born_14/VBN (r_acl) infants_13/NNS (r_pobj) in_11/IN (r_prep) reported_10/VBN (l_nsubjpass) hypoplasia_1/NN (l_prep) with_2/IN (l_conj) without_4/IN (l_pobj) epiphyses_6/NNS
23666265
D003520_D003556 CID cyclophosphamide_10/NN (r_npadvmod) induced_12/VBN (r_amod) cystitis_13/NN
D003520_D003556 CID cyclophosphamide_18/NN (r_pobj) on_17/IN (r_prep) antagonists_16/NNS (r_pobj) of_11/IN (r_prep) function_10/NN (r_dobj) explore_8/VB (r_xcomp) is_6/VBZ (l_attr) cystitis_21/NN
D003520_D003556 CID CYP)-induced_20/JJ (r_punct) is_6/VBZ (l_attr) cystitis_21/NN
D003520_D003556 CID CYP_1/NNP (r_npadvmod) induced_3/VBN (r_amod) cystitis_4/NN
D003520_D010146 CID CYP_7/NNP (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) following_3/VBG (r_acl) behaviors_2/NNS (l_compound) pain_1/NN
D003520_D010146 CID Cyclophosphamide_0/NNP (r_compound) treatment_1/NN (r_nsubj) increased_2/VBD (l_ccomp) scores_7/NNS (l_compound) behaviors_6/NNS (l_compound) pain_5/NN
15366550
D008094_D059606 NONE lithium_24/NN (r_compound) use_25/NN (r_conj) polydipsia_19/NN
D008094_D018500 CID Lithium_0/NN (r_nsubjpass) implicated_2/VBN (l_prep) in_3/IN (l_pobj) DI_8/NNP
D008094_D018500 CID Lithium_0/NN (r_nsubjpass) implicated_2/VBN (l_conj) changed_27/VBD (l_advcl) focus_29/VB (l_prep) on_30/IN (l_pobj) DI_32/NNP
D008094_D018500 CID lithium_17/NN (r_dobj) received_16/VBN (r_advcl) changed_27/VBD (r_conj) implicated_2/VBN (l_prep) in_3/IN (l_pobj) DI_8/NNP
D008094_D018500 CID lithium_17/NN (r_dobj) received_16/VBN (r_advcl) changed_27/VBD (l_advcl) focus_29/VB (l_prep) on_30/IN (l_pobj) DI_32/NNP
D008094_D018500 CID lithium_32/NN (r_npadvmod) induced_34/VBN (r_amod) DI_36/NNP
D008094_D018500 CID lithium_32/NN (r_npadvmod) induced_34/VBN (r_amod) DI_36/NNP (r_dobj) treating_30/VBG (l_conj) developed_38/VBD (l_dobj) secondary_41/JJ (l_compound) DI_40/NNP
D008094_D001930 NONE lithium_32/NN (r_npadvmod) induced_34/VBN (r_amod) DI_36/NNP (r_dobj) treating_30/VBG (l_conj) developed_38/VBD (l_prep) to_42/IN (l_pobj) trauma_44/NN
573555
D011433_D007003 NONE propranolol_27/NNS (r_compound) therapy_28/NN (r_pobj) with_25/IN (r_prep) correlated_24/VBN (r_conj) are_16/VBP (r_ccomp) conclude_1/VBP (l_ccomp) reported_4/VBD (l_dobj) hypoglycemia_5/NN
D011433_D006932 NONE propranolol_27/NNS (r_compound) therapy_28/NN (r_pobj) with_25/IN (r_prep) correlated_24/VBN (r_conj) are_16/VBP (r_ccomp) conclude_1/VBP (l_ccomp) reported_4/VBD (l_dobj) hypoglycemia_5/NN (l_conj) hyperbilirubinemia_7/NNP
D011433_D011086 NONE propranolol_27/NNS (r_compound) therapy_28/NN (r_pobj) with_25/IN (r_prep) correlated_24/VBN (r_conj) are_16/VBP (r_ccomp) conclude_1/VBP (l_ccomp) reported_4/VBD (l_dobj) hypoglycemia_5/NN (l_conj) hyperbilirubinemia_7/NNP (l_conj) polycythemia_9/NN
D011433_D001049 NONE propranolol_27/NNS (r_compound) therapy_28/NN (r_pobj) with_25/IN (r_prep) correlated_24/VBN (r_conj) are_16/VBP (r_ccomp) conclude_1/VBP (l_ccomp) reported_4/VBD (l_dobj) hypoglycemia_5/NN (l_conj) hyperbilirubinemia_7/NNP (l_conj) polycythemia_9/NN (l_conj) apnea_12/NN
D011433_D001919 NONE propranolol_27/NNS (r_compound) therapy_28/NN (r_pobj) with_25/IN (r_prep) correlated_24/VBN (r_conj) are_16/VBP (r_ccomp) conclude_1/VBP (l_ccomp) reported_4/VBD (l_dobj) hypoglycemia_5/NN (l_conj) hyperbilirubinemia_7/NNP (l_conj) polycythemia_9/NN (l_conj) apnea_12/NN (l_conj) bradycardia_15/NN
8996419
D003276_D054556 CID contraceptives_13/NNS (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) thromboembolism_8/NN
D003276_D054556 CID contraceptives_25/NNS (r_dobj) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_prep) of_12/IN (l_pobj) thromboembolism_14/NN
D003276_D054556 CID contraceptives_25/NNS (r_dobj) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_appos) VTE_16/NNP
D003276_D054556 CID OCs_27/NNP (r_appos) contraceptives_25/NNS (r_dobj) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_prep) of_12/IN (l_pobj) thromboembolism_14/NN
D003276_D054556 CID OCs_27/NNP (r_appos) contraceptives_25/NNS (r_dobj) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_appos) VTE_16/NNP
D003276_D054556 CID OCs_42/NNP (r_pobj) of_41/IN (r_prep) users_40/NNS (r_pobj) in_39/IN (r_prep) than_38/IN (r_prep) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_prep) of_12/IN (l_pobj) thromboembolism_14/NN
D003276_D054556 CID OCs_42/NNP (r_pobj) of_41/IN (r_prep) users_40/NNS (r_pobj) in_39/IN (r_prep) than_38/IN (r_prep) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_appos) VTE_16/NNP
D003276_D054556 CID OC_17/NNP (r_conj) VTE_15/NNP
D003276_D054556 CID OC_17/NNP (r_compound) preparations_18/NNS (r_pobj) of_14/IN (r_prep) users_13/NNS (r_pobj) in_12/IN (r_prep) incidence_9/NN (l_prep) of_10/IN (l_pobj) VTE_11/NN
D003276_D054556 CID OC_17/NNP (r_compound) preparations_18/NNS (r_pobj) of_14/IN (r_prep) users_13/NNS (r_pobj) in_12/IN (r_prep) incidence_9/NN (r_dobj) compare_8/VB (r_conj) estimate_6/VB (r_relcl) analysis_4/NN (r_dobj) did_1/VBD (l_conj) study_26/NN (l_acl) calculate_28/VB (l_dobj) ratios_31/NNS (l_prep) of_32/IN (l_pobj) VTE_33/NNP
D003276_D054556 CID OC_41/NNP (r_pobj) of_40/IN (r_prep) types_39/NNS (r_pobj) of_37/IN (r_prep) use_36/NN (r_pobj) with_35/IN (r_prep) associated_34/VBN (r_acl) ratios_31/NNS (r_dobj) calculate_28/VB (r_acl) study_26/NN (r_conj) did_1/VBD (l_dobj) analysis_4/NN (l_relcl) estimate_6/VB (l_conj) compare_8/VB (l_dobj) incidence_9/NN (l_prep) of_10/IN (l_pobj) VTE_11/NN
D003276_D054556 CID OC_41/NNP (r_pobj) of_40/IN (r_prep) types_39/NNS (r_pobj) of_37/IN (r_prep) use_36/NN (r_pobj) with_35/IN (r_prep) associated_34/VBN (r_acl) ratios_31/NNS (l_prep) of_32/IN (l_pobj) VTE_33/NNP
D003276_D054556 CID OCs_18/NNP (r_appos) progestagen_15/NNP (r_pobj) of_14/IN (r_prep) users_13/NNS (r_attr) were_12/VBD (r_relcl) VTE_7/NNP
D003276_D054556 CID OCs_11/NNP (r_pobj) of_9/IN (r_prep) use_8/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) cases_3/NNS (l_prep) of_4/IN (l_pobj) VTE_5/NNP
D003276_D054556 CID OC_17/NNP (r_pobj) of_15/IN (r_prep) users_14/NNS (r_pobj) in_12/IN (r_prep) 4.10_11/CD (r_attr) was_10/VBD (l_nsubj) rate_2/NN (l_prep) of_3/IN (l_pobj) VTE_4/NN
D003276_D054556 CID OCs_26/NNP (r_pobj) of_22/IN (r_prep) users_21/NNS (r_pobj) in_20/IN (r_prep) 3.10_19/CD (r_appos) OC_17/NNP (r_pobj) of_15/IN (r_prep) users_14/NNS (r_pobj) in_12/IN (r_prep) 4.10_11/CD (r_attr) was_10/VBD (l_nsubj) rate_2/NN (l_prep) of_3/IN (l_pobj) VTE_4/NN
D003276_D054556 CID OCs_21/NNP (r_pobj) to_17/IN (r_prep) relative_16/NN (r_pobj) of_12/IN (r_prep) users_11/NNS (r_pobj) in_10/IN (r_prep) ratio_7/NN (l_prep) of_8/IN (l_pobj) VTE_9/NN
D003276_D054556 CID OCs_21/NNP (r_pobj) of_13/IN (r_prep) users_12/NNS (r_pobj) between_11/IN (r_prep) risk_8/NN (l_prep) of_9/IN (l_pobj) VTE_10/NNP
D003276_D054556 CID OCs_5/NNP (r_pobj) With_0/IN (r_prep) were_15/VBD (l_nsubj) ratios_12/NNS (l_prep) for_13/IN (l_pobj) VTE_14/NNP
D011374_D054556 NONE progestagens_34/NNP (r_compound) gestodene_35/NNP (r_dobj) containing_29/VBG (r_acl) contraceptives_25/NNS (r_dobj) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_prep) of_12/IN (l_pobj) thromboembolism_14/NN
D011374_D054556 NONE progestagens_34/NNP (r_compound) gestodene_35/NNP (r_dobj) containing_29/VBG (r_acl) contraceptives_25/NNS (r_dobj) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_appos) VTE_16/NNP
D011374_D054556 NONE progestagens_47/NN (r_dobj) containing_43/VBG (r_acl) OCs_42/NNP (r_pobj) of_41/IN (r_prep) users_40/NNS (r_pobj) in_39/IN (r_prep) than_38/IN (r_prep) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_prep) of_12/IN (l_pobj) thromboembolism_14/NN
D011374_D054556 NONE progestagens_47/NN (r_dobj) containing_43/VBG (r_acl) OCs_42/NNP (r_pobj) of_41/IN (r_prep) users_40/NNS (r_pobj) in_39/IN (r_prep) than_38/IN (r_prep) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_appos) VTE_16/NNP
D011374_D054556 NONE progestagens_6/NN (r_pobj) of_2/IN (r_prep) users_1/NNS (r_pobj) Among_0/IN (r_prep) was_12/VBD (l_nsubj) risk_9/NN (l_prep) of_10/IN (l_pobj) VTE_11/NNP
D011374_D054556 NONE progestagens_41/NN (r_pobj) for_35/IN (r_prep) 3.49_16/CD (r_attr) were_15/VBD (l_nsubj) ratios_12/NNS (l_prep) for_13/IN (l_pobj) VTE_14/NNP
C033273_D054556 NONE gestodene_35/NNP (r_dobj) containing_29/VBG (r_acl) contraceptives_25/NNS (r_dobj) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_prep) of_12/IN (l_pobj) thromboembolism_14/NN
C033273_D054556 NONE gestodene_35/NNP (r_dobj) containing_29/VBG (r_acl) contraceptives_25/NNS (r_dobj) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_appos) VTE_16/NNP
C033273_D054556 NONE gestodene_26/NN (r_pobj) of_25/IN (r_prep) users_24/NNS (r_pobj) in_23/IN (r_prep) than_22/IN (r_prep) higher_13/JJR (r_acomp) was_12/VBD (l_nsubj) risk_9/NN (l_prep) of_10/IN (l_pobj) VTE_11/NNP
D017135_D054556 NONE desogestrel_37/NN (r_conj) gestodene_35/NNP (r_dobj) containing_29/VBG (r_acl) contraceptives_25/NNS (r_dobj) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_prep) of_12/IN (l_pobj) thromboembolism_14/NN
D017135_D054556 NONE desogestrel_37/NN (r_conj) gestodene_35/NNP (r_dobj) containing_29/VBG (r_acl) contraceptives_25/NNS (r_dobj) used_23/VBD (r_relcl) women_21/NNS (r_pobj) in_20/IN (r_prep) was_18/VBD (l_nsubj) incidence_11/NN (l_appos) VTE_16/NNP
D017135_D054556 NONE desogestrel_17/NNS (r_pobj) of_16/IN (r_prep) users_15/NNS (r_pobj) in_14/IN (r_prep) was_12/VBD (l_nsubj) risk_9/NN (l_prep) of_10/IN (l_pobj) VTE_11/NNP
D017135_D054556 NONE desogestrel_28/NN (r_conj) gestodene_26/NN (r_pobj) of_25/IN (r_prep) users_24/NNS (r_pobj) in_23/IN (r_prep) than_22/IN (r_prep) higher_13/JJR (r_acomp) was_12/VBD (l_nsubj) risk_9/NN (l_prep) of_10/IN (l_pobj) VTE_11/NNP
D017135_D054556 NONE desogestrel_23/NNP (r_pobj) for_22/IN (r_prep) 3.49_16/CD (r_attr) were_15/VBD (l_nsubj) ratios_12/NNS (l_prep) for_13/IN (l_pobj) VTE_14/NNP
D011372_D054556 NONE progestagen_15/NNP (r_pobj) of_14/IN (r_prep) users_13/NNS (r_attr) were_12/VBD (r_relcl) VTE_7/NNP
D003276_D020246 NONE OCs_11/NNP (r_pobj) of_9/IN (r_prep) use_8/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) cases_3/NNS (r_pobj) Of_0/IN (r_prep) recorded_15/VBN (l_prep) as_16/IN (l_pobj) thrombosis_20/NN
D003276_D020246 NONE OCs_11/NNP (r_pobj) of_9/IN (r_prep) use_8/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) cases_3/NNS (r_pobj) Of_0/IN (r_prep) recorded_15/VBN (l_prep) as_16/IN (l_pobj) thrombosis_20/NN (l_appos) 35_22/CD (l_conj) five_28/CD (l_advcl) specified_34/VBN (l_nsubjpass) thrombosis_31/NN
D003276_D013927 NONE OCs_11/NNP (r_pobj) of_9/IN (r_prep) use_8/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) cases_3/NNS (r_pobj) Of_0/IN (r_prep) recorded_15/VBN (l_prep) as_16/IN (l_pobj) thrombosis_20/NN (l_appos) 35_22/CD (l_prep) as_23/IN (l_pobj) thrombosis_25/NN
D004997_D054556 NONE ethinyloestradiol_21/NN (r_pobj) with_18/IN (r_prep) was_12/VBD (l_nsubj) risk_9/NN (l_prep) of_10/IN (l_pobj) VTE_11/NNP
D004997_D054556 NONE ethinyloestradiol_32/NN (r_pobj) with_29/IN (r_prep) was_12/VBD (l_nsubj) risk_9/NN (l_prep) of_10/IN (l_pobj) VTE_11/NNP
D004997_D054556 NONE ethinyloestradiol_27/NN (r_conj) 3.49_16/CD (r_attr) were_15/VBD (l_nsubj) ratios_12/NNS (l_prep) for_13/IN (l_pobj) VTE_14/NNP
146391
D010672_D012010 CID diphenylhydantoin_13/NNP (r_dobj) taking_12/VBG (r_acl) patient_11/NN (r_pobj) in_9/IN (r_prep) aplasia_3/NN
D010672_D012010 CID diphenylhydantoin_3/NN (r_dobj) taking_2/VBG (r_acl) patient_1/NN (r_nsubj) developed_7/VBD (l_dobj) rash_11/NN (l_conj) lymphadenopathy_13/JJ (l_conj) aplasia_18/NNP
D010672_D012010 CID diphenylhydantoin_6/NNP (r_compound) medication_7/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) aplasia_3/NNP
D010672_D012010 CID diphenylhydantoin_10/NNP (r_pobj) of_9/IN (r_prep) ingestion_8/NN (l_conj) occurrence_13/NN (l_prep) of_14/IN (l_pobj) rash_17/NN (l_conj) lymphadenopathy_19/JJ (l_conj) aplasia_24/NNP
D010672_D003875 CID diphenylhydantoin_13/NNP (r_dobj) taking_12/VBG (r_acl) patient_11/NN (r_pobj) in_9/IN (r_prep) aplasia_3/NN (l_appos) dermatitis_6/NN
D010672_D008206 CID diphenylhydantoin_13/NNP (r_dobj) taking_12/VBG (r_acl) patient_11/NN (r_pobj) in_9/IN (r_prep) aplasia_3/NN (l_appos) dermatitis_6/NN (l_conj) lymphadenopathy_8/NN
D010672_D008206 CID diphenylhydantoin_3/NN (r_dobj) taking_2/VBG (r_acl) patient_1/NN (r_nsubj) developed_7/VBD (l_dobj) rash_11/NN (l_conj) lymphadenopathy_13/JJ
D010672_D008206 CID diphenylhydantoin_9/NNP (r_compound) treatment_10/NN (r_pobj) of_8/IN (r_prep) complication_7/NN (l_advcl) is_12/VBZ (l_attr) lymphadenopathy_16/NN
D010672_D008206 CID diphenylhydantoin_10/NNP (r_pobj) of_9/IN (r_prep) ingestion_8/NN (l_conj) occurrence_13/NN (l_prep) of_14/IN (l_pobj) rash_17/NN (l_conj) lymphadenopathy_19/JJ
D010672_D005076 NONE diphenylhydantoin_3/NN (r_dobj) taking_2/VBG (r_acl) patient_1/NN (r_nsubj) developed_7/VBD (l_dobj) rash_11/NN
D010672_D005076 NONE diphenylhydantoin_9/NNP (r_compound) treatment_10/NN (r_pobj) of_8/IN (r_prep) complication_7/NN (r_attr) is_2/VBZ (l_nsubj) rash_1/NN
D010672_D005076 NONE diphenylhydantoin_10/NNP (r_pobj) of_9/IN (r_prep) ingestion_8/NN (l_conj) occurrence_13/NN (l_prep) of_14/IN (l_pobj) rash_17/NN
17879100
D001241_D005334 NONE aspirin_4/NN (r_pobj) on_3/IN (r_prep) put_2/VBN (l_conj) took_8/VBD (l_prep) for_10/IN (l_pobj) fever_11/NN
D007052_D005334 NONE ibuprofen_9/NN (r_dobj) took_8/VBD (l_prep) for_10/IN (l_pobj) fever_11/NN
9578276
16369751
D005472_D066126 NONE 5-Fluorouracil_0/LS (r_punct) cardiotoxicity_1/NN
D005472_D066126 NONE 5-fluorouracil_7/CD (r_punct) treatment_11/NN (r_pobj) during_6/IN (r_prep) occurring_5/VBG (r_acl) complication_4/NN (r_attr) is_1/VBZ (l_nsubj) Cardiotoxicity_0/NNP
D005472_D066126 NONE 5-FU_9/CD (r_nmod) treatment_11/NN (r_pobj) during_6/IN (r_prep) occurring_5/VBG (r_acl) complication_4/NN (r_attr) is_1/VBZ (l_nsubj) Cardiotoxicity_0/NNP
D005472_D066126 NONE 5-FU_12/CD (r_npadvmod) induced_14/VBN (r_amod) cardiotoxicity_15/NN
D005472_D066126 NONE 5-FU_14/CD (r_amod) induced_16/VBN (r_amod) cardiotoxicity_17/NN
D005472_D066126 NONE 5-FU_22/CD (r_pobj) of_21/IN (r_prep) administration_20/NN (r_nsubjpass) abandoned_24/VBN (l_advcl) considered_8/VBN (l_xcomp) been_11/VBN (l_acomp) due_12/JJ (l_prep) to_13/IN (l_pobj) cardiotoxicity_17/NN
D005472_D066126 NONE 5-FU_20/CD (r_npadvmod) induced_22/VBN (r_amod) cardiotoxicity_23/NN
D005472_D066126 NONE 5-FU_8/CD (r_npadvmod) induced_10/VBN (r_amod) cardiotoxicity_11/NN
C032348_D066126 NONE alanine_10/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) cardiotoxicity_1/NN
C032348_D066126 NONE alanine_30/NN (r_pobj) of_23/IN (r_prep) level_22/NN (r_nsubjpass) observed_35/VBN (r_relcl) cardiotoxicity_15/NN
C032348_D066126 NONE FBAL_32/NNP (r_appos) alanine_30/NN (r_pobj) of_23/IN (r_prep) level_22/NN (r_nsubjpass) observed_35/VBN (r_relcl) cardiotoxicity_15/NN
C032348_D066126 NONE FBAL_16/NNP (r_nsubjpass) related_18/VBN (l_prep) to_19/IN (l_pobj) cardiotoxicity_23/NN
D005472_D009369 NONE 5-fluorouracil_7/CD (r_punct) treatment_11/NN (l_prep) for_12/IN (l_pobj) malignancies_13/NNS
D005472_D009369 NONE 5-FU_9/CD (r_nmod) treatment_11/NN (l_prep) for_12/IN (l_pobj) malignancies_13/NNS
D005472_D002637 CID 5-FU_11/CD (r_pobj) of_10/IN (r_prep) infusion_9/NN (l_relcl) occurred_28/VBD (l_nsubj) pain_22/NN
D005472_D002637 CID 5-FU_14/CD (r_pobj) of_13/IN (r_prep) discontinuation_12/NN (r_pobj) after_10/IN (r_prep) disappeared_8/VBD (l_nsubj) pain_3/NN
D005472_D002637 CID 5-FU_14/CD (r_amod) induced_16/VBN (r_amod) cardiotoxicity_17/NN (r_pobj) to_13/IN (r_prep) due_12/JJ (r_acomp) been_11/VBN (r_xcomp) considered_8/VBN (l_nsubjpass) pain_3/NN
D005472_D002637 CID 5-FU_22/CD (r_pobj) of_21/IN (r_prep) administration_20/NN (r_nsubjpass) abandoned_24/VBN (l_advcl) considered_8/VBN (l_nsubjpass) pain_3/NN
D005472_D002037 CID 5-FU_11/CD (r_pobj) of_10/IN (r_prep) infusion_9/NN (l_relcl) occurred_28/VBD (l_nsubj) pain_22/NN (l_prep) with_23/IN (l_pobj) block_27/NN
C032348_D002637 NONE FBAL_34/NN (r_compound) concentration_35/NN (r_pobj) with_30/IN (r_prep) occurred_28/VBD (l_nsubj) pain_22/NN
C032348_D002037 NONE FBAL_34/NN (r_compound) concentration_35/NN (r_pobj) with_30/IN (r_prep) occurred_28/VBD (l_nsubj) pain_22/NN (l_prep) with_23/IN (l_pobj) block_27/NN
2429800
D006632_D007022 NONE Histamine_0/JJ (r_compound) antagonists_1/NNS (l_conj) hypotension_8/NN
D014403_D007022 CID tubocurarine_5/NN (r_npadvmod) induced_7/VBN (r_amod) hypotension_8/NN
24653743
C042288_D016757 CID Pilsicainide_8/NNP (r_nmod) Pointes_13/NNP (r_pobj) to_7/IN (r_pcomp) due_6/IN (r_prep) Case_1/NN (l_prep) of_2/IN (l_pobj) Death_5/NNP
C042288_D016757 CID pilsicainide_7/NN (r_dobj) received_5/VBD (r_ccomp) developed_32/VBD (l_dobj) death_35/NN
C042288_D016171 CID Pilsicainide_8/NNP (r_nmod) Pointes_13/NNP
C042288_D016171 CID pilsicainide_14/NN (r_pobj) of_13/IN (r_prep) dose_12/NN (r_nsubj) was_15/VBD (r_conj) impaired_9/JJ (r_acomp) was_6/VBD (r_advcl) been_25/VBN (l_advcl) produce_30/VB (l_dobj) pointes_33/FW
C042288_D016171 CID pilsicainide_22/NN (r_pobj) of_21/IN (r_prep) concentration_20/NN (r_nsubj) been_25/VBN (l_advcl) produce_30/VB (l_dobj) pointes_33/FW
C042288_D001281 NONE pilsicainide_7/NN (r_dobj) received_5/VBD (l_advcl) convert_20/VB (l_dobj) fibrillation_24/NN
C042288_D001281 NONE pilsicainide_10/NN (r_pobj) including_9/VBG (r_prep) drugs_7/NNS (r_pobj) of_4/IN (r_prep) administration_3/NNP (r_nsubj) is_12/VBZ (l_acomp) effective_13/JJ (l_xcomp) terminate_15/VB (l_dobj) fibrillation_17/NN
D012964_D001281 NONE sodium_11/NN (r_compound) channel_12/NN (r_compound) blocker_13/NN (r_appos) pilsicainide_7/NN (r_dobj) received_5/VBD (l_advcl) convert_20/VB (l_dobj) fibrillation_24/NN
D012964_D016757 NONE sodium_11/NN (r_compound) channel_12/NN (r_compound) blocker_13/NN (r_appos) pilsicainide_7/NN (r_dobj) received_5/VBD (r_ccomp) developed_32/VBD (l_dobj) death_35/NN
3708328
D010862_D012640 CID pilocarpine_5/NNP (r_pobj) by_4/IN (r_agent) produced_3/VBN (r_acl) seizures_2/NNS
D010862_D012640 CID Pilocarpine_0/NNP (r_nsubj) reproduces_7/VBZ (l_conj) provides_16/VBZ (l_dobj) model_20/NN (l_prep) for_21/IN (l_pcomp) studying_22/VBG (l_dobj) mechanisms_23/NNS (l_prep) of_24/IN (l_pobj) buildup_25/NN (l_prep) of_26/IN (l_pobj) operative_31/JJ (l_nmod) activity_28/NN (l_amod) convulsive_27/JJ
D010862_D012640 CID Pilocarpine_0/NNP (r_nsubj) reproduces_7/VBZ (l_conj) provides_16/VBZ (l_dobj) model_20/NN (l_prep) for_21/IN (l_pcomp) studying_22/VBG (l_dobj) mechanisms_23/NNS (l_prep) of_24/IN (l_pobj) buildup_25/NN (l_prep) of_26/IN (l_pobj) operative_31/JJ (l_prep) in_32/IN (l_pobj) generalization_34/NN (l_prep) of_37/IN (l_pobj) seizures_38/NNS
D010862_D012640 CID pilocarpine_29/NNP (r_pobj) by_28/IN (r_agent) produced_27/VBN (r_acl) seizures_26/NNS
D010862_D012640 CID pilocarpine_45/NNP (r_pobj) of_44/IN (r_prep) doses_43/NNS (r_appos) reticulata_33/NN (r_pobj) into_28/IN (r_prep) inhibitor_12/NN (r_appos) micrograms_9/NNS (r_nsubj) resulted_52/VBN (l_prep) in_53/IN (l_pobj) seizures_57/NNS
D010862_D012640 CID pilocarpine_12/NN (r_npadvmod) induced_14/VBN (r_amod) convulsions_15/NNS
D010862_D012640 CID pilocarpine_36/NNP (r_pobj) with_35/IN (r_prep) observed_34/VBN (r_relcl) formation_17/NN (r_pobj) to_14/IN (r_prep) damage_13/NN (l_amod) related_12/VBN (l_npadvmod) seizure_10/NN
D010862_D012640 CID pilocarpine_11/NNP (r_pobj) by_10/IN (r_agent) produced_9/VBN (r_acl) seizures_8/NNS
D010862_D012640 CID pilocarpine_42/NNP (r_pobj) by_41/IN (r_agent) produced_40/VBN (r_acl) seizures_39/NNS
D010862_D012640 CID pilocarpine_27/NNP (r_pobj) by_26/IN (r_agent) produced_25/VBN (r_acl) convulsions_24/NNS
D010862_D012640 CID pilocarpine_7/NN (r_npadvmod) induced_9/VBN (r_amod) seizures_10/NNS
D007538_D012640 NONE isoniazid_11/NN (r_pobj) of_10/IN (r_prep) microinjection_9/NN (r_pobj) after_8/IN (r_prep) produced_3/VBN (r_acl) seizures_2/NNS
D007538_D012640 NONE isoniazid_6/NNP (r_pobj) of_5/IN (r_prep) microinjections_4/NNS (r_pobj) with_3/IN (r_prep) pretreated_2/VBN (r_acl) animals_1/NNS (r_pobj) In_0/IN (r_prep) resulted_52/VBN (l_prep) in_53/IN (l_pobj) seizures_57/NNS
D007538_D012640 NONE isoniazid_4/NNP (r_pobj) of_3/IN (r_prep) injections_2/NNS (r_nsubj) augment_7/VB (l_dobj) seizures_8/NNS
D020888_D012640 NONE GABA_17/NN (r_conj) isoniazid_11/NN (r_pobj) of_10/IN (r_prep) microinjection_9/NN (r_pobj) after_8/IN (r_prep) produced_3/VBN (r_acl) seizures_2/NNS
D020888_D012640 NONE GABA_13/NN (r_appos) transaminase_7/NN (r_pobj) of_5/IN (r_prep) inhibitor_4/NN (r_pobj) of_1/IN (r_prep) Application_0/NN (r_nsubj) suppressed_32/VBD (l_dobj) appearance_34/NN (l_prep) of_35/IN (l_pobj) electrographic_36/JJ (l_conj) seizures_39/NNS
D020888_D012640 NONE acid_20/NN (r_appos) D_15/NNP (r_appos) GABA_13/NN (r_appos) transaminase_7/NN (r_pobj) of_5/IN (r_prep) inhibitor_4/NN (r_pobj) of_1/IN (r_prep) Application_0/NN (r_nsubj) suppressed_32/VBD (l_dobj) appearance_34/NN (l_prep) of_35/IN (l_pobj) electrographic_36/JJ (l_conj) seizures_39/NNS
D020888_D012640 NONE GABA_6/NNP (r_pobj) of_1/IN (r_prep) Microinjections_0/NNS (r_nsubj) failed_18/VBD (l_xcomp) prevent_20/VB (l_dobj) development_22/NN (l_prep) of_23/IN (l_pobj) convulsions_24/NNS
D010862_D004833 NONE Pilocarpine_0/NNP (r_nsubj) reproduces_7/VBZ (l_dobj) sequelae_10/NNS (l_prep) of_11/IN (l_pobj) epilepsy_14/NN
D005680_D012640 NONE acid_16/NN (l_appos) inhibition_20/NN (l_prep) within_21/IN (l_pobj) nigra_24/FW (l_prep) on_25/IN (l_pobj) seizures_26/NNS
D005680_D012640 NONE GABA)-mediated_18/VBN (r_nmod) inhibition_20/NN (l_prep) within_21/IN (l_pobj) nigra_24/FW (l_prep) on_25/IN (l_pobj) seizures_26/NNS
D005680_D012640 NONE GABA_17/NNP (r_npadvmod) synthesizing_19/VBG (r_amod) enzyme_20/NNS (r_pobj) of_15/IN (r_prep) activity_14/NN (r_pobj) of_13/IN (r_prep) inhibitor_12/NN (r_appos) micrograms_9/NNS (r_nsubj) resulted_52/VBN (l_prep) in_53/IN (l_pobj) seizures_57/NNS
D005680_D012640 NONE GABA_6/NNP (r_compound) transaminase_7/NN (r_pobj) of_5/IN (r_prep) inhibitor_4/NN (r_pobj) of_1/IN (r_prep) Application_0/NN (r_nsubj) suppressed_32/VBD (l_dobj) appearance_34/NN (l_prep) of_35/IN (l_pobj) electrographic_36/JJ (l_conj) seizures_39/NNS
D005680_D012640 NONE GABA_20/NNP (r_npadvmod) mediated_22/VBN (r_amod) inhibition_24/NN (r_pobj) of_18/IN (r_prep) regulation_17/NN (r_pobj) to_15/IN (r_prep) subjected_14/VBN (l_nsubjpass) threshold_5/NN (l_prep) for_6/IN (l_pobj) seizures_10/NNS
D007538_D013226 NONE isoniazid_6/NNP (r_pobj) of_5/IN (r_prep) microinjections_4/NNS (r_pobj) with_3/IN (r_prep) pretreated_2/VBN (r_acl) animals_1/NNS (r_pobj) In_0/IN (r_prep) resulted_52/VBN (l_prep) in_53/IN (l_pobj) seizures_57/NNS (l_conj) epilepticus_60/NN
D005680_D013226 NONE GABA_17/NNP (r_npadvmod) synthesizing_19/VBG (r_amod) enzyme_20/NNS (r_pobj) of_15/IN (r_prep) activity_14/NN (r_pobj) of_13/IN (r_prep) inhibitor_12/NN (r_appos) micrograms_9/NNS (r_nsubj) resulted_52/VBN (l_prep) in_53/IN (l_pobj) seizures_57/NNS (l_conj) epilepticus_60/NN
D018698_D012640 NONE acid_25/NN (r_compound) decarboxylase_26/NN (r_appos) enzyme_20/NNS (r_pobj) of_15/IN (r_prep) activity_14/NN (r_pobj) of_13/IN (r_prep) inhibitor_12/NN (r_appos) micrograms_9/NNS (r_nsubj) resulted_52/VBN (l_prep) in_53/IN (l_pobj) seizures_57/NNS
D018698_D013226 NONE acid_25/NN (r_compound) decarboxylase_26/NN (r_appos) enzyme_20/NNS (r_pobj) of_15/IN (r_prep) activity_14/NN (r_pobj) of_13/IN (r_prep) inhibitor_12/NN (r_appos) micrograms_9/NNS (r_nsubj) resulted_52/VBN (l_prep) in_53/IN (l_pobj) seizures_57/NNS (l_conj) epilepticus_60/NN
D010862_D013226 NONE pilocarpine_45/NNP (r_pobj) of_44/IN (r_prep) doses_43/NNS (r_appos) reticulata_33/NN (r_pobj) into_28/IN (r_prep) inhibitor_12/NN (r_appos) micrograms_9/NNS (r_nsubj) resulted_52/VBN (l_prep) in_53/IN (l_pobj) seizures_57/NNS (l_conj) epilepticus_60/NN
44072
C024986_D001145 CID BaCl2_9/NNP (r_pobj) with_8/IN (r_prep) used_6/VBN (l_nsubjpass) types_1/NNS (l_prep) of_2/IN (l_pobj) arrhythmia_4/NN
C024986_D001145 CID BaCl2_32/NNP (r_pobj) with_31/IN (r_conj) manifests_2/VBZ (l_prep) in_5/IN (l_pobj) models_7/NNS (l_prep) of_8/IN (l_pobj) arrhythmia_10/NN
C024986_D001145 CID BaCl2_32/NNP (r_pobj) with_31/IN (r_conj) manifests_2/VBZ (l_prep) in_5/IN (l_pobj) models_7/NNS (l_acl) used_11/VBD (l_advcl) causing_13/VBG (l_dobj) inhibition_15/NN (l_prep) on_16/IN (l_pobj) arrhythmia_18/NN
D002725_D001145 CID chloroform_12/NN (r_compound) adrenaline_14/NN (r_pobj) with_11/IN (r_prep) used_6/VBN (l_nsubjpass) types_1/NNS (l_prep) of_2/IN (l_pobj) arrhythmia_4/NN
D002725_D001145 CID chloroform_21/NN (r_compound) adrenaline_23/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) arrhythmia_18/NN (r_pobj) on_16/IN (r_prep) inhibition_15/NN (r_dobj) causing_13/VBG (r_advcl) used_11/VBD (r_acl) models_7/NNS (l_prep) of_8/IN (l_pobj) arrhythmia_10/NN
D002725_D001145 CID chloroform_21/NN (r_compound) adrenaline_23/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) arrhythmia_18/NN
D004837_D001145 CID adrenaline_14/NN (r_pobj) with_11/IN (r_prep) used_6/VBN (l_nsubjpass) types_1/NNS (l_prep) of_2/IN (l_pobj) arrhythmia_4/NN
D004837_D001145 CID adrenaline_23/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) arrhythmia_18/NN (r_pobj) on_16/IN (r_prep) inhibition_15/NN (r_dobj) causing_13/VBG (r_advcl) used_11/VBD (r_acl) models_7/NNS (l_prep) of_8/IN (l_pobj) arrhythmia_10/NN
D004837_D001145 CID adrenaline_23/NN (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) arrhythmia_18/NN
D010042_D001145 CID G_18/NNP (r_pobj) with_16/IN (r_prep) used_6/VBN (l_nsubjpass) types_1/NNS (l_prep) of_2/IN (l_pobj) arrhythmia_4/NN
D000157_D001145 CID aconitine_21/NN (r_pobj) with_20/IN (r_conj) with_16/IN (r_prep) used_6/VBN (l_nsubjpass) types_1/NNS (l_prep) of_2/IN (l_pobj) arrhythmia_4/NN
19293073
D001241_D003327 NONE aspirin_17/NN (r_dobj) discuss_16/VBP (l_prep) with_18/IN (l_pobj) adults_19/NNS (l_relcl) are_21/VBP (l_prep) at_22/IN (l_pobj) risk_24/NN (l_prep) for_25/IN (l_pobj) disease_28/NN
D001241_D009203 NONE aspirin_8/NN (r_dobj) taking_7/VBG (l_prep) for_9/IN (l_pobj) prevention_12/NN (l_prep) of_13/IN (l_pobj) infarctions_15/NNS
D001241_D009203 NONE Aspirin_0/NN (r_nsubj) reduces_1/VBZ (l_dobj) risk_3/NN (l_prep) for_4/IN (l_pobj) infarction_6/NN
D001241_D020521 CID aspirin_8/NN (r_dobj) taking_7/VBG (l_prep) for_9/IN (l_pobj) prevention_12/NN (l_prep) of_13/IN (l_pobj) infarctions_15/NNS (l_conj) strokes_17/NNS
D001241_D020521 CID aspirin_3/NN (r_pobj) of_2/IN (r_prep) reviews_1/NNS (r_nsubjpass) selected_17/VBN (l_dep) aspirin_25/NN (l_dobj) events_29/NNS (l_conj) strokes_31/NNS
D001241_D020521 CID aspirin_3/NN (r_pobj) of_2/IN (r_prep) reviews_1/NNS (r_nsubjpass) selected_17/VBN (l_dep) aspirin_25/NN (l_dobj) events_29/NNS (l_conj) strokes_31/NNS (l_conj) death_33/NN (l_prep) from_34/IN (l_pobj) events_37/NNS (l_conj) stroke_39/NN
D001241_D020521 CID aspirin_25/NN (l_dobj) events_29/NNS (l_conj) strokes_31/NNS
D001241_D020521 CID aspirin_25/NN (l_dobj) events_29/NNS (l_conj) strokes_31/NNS (l_conj) death_33/NN (l_prep) from_34/IN (l_pobj) events_37/NNS (l_conj) stroke_39/NN
D001241_D020521 CID aspirin_1/NN (r_compound) increase_2/VB (r_nmod) strokes_7/NNS
D001241_D020521 CID aspirin_9/NN (r_compound) use_10/NN (r_pobj) with_8/IN (r_prep) risk_4/NN (l_prep) for_5/IN (l_pobj) strokes_7/NNS
D001241_D020521 CID Aspirin_0/NN (r_nsubj) reduces_1/VBZ (l_dobj) risk_3/NN (l_prep) for_4/IN (l_pobj) infarction_6/NN (l_prep) in_7/IN (l_pobj) men_8/NNS (l_conj) strokes_10/NNS
D001241_D002318 NONE aspirin_3/NN (l_prep) versus_4/IN (l_pobj) control_5/NN (l_prep) for_6/IN (l_pobj) prevention_9/NN (l_prep) of_10/IN (l_pobj) disease_12/NN
D001241_D002318 NONE aspirin_3/NN (l_prep) versus_4/IN (l_pobj) control_5/NN (l_prep) for_6/IN (l_pobj) prevention_9/NN (l_prep) of_10/IN (l_pobj) disease_12/NN (l_appos) CVD_14/NNP
D001241_D002318 NONE aspirin_3/NN (r_pobj) of_2/IN (r_prep) reviews_1/NNS (r_nsubjpass) selected_17/VBN (l_dep) aspirin_25/NN (l_prep) without_48/IN (l_pobj) CVD_50/NNP
D001241_D002318 NONE aspirin_25/NN (r_dep) selected_17/VBN (l_nsubjpass) reviews_1/NNS (l_prep) of_2/IN (l_pobj) aspirin_3/NN (l_prep) versus_4/IN (l_pobj) control_5/NN (l_prep) for_6/IN (l_pobj) prevention_9/NN (l_prep) of_10/IN (l_pobj) disease_12/NN
D001241_D002318 NONE aspirin_25/NN (r_dep) selected_17/VBN (l_nsubjpass) reviews_1/NNS (l_prep) of_2/IN (l_pobj) aspirin_3/NN (l_prep) versus_4/IN (l_pobj) control_5/NN (l_prep) for_6/IN (l_pobj) prevention_9/NN (l_prep) of_10/IN (l_pobj) disease_12/NN (l_appos) CVD_14/NNP
D001241_D002318 NONE aspirin_25/NN (l_prep) without_48/IN (l_pobj) CVD_50/NNP
D001241_D002318 NONE aspirin_27/NN (r_compound) use_28/NN (r_nsubj) reduces_29/VBZ (l_dobj) number_31/NN (l_prep) of_32/IN (l_pobj) events_34/NNS (l_compound) CVD_33/NNP
D001241_D002318 NONE aspirin_27/NN (r_compound) use_28/NN (r_nsubj) reduces_29/VBZ (l_dobj) number_31/NN (l_prep) of_32/IN (l_pobj) events_34/NNS (l_prep) in_35/IN (l_pobj) patients_36/NNS (l_prep) without_37/IN (l_pobj) CVD_39/NNP
D001241_D002318 NONE Aspirin_0/NN (r_nsubj) seem_3/VB (l_xcomp) affect_5/VB (l_dobj) mortality_7/NN (l_compound) CVD_6/NNP
D001241_D002318 NONE aspirin_3/NN (l_prep) for_4/IN (l_pobj) prevention_7/NN (l_prep) of_8/IN (l_pobj) CVD_9/NNP
D001241_D006471 CID aspirin_1/NN (r_compound) increase_2/VB (r_nmod) strokes_7/NNS (l_amod) bleeding_4/NN
D001241_D006471 CID aspirin_3/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubj) increases_7/VBZ (l_dobj) risk_9/NN (l_prep) for_10/IN (l_pobj) events_13/NNS (l_appos) events_18/NNS (l_amod) bleeding_17/VBG
D001241_D020300 CID aspirin_1/NN (r_compound) increase_2/VB (r_nmod) strokes_7/NNS
D001241_D020300 CID aspirin_9/NN (r_compound) use_10/NN (r_pobj) with_8/IN (r_prep) risk_4/NN (l_prep) for_5/IN (l_pobj) strokes_7/NNS
D001241_D006470 NONE aspirin_3/NN (r_pobj) of_2/IN (r_prep) use_1/NN (r_nsubj) increases_7/VBZ (l_dobj) risk_9/NN (l_prep) for_10/IN (l_pobj) events_13/NNS (l_amod) bleeding_12/VBG
D001241_D006470 NONE Aspirin_0/NN (r_compound) use_1/NN (r_nsubj) increases_2/VBZ (l_dobj) risk_4/NN (l_prep) for_5/IN (l_pobj) events_8/NNS (l_amod) bleeding_7/VBG
18165598
D002045_D010146 NONE bupivacaine_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) on_7/IN (l_pobj) release_10/NN (l_appos) expression_14/NN (l_conj) pain_16/NN
D002045_D010146 NONE bupivacaine_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) in_17/IN (l_pobj) model_21/NN (l_compound) pain_20/NN
D002045_D010146 NONE bupivacaine_1/NN (r_nmod) group_4/NNP (r_nsubj) reported_5/VBD (l_dobj) pain_8/NN
D002045_D010146 NONE bupivacaine_3/NN (r_compound) placebo_5/NN (r_compound) group_6/NN (r_nsubj) reported_7/VBD (l_dobj) pain_10/NN
D002045_D010146 NONE bupivacaine_4/NN (r_nsubj) stimulates_5/VBZ (l_prep) after_9/IN (l_pobj) injury_11/NN (l_relcl) associated_15/VBN (l_prep) with_16/IN (l_pobj) production_19/NN (l_conj) pain_21/NN
D008012_D010146 NONE lidocaine_6/NN (r_conj) bupivacaine_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) on_7/IN (l_pobj) release_10/NN (l_appos) expression_14/NN (l_conj) pain_16/NN
D008012_D010146 NONE lidocaine_6/NN (r_conj) bupivacaine_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) in_17/IN (l_pobj) model_21/NN (l_compound) pain_20/NN
D015232_D010146 NONE E2_9/NN (r_compound) release_10/NN (l_appos) expression_14/NN (l_conj) pain_16/NN
D015232_D010146 NONE E2_9/NN (r_compound) release_10/NN (r_pobj) on_7/IN (r_prep) effects_2/NNS (l_prep) in_17/IN (l_pobj) model_21/NN (l_compound) pain_20/NN
D015232_D010146 NONE PGE2_15/NNP (r_conj) h_13/NN (r_nmod) levels_16/NNS (r_pobj) at_11/IN (r_prep) reported_7/VBD (l_dobj) pain_10/NN
D015232_D010146 NONE PGE2_18/NNP (r_compound) production_19/NN (l_conj) pain_21/NN
D002045_D010149 CID bupivacaine_11/NN (r_pobj) of_10/IN (r_prep) effects_9/NNS (l_appos) expression_26/NN (l_relcl) increases_28/VBZ (l_dobj) pain_30/NN
D015232_D010149 NONE E2_15/NN (r_pobj) on_12/IN (r_prep) effects_9/NNS (l_appos) expression_26/NN (l_relcl) increases_28/VBZ (l_dobj) pain_30/NN
D015232_D010149 NONE PGE2_17/NNP (r_nmod) production_19/NN (r_appos) E2_15/NN (r_pobj) on_12/IN (r_prep) effects_9/NNS (l_appos) expression_26/NN (l_relcl) increases_28/VBZ (l_dobj) pain_30/NN
C116926_D010146 NONE rofecoxib_3/NNP (r_compound) group_4/NNP (r_nsubj) reported_5/VBD (l_dobj) pain_8/NN
D002045_D017695 NONE bupivacaine_4/NN (r_nsubj) stimulates_5/VBZ (l_prep) after_9/IN (l_pobj) injury_11/NN
D015232_D017695 NONE PGE2_18/NNP (r_compound) production_19/NN (r_pobj) with_16/IN (r_prep) associated_15/VBN (r_relcl) injury_11/NN
26002693
C031763_D015464 NONE 1,3-Butadiene_0/CD (l_appos) CML_2/NNP
C031763_D015464 NONE 1,3-butadiene_3/CD (r_pobj) of_2/IN (r_prep) studies_1/NNS (r_nsubj) suggest_5/VBN (l_ccomp) associated_11/VBN (l_prep) with_12/IN (l_pobj) leukemia_15/NN
C031763_D015464 NONE 1,3-butadiene_3/CD (r_pobj) of_2/IN (r_prep) studies_1/NNS (r_nsubj) suggest_5/VBN (l_ccomp) associated_11/VBN (l_prep) with_12/IN (l_pobj) leukemia_15/NN (l_appos) CML_17/NNP
24158386
C056507_D006689 NONE GEM_0/NN (r_compound) P_2/NN (r_compound) chemotherapy_3/NN (r_nsubj) is_4/VBZ (l_acomp) active_5/JJ (l_prep) in_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) lymphoma_12/NN
C056507_D006689 NONE Gemcitabine_0/NNP (r_nsubj) have_3/VBP (l_dobj) activity_4/NN (l_prep) in_5/IN (l_pobj) HL_6/NNP
C056507_D006689 NONE gemcitabine_16/NNP (r_nmod) day_22/NN (r_pobj) with_15/IN (r_prep) treated_14/VBN (l_nsubj) patients_8/NNS (l_prep) with_9/IN (l_pobj) HL_13/NNP
C056507_D006689 NONE GEM_0/NN (r_compound) P_2/NNP (r_nsubj) is_3/VBZ (l_prep) in_21/IN (l_pobj) treatment_23/NN (l_prep) of_24/IN (l_pobj) HL_28/NN
D002945_D006689 NONE cisplatin_2/NN (r_conj) Gemcitabine_0/NNP (r_nsubj) have_3/VBP (l_dobj) activity_4/NN (l_prep) in_5/IN (l_pobj) HL_6/NNP
D008775_D006689 NONE methylprednisolone_30/NN (l_ccomp) treated_14/VBN (l_nsubj) patients_8/NNS (l_prep) with_9/IN (l_pobj) HL_13/NNP
20859899
D000809_D013575 NONE angiotensin_12/NN (r_npadvmod) converting_14/VBG (r_amod) inhibitor_16/NN (r_pobj) with_10/IN (r_prep) therapy_9/NN (r_pobj) of_6/IN (r_prep) use_5/NN (r_pobj) during_4/IN (r_prep) caused_1/VBN (r_acl) Syncope_0/NN
D000809_D006947 NONE angiotensin_12/NN (r_npadvmod) converting_14/VBG (r_amod) inhibitor_16/NN (r_pobj) with_10/IN (r_prep) therapy_9/NN (r_pobj) of_6/IN (r_prep) use_5/NN (r_pobj) during_4/IN (r_prep) caused_1/VBN (l_agent) by_2/IN (l_pobj) hyperkalemia_3/NN
D013148_D013575 NONE spironolactone_18/NN (r_conj) inhibitor_16/NN (r_pobj) with_10/IN (r_prep) therapy_9/NN (r_pobj) of_6/IN (r_prep) use_5/NN (r_pobj) during_4/IN (r_prep) caused_1/VBN (r_acl) Syncope_0/NN
D013148_D006947 CID spironolactone_18/NN (r_conj) inhibitor_16/NN (r_pobj) with_10/IN (r_prep) therapy_9/NN (r_pobj) of_6/IN (r_prep) use_5/NN (r_pobj) during_4/IN (r_prep) caused_1/VBN (l_agent) by_2/IN (l_pobj) hyperkalemia_3/NN
D013148_D006947 CID spiranolactone_11/NNP (r_pobj) of_10/IN (r_prep) doses_9/NNS (r_attr) be_7/VB (r_xcomp) considered_5/VBN (l_nsubjpass) cause_1/NN (l_prep) of_2/IN (l_pobj) hyperkalemia_3/NN
D000450_D006947 NONE aldosterone_14/NN (r_compound) antagonist_15/NN (r_appos) spiranolactone_11/NNP (r_pobj) of_10/IN (r_prep) doses_9/NNS (r_attr) be_7/VB (r_xcomp) considered_5/VBN (l_nsubjpass) cause_1/NN (l_prep) of_2/IN (l_pobj) hyperkalemia_3/NN
D017257_D006947 CID ramipril_26/NNP (r_pobj) of_25/IN (r_prep) intake_24/NN (r_pobj) to_19/IN (r_prep) addition_18/NN (r_pobj) in_17/IN (r_prep) considered_5/VBN (l_nsubjpass) cause_1/NN (l_prep) of_2/IN (l_pobj) hyperkalemia_3/NN
D011188_D006947 NONE potassium_21/NN (r_compound) agents_23/NNS (r_pobj) with_20/IN (r_prep) combination_19/NN (r_pobj) in_18/IN (r_prep) using_14/VBG (r_acl) patients_13/NNS (r_pobj) in_11/IN (r_prep) possibility_6/NN (l_prep) of_7/IN (l_pobj) hyperkalemia_8/NN
D011188_D007674 NONE potassium_21/NN (r_compound) agents_23/NNS (r_pobj) with_20/IN (r_prep) combination_19/NN (r_pobj) in_18/IN (r_prep) using_14/VBG (l_conj) have_26/VBP (l_dobj) disturbance_29/NN
11708428
D011241_D001008 CID Prednisone_0/NN (r_nsubj) induces_1/VBZ (l_dobj) anxiety_2/NN
D011241_D001008 CID prednisone_3/NN (r_nsubj) produces_7/VBZ (l_dobj) anxiety_8/NN
D011241_D001008 CID PDN_5/NNP (r_appos) prednisone_3/NN (r_nsubj) produces_7/VBZ (l_dobj) anxiety_8/NN
D011241_D001008 CID PDN_7/NNP (r_pobj) of_6/IN (r_prep) groups_5/NNS (r_pobj) in_3/IN (r_prep) documented_2/VBN (l_nsubjpass) Anxiety_0/NN
D011241_D001008 CID PDN_3/NNP (r_pobj) to_2/IN (r_prep) exposure_1/NN (r_nsubj) induced_4/VBD (l_dobj) anxiety_5/NN
12559315
D007213_D018856 CID Indomethacin_0/NNS (r_nsubj) resulted_1/VBD (l_prep) in_2/IN (l_pobj) findings_4/NNS (l_amod) typical_5/JJ (l_prep) of_6/IN (l_pobj) cystitis_8/NN
D007213_D008415 CID Indomethacin_0/NNS (r_nsubj) resulted_1/VBD (l_prep) in_2/IN (l_pobj) findings_4/NNS (l_amod) typical_5/JJ (l_prep) of_6/IN (l_pobj) cystitis_8/NN (l_prep) as_11/IN (l_pobj) epithelium_14/NN (l_conj) mastocytosis_17/NN
10933650
D000666_D064420 NONE B_7/NNP (r_nsubj) is_9/VBZ (l_conj) has_15/VBZ (l_dobj) toxicity_17/NN
D000666_D064420 NONE Fungizone_9/NNP (r_pobj) of_8/IN (r_prep) that_7/DT (r_pobj) with_6/IN (r_prep) compared_1/VBD (l_dobj) toxicity_3/NN
D000666_D064420 NONE B_44/NNP (r_pobj) of_42/IN (r_prep) study_41/NN (r_pobj) of_36/IN (r_prep) study_35/NN (r_dobj) using_23/VBG (r_advcl) compared_1/VBD (l_dobj) toxicity_3/NN
C059765_D064420 NONE deoxycholate_15/NN (r_appos) Fungizone_9/NNP (r_pobj) of_8/IN (r_prep) that_7/DT (r_pobj) with_6/IN (r_prep) compared_1/VBD (l_dobj) toxicity_3/NN
C059765_D064420 NONE AmB_19/NNP (r_appos) deoxycholate_15/NN (r_appos) Fungizone_9/NNP (r_pobj) of_8/IN (r_prep) that_7/DT (r_pobj) with_6/IN (r_prep) compared_1/VBD (l_dobj) toxicity_3/NN
C059765_D007683 CID AmB_11/NN (r_npadvmod) treated_13/VBN (r_amod) rats_14/NNS (r_pobj) in_8/IN (r_prep) showed_5/VBD (l_dobj) necrosis_7/NN
D000666_D007674 NONE B_12/NNP (r_pobj) of_10/IN (r_prep) incorporation_9/NN (r_nsubj) attenuates_18/VBZ (l_dobj) nephrotoxicity_20/NN
D000666_D007674 NONE B._23/NNP (r_pobj) of_21/IN (r_prep) nephrotoxicity_20/NN
